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II Abstract     
Understanding the processes that control the formation of blood 
(haematopoiesis), and blood vessels (vasculogenesis and angiogenesis) in vivo has 
huge clinical importance. The complex three-dimensional architecture of blood 
vessels is dynamic and aberrant regulation of either the growth or function of the 
vascular system may potentiate the spread of tumours, resulting in failure of 
physiological processes such as implantation and placental development, leading to a 
range of angiogenesis associated disorders for example diabetic retinopathy. Both 
embryonic and adult haematopoiesis are also three-dimensional, dynamic processes in 
which deregulation may result in blood disorders or leukaemia.  
The experiments herein describe my contribution to investigations into the 
molecular mechanisms involved in haematopoiesis and angiogenesis over a period of 
approximately 15 years, taking advantage of technical advances as they became 
available and adapting them to specific cell models. For example, microarray 
technology has facilitated discovery of new pathways and transcripts implicated in 
normal and pathological angiogenesis; central to this mechanism is the role of 
vascular endothelial growth factor (VEGF), a mitogen specific to endothelial cells. 
Chromosome immunoprecipitation (ChIP) technology subsequently revealed 
pathways of early mesoderm formation and the importance of gastrulation in this 
process. Transcriptional targets of the T-box transcription factor Brachyury were 
subsequently determined.  
Throughout this work, the human female reproductive tract provided a unique 
resource, as one of the rare sites of physiological angiogenesis with which to 
investigate endothelial cell biology and haematopoiesis. Embryonic stem cell-derived 
embryoid bodies subsequently proved to be an excellent model for the study of early 
blood vessel development in three dimensions (2003-5), and to follow early 
mesoderm development (2006-2010). Targets of Brachyury revealed the close 
association between blood vessel development, haematopoiesis and early mesoderm 
formation via a common haemangioblast precursor for blood and endothelial cell 
lineages.  
Data gathered by myself, and colleagues, from gene expression and 
transcription factor analysis is now being used to create lineage codes or routemaps 
for differentiation of stem cells to mature cells in-vitro and it is now possible to 
produce mature megakaryocytes and erythrocytes in vitro. The current challenge is to 
produce fully functional human platelets and enucleated red blood cells. Combined 
with the use of autologous induced pluripotent stem cells (iPSCs) this makes patient-
specific tailoring of cell-based therapies a real possibility.  
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VI Preface 
After completing my initial training during the late 80’s and early 90’s at the 
Department of Zoology, University of Cambridge with the Cancer Research 
Campaign, Mammalian Cell DNA Repair Group, with Dr. Andy Ryana, I was already 
developing an interest in the blood and vascular system as one of the main routes of 
cancer metastasis. At the same time I acquired a thorough grounding in cellular and 
molecular biology skills. 
 In 1996 I moved to the Molecular Reproductive Medicine Group, then based 
solely at the Rosie Maternity Hospital Department of Obstetrics and Gyneacologyb. 
The attraction was to set up a project using Serial Analysis of Gene Expression 
(SAGE) to investigate gene expression during placental development and in the 
cycling human endometrium. The group subsequently expanded to a second location 
at the Department of Pathology, Tennis Court Road, Cambridge, where most of the 
work on a tailored angiogenesis array took place, as well as the largescale production 
of an anti-VEGF antibody. The opportunity arose for a post with a new principal 
investigator, Dr Cris Printc, in an offshoot from the group, which meant becoming a 
research assistant with responsibility for a project to develop 3D cultures of 
embryonic stem cells as a tool for the study of blood and vascular development. 
Despite having only a year of BHF funding remaining we were able to show that 
mouse embryoid bodies provide a means to investigate the effects of anti-angiogenic 
agents in a three dimensional environment. Vascular Endothelial Growth Factor 
(VEGF), a key player in both vasculogenesis and angiogenesis featured in much of 
the work. 
 Another move in 2005 to the Wellcome Trust/Cancer Research UK Gurdon 
Institute, and eventually to the MRC National Institute for Medical Research, Mill 
Hill, provided the opportunity to work with Dr. Jim Smithd whose expertise and 
interest is the molecular basis of mesoderm formation using two frog species, 
Xenopus laevis and Xenopus tropicalis, and the zebrafish, Danio rerio as model 
organisms. Jim was interested in building on recent work in the zebrafish by 
transferring to a mammalian system. Since vertebrate blood and vascular systems 
emerge with mesoderm induction this was an ideal opportunity to investigate the early 
stages of their formation. The transcription factor Brachyury, was central to this work. 
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 In 2010, I returned to the investigation of human blood and vascular cells at 
the Division of Transfusion Medicine, Department of Hematology, University of 
Cambridge, NHSBT Cambridge, where utilization of the same mesodermal pathways 
involving Brachyury and VEGF provided the means by which we can now direct and 
manipulate the differentiation of haematopoietic progenitors into mature blood cells. 
This has made it possible to produce human platelet-like particles from human 
induced pluripotent stem cells (hiPSCs), bringing the technology a step closer to the 
in-vitro production of blood products for transfusion. 
 
a Dr Anderson Ryan is now Senior Group Leader, Gray Institute for Radiation 
Oncology and Biology, University of Oxford, UK 
anderson.ryan@oncology.ox.ac.uk 
 
b Then led by Professor S.K.Smith DSc, FMedSci, now vice president Research 
Nanyang Technological University, Singapore 
d-po@ntu.edu.sg 
 
c Dr Cristin Print is now Associate Professor, Clinical Molecular Medicine & 
Pathology School of Medical Sciences, The University of Auckland , New Zealand 
c.print@auckland.ac.nz 
 
d Dr James C Smith is now the director of the MRC National Institute for Medical 
Research The Ridgeway, Mill Hill, London, UK 
jim.smith@nimr.mrc.ac.uk 
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Towards next generation regenerative medicine 
The integrity of blood vessel and blood cell formation is essential to human life, 
forming the driver for exploring the origins and regulation of blood cells and blood 
vessels. These cells have common developmental origins in nascent mesoderm and 
overlapping genetic programs. Endothelial and haematopoietic cells differentiate in 
close proximity, with endothelial cells playing an active role in haematopoiesis. 
Therefore, knowledge gained from studying the role of angiogenesis in blood vessel 
development compliments studies reconstructing the route-map to haematopoietic 
differentiation using embryonic stem cells. The studies presented employ the constant 
advancement in molecular profiling technologies, allowing an increasingly complete 
genetic classification of tissue, including transcriptional and epigenetic control.  
As a direct consequence of the close overlap in the gene networks controlling 
differentiation the same basic protocols can be designed for directing cells in vitro to 
haematopoietic lineages or endothelial cells. By modifying the genetic and 
environmental cues cells are exposed to, we are increasingly able to control the route of 
terminal differentiation. Adult haematopoiesis occurs in the bone marrow 
haematopoietic stem cell niche, a complex three-dimensional tissue containing multiple 
cell types. Current regenerative medicine projects using human induced pluripotent stem 
cells to produce megakaryocytes, large platelet producing cells, requires recapitulation 
of the haematopoietic differentiation hierarchy that occurs in the niche. Understanding 
the developmental origins of these cells together with the biology of closely associated 
cells in the niche provide the tools to achieve the ultimate goal of in vitro produced 
human blood cell products. 
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Introduction    
Coincidental with size and complexity, humans have evolved a highly developed 
blood and vascular system to transport oxygen and nutrients to all body cells. The 
vascular system is formed and maintained by a balance of several mechanisms including 
vasculogenesis, angiogenesis and apoptosis. During embryogenesis primitive endothelial 
cells become organised into vessels by vasculogenesis. The vascular system is then 
maintained by angiogenesis, the sprouting of new vessels from pre-existing ones, and 
further fined tuned by selective programmed cell death (apoptosis). The vascular 
endothelial growth factors (VEGFs) are the most prominent family of growth factors 
influencing the growth and the architecture of these vessels in normal and abnormal 
angiogenesis (Hoeben et al., 2004).  The dynamic nature of these systems is of particular 
relevance to female reproductive medicine where angiogenesis and apoptosis are part of 
the cyclic growth and destruction of the endometrial lining, the stratum functionalis 
(Chapter 1.2).  
One of the aims of the experiments described in the first part of this thesis was to 
establish molecular and morphological changes that result in blastocyst attachment and 
ask to what extent angiogenesis and apoptosis are a part of the process. Specifically, we 
wanted to test the hypothesis that implantation could be influenced by anti-angiogenic 
intervention. Deregulated angiogenesis is a key event in tumour metastasis and we 
further asked whether the VEGF family and angiogenesis were part of the etiology of 
endometrial cancer.  
To address some of these aims we developed cell-based models (Chapter 1) 
using endothelial cells and endometrial explants. However, human endometrium was 
always a limited resource and once removed from the uterus is only suitable for short-
term culture (Chapters 3 and 4). Experiments using this model led us to consider 
exploiting the similarities between neovascularisation in cancer and embryonic vessel 
development. This led to the development of a spinner culture system to create large 
numbers of mouse embryonic stem cell-derived embryoid bodies (EBs). Using carefully 
screened serum batches, EBs provided a supply of developing vessel networks sensitive 
to intervention (Chapters 1, 5), in particular for experiments using anti-angiogenic 
agents, not relating to steroidal control of angiogenesis. Anti-angiogenic therapy is 
relevant to many diseases characterized by excessive or abnormal angiogenesis, for 
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example diabetic retinopathy (Carmeliet, 2003). These experiments also suggested EBs 
as a suitable model for early mesoderm development complementing the Zebrafish Danio 
rerio and Xenopus models already used in Jim Smith’s laboratory, and I went on to use 
this model at the Gurdon Institute in Cambridge (Chapter 6). 
Alongside the cell based models advances in molecular profiling technology 
were incorporated and adapted to complement the studies (see timelines VIII). Thus, 
expression arrays (Chapter 2) were developed to discover pathways involved in 
endometrial cancer, and implantation. Chromatin immunoprecipitation (chIP) was used 
(Chapters 6 and 7) to elucidate transcriptional targets of Brachyury, a T-box 
transcription factor required for mesoderm induction, gastrulation and subsequent blood 
and vascular development.  
ChIP-chIP produced a list of targets associated with morphogenesis, vascular and 
endothelial biology and cancer. Selected putative targets were empirically verified in 
wild type and Brachyury mutant mice by in-situ hybridisation. Experiments using 
human embryonic stem cells then suggested the role of Brachyury in development 
appears to be conserved between mouse and human cells. 	  
The debate concerning the origins of the blood and vascular system in early 
embryonic life is a longstanding one. Evidence points to a common haemangioblast 
precursor for blood and endothelial cell lineages with a sensitive molecular switch 
controlling the balance between the two fates (Choi et al., 1998; Eilken et al., 2009; Yue 
et al., 2012). Invertebrate and vertebrate studies both in vitro and in vivo have 
established the cellular sequence from a common progenitor cell (Messner and Jamal, 
1993; Stainier et al., 1995; Gering et al., 1998; Meister and Lagueux, 2003; Huber et al., 
2004) and evidence from our work in EBs suggests Brachyury may play a role in both 
primitive and definitive haematopoiesis. 
The significance of the close relationship between the origins of the blood and 
vascular systems lies in their overlapping genetic programs. They share common 
markers; for example VEGFR2 receptor or kinase domain region/ foetal liver kinase 
(VEGFR2/KDR/FLK1) is found on precursor haemangioblasts (Kubo and Alitalo, 2003)	  
and endothelial progenitors (George et al., 2011). In addition they are influenced by 
common signals such as VEGF, bone morphogenetic protein 4 (BMP4) and Brachyury, 
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and also influence each other. As a result, the use of differentiation protocols using the 
same basal media and starting conditions is possible. Protocols can be further 
manipulated with specific cytokines or transcription factors to produce cells of our 
choice. Different groups are working on endothelial cell production (Morgan et al., 
2013; Samuel et al., 2013) and erythroblast production (Giarratana et al., 2005; Dias et 
al., 2011), while, together with my colleagues at the NHSBT, I am now concentrating on 
the myeloid lineage; specifically megakaryopoiesis and the production of platelets, using 
patient specific induced pluripotent stem cells (iPSCs) (Chapter 8). We now know for 
example that a wave of Brachyury expression, which accompanies mesoderm formation, 
is a requirement in both mESC and hESC for haematopoietic development. Progenitor 
cells at this stage are multipotent and can be directed or reprogramed towards different 
blood lineages, leading to the possibility of patient specific cell therapies in the future.  
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Chapter 1 The development of cell-based models for vasculogenesis, 
angiogenesis and haematopoiesis 
Experiments performed at the Rosie Maternity Hospital, Department of 
Obstetrics and Gynaecology, when I joined in 1996, were based on the use of cell lines, 
and tissue samples for in-situ detection of transcripts, immunohistochemistry and 
ribonucleic acid (RNA) extraction to study individual genes. The primary aim was to 
investigate causes and possible treatments for reproductive disorders. One of the 
objectives was to investigate the role of angiogenesis in both endometrial cancer and 
implantation and the significance of the VEGF family in these processes. Since 
angiogenesis plays a role in the development of a receptive endometrium (Gordon et al., 
1995; Torry and Torry, 1997; Abulafia and Sherer, 1999; Smith, 2001),	  we believed it 
could also play a critical role in implantation. In endometrial cancer we hypothesized, 
that invasion of healthy tissue during malignancy maybe analogous to angiogenic 
invasion of the decidua during placental development (Jackson et al., 1994).  
Many in vitro and in vivo models of angiogenesis have been extensively used 
and reviewed (Vailhe et al., 2001; Auerbach et al., 2003; Hasan et al., 2004; Staton et 
al., 2009), however, our interest also extended to steroid control of VEGF. Regulation of 
VEGF occurs at many levels. In the female reproductive tract oestrogen (Mueller et al., 
2000) is an important VEGF regulator resulting in endothelial angiogenesis and 
endometrial growth in the follicular phase. Therefore we were interested in developing a 
model that incorporated steroid control. 
1.1 The female reproductive tract: a unique resource 
The human female reproductive tract offers a unique resource to study 
angiogenesis in the adult vascular system. It is the site of physiological and pathological 
vasculogenesis, angiogenesis and endothelial apoptosis as the vessel networks undergo 
cyclic remodelling. Aside from pathology and trauma there are limited opportunities to 
do this, while in the female reproductive tract angiogenesis occurs normally as part of 
ovulation, menstruation, implantation and placental development (Demir et al., 1989).  
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1.1.2 The endothelial cell (EC) 
All the blood vessels in the body are lined with endothelial cells (ECs) and 
endothelial cell biology is central to normal and pathological angiogenesis (Figure 1.2). 
Human umbilical vein endothelial cells (HUVEC) (Figure 1.1) isolated from the 
umbilical vein using gentle digestion with collagenase (Jaffe et al., 1973), were used for 
many of our experiments.	   
 
 
 
 
 
 
 
 
 
HUVEC express the VEGF family of receptors (Appendix figure 1), but lack 
some of the physiological cell contacts, such as basement membranes and supporting 
Figure 1.1 Light microscope image of cultured Human Umbilical Vein 
Endothelial Cells (HUVEC) passage 6 maintained in Endothelial cell basal media-2 
(EBM™-2) Clonetics™ (Lonza, Verviers, Belgium) supplemented with 2% FBS, 
hEGF, Hydrocortisone, GA-1000 (Gentamicin, Amphotericin-B), VEGF, rhFGF-B, 
R3-IGF-1, Ascorbic Acid, and Heparin. Scale bar =100µm. HUVEC grow as 
adherent cells on tissue culture plastic and have a typical cobblestone-like 
appearance but do not form tubes unless seeded in Matrigel (BD Biosciences), a 
mixture of extracellular and basement membrane proteins,  
Abbrvs: foetal bovine serum (FBS), human epidermal growth factor (hEGF), 
vascular endothelial growth factor (VEGF), recombinant human fibroblast growth 
factor B (rhFGF-B), recombinant insulin growth factor 1 (R3-IGF-1) 
Photographed using a Leica DM IL LED microscope (Leica microsystems, UK). 	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vascular smooth muscle cells (VSMC), or pericytes (Armulik et al., 2005), usually 
associated with mature endothelial cells (Figure 1.2). 
 
Figure 1.2 Endothelial cells and supporting pericytes 
ECs (red) express a number of receptors, the most significant of which are 
VEGFR1/FLT1 fms- like tyrosine kinase (Quinn et al., 1993), VEGFR2/KDR/FLK1 
kinase domain region/fetal liver kinase (Waltenberger et al., 1994) and the TEK tyrosine 
kinase (Tie2/Tek) receptor, important in haematopoietic and vascular development 
(Korhonen et al., 1994). Mature ECs are surrounded by supporting vascular smooth 
muscle cells (VSMC) or pericytes (blue), linked by transmembrane adhesion proteins. 
Endothelial storage organelles, Weibel-Palade bodies (Weibel and Palade, 1964), 
secrete cytokines including angiopoietin 2 (ANGPT2, Ang2); platelet derived growth 
factor β (PDGFβ); vascular endothelial growth factor (VEGF) which act in autocrine 
and panacrine signalling (red dashed arrows). Robo 4, an endothelial specific guidance 
receptor stabilises endothelial networks (Acevedo et al., 2008; Jones et al., 2008) and is 
involved in homing of haematopoietic stem cells (HSCs) to the bone marrow niche  
(Chapter 8.1). 
 Key: Platelet-derived growth factor receptor (PDGFR); magic roundabout, axon 
guidance receptor, homolog 4 (Robo 4); Slit homolog 2, the secreted ligand for Robo 4 
(Slit2). 
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1.2 The endometrium 
The endometrium, the inner layer lining the uterus, undergoes extensive 
remodelling under the influence of steroid hormones (Figure 1.4). A complex and highly 
dynamic tissue, it contains many closely associated cell types (Figure 1.3).  
  
 
 
 
 
 
Model cell lines such as ECC-1, a human epithelial endometrial cancer cell line 
(Clarke et al., 1987) and Ishikawa, a glandular epithelial cell line from human 
endometrial adenocarcinoma (Nishida et al., 1985), although influenced by steroid 
regulation, are all epithelial cells, and HUVEC do not respond to steroid hormones.  
Figure 1.3 The key components of the human endometrium 
The functional layer, contains stromal cells (blue), glandular epithelial cells 
(green), endothelial cells in spiral arteries and sub-epithelial capillary plexus 
(pink) and immune cells particularly macrophages and natural killer cells 
(grey). The basal layer or myometrium is not shed and the functional layer 
develops from it. 	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1.2.1 Endometrial explants 
With the aim of investigating active angiogenesis during the secretory phase of 
the endometrial cycle (Figure 1.4) and how this may influence implantation of the 
blastocyst we decided to use freshly acquired endometrial biopsies. Short term explants 
Figure 1.4 Steroid hormone regulation of the endometrium during the Menstrual Cycle 
Cyclic regeneration of the spiral arteries of the endothelium in the highly vascularised stratum 
functionalis associated with menstruation and implantation. 
Oestrogen (blue line) induces proliferation (follicular phase) and progesterone (red line), 
produced by the corpus luteum following follicle release, then results in glandular 
differentiation of the stroma (luteal phase). In the brain the pituitary gland secretes luteinizing 
hormone (LH, yellow) and follicle stimulating hormone (FSH, green). FSH stimulates the 
ovary to ripen an ovule and with the help of a spike in LH, to produce an egg. An average 28 
day cycle is shown. On implantation, 5-9 days after ovulation, progesterone further regulates 
the establishment and maintenance of pregnancy by decidualization. Human chorionic 
gonadotropin (hCG) secreted by the growing embryonic placental villi signals the corpus 
luteum to continue producing progesterone (P). Information based on a number of sources. 	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taken from the endometrial surface survive well in tissue culture provided care is taken 
to ensure the samples are aseptically biopsied and immediately put into sterile phosphate 
buffered saline solution (PBS).  
 
 
Endometrial biopies were obtained using a pipelle endometrial biopsy instrument 
at the time of laparoscopy or hysteroscopic examination (Figure 1.5). Biopsies were 
washed 2-3 times in sterile Dulbecco’s modified Eagle media (DMEM)/Ham’s F-12 
(Life Technologies, UK), to remove blood from the sampling process, before cutting 
into pieces. If the endometrial explants were not cut into 1-2mm3 uniform pieces they 
cDNA 
arrays
ELISA
tissue collected aspectically 
in theatre
cut into small pieces to 
culture
tenaculum 
to hold the 
cervix open
tissue homogenised 
for RNA isolation 
supernatant 
collected 
uterus
endometrium
cervix
speculum to 
hold the vagina 
open
pipelle biopsy 
needle
withdrawing 
plunger creates a 
vacuum
vagina
 longitudinal section of the human uterus 
Figure 1.5 Endometrial explants 
 Image (left) illustrates endometrial sampling in theatre. The surgeon inserts a 
speculum to open the vagina, and tenaculum forceps to open the cervix and allow the 
insertion of the pipelle biopsy needle. The pipelle is a piston device to sample the 
lining of the uterus. Samples are then used in explant culture (right). Enzyme-linked 
immunosorbent assays (ELISA), and complementary DNA (cDNA) arrays were then 
performed). 
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became hypoxic at the centre accompanied by VEGF up regulation, before necrosis 
occurred. 
Samples were sent for histological dating of the endometrium. Mid-secretory 
biopsies were required for implantation experiments. The explants maintain all the 
correct types and ratios of cells found in the lining of the uterus and to a degree the 
original in-vivo connections between the cells and extracellular matrix (ECM). 
1.3 The placenta and umbilical cord 
Aside from the study of placental pathologies such as pre-term birth and pre-
eclampsia, the placenta and umbilical cord were another important resource both for 
endothelial cells and an invaluable supply of RNA for cloning transcripts associated 
with angiogenesis (Chapter 2). 
 
 
 
 
 
 
Villous endothelial tubes and foetal vessels form the umbilical cord (Demir et al., 
1989) and from this HUVEC were isolated as soon as possible following delivery 
(Chapter 1.1.2). 
Figure 1.6 A fresh human term placenta  
Image from maternal side after delivery of foetus, white arrow indicates the 
umbilical cord and the dashed white line the amnion: this membrane would have 
surrounded the foetus. Note the extensive amount of blood from this highly 
vascularised organ. 	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The umbilical cord (Figures 1.6 and 1.7) and placental blood are also the source 
of CD34-positive haematopoietic progenitors from which all blood cells can be derived 
(Figures 1.8, 1.9). Approximately 0.1-0.5% of cord blood cells are CD34-positive, a 
marker for haematopoietic precursors. Bone marrow contains a relatively high 
percentage of CD34+ cells (0.5-3%) but requires a highly invasive procedure for 
collection. Peripheral blood requires whole units of blood to obtain useful numbers 
having the lowest percent (0.05-0.2). 
Figure 1.7 The Human Placenta Reproduction of a lithograph plate from the 20th 
U.S. edition of Gray's Anatomy of the Human Body, published in 1918 Trophoblast - 
cells surrounding the early embryo important in implantation and interaction with the 
maternal decidualised uterus, Chorion - outer extraembryonic membrane of the 
trophoblast lined with mesoderm, Amnion- membrane surrounding the fetus, Villus-
vascular extensions of membrane increasing surface area of maternal-foetal contact, 
Placental septum- delineates the cotyledons but maternal blood circulates freely. 
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From experience, an average placenta supplies approximately 90ml of cord 
blood, which will contain at least a million CD34+ progenitors. By manipulation of the 
cytokine cocktail and specific culture conditions these progenitors are a valuable source 
of differentiated cell lineages (Figure 1.8, 8.5). 
Figure 1.8 The haematopoietic hierarchy.  
All blood cells differentiate from a common progenitor, the haematopoietic stem cell 
(HSC). As cells progress to terminally differentiated cells the potential to become cells of 
alternate lineages diminishes. Closely related cells, such as megakaryocytes (MK) and 
erythroblasts (myeloid lineages), or B- and T-cells (lymphoid lineages) share common 
progenitors restricted to the production of these cells only. Adapted from (Deutsch and 
Tomer, 2006;	  Laiosa et al., 2006). 
Abbrvs: common myeloid progenitor (CMP); common lymphoid progenitor (CLP); 
megakaryocyte/erythoblast precursor (MEP); colony forming unit-granulocyte/monocyte 
(CFU-GM); natural killer (NK).  	  
	                                                                                                                              Chapter 1 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 14	  
 
 
 
C
gated population
A B
fluorescent shift indicates positively 
labeled cells
99.63%
unstained cells confined to the first 
log of fluorescent intensity
Cells in histograms represent the gated 
population R1 in A eliminating cell debris 
Figure 1.9 Flow cytometry data for isolated cord blood CD34+ progenitor cells 
Precursor cells are isolated by positive selection with CD34 magnetically labelled 
MicroBeads (MACS®) (Miltenyi Biotec, GmbH). Peripheral blood mononuclear cells 
(PBMNCs) are isolated from anticoagulated cord blood by density gradient centrifugation 
using Ficoll-Paque™ (GE Healthcare). The cell suspension is then loaded onto a column 
and placed in a magnetic field. On removal positively selected cells are eluted. 
A Dot plot shows linear side scatter (SS lin) against linear forward scatter (FS lin). SS is 
linked to the granularity/complexity of the particles and FS to cell size. Region R1 is a 
gated CD34+ population isolated using positive selection.  
B Histogram shows number of events or gated cells (y axis) against the log of signal 
intensity (x axis) for an unstained control sample of sorted cells. 
C Cells stained with anti-CD34 labeled phycoerythrin-conjugated (PE) antibody 
(Beckman Coulter), a marker for haematopoietic precursors, capillary endothelium and the 
ligand for CD62 (L-selectin). 
A CyAnTM Advanced Digital Processing (ADP) Analyser (Beckman Coulter) was used 
together with Summit 4.3 software. Performed by A. Evans 
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1.4 Embryoid bodies as a model for endothelial network development 
Endometrial explants are only suitable for short-term culture and are not suitable 
to follow new vessel formation. A mouse embryonic stem cell model was therefore 
developed to produce networks of endothelial cells, with the aim of testing the efficacy 
of anti-angiogenic reagents and to quantify these effects by computer based stereological 
methods. 
 Embryoid bodies (EBs) are aggregates of embryonic stem cells (ESCs), released 
from pluripotent culture constraints, which then start the process of differentiation with 
the potential to form all three germ layers (Bradley et al., 1984).	   
1.4.1 A three dimensional model for early mouse development 
 The inner cell mass can generate all the cells of the embryo (Kanatsu and 
Nishikawa, 1996), and from these cells mouse embryonic stem cells (mESCs) are 
derived (Evans and Kaufman, 1981). ESCs can be maintained for long periods (Evans 
and Kaufman, 1981; Brook and Gardner, 1997; Nichols et al., 1998)	   in the 
undifferentiated state using appropriate conditions (Ying et al., 2003)	   enabling 
expansion of the starting population and a continuous experimental supply.  
For these experiments (Evans et al., 2007)*9 R1 mouse ES cells were (Nagy et 
al., 1993) maintained in the pluripotent state by culturing on mouse	   embryonic STO 
feeder cells (Martin and Evans, 1975), which were genetically modified to produce  
leukaemia inhibitory factor (LIF) protein. Single ESCs re-aggregate during the first 24-
48 hours of feeder-free culture, starting as small spheres of 50-100µM with an irregular 
surface which becomes smooth by day 3 (see Figure 1.10), resembling morula 
compaction of the blastocyst in vivo. The potential of EBs as embryonic surrogates is 
explored further in chapter 6. 
Culturing EBs in spinner culture (Figure 1.10) produced a homogeneous 
population of cells in which sustained gradients of cytokines cannot develop due to slow 
stirring. The media, containing extensively batch tested serum but no additional 
cytokines, needs regular replenishment and therefore the timing of differentiation stages 
is unlikely to reflect those seen in vivo. Samples are easily withdrawn via side arms in 
the spinner flasks and either frozen and sectioned, embedded in wax to section or 
mounted whole for confocal microscopy. 
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Having developed this reliable way of consistent differentiation of EBs, we were 
confident it could be adapted for use in monitoring anti-angiogenic agents and for 
transgenic intervention as described later in chapter 5.  
 
Oocyte + sperm
embryo
embryo
ICM
+LIF
-LIF
Ectopic embryo
 implantation
Teratocarcinoma
Embryoid 
body
ESC
self renewal
pluripotency and gene 
specific genetic
manipulation
Functional Repopulation
+BMP4 or 
serum
epiblast cells
Figure 1.10 Mouse ESCs are derived from the inner cell mass of the embryo 
and are capable of forming all germ layers. Key: inner cell mass (ICM), 
embryonic stem cell (ESC), leukaemia inhibitory factor (LIF). Mesoderm 
induction requires the addition of bone morphogenetic protein 4 (BMP4) or the 
presence of serum. Insert images are of a single day 3 embryoid body and spinner 
culture flask used for all these experiments. The flasks are siliconised and are 
magnetically controlled using glass impellers via an adjustable speed and rotation 
angle control unit.  
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Chapter 2 Transcriptome analysis using cDNA expression arrays 
 
The advent of DNA array technology and the availability of cDNA collections 
led to a progression towards profiling of complete pathways and eventually whole 
genomes (Lashkari et al., 1997). Commercially produced arrays were expensive, and 
academically produced generic arrays were of limited availability at the time therefore, 
the aim was to produce a tailored cDNA based on vasculogenesis, angiogenesis, 
apoptosis and vascular remodelling.  Aiming for a reliable, reproducible and affordable 
tool, each step was quality controlled to produce a standardized protocol designed for 
multiple users. Not only did this speed up our research, but we could also address 
specific issues such as pathways influencing the establishment of a receptive 
endometrium leading to possible intervention. 
2.1 An aside - Serial Analysis of Gene Expression (SAGE) 
Before settling on cDNA arrays as the best option for the group, serial analysis 
of gene expression (SAGE) (Velculescu et al., 1995) was explored as an alternative 
(Appendix figure 2 for technical details). The attraction was that SAGE is not limited to 
the arrayed transcripts and would enable a complete inventory of differentially 
expressed transcripts in placenta and endometrium. However, SAGE required some 
molecular experience, a large sequencing capacity and downstream computing capacity 
to extract tags and convert them to transcripts. As a result, SAGE was replaced by 
cDNA arrays, but components of this elegant technique are now recognisable in parts of 
the library construction for RNA-sequencing (RNA-seq) using current massively 
parallel or next generation sequencing. 
2.2 The development of a tailored expression microarray to investigate 
vascular biology 
There are two main types of gene arrays, large generic ones and much smaller 
tailored arrays. With that in mind we set out to create the latter, comprising a gene list of 
approximately a thousand genes covering all aspects of research at the Rosie. Prior 
knowledge of angiogenesis, apoptosis, implantation and vascular remodelling produced 
a list that included a number of in-house clones and others obtained from the IMAGE 
(Integrated Molecular Analysis of Genomes and their Expression) Consortium (then 
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based at UK MRC Hinxton Genome Mapping project Resource Centre, Hinxton, 
Cambridge, UK). The array included many cytokines and growth factors involved in the 
co-ordinated growth and regression of blood vessels including the VEGF family and its 
receptors. A number of known oncogenes and transcription factors such as c-myc, and 
set of blood cell surface antigens were also included (see RMRG genelist following 
(Evans et al., 2003)*1 appendices). 
Using radiolabeled probes enabled studies with very limited material (5µg total 
RNA) such as post-menopausal endometrium. Although 33P was more expensive with 
lower energy particles than the more commonly used 32P, at this time there were good 
reasons for its choice. The arrays were exposed to low energy phosphor screens as these 
have a wider dynamic range than X ray film. The spots produced were cleaner and better 
recognised by automatic grid-placing software during analysis, and the smaller angle of 
radiation scatter meant better overall spot resolution. In addition, the half-life of 33P is 
25.4 days compared to 14 days for 32P.  
2.3 Choice of genes, clones and their authentication 
The final set of cDNAs printed on the arrays included all the clones already 
being used in our research and those from the list that were verified as correct after 
sequencing. In a number of cases this meant inclusion of genes not originally chosen, an 
example of this is the apoptosis associated gene transglutaminase 2 (TGM-2) (Table 1). 
TGM-2 is a calcium dependent enzyme found to be upregulated in apoptotic cells and 
for this reason was included in the final plate layout (Fesus et al., 1989; Taresa et al., 
1992; McConkey and Orrenius, 1997). Bacterial stocks of IMAGE clones were then 
available from Hinxton free of charge. Duplicating complete multiwell plates or 
individual clones selected from their vast collection was inevitably an error prone 
process. Plates were sometimes replaced in the wrong orientation compared to the 
database; bacterial clones were contaminated or failed to grow in culture; and many 
were also miss-assigned in the database. For some genes, six different clones were 
sequenced before a correct one was found. Sequencing data was then fed back to 
continually improve the resource. The collection is currently held by Source BioScience 
LifeSciences and a single sequence-verified clone now costs £120 
(http://www.lifesciences.sourcebioscience.com). 
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Table 1 Summary table of gene groups included in cDNA array tailored to 
investigate all aspects of vascular biology 
Note as with the complete list categories are not exclusive 
For full list in alphabetical order see appendix following (Evans et al., 2003)*1  
 
Process /pathway Example  Gene Name 
Apoptosis 
Bcl-2 family  anti-apoptotic 
pro-apoptotic 
Bcl-2, B-cell CLL/lymphoma  
Bax, Bcl-2 associated protein 2 
Bcl-2 interacters APAF1 Apoptosis protease activating factor 1 
Death receptor ligands TNFα Tumour necrosis factor alpha 
Death receptors TRAIL/ APO2L TNF-related apoptosis-inducing ligand 
Death receptor 
associated  
TRAF1 TNF receptor associated factor 1 
Cytoplasmic signaling molecules 
Signaling/transcription JNK1 Mitogen activated protein kinase 8 
Caspase family  
programmed cell death 
Caspases e.g. 
caspase1/IL1BCE 
Interleukin1 beta converting enzyme,  
caspase 1 
 
Jak/STAT pathway STAT1 
 
Signal transducer and activator of 
transcription-1 
wnt pathway Wnt 11 
 
Wingless-type MMTV integration site 11 
NFκβ pathway 1-kB epsilon/ 
NFκβIE 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, epsilon 
MAPK pathway MEK1, MAPKK1 MAP kinase kinase 1 
 
NFκβ pathway NFκβp65 Nuclear factor κβ p65 
Growth factors/ Chemokines /cytokines 
EGF family BTC Betacellulin, ligand for  EGF receptor 
VEGF family  VEGF A 
 
Vascular endothelial growth factor A 
Chemokines  MCP-1, CCL2 
 
Monocyte chemoattractant protein 1 
Cytokine families 
 eg TGF family 
TGFβ Transforming growth factor beta 
Receptors 
Angiogenesis VEGF family e.g. 
KDR 
Kinase Domain receptor, VEGFR2, Flk-1 
Integrins ITGA1 Integrin alpha 1 
cluster of differentiation  CD56 isoform of Neural Cell Adhesion Molecule 
(NCAM), adhesion molecule 
Wnt receptors FZD1 Frizzled (Drosophila) homolog 1 
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Process /pathway Example  Gene Name 
Receptors (continued) 
Nuclear receptors RARA Retinoic acid receptor, alpha 
Tumour associated 
antigens 
MUC1 cell surface associated (MUC1) or 
polymorphic epithelial mucin (PEM) mucin1 
Chemokine receptors MCP-1R, CCR2 
 
Monocyte chemoattractant protein 1 receptor, 
chemokine R2 
Cytokine receptors 
eg TGF family 
TRFBR3 
 
Transforming growth receptor  beta receptor 
III, betaglycan 
Cell division 
Cell division CDC2  cell division cycle 2  
cell cycle checkpoint 
proteins 
RAD1 RAD1 homolog,  
DNA repair exonuclease REC1 
Extracellular matrix molecules 
interstitial collagenases MMP1 Matrix metalloproteinase  
 THBS1 Thrombospondin-1 
apical cell adhesion TRO Trophinin (trophoblast) 
Controls   
Non human exogenous ATC ab 
 
Arabidopsis thaliana chlorophyll a/b binding 
Human endogenous G3PDH, GAPDH 
 
Glyceraldehyde-3-phosphate dehydrogenase 
Unexpected inclusion: Example of an imposter resulting from clone errors 
apoptosis associated TGM2 Transglutaminase 2  
 
The organisation of the array required some biological knowledge as it was 
important not to print very highly expressed genes, such as some of the endogenous 
control transcripts, next to much less well expressing genes and, in addition, to distribute 
them in different subgrids (as in Figure 1, (Evans et al., 2003)*1). 
2.4 Quality control 
 
Control spots were included, endogenous normalisation controls and exogenous 
controls, in this case Arabidopsis thaliana cDNAs, to enable monitoring of variability 
between arrays (Figure 3, p96, (Evans et al., 2003)	   *1). Keeping variation due to 
technique to a minimum is always a concern when arrays are distributed to different 
users and laboratories across the world, and this factor was built into the analysis of each 
experiment. All the genes were spotted as duplicates and the number of strikes of the 
robotic printing tool was constant, as was the humidity of the robot and concentrations 
of the spotted templates.  
Variable experimental parameters including hybridisation temperature, 
hybridisation buffer concentration, hybridisation length as well as the duration of 
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phosphor screen exposure after optimising, were set as constants to enable consistency 
within and between experiments. The membranes were denatured post-printing rather 
than the templates, since denatured templates do not store well. For each experiment, a 
set of filters was allocated and set aside to ensure that only a single printing batch was 
used. A datasheet was produced for each array hybridised (Figure 2.1).  
 
 
 
 
 
Figure 2.1 An example of a completed technical datasheet 
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2.5 Data analysis 
The data analysis pipeline was another potential source of variation. After 
verification of linearity of the hardware-software interface for primary data acquisition 
(Figure 4, p98, (Evans et al., 2003)*1), the filtering steps used for image processing were 
standardised and applied to each array. An analysis grid was created for each batch of 
arrays (Figure 2.2). Hybridisation intensities were calculated for each spot, and local 
background subtracted, control spots and positive controls were filtered out, and intra-
array noise avoided by excluding outliers with discordance between duplicate pairs.  
 
 
 
 
 
 
 
 
12 x 8 metagrid
5 x 5 subgrid
         ink
        empty A A B B
 C C D D E
 G G F F E
 J J I H H
 K K I empty
CSH1 ITGA4    CSH2 APAF1
Figure 2.2 Primary data acquisition from hybridised fluorescent intensities  
A grid is placed across the array. x indicates empty or blank wells. Poor quality 
spots are flagged for exclusion by the software package at this stage. The image 
is coloured red to aid spot-finding during analysis. The complete array forms a 
12x8 metagrid made up of 5x5 spots in a subgrid, with a theoretical maximum of 
2400 spots. A-K indicates the reference plates storing the clones. Duplicate spots 
are adjacent. This example is easily recognised as placenta by the characteristic 
pattern of highly expressed genes circled in white: placental lactogen 1/ 
chorionic somatomammotropin hormone 1 (CSH1), integrin alpha 4/antigen 
CD49 (ITGA4), chorionic placental lactogen 2/ somatomammotropin hormone 2 
(CSH2), apoptotic protease activating factor 1 (APAF1). 
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Experiments to assess both intra- and inter-array variability led to the conclusion 
that to obtain biologically relevant data there was an absolute requirement for technical 
and biological replicates. At least three independent replicates were needed to define 
differential expression between samples and to reduce the chance of false positive 
results.  
There are further sources of variation that influence data, including the efficiency 
of transcription and labelling of probes (see p99, (Evans et al., 2003)*1); therefore 
normalisation in the form of mathematical adjustment needs to be made. Loess 
normalisation, a type of intensity-dependent normalisation, was used (Figure 2.3).  
Following normalisation the datasets were compared by various statistical 
methods. Cyber T (Baldi and Long, 2001) based on the Student’s t-test but including a 
computational method to account for large sample numbers was used, along with 
significance analysis of microarrays (SAM) which uses non-parametric analysis, as 
samples may not be normally distributed (Tusher et al., 2001). Both Cyber T and SAM 
focus on significance of single genes. Multigene approaches to search for patterns of co-
regulated genes are more biologically relevant when dealing with complex tissue 
samples. To do this independent component analysis (ICA) was used in which the 
components are statistically independent (Leimeister et al., 2000; Saidi et al., 2004) and 
provides a global view of trends in expression between samples (see Figure 5, p151 
(Schoenfeld et al., 2004)*5 
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Figure 2.3 Loess Normalisation of intensity dependent errors  
A: Signal intensity filter 705 against 703 after global scaling, this fails to completely 
normalise to the alignment line, although these two filters were hybridised with RNA 
from different lobules of the same placenta.  
B: Rotation and transformation using a Bland-Altman Plot (Bland and Altman.D.G, 
1999). Difference in log signal intensity plotted against the mean log signal intensity to 
demonstrate intensity dependent deviation on the x axis. Loess normalisation is applied 
(the red smoothing line) 
C: Data corrected to filter 703, the most representative by Euclidean distance of a set of 
six arrays (see Figure 2.1). 
D: Data plotted as in A 
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2.6 Pitfalls and limitations 
Unlike SAGE and RNA-seq the analysis is limited to genes already on the array, 
which in practice are genes already reported or suspected to be involved. Microarrays 
also cannot detect tissue-specific isoforms, without prior knowledge, which is the real 
strength of current next generation sequencers. Additionally, half-life variations for 
mRNA and changes in transcriptional regulation are not considered. Given these 
limitations, with strict monitoring of the hardware-software pipeline we were 
nevertheless able to have high confidence in the data produced. 
2.7 Use and distribution 
The most time-consuming step of the whole process was the assembly and 
verification of all the clones, so once this was achieved several large printing batches 
were produced and distributed. At each printing batch, random clones were sequenced to 
check all the quality control systems were working, and to prevent any errors from the 
many steps in the production pipeline. These arrays formed the basis of a number of 
PhD projects (see facing page for publication 1 in appendices). The entire genelist later 
formed part of a larger generic human array produced on glass slides (Rossi et al., 2005).  
By the design and use of a small tailored array system to focus on our research 
needs we were able create hypothesis driven experiments in the field of angiogenesis 
and vascular biology. We also demonstrated reliability using individual isolates of 
HUVEC. During the validation process we concluded there was an absolute requirement 
Figure 2.3 legend (continued) 
A full description for loess normalisation of gene intensities is available at 
http://www.obgyn.cam.ac.uk/genearray  
Below A-D are frequency histograms. Left: The distribution of raw data for filter 705. 
Centre: The distribution for the index array 703, the most representative of the set by 
Euclidean distance. The reference array is the array closest, in terms of Euclidean 
distance to the geometric average array (Workman et al., 2002). Right: The distribution 
of normalised data for filter 705. Since the two arrays in this illustration are both from 
different parts of the same placenta the distribution of signals was already very similar. 
Analysis and arrays performed by A. Evans 
See also Figure 7, p100, (Evans et al., 2003)*1 
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for technical and biological replicates, ideally at least three biological replicates, to 
maximise experimental power. The requirement for only 5µg of template RNA 
permitted the discovery of pathways involved in implantation in normal endometrium 
(Chapter 3), and changes involved in endometrial carcinoma (Chapter 4). For example, 
we were able to confirm earlier work revealing changes in the expression of VEGFA in 
endometrial cancer and at the same time a possible mechanism for this via the 
upregulation of hypoxia-inducible factor 1, alpha (HIF1α) (Chapter 4.2).  
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Chapter 3 Insights into the role of angiogenesis in implantation and 
endometriosis using in vivo and in vitro models 
Aspects of birth control and infertility impact all our lives. Therefore, a clear 
understanding of the molecular and morphological changes that result in blastocyst 
attachment has huge significance. In humans the endometrial lining is only receptive for 
a narrow implantation window 5-9 days post-ovulation (Figure 1.4). The action of 
progesterone on oestrogen-primed endometrium results in morphological and genetic 
changes rendering the endometrium receptive. Successful implantation also requires the 
development of a hatched blastocyst.  Both processes involve vascular remodelling, and 
one question we addressed was whether anti-angiogenic intervention alone could 
prevent implantation, by neutralising antibodies to the principal angiogenic regulator 
VEGF. Another question was whether direct steroidal control of angiogenesis was part 
of the process. In a further study designed to examine indirect control mechanisms using 
soluble factors produced by the endometrium, we included samples from patients with 
endometriosis, in which endometrial fragments are found in ectopic sites. The cell-based 
and molecular techniques described in chapters 1 and 2 were used in these studies. 
3.1 Angiogenesis and implantation 
Attachment and implantation of the blastocyst is critical for the establishment of 
pregnancy in eutherian mammals. With the hypothesis that in humans and primates 
implantation involves vascular remodelling of the endometrium, systemic injection of a 
mouse anti-human VEGF monoclonal antibody was carried out in collaboration with the 
Oregon National Primate Research Center, USA and colleagues at the All India Institute 
of Medical Sciences (AIIMS), New Delhi, India (Sengupta et al., 2007)*11. My role was 
the production and purification of monoclonal anti-human VEGF-A and anti-IgG1 
isotype control (see (Xu et al., 2005)*7 facing page). In both studies the route of 
administration was subcutaneous injection into fertile, ovulating rhesus monkeys 
(Macaca mulatta). 
There are two sites of potential antiangiogenic intervention likely to influence 
implantation. The first site is the receptive endometrium itself where spiral arterioles 
develop around the endometrial glands and below the luminal epithelium. On 
implantation local remodelling and changes in permeability will influence placental 
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development. The second is the maturing ovary itself, or corpus luteum after the release 
of the follicle, required for high progesterone release until the placenta is established. 
In the first study, systemic injection of the VEGF neutralizing antibody was 
either in the early follicular phase or mid-cycle (see Figure 1.4) and had little effect on 
ovarian function, although in the same study, the soluble form of the VEGFR1 receptor 
(sflt1) intra-follicular injection did reduce serum progesterone levels and ovulation. The 
placenta produces sflt1 as a VEGF antagonist and natural regulator (Kendall and 
Thomas, 1993; Clark et al., 1998) and, sflt1 injection would form a sink for VEGF 
blocking local angiogenesis. 
In the AIIMS study (Sengupta et al., 2007)*11, designed to study the effects of 
immunoneutralization slightly later during the peri-implantation stage, when the 
blastocyst is free before recognition and implantation, did show significant (p<0.04) 
inhibition of pregnancy when two doses of antibody were given on day 5 and 10, at 
10mg per dose, post-ovulation. This provided proof of principle that in the rhesus 
monkey, VEGF neutralizing antibody can act as a contraceptive agent. 
3.2 The role of the antiprogesterone RU486 in the prevention of 
implantation and in steroid control of angiogenesis 
Steroid hormone regulation of endometrial cycling and implantation is another 
potential target for intervention. RU486 (mifepristone) is a progesterone analogue 
binding with high affinity to the progesterone receptor as well as glucocorticoid 
receptors. It is most well known as an emergency post-coital contraceptive.  
The mechanism of action of RU486 is unclear as the progesterone receptor can 
still bind DNA, but the net result is an unproductive association with no transcription of 
progesterone target genes such as VEGFA (Leonhardt and Edwards, 2002). It is thought 
that RU486 changes the conformation of the progesterone receptor to favour corepressor 
rather than coactivator recruitment (Leonhardt et al., 2003). Studies at AIIMS showed 
post-coital RU486 prevented pregnancy in the rhesus monkey (Ghosh and Sengupta, 
2005) and a single oral 600mg dose will induce abortion in humans (Sarkar, 2002).  
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To identify pathways involved in receptivity, endometrial explants (Chapter 
1.2.1) from five normal fertile women at mid-secretory phase were cultured in the 
presence of estradiol and progesterone with or without RU486 for 12 hours (Catalano et 
al., 2003)*3. For short periods of incubation all the normal epithelial to stromal cell 
interactions remain intact. cDNA probes from the paired endometrial samples were 
hybridized to the arrays described in Chapter 2 and hybridization signals were 
quantified.  
 
3.2.1 The JAK/STAT3 and the MAPK signaling pathways are 
modulated by RU486 treatment 
 
In the presence of RU486, Janus kinase 1 (JAK1) and Jun-N terminal kinase 
(JNK1), a mitogen-activated protein kinase, were downregulated compared to steroid 
hormone only treated samples. Results were verified by quantitative PCR (qPCR). This 
implicates the JNK/p38 MAP kinase (MAPK) signaling pathway in implantation. Mice 
lacking the p38 kinase had been shown to lack vascularization and have defects in 
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placental angiogenesis (Mudgett et al., 2000) and since this publication                                                               
others have shown that inhibition of either the JNK kinase or p38 kinase pathway results 
in the inhibition of cavity formation in the endometrium at the peri-implantation stage 
(Maekawa et al., 2005).  
JAK1 is expressed in endometrial glands throughout the cycle and also in the 
stromal cells at the mid-secretory phase (Figure 4, (Catalano et al., 2003)*3). The 
JAK/STAT (signal transducer and activator of transcription) pathway is activated by a 
number of cytokines and growth factors, including LIF, important in mouse and human 
implantation (Charnock-Jones et al., 1994; Arici et al., 1995; Smith et al., 1998;	  Sharkey 
et al., 1999). STAT3 is activated in the mouse during implantation and is at its highest at 
the time of blastocyst attachment (Teng et al., 2004).	  Reduction of JAK1 signals by 
RU486 suggests a role for JAK/STAT signaling in successful blastocyst attachment in 
humans reflecting downstream inflammatory responses, cell survival promotion and 
angiogenic changes (Figure 3.2).  
 
3.2.2 Immunity, inflammation and the non-canonical NF-κβ2 pathway 
are regulated by anti-progesterone treatment 
 
Treatment with RU486 also upregulated a number of transcripts including 
cystolic phospholipase A2 (cPLA2), NFKβ inducing kinase (NIK) and the natural killer 
cell receptor CD94. Upregulation of NIK, expressed in the glandular epithelium and 
endothelium implies tight regulation of the non-canonical nuclear factor Kappa 2 (NF-
κB2) pathway is required to control inflammatory responses and allow successful 
implantation (King et al., 2001).  
cPLA2, which promotes inflammation by releasing arachidonic acid in a rate-
limiting step of prostanoid synthesis, also fits the notion of ovulation and implantation as 
a controlled inflammatory-like reaction. Inflammation is an inducer of angiogenesis 
(Carmeliet and Jain, 2000) and deregulation during implantation prevents blastocyst 
attachment. At the time of the study (2002-3) cPLA2 upregulation by RU486 had 
already been reported (Kol et al., 1998).  
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Figure 3.2 Pathways modulated by RU486 treatment of endometrial explants 
Genes in red ovals were modulated by the anti-progesterone RU486 implicating the 
associated cells and pathways in blastocyst implantation. Decreased expression of 
progesterone targets such as DKK1 (blue line) and VEGF (red line) for example, 
influences more than one cell type. Cell types as in Figure 1.3, immune cells include 
macrophages (MΦ) and natural killer (NK) cells. The pathways and their components 
below contribute to the remodelling required for implantation. 	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Natural Killer (NK) cells play a role in the prevention of maternal rejection of 
the foetus and alterations in NK activity are implicated in endometrial receptivity 
(McGrath et al., 2009), local upregulation of CD94 in the secretory phase may 
contribute to unexplained infertility. Natural killer cells make up 70-80% of the 
endometrial leucocyte population, and CD94 with its KIR (Killer cell immunoglobulin-
like receptor) partner NKG2A, is a ligand for HLA-E (major histocompatibility 
complex, class I, E) modulating NK activity, thought to be critical for spiral artery 
remodelling and trophoblast survival (Rabot et al., 2005).  
3.2.3 Wnt pathway modulation by RU486 
 
The Wnt-1 inducible signaling pathway protein 1 (WISP1 or CCN4 CCN family 
member 4) is upregulated by RU486 treatment. Wisp1 is a wingless-Type MMTV 
Key to Figure 3.2: Phosphorylation (P), progesterone (P in red ovals), progesterone 
receptor (PGR). 
The Wnt pathway: wnt-1 inducible signaling pathway protein 1 (wisp); frizzled 
receptor ligand (wnt1); dickkopf1 (DKK1) a negative regulator; disheveled (dvl); 
Glycogen synthase kinase 3 beta (GSK3β); adenomatous polyposis coli (APC); T cell 
factor (TCF).  
The Jak/Stat pathway: Janus kinase 1 (Jak); signal transducer and activator of 
transcription 3 (STAT3). Downstream targets: cyclooxygenase 2 (cox2); B-cell 
lymphoma 2 anti-apoptotic (Bcl-2); fibroblast growth factor 2 (FGF2). 
The non-canonical NFκβ2 pathway: NFKβ inducing kinase (NIK); Ikappa B kinase 
alpha (IKKα); nuclear factor of kappa light polypeptide gene enhancer in B-cells 2; 
p100 and p52 subunits (NFκβ2), v-rel reticuloendotheliosis viral oncogene homolog 
B (RelB), a transcription factor. 
The MAPK/ERK pathway: guanine nucleotide exchange factor (VAV2); mitogen-
activated protein kinase kinase 1 (MEKK1); mitogen-activated protein kinase kinases 
4 and 7 (MKK4/7), extracellular signal-regulated protein kinases 1 and 2 (ERK1/2); 
c-jun N terminal kinase (JNK); P38 mitogen-activated protein kinase (p38). Down 
regulation of guanine nucleotide exchange factor (vav2) enhances the reduction in 
JNK-mediated transcription since vav2 acts upstream of JNK (Abe et al., 2000) 
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Integration Site Family, member 1 (Wnt 1) responsive gene and high Wisp1 has since 
these experiments been associated with poor prognosis in endometrial endometroid 
carcinoma (Tang et al., 2011), as well as breast (Davies et al., 2007;	  Faivre and Lange, 
2007) and lung cancer (Chen et al., 2007). Secretion of Wisp1 further upregulates the 
Wnt pathway in stromal cells via autocrine regulation (see Figure 3.2).  
Increased blood flow is associated with follicle release and endometrial 
thickening during the periovulatory phase and the effects of RU486 suggest steroid 
control of angiogenesis in the endometrium.  
 
3.3 Soluble factors produced by the endometrium promote angiogenesis 
 
Endometriosis, a condition in which ectopic endometrial fragments are found in 
the peritoneum or scarring the fallopian tubes, is accompanied by elevated VEGF in the 
peritoneal fluid (McLaren et al., 1996). A major cause of infertility and abdominal pain, 
endometriosis has a huge impact on quality of life for women with the condition. 
Endometriosis is a disease of the 20th and 21st centuries, whereas previous generations of 
woman had in the region of forty menstrual cycles in a lifetime, largely due to 
pregnancy and lactation, that number is now nearer five hundred. If the attachment of 
tissue fragments to the peritoneum does contribute to endometriosis, the chances of 
aberrant angiogenesis caused by menstrual fragments will increase with the number of 
cycles.  
Soluble factors produced by endometrial tissue are thought to promote 
angiogenesis. In a series of experiments using endometrial supernatants and menstrual 
effluent, these factors were shown to influence the transcriptome of cultured HUVEC 
cells (Print et al., 2004)*6. When combined in coculture with dermal fibroblasts 
endometrial supernatants also influenced the sprouting of new vessels in an in-vitro 
angiogenic assay (Figure 3.3), both proliferative and secretary phase supernatants 
significantly increased vessel formation.  
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ELISA confirmed the presence of VEGFA protein in endometrial supernatants 
and in menstrual effluent. However, there was no detectable difference between 
supernatants of samples from patients with endometriosis compared to those from 
normal tissues. Microarray and clustering analysis of HUVEC cells following exposure 
to proliferative, secretory or endometriotic supernatants Clustering (Figure 4C (Print et 
al., 2004)*6) could not separate the normal samples from those with endometriosis. Clear 
cDNA 
arrays
tissue collected 
aseptically
 in theatre
enzymatic disruption 
of endometrial 
clumps
culture for 24hrs
HUVEC monolayer
transfer 
supernatant
In vitro angiogensis assay 
co-culture HUVEC and 
dermal fibroblasts 
Quantify vessels formed
by length and branching
RNA
culture for 4 daysVEGFA ELISA
Figure 3.3 Soluble angiogenic factors produced by the endometrium alter gene 
expression in cultured HUVEC cells  
To ensure uniform oxygen tension the tissue samples were dissociated enzymatically 
since this experiment required longer incubation times than the explant experiments.  
 Ribonucleic acid preparations (RNA) were transcribed and applied to the tailored 
cDNA array described (Chapter 2). Coculture with dermal fibroblasts showed a 
significant increase in vessel length (left graph *) and vessel junctions (right graph*) 
(Students’ t-test p<0.05) for both secretory phase and proliferative phase endometrial 
supernatants compared to the controls. 10ng/ml VEGFA was used as a positive 
control, graph reproduced from (Print et al., 2004)*6, Figure 1B, C.  
Abbrv. enzyme-linked immunosorbent assay (ELISA). 
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proliferative and secretory clusters were distinguishable. In hindsight, perhaps a better 
experiment for the endometriotic samples may have been to compare eutopic (uterine) 
and ectopic (peritoneal) tissues directly from the same patient. However, these results 
provide a clear indication that, in this study group, soluble factors from the lesions 
themselves, including VEGF, are not the major causal factor in the disease.  
The Sampson theory of retrograde menstruation cannot explain cases of 
endometrial lesions far removed from the peritoneal cavity in the lung or even nasal 
passage (Sampson, 1927). There is some evidence that excess VEGF and other 
angiogenic factors are produced by macrophages in the peritoneum (McLaren et al., 
1996; McLaren, 2000) and that these macrophages are M2 type, or alternatively 
activated macrophages, in endometriosis. There are two extremes of macrophage 
differentiation, classically activated type 1 (M1) or M2 macrophages with similar 
properties to tumour-associated macrophages (TAMS) in endometrial carcinoma, 
although TAMS have a more mixed phenotype depending on the cytokine environment 
(Mantovani et al., 2002). 
We demonstrated that anti-angiogenic intervention can prevent implanation in 
primates (Sengupta et al., 2007)*11 and provided strong support for an angiogenic role in 
pre-ovulatory follicle and post-ovulatory corpus luteum development (Xu et al., 2005)*7.  
In addition, we have shown direct steroidal control of at least two important intracellular 
pathways, the JAK/STAT and JNK pathways in the endometrium (Catalano et al., 
2003)*3 therefore targeting components of these pathways may prevent implanation. 
Prevention by RU486 of the JAK/STAT promotion of angiogenesis and inflammation 
points to a controlled angiogenic and inflammatory remodeling as a requirement of 
successful implantation. Leucocyte involvement in the attachment and survival of the 
blastocyst is also suggested by our findings. Immunity has important implications in pre-
eclampsia, a major complication of pregnancy characterised by shallow cytotrophoblast 
invasion of decidua, and associated with altered HLA profiles (Le Bouteiller et al., 
2003).   
Control is perhaps the key word, since the processes described are also features 
of metastatic tumour growth. Insufficient angiogenesis can alter fertility while altered or 
excess will lead to cancer and many more disorders. The following experiments explore 
this further.   
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Chapter 4 Gene expression analysis implicates angiogenesis and 
inflammation as key processes in endometrial cancer  
 
Angiogenesis is an important component of the metastatic pathway (Folkman, 
1990;	   Zetter, 1998) and, metastasis is the major cause of death for cancers of solid 
tumours, accompanied by cell invasion (Tirino et al., 2013). Endometrial cancer, the 
most common gynaecological malignancy, is associated with poor survival once the 
disease has progressed to extrauterine sites. We investigated the role of the VEGF 
family in endometrial cancer and go on to profile the gene expression changes in these 
tumours with the aim of establishing the molecular basis of the disease and, to search for 
potential therapeutic targets. 
4.1 VEGF upregulation in endometrial cancer 
 
Prior to completing the microarrays described in chapter 2, RT-PCR and in-situ 
hybridisation had shown VEGF upregulation in endometrial cancer (Holland et al., 
2003)*2. Samples were collected during endometrial curettage or in the case of 
carcinoma, total hysterectomy. Both benign and atypical complex hyperplasia (ACH) 
showed no in-situ signal for VEGFA, but all the stages of carcinoma were positive. It 
could be argued that more modern techniques would be more sensitive, but nevertheless 
our work indicated that increased VEGFA expression may be associated with invasive 
tumours of the endometrium as with other cancers such as gliomas (Plate et al., 1992), 
poor outcome in breast cancer (Bando et al., 2005), and many other cancers reviewed by 
Kut (Kut et al., 2007). 
Levels of some of the other VEGF isoforms (Appendix figure 1) showed 
different patterns of staining. An interesting finding was that VEGFD expression was 
specific to TAMS (Mantovani et al., 2002) and co-localised with anti-human CD68, a 
trans-membrane glycoprotein expressed in tissue macrophages (Figure 4.1). This 
implied a role for TAMS in the promotion of tumour angiogenesis and clinical studies 
have since shown a correlation between numbers of TAMS and poor prognosis in a 
number of cancers including endometrial (Hashimoto et al., 2000; White et al., 2002; 
Ohno et al., 2004; Soeda et al., 2008).  
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Angiopoietin 2 (ANGPT2, Ang 2), a ligand for Tie 2 in newly formed vessels, 
was upregulated in endometrial cancer measured by RT-PCR analysis. In the absence of 
pericytes around the immature tumour vessels this facilitates vessel sprouting via Tie 2, 
increased tumour microvessel density (MVD) and tumour invasion. It is also thought to 
increase vessel sensitivity to VEGFA (Oshima et al., 2004) and promote the angiogenic 
switch.  
Apoptosis or programmed cell death is an important feature of endothelial cell 
biology (Kerr et al., 1972). As a morphogenetic tool apoptosis allows capillary networks 
Figure 4.1 Reproduction of Figure 3 A-D p895 (Holland et al., 2003)*2 
In situ hybridisation of a formalin-fixed paraffin-embedded section from a 
poorly differentiated endometrial carcinoma. The isoform VEGFD is 
associated with mature lymphatic endothelial cells. 
A dark field VEGFD antisense probe 33P-UTP radiolabeled riboprobes  
B dark field VEGFD sense probe no specific hybridisation  
C As A but light field conditions  
D Immunostaining with anti human CD68 (clone PG-1, Dako Ltd) in a serial 
section localises silver grains to tumour-associated macrophages (TAMS) (black 
arrows). White scale bar applies to A, B; black scale bar applies to C, D. 
In-situ hybridisation by C. Holland 
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to be remodelled as they develop for correct vessel patterning and organ size. In normal 
tissues it is a function of cell turnover but has important implications in the immature 
vessels of tumours. High Ang 2 would usually cause apoptosis of newly formed tumour 
vessels (Maisonpierre et al., 1997). However in combination with high VEGF, as we see 
here, new vessels survive promoting tumour invasion. 
Despite the limitations of surveying small numbers of transcripts these 
experiments identified VEGF and Ang 2 as potential therapeutic targets.  
4.2 Transcriptome analysis of endometrial cancer reveals further 
signalling pathways in human endometrium 
 Changes in the expression of VEGF isoforms revealed by means of RT-PCR and 
in-situ (Holland et al., 2003)*2 indicated angiogenesis may contribute to the progression 
of endometrial cancer. To identify pathways involved in endometrial carcinoma and 
identify possible therapeutic targets, the cDNA arrays described in Chapter 2 were used 
to compare malignant samples to atypical complex hyperplasia (ACH) samples and 
postmenopausal benign tissues. The total sample size, 31 patients in this case, would 
have been prohibitively expensive at the time if using commercial arrays. By using ICA 
(see Chapter 2.5) a component consisting of a set of genes representing the “cancer 
phenotype” was identified.  
The upregulation of ANGPT2 and VEGFA in endometrial carcinoma and 
downregulation of VEGFB agreed with earlier findings (Holland et al., 2003)*2. Table 2 
lists key genes that were found to be upregulated in endometrial cancer and are therefore 
potential therapeutic targets (Figure 4.2 illustrates these changes). The overexpression of 
cyclooxygenase 2 (cox-2), the rate limiting step in the biosynthesis of prostaglandins 
(PG) from arachidonic acid, has already been described in cancer (Eberhart et al., 1994; 
Fosslien, 2000; Costa et al., 2002) including endometrial carcinoma (Tong et al., 2000; 
Fujiwaki et al., 2002;	   Tamura et al., 2002). Changes in cox-2 and PPARα indicate 
altered lipid metabolism in endometrial carcinoma (Littman et al., 2001).  
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Figure 4.2 Changes in the endometrium in endometrial carcinoma 
Glandular epithelial /stromal cell ratio increases in cancer, TAMS (grey) promote tumour 
growth and matrix remodelling by matrix TGFa  and matrix metalloproteinase production. 
The upregulation of Flt4 (or VEGFR3) increases metastasis by the formation of a positive 
feedback loop with its specific ligand VEGFC (Su et al., 2006). 
Overexpressed transcripts (RED): angiopoietin 2 (Ang2); cyclooxygenase 2 (cox2); E-
cadherin (CDH1); Fatty acids (FA); Fms-related tyrosine kinase 4 (Flt4/VEGFR3); hypoxia 
inducible factor 1 alpha (HIF1α); N-myc (STAT) interactor (NMI); prostaglandin 
(PG); peroxisome proliferative activated receptor alpha (PPARα); peroxisome proliferative 
activated receptor gamma (PPARγ)**; transforming growth factor alpha (TGFα). 
**PPARγ has since been reported as both upregulated (Knapp et al., 2012)	   and 
downregulated (Knapp et al., 2012; Nickkho-Amiry et al., 2012) in endometrial cancer 
indicating a complex relationship between lipid metabolism and endometrial cancer. 
Key: phosphorylation (P); retinoic X receptor (RXR); TEK tyrosine kinase receptor (Tie2); 
tumour protein 53 (p53). The Jak/Stat pathway: Janus kinase 1 (Jak); signal transducer 
and activator of transcription 3 (STAT3). The MAPK/ERK pathway: extracellular signal-
regulated protein kinases 1 and 2 (ERK1/2); p38 mitogen-activated protein kinase (p38). 
The PI3Kinase Akt/PKB pathway: phosphatidylinositol-3 Kinase (PI3K); pyruvate 
dehydrogenase kinase, isozyme 1 (PDK1); protein kinase-B (PKB). 
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4.2.1 Altered oxygen tension in tumours may contribute to the 
angiogenic switch 
Oxygen tension is an important VEGF regulator and VEGF mRNA is rapidly 
induced by exposure to low oxygen tension. Hypoxia-inducible factor 1 alpha (HIF-1α), 
the mediator of VEGF transcriptional responses to hypoxia (Wang and Semenza, 1995) 
was also upregulated. This contributes towards overexpression of both VEGF and 
ANGPT2 and the angiogenic switch (Figure 4.3) (Sharkey et al., 2000;	  Holash et al., 
1999). 
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Figure 4.3 Tumour progression and the angiogenic switch 
HIF1α is upregulated in endometrial cancer contributing to tumour progression, 
once the tumour becomes vascularised the possibility of malignant invasion of 
other sites increases. Anti-angiogenic intervention forms part of many cancer 
therapies targeting VEGF directly via anti-VEGF (Bevacizumab/Avastin®, Roche) 
or tyrosine kinase inhibitors (TKIs) (sunitinib/Sutent®,Pfizer) 
Abbrvs: Hypoxia inducible factor 1 alpha (HIF-1α) 
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GENE ID GENE  Pathway/Process 
Transcription factors/nuclear receptors  
NMI N-myc (STAT) interactor  Interacts c-myc/n-myc/STATS 
Mediates ARF (alternate reading 
frame) tumour suppressor controls p53 
PPARα/NRIC1 Peroxisome proliferative 
activated receptor alpha 
Transcription factor complex leads to 
increased breakdown of triglycerides 
and fatty acids, expressed endometrial 
cancer cells not stromal cells 
PPARγ/NRIC3 Peroxisome proliferative 
activated receptor, gamma 
Acts in a transcription factor complex 
anti-inflammatory, high expression 
endothelial cells 
HIF1α Hypoxia -inducible factor1, alpha 
subunit 
 
Hypoxia activates HIF1α expression 
via apurinic apyrimidinic endonuclease 
redox effector factor-1 (APE1/Ref-1) 
transactivation domain. 
RARβ Retinoic acid receptor, beta Receptor for all-trans 9-cis retinoic 
acid. RAR /RXR (retinoid X receptor) 
heterodimer required for growth arrest. 
Angiogenesis 
VEGF189 vascular endothelial growth 
factor, splice variant 189 
Bound to cell surface or extracellular 
matrix, usually present low amounts 
compared to VEGF121 and 165 also 
induces Flt1/KDR 
ANGPT2 Angiopoietin 2, Ang 2 Increases vascular permeability, 
angiogenesis in particular of newly 
formed vessels 
Flt4 Fms-related tyrosine kinase 4 
(VEGFR3) 
Receptor for VEGFC and D, also up 
regulates VEGFC by positive feedback 
Cell-cell/cell-matrix adhesion 
CDH1 E cadherin, epithelial 
Cadherin 1, uvomorulin 
Its down regulation in most cancers 
usually associated cellular motility 
MMP1 Matrix metalloproteinase 1 
(interstitial collagenase)  
Involved in matrix remodelling, tumour 
invasion 
MMP3 Matrix metalloproteinase 3 
(stromelysin 1, progelatinase) 
Breakdown extracellular matrix, 
associated tumour initiation and 
enhanced cancer cell invasion 
Growth factors  
TGFα Transforming growth factor alpha Produced by TAMs contributes to 
tumour growth 
EGFR, c-erbB Epidermal growth factor receptor EGFR signalling regulates growth, 
survival, proliferation and 
differentiation 
Enzymes 
COX2 cyclooxygenase 2, prostaglandin-
endoperoxide synthase 2 PTGS2 
gene 
Rate limiting step in prostaglandin 
synthesis, expressed TAMS and 
glandular epithelial cells 
Table 2 Genes upregulated in endometrial cancer  
(see Table 1 p996 (Holland et al., 2004)*4), genes from a significantly regulated cancer 
associated independent component (P<0.001).  
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4.2.2 Altered cell-cell adhesion may also contribute to the progression 
of endometrial cancer 
The cell-cell adhesion protein, E cadherin, often reduced in cancer (Chen et al., 
2003), is associated with the promotion of adenocarcinomas (Pecina-Slaus, 2003; 
Rodriguez et al., 2012) originating in glandular tissue like many endometrial cancers. E-
cadherin over-expression in primary breast carcinomas has also been reported in 
metastatic tumors of the ductal type derived from glandular epithelium (Kowalski et al., 
2003).  
Altered expression of matrix metalloproteinases (Park et al., 2001;	  Hua et al., 
2011) indicates breakdown of the extracellular matrix may enhance cancer cell invasion 
(Table 2).	  
 
4.3 Tumour vessels resemble those found during embryonic 
angiogenesis  
 
The use of explants (Chapter 3) and endometrial samples (Chapter 4) 
demonstrated that angiogenesis is a major process in the biology of the endometrium. 
Abnormal angiogenesis forms part of the etiology of reproductive tract disorders 
including endometriosis and endometrial cancer and increasing MVD is a prognostic 
indicator in endometrial cancer (Kaku et al., 1997). Endometrial cancer showed altered 
expression of angiogenic factors: upregulation of both VEGFA and Ang 2 and 
downregulation of VEGFB. The molecular profile of endometrial cancer revealed an 
association with lipid metabolism suggesting PPARα as a potential therapeutic target. 
One of the hallmarks of cancer is sustained angiogenesis, and the TEK tyrosine 
kinase receptor (Tie2), on the endothelial cells is a characteristic marker of newly 
formed immature vessels associated with tumours. Newly formed tumour vessels are 
vulnerable to intervention without the stabilising effect of supporting cells, much like 
embryonic vasculature before mesenchyme-derived progenitors form supporting cells 
(Benjamin et al., 1999; Bergers and Song, 2005) indicating a potential control point for 
metastasis. The development of newly formed vessels is explored further in chapter 5 by 
the use of a three-dimensional model for vessel development. 
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Chapter 5 Embryoid body derived endothelial networks 
 
 Endometrial explants were designed to allow all the normal contact-mediated 
and panacrine signalling to be preserved, with the caveat that function will only be 
preserved for a few hours. Molecular analysis of endometrial cancer indicated new 
vessel growth as a potential therapeutic target and to investigate this we moved to the 
embryoid body (EB) model, maintaining a whole tissue environment in which to 
manipulate vessel formation. Soluble agents and cell-specific transgenes were tested 
with minimal intervention during vessel formation. Key questions were whether it was 
possible to influence vessel progression using this model, to quantify these changes, and 
to investigate the extent to which apoptosis forms part of vessel formation. 
 
5.1 Haematopoietic and vascular development in embryoid bodies 
 
EBs cultured in spinner flasks (Figure 1.10) for ten days have clearly visible 
“blood islands” containing red haemoglobin expressing cells (Figure 5.1) indicating 
mesodermal precursors committed to a haematopoietic fate (Choi et al., 1998). 
                   
          Figure 5.1 Mouse embryoid bodies differentiated in spinner flasks 
Day 6 Day 8
Day 11 Day 13
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The EBs must be fixed and stained or sectioned to show vessel networks around 
the edges of the cystic cavities. Stained vessels are CD31-positive (PECAM-1, platelet 
endothelial cell adhesion molecule-1), a marker for endothelial cells (Vecchi et al., 
1994). 
	   	  	  	  	  	  	  
 
Legend: Figure 5.1 Mouse EBs differentiated in spinner flasks 
Day 6 EB: cystic structures and a central cavity; Day 8 EB: the cavity is now 
septate (red arrow); Day 11 and 13: cystic EBs containing haemoglobin-filled 
blood islands (black arrows). To visualise the three-dimensional networks of 
endothelial cells requires specific staining. Live cell images captured using a 
Nikon Coolpix 995. EB experiments, and imaging by A. Evans 
White bar is 200µm 
Figure 5.2 Images of a day 14 cystic embryoid body. 
Left: Light microscope image of part of a cystic EB captured using a Nikon 
Coolpix 995. Red arrows: indicate regions where endothelial cells form 
vessels Black arrows: indicate groups of haemoglobin containing cells. 
Right: Maximum projection confocal image of a whole mount EB stained 
with anti-CD31 antibody (clone MEC13.3, Beckon Dickinson) visualised 
using Alexa Fluor 488 (green) plus Hoechst 33528 nuclear staining (blue). 
The newly formed vessels are branched, interconnected, and some appear to 
form lumens. Confocal image captured using a Leica TCS laser scanning 
confocal microscope. 
White bar represents 100µm. Imaging, staining and confocal by A. Evans. 
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EBs grown in spinner cultures for 14 days using these culture conditions have 
both haemoglobin- containing cells and endothelial cells forming vessels; however, none 
of the vessels contained blood cells, as described using quail EBs (Krah et al., 1994), 
indicating a lack of the correct patterning seen in vivo. 
 
 
 
 
 
 
 
 
CD31-positive vessels are variable in diameter and degree of branching (Figures 
5.3 and 5.4). Local nutrient and cytokine gradients set up within each EB, in part 
governed by the distance from the endothelial cells to either a cystic cavity or the 
A B
C D
Figure 5.3 Confocal images from a single day 15 whole mount EB 
Maximum projection confocal images from a whole mount EB stained with 
monoclonal CD31 antibody (clone MEC13.3, Beckon Dickinson) visualised 
using Alexa Fluor 488 (green). The reconstructed Z stacks A-D illustrate the 
three-dimensional interconnected vessels and the variability in their size and 
degree of branching. Confocal image captured using a Leica TCS laser 
scanning confocal microscope. 
White bar represents 100µm  
Staining and confocal by A. Evans 	  	  
	                                                                                                                              Chapter 5 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 46	  
surface of the EB, influence vessel growth and branching. Some larger vessels do appear 
to possess a lumen (Figure 5.4). There was no evidence of supporting cells or pericytes, 
all attempts at smooth muscle actin staining were negative unlike in quail EBs (Krah et 
al., 1994). Vessels are therefore likely to be sensitive to VEGF withdrawal (Benjamin et 
al., 1999) or anti-angiogenic intervention.  
 
 
 
 
 
 
 
 
 
Figure 5.4 A large vessel from a day 11 EB which appears to 
possess a lumen 
Maximum projection confocal image from a whole mount EB 
stained with monoclonal CD31 antibody (clone MEC13.3, 
Beckon Dickinson) visualised using Alexa Fluor 488 (green). 	  
Confocal image captured using a Leica TCS laser scanning 
confocal microscope. White arrow vessel diameter 150µm 
EBs fixed whole in zinc fixative (BD Biosciences) 
Staining and confocal by A. Evans 
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5.2 Antiangiogenic agents to modulate vascular development in EBs 
 The spinner culture system is particularly suited to treatment with antiangiogenic 
agents. Soluble agents were introduced via side arms in the flasks. Pilot experiments 
using 100µg/ml Thalidomide (Sauer et al., 2000) had a dramatic effect on EB 
development. Berberine, a naturally occurring isoquinoline alkaloid from a number of 
plant species including Berberis and Coptis, with a wide range of pharmacological 
activities (Figure 5.5) and uses in traditional Chinese medicine, was chosen to test in the 
EB system for its reported anti-inflammatory properties (Fukuda et al., 1999).	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CASPASE 8APOPTOSIS
Many additional “anti” activities
Anti-bacterial       Singh 2010
Anti-fungal        Singh 2010
Anti-protozoal      Singh 2010
Anti-diarrheal      Eaker 1989
Anti-diabetic        Yin 2012
Anti-platelet         Singh 2010
Anti-lipidemic      Chen 2008
Anti-cholesterol    Kong 2004
Anti-hypertensive Liu 1999
Mantena 2006
Lin 2004
Murthy 2012
Mantena 2006
ANGIOGENESIS
INFLAMMATION
Figure 5.5 The effects of Berberine, a natural alkaloid in mammalian cells 
Berberine has a wide range of biological effects for example anti-inflammatory and anti-
angiogenic and is in common use in Chinese medicine. 
Key: Bcl-2 associated protein 2 (Bax), pro-apoptotic; B-cell CLL/lymphoma (Bcl2), anti-
apoptotic; cysteine-dependent aspartate-directed proteases (caspases); cyclooxygenase 2 
(cox2); hypoxia inducible factor 1 alpha (HIF1α); nuclear factor κβ (NFKβ). 
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References for Figure 5.5: (Eaker and Sninsky, 1989; Fukuda et al., 1999; Liu et al., 1999; 
Kong et al., 2004; Lin et al., 2004; Mantena et al., 2006a; Mantena et al., 2006b; Chen et al., 
2008; Singh et al., 2010; Singh et al., 2011; Murthy et al., 2012; Yin et al., 2012)	  
Treating EBs with 10µM Berberine significantly altered CD31 distribution. EBs 
failed to become cystic and cavitated, instead dense central staining is seen (Figure 5.6 
below and Figure 5 (Evans et al., 2007)*9).	  The differences in CD31 distribution indicate 
altered angiogenic development of the EBs. 	  
 
 
 
 
 
 
 
 
 
Control
Control Berberine
10µM
Berberine
10µM
Figure 5.6 Immunohistochemistry of day 15 EB frozen sections 
Endothelial cells were stained with monoclonal rat anti-mouse CD31 antibody 
(clone MEC13.3, Beckton Dickinsion) followed by biotinylated anti-rat IgG (Vector 
Laboratories) and 3,3' Diaminobenzidine (DAB) chromagen (Dako). Slides were 
counterstained with Carazzi’s haematoxylin (to stain nuclei). Berberine significantly 
altered regional volume fraction of CD31+ vessels, but not the total volume fraction 
(Figure 5A, C, D in (Evans et al., 2007)*9). 
Left: control day15 EBs Right: EBs treated with 10µM Berberine.  
Black bar represents 200µm 
Frozen in optimal cutting compound (OCT, Tissue Tek, Sakura, USA), sectioned 
and stained by A. Evans. 	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Berberine has been reported to alter the apoptotic protein ratio of a cell. The pro-
apoptotic Bcl-2–associated X protein (Bax) to anti-apoptotic B-cell CLL/lymphoma 
(Bcl2) ratio increases (Mantena et al., 2006a) and pro-apoptotic activated caspases also 
increase (Mantena et al., 2006b).	  Cavitation of EBs and angiogenic growth of vessels is 
driven by central hypoxia and accompanied by apoptotic remodelling. However, the 
presence of Berberine at 10µM does not appear to enhance apoptosis in these 
experiments. This may be due to higher concentrations of Berberine used in the studies 
citied in Figure 5.5 or the direct down regulation of HIF1α (Lin et al., 2004) and VEGF 
(Murthy et al., 2012;	  Hamsa and Kuttan, 2012), which also suggests Berberine may be 
beneficial in endometrial cancer (Chapter 4.2).  
An alternative explanation for the effects seen (Figure 5.6) is that the primary 
effect seen here is cytostatic rather than cytotoxic, central CD31 staining indicating 
endothelial progenitor cells which have failed to form or not yet contributed to vessels. 
Berberine has been shown to reduce cell proliferation in both mouse and human cancer 
cells (Bonon et al., 2013). Both scenarios may apply to some degree since Berberine’s 
multiphasic effects appear to vary with dose and length of exposure (Serafim et al., 
2008).  
Since this work, adenosine monophosphate-activated protein kinase (AMPK) 
activation by Berberine has been described as one mechanism of its action (Lee et al., 
2006b). This finding is consistent with its anti-diabetic properties similar to oral 
hypoglycaemic agents for example Metformin, (Marles and Farnsworth, 1995; Wang 
and Ng, 1999), which also activates AMPK. Activation of AMPK acts as an energy 
sensor linking low glucose and resulting G1 cycle arrest to its effects on mitochondrial 
function and downstream pathways (van den Bogert et al., 1986; Nagata et al., 2003;	  Cui 
et al., 2009;	  Fu et al., 2013).	  In	  proliferative	  disorders	  these	  multiphasic	  actions	  may	  be	  exploited	  to	  advantage	  since	  arrest	  of	  cell	  growth	  may	  be	  an	  acceptable	  outcome	  alongside	  additional	  chemotherapeutics. 
5.3 Apoptosis is necessary for normal blood vessel patterning in vitro 
and in vivo 
To clarify the role of apoptosis during blood vessel development, we created an 
endothelial specific vector construct containing the Tie2 promoter to drive the 
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expression of transgenes (Figure 2, (Evans et al., 2007)*9), stable mESC clones were 
generated expressing wild type Bcl2 or a mutant G145E Bcl2 in which the apoptotic 
function but not the proliferation function was deleted.  
In these experiments volume fraction analysis, expressed as percentage of 
CD31/DAPI, of vessels in differentiating EBs was reduced when wild type Bcl2 was 
overexpressed compared to the loss of function mutant G145E Bcl2 (Figure 5.7). This 
finding shows that in vitro apoptosis plays a role in the normal development of CD31-
positive vessels. 
   
 
 
 
 
 
 
 
We then used a transgenic approach to elucidate EC apoptosis in-vivo shown by 
others in neonatel vessel remodelling (Kim et al., 2000). When the anti-apoptotic Bcl2 
Transgenic 
EBs 
Mutant  
G145E 
Bcl2 
Apoptosis 
 
Wild type   
Bcl2 
Apoptosis  
Large cavitated EBs 
Higher vessel volume 
fraction 
Smaller dense EBs 
Lower vessel volume 
fraction  
Figure 5.7 Apoptosis is required for normal vessel formation 
Summary of the results of CD31/DAPI volume fraction analysis of frozen 
sections stained with anti-CD31 antibody (clone MEC13.3, Beckon Dickinson) 
plus Alexa Fluor 488 and Hoechst 33528 nuclear staining. Quantifying the 
morphological changes in a three dimensional network was achieved by 
importing images into Computer-Aided Stereological Toolbox (CAST) 
software (Olympus Denmark) as described (Evans et al., 2007)*9. 
Quantification: point counting of CD31/DAPI staining from 5 random images 
from each of 5 random sections, slides were numbered and later assigned to 
their respective experimental groups. 	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was expressed in transgenic mice under the control of the Tie2 promoter, including the 
enhancer region, the mice died during gestation (Duval et al., 2007)*10. In wild type mice 
active caspase 3, a key component of the apoptotic programme, was co-expressed with 
CD31 in the smaller vessels (Figure 1 (Duval et al., 2007)*10). When the transgenic mice 
were examined and compared to wild type littermates there were vascular defects 
including areas of haemorrhage, excess capillary networks around the face, retarded 
interdigital cleft formation (Figure 5.8), and abnormalities of placental vasculature. 
Vessels that were destined to regress in normal embryos persisted. 
 
 
 
 
EBs proved ideal to model and quantify early vessel development in a complex 
tissue, demonstrating angiogenic and apoptotic control of vessel development. These 
experiments further suggest that apoptosis is a normal feature of development, shown in 
vitro and in vivo. In addition, the findings indicate that once they are established and 
invested with support cells, vessels are less vulnerable to intervention, as seen in the 
transgenic mice where the larger established vessels are less vulnerable to the over-
expression of Bcl2. Remodelling of newly formed smaller vessels appears to be an 
important developmental function of apoptosis. Apoptosis may therefore have important 
implications in tumour regression, since tumour vessels resemble neovascularisation in 
development, and also for intrauterine growth restriction (IUGR) defects.  
Figure 5.8 Failure of vascular remodelling in embryos overexpressing Bcl-2 
14.5 dpc embryos expressing human Bcl2 in endothelial cells appear to have 
failed vascular remodelling and regression (right) compared to control embryos 
(left). From figure 4 (Duval et al., 2007)*10. 	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Chapter 6 The emergence of mesoderm and the haemangioblast  
 
More than 80% of known animal phyla develop from three germ layers (Technau 
and Scholz, 2003). The third layer, mesoderm, is recognised as a widely distributed 
germ layer in adult organisms (Figure 6.1). Mesoderm forms part of the many adult 
tissues including cells of the haematopoietic and vascular systems. Given the origins of 
the vertebrate blood and vascular systems in the emerging mesoderm of the embryo, it 
was a natural progression from previous work to look closer at their origin. 
 
 
  
 
 
It was clear EBs model both vascular and haematopoietic development (Figure 
5.1), and that EBs cultured as described (Chapter 1.4.1) may also be suitable to trace 
mesoderm induction in-vitro (Figure 6.1), as one of the early events prior to formation of 
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Figure 6.1 The origins of mesoderm from the epiblast. A large number of cells 
of an adult vertebrate, in many areas of the body, are mesoderm derivatives.  
As early as the 1880’s (Minot, 1883) it was thought mesoderm was “derived from 
scattered and isolated cells.” 
Abbreviations: Inner cell mass (ICM) 
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the blood and vascular systems. The aim of the work described in this and the following 
chapter was to review mesoderm specification in a mammal, as an extension to the 
wealth of knowledge already derived from amphibians and fish. 
6.1 Brachyury: a key transcription factor in mesoderm development 
Brachyury, a T-box transcription factor, found in all bilaterian animals plays a 
key role in mesoderm development in all vertebrates. The Brachyury protein binds DNA 
at a specific promoter sequence, the T-box (TCACACCT), and influences the 
transcription of target genes. T-box genes appeared in evolutionary terms when body 
plans diversified and this in itself suggests a crucial role. Brachyury, or T, is expressed 
in the primitive streak (Figure 6.7), tailbud and notochord (Figure 6.3A, C) of the early 
mouse embryo (Dobrovolskaïa-Zavadskaïa, 1927; Herrmann et al., 1990; Wilkinson et 
al., 1990). 
Much of the early work on Brachyury was carried out using frogs (Xenopus 
laevis) and zebrafish (Danio Rerio), and in Xenopus Brachyury appears to be sufficient 
for mesoderm formation (Cunliffe and Smith, 1992). The expression patterns of 
Brachyury homologs for Xenopus Xbra, (Smith et al., 1991) and zebrafish no tail ntl 
(Schulte-Merker et al., 1992; Martin and Kimelman, 2008; Morley et al., 2009), 
resemble that seen in the mouse (Figure 6.2). These transcripts play similar roles in early 
development (Schulte-Merker et al., 1994; Conlon et al., 1996; Martin and Kimelman, 
2008) indicating conservation of Brachyury protein function.  
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Figure 6.2 Brachyury conservation in vertebrate embryos 
a. Frog Xenopus laevis stage 33-34 (Late tailbud stage, Xenbase). F1 outcross male GFP 
transgenic frog pSceGFPXbra x wildtype female using the I-SceI meganuclease system, 
created by A. Evans 2006-7, by cloning the Xenopus Brachyury Xbra promoter sequence 
into pSceGFP. GFP expressed from Xbra promoter shows GFP signal in the notochord and 
tailbud. The meganuclease I-Sce-I is an intron-encoded endonuclease isolated from the 
yeast Sacchoromyces cerevisiae (Thermes et al., 2002). 
b. Light microscope image of the same embryo. 
c. Mouse Mus musculus embryo 9.5 dpc in-situ showing Brachyury RNA expression in the 
tailbud and notochord (Figure S6 B from (Evans et al., 2012)*12) detected with NBT/BCIP.  
d. Zebrafish Danio rerio embryo 24 hpf (Zfin) shows expression of notail RNA in ntl: CFP 
transgenic fish, specific staining for notail in the notochord, image from Steven Harvey 
(Harvey et al., 2010). 
Xenopus developmental data from Nieuwkoop and Faber (1994) Normal Table of Xenopus 
laevis (Daudin) from Xenbase website. Zebrafish embryonic stages are modified from 
Kimmel (Kimmel et al., 1995) Zfin website. 
(see section III for abbreviations and appendix for websites) 
Mouse dissection and staining, Xenopus  Xbra transgenic frog by A. Evans,  
Zebrafish transgenic by S.Harvey. 
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Mouse embryos lacking functional Brachyury protein fail to gastrulate properly, 
do not form a differentiated notochord, and lack structures posterior to somite seven 
(Yanagisawa et al., 1981; Wilson et al., 1995; Naiche et al., 2005)(Figure 6.3B). In the 
mouse, mRNA and protein are detectable by 6.5-7.0 dpc and homozygous embryos 
lacking T activity die in utero around 9.5-10 dpc (Chesley, 1935; Gluecksohn-
Schoenheimer, 1944).	  
	  
A B
C D
+/+
+/+
T/T
T/+
Figure 6.3 Brachyury in the mouse embryo 
A Wildtype (+/+) 8.5.dpc mouse embryo in-situ for digoxigenin-labeled antisense mouse 
Brachyury detected with Mag/INT (brown) shows Brachyury staining in the tailbud and 
notochord, black arrow indicates somites. Somites form in pairs from paraxial mesoderm 
flanking the notochord and the neural tube.  
B Homozygous 8.5 dpc T/T mutant stained as A note absence of Brachyury staining in 
the tailbud, lack of notochord and somites (black arrowhead). The embryo in A was about 
to undergo axial rotation but B would have died soon after. Black bars A and B 250µm. 
Orientation anterior-posterior, dorsal views shown. C Wildtype (+/+) 11.5.dpc mouse 
embryo stained as A Note tailbud, notochord staining and straight neural folds, inset 
lateral view of the same embryo. D Heterozygote (T/+) stained as A note faint staining, 
distinctly kinked notochord, inset lateral view shows lack of tail elongation. Black bars 
1000µm for 11.5dpc embryos. Orientation for C, D as in A, B. See Appendix Table 1 for 
mouse staging. Embryo dissection and in-situ hybridisation A. Evans. 
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Using mouse EBs to reveal mammalian Brachyury binding targets was a means 
of establishing the contribution of gastrulation and mesoderm induction on the formation 
of the blood and vascular systems. Culturing EBs in suspension (Evans et al., 2007)*9 
allowed the production of sufficient quantities of cross-linked chromatin from 
Brachyury expressing cells to carry out chromatin immunoprecipitation or chIP (Figure 
6.4). To obtain sufficient Brachyury positive cells in vivo would have required large 
numbers of experimental animals at a high cost.	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Figure 6.4 Chromatin Immunoprecipitation or Location Analysis 
A: ChIP on chIP workflow EBs grown in spinner culture as described 
(Chapter 1) are cross-linked (X-linked) using formaldehyde at the peak of 
Brachyury expression. EBs are lysed and the chromatin sonicated to 100-
200 bp. Samples are divided, one labeled with antibody specific to 
Brachyury protein or an isotype control (IP) and the other is the whole 
chromatin extract (WCE) sample, cross-links are reversed and the DNA 
amplified using whole genome amplification (WGA). Samples are 
fluorescently labelled and hybridised to promoter chips. For more details see 
materials and methods (Evans et al., 2012)*12. 	  
	                                                                                                                              Chapter 6 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 57	  
 
 
 
 
 
 
 
6.2 The embryoid body as an in-vitro surrogate for mouse gastrulation 
and mesoderm formation 
Pilot experiments in spinner cultures showed Brachyury mRNA peaking 
consistently on day 4-5 of differentiation (Figure 6.6). This finding indicated EBs may 
mimic the early stages of eutherian embryo development acting as surrogates for the 
embryo at a stage where it becomes inaccessible once implanted.  
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Figure 6.4 Chromatin Immunoprecipitation or Location Analysis 
B: A log-log scatter plot of immunoprecipitated (IP) chromatin using anti-Brachyury 
antibody (y axis) labelled with Cy5-dUTP, against whole chromatin extract for that 
sample (x axis) labelled with Cy3-dUTP. Arrow indicates region of genes that are 
significantly enriched in the Brachyury IP samples. 
All chIP-chip experiments were performed by A. Evans. 
Key: Cyanine 3-2´-Deoxyuridine, 5´-Triphosphate (Cy3-dUTP); Cyanine 5-2´-
Deoxyuridine, 5´-Triphosphate (Cy5-dUTP), fluorescent nucleotide analogs 
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Late primitive streak mouse embryos (Figure 6.7) possess polarity and have their 
own three-dimensional geometry (Figure 6.5). Brachyury-positive posterior primitive 
streak cells undergo epithelial-to-mesenchymal transition (EMT). In using the EB as a 
model, one of the important questions was whether the differentiation events seen in 
vivo will be faithfully reproduced without these precise morphological movements. 
Figure 6.5 Schematic representation of mouse embryo development 
Development of the three germ layers from the blastocyst, and the key signaling genes 
involved. ESCs derived from the ICM can form all three germ layers in vitro  
Mesoderm and definitive endoderm are established in mouse embryos during 
gastrulation. At the start of gastrulation, the primitive streak (PS) forms from the 
epiblast-extraembryonic border and will become the posterior of the embryo (6.5dpc 
above). 
Key: extraembryonic ectoderm (ExE); days post coitus (dpc); embryonic stem cells 
(ESC); anterior visceral endoderm (AVE); primitive streak (PS); inner cell mass 
(ICM); bone morphogenetic protein 4 (BMP4); leukaemia inhibitory factor (LIF); 
forkhead box A2 (foxa2) transcription factor; wingless-type MMTV integration site 
family, member 3 (wnt3). Based on (Gadue et al., 2005). 
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At day 3 cells expressing Brachyury and other mesoderm markers (Figure 6.6A) 
(Keller et al., 1993) and markers for definitive endoderm such as forkhead box A2 
(Foxa2) are detectable in EBs. At the same time markers of pluripotency rapidly 
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Figure 6.6 Expression of stage-specific markers in mouse EB differentiation 
Quantitative PCR data expressed relative to β actin (endogenous control), and 
undifferentiated ESC as 100%. Key: mouse embryonic fibroblasts (MEF); 
undifferentiated embryonic stem cells (ESC); Day 1-6 differentiating EBs (D1-D6 EBs). 
A: A wave of mesoderm induction occurs in early vertebrate development. 
Brachyury marking early mesoderm; fibroblast growth factor 8 (FGF8) expressed in 
embryonic ectoderm and mesoderm; forkhead A2 (foxa2/HNF3beta) regarded as a 
marker for endoderm, expressed in the primitive streak and node in vivo; vascular 
endothelial growth factor receptor 2 (VEGFR2/KDR/Flk1) indicates presence of early 
haemangioblast progenitors.  
B: A decrease in stem cell/ pluripotency markers occurs on differentiation.  
E cadherin (CDH1) down regulation is associated with epithelial-mesenchymal transition 
and cell movements, octamer-binding transcription factor 4/POU domain, class 5, 
transcription factor 1 (Oct4/Pou5F1) a marker for undifferentiated cells and RNA 
exonuclease 1 homolog (Rex1) or Zfr42 is a transcription factor highly expressed in 
embryonic stem cells. 
Performed by A. Evans from a timecourse sampling experiment and the Roche 
LightCycler®480 System (Roche Diagnostics). 
Primer sequences are listed in Appendix Table 2. 
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decrease (Figure 6.6B), for example, octamer-binding transcription factor 4/POU 
domain, class 5, transcription factor 1 (Oct4/Pou5F1) a marker for undifferentiated cells. 
Changes in cell adhesion molecules also occur for example, E-cadherin (CDH1) 
downregulation, associated with EMT.  
 
6.3 Origins of the blood and vascular system from a haemangioblast 
progenitor 
Following the proposal by Sabin (Sabin, 1917) of the existence of a bipotent 
haematopoietic and endothelial precursor, Murray used the term haemangioblast 
(Murray, 1932) to describe a common precursor.  
Blood and vascular development occur following a wave of Brachyury 
expression associated with the expression of BMP4 and fibroblast growth factor 2, basic 
(FGF2). Mouse haemangioblast commitment occurs in the posterior primitive streak 
(Figure 6.7) in Brachyury-positive VEGFR2/KDR/Flk1-positive cells (Huber et al., 
2004; Shalaby et al., 1995;	  Shalaby et al., 1997).	   
6.4 Developmental noise or chaos in embryoid bodies 
The patterning and development of an embryo requires intricate transcriptional 
and cellular interactions but nevertheless EBs are capable of spontaineous, rhythmical 
contractions after 7-8 days of culture. If allowed to attach, EBs do show a degree of axis 
formation and form assymetric sacs of attached cells. A key question for lineage 
progression of haematopoietic cells is whether primitive blood islands progress through 
definitive haematopoiesis to mature lineages.  EB differentiation does not appear 
completely chaotic, although local gradients within the EBs may cause a high degree of 
stochastic patterning.  
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Figure 6.7 A model for haemangioblast formation in the mouse late primitive 
streak embryo. 
Brachyury expressing EBs act as in-vitro surrogates for these events. 
Image shows a 7.5 dpc wild type 129 mouse embryo in-situ using digoxigenin-labeled 
antisense mouse Brachyury RNA visualised with BM purple. Specific staining in the 
node and primitive streak was observed. Staining was absent in a sense control. 
Mesoderm cells (blue dots) in the posterior primitive streak migrate and differentiate 
into haemangioblasts (red dots) that are Brachyury + and VEGFR2/KDR/Flk-1+. 
Primitive endothelial cells (EC), smooth muscle cells (smc) and haemangiopoietic cells 
(H) are formed, and a blood band and endothelial plexus will form around the border of 
the extra embryonic and embryonic mesoderm. Embryo dissection and in-situ 
hybridisation by A. Evans. Scheme based on Huber (Huber et al., 2004).	  	  
White bar indicates 200µm. 
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We investigated use of EBs as a model system for early mesoderm and by using 
chIP-chIP analysis of cultures cross-linked at peak Brachyury expression this led to the 
discovery of previously unknown Brachyury targets (Chapter 7). The faithful 
recapitulation of the key events of early development fits the principal of the 3Rs 
(Replacement, Refinement and Reduction) regarding the use of mouse embryos.  
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Chapter 7 Brachyury target genes  
 
Transcriptional targets form the basis of a Brachyury-driven regulatory network 
involving a complex interplay of genes and transcription factors directing the 
establishment of mesoderm. After testing the efficacy of the model (chapter 6) we were 
able to successfully achieve the main aim of discovering unknown Brachyury targets in 
the mouse. Even in the rather chaotic form of an embryoid body, elements of the key 
systems of the developing embryo are present, as illustrated by their ability to form 
networks of endothelial cells (Chapter 5.1). 
 
7.1 ChIP-on-chip technology  
The technique of chromatin immunoprecipitation (chIP) or location analysis 
appeared about the same time as expression arrays (Timeline 2). ChIP-chip (or chIP-on-
chip) using immobilized oligonucleotides, from known promoter sequences, on glass 
chips was the most affordable option at this time (2006-7) (Figure 6.2). The most 
important requirement is an antibody of high specificity to recognise the crosslinked 
epitope (Figure S1 (Evans et al., 2012)*12	  ).  
7.2 Brachyury binding targets reflect a key role in development 
Evans et al., 2012 describes components of the wingless-type MMTV integration 
site family (wnt) pathway and other binding targets, for example, fibroblast growth 
factor 8 (fgf8), consistent with the role of Brachyury in mesoderm formation. A number 
of further well-documented signalling pathways are also targeted by Brachyury 
including the MAPK, c-Jun N-Terminal Kinase (JNK), TGFβ, Hedgehog, integrin, 
Jak/STAT and ubiquitination pathways ((Evans et al., 2012)*12 (Table S2)). Gene 
ontology and motif analysis was performed as described (p12(Evans et al., 2012)*12) (see 
appendix websites). Targets emphasize the links between embryonic morphogenesis 
(Chapter 7.2.2) and tumour associated cell migration (Chapter 7.3). Both of these 
processes are dependent on the establishment of the vascular and haematopoietic 
systems (Chapter 7.2.1) in a growing embryo. In situ hybridisation performed using wild 
type embryos and heterozygote crosses of a Brachyury mutant mouse (King et al., 1998) 
confirmed the in vivo expression pattern in relation to that of Brachyury for some of 
these targets. 
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7.2.1 Brachyury binding targets associated with haematopoietic and 
endothelial biology 
Genes associated with the developing blood and vascular systems appear in close 
association with mesoderm formation (Figure 7.3) and among these are putative direct 
binding targets of Brachyury (Appendix table 3), including the E-twenty-six (ETS) 
related gene, (Erg) a transcription factor known to be important in self-renewal of HSC 
in embryos (Ng et al., 2011). Together with the transcription factor friend leukaemia 
integration 1 (Fli1), Erg is involved in lineage specification via regulation of the balance 
of erythroid-megakaryocyte differentiation from bipotential megakaryocyte-erythroid 
progenitors (MEP) (Figure 2.6), (Kruse et al., 2009) and is essential for definitive 
haematopoiesis (Loughran et al., 2008). The bZIP transcription factor, CCAAT/ 
enhancer binding protein alpha, Cebpa (C/EBPa) initiates myelopoiesis (Chen et al., 
2009) and influences lineage decisions (Reddy et al., 2002).	   
Central to the biology of the Brachyury-positive haemangioblast (Figure 6.7) is 
the coincident expression of VEGFR2/KDR/Flk1, and a number of targets are associated 
with VEGF and its action. Fucosyltransferase 8 (Fut 8) is required for the expression of 
VEGFR2 (Wang et al., 2009) and magic roundabout protein (Robo4). Robo 4 is 
expressed in the dorsal aorta and intersomitic vessels in 9.5dpc mouse embryos (Brose et 
al., 1999), but is restricted to HSCs and ECs in adults. Robo 4 functions as a guidance 
molecule for localisation of adult HSC to the bone marrow (Huminiecki et al., 2002) 
(see also Figure 8.1).	  
Another target myeloid ecotropic viral integration site 1 (Meis1), a 
homeodomain transcription factor (Moskow et al., 1995) is associated with HSC self-
renewal and essential for definitive haematopoiesis and vascular patterning in the mouse 
embryo (Azcoitia et al., 2005) (Figure 7.1 A, B). Meis1-mutant mice have defects in 
haematopoiesis and angiogenesis (Cai et al., 2012).  
 
	                                                                                                                              Chapter 7 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 65	  
 
 
 
}
}
ectoplacental 
cone
extraembryonic 
tissue
meis 1 positive 
paraxial 
mesoderm
head folds
pre-somitic
mesoderm
somites
A
Figure 7.1 A: In-situ staining for wildtype 8.5dpc mouse embryos showing Meis 1 
staining in the paraxial mesoderm  
Embryos are viewed from the posterior. Left: 8.5dpc embryo still contained in the 
extraembryonic membranes. Right: 8.5dpc embryo dissected away from all 
extraembryonic membranes. Embyro shown has reached the seven somite stage, just 
prior to axial rotation. Stained using digoxigenin-labeled antisense mouse meis 1 RNA 
visualised with BM purple, see abbrvs. (Roche). 
Embyro dissection in-situ hybridisation by A. Evans. White bars indicate 250µm 
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Haematopoiesis occurs in distinct waves in both human and mouse embryos 
(Figure 7.2) and the site of haematopoiesis changes during development. The first wave 
of primitive haematopoieis in the embryonic yolk sac, which occurs at around 7 dpc, 
can be considered equivalent to the blood islands described in the EB system	   (Silver 
and Palis, 1997) producing primitive nucleated erythroblasts (Kennedy et al., 1997).	  By 
8-8.5 dpc circulation begins in the embryo and yolk sac then at 9 dpc intra-embryonic 
mesoderm cells give rise to the aorta-gonad mesonephros (AGM), the site of the second 
wave of definitive haematopoiesis. The AGM of mouse and human embryos is a cluster 
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Figure 7.1 B: Binding events at the Meis 1 promoter  
Peak data generated from Agilent chIP Analytics 1.3 software showing fold 
enrichment (y axis) for combined array data from three chIPs against Meis1 
chromosomal location (x axis). Bound peak is upstream of transcription start site for 
Meis1. See also Figure 2 (Evans et al., 2012)*12	   for the expression profile in 
differentiating EBs. The software uses the whitehead error model (Lee et al., 2006a) 
taking the p value of the probe in question as well as its neighbours, comparing 
groups of three probes and computing a combined p value. 	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of CD34+ haematopoietic cells associated with the ventral floor of the dorsal aorta. 
Long-term repopulation potential is possible once cells migrate to liver and spleen, then 
to the bone marrow (Muller et al., 1994).  
 
 
Despite the lack of correct embryonic patterning it appears that the EB does 
faithfully reproduce lineage progression for haematopoietic cells from a subset of 
Brachyury expressing cells in vitro (Figure 7.3). 
Figure 7.2 Waves of haematopoiesis occur in embryonic development, and the site of 
haematopoiesis changes as development progresses 
Mesoderm induction is followed by the first wave of primitive haematopoiesis in the yolk sac 
in vivo and EB blood islands in vitro. Primitive, nucleated erythroblasts containing foetal 
haemoglobin, macrophages and megakaryocytes are formed and circulation begins in the 
embryo. A wave of definitive haematopoiesis follows as AGM-derived stem cells migrate to 
the liver and eventually bone marrow for long-term haematopoiesis. Erythroblasts are now 
enucleated and stem cells have lymphomyeloid potential.  
Key: aorta-gonad-mesonephros (AGM); embryoid bodies (EBs); haematopoietic stem cells 
(HSC). Based on data from published models (McGrath and Palis, 2005;	  Tavian and Peault, 
2005;	  Eilken et al., 2009; Kardel and Eaves, 2012). 
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Figure 7.3 A model for the formation of blood cells and endothelium from a common 
progenitor, the haemangioblast 
Early mesoderm is Brachyury +, a subset becomes VEGFR2/FLK1/KDR+ and expresses 
SCL in response to cytokines. This haemangioblast then gives rise to both endothelial and 
blood cell lineages in response to cytokines and transcription factors. Phenotypes are based 
on data from flow cytometry and expression. Key surface markers (blue), cytokines (red) 
and transcription factors (purple) are indicated. The model is based on that of Lancrin 
(Lancrin et al., 2009).	  As differentiation proceeds the pluripotent potential decreases. 
The approximate stages in embryos and mouse EBs are also shown.  
Key: bone morphogenetic protein 4 (BMP4); fibroblast growth factor 2 (FGF2); T-cell 
acute lymphocytic leukaemia protein 1(TAL1/SCL); integrin, alpha 2b (CD41); vascular 
endothelial growth factor Receptor 2 (VEGFR2/FLK1/KDR); protein tyrosine 
phosphatase, receptor type, C (PTPRC/CD45); TEK tyrosine kinase receptor (Tie2/TEK); 
cadherin 5, type 2 or VE-cadherin (vascular endothelial) also known as CD144; proto-
oncogene c-Kit or tyrosine-protein kinase Kit  (CD117/ ckit); haematopoietic progenitor 
cell antigen CD34 (CD34); aorta-gonad-mesonephros (AGM) region. 	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7.2.2 Brachyury binding targets associated with epithelial-mesenchymal 
transition (EMT), cell migration, adhesion and left-right determination 
Targets that influence cell surface properties reflect the migration potential of 
mesoderm (Appendix table 4). It is well established that the extracellular matrix of 
Brachyury mutants differs from wildtype embryos (Jacobs-Cohen et al., 1984). 
Brachyury positive cells undergo EMT, accompanied by upregulation of the 
transcription factor snail 2 /slug resulting in a decrease in E cadherin expression (Bolos 
et al., 2003). Rack1, highly expressed in ECs, influences cell-matrix adhesion at focal 
adhesions (Mochly-Rosen et al., 1995; Cox et al., 2003) while camello-like 4 or N-
acetyltransferase 8 (Cml4, Nat 8) is thought to be involved in gastrulation movements 
(Popsueva et al., 2001).   
One of the consequences of the processes occuring during gastrulation is the 
possession of two body axes by bilaterians. In vertebrates a third additional left-right 
asymmetry aligns with respect to the anterioposterior (AP). The first breaking of 
symmetry occurs with right-sided heart looping and then axial rotation or turning of the 
embryo accompanied by twisting with respect to the dorsal-ventral axis (Appendix 
figure 3). Brachyury mutants have consistent abnormalities in heart looping and 50% of 
embryos have inverted heart situs	  (King et al., 1998). The Brachyury target rotatin (Rttn) 
(Figure 7.4B) is required for the correct asymmetric expression of genes associated with 
left-right patterning (Figure 7.4A) and axial rotation (Faisst et al., 2002).  
 It is reassuring to note that despite the absence of the polarity seen in in-vivo and 
the stochastic patterning in the EB, the model is still capable of revealing Brachyury 
regulated transcripts associated with patterning in-vivo.  
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A
Figure 7.4 A: In-situ of wildtype 10.5dpc mouse embryos showing Rttn staining 
Lateral views. Left: Digoxigenin-labeled antisense mouse Rttn RNA visualised with 
BM purple (Roche). White arrowheads: Telencephalon staining in the developing 
brain. Red arrowheads: Forelimb and hindlimb bud staining. White arrows: Staining 
in somites. 
Right: Digoxigenin-labeled sense mouse Rttn RNA visualised with BM purple (Roche). 
Black arrowhead: The optic pit. Inset image top: The same stage embryo stained with 
digoxigenin-labeled antisense mouse Brachyury RNA visualised with magenta/INT 
(brown) shows Brachyury is still present in the tail tip and notochord. Embyro 
dissection and  in-situ hybridisation A. Evans. White bars indicate 1000µm 
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7.3 Brachyury and cancer 
 Brachyury is not expressed in adult tissues but is in many human cancers (Palena 
et al., 2007). Induction of EMT is an important step in the progression of primary 
tumours, for example in colorectal and lung cancer	   (Roselli et al., 2012; Sarkar et al., 
2012). Brachyury is expressed in haemangioblastomas, rare tumours in blood vessels of 
the brain and spinal cord (Tirabosco et al., 2008),	   and chordoma, a rare malignant 
tumour in bone (Yang et al., 2009; Pillay et al., 2012;	  Nelson et al., 2012). Brachyury 
B 
Figure 7.4 B: Binding events for Rttn promoter  
The Brachyury binding peak is upstream of the transcription start site (Rttn gene 
in blue) this image was exported from chIP Analytics 1.3.software (Agilent 
Technologies). Fold enrichment (y axis) for combined array data from three chIPs 
against Rttn chromosomal location (x axis). The software uses the whitehead error 
model (Lee et al., 2006a) taking the p value of the probe in question as well as its 
neighbours, comparing groups of three probes and computing a combined p value. 	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expression is also linked to poor prognosis in colorectal cancers, particularly when 
expressed in primary tumours prior to metastasis (Kilic et al., 2011). During normal 
development, the control of cellular plasticity is under tight control, as the epithelial 
phenotype tends to be polarised while the mesenchymal phenotype is highly motile. In 
cancer the control of genes associated with EMT and migration are deregulated 
highlighting the links between embryogenesis and a cancer phenotype (Fernando et al., 
2010). 
7.4 Brachyury targets in human development, lessons from the mouse 
Analysis of early mesoderm development in the mouse embryo and in mESC -
derived EBs has provided many insights into cell specification. As the mouse 
experiments were almost completed, culture protocols were being developed for 
repeating the experiments in hESCs using chIP-seq technology. FlyB chemically defined 
media (CDM) plus FGF2 (F), LY294002 (ly) a potent inhibitor of phosphoinositide 3-
kinases (PI3Ks) and BMP4 (B) was used to induce mesoderm formation (Bernardo et 
al., 2011). Brachyury’s role in development appears to be conserved between mouse and 
human cells. Brachyury regulation was verified in human ESCs for the target genes 
Axil/Conductin (Axin 2), wnt3a, fgf8 and junction plakoglobin or gamma catenin (JUP) 
(Figure 7, (Evans et al., 2012)*12). Given the data comes from two different technical 
platforms and analysis pipelines there is a high degree of overlap (Figure 7.5). Platform 
differences add to other variables including the dynamic nature of transcription factor 
occupancy and percentage of Brachyury-positive cells in the population.  
Human Brachyury chIP-seq targets also include BMP4, VEGF, Fli1 and Notch1, 
of particular relevance to mesoderm induction and haematopoietic development (Tiago 
Faial, manuscript in preparation). In mouse these transcripts were just outside 
significance, but the human data does suggest they are bona fide targets (see Appendix 
table 6).  
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Figure 7.5 Pie chart indicating mouse Brachyury targets from chIP-chIP also common 
to human chIP-seq Brachyury data. 
396 target transcripts were identified from the chIP-chIP experiments for mouse Brachyury 
and 180 of those targets were also present in the targets from human Brachyury chIP-seq 
data. For the human experiments hESCs were cultured in chemically defined Fly B 
mesoderm media containing Fgf2 (F), LY294002 (ly) a potent inhibitor of phosphoinositide 
3-kinases (PI3Ks) and BMP4 (B) (Bernardo et al., 2011). Common target genes may be 
higher since overlap is limited to comparing genes and isoforms found on the mouse arrays. 
Of the transcripts common to both hESCs and mouse EBs are transcripts described in 
(Evans et al., 2012)*12 and in Chapter 7 of this work as indicated: conductin (Axin2), β 
catenin (Ctnnb1); dickkopf homolog 1 (Dkk1); E-twenty-six (Ets) related gene (Erg); 
fibroblast growth factor 8 (fgf8); forkhead box A2 (Foxa2); Fucosyltransferase 8 (Fut 8); 
Junction plakoglobin (Jup); myeloid ecotropic viral integration site 1 (Meis1); mesogenin 1 
(Msgn1); magic roundabout, axon guidance receptor, homolog 4 (Robo 4); rotatin (Rttn); 
snail homolog 2b (Drosophila) Slug, Snail2 (Snai2). 
Mouse chIP-chip data A. Evans. Human chIP-seq data T. Faial. 	  
	                                                                                                                              Chapter 7 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 74	  
7.5 The elusive T-box 
The T-box domain, found in all T-box proteins binds DNA in a sequence specific 
manner. Morley et al showed enrichment of the canonical T-box binding site 
TCACACCT for no tail (ntl), the zebrafish Brachyury ortholog (Morley et al., 2009). 
Since the original random oligomer binding experiments by Kispert (Kispert and 
Hermann, 1993), revealing a preference of Brachyury for a palindromic form of the 
consensus sequence, the assumption was for many years that the same would apply in 
vivo for the mouse with speculation that dimer binding involved each monomer binding 
a half site. No enrichment for the TCACACCT site was found in the mouse EB 
experiments and we now believe this is due to the limitation of promoter length 
available, in this case 5.5kb upstream and 2.5kb downstream of the transcription start 
site (TSS).  
The three dimensional arrangement of the chromatin may hold the key to the 
control of transcription by Brachyury and involve co-operation with other transcription 
factors or enhancers, since the binding sites from the hESC chIP-seq were in many 
genes far upstream from the TSS (manuscript in preparation by Tiago Faial). Some 
support for this idea comes from recent data using Brachyury expressing chordomas 
(Nelson et al., 2012),	  where only 11% of targets were within +/- 2kb of the TSS and 
58% of targets within -50kb of the TSS to + 5kb of the transcription end site (TES). 
Bending and looping of enhancer regions may explain the lack of T box sites found 
close to many promoters for Brachyury targets (Petrascheck et al., 2005). Unravelling 
the topological organisation of Brachyury promoter complexes will require the analysis 
of long-range interactions using techniques such as chromosome conformation capture 
(3C) (Dekker et al., 2002). 
ChIP-chIP technology has now largely been superseded by chIP-sequencing 
(ChIP-Seq). ChIP-seq, in which immunoprecipitated DNA is analysed by massively 
parallel sequencing, has the huge advantage that there is no restriction to a limited length 
of promoter arrayed on the chips (Barski et al., 2007). To fully resolve the complex 
picture of mesoderm induction combinational analysis of Brachyury, together with 
closely related transcription factors in the embryo such as Eomesodermin (Eomes), 
required for trophoblast and paraxial mesoderm specification (Russ et al., 2000), and 
Tbx 6 downstream of Brachyury and required for somitogenesis (Chapman and 
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Papaioannou, 1998), may be necessary. It is possible many Brachyury targets are 
controlled by more than one T-box gene (Wilson and Conlon, 2002)	   and other 
transcription factors as seen in the complex control of haematopoietic differentiation 
(Wilson et al., 2010). For example mesogenin 1 (msgn1), required for somitogenesis, is 
a target of both Tbx6 and Brachyury (Wittler et al., 2007). 
7.6 A wave of mesoderm induction is required for blood and vascular 
development 
 Despite unanswered questions concerning the exact role of the T box in mouse 
we have shown that Brachyury has a crucial role during the establishment of mesoderm 
and its derivatives. The expression of an embryonic transcript in adult tumours also 
highlights the importance of correct, co-ordinated, transcriptional control of gene 
expression. 
To create robust protocols for the in-vitro production of haematopoietic stem 
cells for blood or endothelial cell differentiation (Tan et al., 2013)	   requires a peak of 
Brachyury expression, which accompanies mesoderm formation, in both mESC and 
hESC.  
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Chapter 8 Translational medicine: the future   
The use of EB differentiation in vitro provided insights into the reconstruction of 
the routemap to blood and vascular cells via mesoderm induction. It is now conceivable 
to develop cell-based therapies in many fields of research and part of this success is due 
to global sharing of knowledge, from its roots in developmental biology, to the advent of 
ESC and induced pluripotent stem cell (iPSC) technology (Takahashi and Yamanaka, 
2006;	  Takahashi et al., 2007),	  leading now to the ability to reprogram cells.  
Red blood cell (RBC) transfusions are the oldest form of cell-based therapy but 
remain dependant on healthy volunteer donations. Platelet transfusions are even more 
vulnerable to availability having a shelf life of only 5-7 days. Platelets have a central 
role in haemostatic plug formation and thrombosis (Clemetson, 2012), and angiogenesis 
via the release of PDGF, VEGF, FGF2  and other stored growth factors.  Humans 
produce approximately 1011 platelets daily from terminally differentiated 
multinucleated, megakaryocytes (MKs) (Kaushansky, 2008)	   (see Figure 8.5). 
Chemotherapy, organ or bone marrow transplant, bleeding from trauma or surgery, and 
inherited blood disorders may all require blood or platelet transfusions. Availability and 
storage is especially challenging in developing nations. Both platelets and erythrocytes 
are anucleate therefore can be subjected to gamma irradiation to prevent teratomas from 
any residual undifferentiated iPSCs and, therefore, are promising targets for the 
translational process. Recent work concentrates on the in-vitro derivation of cells of the 
myeloid lineage, in particular platelet-producing MKs. 
 Cord blood CD34+ progenitor cells have provided the gold standard in the 
production of blood cell lineages (Chapter 1.3) and are used routinely used to produce 
mature MKs. However, this is a limited resource whereas ESC and iPSC can in theory 
provide a continuous supply for differentiation. In addition, cord blood derived cells are 
of foetal origin whereas adult haematopoiesis occurs mainly in the bone marrow (Figure 
7.2). 
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8.1 Translating complex tissue environments to in-vitro production 
protocols: modelling the adult bone marrow niche 
Endothelial and haematopoietic cells differentiate in close proximity and, 
endothelial cells play an active role in haematopoiesis, producing cytokines such as 
VEGF. The transition of VEGFR2+ progenitors (see Figure 7.3) depends on VEGF for 
endothelial cells (Samuel et al., 2013) and either low or absent VEGF for 
haematopoietic development (Eichmann et al., 1997). Adult haematopoiesis occurs in 
the bone marrow HSC niche (Schofield, 1978; Hawkins and Lo Celso, 2013) closely 
associated with bone development or osteogenesis (Patt and Maloney, 1972; Maloney 
and Patt, 1975) (Figure 8.1). This is the site of maturation of platelet producing MKs 
supported by cells and cytokines of the bone marrow niche. 
Thrombopoietin (TPO) and its receptor Mpl, the regulators of megakaryopoiesis, 
are also regulators of HSCs in the osteoblastic niche (Qian et al., 2007; Yoshihara et al., 
2007), as are	  the	  receptor	  roundabout 4 (Robo4), and its ligand slit homolog 2 (Slit 2), 
in the vascular niche	   (Sugiyama et al., 2006).	  To model the functioning bone marrow 
niche in-vitro successfully will require the correct cues, which may include 
physiological, structural, and topographical components. Modelling the shear force of 
blood flow through the vascular niche may be a particular requirement of MK 
maturation since this is known to enhance platelet formation (Machlus and Italiano, 
2013). 
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Figure 8.1 The haematopoietic stem cell niche, the site of terminal differentiation of 
platelets  
The challenge to produce fully mature cells may rest on the ability to recreate this niche. 
Quiescent HSC are closely associated with osteoblasts. Many signals then influence the 
balance between self-renewal, mobilization and differentiation. Both homing and 
mobilization also involve close association with endothelial cells (EC). 
SCF binds proto-oncogene (c-kit) on HSC and is required for stem cell maintenance. 
Osteoblasts express membrane bound SCF and, secrete angiopoietin 1 which binds the 
Tie2 receptor ligand on HSCs. TPO directs cells to the myeloid lineage. 
Mature megakaryocytes release platelets into the bloodstream by extending proplatelets 
via fenestrations in the sinusoidal vessels.  
The osteoblast niche is also hypoxic compared to the vascular niche (low O2). Robo4 is 
high is the vascular niche (Chapter 7.2.1) and acts as a guidance molecule for its ligand 
slit 2 expressed by stromal/mesenchymal cells (Smith-Berdan et al., 2012).	  OP9 cells 
used in MK differentiation protocols (Takayama et al., 2008) also express slit 2. 
Key: Roundabout 4 (Robo4) receptor and its ligand slit homolog 2 (slit 2); stem cell 
factor (SCF); extracellular matrix (ECM); Thrombopoietin (TPO). Based on (Wilson 
and Trumpp, 2006). 
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8.2 Manipulating cell fate 
Development has been likened to a progression via regulatory states defining 
specific phenotypes (Waddington, 1957; Pimanda and Gottgens, 2010). The input is a 
series of transcription factors and expressed genes, and the output or cell fate is 
determined by whether target genes are active or repressed. So, at the molecular level, 
the journey from pluripotency to terminal differentiation requires constant lineage 
decisions by individual cells. Multiple, distinct, terminally differentiated cells are 
formed from branched and interconnected routes. Waddington’s metaphor for 
development implies the landscape and route consists of a fixed set of routes to terminal 
differentiation. However, knowledge of the molecular input for specific lineages 
provides the means to manipulate either the landscape or route followed (Figure 8.2). 
This applies to both translational medicine therapies and the control of metastatic 
invasion such as that described in endometrial cancer (Chapter 5). 
8.2.1 Directed differentiation towards terminally differentiated cells 
In directed differentiation protocols using hESCs, or patient specific iPSCs, cells 
are guided by means of cytokines towards specific fates, for example, via the myeloid 
lineage to megakaryocytes (blue arrows in Figure 8.2). To produce platelets in-vitro, 
progenitor cells are directed along the myeloid lineage using protocols based on those of 
Hiromitsu Nakauchi (Takayama et al., 2008).	  Combined in co-culture with the mouse 
bone marrow stromal cell line OP9 and exogenous cytokines it is possible to direct 
progenitor cells to a MK (thrombopoietin, blue arrow in Figure 8.2) or erythrocyte fate 
(erythropoietin) fate (Gao et al., 2010).	  However, this method has proved both expensive 
and inefficient even after much tweaking of the protocols the best results from 2 x 106 
iPSCs produced 4.5 x 105 CD34+ haematopoietic progenitors (96% purity) and finally 
106 megakaryocytes (99% CD41a+CD42b+, see Figure 8.5).  
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Figure 8.2 Routes to differentiation using Waddington’s metaphor for development  
Directed differentiation based on (Takayama et al., 2008) using co-cultures  
Cytokines: erythropoietin (EPO); Interleukin 3 (IL3); Thrombopoietin (TPO); Stem 
Cell Factor, Kit ligand or steel factor (SCF); Interleukin1β (IL1β). 
Forward programming (Moreau et al in preparation) Lentiviral transcription factors: 
globin transcription factor 1 (Gata 1); Friend leukaemia virus integration1 (Fli1); T-
cell acute lymphocytic leukaemia 1 (TAL1, Scl1). Cytokines: bone morphogenetic 
protein 4 (BMP4) 
 Reprogramming from peripheral blood progenitors to induced pluripotent cells 
using the four Yamanaka transcription factors (Takahashi and Yamanaka, 2006) also 
involves viral transduction using  oct4 , sox2, c-myc, klf4 
Routes to endothelial cells and other blood lineages 
? ? Final maturation steps from MK to PLT and fully enucleated RBC remain elusive 
Abbrvs: human embryonic stem cells (hESC); induced pluripotent stem cells (iPSC); 
embryoid bodies (EBs); long-term haematopoietic stem cells self renewing (LT-HSC); 
haematopoietic stem cells (HSC), multipotent progenitors (MPP), megakaryocyte/erythoblast 
precursor (MEP); megakaryocyte (MK); endothelial cell (EC); red blood cell (rbc).  
Transcription factors: purple 
Cytokines; red 
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8.2.2 Forward programming towards terminally differentiated cells 
  Haematopoiesis is controlled by a core group of transcription factors, shown by 
multiple transcription factor mapping, using genome wide sequencing data (Gottgens et 
al., 2002; Pimanda et al., 2007a; Pimanda and Gottgens, 2010). By manipulation of the 
transcription factor input it is possible to push progenitors forward to a myeloid 
phenotype and at the same time increase the efficiency of the differentiation process in-
vitro by programming the cells to myeloid precursors, in a way analogous to that of 
iPSC production using the four Yamanaka transcription factors (Takahashi and 
Yamanaka, 2006)	  (Figure 8.2). In effect, this manipulation causes re-wiring of the local 
gene regulatory network using combined ectopic expression of transcription factors and 
environmental stimuli. 
  By comparative analysis of the hESC line H9 (WA09, University of Wisconsin, 
USA) and cord blood MKs a set of key transcription factors were identified as 
candidates for lineage progression. Cloning of the transcription factors into lentiviral 
vectors, followed by transduction of hESCs and iPSCs, eventually led to three factors 
globin transcription factor 1(Gata1), Fli1 and T-cell acute lymphocytic leukaemia 1 
(Tal1, Scl1) which we now use to forward programme pluripotent iPSCs to the myeloid 
lineage (Thomas Moreau, in preparation) (Figure 8.2 red arrows). The three factors fit 
closely with the core regulatory circuit for haematopoiesis in the mouse, identified as a 
fully connected triad (Pimanda et al., 2007b)	  of the transcription factors:	  Gata 2, Fli1 
and Tal1/ Scl1 (Figure 8.3). All three factors are expressed in the dorsal aorta AGM 
(Figure 7.2) when HSC are formed, in the fetal liver where they are amplified (Dzierzak, 
2005), and in MKs highlighting a number of links between MK maturation and HSC 
development in the AGM (Gottgens et al., 2002; Huang and Cantor, 2009).  
  If the system is then made three-dimensional by the introduction of a human 
embryoid body (hEB) step the recovery of mature megakaryocytes is increased further.  
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Figure 8.3 The kernel gene regulatory network (GRN) responsible for 
early haematopoietic and endothelial development 
Part of a larger transcriptional network beginning with mesoderm induction, 
all but that of GATA1 involve positive interactions, GATA 1 interrupts GATA 
2-positive autoregulation pushing cells to differentiate. 
Gata 2 is required for early stages of myeloid differentiation and is 
overlapping with Gata 1, which is required for terminal differentiation (Chang 
et al., 2002). Fli 1 is an Ets transcription factor and in knockout mice vascular 
integrity and megakaryocyte differentiation are impaired (Spyropoulos et al., 
2000). Scl/Tal1 is a basic loop helix transcription factor required for 
specification HSC and the differentiation of erythroid and megakaryocyte 
lineages (Porcher et al., 1996). Transcription factors: globin transcription 
factor 1 (Gata 1); globin transcription factor 2 (Gata 2); Friend leukaemia virus 
integration1 (Fli1); T-cell acute lymphocytic leukaemia 1 (TAL1, Scl1). 
Cytokines: bone morphogenetic protein 4 (BMP4); vascular endothelial 
growth factor (VEGF). Adapted from (Pimanda et al., 2007b). Solid lines 
indicate direct binding. Red arrows indicate autoregulation. 
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  The size of hEBs now appears to be of particular relevance to the direction of 
stem cell development (Ng et al., 2005; Hwang et al., 2009). Recent technologies such 
as AggrewellTM (Stem Cell Technologies) allow for uniformity of size and shape of the 
hEBs, together with improved cell viability and transduction efficiency (Ungrin et al., 
2008). Manipulation of cell number per hEB, can alter potential fate, for example, 500 
cells per hEB favours the formation of haematopoietic cells (Figure 8.4). This applies to 
hEBs in particular which usually are more heterogenous in size than mouse EBs 
described in chapters 5 and 6.  
 
 
 
 
 
 
 
 
 
clumps of cells 
bursting out 
from EBs are 
haematopoietic 
progenitors
Figure 8.4 Going three-dimensional: Day 8 hEBs produced using AggrewellTM 
Images captured using a Leica DM IL LED microscope (Leica microsystems, UK). 
The cells are Bob iPSCs (originally from Ludovic Vallier, The laboratory of 
Regenerative Medicine, Cambridge). Top left: A single undifferentiated colony 
grown in feeder free conditions. Main Image: Day 8 cystic hEBs, formed using 
AggrewellTM plates with 400µm microwells, contain haematopoietic progenitors. 
Each EB was created from 500 iPSCs cells using TrypLETM (Life Technologies) to 
dissociate colonies, in the presence of a ROCK inhibitor Y27632 (Sigma) plus Gata 
1, Fli1 and Tal 1 lentivirus. Y27632 inhibits rho-associated protein kinase (ROCK) 
signaling allowing iPSC survival as single cells (Watanabe et al., 2007), by 
preventing apoptosis. White bars represent 500µM. 
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Table 3 Numbers of megakaryocytes from different in-vitro differentiation methods 
 
Source of 
Cells 
Mononuclear 
cell number 
 
iPSCs CD34+* 
Progenitors 
(positive 
selection) 
CD41a/CD42b* 
MK 
(positive 
selection) 
Expansion 
Cord blood 
75ml  
5.5 x 108  2 x 106 4.4 x 107 x 22 from 
CD34+ 
Mobilised 
peripheral 
blood 1ml 
3.0 x 108  2 x 106 2 x 107 x 10 from 
CD34+ 
Directed 
differentiation 
using OP9 
feeders then 
feeder free 
maturation  
N/A 2 x 106 4.5. x 105 1.1 x 106 x 2.4 from 
CD34+ 
 
x 0.5 from 
iPSCs 
Forward 
programming 
using 3 TFs, 
EBs and 
feeder free 
conditions 
N/A 1 x 106 N/A via 
EBs 
1.9 x 107 x 19 from 
iPSCs 
 
Table 3 Key: N/A Not Applicable; transcription factors (TFs); * absolute numbers of live 
purified cells; OP9 a murine stomal cell line established from newborn B6C3F1 op/op mouse 
(Kodama et al., 1994). The same iPSC line was used for directed differentiation and forward 
programming. The inclusion of both a brief mesoderm and an EB step have increased 
efficiency, contributing to the reduction of this bottleneck in production. On the basis of 106 
iPSCs (equivalent to half a well from a six well plate of cells) producing 1.9 x 107 MKs, and if 
100% of these (highly improbable at this point) produced 103 platelets each then 10 times this 
would be required for a single dose of 1011 platelets. 
 
  Forward programming increases efficiency compared to directed differentiation. 
From a starting population of 106 undifferentiated iPSCs it is possible to obtain nearly 
20 million double positive (for the MK antigens CD41a+CD42+) MKs, ~ 40 times the 
number obtained with directed differentiation protocols. 
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Figure 8.5 Sources of in-vitro derived megakaryocytes 
From left to right: cord blood derived MKs from CD34+ isolated progenitors (see chapter 
1.3); mobilised peripheral blood derived MKs isolated in the same way; iPSC derived MK by 
directed differentiation (Chapter 8.2.1); iPSC derived MK by forward programming using 
lentivirus (Chapter 8.2.2), using the same iPSC line. 
Top panel: Cytospins from sorted populations using EasySep PE positive selection kit (Stem 
Cell Technologies), of cultured megakaryocytes (MKs) stained with Rapid Romanisky (a 
mixture of cationic modified methylene blue nuclear stain and anionic eosin Y). Black Bars 
=10µm, numbers indicate ploidy, all four populations contain large multinucleated cells. 
Bottom panel: Flow cytometry plots of sorted MKs. Top right quadrants show positive 
staining for anti-CD41a APC (allophycocyanin conjugated), y axis and anti-CD42b PE 
(phycoerthrin conjugated), x axis. CD41a is integrin, alpha 2b, which is non-covalently 
associated with CD61 or GPIIIa (the integrin beta 3 chain) to form the GPIIb/IIIa complex, 
which binds fibrinogen, fibronectin, von Willebrand factor and thrombospondin. CD42b is 
the more mature marker of the two and reacts with GPIb (integrin I beta), which binds von 
Willebrand factor.  
Percentages are of CD41a/CD42b + sorted cells, all are gated on MK window by isotype 
control and are diamidino-2-phenylindole (Dapi) negative (live gate). 
All experimental data by A. Evans at the NHSBT Centre, Cambridge. 	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8.3 Cell - based therapies 
Using screened iPSCs it is conceivable that on-demand, controllable and 
biocompatible stocks of human leucocyte antigen (HLA) and human platelet antigen 
(HPA) phenotyped platelets can be made available to reduce the incidence of 
alloimmunization following transfusion. 
In addition, iPSC derived cells provide opportunities for drug screening and 
targeted gene repair for example in specific platelet disorders such as gray platelet 
syndrome (GPS) (Cramer et al., 1985) and thrombocytopenia with absent radius (TAR) 
(Hall et al., 1969) where the genetic defects have been identified. Mutations in 
Neurobeachin-like 2 (NBEAL 2), which encodes a BEACH/ARM/WD40 domain 
protein, are responsible for GPS (Albers et al., 2011; Kahr et al., 2011) and in RBM8A, 
encoding the Y14 subunit of exon-junction complex (EJC), cause TAR (Albers et al., 
2012). Using PBMNCs as the source, iPSC lines have been established for both GPS 
and TAR syndrome as the first step in the experiments depicted in Figure 8.6. 
The impact of reprogramming on the genomic and epigenetic integrity of iPSCs 
needs to be determined (Lister et al., 2011; Gore et al., 2011; Hussein et al., 2011). We 
now know the genetic code itself is not sufficient to determine gene expression or 
phenotype of a cell. A large consortium (BLUEPRINT http://www.blueprint-
epigenome.eu/) is currently deciphering both the epigenetic, and expression blueprint, of 
every cell type in the blood to provide a huge resource of data for researchers and 
clinicians. The source of the iPSC used may also prove to be a factor in the 
differentiation potential towards some cell types (Figure 8.6) and use of viral-free and 
non-integrating approaches are being explored (Warren et al., 2010). It is considered 
standard to assess generated induced pluripotent stem cells (iPSCs) for use in 
differentiation protocols by RNA-seq to profile global gene expression, bisulpite 
sequencing to assess epigenetic status and also chIP-seq using histone markers to give a 
profile of active and inactive genes (Rada-Iglesias et al., 2011). 
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Figure 8.6 Disease modeling and cell therapy using patient specific iPSC 
Creating patient specific stem cells allows disease modeling and drug screening in a human cell 
setting. It also allows the possibility of targeted gene repair. Inherited blood disorders for 
example gray platelet syndrome (GPS) an abnormality of platelet alpha storage granules, and 
thrombocytopenia absent radius (TAR) associated with thrombocytopenia and bilateral radial 
aplasia. 
Sources of iPSC include: peripheral blood mononuclear cells (PBMNCs); endothelial 
progenitor cells (EPCs), EPC are rare bone marrow derived cells that are recruited into the 
peripheral blood in situations of vascular repair/angiogenesis or vascular stress (Geti et al., 
2012); fibroblast cells (FBs) from dermal fibroblasts (using punch biopsies). 
Reprogramming to iPSCs using the four Yamanaka transcription factors (Takahashi and 
Yamanaka, 2006): Octamer-binding transcription factor 4 (Oct4); SRY (sex determining region 
Y)-box 2 (Sox2); Avian Myelocytomatosis Viral Oncogene Homolog (c-Myc); Kruppel-like 
factor 4 (Klf4). For GPS iPSCs both a polycistronic lentivirus STEMCCA (A.Evans) or 
individual retroviral constructs (A.Evans and The laboratory of Regenerative Medicine, 
Cambridge) were used. For TAR iPSCs STEMCCA (Somers et al., 2010) or Sendai virus 
(Nishimura et al., 2011)	  were used (The Childrens Hospital of Philadelphia, USA). 
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8.4 Scale-up 
Translation to the clinic requires many technical, ethical, regulatory and financial 
hurdles to be overcome. More than 200,000 units of 1011 platelets per unit are supplied 
annually (NHSBT, 2011) and each megakaryocyte produces around 103 platelets 
(Kaufman et al., 1965) in a self limiting process, since the megakaryocytes fragment 
during this process forming proplatelet extensions which bud platelets at their tips. 
Estimates for the required number of in-vitro produced megakaryocytes vary widely 
from 6 x 106 (about 60 culture plates) to 109 (about 1000 culture plates) (Lambert et al., 
2013) per unit of platelets for transfusion, clearly a huge challenge. 
 
8.4.1 Moving towards fully defined and xeno-free culture 
 
  Most “chemically defined media” contain animal derived lipids and bovine 
serum albumin so the next challenge is to convert entirely to xeno-free culture. 
Conversion to feeder-free conditions is another requirement, both for ESC and iPSC 
culture and in differentiation protocols, and work is underway to establish exactly what 
feeder lines such as OP9 provide.  
Complete profiling of any cells likely to be used in the translational process will 
be needed to follow good manufacturing process (GMP) criteria (The HipSCi, Human-
Induced Pluripotent Stem Cells Initiative, Wellcome Trust Sanger Institute).  
 
8.4.2 Preservation or recreation of normal physiological cues 
 
Tissue culture has come a long way since the establishment of the first human 
immortal cells in 1951 from tissue cut from the cervix of Henrietta Lacks (Skloot, 2010), 
starting an explosion in the use of in vitro cultured human cells. A PubMed search 
(August 2013) for HeLa, the acronym by which these cells are known, yielded > 75,000 
articles, producing masses of data relevant to our collective understanding of cell 
biology. But, this is tempered by the knowledge that in practice we are trying to describe 
and ultimately recapitulate three dimensional, in vivo, events. 
In vitro culture may lack biological relevance to the whole organism since life is 
in three dimensions where cells are ellipsoids, with their surface area either in touch 
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with other cells or with extra cellular matrix rather than flat with 50% of their surface 
touching a culture dish. Stem cell and replacement therapy may require another 
revolution in the adaption of biological matrices (Taylor, 2007) to resemble the in vivo 
state (Chiang et al., 2010). 
 Most cells, like those in the bone marrow niche where MKs mature, are in 
contact with ECM to which they adhere by surface receptors such as integrins, and are 
able to sense mechanical cues. Stem cell signalling can be altered by exposure to 
different porosity and stiffness of hydrogels (Watt and Huck, 2013). Modular bioreactor 
chambers are now manufactured under the patent name Quasi-vivo®  (Kirkstall Ltd, 
Sheffield, UK) to mimic the dynamic flow of nutrients in tissues and can incorporate 
scaffolds or tissue slices to create organ like chambers.  
8.5 The roadmap from stem cells to terminal differentiation: 
Concluding remarks 
  Taking advantage of new technologies as they appear and adapting these to 
specific questions, such as those described earlier for endometrial biology and then 
mesoderm induction, has left the overwhelming impression that to be able to achieve 
cell therapies of the future, we need to fully understand cells in the context of complex 
tissues. In addition, both normal and abnormal physiology gives us the boundaries 
within which we can manipulate the environment in which we produce in-vitro 
surrogates that are fit for purpose. In endothelial cell biology, control of the angiogenic 
switch is crucial to prevent metastatic invasion. In haematopoiesis, specifically myeloid 
differentiation, a pivotal point is in the decision to follow the megakaryocyte or 
erythrocyte route. 
  The close overlap in the hierarchal development and gene networks controlling 
the differentiation of haematopoietic cells and endothelial cells allow us to use the same 
basic protocols to drive cells towards the cell lineage of our choice. By modifying the 
genetic and environmental cues cells are exposed to, we are increasingly able to control 
the route of terminal differentiation. 
The greatest hurdle still to be overcome is the final maturation steps of both 
megakaryocyte platelet production and the enucleation of erythroid cells (Niwa et al., 
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2009; Dias et al., 2011). A few authors have published claims of having achieved 
platelet production in-vitro, but the evidence is not strong (Takayama et al., 2010 ; 
Nakagawa et al., 2013) and both directed differentiation and forward programming so 
far have produced far fewer platelet-like-particles (PLPs) or proplatelet extensions 
compared to cord blood-derived megakaryocytes. Efficient production of PLPs may 
require recapitulation of the bone marrow niche by use of three dimensional 
functionalised scaffolds with a mix of the cells types from the niche (Figure 8.1). RNA-
seq profiling and chIP-seq of these cells is allowing us to address these issues as the 
protocol evolves.  Both cell types provide a huge challenge particularly in the final 
crucial stages of maturation, but the goal is production of a fully functional alternative to 
donated blood and platelets. 
Future experiments, will include establishment of the final maturation steps of 
platelet formation to improve yield and activity, in the first instance, via creation of 
lentiviral vectors for genes differentially expressed in mature cord blood MKs and iPSC 
generated cells. Generating mesenchymal precursors and ECs in parallel from the same 
iPSCs (Eberle et al., 2012) may be a practical way to recapitulate the bone marrow niche 
in xeno-free conditions. Since, in-vivo, the vascular niche (Figure 8.1) of the bone 
marrow is the site of MK maturation, the timing of co-culture may be critical for this to 
be a positive effect on maturation.  
Many exciting challenges lay ahead. It may prove judicious, for example, to 
exploit the bipotential precursor origins of blood and vascular cells and expand stocks of 
multipotential cells as the starting point for patient specific endothelial tubules, RBCs or 
platelets (Lu et al., 2007). Advances in molecular profiling techniques and in somatic 
cell reprogramming have opened the door to potential new therapies and discoveries to 
improve human health. Alongside the use of autologous induced pluripotent stem cells 
(iPSCs), my hope is that I may contribute to the development of patient specific 
treatments and cell therapies using knowledge gained from these studies. 
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Appendices  
Web addresses 
Blueprint epigenome:      http://www.blueprint-epigenome.eu 
Cyber T:                           http://cybert.ics.uci.edu 
GOToolBox:                    http://genome.crg.es/GOToolBox/ 
HipSci:                             http://www.hipsci.org 
Mouse Atlas: The Medical Research Council and The University of Edinburgh.  
          http://www.emouseatlas.org/ 
NestedMICA:                  http://www.sanger.ac.uk/resources/software/nestedmica/ 
RMRG genelist:                         
http://www.obgyn.cam.ac.uk/genearray/supplementary/RMRG
_genelist.xls 
RSAT:                             http://rsat.ulb.ac.be 
SAM:                               http://www-stat.stanford.edu 
Source BioScience LifeSciences:  
                                         http://www.lifesciences.sourcebioscience.com 
WebLogo:                        http://weblogo.berkeley.edu 
Xenbase:                   http://www.xenbase.org/anatomy/alldev.do 
Zfin:                   https://zfin.org/zf_info/zfbook/stages/stages.html 
 
 
 
 
	                                                                                                                             Appendices 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 92	  
Appendix figure 1 VEGF Growth factor family and its receptors on endothelial 
cells display isoform specific functions 
Key: Vascular endothelial growth factor A and some of its 9 isoforms (VEGFA121, 145, 165), 165 
being the most abundant splice variant; Vascular endothelial growth factor B/C/D 
(VEGFB/C/D); Placental growth factor 2 (PlGF2); Vascular endothelial growth factor receptor 2 
(VEGFR2)/ Fetal liver kinase (Flk1)/ Kinase domain receptor (KDR); Vascular endothelial 
growth factor receptor1 (VEGFR1) /Fms-like tyrosine kinase (Flt1); soluble Flt1 (sFlt1); 
Semaphorin (SEMA), a ligand for neuropilin-1 (NRP1), and neuropilin-2 (NRP2) 
transmembrane non-tyrosine kinase glycoproteins; angiopoietins 1/2 (ANGPT1/2, Ang1/2) 
ligands  for the TEK tyrosine kinase (Tie2/TEK) receptor; Extracellular regulated kinase 
pathway (Erk) (mitogen activated protein kinase, MAPK); Phosphatidylinositol 3’ kinase (PI3K) 
activating protein kinase B (Akt/PKB). Based on a number of sources. 
VEGFD, also known as C-fos induced growth factor (FIGF) is associated with lymphatic 
endothelial cells and signals via VEGFR2 and vascular endothelial growth factor receptor 3 or 
Fms-related tyrosine kinase 4 (VEGFR3, Flt4) usually found on lymphatic endothelium (Achen 
et al., 1998) 
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Appendix Figure 2  Serial Analysis of Gene Expression (SAGE) 
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The technique of SAGE uses multiple enzymatic, amplification, purification, and 
cloning steps. Unlike cDNA arrays, no prior knowledge of transcripts is necessary and 
the frequency of each tag provides quantitative expression data.  SAGE can reliably 
detect rare transcripts but this requires the sequencing of many tags; 60,000 tags per 
sample for robust statistics means sequencing 3000-6000 clones.  
SAGE libraries were generated from serum-starved HUVEC treated with or 
without 10ng/ml VEGFA (Schoenfeld et al., 2004)*5. Sequencing cloned ditags on a 
small scale (5400) identified the same most abundant endothelial transcripts for 
example, the receptor for activated kinase C1 (Rack1), as Affymetrix Human U95A 
gene-chips (Affymetrix UK Ltd, UK) but did not identify VEGF regulated transcripts. 
This illustrates the need for large numbers of sequenced tags, in the tens of thousands, 
Appendix figure 2 Serial analysis of gene expression (SAGE) 
Illustrating the stages of SAGE, each of which needs to be optimised.  
SAGE is based on two principles. Firstly, short nucleotide sequence tags of 9-10 base 
pairs (bp) contain sufficient information to uniquely identify a transcript provided it is 
from a defined position within the transcript, for this purpose at the 3’ non-coding end of 
a transcript. A 9bp sequence can distinguish 262144 (49) transcripts. Secondly, 
concatenation of the short sequence ditags (when the tags have been ligated head to 
head) allows efficient analysis of transcripts in a serial manner by sequencing multiple 
tags within a single clone, ideally 10-20 tags per clone. 
Clones were sequenced using the ABI373 fluorescent DNA sequencer or the ABI 
PRISM 310 genetic analyser (PE Biosystems). Each machine could run 48 samples per 
run therefore requiring 60-120 runs per sample of 3000-6000 clones for representative 
data. 
Key: pppG7m-5'-triphosphate 7 methylguanosine cap; oligo dT 5’ biotin-NH (T)25-
oligonucluotide primer; RNase H enzyme to allow second strand synthesis by nick 
translation, b biotin; s Streptavidin Paramagnetic Particles (SA-PMPs); AE-anchoring 
enzyme Nla III recognizing the sequence CATG, which cleaves approximately every 24 
(256) bp; TE-tagging enzyme BsmF1 which cuts 10/14 bp from its recognition site; 
pGEM 3Zf (+) sph1/CIP-the cloning vector (Promega, UK) linearized with the enzyme 
SpH1 and treated with calf intestinal phosphatase 	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for each experiment. The technique required some molecular experience, a large 
sequencing capacity and downstream computing capacity to extract tags and convert 
them to transcripts. 
A disadvantage for studies of human endometrium was that SAGE required 5µg 
mRNA whereas the nylon cDNA arrays described in chapter 2, using alpha-33P 
deoxycytidine 5’ triphosphate (α-33P dCTP) labelled complex probes, required only 
0.5µg mRNA or approximately 5µg total RNA.	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Appendix	  figure	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Appendix figure 3 Axial Rotation of the mouse embryo 
Wildtype mouse embryo in-situ digoxigenin-labeled antisense mouse Brachyury 
detected with Mag/INT (brown) and FITC labelled antisense mouse axin 2 detected 
with BCIP/NBT (purple). 
A 8.5 dpc unturned embryo in embryonic sac shows specific staining in the node 
and primitive streak for Brachyury mRNA and for Axin 2 additional head process 
and paraxial mesoderm staining.  
B Before turning, dorsal side in concavity embryo dissected from embryonic sac 
C Embryo in process of axial rotation with respect to the dorsal ventral axis, the 
notochord clearly visible stained with Brachyury 
D	   8.75 dpc turned embryo with dorsal surface in convexity and the developing 
heart on the ventral surface 
Black bar indicates 250µm. Staining was absent in sense controls 
Embryo dissection and staining by A.Evans 
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Appendix table 1  Mouse developmental stages 
Theiler 
Stage 
dpc (range) / 
Embryonic Day 
E 
Somite  
No 
cell 
number 
Description 
1 
 
0-0.9 (0-2.5)  1 One-cell egg 
2 1 (1-2.5)   2-4 Dividing egg 
3 2 (1-3.5)   4-16 Morula 
4 
 
3 (2-4) 
 
 16-40  Blastocyst, Inner cell mass ICM apparent  
5 4 (3-5.5)   Blastocyst (zona-free)  
6 4.5 (4-5.5)   Attachment of blastocyst, primary 
endoderm covers blastocoel surface of 
ICM 
7 5 (4.5-6)   Implantation, formation of egg cylinder 
Ectoplacental cone appears, enlarged 
epiblast, primary endoderm lines mural 
trophectoderm  
8 6 (5-6.5)   Differentiation of egg cylinder. 
Implantation sites 2x3mm. Ectoplacental 
cone region invaded by maternal blood, 
Reichert's membrane and proamniotic 
cavity form  
9a 
 
6.5(6.257.25)   Pre-streak (PS), advanced endometrial 
reaction, ectoplacental cone invaded by 
blood, extraembryonic ectoderm, 
embryonic axis visible,  
9b 
 
   Early streak (ES), gastrulation starts, first 
evidence of mesoderm  
10a
 
7 (6.5-7.75)   Mid streak (MS), amniotic fold appears 
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Theiler 
Stage 
dpc (range) Somite  
No 
cell 
number 
Description 
10b
 
 
   Late streak, no bud (LSOB), exocoelom  
10c    Late streak, early bud (LSEB), allantoic 
bud first appears, node, amnion closing  
11a 7.5 (7.25-8)   Neural plate (NP), head process 
developing, amnion complete  
11b    Late neural plate (LNP), elongated 
allantoic bud  
11c    Early head fold (EHF)  
11d    Late head fold (LHF), foregut 
invagination  
12a
 
8 (7.5-8.75)   1-4  1-4 somites, allantois extends, 1st 
branchial arch, heart starts to form, 
foregut pocket visible 
12b    5-7  5-7 somites, allantois contacts chorion at 
the end of TS12   Absent 2nd arch, >7 
somites  
13 
 
8.5 (8-9.25)   8-12  Turning of the embryo, 1st branchial 
arch has maxillary and mandibular 
components, 2nd arch present Absent 3rd 
branchial arch 
14 
 
9 (8.5-9.75)  13-20  Formation & closure of ant. neuropore, 
otic pit indented but not closed, 3rd 
branchial arch visible Absent forelimb 
bud    
15 9.5 (9-10.25)  21-29  Formation of post. neuropore, forelimb 
bud, forebrain vesicle subdivides Absent 
hindlimb bud, Rathke's pouch  
16 10 (9.5-10.75)  30-34  Posterior neuropore closes, Formation of 
hindlimb & tail buds, lens plate, Rathke's 
pouch; the indented nasal processes start 
to form Absent thin & long tail  
17 10.5 (10-11.25)  35-39  Deep lens indentation, brain tube, tail 
elongates and thins, umbilical hernia starts 
to form  Absent nasal pits  
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Theiler 
Stage 
dpc (range) Somite  
No 
cell 
number 
Description 
18 11 (10.5-11.25)  40-44  Closure of lens vesicle, nasal pits, 
cervical somites no longer visible Absent 
auditory hillocks, anterior footplate  
19 11.5 (11-12.25)  45-47  Lens vesicle completely separated from 
the surface epithelium. Anterior, but no 
posterior, footplate. Auditory hillocks 
visible Absent retinal pigmentation and 
sign of fingers 
20 12 (11.5-13)  48-51  Earliest sign of fingers (splayed-out), 
posterior footplate apparent, retina 
pigmentation apparent, tongue well-
defined, brain vesicles clear Absent 5 
rows of whiskers, indented anterior 
footplate 
21 13 (12.5-14)  52-55  Anterior footplate indented, elbow and 
wrist identifiable, 5 rows of whiskers, 
umbilical hernia now clearly apparent 
Absent hair follicles, fingers separate 
distally    
22 14 (13.5-15)  56-~ 60  Fingers separate distally, only 
indentations between digits of the 
posterior footplate, long bones of limbs 
present, hair follicles in pectoral, pelvic 
and trunk regions Absent open eyelids, 
hair follicles in cephalic region 
23 15   Fingers & Toes separate, hair follicles in 
cephalic region but not at periphery of 
vibrissae, eyelids open Absent nail 
primordia, fingers 2-5 parallel   
24 16   Reposition of umbilical hernia, eyelids 
closing, fingers 2-5 are parallel, nail 
primordia visible on toes Absent wrinkled 
skin, fingers & toes joined together  
25 17   Skin is wrinkled, eyelids are closed, 
umbilical hernia is gone Absent ear 
extending over auditory meatus, long 
whiskers   
26 18   Long whiskers, eyes barely visible 
through closed eyelids, ear covers 
auditory meatus  
27
 
19   Newborn Mouse  
28    Postnatal development  
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Mouse embryos can be staged according to a variety of criteria, the most general of 
which are those described by Theiler in "The House Mouse: Atlas of Mouse 
Development" (Springer-Verlag, New York, 1989).     
Embryos of the same gestational age may differ in their stage of development. Included 
in the table an indication of the expected range of gestational ages (days of gestation, 
dpc) over which each developmental stage may be found. Images are from the mouse 
atlas website to illustrate key stages discussed in text.    
Adapted from emap edinburgh mouse atlas project.  
days post coitum (dpc)/Embyonic Day E  
From the mouse Atlas: The Medical Research Council and The University of Edinburgh.  
http://www.emouseatlas.org/	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Appendix table 2 PCR primers used for quantitative RT-PCR analysis  
For Chapter 6, Figure 6.6 
Markers of differentiation 
Primer  Type Sequence 5’ è3’ Amplicon bp 
β actin F  Endogenous control AGG TCA TCA CTA TTG 
GCA ACG A 
117 
β actin R Endogenous control CAC TTC ATG ATG GAA 
TTG AAT GTA GTT 
 
Brachyury F Mesoderm/primitive 
streak 
GCT TCA AGG AGC TAA 
CTA ACG AG 
117 
Brachyury R Mesoderm/primitive 
streak 
CCA GCA AGA AAG AGT 
ACA TGG C 
 
FOXA2F/ HNF3β 
 
 
Anterior primitive 
streak 
TAG CGG AGG CAA GAA 
GAC C 
150 
FOXA2R/ HNF3β Anterior primitive streak 
CTT AGG CCA CCT CGC 
TTG T 
 
FGF8F Mesoderm marker GTC CTG CCT AAA GTC ACA CAG  
206 
FGF8R Mesoderm marker CTT CCA AAA GTA TCG GTC TCC AC 
 
VEGFR2/KDR/FLK1 VEGF receptor GGA CCT CAG ACT GCA 
AGG AG 
181 
VEGFR2/KDR/FLK1 VEGF receptor TCT TGG AGG ACA GAG 
CCA CT 
 
	  
Markers	  of	  pluripotency	  
Primer  Type Sequence 5’ è3’ Amplicon bp 
CDH1 F/E-cadherin   Pluripotency marker CAG CCT TCT TTT CGG 
AAG ACT 
140 
CDH1 R/E-cadherin Pluripotency marker GGT AGA CAG CTC CCT 
ATG ACT G 
 
Oct 4 F/Pou5f1   Pluripotency marker GGC TTC AGA CTT CGC 
CTC C 
211 
Oct 4 R/Pou5f1 Pluripotency marker AAC CTG AGG TCC ACA 
GTA TGC  
 
Zfp42F/Rex1   Pluripotency marker CCC TCG ACA GAC TGA 
CCC TAA 
117 
Zfp42R/Rex1 Pluripotency marker TCG GGG CTA ATC TCA 
CTT TCA T 
 
	  	  
	                                                                                                                             Appendices 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 103	  
	  
GENE Common Name/s Accession 
numbers 
Gene Ontology                                                                                                         
Molecular 
Function/Biological 
Process/Expression 
Related
Reference 
Bcl6* B-cell leukemia 
lymphoma 6, Bcl5 
NM_009744 BCL6-deficient mice have 
reduced numbers of 
haematopoietic progenitor 
cells (HPC) BCL-6 is a 
transcriptional repressor  
(Kawamata et 
al., 1994) 
Bmp1 Bone morphogenetic 
protein 1 
NM_009755 Expressed in cardiomyocyes, 
placenta and smooth muscle 
(Suzuki et al., 
1996) 
Capns1 calpain, small subunit 
1, Capa4, Capn4 
NM_009795 Embryonic lethal 11.5 dpc, 
cardiac developmental 
defects, accumulation of 
nucleated erythroid cells in 
the heart chambers, blood 
vessels, and developing liver. 
(Fairfax et al., 
2010) 
Ccl1 chemokine (C-C 
motif) ligand 1 Scya1, 
Tca-3, CCR8 ligand 
NM_011329 Chemotaxis, attracts blood 
cells, an inflammatory 
cytokine in developing ECs. 
(Gombert et 
al., 2005) 
Cd300e CD300e antigen, 
Cd300le, Clm2, Trem5 
NM_172050 Cell surface receptor 
expressed on myeloid cells. 
(Brckalo et al., 
2010) 
Cebpa* CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
NM_007678 CEBPA is a bZIP 
transcription factor expressed 
in myeloid cells and drives 
granulocytic differentiation. 
(Reddy et al., 
2002) 
Clnk cytokine-dependent 
hematopoietic cell l 
linker MIST  
  Regulation of 
immunoreceptor signalling in 
T cells, NK cells, and mast 
cells 
(Cao et al., 
1999) 
DppIV* dipeptidylpeptidase 4,        
CD26, THAM 
NM_172256 
 
Expressed from 7.5 dpc 
umbilical artery, heart and 
somites, regulation of cell-
cell adhesion  
(Broxmeyer et 
al., 2012) 
 
Appendix table 3 Brachyury targets associated with key developmental processes 
leading to cell migration and cell specification 
           Genes associated with to haematopoietic and endothelial development *Transcripts	  also	  occur	  in	  list	  of	  Brachyury	  targets	  associated	  with	  cancer	  Appendix	  Table	  4	  
Abbrvs:	   Endothelial	   cells	   (EC);	   Epithelial-­‐mesenchymal	   transition	   (EMT);	   Natural	   killer	  cells	  (NK);	  Primitive	  streak	  (PS);	  T-­‐cell	  factor	  (TCF);	  basic	  Leucine	  Zipper	  Domain	  (bZIP).	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GENE Common Name/s Accession 
numbers 
Gene Ontology                                                                                                         
Molecular 
Function/Biological 
Process/Expression 
Related
Reference 
Ebf1 early B-cell factor 1 
O/E-1, Olf1 
NM_007897 B cell differentiation (Hesslein et 
al., 2009) 
Ebf2 early B-cell factor 2, 
D14Ggc1e, Mmot1 
NM_010095 Homozygous null mutants 
show decreased viability 
(Rajakumari et 
al., 2013) 
Epb4.1l
4a 
erythrocyte protein 
band 4.1-like 4a 
/NBL4 
NM_013512 Cytoskeletal protein involved 
EMT transition PS. 
(Ishiguro et 
al., 2000) 
Erg* avian erythroblastosis 
virus E-26 (v-ets) E-
twenty-six (ETS) 
related gene 
NM_133659 Vascular tissue from 8 dpc, 
regulation of angiogenesis, 
interacts beta catenin and 
gamma catenin, self renewal 
of embryonic HSCs. 
(Gitton et al., 
2002) 
Fut8 fucosyltransferase 8, 
alpha (1,6) 
fucosyltransferase 
NM_016893 Required for VEGFR2 
expression, regulates ECM 
proteins 
(Wang et al., 
2009) 
Fyb FYN binding protein, 
ADAP, FYB-120/130 
  7.5 dpc expressed developing 
HSC, adult T cells and 
thymus 
(Hunter et al., 
2000) 
Gcnt2 glucosaminyl (N-
acetyl) transferase 2 
NM_133219 
 
Expressed from 8 dpc 
allantois, blood islands, PS 
and mesoderm 
(Inaba et al., 
2003) 
Il6 Interleukin 6, 
Interferon, beta 2  
NM_031168 Acts on B-cells, T-cells, 
hepatocytes, HPCs, 
stimulates megakaryopoiesis 
in the bone marrow, 
increasing platelet numbers 
in circulation.  
(Barnes et al., 
2011) 
Krt8 Card2, cytokeratin 8, 
EndoA, K8, Krt-2.8, 
Krt2-8 
NM_031170 Intermediate filament 
protein, mice homozygous 
for a null allele show 
placental defects, impaired 
female fertility, abnormal 
haematopoiesis 
(Jaquemar et 
al., 2003) 
Lama4 laminin, alpha 4 NM_010681 7 dpc blood vessel 
development, cell adhesion 
and migration during 
embryonic development 
(Liu and 
Mayne, 1996) 
Laptm5
/ 
E3* 
lysosomal-associated 
protein transmembrane 
5 Clast 6  
NM_010686 Expressed 9.5d pc yolk sac 
and in resting mature B cells 
(Seimiya et al., 
2003) 
	                                                                                                                             Appendices 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 105	  
GENE Common Name/s Accession 
numbers 
Gene Ontology                                                                                                         
Molecular 
Function/Biological 
Process/Expression 
Related
Reference 
Meis1* Meis homeobox 1 NM_010789 7dpc found paraxial 
mesoderm, required for 
haematopoiesis 
(Cai et al., 
2012) 
Pax5* paired box gene 5, B 
cell-specific activator 
protein EBB-1 BSAP 
NM_008782 Essential for B cell 
development.  
(Busslinger 
and Urbanek, 
1995) 
Ptn pleiotrophin, HBGF-8, 
heparin-binding 
growth factor 8,  
NM_008973 Bone mineralization, cell 
proliferation, potent secreted 
regulator of HSC expansion 
and regeneration  
(Himburg et 
al., 2010) 
Robo4 roundabout homolog 4 
(Drosophila), magic 
roundabout 
NM_028783 Restricted HSCs and ECs, 
thought to counteract VEGF 
signalling via slit 2. 
Guidance molecule, 
localization of HSC to bone 
marrow niche  
(Huminiecki et 
al., 2002)  
 
Sema4a semaphorin 4A 
Semab, SemB 
NM_013658 7.5 dpc haematopoietic 
progenitor cells, suppresses 
angiogenesis  
(Toyofuku et 
al., 2007) 
Syk spleen tyrosine kinase NM_011518 Myeloid differentiation, 
positive selection of 
developing B cells.  
(Henderson et 
al., 2010) 
Tcl1b2 T-cell leukemia 
lymphoma 1B, 2 
NM_013775 Participates in embryonic 
stem (ES)-cells proliferation 
and during lymphoid 
differentiation  
(Ragone et al., 
2009) 
Uqcrh ubiquinol-cytochrome 
c reductase hinge 
protein  
NM_025641 From 7.5 dpc haematopoietc 
progenitors, also heart and 
skeletal muscle.  
(Easterday et 
al., 2003) 
Wasf1 WASP family 1,Scar, 
WAVE, WAVE-1 
NM_001024
936.1 
Robo 4 activation Wiskott-
Aldrich Syndrome Protein 
Family, lack of T cells and 
functional B cells 
(Yamazaki et 
al., 2003) 
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Appendix	   table	   4	   Brachyury	   targets	   associated	   with	   key	   developmental	  
processes	  leading	  to	  cell	  migration	  and	  cell	  specification	  
	  Genes	  associated	  with	  EMT,	  migration,	  adhesion	  and	  left-­‐right	  determination	  	  *Transcripts	  also	  occur	  in	  Brachyury	  targets	  associated	  with	  cancer	  Appendix	  Table	  5	  **	   Transcript	   also	   occurs	   in	   list	   of	   Brachyury	   targets	   associated	   with	   hematopoietic	  development	  Appendix	  Table	  3	  
Abbrvs:	   Epithelial-­‐mesenchymal	   transition	   (EMT);	   human	   embryonic	   stem	   cells	   (hESC);	  protein	  kinase	  C	  (PKC).	  	  
GENE Common Name/s Accession 
numbers 
Gene Ontology                                                                                                         
Molecular 
Function/Biological 
Process/Expression 
Related
Reference 
B4galnt
2 
beta-1,4-N-acetyl-
galactosaminyl 
transferase 2  Dlb1 
NM_008081 
 
Down regulation of cell-cell 
adhesion, maybe required 
implantation mice. 
(Li et al., 
2011) 
Bapx1 NK3 homeobox 2 
Nkx-3.2, Nkx3-2, 
Bagpipe 
NM_007524 9.5 dpc to adult, expressed 
first in the somites, marker of 
ventral domain sclerotome, 
involved left/right signalling  
(Hecksher-
Sorensen et 
al., 2004) 
Cml4 camello-like 4, Nat8 
N-acetyltransferase 8  
NM_023455 7.5 dpc overexpression 
prevents gastrulation 
Xenopus leavis. Integral to 
membrane, negative 
regulation of cell adhesion 
(Popsueva et 
al., 2001) 
Ctnnb1
* 
catenin (cadherin 
associated protein), 
beta 1 Catnb, Mesc 
NM_007614 Homozygous null embryos 
show A-P axis anomalies. 
Part of adherens junction 
complex, key component of 
the canonical wnt pathway. 
(Zhang et al., 
2012) 
Dlx5 distal-less homeobox 5 NM_010056 
 
6 dpc embryonic limb 
development.  
 (Simeone et 
al., 1994) 
Dync2li
1 
dynein cytoplasmic 2 
light intermediate 
chain 1, , D2lic, LIC3 
NM_172256 7dpc cilium biogenesis, 
determination of left/right 
symmetry 
(Vandenberg 
and Levin, 
2013) 
Elmod1 ELMO/CED12 
domain containing 1 
AK164094 GTPase activating protein 
interacts Rac1 
(Johnson et al., 
2012) 
Epb4.1l
4a 
erythrocyte protein 
band 4.1-like 4a 
/NBL4 
NM_013512 Widely expressed component 
of the β catenin / TCF 
pathway. Involved EMT 
transition PS.  
(Ishiguro et 
al., 2000) 
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GENE Common Name/s Accession 
numbers 
Gene Ontology                                                                                                         
Molecular 
Function/Biological 
Process/Expression 
Related
Reference 
Fgf8 Fibroblast growth 
factor 8 Aigf 
NM_010205 Left determination. In vitro 
hESC culture for mesoderm 
formation. 
(Crossley and 
Martin, 1995)  
Foxa2 forkhead box A2 Hnf-
3b, HNF3-beta, Hnf3b, 
HNF3beta, Tcf3b  
NM_010446 
 
From 5.5 dpc visceral 
endoderm then PS and node, 
required anterior axial 
mesoderm and definitive 
endoderm. 
(Ang and 
Rossant, 1994) 
Gcnt2*
* 
glucosaminyl (N-
acetyl) transferase 2, I-
branching enzyme  
NM_133219 
 
Expressed from 8 dpc 
allantois, blood islands, PS 
and mesoderm.  
(Inaba et al., 
2003) 
Gnb2l1/ 
Rack1* 
RACK1, receptor for 
activated kinase C1 
NM_008143 Expressed from 10.5 dpc at 
least, regulates anchorage 
independent growth. 
(Mochly-
Rosen et al., 
1995) 
Jup Junction plakoglobin 
gamma-catenin, 
CTNNG, ARVD12 
NM_010593 
 
Homozygous null mutants 
die with severe heart defects.  
(Asimaki et 
al., 2007) 
Kif23 kinesin family member 
23 CHO1, MKLP1 
NM_024245 Essential for cytokinesis. (Nislow et al., 
1992) 
Lmx1b LIM homeobox 
transcription factor 1 
beta LMX1.2 
NM_010725 
 
7.5 dpc cell specification and 
morphogenesis particularly 
of dorsal limb structures 
(Chen et al., 
2011) 
Mapre2 microtubule-associated 
protein, RP/EB family, 
member 2 EB2 
NM_153058 7 dpc involved proliferation 
& migration of normal cells  
(Tirnauer et 
al., 2002) 
Rttn rotatin (no turning) NM_175542 7.5- 8.5 dpc telencephalon, 
mesoderm, somites, 
notochord 9.5 dpc forelimb 
bud. Failure of axial rotation 
in Rttn mutant  
(Faisst et al., 
2002) 
Snai2* snail homolog 2b 
(Drosophila) Slug, 
Slugh, Snail2 
NM_011415 7.5 dpc in PS, 8dpc 
notochord and somites. 
Migration of neural crest 
cells, controls cardiac EMT 
via Notch/TGF beta-BMP 
pathways and represses E 
cadherin  
(Nelson and 
Nusse, 2004)  
Vangl1
* 
vang-like 1 (van gogh, 
Drosophila) Kitenin, 
Lpp2, mStbm, stbm 2 
NM_177545 
 
Cell polarity and migration, 
Associated neural tube 
defects and spina bifida  
(Kibar et al., 
2007) 
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Appendix table 5 Brachyury targets associated with key developmental processes 
leading to cell migration and cell specification 
                      Brachyury targets associated with a cancer phenotype Many	  of	  these	  genes	  reflect	  similarities	  between	  cancer	  cell	  migration	  and	  the	  gene	  profile	  of	  cells	  involved	  in	  the	  cell	  movements	  of	  gastrulation	  and	  mesoderm	  formation	  and	  embryonic	  development.	  
Abbrvs:	  acute	  myeloid	  leukemia	  (AML);	  acute	  lymphoblastic	  leukemia	  (ALL);	  v-­‐erb-­‐b2	  
erythroblastic leukemia viral oncogene homolog (ErbB2, Her2, Neu); small-cell lung cancer 
(SCLC); non-small cell lung cancer (NSCLC). 
GENE Common Name Accession 
numbers 
Gene Ontology/Cancer 
Association 
Related 
Reference 
Bcl6 B-cell 
leukemia/lymphoma 6 
Bcl5 
NM_009744 BCL-6 represses lymphocyte 
differentiation, Diffuse large 
B cell lymphomas (DLBCL) 
(Shaffer et al., 
2000) 
Cebpa CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
NM_007678 CEBPA is involved in cell 
cycle arrest, repression of 
self-renewal and myeloid 
differentiation during normal 
hematopoiesis. In AML 
mutations in CEBPA result in 
a cellular differentiation 
block 
(Grossmann et 
al., 2012) 
Ctnnb1 catenin (cadherin 
associated protein), 
beta 1 Catnb; Mesc 
NM_007614 Component canonical wnt 
pathway Considered an 
oncogene many cancers  
(Polakis, 
2000) 
DppIV dipeptidylpeptidase 4, 
CD26, THAM, 
adenosine deaminase 
complexing protein 2     
( ADCP 2) 
NM_010074 Expressed in many kinds of 
human malignancy, 
including mesothelioma, 
renal cell carcinoma, and T 
cell leukemia/lymphoma 
(Masur et al., 
2006) 
Erg E-twenty-six (ETS) 
related gene 
 
NM_133659 ERG deregulation associated 
prostate cancer and rare 
myeloid and lymphoid 
leukemias. 
(Narod et al., 
2008) 
Gm879 Gene model 879, Shisa 
6 homolog 6(Xenopus 
laevis)  
NM_001034
874 
p53 inducible gene, pro-
apoptotic and possible anti 
cancer target 
(Furushima et 
al., 2007) 
Gnb2l1/ 
RACK1 
RACK1 receptor for 
activated kinase C1 
NM_008143 Localized to the endothelium 
of tumor neovascularization. 
In vivo associated with 
angiogenesis and carcinoma. 
(Berns et al., 
2000) 
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GENE Common Name Accession 
numbers 
Gene Ontology/Cancer 
Association 
Related  
Reference 
Junb Jun-­‐B	  oncogene/AP-­‐1	  activator	  protein	  1	   	  	   Limits	  HSC	  proliferation	  and	  differentiation,	  reduced	  expression	  metastatic	  prostate	  cancer.	  
(Santaguida 
et al., 2009)	  
Laptm5
/E3 
lysosomal-­‐associated	  protein	  transmembrane	  5	  Retinoic	  acid-­‐inducible	  E3	  	  
NM_010686	   Transmembrane	  receptor	  associated	  with	  lysosomes,	  hematopoietic	  cell-­‐specific	  transcript	  induced	  by	  retinoic	  acid,	  loss	  is	  a	  key	  event	  multiple	  myeloma	  
(Hayami et 
al., 2003)	  	  
Map2k
5 
mitogen	  activated	  protein	  kinase	  kinase	  5,	  MEK5	  MAPK/ERK	  kinase	  5,	  Mapkk5,	  	  
NM_011840	   Homozygous	  mutants	  die	  at	  10.5	  dpc	  and	  exhibit	  abnormal	  cardiac	  development,	  MEK5	  overexpression	  is	  associated	  with	  metastatic	  prostate	  cancer.	  	  
(Mehta et al., 
2003)	  
Meis1 Meis	  homeobox	  1	   NM_010789	   From	  7	  dpc	  paraxial	  mesoderm,	  required	  for	  haematopoiesis	  transcriptional	  regulation	  Pax	  6	  acute	  myeloid	  leukemia	  AML	  and	  ALL	  
(Argiropoulo
s et al., 2007)	  
Mov10 Moloney	  leukemia	  virus	  10	   NM_008619	   Involved	  polycomb	  repression	  of	  INK4a	  tumour	  suppressor.	   (El Messaoudi-Aubert et al., 
2010)	  
Ovgp1 oviductal	  glycoprotein	  1,	  Chit5,	  MOGP,	  MUC	  9,	  	  OGP,	  Ovgp1,	  oviductin	  
NM_007696	   Overexpressed	  human	  endometrial	  hyperplasia	  and	  associated	  with	  ovarian	  cancer.	  
(Maines-
Bandiera et 
al., 2010)	  
Pax2 paired	  box	  gene	  2	   NM_011037	   Mediator	  of	  ER	  repression	  of	  erbB2	  by	  the	  anti-­‐cancer	  drug	  tamoxifen,	  loss	  is	  associated	  with	  endometrial	  adenocarcinoma	  
(Silberstein et 
al., 2002)	  
Pax5 paired	  box	  gene	  5,	  B	  cell-­‐specific	  activator	  protein	  EBB-­‐1	  BSAP	   NM_008782	   Deregulated	  expression	  in	  many	  cancers	  specifically	  SCLC.	  Pax	  5	  expression	  correlates	  with	  increasing	  malignancy	  in	  human	  astrocytomas.	  
(Kanteti et 
al., 2009)	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GENE Common Name Accession 
numbers 
Gene Ontology/Cancer 
Association 
Related 
Reference 
Snai2 snail	  homologmeis1	  2b	  (Drosophila)	  Slug,	  Slugh,	  Snail2	   NM_011415	   EMT	  associated	  cancer	  metastasis,	  and	  induction	  of	  Snail2	  is	  essential	  for	  Twist	  1	  to	  induce	  EMT	  by	  E-­‐	  cadherin	  down	  regulation	  
(Chakrabarti 
et al., 2012)	  	  
Stmn1 stathmin	  1	  19K,	  Lag,	  Lap18,	  leukemia	  associated	  phosphoprotein	  p18,	  metablastin,	  	  
NM_019641	   Involved	  EC	  differentiation	  and	  angiogenesis,	  high	  expression	  in	  leukemic	  cells	  and	  B	  cells.	  Prognostic	  marker	  associated	  colorectal	  cancer	  metastasis	  
(Karst et al., 
2011)	  
Trim28 tripartite	  motif	  protein	  28,	  KAP-­‐1,	  KRIP-­‐1,	  Tif1b	   NM_011588	   DNA	  binding	  and	  regulation	  of	  transcription,	  transcriptional	  co-­‐repressor,	  involved	  EMT	  
(Fitzgerald et 
al., 2013)	  
Vangl1	   vang-­‐like	  1	  (van	  gogh,	  Drosophila)	  KITENIN,	  Lpp2,	  mStbm,	  stbm	  2	  
NM_177545	  	   	  Cell	  polarity	  and	  migration,	  associated	  with	  breast	  cancer	  progression	   (Anastas et al., 2012) 
Wt1 wilms	  tumor	  	  (Nephroblastoma)	  homolog	  	   NM_144783	  	   WT	  protein	  required	  for	  embryonic	  development,	  implicated	  hematologic	  disorders.	  Co-­‐expressed	  with	  pax2	  in	  breast	  cancer,	  associated	  leukemia	  and	  solid	  tumours	  
(Silberstein et 
al., 2002)	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Appendix table 6 Notable/putative Brachyury target genes just outside statistical 
significance using the whitehead error model 
When triplicate chIP arrays are analysed these genes were just outside the strictest criteria but 
called as bound when arrays are analysed individually (combined p values are very close to the p 
values set of < 0.01 for central bound probes to < 0.05 for the neighbouring probe. Of particular 
note are VEGF, BMP4, FLI-1 and Notch1. Using either chIP Analytics software (Agilent 
Technologies) or direct plotting from the data all these genes showed evidence of being genuine 
mouse T targets. 
Abbrvs:  Acute lymphoblastic leukaemia (ALL); anterior-posterior axis (A-P axis); β catenin 
(ctnnb1); Extracellular matrix (ECM); epithelial-mesenchymal transition (EMT); E-twenty six 
(ETS); Natural Killer (NK). 
GENE Common Name/s Gene Ontology/Expression                                                                                                  Reference 
Bmp4 Bone 
Morphogenetic 
Protein 4 
Morphogen for mesoderm 
induction, expressed before 
Brachyury 
(Winnier et al., 
1995) 
Dll1   Delta-like 1 
(Drosophila) 
Notch Ligand, cell-cell 
communication 
7-7.5dpc paraxial mesoderm 
and somites 
(Bettenhausen et 
al., 1995) 
Fgfbp1 Fibroblast Growth 
Factor Binding 
Protein 1 
Associated adenocarcinoma, 
cell proliferation, enhances Fgf 
signalling.  
(Czubayko et 
al., 1997) 
Fgfr2 Fibroblast Growth 
Factor Receptor 2, 
Bek 
Receptor for fgf, implicated 
breast and endometrial cancer 
(Ingersoll et al., 
2001) 
Fli1 Friend leukaemia 
integration 1 
EWSR2, Fli-1, Sic1 
Transcriptional activator, 
required for myeloid 
differentiation, ALL associated 
(Watson et al., 
1992) 
Hhex homeobox, 
haematopoietically 
expressed 
Transcriptional repressor 
expressed specific 
haematopoietic lineages B 
Cells and myleloid cells 
(Bedford et al., 
1993) 
Lef1 Lymphoid Enhancer 
Binding Factor 1, 
TCF1α 
Activation of transcription with 
ctnnb1 in wnt pathway  
(Figure 3A Evans et al *12), 
overexpressed colon cancer 
(Hovanes et al., 
2001) 
Notch1 Notch gene 
homolog1 
(Drosophila) 
Receptor for jagged and delta. 
Left-right patterning and 
haematopoietic differentiation 
(Bigas et al., 
2010) 
Vegfa Vascular Endothelial 
Growth Factor A  
Vascular growth factor and 
mitogen (see Chapter 1) 
(Ferrara and 
Davis-Smyth, 
1997)	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Abstract
Vasculogenesis, angiogenesis and vascular remodelling are complex processes where the fate of several cell types is
determined by diﬀerent signalling networks. Many of these networks ultimately function by changing the
abundance of RNA transcripts within the cells which constitute blood vessel walls. Researchers can now map these
transcript abundance changes using gene array technology. In this review, we describe the design, production and
use of a gene array speciﬁcally tailored to investigate vascular biology. We describe the advantages of tailored gene
arrays, and give detailed protocols based on our experience to allow the reader to use such gene arrays to generate
meaningful data. We list the issues to consider when choosing and verifying the genes and splice variants included in
an array, and describe our use of Arabidopsis sp. RNA spikes for quality control. We present data that illustrates the
absolute necessity for both technical and biological replicates to be incorporated in the design of gene array
experiments using primary cells such as HUVECS. Finally, we describe methods for the normalisation and
interpretation of the data that gene arrays produce. The approach to gene array technology described here is easily
within reach of the budget and expertise of most academic research groups.
Abbreviations: QC – quality control; HUVEC – human umbilical vein endothelial cells; PCR – polymerase chain
reaction
Introduction
The recent development of DNA array technology has
substantially altered the conduct of angiogenesis re-
search. This technology allows the abundance of a large
number of transcripts within complex RNA populations
to be determined simultaneously. For the ﬁrst time this
oﬀers researchers the prospect of understanding the
subtle interactions between multiple genes that may
underlie complex cellular behaviours. For example,
vasculogenesis, angiogenesis and vascular remodelling
are complex processes involving interaction between
several cell types within and outside the vessel wall [1–3].
We are using gene arrays to determine the transcript
abundance regulation that underlies these processes.
Gene arrays come in two main types: large generic
arrays and small tailored arrays. Large generic gene
arrays, are available commercially or by collaboration
with dedicated gene array laboratories. One well estab-
lished large generic technology is the Aﬀymetrix Gene-
chip system (Aﬀymetrix Inc. Santa Clara, California,
USA, http://www.aﬀymetrix.com) [4] in which two-
dimensional arrays of synthetic oligonucleotides are
synthesised using a combination of photolithography
and solid phase DNA synthesis [5, 6]. Aﬀymetrix gene
chips allow thousands of transcripts to be analysed in a
single hybridisation, and are ideal for experiments in
which researchers wish to search for unexpectedly
regulated genes. While we, and others have shown that
this approach can be extremely informative for angio-
genesis research [7], it is inappropriate for many
experimental designs. Commercial generic arrays are
expensive and academically produced generic arrays of
limited availability. Therefore, generic gene arrays may
be impractical when a large number of experimental
replicates are required. In addition, the genes included in
most generic arrays are inﬂexible, and frequently omit
genes and splice variants of interest. An alternative
approach is for individual research laboratories to
construct relatively small tailored gene arrays focussed
on their speciﬁc research interests. These have the
advantage of low cost, which allows researchers to
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Correspondence to: Dr Stephen Charnock-Jones, Reproductive Mo-
lecular Research Group, Department of Obstetrics and Gynaecology,
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perform suﬃcient replicates to maximise experimental
power. In addition, tailored gene arrays encourage
researchers to perform well planned, hypothesis driven
experiments investigating a focused set of transcripts.
New genes and splice variants can be added whenever
required, and detailed quality control (QC) performed.
Small tailored gene arrays also oﬀer the option to use
radioactively labelled complex cDNA probes. These
have been used successfully since 1983 [8], and require as
little as 3–5 lg of total RNA. In contrast most ﬂuores-
cent labelling techniques require 20–50 lg of total RNA
[9]. Although cDNA ampliﬁcation methods such as the
SMART system (BD Biosciences, Clontech, Oxford,
UK) allow ﬂuorescent arrays to be used with small
amounts of starting material, they are yet to gain wide
acceptance due to concerns about linearity and repre-
sentation. The ability to use small amounts of starting
material is essential for many studies involving angio-
genesis. In the female reproductive tract for example,
only small samples of tissue or cells are available from
biopsies.
To perform studies requiring multiple replicates with
limited amounts of RNA, at reasonable cost, we have
designed and produced a tailored gene array focused on
the processes involved in vascular biology (endothelial
and smooth muscle cell proliferation, apoptosis, migra-
tion, diﬀerentiation, activation and morphogenesis).
This tailored array currently comprises 988 unique
cDNAs (1171 total cDNAs including controls and
multiple sequences from some genes) generated by
PCR and spotted in duplicate onto a nylon membrane.
These membranes are hybridised with 33P-labelled
complex cDNA probes derived from 5 lg of total
cellular RNA. We have validated the production,
hybridisation and analysis steps required to utilise this
tool (Figures 1a, b). This approach brings the ability to
monitor the abundance of hundreds of transcripts
within reach of any academic research group. The aim
of this review is to promote the use of gene arrays by
vascular biologists who have no previous genomics
experience. Therefore, we will describe the gene array
methods developed in our laboratory in simple terms,
but we will provide suﬃcient detail to allow our methods
to be easily replicated.
Clone selection and veriﬁcation
The array method described here is based on spotting
cDNA fragments generated by PCR onto nylon mem-
branes. The selection of the cDNA fragment to be
ampliﬁed is a crucial step, since fragments must show
little or no homology to other genes. For closely related
gene families (such as the VEGF family), we have
generated speciﬁc fragments which can distinguish
family members [10, 11], but for most genes we have
obtained appropriate fragments from the IMAGE
consortium (http://www.hgmp.mrc.ac.uk). Ideally,
cDNA fragments should be relatively short (0.6–2 kb).
The inclusion of 3¢ non-coding regions often allows
discrimination between related transcripts that share
close homology within their coding regions. Careful
attention was also given to selection of cDNAs that
would hybridise either to every splice variant of a
transcript, or to individual splice variants of interest. We
have found that web-based software provided by Com-
pugen (http://www-labonweb.com/) is helpful to predict
splice variants. The 988 cDNAs chosen for the array
were selected to include the molecular pathways believed
to be important in vascular biology. These include cell
adhesion, apoptosis, signalling, cell cycle regulation,
extracellular matrix remodelling and angiogenesis. The
entire list can be seen at http://www.obgyn.cam.ac.uk/
genearray. A signiﬁcant proportion of the clones held by
the IMAGE consortium have been miss-assigned there-
fore, all the clones included on the array have been
validated by re-sequencing.
Generation of PCR products
Ampliﬁcation of cDNA clones requires a robust proto-
col to amplify hundreds of diﬀerent inserts of varying
sizes using a universal primer set (see Protocol 1). A
variety of PCR conditions and enzymes were tested to
optimise the yield of PCR product in a 96 well format
(Figure 2). Biotaq DNA polymerase (Bioline, London,
UK) consistently generated the most PCR product at
the lowest cost. Randomly chosen wells from each plate
were checked on 1.2% agarose gels (Figure 1a, Protocol
2); the results forming part of the QC information for
each batch of arrays. In order to produce enough
puriﬁed cDNA to print a large batch of nylon mem-
branes (approx. 600), with suﬃcient cDNA to achieve
satisfactory sensitivity, approximately 40–50 lg of each
puriﬁed PCR product was prepared in 100 ll of water.
Eight PCR reactions each of 50 ll were suﬃcient to
provide this amount from each clone. The PCR prod-
ucts were pooled, puriﬁed and concentrated using the
Millipore Multiscreen 96 system (Millipore, Watford,
UK) with a vacuum manifold as described in Protocol 2.
Quantiﬁcation of PCR products prior to spotting
PCR products were quantiﬁed with SYBR Green I
(Sigma, Poole, UK), an ultrasensitive stain for double
stranded DNA. This method uses Blue Fluorescence
Imaging on a Molecular Dynamics (Buckinghamshire,
UK) Storm 860 Phosphoimager and required only 2 ll
of each product [see protocol 2]. This method was rapid
and contributed to the archive of QC data relating to
each batch of nylon membranes. The concentration of
each cDNA product was adjusted to approximately
400 lg/ml to ensure even spotting.
Printing of nylon membranes
Contact printing was carried out using a BioRobotics
MicroGrid robot (BioRobotics Inc., a subsidiary of
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Figure 1. (a) Production and use of the angiogenesis array, (b) array image produced by probing with radiolabelled cDNA produced from 5 lg
total human secretory phase endometrium RNA.
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Apogent Discoveries, Hudson, New Hampshire, USA)
and a 96 pin tool to create a 12 · 8 metagrid, 5 · 5
subgrid matrix yielding a theoretical maximum of
25 · 96 (2400) individual spots (Figure 1b). The puri-
ﬁed PCR products were spotted in water in duplicate
onto pre-cut (12 · 8 cm) Hybond N+ (Amersham
Pharmacia Biotech UK Limited, Buckinghamshire,
UK). Each spot was printed with two strikes of a
0.4 mm diameter solid pin. and contained approxi-
mately 14 ng of DNA product. After printing, the
membranes were air dried, soaked in a denaturing
solution (0.5 M NaOH, 1.5 M NaCl for 10 min at
room temp.), neutralised (0.5 M Tris pH 7.4, 1.5 M
NaCl for 4 min at room temp.), air dried, cross linked
(70,000 lJ/cm)2) using a Stratalinker UV Crosslinker
model 1800 (Stratagene, La Jolla, California, USA)
and stored dry at room temperature. This protocol is
superior to either baking or air drying [12].
Validation and sensitivity
To enable QC and validation of the hybridisation we
have incorporated several controls into the design of the
array. These comprised:
(i) negative controls, (i.e. target DNAs that should not
hybridise to complex cDNA generated from total RNA)
such as salmon sperm DNA. Poly dA(40–60), and
human Cot-1 DNA (enriched with Alu and Kpn
repeats, [13]) were also spotted to conﬁrm that hybridi-
sation to these sequences was eﬃciently blocked by the
prehybridisation step.
(ii) targets which may be used as normalisation
controls (b-actin, cyclophilin, 18S ribosomal RNA,
hypoxanthine ribosyl transferase, glyceraldehyde-3-
phosphate dehydrogenase, ubiquitin and histidyl tRNA
synthetase). This enable a suitable endogenous control
to be chosen for subsequent real-time PCR conﬁrmation
of transcript abundance changes.
(iii) Exogenous cDNA clones from Stratagene’s Spot
Report Exogenous Array Validation System (Strata-
gene, California, USA). These cDNAs from Arabidopsis
Figure 2. Testing DNA polymerases for eﬃciency of ampliﬁcation.
PCR ampliﬁcation of ﬁve IMAGE clones carried out under identical
conditions, using four diﬀerent polymerises using the protocol de-
scribed in protocol 1. Bioline taq DNA polymerase gave consistently
the best yield. (a) YieldAce Stratagene 2.5 U/reaction, (b) Biotaq
Bioline 1.25 U/reaction, (c) ABgene 2 · Master Mix 1.25 U/reaction,
(d) Promega 2 · Master Mix 1.25 U/reaction.
Figure 3. (a) Reliable detection of Arabidopsis sp. RNAs. Radiola-
belled cDNA was produced from ﬁve separate aliquots of 5 lg human
placental RNA. Prior to labelling each was spiked with Arabidopsis
sp., RNA (500 pg to 1 pg as protocol 3). Following hybridisation,
image analysis and normalisation the means of each spike duplicate
across the ﬁve membranes was plotted. The low coeﬃcients of variance
for each spike RNA indicates close agreement between the ﬁve
hybridisations.
coeﬃcient of variance
Spike 1 CAB Chlorophyll a/b binding protein 0.056
Spike 2 RCA RUBISCO activase 0.078
Spike 3 rbcL Ribulose-1 -5-biphosphate carboxylase/
oxygenase 0.050
Spike 4 LTP4 lipid transfer protein 0.057
Spike 5 LTP6 lipid transfer protein (not shown) 0.046.
(b) Linearity of signal intensity to the amount of DNA spotted is
maintained after reverse transcription. rbcL ribulose-1-5-biphosphate
carboxylase/oxygenase dilution series of DNA spotted in addition to
the set of Arabidopsis sp. in 3a, each point is the mean signal intensity
of 10 spots. Five membranes were hybridised to a radiolabelled mix of
50 pg rbcL RNA spiked into 5 lg human placental RNA. Errors ± 1
SE.
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thaliana show no cross-hybridisation to human
sequences. They provide a convenient method to moni-
tor interarray variability and the sensitivity of the
arrays. For example known amounts of cRNA corre-
sponding to each of the spot report cDNAs were
‘spiked’ into ﬁve separate 5 lg aliquots of the same
placental total RNA. The amounts of each spike
RNA used are shown in Protocol 3. The spiked total
RNA samples were then labelled and hybridised to
ﬁve separate arrays. Following image analysis and
normalisation, the mean intensity of the cDNA spots
corresponding to each of the spikes was determined
(Figure 3). As expected the CAB RNA, which was
added at 500 pg, gave the strongest signal. The re-
sults for each spike exhibited low coeﬃcients of variance
(Figure 3) indicating reliable detection of these RNAs
in the placental RNA sample. We were also able to
determine the sensitivity of the arrays using this data. By
depositing 14 ng cDNA per spot on the membrane we
were able to detect 10 pg of mRNA (LTP4) at a signal
intensity ﬁve times above background. Thus we are able
to detect transcripts at an abundance of approximately
0.01% with good consistency.
RNA preparation and QC
High quality RNA is essential for eﬃcient labelling and
optimal hybridisation. Several issues need to be consid-
ered: labelling of degraded RNA or RNA contaminated
with protein or carbohydrate will be variable, producing
misleading results. In addition, contaminating genomic
DNA may increase the background signal and therefore
should be eliminated. Finally, when limited amounts of
tissue or cells are available, the method chosen should
produce a high RNA yield [14]. Of a wide variety of
methods tested, Trizol (Gibco, Life Technologies,
Paisley, UK) produced the highest yield with acceptable
purity. After isolation, all RNAs are treated with
DNAse (using DNase I at 8 units/100 ll RNA for
30 min at 37 C, Ambion, Inc., Texas, USA), followed
by a further Trizol extraction. Samples were checked
for genomic DNA contamination by PCR using primers
for the Histydyl tRNA Synthase gene (forward 5¢
CCGCAGGTCGAGACAGC 3¢, reverse 5¢ TCAT-
CAGGACCCAGCTGTGC 3¢; 94 C 4 min (1 cycle);
94 C 30 s, 65 C 30 s, 72 C 30 s (30 cycles); 72 C
3 min (1 cycle)). PCR products of 186 and 270 bp are
produced from cDNA and genomic DNA respectively.
The integrity and purity of the RNA are determined
using an Agilent Technologies 2100 Bioanalyser, (Agi-
lent technologies UK Limited, Cheshire, UK). This
instrument gives detailed information about RNA
quality and quantity and requires only a 50–500 ng of
sample. Inspection of the electrophoretograms produced
reveals any RNA degradation or genomic DNA con-
tamination present in the samples and ensures that only
high quality RNAs are labelled (Figure 1a).
Production of labelled cDNA from total RNA samples
Reverse transcription is used to produce cDNA from
total cellular RNA (5 lg) labelled to high speciﬁc
activity with 33P-dCTP (Amersham PLC, Amersham,
UK). To minimise non-speciﬁc priming the reaction is
performed at 48 C with an anchored Oligo d(T) primer
using the EndoFree Reverse Transcriptase (RT) sys-
tem (Ambion, Texas, USA). EndoFree RT produces
greater signal intensities and better sensitivity compared
to Superscript II RT (Gibco, Life Technologies,
Paisley, UK) [15]. Residual RNA is removed and the
probes puriﬁed using NICK columns (Amersham Phar-
macia Biotech) [Protocol 3]. Incorporation is checked
using a scintillation counter (Tri-Carb1600Tr Liquid
Scintillation Analyser Packard Instrument Company,
Connecticut, USA).
Hybridisation
We have tested a number of diﬀerent buﬀers and
hybridisation conditions. The best results were obtained
using ExpressHyb Hybridisation Solution (BD Bio-
sciences Clontech, USA) (Figure 1b). Membranes are
hybridised in 15 cm · 4 cm roller bottles in a Hybridisa-
tion Oven (Hybaid Limited, Middlesex, UK) enabling
continual mixing in a small volume. Both prehybridisa-
tion and hybridisation buﬀer include non-speciﬁc block-
ing agents [Protocol 4]. Stripping and re-use of
membranes has been suggested as a way to reduce costs
[16]; however, this can lead to loss of signal. We have not
tested the performance of stripped membranes. We
recommend drying the membranes by baking at 60 C
for 1 h prior to exposure to phosphor screens [Protocol 4].
Image processing and primary data acquisition
Membranes are exposed to Low Energy Storage Phos-
phor Screens (Amersham Pharmacia Biotech UK Limi-
ted, Buckinghamshire, UK) optimised for use with 33P,
and scanned at high resolution (50 lm) using a Mole-
cular Dynamics Storm 860 Phosphoimager (Molecular
Dynamics Inc, California, USA). Images are then
transferred directly to IMAGENE 5 (BioDiscovery,
California, USA) software, which provides sophisticated
tools for spot ﬁnding, quantitation and data export.
Linearity
Image generation and data acquisition are complex
repetitive tasks and therefore software automation to
assist in this progress is advantageous. However, this
leads to many of the underlying processes and data
manipulations being hidden from the user. Along with
others [17], we have found that scanner and phosphor-
imager software compress the data using non-linear
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transformations (e.g. square-root) and that some image
processing software packages do not correct for this.
This can introduce catastrophic artefacts into the data
and so is a serious concern. We strongly recommend
that the performance of the phosphorimager and image
analysis software are validated. To do this we produced
an artiﬁcial ‘array’ by manually spotting 2-fold serial
dilutions of 33P-dCTP onto a nylon membrane. Each
dilution was spotted eight times. The mean signal
intensity for each set of eight spots was determined
and showed a direct relationship with the dilution
factor.
The combination of Molecular Dynamics Storm 860
Phosphorimager and ImageQuant 4 or Imagene 5.1
faithfully replicated the serial dilution curves of the input
33P-dCTP (Figure 4). We found other image analysis
software packages for which this was not the case.
Reproducibility and technical replication
Gene arrays are of little use if the data they produce is so
noisy that only very large changes in transcript abun-
dance can be detected above the noise. To reduce the
eﬀects of noise, each cDNA represented on the array is
spotted in duplicate. In addition, for a small subset of
genes, multiple cDNA sequences from distinct regions of
the gene are spotted. When ﬁve aliquots of the same
placental RNA were labelled and hybridised to ﬁve
diﬀerent arrays we found that less than 4% of the
duplicates on each array diﬀered by >50% (Table 1,
Intra-array variability).
To determine inter-array variability, each membrane
was compared to the other four. When the mean log
signal intensity for each spot in an array is plotted
against the results of another array as shown in
Figure 5, regression coeﬃcients were close to 1, indicat-
ing a close positive correlation. Figure 6 shows that the
percentage of array elements in each pairwise compari-
son of these membranes (technical replicates) which
appear to be regulated up or down by more than 2-fold.
These ‘apparent’ changes (given that the same RNA was
used for all experiments) represent false positive rates
due to technical ‘noise’ and ranged between 0.5% and
5.0%. Combined with the data presented in Figure 5,
this demonstrates that our tailored array is reproducible.
However, averaging the results of two or more arrays
(technical replication) reduces the impact of chance or
technical diﬀerences between arrays.
Biological replicates
There is considerable variation in the behaviour of
individual isolates of human umbilical vein endothelial
cells (HUVEC) ([18] and our unpublished Aﬀymetrix
data). This is also likely to be true of other primary cells.
Figure 4. Validation of phosphorimager and image analysis software
compatability. A 2 fold dilution series of 33P-dCTP from 1 · 10)3 lCi/
ll to 4 · 10)6 lCi/ll was produced. Eight spots of 1 ll of each dilution
were manually deposited onto a nylon membrane, which was exposed
to a phosphor screen for 48 h and the mean signal intensity for each
spot determined. These values were plotted against the theoretical 33P-
dCTP dilution. The combination of Imagequant 4 and Imagene 5.1
produced the expected linear response indicating correct image
processing.
Table 1. Intra – array variability within each of the arrays in Figure 5
less than 4% of the duplicated spots diﬀered by greater than 50%.
Filter Percentage of duplicates with
errors >50%
663 2.9
664 3.3
665 2.4
666 1.8
667 3.1
Figure 5. Determination of Inter-array variability. Five aliquots of the
same human placental RNA were labelled and hybridised to ﬁve
membranes. Inter-array variability was assessed using scatter plots
of mean signal intensity for each membrane against any other, as
presented above for ﬁlters 666 and 667, for all ﬁlter combinations.
There is a high degree of correlation.
98 A.L. Evans et al.
Therefore, experiments using primary cells from a single
individual donor may reveal idiosyncratic results that
cannot be generalised. To illustrate this problem, we
prepared RNA from HUVEC obtained from ﬁve
diﬀerent individuals. Labelled cDNA was generated
from these RNAs and hybridised to our arrays. Pairwise
comparisons between the diﬀerent patients were per-
formed. The percentage of array elements that appear to
be regulated by more than 2-fold (up or down) between
any two of these ‘biological replicates’ ranges between
2% and 13.5% (Figure 6a). Since no treatment has been
applied to the HUVEC cultures used in this experiment,
these diﬀerences represent genetic diﬀerences, as well as
technical diﬀerences between cultures or hybridisations.
There is approximately ﬁve times more variation be-
tween biological replicates (where labelled cDNAs are
generated from cells from diﬀerent individuals) than
there is between technical replicates (where separate
labelled cDNAs are generated from a single RNA).
To demonstrate the importance of biological replicates
in a real experiment, HUVEC isolated from three
individuals (three biological replicates) were treated with
a low dose of a growth factor, and RNA collected after
24 h. Hybridisation of these RNAs to our tailored arrays
showed that none of the 998 genes present on our array
were regulated signiﬁcantly in the cells derived from all
three individuals. This was confrimed using Aﬀymetrix
genechips. However, if the experiment had been con-
ducted only once using HUVECs donated by any one of
the three individuals, we would have been mislead into
concluding that a signiﬁcant percentage of the transcripts
interrogated by the arrays were regulated in response to
the growth factor (Figure 6b, x-axis ¼ 1). When the
results for any two biological replicate experiments were
averaged, the number of apparently regulated transcripts
is substantially reduced (Figure 6b, x-axis ¼ 2). Aver-
aging all three biological replicate experiments further
reduced the number of ‘false positives’ to zero (Fig-
ure 6b, x-axis ¼ 3). Therefore, we believe that two, and
preferably three or more biological replicates is essential
for any gene array experiment. This is particularly true of
experiments in which primary cell cultures or tissues
from diﬀerent individuals are used.
When planning complex experiments, a critical con-
sideration is the number of replicates required, to ensure
suﬃcient statistical power to distinguish between genu-
inely regulated genes and false positive results, due to
biological variation [19]. Additionally, randomising the
order of tissues (or operators) during the hybridisation
process is fundamental to minimising bias [20].
Data normalisation and analysis
One of the biggest problems in extracting biologically
relevant data from gene array experiments is making
valid comparisons between arrays. Numerous factors
inﬂuence the signal generated for any particular spot.
Some of these relate to the specimen quality (protein
contamination, RNA degradation), others to array
quality and image processing (spotting eﬃciency signal
quantiﬁcation, and ‘background’ correction). Finally
there is variation due to reverse transcription eﬃciency,
hybridisation speciﬁcity and most importantly the spe-
ciﬁc activity of labelled RNA.
To obtain meaningful comparisons between data sets
it is necessary to make some mathematical adjustment to
the data. Although this is commonly termed normali-
sation, scaling is more often applied in practice. There
are several normalisation methods currently in use for
Figure 6. (a) Comparing of the degree of technical and biological variation evident when using our tailored gene arrays, ‘technical’ designates
technical variation, where complex probes were prepared from a single RNA and hybridised to ﬁve separate ﬁlters. For each possible combination
of any two ﬁlters, the % of array elements which varied >2-fold (up or down) is shown, ‘biological’ designates biological variation, where RNA
was isolated from ﬁve separate primary HUVEC cultures each collected from a diﬀerent individual. Radiolabelled cDNAs prepared from each
separate RNA were hybridised to ﬁve separate ﬁlters. For each possible combination of any two ﬁlters, the percentage of array elements which
varied >2-fold (up or down) is shown. (b) Biological replicates are essential to reduce the incidence of false-positive results. HUVEC from 3
separate individuals were cultured for 24 h in the presence or absence of a low concentration of growth factor, which had no statistically
signiﬁcant eﬀect on transcript abundance in these cells. RNAs were prepared from these cultures and used to generate radiolabelled cDNAs that
were hybridised to ﬁlters. Averaging the results of any two or all three biological replicates reduced the % of false positives’ (array elements that
appeared to be regulated >2-fold (up or down) due to the idiosyncratic properties of a single HUVEC culture or due to chance).
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microarray data. Internal reference methods utilise a set
of predetermined genes expected to give consistent
signal intensities across diﬀerent experiments [21]. In-
ternal globalisation methods allow normalisation to
be dictated by the observed data rather than by the
expression level of genes determined a priori to be
expressed at consistent levels. There are a number of
ways this can be done. Global scaling applies a constant
scaling factor based on ﬁrst-order statistics (e.g. the
mean or median) to deﬁne a scaling quotient. Applying
a constant factor, however, is not always appropriate
when the error is non-linear. Rank transformation of
data can deal with diﬀering data distributions but is
insensitive and may lead to data loss.
In most gene array experiments, only a few transcripts
are regulated by the treatment or experimental condition
under investigation, and the abundance of the majority
of transcripts on the array is unchanged. In a graph
comparing the abundance of transcripts in the two
RNAs we would therefore expect the majority of
transcripts (those which are not regulated) to lie on a
diagonal line (e.g. Figure 5). However, this is frequently
not the case following global scaling. Small diﬀerences
in probe labelling, hybridisation and scanning may
cause intensity-dependant errors, where all transcripts
of a particular intensity are shifted oﬀ the diagonal
(Figure 7a). If not corrected, this can lead to the
mistaken conclusion that these transcripts are more
abundant in one RNA population than another. An
approach for dealing with this type of distribution
discrepancy, as well as global scaling errors, is to use a
smoothing function aiming to return the position of all
unregulated transcripts to the diagonal. This is known
as intensity-dependant normalisation. The eﬀect is seen
easily in a Bland–Altmann plot [22, 23], shown in
Figure 7b, where the diﬀerence between the log signal
intensities of transcripts within two RNA populations is
plotted against the average of the log signal intensities.
The majority of transcripts, which are not diﬀerentially
expressed, should lie along the x-axis. Transcripts more
abundant in one RNA, than the other, will lie above or
below the x-axis. Any intensity-dependent deviation
Figure 7. Loess normalisation to correct intensity dependent errors. Two closely related samples were labelled and hybridised. (a) Global scaling
fails to correct intensity-dependent scaling errors, (b) rotation and log transformation. Diﬀerence in log signal intensity is plotted agains mean log
signal intensity, (a Bland–Altman plot), demonstrates intensity-dependent deviation from the x-axis. A Loess smoothing regression is applied (red
line) to correct the intensity-dependent deviation from the x-axis. (c) Corrected data and (d) transformed back to the original scale.
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from this axis can be seen by applying a smoothing ﬁt
line as shown in Figure 7b. This allows the data points
to be adjusted back to the x-axis to correct for the
intensity-dependant error (Figure 7c). In most cases the
smoothing function applied is derived from the ‘Lowess’
function [24] of the S statistical package (or its R
equivalent, ‘Loess’). The disadvantage of this method
is that there is a tendency to over-ﬁt data where there
are few data points, typically at the upper range of
expression values. This may have the eﬀect of reducing
fold-change values, even when these represent true
biological diﬀerences. It is important, therefore to
appreciate the eﬀect of such normalisations on reducing
the observed fold change in gene expression.
The aim of all normalisation methods is essentially to
reduce inter-array variance due to noise, whilst main-
taining the ability to detect signiﬁcant biological diﬀer-
ences in gene expression. More sophisticated methods
have recently been developed to enhance sensitivity to
identify signiﬁcant change, despite normalisation. The
methods of Yang [25], and Huber [26] attempt to
improve the sensitivity of detection of diﬀerentially
expressed genes over Loess-based normalisation alone.
However, these methods are complex. We have there-
fore chosen to adopt the Loess approach to normalisa-
tion described above.
There is a further issue arising from the use of Loess
for unpaired data sets, the concept of a reference array.
Loess normalisation must be applied sequentially be-
tween arrays, typically against a standard reference
array. For paired experiments the control array in each
pair is a natural reference but there is no such natural
reference in unpaired data sets (e.g. tumour and normal
tissue from diﬀerent patients). One approach [27] is to
use an ‘average array’, comprising the geometric mean
of the data (by genes), as a reference array, to which to
normalise all the array data. An alternative approach is
to select, as the reference array, the array which is
closest (in terms of Euclidean distance) to this average
array. A full description of this approach with an
example of its application is available at http://www.
obgyn.cam.ac.uk/genearray.
Following normalisation, advanced statistical meth-
ods are typically required to generate a list of candidate
genes for validation by quantitative PCR. Student’s t-
test is often inappropriate in the context of gene array
data, due to the large number of genes tested simulta-
neously. This leads to the problem of multiple com-
parisons [28] and susceptibility to a high false positive
rate. Cyber-T [29] employs a Bayesian modiﬁcation of
the t-test, and SAM [30] uses a permutation-based
approach to identify the false discovery rate for
individual genes. Packages such as Bioconductor
(http://www.bioconductor.org) or Genespring (Silicon
Genetics, California, USA) can be used for data
visualisation and clustering [31]. Reducing the data to
a minimal number of components by the use of
principal components analysis (PCA) or, more recently,
independent component analysis (ICA) [32, 33] may
lead to the identiﬁcation of gene signatures involved in
vascular remodelling.
Clearly the production of nylon ﬁlters requires multi-
ple steps each of which incurs consumable costs. We have
determined these and made allowances for possible
failures of some of the steps and therefore the cost per
ﬁlter is the maximum foreseeable. Thus to produce a
batch of 400 ﬁlters the cost works out at £19.35 per ﬁlter.
This compares very favourably with similar commercial
ﬁlters which cost approximately £1200 for four (how-
ever, this does include the cost of some of the labelling
reagents as well). We have also costed our optimised
labelling and hybridisation protocols and the cost of the
isotope, labelling and hybridisation reagents works out
at £40 per hybridisation. Since a major portion of the
labelling and hybridisation cost is attributable to the
purchase of 33P-dCTP, volume discounts may reduce
this. The personnel cost associated with the generation of
the ﬁlters has not been included in the ﬁgure above
however once the protocols have been developed and
optimised it is possible to produce the PCR products
necessary and to generate the ﬁlters in approximately 6–
8 weeks. In fact the most time consuming step is the
assembly and veriﬁcation of the cDNA clone collection.
All in all using our optimised protocols we believe it is
feasible for modest size laboratories to produce large
number of ﬁlters which allow many biological replicates
to be analysed.
Summary
Over 2000 microarray papers have been published in the
last few years. The majority are now ﬂuorescence based
studies using commercially produced arrays of tens of
thousands of features, but the range also includes a 59
gene rat array [34].
We believe small targeted gene arrays such as our
angiogenesis array has an important place in this range,
especially in situations where limited RNA is available
(such as investigations into reproductive angiogenesis
using small tissue samples) or when the use of primary
cells and tissues necessitates multiple biological repli-
cates. The array methods presented here are targeted,
sensitive, ﬂexible and relatively inexpensive. This type of
array is well within the funding and expertise of many
laboratories, but generation of meaningful results de-
pends on careful validation of every step in the process. If
this is done, tailored gene arrays provide a reliable tool
to address the complex regulation of RNA transcript
abundance that underlies much of vascular biology.
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ANGIOGENESIS GENE ARRAY
j 11 · Master Plates glycerols )70 C
j Grow fresh cultures 96 well plates 37 C/48 h in LB/Amp
50 lg/ml
j Heat 25 ll culture + 75 ll dH20 95 C/10 min
j Lysates stored )20 C
Spin 5 min 1000 rpm to pellet debris prior to use
Use supernatent as PCR template
96 well PCR
PCR mix 1 · 50 ll 100 · 50 ll
10 · Bioline buﬀer 5 500
2 mM dNTPs 5 500
M13F 10 lM 2.5 250
M13R 10 lM 2.5 250
50 mM MgCl2 1.5 150
dH20 31.25 3125
Bioloine Taq5 u/ll 0.25 25
Template (boiled lysate) 2
Parameters for PCR
(94 C 1 min) · 1,
(94 C 30 s, 55 C 30 s, 72 C 1 min) · 30,
(72 C 7 min) · 1
Hold 4 C
M13F (-20) GTA AAA CGA CGG CCA GTG
M13R (-48) AGC GGA TAA CAA TTT CAC AC
Random empty wells serve as negative controls
Reverse Transcription (EndoFree RT)
RNA 3–5 lg (cone., ‡0.7lg/ll)
1 ll 10 lM Anchored Oligo(dT) Primer
1 ll RNA Spike mix (below)
ll RNase-free H2O upto to 8 ll total volume
70 C, 5 min
48–50 C, 5 min
2 ll 10X RT Buﬀer
4 ll dNTPs (2.5 mM dATP, dTTP, dGTP, 10 lM dCTP)
1 ll RNase Inhibitor
3 ll [a-33P] dCTP 10 lCi/ll, 2500 Ci/mmol
48–50 C for 5 min.
1 ll of Reverse Transcriptase
Incubate at 48–50 C for 2 h.
RNA SPIKE MIX
1 ll spike mix Spike CAB RCA rbcL LTP4 LTP6
contains pg 500 100 50 10 1
Remove RNA
Add
2 ll 10% SDS
1 ll 0.5 M EDTA pH 8.0
3 ll 3M NaOH (fresh)
68 C 20 min
RT 10 min
Add
10 ll 1 M Tris pH 7.5
3 ll 3 M HCI
Remove unincorporated dNTPS using Nick column (Amersham)
Protocol 1. Ampliﬁcation of cDNA inserts for spotting. Protocol 3. Labelling of cDNA using EndoFree RT.
Protocol 2. Puriﬁcation of ampliﬁed cDNA inserts for spotting.
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Appendix A
Agilent http://www.agilent.com/chem/labonachip
Apogent http://www.apogentdiscoveries.com
Amersham http://amershambiosciences.com
Bd Biosciences http://bdbiosciences.com
Caliper http://www.calipertech.com
Genespring http://www.silicongenetics.com
Imagequant http://www.mdyn.com/products/lmageQuant/
default.htm
Imagene http://www.biodiscovery.com/products/lmagene/
imagene.html
SpotReport http://www.stratagene.com
A comprehensive list of array web sites is available from Molecular
Cloning, A Laboratory Manual, Volume 3, Sambrook and Russel.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New
York.
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Pre-Hybridisation of nylon membranes
Pre wet membranes in dH2O
Pre-heat Express Hyb

buﬀer at 68 C
Heat – denature at 95 C, 5 min the following
10 ll human Cot-1 DNA (1 mg/ml)
10 ll polyA (1 mg/ml)
200 ll salmon sperm DNA (5 mg/ml)
Add to 10 mls Express Hyb.

pre-warmed
Pre-Hybridise at 65 C 3 h at 5–7 rpm in a roller bottle
Hybridisation
Heat denature at 95 C, 5 min the following
400 ll puriﬁed radiolabelled cDNA
10 ll MEDTA
5 ll human Cot-1 DNA (1 mg/ml)
5 ll poly A (1 mg/ml)
100 ll salmon sperm DNA (5 mg/ml)
Add to 4.5 ml pre-warmed Express Hyb

Replace the.Pre-Hyb. Buﬀer with the hyb. Mix.
Hybridise 65 C 16 h 5–7 rpm
Washing
Pour oﬀ the hyb. buﬀer
2 · SSC/0.5% SDS 30 min 60 C Twice
0.1 · SSC/0.1% SDS 30 min 60 C Twice
Rinse dH20 for 5 sec only
Bake 60 C for 1 h
Expose to Molecular Dynamics LE screen 48 h
Scan at 50 lm resolution
Protocol 4. Hybridisation and washing nylon membrane.
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RMRG_list .xls
Reproductive Molecular Research Group Genelist 
Gene ID IMAGE Gene Abbrev clone source list Acc.No./Unigene ID clone details other information & changes to list name
1-kB epsilon 1580042
I-kB epsilon, NFKBIE nuclear factor of 
kappa light polypeptide gene enhancer in B-
cells,inhibitor, epsilin
NFKBIE,  IKBe apoptosis array U91616 /Hs.91640 0.6 kb, NO 5's, 3's, NO pA, no sig O/L
1-TRAF 2731092 I-TRAF (TANK) TANK apoptosis array U63830/Hs146847 unknown size, 3's, NO 5's, pA, no sig O/L
14-3-3eta 357633
14-3-3 eta ,tyrosine-3-
monooxygenase/tryptophan -5-
monooxygenaseactivation protein,eta 
polypeptide
14-3-3 
eta,YWHAH apoptosis array L20422 /Hs.349530
0.6 kb, pA, 5's3's, no 
extraneous o/l
14-3-3zet 195321
14-3-3 zeta,tyrosine-3-
monooxygenase/tryptophan -5-
monooxygenase
YWHAZ apoptosis array NM_003406/Hs.75103 0.8 kb, pA, 5's3's, no extraneous o/l
A-Raf 1350927 A-raf 1 oncogene putative raf related protein A-Raf apoptosis array L24038 
0.8 kb, NO 5's, 3's, pA, no sig 
O/L  stimulates the Raf/MAPK pathway
A1(Bfl-1) 686515 Bcl -2 related protein A1 (Bfl-1 / GRS) A1,BCL2A1,Bfl-1,GRS apoptosis array U29680 /Hs227817
0.8 kb, pA, 5's3's, no 
extraneous o/l
A20 714022 A20,TNFAIP3 tumour necrosis factor,alpha-induced protein 3 A20 apoptosis array Hs.211600 0.7 kb, 5's, 3's, pA, no sig O/L
TNFalpha-induced protein-3, zinc finger protein, inhibitor of apoptosis 
in endothelial cells
A2M 878182 alpha macroglobulin 2 A2M Implantation array M11313/Hs74561
ACP5 125101 uteroferrin, acid phosphatase type 5 ACP5 Implantation array J04430/Hs.1211 tartrate-resistant acid phosphatase
ACTB 324822 actin beta ACTB endogenous control X00351 last 0.5kb
ACVR1 343354 activin A receptor, type I ACVR1 apoptosis array Z22534/Hs.150402  0.7 kb, 5's, 3's, pA, no sig O/L
ACVR2 344197 activin A receptor Type II ACVR2 Implantation array M93415
ACVR2B 2516456 activinA receptor type IIB ACVR2B apoptosis array Hs.23994/X77533 0.9 kb, 3's, NO 5's, NO pA, no sig O/L
AES 145324 Amino -terminal enhancer of split AES unknown AF269289/Hs.244 aka pp2150 mRNA, BUT BAD CLONE AS ALSO MATCHES Hs.248156 HBOA histone acetyltransferase
AIF 122860 Apoptosis Inducing factor AIF apoptosis array NM_004208 0.7 kB, 5's, 3' s, pA, no unwanted homology PCD8, flavoprotein
Akt (PKB) 486251 Akt (PKB) protein kinase B Akt apoptosis array M63167 1.0 kB, 5's, 3' s, pA, no unwanted homology
Rac PK alpha, prosurvival signal downstream of PI3K, implicated in the 
phosphorylation of Bad
ALOX5 132574 Arachidonate -5- lipoxygenase ALOX5 Implantation array Hs.89499/J03571
alphaNAC 589666 Nascent-polypeptide associated complex alpha polypeptide NACA in-house clone X80909/Hs32916 0.9kb
ALPP 131419 alkaline phosphatase, placental (Regan isozyme) ALPP Implantation array X53279
Ang 1 34 Angiopoetin 1 ANG-1 in-house clone pCR-Script
Ang 2 Angiopoetin 2 ANGPT2 in-house clone Hs.115181/AB009865 pCR-Script
ANGPT1 252787 Angiopoietin 1 ANGPT1 Implantation array U83508 last 0.3 kb
ANGPT2 668204 Angiopoietin 2 ANGPT2 Implantation array AF004327 last 0.5kb
ANGPTL4 1188593 Angiopoietin -like 4 ANGPTL4 in-house clone Hs.9613/AF202636
angtenaseC 2018808 Angiotensinase C, PRCP Implantation array L13977
ANPEP 625609 alanyl (membrane) aminopeptidase, aminopeptidase N or M ANPEP Implantation array AI685221 CD13,p130
ANXA5 1665821 Vascular anticoagulant protein, annexin A5 ANXA5 in-house clone AI042581/Hs300711 3's, no 5's,0.8kb anticoagulant protein PAP, annexin A6
Apaf-1 253554 Apoptosis protease activating factor 1 APAF-1 apoptosis array Hs.77579/AF013263 0.4 kb, pA, 5's3's, no extraneous o/l
Drosophilsa homologue = "DARK" NB clone also contains some 
repetitive seq
APAF1 244146  apoptotic protease activating factor APAF1 Implantation array AF013263
APC 470992 adenomatosis polysis coli APC Implantation array M74088
APG5 134320 APG5 (autophagy 5) APG5 apoptosis array NM_004849 0.7 kb, 5's, 3's, pA, no sig O/L expressed after induction of apoptosis
Arabidops Arabidopsis Thaliana exogenous control
ARF-2 449487 ADP ribosylation factor-like 2 ARF-2 Implantation array L13687
ARNT-3 1939053 aryl hydrocarbon receptor translocator-3 ARNT-3 apoptosis array Hs.74515/U51627 0.8 kb, 3' no 5', pA no sig O/l "=MOP3 =BMAL1"
RMRG_list .xls
Gene ID IMAGE Gene Abbrev clone source Acc.No./Unigene ID clone details other information & changes to list name
ATCab 46916 Arabidopsis thaliana chlorophyll a/b binding ATCab exogenous control At.23982
ATM 1868266 Ataxia Telangiestasia Mutated (cluster includes complementation groups A,C &D) ATM apoptosis array AI262879/Hs194382 3'0.6kb
ATM(2) 1864692 Ataxia Telangiestasia Mutated ATM apoptosis array Hs.194328
ATP6S14 1758635 ATPase vascuolar 14KD ATP6V1F was not listed Hs.78089/BF314603
Component of vacuolar ATPase (V-ATPase), a multisubunit enzyme that 
mediates acidification of eukaryotic intracellular organelles.Protein 
sorting, zymogen activation, receptor-mediated endocytosis, and 
synaptic vesicle proton gradient generation. 
ATR (1) 1879175 Ataxia Telangiestasia and rad 3 related ATR apoptosis array Hs.77613 0.6 kb, 3', pA some homology to Human FRAP-related protein (FRP1) mRNA
ATR (2) 2339873 Ataxia telangiestasia & Rad 3 related ATR apoptosis array Hs.77613/NM_001184 0.6 kb, 3', pA some homology to Human FRAP-related protein (FRP1) mRNA
AXIN 1 158891 axin AXIN1 Implantation array Hs.184434/AF009674
B-Raf 1878531 B-Raf,v-raf murine sarcoma viral oncogene homolog B1 BRAF apoptosis array Hs.622/M21001
0.7 kb, 3's, NO 5's, pA, no 
O/L 95kDa b-Raf serine/threonine kinase
B12 2325878 Tumour necrosis factor,alpha -induced protein-1(endothelial) B12 = TNFAIP1 apoptosis array Hs.76090 0.5kb, no5's, 3's, pA, no O/L
Tumor necrosis factor, alpha-induced protein 1 (endothelial), induced in 
HUVEC by TNFalpha, no known function
B7-1 2723769 B7-1, CD80 antigen ligand B7-1 apoptosis array Hs.838 3's, NO 5's, no sig O/L, size unknown CD80 ligand
B7 -2 1634297 B7-2 antigen, CD86 ligand B7 -2 apoptosis array Hs.27954 0.8 kb, 3's, NO 5's, pA, no sig O/L CD86 also CTLA4 counter receptor 
Bad (1) 2108212 Bcl-2 antagonist of cell death Bad apoptosis array U66879 /Hs76366 0.6 kb, pA, 5's3's, no extraneous o/l
Bad (2) 2068876 Bcl-2 antagonist of cell death Bad apoptosis array pA, 3'seq, no 5'seq
BAG-1 1046695 Bcl2-associated athanogene -1 BAG-1 apoptosis array Hs.41714 0.6 kb, NO pA, 3's, no extraneous o/l  transduces anti-apoptotic function of cytokines
Bak 235938 BAK1,Bcl-2 antagonist/ killer 1 Bak apoptosis array U23765/Hs93213 0.9 kb, pA, 5's3's, no extraneous o/l
BAR 2046408 BAR,apoptosis regulator LOC51283 BAR apoptosis array Hs.168159 0.7 kb, 3' read, pA, search -> no homol apoptosis regulator which binds pro-caspase 8 and bcl-2
basigin 756533 Basigin (OR blood group) BSG Implantation array Hs.74631/BF316943
basigin 756533 Basigin (OR blood group) BSG Implantation array Hs.74631/BF316943
Bax(1) 2049495 BCL-2 associated protein X Bax Implantation array L22473/4/Hs159428 mito protein/pro-apoptotic/alpha-beta, same clone as H/G10
Bax(2) 2049495 Bcl-2 associated protein X Bax apoptosis array L22474 /Hs159428 0.6 kb, pA, NO 5' but has 3', EST from whole embryo, same clone as D/E7
Bcl-2 1554409 bcl-2 Bcl-2 apoptosis array NM_004050
0.7 kb, pA, NO 5' but has 3', 
no extraneous o/l, not in 
limited cds
BCL-2 667231 B-cell CLL/lymphoma 2 BCL2 Implantation array M14745 mito protein/CED9 C.elegans/anti-apoptotic
Bcl-2 667231 Bcl-2,B cell CLL lymphoma 2 Bcl-2 apoptosis array M14745 /Hs.79241 0.8 kb, pA, 5's3's, no extraneous o/l
Bcl-XL 1518718 Bcl-2 like Bcl-xL,Bcl2L1 apoptosis array Z23115/Hs.305890 0.6 kb, pA, 5's3's, no extraneous o/l
Bid 2330073 Bid, BH3 interacting domain death agonist Bid apoptosis array AF042083/Hs.172894 0.9 kb, 3's, NO 5's, pA, no sig O/L
BID 627125 BH3 interacting domain death agonist BID Implantation array AF042083
Bik (NBK) 685783 Bik (NBK),Bcl-2 interacting killer(apoptosis-inducing) Bik (NBK) apoptosis array U34584/Hs155419
0.7 kb, pA, 5's3's, no 
extraneous o/l
Bim 2488679 BCL2-likeII(apoptosis facilitator) Bim(Bod) apoptosis array AF032457/Hs202657 0.7 kb, 3' seq, no 5' seq, pA unknown, no sig O/L BOD Bcl-2 related ovarian death gene,not verified
BLK 2027963 B lymphoid tyrosine kinase BLK apoptosis array AA465174  3' NO 5', 1.1KB,  pA, NO EXTRANEOUS O/L
BPI 2130568 Bactericidal/permeability-increasing protein BPI apoptosis array Hs.89535 0.7 kb
BRAC1 241474 breast cancer 1, early onset BRCA1 Implantation array U14680
BRCA2 415529 Breast cancer 2 ,early onset BRAC2 Implantation array Hs34012
BTC 1535554 Betacellulin BTC implantation array Hs.73105/S55606
BTK 2014424 Bruton agammaglobulinemia tyrosine kinase BTK apoptosis array Hs.159494/AF153764
0.6 kb, 3's, NO 5's, pA, no sig 
O/L Bruton agammaglobulinemia tyrosine kinase
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bystin 564538 bystin-like BYSL Implantation array L36720/Hs.106880
c-abl 284452 v-ablAbelson murine leukemia viral oncogene homolog1 c-abl apoptosis array X16416 /Hs146355
0.8 kB, 5's, 3' s, pA, no 
unwanted homology
multifunctional, regulates DNA damage-induced apoptosis, integrin 
ligation recruits abl from the nucleus
c-fos(1) 1594287 c-fos, V-fos FBJ murine osteosarcoma viral oncogene homolog FOS apoptosis array Hs.25647/K00650
0.7kb, 3's, NO 5's, pA, no sig 
O/L
c-jun 345170 c-jun proto oncogene c-jun Implantation array U65928
c-myc 739849 c-myc, avian myelocytomatosis viral oncogene homolog c-myc Implantation array V00568/Hs.79070
c-raf 489327 c-raf (Raf1) V-raf murine leukeamia viral oncogene homolog 1 RAF 1 apoptosis array X03484  /Hs 85181
0.6 kb, 3's no 5', pA, no sig 
O/L downstream of Ras, upstream of MAP kinases
C1orf29 754479 Hypothetical protein, expressed osteoblasts C1orf29 in-house clone AB000115/Hs.75470 3's & 5's, no pA, chromosome 1 open reading frame 29
C3 489327 C3 complement component C3 Implantation array K02765/Hs284394
CA125 117106 CA125, membrane component chr.17 surface marker 2 CA125, M17S2 Implantation array X76952 ovarian carcinoma antigen CA125
CA4 unknown carbonic anhydrase 4 CA4 Implantation array Hs.89485/M83670
CAB spike 1 Arabidopsis Thaliana,Photosystem 1chlorophyll a/b binding protein CAB exogenous control X56062 pGEMT, 500bp
CAB (1) 667409 Arabidopsis thaliana chlorophyll a/b/binding protein CAB exogenous control X56062
CAB (2) Arabidopsis thaliana chlorophyll a/b/binding protein CAB exogenous control X56062
CAB (3) Arabidopsis Thaliana CAB mRNA for photosystem I CAB exogenous control X56062
CAB (5) Arabidopsis Thaliana CAB mRNA for photosystem I CAB exogenous control X56062
Cadherin-13 1509342 Cadherin-13,cadherin H(heart) CDH13 in-house clone L34058/Hs.63984 3's, no 5's,0.8kb Adhesion
CALCB 1268215 calcitonin-related polypeptide beta CALCB Implantation array X02404 hom. Alpha
CALCR (1) 3033121 Calcitonin receptor CALCR apoptosis array Hs.640/X69920 unknown size, 3's, NO 5's,
CALCR (2) 2115715 calcitonin receptor CALCR Implantation array U26553
CASP1 120106 interleukin1 beta converting enzyme, caspase 1 IL1BCE, CASP 1 Implantation array Hs.2490/U13698 apoptosis related cysteine protease
caspase 3 (1) 429574 caspase 3, apoptosis-related cysteine protease casp 3 Implantation array NM_004346
caspase 3 (2) 30772 caspase-3,apoptosis-related cysteine protease CASP3 apoptosis array U13737 /Hs74552
0.9 kb, pA, 5's3's, no 
extraneous o/l short prodomain = class II; YAMA PROTEIN; CPP-32
caspase 4 131502 caspase-4, ICH-2 caspase-4 apoptosis array Hs.74122/U25804 0.8 kb, 5's, 3's, pA  TX PROTEASE (Mih1), note homol with caspase 13 and 1
caspase 5 341763 caspase 5, apoptosis-related cysteine protease,ICE rel III,TY protease CASP5 apoptosis array U28015/Hs.3257
caspase 7 1651252 cysteine protease cleaving an aspartic acid residue 7 caspase-7,Mch-3 apoptosis array U67320/Hs.9216
0.6 kb, NO 5's, 3's, pA, no sig 
O/L short prodomain = class II; MCH3, ICE-LAP3
caspase 8(1) 594361 caspase-8,apoptosis-related cysteine protease CASP 8 apoptosis array Hs.19949/NM_033356
0.6 kb, 5's, 3's, pA, note some 
homol to unidentified 
database sequnces
long prodomain = class I; MCH-5, MACH, FLICE
caspase 8(2) 594361 caspase 8 ,apoptosis related cysteine protease CASP8 apoptosis array Hs.19949/X98173
0.6 kb, 5's, 3's, pA, note some 
homol to unidentified 
database sequnces
long prodomain = class I; MCH-5, MACH, FLICE
caspase 8(3) 782488 caspase 8, apoptosis-related cysteine protease, Mach alpha 2 protein caspase 8 Implantation array NM_001228
caspase 9 705110 caspase 9, apoptosis-related cysteine protease Casp 9/Mch 6 Implantation array AB015653
caspase 9 121693 cysteine protease cleaving an aspartic acid residue 9 caspase-9 apoptosis array Hs.100641/U60521
1.0 kb, 5's, 3's, pA, no sig 
homol long prodomain = class I; APAF3, ICE-LAP-6, MCH-6
caspase 10 (1) 241481 caspase-10,apoptosis related cysteine protease casp10 apoptosis array U60519 /Hs5353
0.8 kb, NO pA, 5's3's, no 
extraneous o/l
long prodomain = class I; FLICE2, MCH-4,NB same clone as 
implantation array E/H11
caspase 10 (2) 241481 caspase10, apoptosis-related cysteine protease casp10/Mch 4 Implantation array U60519/Hs.5353 same clone as apoptosis array G/E2
catalase catalase 1 CAT in-house clone Hs.76359/X04076 B/S11 KS +/-, sense, Exons 1-4
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Cathepsin S 687875 Cathepsin S CTSS in-house clone M90696/Hs181301 0.4 kb,3' & 5's, 0.4kb Proteolytic enzyme,homology to colon human cDNA clone
cathepsinB 2595361 cathepsin-B CTSB apoptosis array Hs.249982 size unknown
cathepsinH cathepsin H CTSH in-house clone Hs.288181/AA973763X07549 pCMVSPORT 2
CCNB1 531805 cyclin B1 CCNB1 Implantation array M25753/Hs.23960 3'end
CD9 727251 CD9 antigen p24 CD9 Implantation array M38690
CD10 471700 CD10 (membrane metallo-endopeptidase) CD10/MME/CALLA Implantation array J03779
CD28 1711889 CD28 antigen (Tp44) CD28 apoptosis array Hs.1987/J02988 1.3 kb, 3's, NO 5's, pA, no sig O/L T cell costimulatory molecule
CD31 134521 platelet endothelial cell adhesion molecule PECAM-1/CD31 Implantation array M28526
CD34 364487 CD34 antigen CD34 apoptosis array M81104 /Hs.85289 0.7 kb, pA, 5's3's, no extraneous o/l
CD36 1739990 CD36 antigen CD36 thrombospondin receptor
CD40 152683 CD40,TNF receptor superfamily member 5 TNFRSF5 apoptosis array X60592 /Hs.25648 0.7 kb, pA, 5's3's, no extraneous o/l expressed on EC (Mach et al, UI 97203164)
CD44 265052 CD44/H-CAM/p80 /GP90 CD44 Implantation array U40373
CD56 (1) 1883065 NCAM-1 (CD56) CD56 apoptosis array Hs.167988 3's, 0.6 kb, NO 5's, pA, no sig O/L neural cell adhesion molecule
CD56 (2) 276764 neural cell adhesion molecule 1 NCAM1 (CD 56) Implantation array U63041/Hs167988
CD58 287620 CD58 antigen, lymphocyte function-associated antigen -3 LFA-3 CD58 Implantation array Y00636
CD59 1735518 CD59 antigen p18-20 CD59 in-house clone M34671/Hs.278573 3's, no 5's Complement restriction, Ly-6-like protein, MEM43
CD63 471872 CD63 antigen (melanoma 1 antigen) CD63 Implantation array M59907
CD69 2130345 CD69antigen,(p60,early T-cellactivation antigen) CD69 apoptosis array Hs.82401/L07555
1.3 kb, 3's, NO 5's, pA, no sig 
O/L early T-cell activation antigen, also part of NK gene complex
CD84 2099041 CD84antigen(leukocyte antigen) CD84 apoptosis array Hs.137548 0.8 kb, 3' no 5', no pA, no extran o/l MAX.3
CD94 1901363 CD 94,killer cell lectin-like receptor subfamily D,member1 KLRD1,CD 94 apoptosis array U30610 /Hs.41682
1.5 kb, NO 5's, 3's, pA, no sig 
O/L
KLRD1, associates with one of five different NKG2 isoforms, part of 
NK gene complex
CDC 6 204214 cell division cycle 6 homolog, S.cerevisiae CDC6 Implantation array U77949
CDC2 (1) 712505 cell division cycle 2 ,G1 to S and G2 to M CDC2 apoptosis array X05360/Hs334562 0.6 kb, 3's, 5's, pA, no sig O/L
CDC2 (2) 712505 cell division cycle 2 ,G1 to S and G2 to M CDC2 apoptosis array Hs.334562/Y00272 3', pA, 0.6 kb, no o/l
CDC25A 204301 Cell division cycle 25A CDC25A apoptosis array M81933 0.6 kb, 3's, 5's, NO pA, no sig O/L dephosphorylates, and activates the cell cycle kinase cyclin E-cdk2
CDC25B 172466 Cell division cycle 25B CDC25B apoptosis array  M81934/Hs153752 0.6 kb, 3's, 5's, pA, no sig O/L dephosphorylates p34(cdc2)
CDC25C 1878149 cell division cycle 25C CDC25C apoptosis array M34065 /Hs 656 0.6 kb, 3's, pA, no sig O/L activates the p34cdc2 protein kinase at mitosis
CDC37 111650 cell division cycle 37(S.cerevisiae),Homolog CDC37 apoptosis array U63131 /Hs.160958 0.6 kb, 3's, 5's, pA, no sig O/L
CDC6 1089493 cell division cycle 6 CDC6 apoptosis array Hs.69563 1.0 kb, 3' no 5', pA, note great homology to CDC 18 CDC6 (cell division cycle 6, S. cerevisiae) homolog
CDH1 WHO cl.4 cadherin E (uvomorulin) CDH 1 Implantation array L08599 pGEMT homology with N-cadherin/primers7/8
CDH3 359051 cadherin P (placental) also cadherin 3 CDH 3 Implantation array X63629 hom. cadherin E
CDI-1 843110 GDP-dissociation inhibitor 1 CDI-1 Implantation array Hs.74576
CDK4 842806 cyclin dependent kinase 4 CDK4 apoptosis array M14505 /Hs.95577 0.7 kb, 5's, 3's, NO pA, no sig O/L
CDK5 220505 cyclin dependent kinase 5 CDK5 apoptosis array X66364 /Hs.166071 0.8kb, 5's, 3's, NO pA, no sig O/L
CDK6 1646946 cyclin dependent kinase 6 CDK6 apoptosis array X66365 /Hs.38481 1.0 kb, 3's, 5's, pA, no sig O/L
CDK7 1516792 Cyclin dependent kinase 7(homolog of Xenopus MO15 cdk-activating kinase) CDK7 apoptosis array Hs.184298 0.7 kb, 3', pA, no o/l
CdKn2a (1) 15523215 cyclin -dependent kinase inhibitor 2A,p16, inhibits CDK4 CdKn2a Hs1174
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CdKn2a (2) 2242420 cyclin -dependent kinase inhibitor 2A,p16, inhibits CDK4 CdKn2a Hs.1174
CERB 135178 CREB binding protein (Rubinstein-Taybi syndrome)
CERB 
(CREBBP) Implantation array U47741
CFL1 625792 cofilin 1(non-muscle) CFL1 apoptosis array Hs.180370 5's, 3's, pA, 0.6 kb, no sig O/L previously listed as cofilin
CGI-134 (2) 1639562 novel protein conserved C.Elegans by comparative proteomics CGI-134 Implantation array AAD34129
Chk1 206717 Chk1 checkpoint (S.pombe) homolog CHK1 apoptosis array Hs.20295/AF016582 1.0 kb, 3' and 5', pA, no o/l
Chk2 2349044 Chk2,checkpoint s.pombe homolog CHK2/CHEK2 apoptosis array Hs.146329 0.6 kb, 3', pA, no o/l Rad53,protein kinase
CHST1 1853818 keratan sulphotransferase 1/chondroitin 6 CHST 1 Implantation array U65637 hom last 0.6
CIS4 (1) 668977 Supressor of cytokine signalling 4, STAT induced STAT inhib. 5  STATI-4, CIS5 Implantation array AB006968
CIS4 (2) 668977 Supressor of cytokine signalling 4, STAT induced STAT inhib. 7  STATI-4, CIS7 Implantation array AB006968
CKN1 2881290 Cockayne's syndrome 1(classical) CKN1 Implantation array Hs32967
Clathrin 79364 Clathrin, heavy chain,Hc CLTC in-house clone D21260/Hs178710 3's, no 5's,0.5kb Membrane trafficking
CLK1 727344 CDC-like kinase 1 CLK1 apoptosis array L29222 0.8 kb, 3's, 5's, pA, no sig O/L CDC-like kinase 1
CLK2 668070 CDC like kinase 2 CLK2 apoptosis array L29216 0.5 kb, 3's, 5's, pA, no sig O/L CDC-like kinase 2
CLK3 1187803 CDC-like kinase 3 CLK3 apoptosis array L29220 /Hs73987 0.6 kb, 3's, 5's, pA, no sig O/L CDC-like kinase 3
CLU 246127 apolipoprotein J, clusterin, complement lysis inhibitor CLU Implantation array Hs.75106/AL048744
Clusterin 344538
Clusterin,Complement lysis inhibitor,SP-
40,40,sulfated glycoprotein2,testosterone -
repressed prostate message 
2,apolipoprotein J
CLU apoptosis array M74816 0.6 kb, pA, 5's, 3's, no signif O/L multifunctional secreted protein, initiates apoptosis
CNTFR 156431 ciliary neurotrophic factor receptor CNTFR Implantation array M73238
COL4A1 359084 collagen IV alpha 1 COL4A1 Implantation array M11315 last 0.3kb
COL4A2 726808 collagen,type IV alpha 2(canstatin) COL4A2 Implantation array Hs.75617/X05610 last 0.5kb
COL4A4 562397 collagen IV alpha 4 COL4A4 Implantation array X81053 last 1kb
COL4A5 284501 collagen IV alpha 5 (Alport syndrome) COL4A5 Implantation array NM_000495 last 0.8kb
COL4A6 2070789 collagen IV alpha 6 COL4A6 Implantation array U04845 last 1kb
COL5A2 489919 COL5A2 Collagen, type V, alpha 2 COL5A2 Implantation array Hs.82985/AA725207
COL6A1 152687 collagen VI alpha 1 COL6A1 Implantation array X15880/Hs.108885
COL6A2 365455 collagen VI alpha 2 COL6A2 Implantation array M34570 (3'end)
connexin 201273 Connexin 32/gap junction protein beta 1 GJB1 Implantation array X04325 Charcot-Marie_Tooth neuropathy
COPA 843200 coatomer protein alpha COPA in-house clone U20105 0.7kb
cox1(1) 703713 cyclooxygenase 1, prostaglandin-endoperoxide synthase 1 cox 1/PTGS1 Implantation array M59979 different clone from cox[2]&[3] H/B1 & F/E5
cox1(2) 1589081 cyclooxygenase 1, prostaglandin-endoperoxide synthase 1 cox 1/PTGS1 apoptosis array U63846
0.7 kb, pA, 3's, NO 5's, No sig 
O/L cyclooxygenase-1,same clone as F/E5 cox1[3] not same as A/d2
cox1(3) 1589081 cyclooxygenase 1, prostaglandin-endoperoxide synthase 1 cox 1/PTGS1 apoptosis array U63846/M59979
0.7 kb, pA, 3's, NO 5's, No sig 
O/L
cyclooxygenase-1,same clone as H/B1 cox1[2] not same clone as 
cox1[1] A/D2
cox2 (1) 147050 cyclooxygenase 2, prostaglandin-endoperoxide synthase 2 cox 2/PTGS2 apoptosis array M90100/U04636 0.5 kb, 5's, 3's, pA, no sig O/L
cyclooxygenase-2; prostaglandin endoperoxidase synthase2,same clone 
as B/B3
cox2 (2) 147050 cyclooxygenase 2, prostaglandin-endoperoxide synthase 2 cox 2/PTGS2 Implantation array M90100 same clone as H/A12
cPLA2 1676293 phospholipase A2 cytoplasmic cPLA2 Implantation array M68874
CRABP1 357838 retinoic acid BP CRABP1(cellular) CRABP1 Implantation array S74445
CRABP2 739913 retinoic acid BP CRABP2 (cellular) CRABP2 Implantation array M68867
CRADD 700353 CASP2 and RIPK1 domain containing adapter with death domain CRADD apoptosis array U84388 /Hs155566
1.1 kb, pA, 5's3's, no 
extraneous o/l, NOTE SIZE interacts with RIP (DD)& caspase2, constitutively expressed
CRH 143383 corticotropin releasing hormone CRH Implantation array NM_000756/Hs.75294
CRHR1 178169 corticotrophin releasing factor receptor1 CRHR1 Implantation array L23332
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CRYAA 190072 crystallin alpha A CRYAA Implantation array U66584
CRYAB 172505 crystallin alpha B CRYAB Implantation array S45630/Hs,1940
CSF1R 142323 colony stimulating factor 1 receptor (c-fms) CSF1R (c-fms) Implantation array Hs.174142/R70654/X03663  feline sarcoma viral (v-fms) oncogene homolog
CSF2 1601601 Colony stimulating factor 2 CSF2 Implantation array M11220 granulocyte-macrophage
CSF2RA 140352 colony stimulating factor 2 receptor alpha,low affinity granulocyte macrophage CSF2RA Implantation array M37435/Hs.182378 0.5 kb, 5's, NO 3's, NO pA same clone as G/G8 apoptosis array
CSF2RA 140352 colony stimulating factor 2 receptor alpha CSF2RA apoptosis array Hs.182378/X54935 0.5 kb, 5's, NO 3's, NO pA
CSF2RB 141115 colony stimulating factor 2 receptor B CSF2RB Implantation array M59941
CSF3 1074540 Colony stimulating factor 3 (granulocyte) CSF3 Implantation array M17706/Hs.2233
CSF3R 247087 colony stimulating factor 3 receptor (granulocyte) CSF3R Implantation array M59820
CSFRA 289342 colony stimulating factor 2 receptor A (granulocyte-macrophage) CSF2RA Implantation array L29348
CSH1 60749 placental lactogen, chorionic somatomammotropin hormone 1 CSH1 Implantation array J00118 from SAGE set
CSH2 140370 chorionic somatomammotropin hormone 2 CSH2 Implantation array Hs.3344372/NM_020991
cst3 949938 cystatin C,amyloid angiopathy & cerebral hemorrhage CST3 Implantation array X05607 homology with CST…
CTF1 1562882 cardiotrophin 1 CTF1 Implantation array U43030
CTGF 2142125 connective tissue growth factor CTGF apoptosis array Hs.75511 0.7kb, No 5's, 3's, pA, no sig O/L
cysteine-rich mitogen secreted by human vascular endothelial cells 
(U14750)
CTNA 203313 catenin alpha CTNA apoptosis array D13866 1.0 kb, 5's, 3's, pA, no sig O/L
CTNNB1 415546 catenin,beta 1 (cadherin associated protein) CTNNB1 Implantation array X87838
CTP unknown mitochrondrial citrate transporter,citrate transport protein CTP,SLC25A1 Implantation array Hs.111024/BC004980
CTSB 898035 cathepsin B CTSB Implantation array L16510
CTSL 130796 cathepsin L CTSL Implantation array NM_001912
CXC-R4 713888 CXC-R4 = fusin,chemokine (C-X-C) motif ,receptor 4 CXC-R4 = fusin apoptosis array Hs.89414
0.3' pA, 0.6 kb, note great 
homology to H.sapiens mRNA 
for neuropeptide Y-like 
receptor
cyclin A 683100 cyclin A CCNA apoptosis array X51688 0.8 kb, 3's, 5's, pA, no sig O/L
cyclin C (1) 163424 cyclin C CCNC apoptosis array M74091 /Hs118442 0.8 kb, 3's, no5's, pA
cyclin C (2) 503756 cyclin C CCNC apoptosis array Hs.118442 0.6 kb, 3's, 5's, pA, no sig O/L
cyclin D1(1) 325020 cyclinD1 CCND1 apoptosis array X59798/Hs.82932 0.7 kb, 3's, 5's, pA, no sig O/L bcl-1, PRAD1: parathyroid adenomatosis 1
cyclin D1(2) unknown cyclin D1 CCND1 Implantation array Hs.82932/M64349 bcl-1, PRAD1: parathyroid adenomatosis 1
cyclin D2 366412 cyclin D2 CCND2 apoptosis array  D13639 0.9 kb, 3's, 5's, pA, no sig O/L
cyclin D3 1877087 cyclin D3 CCND3 apoptosis array M92287 /Hs.83173 0.6 kb, 3's, pA, no sig O/L
cyclin E 68950 cyclin E CCNE apoptosis array M73812 0.6 kb, 3's, 5's, pA, no sig O/L
cyclin G1 2115540 cyclin G1 CCNG1 apoptosis array U47413 0.6 kb, NO 5's, 3's, pA, no sig O/L
cyclin G2 1637315 cyclin G2 CCNG2 apoptosis array U47414/Hs79069 1.0kb, 3's, NO 5's, pA, no sig O/L
cyclin H 730411 cyclin H CCNH apoptosis array  U11791 1.4 kb, 3's, 5's, pA, no sig O/L
CYP11A 69087 cytochrome P450 subfamily XIA,17, 20-desmolase CYP11A Implantation array M14565/Hs.76205
cyt C 264845 cytochrome C HCS apoptosis array Hs.169248/M22877 1.0 kB, 5's, no 3' s, no unwanted homology unigene cluster listed Hs.697 now "retired"
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Cyt C Ox 79597 cytochrome C  oxidase,subunit IV isoform 1 COX4I1,COX4 in-house clone M21575/Hs347969 0.7kb
DAD-1 139702 Defender against cell death-1 DAD-1 apoptosis array D15057 /Hs.82890 0.7kb, 3's5's, pA, note some homol with TCR
component of oligosaccharyltransferase which inhibits apoptosis of 
BHK21-derived tsBN7 cell line
DAK-P 1607097 death associated protein kinase 2 related protein DAPK2 apoptosis array AF052941/Hs.129208
0.5 kb, NO 5's, 3's, pA, no sig 
O/L
DAP1 208557 death associated protein1 DAP1 apoptosis array Hs.75189/X76105  1.0 kB, 5's, 3' s, pA, no unwanted homology mediates IFN-gamma-induced cell death
DAPK1 364934 Death-associated protein kinase 1 DAPK1 apoptosis array X76104 /Hs153924 0.7 kB, 5's, 3' s, pA, no unwanted homology
thymidine kinase II, calmodulin-dependent serine/threonine kinase, 
mediator of gamma IF-induced apoptosis
DAPK3 2107336 DAPK 3 (ZIP kinase) death associated protein kinase 3 DAPK3 apoptosis array NM_001348/Hs25619
0.7 kb, NO 5's, 3's, pA, no sig 
O/L - watch for homol with 
DAPK-rel-prot
cytoskeletal reorganisation in apoptosis
DCC 1540499 deleted in colon carcinoma DCC Implantation array X76132
DCL1 869233 deleted in liver cancer 1 DLC1 Implantation array AF035119
destrin 152271 Destrin,actin depolymerising factor DSTN apoptosis array Hs.82306 0.6 kb, 5's, 3's NO pA, no sig O/L, but there is a pseudogene (actin depol factor)
DFFA 841357 DNA fragmentation factor,45KD alpha polypeptide DFFA apoptosis array NM_004401/hs.105658
0.8 kb, NO pA, 5's3's, no 
extraneous o/l ICAD (p40)
DFFB 1030349 DNA fragmentation factor beta,40KD caspase -activated Dnase DFFB apoptosis array NM_004402/Hs133089
0.6 kb, pA, NO 5', has3's, no 
extraneous o/l probably human CPAN homologue of mouse CAD (p45)
DIO2 deiodinase iodothyonine type II DIO2 in-house clone U53506/Hs.154424 pCMVSPORT 2
DLX4 134789 distal-less homeobox 4 DLX4 Implantation array NM_001934 hom DLX3 but not last 0.8kb
DLX4 252364 distal-less homeobox 4,distal-less homeobox 7&also BP1 DLX4 Implantation array Hs.172648/BE883924 hom DLX4/DLX7 100%
DNA PK 1301908 DNA-activated protein kinase catalytic polypeptide
DNA-
PK,PRKDC apoptosis array Hs.155637/U47077
0.6 kb, 3', pA, some homology 
to Human HepG2 3' region 
cDNA, clone hmd3h01
catalytic subunit, Ser/Thr kinase, ? tethers DNA strands as additional 
function, mutation-> SKID
DNHC 116552 dynein,cytoplasmic, heavy chain 1 DNHC1 Implantation array Hs.7720/AB002323
DRAK1 687542 DRAK1,Serine/threonine kinase 17a(apoptosis -inducing)
STK17A,DRAK
1 apoptosis array NM_004760/Hs.9075
0.6 kB, 5's, 3' s, pA, no 
unwanted homology ]ubiquitous, nuclear, pro-apoptotic
DRAK2 594966 DRAK2,serine/threonine kinase 17B DRAK2,STK17B apoptosis array  NM_004226 1.4 kB, 5's, 3' s, no pA  pro-apoptotic
DVL 147182 dishevelled 3 DVL3 Implantation array U75651/Hs.174044 last 1.2kb phosphoprotein
E-cadherin 900290 E-cadherin, cadherin 1, type1 CDH1 apoptosis array Z13009 0.6 kb, 3's, NO 5's, pA, no sig O/L (uvomorulin UVO, L-CAM,  cell-CAM 120/80, Arc-1) 
E-selectin 1518164 E-Selectin (ELAM1) ELAM-1 apoptosis array M24736 0.7 kb, 3's, NO 5's, pA, no sig O/L
transcription induced by TNF alpha or IL1 beta, mediates leucocyte 
rolling on endothelial cells, Survival function
E2F1 768260 E2F transcription factor 1 E2F1 endogenous control M96577
E2F2 2112387 E2F transcription factor 2 E2F2 apoptosis array Hs.121487 5' no 3', 0.7 kb, some homology to E2F3
E2F3 1627984 E2F transcription factor 3 E2F3 apoptosis array Hs.1189 0.6kb, 3's, NO 5's, pA, no sig O/L
E2F4 (1) 700683 E2F transcription factor 4,p107/p130-binding E2F4 apoptosis array Hs.108371
1.0 kb, 5's, 3's, NO pA, no sig 
O/L
E2F4 (2) 768048 E2Ftranscription factor4, p107/p130-binding E2F4 Implantation array U15641
E2F5 (1) 701492 E2F transcription factor 5,p130 binding E2F5 apoptosis array U15642 /Hs.2331 1.0 kb, 5's, 3's, NO pA, some O/L with E2F4
E2F5 (2) 809828 E2Ftranscription factor 5, p130-binding E2F5 Implantation array U31556
E2F6 1557277 E2Ftranscription factor 6 E2F6 Implantation array AF059292
EDG-2 1624490 Endothelial differentiation G coupled protein receptor 2 EDG-2 apoptosis array Hs.75794
0.7kb, 3's, NO 5's, pA, no sig 
O/L is VZG-1, lysophosphatidic acid receptor
EDG-4 2312192 Endothelial differentiation gene 4 EDG-4 apoptosis array Hs.122575 0.6kb, 3's, NO 5's, NO pA, no sig O/L lysophosphatidic acid receptor G protein coupled
EDG-5 1844972 Endothelial differentiation gene 5 EDG-5 apoptosis array Hs.202672 1kb, 5's, no 3's, no pA, no sig O/L
EDN1 40813 endothelin 1 EDN1 Implantation array NM_001955
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EDN2 1693357 endothelin 2 EDN2 Implantation array M65199/Hs.1407
EDN3 341732 endothelin 3 EDN3 Implantation array J05081/Hs.1408
EDNRA 489571 endothelin receptor type A EDNRA Implantation array L06622
EDNRB 264557 endothelin receptor type B EDNRB Implantation array L06623
EEF1A1 1412228 Eukaryotic translation factor 1 alpha 1 EEF1A1 apoptosis array Hs.181165/BG177198
SIZE UNKNOWN (all known 
sizes were 1.8 kb and above), 
3'  no 5', pA,  no O/L
EEF1B2 unknown Eukaryotic translation elongation factor 1 beta 2 EEF1B2 Implantation array Hs.275959/BC000211
EEF2 34849 eukaryote translation elongation factor 2 EEF2 Implantation array Z11692/Hs 75309
EEF2 2096525 Eukaryotic translation elongation factor 2 EEF2 apoptosis array Hs.75309/X51466 0.6 kb, 3', pA, no O/L Eukaryotic translation elongation factor 2
EGF 2092678 Epidermal growth factor (beta-urogastrone) EGF Implantation array Hs.2230/X04571 0.9kb,3',pA
EGF-LIKE 470706 heparin-binding EGF-like GF,Diptheria toxin receptor DTR Implantation array M60278/Hs.799
EGFR 149925 epidermal growth factor receptor (c-erb B) EGF-R Implantation array X00588/Hs.77432
EGR-1 68041 Early growth response 1 EGR-1 apoptosis array M62829 /Hs.326035 0.7 kb, 5's, 3's, pA, no sig O/L
ELF 1a(2) eukaryotic translation elongation factor 1 alpha 1 EEF1A1 Implantation array Hs.181165/BF700509
ELF 1a(3) eukaryotic translation elongation factor 1 alpha 1 EEF1A1 Implantation array Hs.181165/BF700509
ELF 1a(4) eukaryotic translation elongation factor 1 alpha 1 EEF1A1 Implantation array Hs.181165/BF700509
ELF 1a(5) eukaryotic translation elongation factor 1 alpha 1 EEF1A1 Implantation array Hs.181165/BF700509
ELF 1a(6) eukaryotic translation elongation factor 1 alpha 1 EEF1A1 Implantation array Hs.181165/BF700509
Elf 1alpha eukaryotic translation elongation factor 1 alpha 1 EEF1A1 Implantation array X16869
endoglin 72461 endoglin,Osler-Rendu-Weber syndrome ENG apoptosis array X72012/Hs.76753 0.7 kb, pA, 5's3's, no extraneous o/l implicated in embryonic vascular assembly
ENG 134791 endoglin (Oster-Rendu-Weber syndrome 1) ENG Implantation array X72012/Hs.76753
enigma enigma (LIM domain protein) ENIGMA Implantation array NM_005451 image ID unknown
ENPEP 1714899 aminopeptidase A, glutamyl aminopeptidase ENPEP Implantation array L12468
EphA1 591828 ephrin type-A receptor 1 EPHA1 apoptosis array M18391/Hs89839 0.9 kb, 3's, NO 5's, pA, no sig O/L
EphA2 592634 ephrin type-A receptor 2 EPHA2 apoptosis array M59371/Hs171596 0.8 kb, pA, 5's3's, no extraneous o/l
EphB1 ephrin receptor 1 type B EpHB1 in-house clone pCR-Script EpH like receptor kinase (also NET PTK)
EphB2 ephrin receptor 2 type B Eph B2 in-house clone pCR-Script,
EPHB2 2062345 EphB2,ephrin type-B receptor 2 EPHB2 apoptosis array L41939/Hs.125124 0.8 kb, no pA, 3's erk protein tyrosine kinase some o/l with receptor protein-tyrosine kinase (HEK5)
EphB2 2062345 ephrin type-B receptor 2 EPHB2 apoptosis array L41939/Hs 125124 0.8 kb, no pA, 3's,  some o/l with receptor protein-tyrosine kinase (HEK5)
EPHB3 796057 Ephrin type-B receptor 3,EphB3, HEK1 EPHB3 apoptosis array X75208/Hs 2913 length not determined, pA, 5's3's also Hek-2  note some o/l with other Eph's
EphB4 erythropoietin producing hepatocellular ,ephrin  receptor B4 EpHB4 in-house clone pCR-Script, antisense, homolgy ACHE,TRIP6 ,CIP1, ZAN zonadhesion
ephrinB1 EphrinB1,EPLG2(LERK-2) ligand eph related kinase EFNB1 in-house clone EpH like receptor tyrosine kinase
ephrinB2 Ephrin B 2 EFNB2 in-house clone 
ErbB2 365147 V-erb-b2 avian erythroblastic leukemia viral oncogene hom. ErbB2 Implantation array X03363 last 1.8kb
ErbB4 79829 V-erb-a avian erythroblastic leukemia viral oncogene hom.4 ErbB4 Implantation array L07868
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EREG 1256213 epiregulin EREG Implantation array D30783
Erk1 927361 Erk1,extracellular-signal related kinase 1 MAPK3 apoptosis array X60188 0.6 kb, 3's, no 5's, pA, no sig O/L mitogen activated protein kinase 3
Erk2 195122 Erk2, MAPK1 mitogen-activated protein kinase 1 Erk2 apoptosis array M84489 /Hs.324473 0.7 kb, 5's, 3's, pA, no sig O/L  (MAP K 1)
Erk3(1) 1129873 MAPK6, Erk3 mitogen-activated protein kinase 6 MAPK6,Erk3 apoptosis array X80692 /Hs.271980 0.7kb, 3's, pA, no sig O/L  (p97 MAP K6)
Erk3(2) 1129873 Erk3, mitogen-activated protein kinase 6 Erk3,MAPK6 apoptosis array X80692 0.7kb, 3's, pA, no sig O/L  (p97 MAP K6)
Erk4 32410 mitogen activated protein kinase kinase 4 Erk4 apoptosis array Hs.75217/L36870 0.6 kb, 3' only, pA, no O/L  (MAP2 K 4), Mitogen-activated protein kinase kinase 4
Erk5 472099 Erk5 ,mitogen-activated protein kinase 7 MAPK7,Erk5 apoptosis array U25278 /Hs.3080 0.6 kb, NO 5's, 3's, no Pa, no sig O/L BMK1 (big map kinase 1), MAPK7
Erk6 (2) 2467159 Erk6, MAPK12 mitogen -activated protein kinase 12 Erk6 apoptosis array X79483 
0.7 kb, 3's, NO 5's, no pA, no 
sig O/L SAPK3, MAPK12
Erk6(1) 2467159
MAPK12, mitogen -activated protein 
kinase 12, extracellular signal related 
kinase 6, Erk6
MAPK12,Erk6 apoptosis array X79483 /Hs.55039 0.7 kb, 3's, NO 5's, no pA, no sig O/L SAPK3, MAPK12
ESM1 324122 endothelial cell specific molecule 1 ESM 1 Implantation array X98426
ESPN ESPIN ESPN Implantation array Hs.251216/BM017262
ESR2 Who cl.15 estrogen receptor 2 (ER beta) ESR2 Implantation array AF051427 primers29/30
ESRA WHO cl.14 estrogen receptor alpha ESRA Implantation array M12674 primers 27/28
ESRR WHO cl.6 estrogen R related-protein ESRR Implantation array M69296 primers 11/12
EST 1 1553406 EST  1 implantation array uterus-specific EST
EST 2 15383778 EST  2 implantation array uterus-specific EST
EST 3 14750 EST  3,maybe poor clone CCND1 implantation array  seq poor but partial match to CCND1,Hs.82932/M74092
EST 4 595154 EST  4 implantation array uterus-specific EST
EST 5 2204189 EST  5 Implantation array uterus
EST 6 2207731 EST  6 Implantation array uterus
EST 7 487548 EST  7 Implantation array AA045001 uterus
EST 8 2493987 EST  8 implantation array uterus-specific EST
EST 9 470067 EST  9 Implantation array AA029063 uterus
EST 10 469652 EST 10 Implantation array AA027953 uterus
EST 11 486325 LOC51241,hypothetical protein LOC51241 implantation array Hs.171566/AF151037 uterus-specific EST
EST 13 1697909 EST  13 Implantation array uterus
EST 14 2276569 EST 14(SEE NOTES col R) Implantation array Hs.37106/BC004479 MAGEA11 Melanoma Antigen,family,A
EST15 EST expressed in CD34+ hematopoietic stem/progenitor cells Implantation array 5'end
EST16 EST16 Implantation array listed as MUC1(590873)  is EST found germinal center B cells and differentiated psot mitotic neurones
EST17 725124 EST17,cDNA expressed CD34+ hematopoietic stem/progenitor cells EST17 Implantation array M34225 NOT KRT8 keratin as previously listed 
EST18 1742759 EST Implantation array sequence has similarity to laminin binding protein (receptor) but NO match pairwise BLAST to laminin receptor Hs.181357
EST19 EST19 good match EST fetal brain Implantation array AL565639
EST20 EST20 Implantation array
EST21 unknown EST21,not strictly an EST BAC clone on chr.14 Implantation array AC009469 NB also contains repetitive elements
EST22 145503 lysosome associated membrane glycoprotein 1 precursor EST22 Implantation array AI201935
EST23 247281 EST23 EST23 apoptosis array 3', pA, 0.7 kb, no sign. O/l
EST24 150685 Hypothetical protein EST24 Implantation array Hs.319946/AB051514
EST25 954771 EST25 EST25 Implantation array
EST26 EST26 in-house clone 
EST27 2218885 EST27 EST27 apoptosis array size unknown, 3's No 5', pA unknown
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EST28 1101471 EST28,MGC18386 similar to RIKEN cDNA 2610036L13 EST28 apoptosis array Hs.23044 3', 0.6 kb, pA, no o/l previously listed as RAD-51
EST29 212059
partial match to enoyl-co hydratase,Alu 
elements similar to TNF alpha induced 
protein1
Implantation array L07077,Hs.119683
EST30 147628 DKFZP56600424 hypothetical protein Implantation array Hs.226770/AI669519 in IMAGE database as PDGFRA originally
EST31 part matches novel EST & part of sequence matches ribosomal proteins EST31 Implantation array not assigned
EST31 part matches novel EST & part of sequence matches ribosomal proteins EST31 Implantation array not assigned
EST32 2435972 uterus ESTs EST32 Implantation array Hs.345027 previously listed as MAGEA11
EST33 131044 EST33 Implantation array BG289550 miss-assigned clone was listed as CTNND1 catenin
EST34 546171 EST 34 apoptosis array 0.8 kb, pA, 3's, NO 5's, no extraneous o/l
EST35 1523225 EST35 EST35 Implantation array AV734688
EST36 unknown EST36 Implantation array
EST37 WHO cl.2 unclassified,unidentified EST37 Implantation array pGEMT
EST38 2016609 EST38 very similiar to retinoblastoma protein 3 EST38 apoptosis array 1.3 kb
EST39 591683 EST39 EST39 Implantation array BF526248
EXO1 1523478 exonuclease 1 EXO1 apoptosis array Hs.47504/AF060479 0.9 kb, 3', no pA, great homology to hex1 
F3 136590 tissue factor , thromboplastin, coagulation factor III F3 Implantation array J02931/Hs62192
FADD 2428304 FAS associated via death domain FADD apoptosis array U24231/Hs.86131 0.6 kb, pA, 3's no 5', no extraneous o/l
DD-containing adapter between Fas/TNFR1&caspase8, aka MORT-1 
mediator of receptor induced cytotoxicity
FAF1 344282 Fas (TNFRSF6) associated factor 1 FAF1 Implantation array NM_007051
FAK-1 343717 Focal adhesion kinase 1 FAK-1 apoptosis array Q05397/Hs740 0.7 kB, 5's, 3' s, pA, no unwanted homology
PTK2, non-receptor TK, suppresses apoptosis following adhesion, 
cleaved by caspases during apoptosis
FAK-2 739904 PTK2B protein tyrosine kinase 2 beta FAK-2 apoptosis array L49207/Hs.20313
1.3 kB, 5's, no 3' s, no 
unwanted homolog, NOTE 
SIZE
PYK2
FAS 1949870 Fas,Apo1 fas soluble protein,TNF superfamily member6 FAS,TNFRSF6 apoptosis array Z70519 
0.6 kb, pA, NO 5' but 3', no 
extraneous o/l key death receptor/CD95
FASTK 127525 FAST Kinase FASTK apoptosis array X86779 /Hs75087 0.8 kb, pA, 5's3's, no extraneous o/l
FAU 783057 Finkel-Biskis-Reilly murine sarcoma virus FAU (MNSF beta) Implantation array X65923/Hs.177415 monoclonal nonspecific repressor factor
FBN5 WHO cl.7 fibrillin 5 FBN5 Implantation array X62009 primers 13/14,NB note homology to FBN2 Hs.79432/X6200
FGF R1 154472 fibroblast growth factor receptor 1 FGF R1 Implantation array Hs.748/M60485 fms-related tyrosine kinase 2,pfeiffer syndrome
FGF-1 30869 fibroblast growth factor 1, acidic FGF1 Implantation array X51943
FGF-2 323776 fibroblast growth factor 2, basic FGF2 Implantation array M27968
FGF7 365515 keratinocyte GF (FGF 7) FGF 7 Implantation array M60828 last 0.5kb
FGFR3 669416 FGF receptor-III,achondroplasia,thanatophoric dwarfism FGFR3 apoptosis array Hs.1420 0.9 kb, 5's, 3's, no sig O/L
FHIT 681997 fragile histidine triad gene FHIT Implantation array U46922/Hs.77252 DXL5
fibulin fibulin-1CX53743 FBLN1 in-house clone X53743/Hs.79732 pCMVSPORT 2
FKBP3 FK506 binding protein 3 (25KD) FKBP3 in-house clone Hs.350402/NM_002013 pCMVSPORT 2, Clones from J&J previously listed as RBP 
FLIP 2096139 FLIP (casper, CLARP, FLAME-1) FLIP apoptosis array AF010127
0.7 kb, pA, 3's, homologies to 
caspase-like apoptosis protein 
2 (clarp), CASH beta protein, 
FLICE-like inhibitory protein
antiapoptotic, interacts with FADD, caspase-8, caspase-3, TRAF1, and 
TRAF2, DED and caspase-like domains
FLJ20886 130951 HSP22 like hypothetical protein FLJ20886 apoptosis array Hs.6289/AF302079 0.7 kb, 3's, 5's, pA, no O/L previously listed as GRB2 miss-assigned
Flt UD2 FLT 1, Fms-related tyrosine kinase 1 (vascular endothelial growth factor) FLT in-house clone Hs.138671 B/S11 KS +/- 5'end all flt
Flt 1 Fms-related tyrosine kinase 1 Flt 1 in-house clone X51602/Hs.138671 pCMVSPORT 2
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flt4 1716286 flt 4(VEGFR-3) Fms related tyrosine kinase 4 Flt 4 apoptosis array Hs.74049/X69878
0.7 kb, pA, 3's, no 5' 
sequence, no extraneous o/l fms-related tyrosine kinase 4,some homology to MHC I
FLT4 (1) 25 Fms-related tyrosine kinase 4 (VEGFR3) Flt 4 in-house clone Hs.74049/U43143 pCR-Script, 3' end
flt4 (2) 5 Fms-related tyrosine kinase 4 Flt 4 in-house clone Hs74049 pCR-Script,  3' end
Flt4 (3) 3 Fms-related tyrosine kinase 4 Flt 4 in-house clone B/S11 KS +/-,  5'end seq matches chr.8 ESTs & partially vimentin but unconfirmed as flt4 (chr.5),ED6 clone 25 verified
flt4 (4) 15 Fms-related tyrosine kinase 4 flt-4 in-house clone B/S11 KS +/-,  full length Kendal ED6 clone 25 verified
FN1 550038 fibronectin 1 FN1 Implantation array X02761
Fork 01A 1572033 Forkhead box  O1A(rhabdomyosarcoma) FOXO1A in-house clone Hs170133/AF032885 3's, no 5's,0.6kb FKHR forkhead protein
Fork 03A 594389 Forkhead box O3A FOXO3A in-house clone Hs169277/AA169707 3's & 5's,0.7kb forkhead protein FKHRL1
FR2 214573 thrombin receptor (coagulation factor 2) F2R Implantation array M62424
friz7 162847 frizzled homolog 7 (drosophila) FZD7 Implantation array AB017365 last 1.2kb
frizzled1 1881856 frizzled1 FZD1 apoptosis array Hs.94234/AB017363 0.7 kb, 3' no 5', pA, No sig O/L
FRZB 364200 frizzled related protein FRZB,fritz Implantation array U24163
FSHB WHO cl 1 follicle stimulating hormone beta FSHB Implantation array NM_000510 pGEMT WHO cl.1 primers 1/2(444bp)
FSHB 2177805 follicle stimulating hormone beta FSHB Implantation array NM_000510
FST 124543 follistatin FST Implantation array NM_006350
FTH1 68958 ferritin heavy polypeptide 1 FTH1 Implantation array M11146
FZD1 frizzled (Drosophila) homolog 1 FZD1 in-house clone AB017363/Hs.94234
FZD2 2288713 frizzled 2 FZD2 Implantation array AB017364 hom friz 1 7 3 5 9
FZD2 1574734 frizzled (Drosophila) homolog 2 FZD2 apoptosis array Hs.81217
FZD3 756467 frizzled 3 FZD3 Implantation array U82169 hom friz 6
FZD4 (1) 2171485 frizzled homolog 4 (Drosophilla) FZD4 Implantation array AB032417/Hs.19545
FZD 4 (2) frizzled (Drosophila) homolog 4 FZD4 in-house clone Hs.19545/AB032417
FZD5 1076089 frizzled homolog 5 (Drosophilla) FZD5 Implantation array U43318 last 0.4kb
FZD6 283451 frizzled homolog 6 (drosophila) FZD6 Implantation array AB012911
FZD6 frizzled (Drosophila) homolog 6 FZD6 in-house clone Hs.114218/AB012911
FZD7 frizzled (Drosophila) homolog 7 FZD7 in-house clone Hs.173859/AB017365
FZD8 219666 frizzled homolog 8 (drosophila) FZD8 Implantation array AF086500/Hs302634
FZD 9 2338452 frizzled (Drosophila) homolog 9 FZD9 apoptosis array Hs.158335
0.7 kb, 3's, NO 5's, NO pA, 
notice homology with frizzled 
3
FZD10 frizzled (Drosophila) homolog 10 FZD10 in-house clone Hs.31664/AB027464
G3PDH 2166731 glyceraldehyde-3-phosphate dehydrogenase G3PDH, GAPD Implantation array M17851
GADD34 2019582 GADD34,PPP1R15A protein phosphatase 1,regulatory (inhibitor)subunit 15A GADD34 apoptosis array Hs.76556/U83981
0.6 kb, 3', pA, some homology 
to junB
GADD45(1) 135381 Growth arrest and DNA damage -inducible GADD45 apoptosis array U83981/L24498 0.7 kb, 3's, 5's, pA, no sig O/L
GADD45(2) 415112 Growth arrest and DNA damage -inducible alpha GADD45 apoptosis array M60974/Hs80409 0.8 kb, 3's, 5's, pA, no sig O/L NB same gene diff clone I/E3
GAPDH Glyceraldehyde-3-phosphate dehydrogenase GAPD in-house clone Hs.169476/M33197 B/S11 KS +/-
GBE1 2140558
 glucan 1,4-alpha,branching enyzme 1 
(glycogen branching enzyme, Andersen 
disease, glycogen storage disease type (IV)
GBE1 in-house clone L07956/Hs.1691 3's, no 5's,0.9kb
GDH 1873366 glutamate dehydrogenase GDH apoptosis array Hs.149155 0.6 kb, 3' read, pA, search -> no O/L Originally assigned for VDAC-1 by Image
gDNA 857612 genomic clone chr. 19 gDNA Implantation array miss-assigned
GHR 2692010 growth hormone receptor GHR apoptosis array  Hs.125180/X06562 3' no 5', unknown size, pA, no sig o/l
GJA1 132891 gap junction protein, alpha 1, Connexin 43 GJA1 Implantation array M65188
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GP130 429893 gp130, interleukin 6 signal transducer,oncostatin m receptor GP130/IL6ST Implantation array M57230 subunit il 6
GPR49 2149968 G-protein coupled receptor 49,orphan G protein GPR49 Implantation array Hs.285529/G51260
GPX Glutathione peroxidase GPX in-house clone Hs76686/AA074470 B/S11 KS +/-
GRB10 137049 Growth factor receptor-bound protein 10 GRB10 apoptosis array U69276/Hs81875 0.7 kB, 5's, 3' s, pA, no unwanted homology binds insulinR and IGF-1 R  and suppresses receptor survival activity
GRL 140925 Glucocorticoid receptor alpha and beta GRL apoptosis array Hs.75772/U80947 3's, 5's, pA, 0.7 kb, no sig O/L alpha and beta are alternative splice variants
GRO 2 841361 GRO2 oncogene GRO 2 Implantation array M36820 hom GRO1/3
GRO1 323238 GRO1oncogene GRO 1 Implantation array X12510 hom GRO2/3
GRP58 261497 phospholipase C alpha,glucose regulated protein,58KD GRP58 Implantation array D16234/Hs289101
GSK3B 1072113 GSK3B glycogen syntyetase 3 beta GSK3B Implantation array Hs.78802/AA641950
GSK3B 1853459 glycogen synthase kinase 3 beta GSK3B Implantation array L33801
GSR 1056796 glutathione reductase GSR,GRD1 apoptosis array X15722 /Hs.121524 0.7 kb, NO 5's, 3's, NO pA, no sig O/L detoxication of xenobiotics
GST P1 2224433 Glutathione S transferase pi GSTP1 apoptosis array Hs.226795/U12472 0.6 kb, 3's, pA, no sig O/L detoxication of xenobiotics
GST T1 125180 Glutathione S transferase,theta GSTT1 apoptosis array X79389 /Hs77490 0.8 kb, 5's, 3's, pA, no sig O/L detoxication of xenobiotics, theta
GSTA1 1573402 Glutathione S-transferase A1 (contains gene for A2) GST A1 apoptosis array M14777 /Hs89552 0.7kb, 3's, pA, no sig O/L detoxication of xenobiotics, A1 and A2 homologous
H-Ras 2114795 HRAS,v-Ha-ras Harvey rat sarcoma viral oncogene homolog HRAS apoptosis array Hs.37003 0.6 kb, 5's, 3's, pA, no sig O/L Harvey Ras
Harikari 1519582 Harakiri Bcl-2 interacting protein HRK apoptosis array U76376/Hs87247 0.4 kb, NO pA, NO 5's but has 3's, no extraneous o/l an activator of apoptosis,DR5
HBA1 unknown alpha globulin ,hemoglobin HBA1 Implantation array NM_000558
HCG alpha 13184 human chorionic gonadotrophin, alpha polypeptide HCG alpha Implantation array V00518
HCGbeta 252284 human chorionic gonadotrophin, beta polypeptide HCG beta (CGB) Implantation array J00117 hom LH beta
HDAC1 898976 histone deacetylase 1 HDAC1 Implantation array U50079 last 0.3kb last 0.3kb
HDAC1 898976 histone deacetylase 1 HDAC1 Implantation array U50079 last 0.3kb last 0.3kb
HDAC2 491639 histone deacetylase 2 HDAC2 Implantation array U31814/Hs.3352 last 0.5kb likely to have been a miss-assigned clone
HDAC3 144052 histone deacetylase 3 HDAC3 Implantation array Hs.350277/U66914 last 0.7kb
HDAC4 2177805  Histone deacetylase 4, KIAA0288 HDAC4 Implantation array AI491868/Hs.91400 1.6kb
HDAC4 1606829 KIAA0288, histone deacetylase 4 HDAC4 Implantation array Hs.91400/AB006626 0.4kb,3' ,poly A
HDAC6 669295 histone deacetylase 6 HDAC6 Implantation array AB020708/Hs.6764
HEC/SS24 WHO cl.9 Retinoblastoma associated protein HEC HEC/SS24 Implantation array AF017790 with WHO 17/18/primers (OKA FSHR primers)
HEXB 251802 hexosaminidase B(beta polypeptide)N-acetyl-beta-glucosaminidase HEXB in-house clone M13519/Hs.51043
3's, no 5's, some homology to 
alpha subunit
HGF(1) Hepatocyte growth factor,hepapoietinA,scatter factor HGF in-house clone Hs809/M29145 pCR-Script hepapoietin A:scatter factor
HGF(2) 375833 hepatocyte growth factor (hepapoietin, scatter factor) HGF Implantation array M60718/Hs.809  homologous to HGF heavy chain & has homolgy to CD34+ 
HIF1-alpha 142934 Hypoxia inducible factor1 alpha subunits (basic helix-loop-helix transciption factor) HIF 1 alpha apoptosis array Hs.197540/U22431 0.9 kb, 5's, 3's, pA, no O/L MOP1, ARNT interacting protein
HIF2 alpha 1733081 Hypoxia inducible factor 2 alpha EPAS1 apoptosis array Hs.8136/U51626 0.6 kb, 3' no 5' pA no sig. O/L MOP2, HLF,  EPAS1 endothelial PAS domain protein 1
HIFIA 897806 hypoxia -inducible factor1, alpha subunit HIF1A Implantation array U22431
HIFIA 897806 hypoxia -inducible factor1, alpha subunit HIF1A Implantation array U22431
His Histidyl tRNA synthase HIS in-house clone X05345/Hs.77798
Histone 899722  H2A histone family member.X H2AFX apoptosis array Hs.147097 0.6 kb, 3', pA, no o/l phosphorylated by ATM after DNA damage
HLA-C 725228 major histocompatibility complex, class 1, C HLA-C Implantation array M26429/Hs.277477
HMGIY 701054 high mobility group (nonhistone chromosomal)proteins I&Y HMGIY apoptosis array Hs.139800/AA287531
0.8 kb, pA, NO 5' but 3', no 
extraneous o/l
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HNRPA3 192262 Heterogeneous nuclear ribonucleoprotein A3 HNRPA3 Implantation array Hs.249247/BM458287 previously listed as INHBC ,miss-assigned
Homocyst 545222 homocysteine-responsive gene in-house clone 0.7kb
HOXA10 487978 homeo box A10 HOXA10 Implantation array AF040714/Hs.110637
HOXA11 491209 homeobox A11 HOXA11 Implantation array NM_005523
HOXA13 591699 homeobox A13 HOXA13 Implantation array NM_000522
HOXA9 897497 homeo box A9 HOX A9 Implantation array U82759
HP 595154 Haptoglobin HP Implantation array Hs 75990
HPRT 727246 hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan) HPRT Implantation array M31642
HSCPCO34 2045711 CD34+ hematopoietic stem/progenitor cell HSPCO34 in-house clone X79302 3's, no 5's,0.7kb should really be listed as an EST think same as E/G3 EST15
HSD17B1 136491 hydroxysteroid (17-beta) dehydrogenase 1 HSD17B1 Implantation array M36263
HSDB 1759603 3-beta-hydroxy-5-ene steroid dehydrogenase (beta) HSDB Implantation array M27137
hsp60 69928 heat shock protein 60 kD protein 1 (chaperonin) HSP60,HSPD1 Implantation array M22382/Hs.79039
hsp70 72831 heat shock protein 70 kD HSP70 Implantation array NM_005345
HSP90 595057 Heat Shock Protein 90 HSP90 in-house clone M16660 3's, no 5's,0.7kb
HUS-1 1751692 HUS1(S.pombe) checkpoint homolog HUS1 apoptosis array Hs.152983/AF076844 0.6kb, 3', no pA, no o/l
HXB 484707 tenascin C,hexabrachion,cytotactin HXB Implantation array M55618/Hs.28914
Hyp prot 2252160 GS3686 hypothetical protein expressed in osteoblast in-house clone AB000115/Hs75470 0.8kb C1orf 29
I-kBalpha 358896
I-kB alpha,nuclear factor of kappa light 
polypeptide gene enhancer in Bcells 
inhibitor alpha
I-kB alpha,      
NFKB1A apoptosis array M69043/Hs.81328 0.7 kb, 3's, 5's, pA, no sig O/L
ICAM-1 1535767  Intercellular adhesion molecule 1,ICAM-1 (CD54) ICAM-1 apoptosis array J03132 /Hs.168383
0.6 kb, 3's, NO 5's, NO pA, no 
sig O/L expressed endothelium,  binds LFA-2
ICAM1 145112 intercellular adhesion molecule 1 (CD54) ICAM1 Implantation array J03132
ICAM2 127191 ICAM-2,intercellular adhesion molecule 2 ICAM2 Implantation array Hs.347326/X15606 ligand for LFA-1
IEX-IL 588382 IEX-1L (DIF2) anti-death protein,also IER3 immediate early response protein
 IER3,IEX-
1L,DIF2 apoptosis array AF09067/Y14551
0.8 kB, 5's, 3' s, pA, no 
unwanted homology  promotes NF-kappaB-mediated cell survival
IFN alpha5 WHOcl.10 interferon alpha-5 IFN alpha-5 in-house clone Hs.37113/V00541 pGEMT primers 19/20/424bp,chromosome 9
IFNG 1579639 interferon gamma IFNG Implantation array M29383
IFNGR1 151378 interferon gamma receptor 1 IFNGR1 Implantation array J03143/Hs.180866
IFNGR2 310905 interferon gamma receptor 2 IFNGR2 Implantation array U05877
IGF1 287327 insulin-like growth factor 1 (somatomedin C) IGF 1 Implantation array M29644
IGF1R(1) 148379 insulin-like growth factor 1 receptor IGF1R Implantation array X04434 last 1kb
IGF1R(2) 148379 insulin-like growth factor 1 receptor IGF1R Implantation array X04434 last 1kb
IGF2 206372 insulin-like growth factor 2 (somatomedin A) IGF 2 Implantation array Hs.349109/X06159
IGF2R(1) 668002 insulin-like growth factor 2 receptor IGF2R Implantation array Y00285
IGFBP1 469216 insulin-like growth factor binding protein 1 IGFBP1 Implantation array NM_000596 NB contains repeat seqs
IGFBP2 2163663 insulin-like growth factor binding protein 2 IGFBP2 Implantation array M35410
IGFBP3 138707 insulin-like growth factor binding protein 3 IGFBP3 Implantation array NM_000598
IGFBP4 70980 insulin-like growth factor binding protein 4 IGFBP4 Implantation array M62403
IGFBP5 150555 Insulin-like growth factor binding protein 5 IGFBP5 Implantation array Hs.180324/L27560 correct gene but recently assigned to different cluster
IgH 2178483 EST similiar to Ig Gamma-1 chain C IgH Implantation array
IL1alpha 1645252 interleukin 1 alpha IL1alpha Implantation array M28983
IL1R2 137575 interleukin 1 receptor type II IL1R2 Implantation array X59770
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IL1RL1 486393 interleukin 1 receptor like 1 IL1RL1 Implantation array NM_003856/Hs.66
IL3 WHO cl.12 interleukin 3/mast cell growth factor IL 3/MCGF Implantation array M14743 primers 23/24
IL6 2148410 Interleukin 6 (B-cell stimulatory factor-2) IL6 Implantation array Hs.93913/M18403
IL6 1508411 interleukin 6 (interferon, beta 2) IL6 Implantation array M14584
IL6R 80474 interleukin 6 receptor IL6R Implantation array X58298 alpha chain + GP130
IL8 1651203 interleukin 8 IL8 Implantation array M26383
IL8 (2) unknown interleukin 8 IL8 Implantation array M26383
IL11 310124 interleukin 11 IL11 Implantation array M57765
IL11RA 182152 interleukin 11 receptor, alpha IL11RA Implantation array U32324/Hs.64310
IL11RA 182152 IL11 receptor alpha IL11RA apoptosis array Hs.64310 0.9 kb, 5's, 3's, NO pA
IL15 2064047 interleukin 15 IL15 Implantation array U14407/X91233
ILIRN 152577 interleukin 1 receptor antagonist IL1RN Implantation array Hs.81134/X52016
ILK 194179 integrin linked kinase ILK apoptosis array U40282 0.6 kb, 5's, 3's, pA, no sig O/L (beta1-integrin-linked protein kinase)
ING1 1641423 inhibitor of growth family,member1 ING1 apoptosis array AF001954 /Hs46700 0.9 kb, 3's, NO 5's, pA, no sig O/L cooperates with p53-indcued apoptosis
INHA 1711449 inhibin alpha INHA Implantation array M13981
INHBA 1723823 inhibin Beta A INHBA apoptosis array Hs.727/M13436 0.7 kb, 3's, 5's, pA, no sig O?L activin A, activin AB alpha polypeptide
INHBB (1) 323599 inhibin beta B (also Activin B) INHBB Implantation array Hs.1735/BM31682
INHBB (2) 1074867 inhibin beta B (also Activin B) INHBB Implantation array M13437 last 0.7kb
INHBB (3) 415058 Inhibin beta B INHBB apoptosis array Hs.1735/AL355334 0.4kb,3',pA unknown previously listed as CLAP but not confirmed seq is INHBB 
INK-4 1523215 p16/INK-1,CDK4- inhibitor =cyclin -dependent kinase inhibitor 2A CDKN2A apoptosis array Hs1174  0.6 kb, 3', pA, no O/L
INSR (1) 427812 insulin receptor INSR Implantation array M10051 last 0.6kb
INSR (2) 427812 insulin receptor INSR Implantation array M10051 last 0.6kb
IRF1 685033 Interferon regulatory factor 1 IRF1 Implantation array NM_002198
IRF2 122308 Interferon regulatory factor 2 IRF2 in-house clone X15949 3's, no 5's,0.5kb
ITGA1 2028225 integrin alpha 1 ITGA1 Implantation array X68742
ITGA2 687871 integrin alpha 2/CD49B ITGA2 Implantation array X17033
ITGA3 505285 integrin alpha 3/CD49C ITGA3 Implantation array M59911/Hs.265829
ITGA4 341922 integrin alpha 4/antigenCD49D ITGA4 Implantation array AI769736/Hs.40034
ITGA5 135671 integrin alpha 5,fibronectin receptor ITGA5 Implantation array Hs.149609/X06256 last 1.7kb alpha polypep.fibronectin receptor
ITGA6 182431 integrin alpha 6 ITGA6 Implantation array X59512 last 1.8 kb
ITGA8 198557 integrin alpha 8 ITGA8 Implantation array Hs.91286/L36531 (3'end)
ITGAM 2216556
Integrin alpha-M,complement component 
receptor 3,macrophage antigen alpha 
polypeptide
ITGAM apoptosis array Hs.172631/NM_000632 0.6 kb, 3's, NO 5's, pA, no sig O/L alpha-M = CD11b,p170
ITGAV 488512 integrin alpha V/vitronectin R/CD51 ITGAV Implantation array M14648/Hs.295726
ITGB1 505555 integrin beta 1(fibronectin receptor, CD29) ITGB1 Implantation array X07979
ITGB2 704517 integrin beta 2 (CD18) ITGB2 Implantation array M15395
ITGB3 1715386 Integrin beta-3 ITGB3 apoptosis array Hs.87149/M25108 0.7 kb, 3's, NO 5's, pA, no sig O/L glycoprotein IIIa
ITGB3 134103 Integrin beta 3 ITGB3 Implantation array Hs.87149/M20311 platelet glycoprotein IIIa, antigen CD61
ITGB4 726248 Integrin beta 4 ITGB4 Implantation array AF011375
ITGB5 486216 integrin beta 5 ITGB5 Implantation array J05633
ITNB7 2107532 Integrin beta-7 ITNB7 apoptosis array Hs.1741 0.7 kb, no 5's, 3's, pA, no sig O/L
JAK1 177471 janus kinase 1 JAK1 Implantation array M64174
JAK2 789379 janus kinase 2 JAK2 Implantation array AF005216
JAK3 2043964 janus kinase 3 JAK3 Implantation array U09607 last 0.6kb
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JNK1 119133 JNK1, mitogen activated protein kinase8 JNK1/MAPK8 apoptosis array L26318 /Hs190913
0.4 kb, 5's, NO 3's, NO pA, 
watch for homology withn 
JNK3
MAPK8, (SAP K 1)
JNK2 1030968 JNK2, Mitogen -activated protein kinase 9 JNK2,MAPK9 apoptosis array L31951 /Hs.246857 0.9 kb, 3's, NO 5's, pA, no sig O/L MAPK9, C-JUN N-TERMINAL KINASE 2
JNK3 2168302 c-JUN N-terminal kinase 3 JNK3 apoptosis array Hs.151051/ U34819 0.7 kb, 3's, NO 5's, pA, no sig O/L MAPK10, C-JUN N-TERMINAL KINASE 3 alpha
junB 153369 junB (transcription factor) JunB Implantation array NM_002229/Hs198951 last 0.8kb proto-oncogene, previously listed as ID 143369
junD 155061 junD proto oncogene junD Implantation array X51346
K-Ras2 1286258 K-Ras2 Kirsten rat sarcoma 2 viral oncogene homolog K-RAS2 apoptosis array Hs.351221/M54968 0.7 kb, 5's, 3's, pA, no sig O/L
KDR 2148038 Kinase Domain receptor,VEGF R2,Flk-1 KDR Implantation array X61656 last 1.5kb
KDR (1) UC1 Kinase Domain receptor,VEGF R2,Flk-1 KDR in-house clone Hs.12337/AF035121 B/S11 KS +/-
KIAA0929 unknown
KIAA0929,SHARP nuclear receptor 
transcription 
cofactor,SMART/HDAC1associated 
repressor protein
Implantation array Hs.184245/AB023146 miss-assigned clone 
KIAAO27 unknown KIAA027 Implantation array Hs.78851
kinectin 1643645 kinectin 1,kinesin receptor KTN1 apoptosis array Hs.211577/Z22551 0.6 kb, pA, 3', no sign. O/l kinesin binding adapter, coiled-coiled transmembrane protein
KISS-1 812955 KiSS-1 metastasis-suppressor KISS-1 Implantation array U43527
KPNB1 684634 Karyopherin (importin beta1)nuclear factor p97(NTF97) KPNB1 in-house clone L38951/Hs.180446 3's, 0.7kb Nuclear import
KPNB2 2055326 Karyopherin (importin beta2), also transportin (TRN) KPNB2 in-house clone U72069/Hs.168075 3's, no 5's, n pA, 0.8kb Nuclear import,beta 2a & beta 2b homology
Ku-70 1571080 Thyroid autoantigen 70KDKu-antigen G22P1 apoptosis array Hs.197345/M32865 0.6 kb, 3', pA, no o/l DNA end-binder, dimerises with Ku-80, recriuts DNA-PK, mutation-> SKID
Ku-80 268333
Ku autoantigen 80KD, XRCC5 Xray repair 
complementing defective repair CHO cells 
(ds break re-joining)
Ku-80 apoptosis array Hs.84981/NM021141 pA, 3'seq, no 5'seq DNA end-binder, dimerises with Ku-70, recriuts DNA-PK, mutation-> SKID
L-myc 1860279 L-myc,similar to lung carcinoma myc related oncogene 1 L-myc apoptosis array Hs.169252
0.9 kb, 3's, NO 5's, pA, no sig 
O/L
LAMA2 131358 laminin alpha 2 (merosin,congenital muscular dystrophy) LAMA2 Implantation array Z26653
LAMA3 156183 laminin alpha 3 (nicein 150 KD)(Kalinin 165Kd) (BM600 150KD) LAMA3 Implantation array L34155/Hs.83450
LAMA3 591760 laminin alpha 3 (nicein 150 KD)(Kalinin 165Kd) (BM600 150KD) LAMA3 Implantation array L34155/Hs.83450
LAMB1 253043 laminin beta 1 LAMB1 Implantation array M61916
LAMB2 74984 laminin beta 2 (laminin S) LAMB2 Implantation array X79683
LAMB3 841907 laminin beta 3 LAMB3 Implantation array L25541
LAMC1 364544 LAMININ GAMMA 1 LAMC1 Implantation array Hs 214982
LAMC2 1057687 laminin gamma 2 LAMC2 Implantation array NM_005562
LAMP1 lysosomal-associated membrane protein 1 LAMP 1 Implantation array Hs.150101/J04182
LEP1 139081 leptin (murine obesity homolog) LEP Implantation array U43653 part of EXON 3 Ob gene/human LEP homolog 3' end  contains ALU repeats so beware if it is positive !!!!!!
LEPR 142069 leptin receptor LEPR Implantation array U43168
LHCGR 1735495 luteinizing hormone/chriogonadotropin receptor LHCGR Implantation array M73746
LIF (1) 2510878 Leukemia inhibitory factor,cholinergic differentiation factor LIF apoptosis array Hs.2250 3's, 0.6kb, pA, no sig O/L also called HILDA
LIF (2) 1942528 leukemia inhibitory factor LIF Implantation array NM_002309 cholinergic differentiation factor
LIFR 137437 LIF receptor LIFR Implantation array Hs.249247/BM458287
LIG3 1847306 DNA ligase III,DNA,ATP-dependent LIG3 apoptosis array Hs.100299 0.7 kb, 3', no pA, no o/l
ligase1 525777 DNA ligase I,ATP dependent LIG1 apoptosis array Hs.1770/M36067 0.6 kb, 3', 5' also, pA, no o/l
Lipocortin 1 1553687 Annexin A1 or Lipocortin 1 ANXA1 in-house clone X05908/Hs.78225 3's, no 5's, 0.6kb PLA2 inhibitor
LTF 160749 lactoferrin/lactotransferrin LTF Implantation array Hs.105938/X53961
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LTP 6 spike 5 Arabidopsis Thaliana,lipid transfer protein 6 LTP6 exogenous control AF159803 pGEMT,537 bp
LTP4 spike 4 Arabidopsis Thaliana,lipid transfer protein 4 LTP4 exogenous control AF159801 pGEMT,527 bp
M-CSF 68599 M-colony stimulating factor M-CSF apoptosis array Hs.173894 0.7 kb, pA, 5', 3', no extraneous o/l CSF-1, expressed by EC, (Kosaki et al UI 98220910)
MAD 788421 MAD, mothers against decapentaplegic, homolog 4 MADH4/DPC4 Implantation array U44378
MAdCAM-1 1564705 MAdCAM-1,mucosal vascular addressin, cell adhesion molecule 1 MADCAM-1 apoptosis array U82483/Hs.102598
0.7 kb, no 5's, 3's, pA, no sig 
O/L
LPAM-1ligand expressed on HEV, ? Survival function/mucosal vascular 
adhesion mol1
MADD 135635 MAP-kinase activating death domain MADD apoptosis array U77352/Hs82548
0.8 kb, pA, 5's3's, no 
extraneous o/l (=DENN + 
cardiac myosin binding prot 
C)
TNFR1-interacting also called DENN
MAG 32444 myelin associated glycoprotein MAG Implantation array M29273
MAT2A 287608 Methionine adenosyltransferase II, alpha MAT2A in-house clone L43509/Hs77502 3's & 5's,0.7kb S-adenosylmethionine synthetase
MBD1(2) 324205 methyl CpG binding protein 1 MBD1 Implantation array Y10746  matches NADPH dependant retinol dehydrogenase /reductase was a missassigned clone
Mcl-1 711870 Myeloid cell leukemia sequnce 1(bcl 2 related) MCL-1 apoptosis array L08246 /Hs.86386
0.9 kb, pA, 5's3's, no 
extraneous o/l
MCM-5 213756 minichromosome maintenance deficient,CDC46 MCM 5 apoptosis array Hs.77171
0.7kb, 3' no 5', pA, no sig o/l 
other than CDC56 (syonym?)
Minichromosome maintenance deficient (S. cerevisiae) 5 (cell division 
cycle 46)
MCP-1 147207 monocyte chemotactic protein-1, small inducible cytokine A2 MCP-1 Implantation array M28226  Chemokine (C-C motif) ligand 2 (CCL2) small inducible cytokine A2
MCP-1 1388786 monocyte chemoattractant protein 1 (MCP-1) MCP-1 apoptosis array Hs.340 0.6 kb Chemokine (C-C motif) ligand 2 (CCL2) small inducible cytokine A2
MCP-1R 430027 monocyte chemoattractant protein 1 receptor, chemokine R2 MCP-1R, CCR2 Implantation array D29984 last 0.5kb
MCP-2 2179757 monocyte chemotactic protein-2, small inducible cytokine A8 MCP-2, SCYA8 Implantation array Y16645 last 0.3kb
MCP3 322873 monocyte chemotactic protein-3, small inducible cytokine A7 MCP-3, SCYA7 Implantation array X72308
Chemokine (C-C motif) ligand 7 (CCL7) is a small cytokine known as a 
chemokine
MCP4 1257779 monocyte chemotactic protein-4, small inducible cytokine A13 MCP-4, SCYA13 Implantation array U59808 last 0.7kb
MCP4 1257779 monocyte chemotactic protein-4, small inducible cytokine A13 MCP-4, SCYA13 Implantation array U59808 last 0.7kb
MDB2 1011311 methyl CPG binding protein 2 MBD2 Implantation array AF072242
MDM2 147075 mouse double minute 2 MDM2 apoptosis array Z12020 /Hs170027 0.5kb, 5's, NO 3's, NO pA, no sig O/L human homolog of, p53 binding protein
MDMx 2615020 homolog mouse double minute MDMx apoptosis array AF007111 size unknown, 3's, NO 5's, pA, no sig O/L
human homologue of mouse double minute 2, upregulated by p53, binds 
to p53 and promotes p53 inactivation
MEK unknown MEK BP partner 1,mitogen activated protein kinase kinase 1 binding protein
MEK,MAP2KIIP
1 Implantation array AI142363/Hs.6361 homology to AV711984 expressed human dendritic cells
MEK K5 1604803 MAP3K5,mitogen activated protein kinase kinase kinase 5 MEKK5,ASK1 apoptosis array D84476 
0.6kb, 3's, NO 5's, pA, no sig 
O/L  (ASK1)
MEK1 712732 MAP kinase kinase 1(MAP2K1) MEK1 apoptosis array L05624 /Hs.3446 0.7 kb, 5's, 3's, pA, no sig O/L MAPKK 1
MEK5 343871 mitogen activated kinase kinase 5 MEK5 apoptosis array U25265 1.0 kb, 5's, 3's, pA, no sig O/L MAPKK5
MEK6 2805416 Mitogen activated protein kinase kinase 6 MEK6,MAP2K6 apoptosis array U39657 /Hs118825 unknown size, 3's, NO 5's, pA, no sig O/L MAPKK6
MET (1) Met proto-oncogene (hepatocyte growth factor receptor) MET in-house clone Hs 285754/M54559 pCR-Script
MET (2) 754509 HGF receptor (met, proto-oncogene) HGFR (MET) Implantation array J02958/Hs285754
MGC5618 346860 hypothetical protein MGC5618 in-house clone Hs.177781/C05030 3's, no 5's, 0.7kb
MGST1 564980 microsomal glutathione S-transferase 1 MGST1 apoptosis array J03746 /Hs.790 0.7 kb, 5's, 3's, pA, no sig O/L membrane-bound GST (GST 12)
MHC MHC classI proline rich MHC1 Implantation array U63336
MIF 592998 macrophage migration inhibitory factor MIF Implantation array M25639
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MIHA 1593929
MIHA (XIAP, API 3, ILP) X-linked 
inhibitor of apoptosis protein,IAP like 
protein ILP
MIHA apoptosis array  U45880/hs172777 1.3 kb, pA, NO 5's, 3's, no extraneous o/l, NOTE SIZE BIRC4 Baculoviral IAP repeat containing 4
MIHB 132713
MIHB (IAP2),BIRC2 Baculoviral IAP 
repeat containing 2 inhibitor of apoptosis 
protein homolog B
MIHB apoptosis array  U45879 / Hs.289107 0.6 kb, pA, 5's3's, no extraneous o/l
MIHC 926254 MIHC = API2 = IAP1,Baculoviral IAP repeat containing 3 MIHC,BIRC3 apoptosis array
Hs.127799/U37546 / 
L49431
0.3 kb, 3;s, NO 5's, pA, note 
short size to attempt to avoid 
MIHB homology
binds TRAF1, TRAF2, caspases 3 and 8
MIP1alpha 1898671 macrophage inflammatory protein 1 alpha, small inducible cytokine A3 SCYA3 Implantation array M23452/Hs.73817
MIP1beta 205633 macrophage inflammatory protein 1 beta, small inducible cytokine A4 SCYA4 Implantation array J04130/Hs.75703 last 0.4kb Hom. to mouse MIP 1b
MK167 769513 Ki 67, antigen identified by monoclonal antibody MKI67 Implantation array X65551
MLC-B 139375 myosin light chain  regulator,nonsarcomeric MLC-B apoptosis array AA772131/Hs.180224 0.6 kb, pA, 5's3's
MLH-1 2311591 MutL (E.coli) homolog 1,colon cancer /nonpolyposis type 2 MLH1 Implantation array Hs.57301/U07343 0.7kb,3',pA
MMP1 309938 matrix metalloproteinase 1(interstitial collagenase) MMP1 Implantation array M13509 interstitial collagenase NB same clone asH/B12
MMP-1 309938 Matrix metalloproteinase 1 MMP-1 apoptosis array Hs.83169 0.6 kb Matrix metalloproteinase 1 (interstitial collagenase)NB same clone asB/A8
MMP-2 2347072 matrix metalloproteinase 2 MMP-2 apoptosis array Hs.111301 0.6 kb gelatinase A, 72kD type IV collagenase
MMP2 486460 matrix metalloproteinase 2 (gelatinase A) MMP2 Implantation array M55593
MMP-3 323977 Matrix metalloproteinase 3 MMP-3 apoptosis array Hs.83326 0.6 kb stromelysin 1, transin-1
MMP3 324700 matrix metalloproteinase 3 (stromelysin 1, progelatinase) MMP3 Implantation array J03209
MMP7(1) 471134 Matrix metalloproteinase 7 MMP-7 apoptosis array Hs.2256 0.9 kb matrilysin, COG-7 NB same clone asC/E10
MMP7(2) 471134 matrix metalloproteinase 7 (matrilysin, uterine) MMP7 Implantation array X07819 homolog to stromelysin (pump-1)NB same clone as H/C2
MMP9 2522550 MMP9 = type 4 collagenase MMP9 apoptosis array Hs.151738 0.6 kb COG9, gelatinase B
MMP10(1) 1664074 matrix metalloproteinase 10 (stromelysin 2) MMP10 Implantation array Hs 2258/X07820 0.6kb
MMP10(2) 1664074 matrix metalloproteinase 10 (stromelysin 2) MMP-10 apoptosis array Hs.2258 0.6 kb stromelysin 2
MMP11(1) 133842 matrix metalloproteinase 11 (stromelysin 3) MMP11 Implantation array X57766
MMP-11(2) 71651 Matrix metalloproteinase 11 MMP-11 apoptosis array Hs.155324 0.8 kb stromelysin-3
MMP12 2062289 matrix metalloproteinase 12 (macrophage elastase) MMP12 Implantation array L23808/Hs.1695 macrophage elastase
MMP13 1555874 matrix metalloproteinase 13 (collagenase 3) MMP13 Implantation array X75308
MMP14 1661893 matrix metalloproteinase 14 (membrane -inserted)
MMP14/MT-
MMP Implantation array Hs.2399/Z48481 last 1.1kb
MMP15 284428 matrix metalloproteinase 15 (membrane inserted) MMP15 Implantation array NM_002428/Hs.80343 last 2kb
MMP16 46916 matrix metalloproteinase 16 (membrane -inserted)
MMP16/MT3 
MMP Implantation array AB009303
MMP17 30850 matrix metalloproteinase 17 (membrane -inserted)
MMP17/MT2-
MMP Implantation array X89576 poor match from random seq 7.2.02/12
MMP19 149932 matrix metalloproteinase 19 MMP19 Implantation array U38320/Hs154057 MMP18,RASI-1
MMP23B 1579964 matrix metalloproteinase 23B MMP23B Implantation array NM_004659
Mn SOD Manganese-containing superoxide dismutase SOD2 in-house clone Hs.318885/X14322 mitohondrial
MRE-11A 1879728 Meiotic recombination (S.cerevisiae) 11 homolg A MRE-11A apoptosis array Hs.20555/U37359
0.7 kb, 3', pA, some homology 
to MRE-11A
MSH2 2295786 MutS (E.coli) homolog 2 / colon cancer nonpolyposis type1 MSH2 apoptosis array Hs.78934/U04045 0.6 kb, 3', pA, no o/l (homologue of bacterial MutS), implicated in most HNPPC
MSH3 738899 mismatch repair protein homolog 3 MSH3 Implantation array J04810/Hs.42674 (homologue of bacterial MutS), implicated in some HNPPC
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msh5 795640 mismatch repair protein homolog 5 MSH5 Implantation array AF048986
MSH6(1) 841478 mismatch repair protein homolog 6 MSH6 Implantation array U54777
MSH6(2) 2463136 mismatch repair protein homolog 6 MSH6 apoptosis array Hs.3248/U54777 0.6 kb, 3', pA, some homology to VIT-1 (homologue of bacterial MutS)
MSP Macrophage stimulating protein (hepatocyte growth factor -like) MST1 in-house clone Hs.349110/L11924 pCR-Script, ligand for RON
MSX1 135694 Msh (drosophila ) homeo box homolog 1 MSX1 Implantation array M97676/Hs1494 last 0.8kb, formerly homeo box 7 now Msh hom. 1
MT2A 1711581 metallothionein 2A MT2A Implantation array X97260
MT3 2104626 metallothionein 3 (growth inhibitory factor) MT3 Implantation array NM_005954 hom M1,product seq sim to MT3
MT6AA 487441 metallothionein 6AA MT6AA Implantation array AA046711
MTA1 298963 Metastasis -associated 1 MTA1 Implantation array Hs101448/U35113
MUC1 590873 mucin 1, transmembrane MUC1 Implantation array NM_002456/Hs.89603
MUC2 1871480 mucin 2,intestinal/tracheal MUC2 Implantation array L21998/Hs.315 last 1kb
MUC4 2173976 mucin 4, tracheobronchial MUC4 Implantation array AJ010901(partial)
MUC5B(1) 592592 mucin 5B, tracheobronchial, placental MUC5B Implantation array AJ001403
MUC5B(2) 937208 mucin 5B tracheobronchial, gallbadder MUC5B, partial Implantation array U06711(partial)
MUC6 2095547 Mucin 6, gastric MUC6 Implantation array U97698(partial)
MUT L 128493 mutL (E.coli) homolog 1, colon cancer nonpolyposis type 2 Mut L/MLH1 Implantation array U07343
MUTS 630013 mismatch repair protein homolog 2, colon cancer nonpolyposis 1 MutS/MSH2 Implantation array U04045
MYD88 486287 myeloid differentiation primary response gene MYD88 Implantation array U70451
MYO1C myosin 1C MYO1C in-house clone Hs.286226/X98507 pCR-Script, 
MYST1 histone acetyltransferase MYST1 MYST1 implantation array previously listed as ILBRbeta MISSASSIGNED also homology to SW_MOF_DROME males absent on the first protein
N-cadherin 1737662 N-Cadherin(neuronal),cadherin 2 CDH2 apoptosis array Hs.161 0.9 kb, pA, 3', no extraneous o/l Cadherin-2
N-myc 2006037
N-myc,V-myc avian myelocytomatosis 
viral related oncogene ,neuroblastoma 
derived
MYCN apoptosis array Hs.25960/M13228 1.0 kb, 3's, NO 5's, pA, no sig O/L
N-Ras 839623 N-Ras related gene,D1S155SE N-Ras apoptosis array Hs.69855/NM_007158 0.6 kb, 5's, 3's, pA, no sig O/L Neuroblastoma Ras,NB related to N-ras
NAIP 1734928 NAIP,neuronal apoptosis inhibitory protein NAIP,BIRC1 apoptosis array NM_004536/Hs.79019 1.4 kb, pA, NO 5's, 3's, no extraneous o/l, NOTE SIZE
a mammalian IAP implicated in SMA,Baculoviral IAP repeat containing 
1
Nbs1 153757 Nijmegen breakage syndrome 1(nibrin) NBS1 apoptosis array Hs.25812 0.7 kb, 3', no pA, no o/l
Nijmegen breakage syndrome gene, part of endo/exo-nuclease complex, 
signals DNA damage to cell cycle, regulates MRE11 / Rad50 complex 
(homologous to yeast Xrs2)
NCKAP1 135176 NCK-associated protein 1 NCKAP1 in-house clone Hs.278411/AB014509 3's & 5's Apoptosis NOTE NOT NAP1 pronapsin Hs 322854
NDUFS5 343461
NADH-dehydrogenase (ubiquinone) Fs.S 
protein 5 (15KD)NADH coenzyme Q 
reductase
NDUFS5 in-house clone Hs.80595/AF020352 0.6kb
Neu1 Neuropilin 1 NRP1 in-house clone Hs.69285/AF016050 pCR-Script, 
Neur2 Neuropilin 2 NRP2 in-house clone Hs.17778/AF022860 pCR-Script, 
NF kappa 154818 NF kappa B transcription factor p65 NF k B Implantation array L19067/Hs.75567 0.7 kb, 3' seq, 5' seq, pA, no extra o/L V-rel hom A,same clone as I/C4 apoptosis
NF-kbp105 1670273 NF-kB p105 (pre p50) NF-KB apoptosis array M58603 0.5 kb, 3' seq, no 5' seq, pA, no extra o/L (pre-p50)
NF-KBp65 154818
NF-kB p65, V-rel avian 
reticuloendotheliosis viral oncogene 
homolog A(nuclear factor of kappa light 
polypeptide gene enhancer in B cells 3 
(p65)
RELA,       NF-
KBp65 apoptosis array L19067/Hs.75567
0.7 kb, 3' seq, 5' seq, pA, no 
extra o/L (Rel A),same clone as B/C9
NICE-3 595099 DKFZP586G1722 hypothetical protein NICE-3 Implantation array Hs.31989/BG260819
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NIK 342349
serine -threonine protein kinase MAP3K14 
mitogen activating protein kinase kinase 
kinase 14
NIK, MAP3K14 apoptosis array Y10256 /Hs.47007 1.2 kb, pA, 5's3's, no extraneous o/l, NOTE SIZE
NIP3 504930 BNI3 Bcl2 adenovius E1B 19 kd interacting protein 3 BNIP3 in-house clone Hs79428/AF002697 0.7kb,5's & 3's
NIX 196582 Bcl2 interacting protein 3 like NIX apoptosis array AF067396/Hs132955 0.8 kB, 5's, 3' s, pA, no unwanted homology
pro-apoptotic mitochondrial protein (BCL2/adenovirus E1B 19kD-
interacting protein 3-like) 
NKG2 2469790
 Est highly similar to human NKG2-d type 
II integral membrane protein,NKG2-
A/NKG2-B
NKG2 apoptosis array Hs.311389  0.6 kb, 3's, NO 5' s, no pA associates with CD94 - note homology to other NKG2 family members
NKR-P1A 2298045 NKR-P1A (CD 161, human homologue of NK1.1)
KLRB1,NKR-
P1A apoptosis array Hs. 169824
0.8 kb, NO 5's, 3's, pA, no sig 
O/L
KLRB1, part of NK gene complex, killer cell lectin like receptor 
subfamily B member 1
NMI 704532 N-myc (STAT) interactor NMI Implantation array U32849
Nod1 668297 caspase recruitment domain 4 Nod-1,CARD4 apoptosis array NM_006092/Hs.19405 0.6kb APAF-1-like 
NOS1 277404 nitric oxide synthase 1 (neuronal) NOS1 Implantation array U17327 5'end only 1 x image clone
NOS2A 1086482 nitric oxide synthase 2A (inducible, hepatocytes) NOS2A Implantation array U31511 hom NOS1
NOS3 2002673 nitric oxide synthase 3 (endothelial cell) NOS3 Implantation array M93718/Hs.16673 last 0.5kb homology to Hs.278222
NPR2L 1508338
tumor suppr. gene 21 
candidate,homologous to yeast nitrogen 
permease 
NPR2L Implantation array AF040708/Hs.356137
NRP1 254408 neuropilin I NRP1 apoptosis array Hs.69285/AF145712 0.6 kb, 3' no 5', No sig O/L VEGF 165 receptor,previously listed as neuropil 1
NRP2 1689788 neuropilin 2 NRP2 apoptosis array Hs.17778/NM003872 0.6 kb, pA, 3' no 5', no extran. O/l  VEGF165 receptor 2
OSM 1677457 oncostatin M OSM Implantation array M27288/Hs.248156
OXT unknown oxytocin OXT in-house clone M25650
OXT WHO cl.16 oxytocin, prepro - (neurophysin I) OXT Implantation array Hs.113216/M25650 primers 31/32
OXTR 470101 oxytocin receptor OXTR Implantation array X64878
P-450 146270 P450 aromatase,CYP19 P-450 Implantation array M28420/Hs.79946 aromatization of androgens ,estrogen synthetase
P1 214255 alpha-1-antitrypsin, protease inhibitor 1 PI Implantation array X01683
p27 KIP1 202710 CDKN1B cyclin dependent kinase inhibitor 1B p27 KIP1 apoptosis array Hs.238990
5's, 3's, pA, no extra o/l, no 
direct homology to cDNA, 
linked thru gen. Cl.
p38MAPK 34416 p38 MAP K,mitogen -activated protein kinase 14 MAPK14 apoptosis array  L35253/Hs.79107
0.7 kb, 5's, 3's, pA, some 
homology to Human CSaids 
binding protein (CSBP1)
SAPK2A, MAPK14, CSaids binding protein1 = CSBP1, MXI2
p53(1) 24415 tumour protein p53 Li-fraumeni syndrome TP53 apoptosis array M14694 /Hs.1846 1.4 kb, 5's, 3's, NO pA, no sig O/L same clone as E/E10
p53(2) 24415 tumour protein p53 , Li-Fraumeni syndrome TP53 Implantation array M14694 same clone as I/D3 so seq confirmed
p53(3) 2573232 tumour protein p53 , Li-Fraumeni syndrome TP53 apoptosis array M14694 
unknown size, 3's, no 5', pA, 
no sig O/L
P73(1) 1486099 Tumour protein p73 TP73 apoptosis array Hs.247753/NM_005427 3', no pA, no sig o/l anti-apoptotic, inhibits expression of VEGF gene, asscociates with p53
P73(2) 1486099 tumuor protein P73 TP73 apoptosis array 1.2kb,pA, 3'seq, no 5'seq
PA11 70891 Plasminogen activating inhibitor 1 PAI1 Implantation array M16006/Hs.54576
PAFAHIB3 26467 platelet activating factor acetylhydrolase isoform1b,gamma subunit PAFAH1B3 Implantation array D63391/Hs6792 3 end 0.9kb
PAFAHIBI 201664 platelet activating factor acetylhydrolase alpha PAFAH1B1 Implantation array L13386 lissencephaly protein
PAI-1 324165 Plasminogen activator inhibitor 1 PAI-1 apoptosis array Hs.82085/M14083 0.7 kb, 5's 3's, pA, (some homol with alpha PAI-1
PAI2(1) 138654 Plasminogen activating inhibitor 2/arg-ser PAI2 Implantation array M18082 same clone as I/H10
PAI2(2) 138654 Plasminogen activating inhibitor 2/arg-ser PAI-2 apoptosis array Hs.75716 0.9 kb arginine-serpin,same clone as C/C12
PAM 490409 Peptidylglycine alpha-amidating monooxygenase PAM in-house clone M37721/Hs83920 3's, no 5's
PAPPA 241368 pregnancy-associated plasma protein A PAPPA Implantation array U28727
PARP 1013951 poly(ADP-ribose) polymerase-1 PARP apoptosis array Hs.177766/J03473 0.6 kb, 3', pA, no o/l poly(ADP-ribose) polymerase-1
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PARP-2 2014562 poly(ADP-ribose) polymerase-2 PARP-2 apoptosis array Hs.271742
 0.6 kb, 3' no 5', no pA, some 
homology NAD+ ADP-
ribosyltransferase 3 
(ADPRT3)
PAX6 230882 paired box gene 6 ( aniridia, keratitis) PAX6 Implantation array M93650
PCNA 340634 Proliferating cell nuclear antigen PCNA apoptosis array  M15796/Hs78996 0.7 kB, 5's, 3' s, pA, no unwanted homology multifunctional; p21, Fen1, MCMT and XPG compete to bind PCNA
PCTK1 267308 PCTAIRE protein kinase 1 PCTK1 apoptosis array X66363 /Hs171834 0.8 kb, 3's, 5's, NO pA, no sig O/L PCTAIRE protein kinase 1
PCTK2 2471125 PCTAIRE protein kinase 2 PCTK2 apoptosis array Hs.123063 PCTAIRE protein kinase 2
PCTK3 2327552 PCTAIRE protein kinase 3 PCTK3 apoptosis array Hs.2994/H51577
unknown size, 3's, NO 5's, no 
pA, no sig O/L, homology not 
long
PCTAIRE protein kinase 3
PDCD2 172057 PDCD2 (Prog. Cell death 2) PDCD2 apoptosis array S78085 0.7 kb, 5's, 3's, pA, no sig O/L homologous to Rp8, a rat gene associated with apoptosis
PDGF-A(1) 1877285 platelet derived growth factor alpha polypep. PDGF-A apoptosis array X06374 
0.7 kb, pA, NO 5' but 3', no 
extraneous o/l PDGF-1
PDGF-beta 145844 Placental derived growth factor-B PDGF-B apoptosis array X02811 
1.9 kb, 5' only, NO 3', NO pA, 
no extraneous o/l, Note length 
(will need to trim)
PDGF-2
PDGFRA 147628 platelet derived growth factor receptor alpha polypep. PDGFRA Implantation array L27560/Hs.180324 previously listed as PDGFA but it’s the receptor !!!
PDGFRA 376499 Platelet derived growth factor -A receptor PDGFRA apoptosis array 0.8kb, 5's + 3's, pA, no O/L previously listed as PDGF-A[2] it’s the receptor
PDGFRB 344874 platelet derived growth factor receptor beta PDGFRB Implantation array NM_002609/Hs.76144 hom PDGFRA except last 2kb
PEG10 111654 Paternally expressed 10 PEG10 in-house clone Hs.137476/T84579 3's, no 5's,1kb
PG12R 1553933 prostagladin I2 (prostacyclin) receptor PTGIR Implantation array D25418/Hs.393
PGDH NAD+dependent 15-hydroxyprostaglandin dehydrogenase(PGDH) PGDH unknown origin
PGR WHO cl.13 progesterone receptor B 392 PGR Implantation array M15716 primers 25/26 match for PGR and a splice variant of PGR
PGR (2) progesterone receptor B180 PGR Implantation array Hs.20905/AF016381 B.Vivellecl.17  (none of three specific for A only)
PIG3 1928657 Quinone oxidoreductase homolog 3 PIG3 apoptosis array AF010309/Hs50649 0.6 kb, NO 5's, 3's, pA, no sig O/L
induced by p53 expression before the onset of apoptosis, quinone 
oxidoreductase homolog
PIG7 376814 PIG7, LPS-induced TNF-alpha factor PIG7 apoptosis array AF010312 /Hs.76507 0.6 kb, 5's, 3's, pA, no sig O/L induced by p53 expression before the onset of apoptosis
PIG8 2017310 etoposide induced mRNA PIG8 apoptosis array Hs.343911/NM_004879 0.7 kb, NO 5's, 3's, pA, no sig O/L
induced by p53 expression before the onset of apoptosis, etoposide-
induced mRNA
PIG 10 345985 PIG10, ENC1 Ectodermal -neural cortex (with BTB -like domain) PIG10 apoptosis array AF010314 /Hs.104925 0.6 kb, 5's, 3's, pA, no sig O/L induced by p53
PIG11 667514 PIG11, p53 induced protein PIG11 apoptosis array AF010315 /Hs.96908 0.6 kb, 5's, 3's, pA, no sig O/L induced by p53 expression before the onset of apoptosis
PIK3R1 178034
PI3Kinase p85,phosphoinositide -3-kinase 
,regulatory subunit,polypeptide 1(p85 
alpha)
PIK3R1 apoptosis array M61906 /Hs.6241 0.6 kB, 5's, 3' s, pA, no unwanted homology
86 kDa regulatory subunit, is induced in response to oxidative stress, 
mediating cell death via p53
PK1_3 435024 gene from NF2/meningioma region of 22q12 PK1.3 Implantation array NM_003678
PKA 155556 protein kinase A (CATALYTIC SUBUNIT alpha) PKA apoptosis array Hs.77271
0.9 kb, pA, 5's3's, no 
extraneous o/l cAMP-dependent protein kinase
PKCA 469954 protein kinase C alpha PRKCA Implantation array X52479/Hs.169449
PLA2G4C 1677250 phospholipase A2 gamma, groupIVC PLA2G4C apoptosis array Hs.18858 0.6 kb, 3', pA, no sign. O/l cytosolic, calcium-independent phospholipase A3
plakoglobin 1089321 plakoglobin,Junction plakoglobin PLAK/JUP apoptosis array M23410 /Hs2340 0.7 kb, 3's, NO 5's, pA, no sig O/L
component of the cadherin-catenin complex, associates with the 
cytoplasmic region of desmoglein I 
PLAT 321838 tissue-type plasminogen activator tPA, PLAT Implantation array M15518
PLAU 714106 urokinase, plasminogen activator PLAU Implantation array M15476/Hs.77274
PLD1 327355 Phospholipase D1,phosphatidylcholine specific PLD1 apoptosis array U38545 
0.5 kB, 5's, 3' s, no pA, 
unwanted homology phosphorylation induces binding to Grb2
PLGF (1) Placental growth factor 2 PLGF 2 in-house clone pCR-Script, 
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PLGF (2) 133339 placental growth factor  PGF Implantation array Hs.2894/X54936 vascular -endothelial growth factor related protein
PLK 124700 Polo,drosophila -like kinase PLK apoptosis array Hs.77597/U01038 0.8 kb, 3', pA , no o/l Polo (Drosophia)-like kinase
PLOD2 1702704 procollagen-lysine, 2 oxoglutarate 5 -dioxygenase,Lysyl hydroxylase 2 PLOD2 in-house clone U84573/Hs.41270 3's, no 5's,0.6kb
PML 2206977 Promyelocytic leukaemia PML apoptosis array Hs.589633 0.6 kb, 3' read, pA, search -> no O/L promyelocytic leukaemia protein - see Wyllie insight review
PMS1 825726 post meiotic segregation increased 1 (S.crevisiae) PMS1 Implantation array NM_000534
PMS1 1456997 post meiotic segregation increased (S.cerevisiae) 1 PMS1 apoptosis array Hs.111749/U13695 0.7 kb, 3', pA, no o/l (homologue of yeast MutL), implicated in some HNPPC
PMS2 1981063 post meiotic segregation increased (S.cerevisiae) 2 PMS2 apoptosis array Hs.177548/U14658 0.6 kb, 3', pA?, no o/l (homologue of yeast MutL), implicated in some HNPPC
PODXL 365040 Podocalyxin-like protein PODXL in-house clone U97519/Hs16426 3's, no 5's, Adhesion
POLD2 2161249 DNA polymerase delta 2regulatory subunit 50KD POLD2 apoptosis array Hs.74598/U21090 0.6 kb, 3', pA, no o/l delta 2, regulatory subunit (50kD) 
POMC 1565052 proopiomelanocortin POMC Implantation array M38297/J00292 beta endorphin
POR 416159 P 450  cytochrome oxidoreductase POR apoptosis array S90469 /Hs.167246 0.7 kb, 5's, 3's, pA. No sig O/L  P450 (cytochrome) oxidoreductase
POR1 2144971 Partner of RAC1 POR1 apoptosis array Hs.75139 1.0 kb,  3' no 5', pA, no o/l
PP14 235906 Placental Protein 14 PP14 Implantation array M34046/Hs.82269 also called PAEP progestagen-associated endometrial protein
PPAR 2386312 Peroxisome proliferative activated receptor, gamma PPAR gamma apoptosis array Hs.100724 0.6 kb, 3' no 5', pA, no sig o/l
PPAR alpha 2106983 peroxisome proliferative activated receptor alpha PPAR alpha apoptosis array Hs.998/S74349
 0.8 kb, 3's, NO 5's, NP pA, no 
sig O/L peroxisome proliferative activated receptor alpha
PPARA 2106983 peroxisome proliferative activated receptor alpha PPARA Implantation array Y07619
PPARD 726134 peroxisome proliferative activated receptor delta PPARD Implantation array L07592
PPARG 160060 peroxisome proliferative activated receptor gamma PPARG Implantation array L40904/Hs.100724
PPP2R5A 1169776 Protein phosphatase 2, regulatory-subunit B(B56) alpha isoform PPP2R5A apoptosis array L42373 /Hs.155079 0.4 kb, pA, NO 5' 
PRG1 1664152 proteoglycan I, secretory granule PRG1 in-house clone J03223/Hs.1908 0.8kb
PRL 219552 prolactin PRL Implantation array V00566/Hs.1905
PRLR(1) WHO cl.2 prolactin rel. peptide receptor PRLR Implantation array AB015745 pGEMT WHO primers 3/4
PRLR(1) WHO cl.2 prolactin rel. peptide receptor PRLR Implantation array AB015745 pGEMT WHO primers 3/4
PRLR(2) 1650749 prolactin receptor PRLR Implantation array M31661/AF091859 seq matches promoter region 7 alt exon 2
Prog rec 17 Progesterone Receptor PGR in-house
PSMA3 664613 proteosome (prosome, macropain) subunits,alpha type,3 PSMA3 in-house clone D00762/Hs346918 1kb
PTAFR 853625 platelet activating factor receptor PTAFR Implantation array D10202
PTEN 1535806 phosphatase & tensin homolog PTEN Implantation array U93051
PTGDR WHO cl.11 prostaglandin D2 receptor PTGDR,  PGRD2 in-house clone U31099/Hs.158326 pGEMT primers 21/22,401bp insert
PTGDR (2) WHO cl.11 prostaglandin D2 receptor PTGDR,PGRD2 in-house clone U31099/Hs.158326 pGEMT previously listed as prolactin[1], 
PTGDS 725673 prostaglandin D2 synthase gene PTGDS Implantation array M61900/Hs.8272
PTGER2 470821 prostaglandin E receptor 2 (subtype EP2) PTGER2 Implantation array U19487
PTGER3 2131660 prostaglandin E receptor 3 (subtype EP3) PTGER3 Implantation array D86098
PTGER4 WHO cl.5 prostaglandin E receptor 4 (subtype EP4) PTGER4 Implantation array NM_000958 hom. EP2/primers 9/10
PTGES 2097177 PIG12,prostaglandin E synthase PTGES apoptosis array AF010316 /Hs.146688 0.7 kb, No 5's, 3's, pA, ? 2 genes (see notes)
induced by p53 expression before the onset of apoptosis, microsomal 
glutathione S-transferase 1-like
PTGFR 1639562 prostaglandin F receptor PTGFR Implantation array Hs.89418/L24470
PTGFR 151011 prostaglandin F receptor PTGFR Implantation array L24470
PTGIS 469275 prostaglandin 12 (prostacyclin) synthase PTGIS Implantation array D38145
PTGRF 2140347 prostaglandin F2 alpha receptor PTGRF Implantation array AF004021/Hs89418 1.2kb  NB partial match to JAM1 (Hs.286218/AF172398)
RMRG_list .xls
Gene ID IMAGE Gene Abbrev clone source Acc.No./Unigene ID clone details other information & changes to list name
PTN 284476 pleiotrophin/heparin binding growth factor 8 PTN Implantation array X52946
PTP1C Protein -tyrosine phosphatase 1C, PTP non-receptor type 6 PTPN6 in-house clone U47924/Hs.63489 pCMVSPORT 2
PZR 2470870 protein zero related,MPZL1 myelin protein zero -like 1 PZR apoptosis array Hs287832/BC007881
3' no 5', pA, 0.5 kb, no sign. 
O/l
Rac1(1) 364305 Ras- related C3 botulinum toxin substrate 1(rho superfamily,small GTP binding rac-1) RAC-1 apoptosis array  Hs 173737 0.6kb, 3's, NO 5's, pA, no O/L rho family, small GTP binding protein Rac2
Rac1(2) 364305 Rac1,ras -related C3 botulinum toxin susbtrate 1(p21-rac1) Rac1 apoptosis array Hs.268134 0.6kb, 3's, NO 5's, pA, no O/L rho family, small GTP binding protein Rac1
RAC2 195765 Ras related C3 botulinum toxin substrate 2 RAC2 apoptosis array Hs.173466 1.4kb , 5's only, no pA, some homology to Rac3 Ras-related C3 botulinum toxin substrate 2
RAD1 2429435 checkpoint control protein, exonucleaseRAD1 RAD1 apoptosis array Hs.7179
0.6 kb, 3', pA, some homology 
to REC1  human homolog of s.pombe RAD1
Rad9 1523435 Rad9(S.Pombe ) homolog Rad9 apoptosis array Hs.240457/U53174 0.6 kb, 3', pA  cycle checkpoint control protein
RAD27 1454849 RAD2, Fen-1 flap structure specific endonuclease 1 RAD27 apoptosis array Hs.4756/X76771 0.8 kb, 3', pA, no o/l FEN1
Rad50 684652 RAD50 (S.cerevisiae)homolog RAD50 apoptosis array Hs.41587/U63139 0.7 kb, 3' and 5', no pA, no o/l part of endo/exo-nuclease complex
RAD52 2429897 RAD52(S.cerevisiae)homolog RAD52 apoptosis array Hs89571 unknown size, 3' pA, no O/L DNA repair & recombination 
RAD54 2498030 RAD54(S.cerevisiae)homolog like RAD54L apoptosis array Hs.66718 0.9 kb, 3', pA, no o/l homology to mouse RAD54
Rap1 2261011 Ras associated protein 1 Rap1 apoptosis array Hs.47225 0.6 kb, 3' no pA, no sign. o/l Ras-associated protein Rap1 = Rab2
RARA 153166 retinoic acid receptor, alpha RARA Implantation array X06614 last 1kb
RARB 1620270 retinoic acid receptor, beta RARB Implantation array X07282 last 0.4kb
RARG 1865257 retinoic acid receptor, gamma RARG Implantation array M38258/Hs.1497 last 1kb
RASA1 485864 ras p21 protein activator RASA1 Implantation array M23379
RB1 267763 retinoblastoma 1,including osteosarcoma RB1 Implantation array M33647/Hs.75770
rbcl 0 empty well 0 for rcbl std curve exogenous control
rbcL spike 3 Arabidopsis Thaliana,  RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL80 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL160 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL320 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL400 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL500 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL750 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL1000 spike 3 Arabidopsis Thaliana,RUBISCO,ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
rbcL1200 spike 3 Arabidopsis Thaliana, RUBISCO, ribulose 1,5-bisphosphate carboxylase/oxygenase rbcL exogenous control U91966 pGEMT,526 bp
RBL2 321247 Retinoblastoma-like 2 (p130) RBL2 apoptosis array X74594 /Hs79362 0.8 kb, 3', 5', pA, no sig O/L  Retinoblastoma susceptibility gene
RBP2 80086 retinol -binding protein 2 RBP2 Implantation array T63266
RCA spike 2 Arabidopsis Thaliana, RUBISCO activase RCA exogenous control X14212 pGEMT, 513bp
relaxin1 940909 relaxin 1(H1) RLN1 Implantation array NM_006911 rel 1/2 90%
requiem 212756 requiem REQ apoptosis array Hs.13495/AF001433 0.6 kb, 5's, 3's, pA, no sig O/L a ubiquitous zinc finger protein required for the apoptosis response
RFC2 1930725 replication factor C (activator1) RFC2 apoptosis array Hs.139226 3', pA, 0.5 kb, no O/l 40 kDa subunit
Rho7 383898 Rho 7, GTP binding protein RHO7 Implantation array Hs.99034/X95456
Gene ID IMAGE Gene Abbrev clone source Acc.No./Unigene ID clone details other information & changes to list name
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RhoA 511607 RhoA,Ras homolog gene family ARHA apoptosis array L25080 /Hs.77273
0.9 kb, 5's, 3's, pA, no sig O/L 
(care with homology between 
Rho's)
involved in actin organisation and beta 3 integrin signalling
RhoE (1) 923460 RhoE,Ras homolog gene family member E RhoE/ARHE apoptosis array X95282 /Hs6838 0.6 kb, 3' no pA, no sign. O/l  also called Rho8,GTPase
RhoE (2) 923460 Ras homolog family member ,E,RhoE ARHE apoptosis array X95282 /Hs 6838  0.6 kb, 3' no pA, no sign. O/l  Rho9
RhoG (1) 2066382 RhoG, Ras homolog gene family member G RhoG apoptosis array X61587 0.6 kb, 3's, pA, no sig O/L same clone as F/F1but different from B/E11
RhoG (2) 2066382 RhoG, Ras homolog gene family member G RhoG/ARHG apoptosis array X61587 /Hs75082 0.6 kb, 3's, pA, no sig O/L same clone as H/A2,B/E11 is a different clone
RhoG (3) 38398 Rho G ras homolog gene family, GTP binding protein ARHG Implantation array L11317  same gene diff clone as H/A2 &F/F2
RIP K1 2687218 Receptor (TNFRSF) interacting serine threonine kinase 1 RIP (RIP K1) apoptosis array AW236421/Hs.296327
size unknown, pA unknown, 
3' No 5', Some homology to 
Sequences 14 and 16 od US 
patent 5674734 
kinase domain and death domain
RIP2 1304251
Receptor interacting protein 2,receptor 
interacting serine-threonine kinase 
2,RICK,CARD containing ICE
RIP2 ,RIPK2 apoptosis array NM_003821/Hs.103755 0.6 kb, pA, 3's, NO 5's, no extraneous o/l kinase domain and CARD domain
RIP3 2505147 Receptor interacting serine/threonine kinase 3 RIP3 apoptosis array NM_006871/Hs.268551 757 nt, 3 No 5', pA unknown kinase, associates with death receptor complex
Rob band 11 Rob band 11/LOC51316 hypothetical protein band 11 Implantation array Hs.107139/AF208846
RON proto-oncogene RON tyrosine kinase receptor for MSP MST1R in-house Hs.2942/X70040 pCR script
homolgy to MET,Macrophage stimulating 1 receptor (c-met-related 
tyrosine kinase)
RP_S7 1574779 ribosomal protein S7 RPS7 Implantation array NM_001011
RPA3 1524402 Replication Protein A3(14KD) RPA3 apoptosis array Hs.1608/L07493 0.6 kb, 3', pA, no o/l Replication protein A
RPL23 2139225 ribosomal protein L23 RPL23 apoptosis array Hs.234518/AI831644 0.6kb
RPS 9 549925 ribosomal protein S9 RPS9 Implantation array U14971
RPS27 ribosomal protein S27 RPS27 Implantation array U57847
RXRB 357763 retinoic acid receptor,beta RXRB Implantation array M84820 hom RXRA
RYR1 1375309 ryanodine receptor 1 (skeletal) RYR1 in-house clone J05200/Hs.89631
0.5kb,3's, no 5's, 
pA,bhomology to type2 and 
type 3 receptors
Ca2+ release channel of sarcoplasmic reticulum
RYR2 39296 ryanodine receptor 2 (cardiac) RYR2 in-house clone X98330/Hs90821 3's & 5's,0.8kb Ca2+ release
RYR3 72497 ryanodine receptor 3 RYR3 in-house clone AJ001515/Hs9349 1.1kb,3's & 5's Ca2+ release,homology to brain ryanodine
Sag 430330 SAG (CKBBP1)ring finger 7,spliced vaiant of SAG CKBBP1 apoptosis array AF092878 0.4 kb, 5's, 3's, pA, no sig O/L zinc RING finger protein
Scaffold 2207622 Scaffold protein, Syndecan binding protein,syntenin SDCBP in-house clone U83463/Hs8180 3's, no 5's, 0.6kb
homology to syndecan binding protein (syntenin) also called Pbp1 
scaffold protein
SELL 416087 selectin L (lymphocyte adhesion molecule 1) SELL/LAM-1 Implantation array M25280 last 1.3kb
SELP 2004780 P-selectin,granule membrane protein 140kd,CD62 SELP apoptosis array Hs.73800/M25322
0.7 kb, NO 5's, 3's, pA, no sig 
O/L (PAGEM, GMP-140, CD62),  Survival function
SELPLG 471805 selectin P ligand SELPLG Implantation array U02297
Sem 3 (2) Semaphorin III (Hsema1) SEMA3A in-house clone L26081/Hs.2414 pCR-Script previously listed as semaIV but seq shows to be III
Sem3 14 semaphorin 111(HSEMA1) SEMA3A in-house clone Hs.2414/L26081 pCR-Script, sema domain,immunoglobulin domain (Ig) short basic domain,secreted ,sem 3A
sentrin sentrin, ubiquitin-like 1 protein UBL1 Implantation array U83117/Hs.81424
SERPIN A5 341272 serpin A5 serine (or cysteine) proteinase inhibitor,clade A SERPIN A5 Implantation array Hs.76353
sflt Ken (1) sFLT Kendal sFLT[1] in-house clone B/S11 KS +/- full length Kendal
sflt Ken (2) sFLT Kendal sFLT[2] in-house clone B/S11 KS +/-full length Kendal
sflt ken3 3 sFLT Kendal sFLT[3] in-house clone Hs.138671/X51602 pCR-Script, 3' end of kendal soluble VEGFR receptor
sfriz 1 proteasome)subunit,alpha type,4 PSMA3 in-house clone Hs.346918/AU100193
SFRP1 162330 secreted frizzled-related protein 1 SFRP1 Implantation array AF056087
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sfrp2 1559823 secreted frizzled-related protein 2 SFRP2 Implantation array AA927991/Hs.31386
SFRP4 725269 secreted frizzled-related protein 4 SFRP4 Implantation array AF026692/Hs.105700 hom fritz except last 1.6 kb
SFRS2 150062 splicing factor,arginine/serine-rich 2, SC35 SFRS2 Implantation array M90104/Hs.73965 splicing factor SC35
SHC 310534 SHC1,SHC(Src homology) tranforming protein 1 SHC apoptosis array X68148/Hs81972 0.6 kb, 3's, pA, no sig O/L SH2 domain-containing adapter
SHIP2 2074867 SH2 containing inositol phosphatase 2 SHIP2 apoptosis array X66360/Hs155939 0.8 kb, 3's, NO 5's, NO pA, no sig O/L
was misassigned, now in unigene as INPP5D inositol polyphosphate 5 
phosphatase,145KD
Sir2 1705202 Sirtuin silent mating type information regulation 2 hom 2 transcipt variant 2 SIR2,SIRT2 apoptosis array  Hs.112306/AF083107 0.6 kb, 3', pA, no o/l
SIRT3 2012070 Sirtuin silent mating type information regulation 2 hom 3 SIRT3 apoptosis array Hs.19306
0.6 kb, 3', pA ?, some 
homology to Homo sapiens 
sirtuin type 3 (SIRT3) mRNA
Sir2-like protein (sir2-like 3),  check out sir2 at H/E8
SIVA 632137 SIVA,CD27 binding (SIVA)protein SIVA apoptosis array AF033111/Hs 112058 0.9 kb, pA, 5's3's, no extraneous o/l 
DD, ring finger, and zinc finger, pro-apoptotic, binds CD27  note that 
100% homol to alt spliced SIVA-2
SLC25A1 262516
SLC25A1 Solute carrier family 25 
(mitochondrial carrier; citrate transporter) 
member 1
SLC25A1 Implantation array Hs.111024/L75823
SLC6A8 488505 solute carrier 6 (neurotransmitter transporter,creatinine) member 8 SLC6A8 in-house clone Hs.187958/L31409 0.8 kb,3's, no 5's, 
SLP1 378813 secretory leukocyte protease inhibitor SLP1 Implantation array
SLP1 378813 secretory leukocyte protease inhibitor SLP1 Implantation array
Smac(1) 1947740 diablo, Second Mitochondria Derived activator of caspase SMAC apoptosis array Hs169611 3' end 0.6kb
Smac(2) 2400050 diablo, Second Mitochondria Derived activator of caspase DIABLO/SMAC apoptosis array Hs169611 pA, 3'seq, no 5'seq see also KG5/JA3/KE6 same gene different clones 
Smac(3) 266339 diablo, Second Mitochondria Derived activator of caspase SMAC not listed Hs169611/AF262240 see also KG5/JA3/JC9 same gene different clones
Smac(4) 1737818 Second mitochondria -derived activator of caspase SMAC not listed Hs.169611/AK001399 see also KE6/JA3/JC9 same gene different clones 
SNX12 sorting nexin 12,endosome-localized proteins SNX12 Implantation array Hs.287867/AF171229
SOCS2(2) 131550 Supressor of cytokine signalling 2, STAT induced STAT inhib. 2 SOCS2, STATI2 Implantation array AF020590
SOCS3(1) 152398 Supressor of cytokine signalling 3, STAT induced STAT inhib. 3 SOCS3,SSI3 Implantation array AB004904 prevoiusly listed as SOCS3 now SOCS3[1]
SOCS3(2) 152398 Supressor of cytokine signalling 3, STAT induced STAT inhib. 3 SOCS3, SSI3 Implantation array AB004904 prevoiusly listed as SOCS3 now SOCS3[2]
SOCS5 135058 Supressor of cytokine signalling 5, KIAA0671 SOCS5 Implantation array AB014571
SOD1 135618 superoxide dismutase 1 SOD1 Implantation array K00065
SOD1 CU/ZN Superoxide dismutase 1 soluble, amyotrophic SOD1 in-house clone Hs.75428/BG762708 B/S11 KS +/-Exons 1-4
solute 7 115419 Solute carrier family 7 SLC7A7 apoptosis array Hs.194693/NM_003982 0.6 kb cationic amino acid transporter, glycoprotein-associated
SPARC 250654 secreted protein, acidic, cysteine-rich (osteonectin) SPARC apoptosis array Hs.111779/NM003118
1.6 kb, 5's, 3's, NO pA, seq by 
nhgri
 also known as BM-40 extracellular matrix protein, see E/E6 different 
clone
SPARC(1) 1987468 secreted protein, acidic, cysteine-rich (osteonectin) SPARC Implantation array J03040
SPOCK 488409 sparc/osteonectin,cwcv&kazal -like domains proteoglycan (TESTICAN-1) SPOCK Implantation array Hs.93029/X73608 previously listed as CTSD, miss-assigned
SPP1 121165 osteopontin, secreted phosphoprotein 1 SPP1 Implantation array J04765/Hs313 see also in house clone F/D11
SRD5A1 843277 steroid 5-alpha-reductase, alpha polypeptide1 SRD5A1 Implantation array AF052126
SSI-1 712481 JAK binding protein, supressor of cytokine signalling SSI-1 Implantation array U88326 suppressor of cytokine signalling
SSP1 osteopontin, secreted phosphoprotein 1 SSP1 in-house clone X13694/Hs313 pCMVSPORT 2, Clones from J&J see also image clone B/E9, previously listed as osteo
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St calcin2 2113336 Stanniocalcin-2 STC2 apoptosis array Hs.155223 0.9 kb calcium-regulated glycoprotein hormone, ?role in Ca2+ homeostasis?  -fish relatives
STAT1 471667 signal transducer and activator of transcription-1 STAT1 apoptosis array M97935
 0.8 kb, 5's, 3's, pA, no sig 
O/L signal transducer and activator of transcription-1 = ISGF-3
STAT3 612444 signal transducer and activator of transcription-3 STAT3 apoptosis array L29277 0.9kb, 5's, 3's, pA, no sig O/L
STAT4(1) 1524207 Signal transducer and activator of transcription 4 STAT4 apoptosis array Hs.80642/AI700201
0.6 kb, 3's, NO 5's, NO pA, no 
sig O/L
STAT5A signal transducer & activator of transcription 5A STAT5A Implantation array U43185/Hs 1674503 0.8kb
STAT6 Interleukin 4 induced signal transducer & activator of transcription 6 STAT6 Implantation array Hs.181015/NM_003153
STAT6 358375 STAT6 STAT6 apoptosis array Hs.181015 0.7 kb, 3's, NO 5's, pA, no sig O/L
stathmin Stathmin 1 ,oncoprotein 18 STMN1 Implantation array Hs.250811 0.8kb,3'
STE 211956 sulfotransferase, estrogen-preferring STE Implantation array U08098
STM2 Alzheimers disease (STM2) presenilin 2 STM2 Implantation array U50871
survivin 109857 survivin,baculoviral IAP repeat containing 5 BIRC5 apoptosis array U75285 /Hs.1578
0.7 kb, NO pA, 3's, 5's, no 
extraneous o/l
expressed in G2/M, binds to and inhibits caspases 3 and 7,aka EPR1 
effector cell protease 1
TALL-1 593690 TALL-1 (Thank / Blys) TALL-1 apoptosis array NM_006573 0.5 kb, pA, NO 5' but 3', no extraneous o/l
transmembrane TNFR ligand, expressed in macropahges, downregulated 
by PMA
TBXAS1 418423 thromboxane A synthase 1 TBXAS1 Implantation array M80646
TCF7L2 752652 transcription factor 7-like 2 TCF7L2 Implantation array Hs.348412/AA417665
telo ass 2206426 telomerase-associated protein 1 TEP1 apoptosis array Hs.232070 unknown size, NO 5's, 3's, pA, no sig O/L
TERT 2304672 telomerase reverse transcriptase (hTRT) TERT apoptosis array AF015950 /Hs.115256 o.4kb, 3's, NO 5's, pA, no sig O/L human telomerase catalytic subunit (hTRT/hEST2)
TFPI2 67508 tissue factor pathway inhibitor-2 TFPI2 apoptosis array Hs.295944/L27624 0.6 kb,3'&5' placental protein 5 (PP5)
TGF beta 2138946 transforming growth factor beta 1 TGFbeta apoptosis array X02812 0.6 kb
TGFA 1839392 transforming growth factor alpha TGFA Implantation array M31172
TGFB1 132031 transforming growth factor beta 1 TGFB1 Implantation array X02812/Hs 1103 last 0.6kb
TGFB3 485709 TGFB3 Implantation array J03241
TGFB4 (1) 137335 transforming growth factor beta 4, endo.bleeding associated factor TGFB4, EBAF Implantation array U81523  
TGFB4 (2) 137335 transforming growth factor beta 4, endo.bleeding associated factor TGFB4, EBAF Implantation array U81523  
TGFBR3 143723 transforming growth receptor  beta receptor III, betaglycan TRFBR3 Implantation array L07594 betaglycan
TGM2 was empty human transglutaminase 2 TGM-2 an imposter not listed not empty ! transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) apoptosis associated
THBS1 1964654 Thrombospondin 1 THBS1 not listed Hs.87409/X14787
natural inhibitor of neovascularization and tumorigenesis in healthy 
tissue mediates cell-to-cell and cell-to-matrix interactions,roles in 
platelet aggregation, angiogenesis, and tumorigenesis
Tie1 Tie 1,tyrosine kinase with IgG&EGF homology domains TIE in-house clone Hs.78824/X60957 pCR-Script, 
TIE1 376677 TIE 1,tyrosine kinase with immunoglobulin & EGF homology domains TIE Implantation array
Hs.78824/X60957/NM_00
5424 last 0.6kb
Tie2 Tie 2,tyrosine kinase ,endothelial TEK in-house clone Hs.89640/L06139 pCR-Script, 
TIE2 183661 TIE 2 ,TEK tyrosine kinase, endothelial TIE 2 Implantation array L06139 last 0.5kb
TIMP1 740655 tissue inhibitor of metalloproteinase 1 TIMP1 Implantation array X03124
TIMP2 138147 tissue inhibitor of metalloproteinase 2 TIMP2 Implantation array J05593
TIMP3 469940 tissue inhibitor of metalloproteinase 3 TIMP3 Implantation array U67195 sorsby fundus dystrophy
Titin 1475648 Titin TTN in-house clone X69490/Hs.172004 3's, no 5's,0.7kb
TLN 435642 talin TLN Implantation array AF078828
TMP-1 341328 Tropomyosin 1 alpha TMP-1 in-house clone M19267/Hs77899 3's & 5's, 0.5kb Cell motility,skeletal muscle alpha tropomyosin
TMSB10 840788 thymosin beta 10 TMSB10 Implantation array M20259
RMRG_list .xls
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TMSB4X 511921 thymosin beta-4 TMSB4X apoptosis array Hs.75968/M17733
3' and 5', pA, 0.6kb, homology 
to Human interferon-inducible 
mRNA
actin-sequestering protein
TNF-beta 1846402 TNF-beta (=LT-alpha) = (TNF superfamily, member 1) TGF-B apoptosis array D12614 
1.0 kb, pA, NO 5' but 3', no 
extraneous o/l activated lymphocyte-secreted pro-apoptotic cytokine
TNF-C (2) 701054 high mobility group (nonhistone chromosomal) proteins I&Y HMGIY apoptosis array Hs.139800/AA287531
0.8 kb, pA, NO 5' but 3', no 
extraneous o/l
TNF4 2001553 TNFSF4 = OX40 LIGAND = GP34 TNFSF4 apoptosis array 3' read, 1.1 kb, no sig O/L
TNFA 214060 TNF-alpha TNFA apoptosis array X01394 /Hs241570 0.5kb, pA, 5'3', no extraneous o/l
macrophage-secreted pro-apoptotic cytokine (TNF superfamily, member 
2)
TNFB 1672927 tumour necrosis factor beta/lymphotoxin alpha TNFB Implantation array D12614
TNFR2 153751 tumour necrosis factor receptor 1B TNFR2 (TNFRSF1B) Implantation array M32315 hom TNFR1
TNFR2(1) 1896559 TNF receptor superfamily member 1B TNFR2 not listed Hs.256278/AI880380 NB same gene different clone as K/D6
TNFR2(2) 2336400 TNF receptor superfamily member 1B TNFR2 not listed Hs.256278/AI880380 NB same gene different clone as K/B6
TNFRSF1A 2326094 TNF receptor superfamily,member 1A TNFRSF1A apoptosis array M33294 /Hs.159 0.5 kb, pA, 3's no 5', no extraneous o/l caspase activation and also STAT/JAK activation 
TNFRSF6B 2506835 TNF receptor superfamily,member 6b, also decoy receptor 3 DcR3 TNFRSF6B not listed Hs.348183/AF104419 0.5kb,3',pA
TNNC2 627935 Troponin C2,fast TNNC2 in-house clone X07898/Hs182421 3's, no 5's,0.7kb  fast skeletal muscle troponin
TNR 175767 tenascin R (restrictin,janusin) TNR Implantation array X98085
TOSO 1653122 TOSO, regulator of FAS-induced apoptosis TOSO apoptosis array NM_005449/AW401870/Hs.58831 0.7 kb , 3' no 5', no extran. O/l inhibits caspase8 processing, may upregulate FLIP
TPI1 2279444 Triosephosphate isomerase-1 TPI1 in-house clone M10036/Hs83848 3's, no 5's, 0.5kb
TR6(DR3) 2108163 TR6 (DR3),TNFRSF6B TNF superfamily,member6b, decoy TR6 (DR3) apoptosis array AF134240/Hs348183
0.5 kb, pA, 3' no 5', no 
extraneous o/l supresses LIGHT-mediated apoptosis
TRA 1 2328129 Tumour rejection antigen (gp96)1 TRA-1 in-house clone  X15187/Hs82689 3's, no 5's,0.8kb Tumour rejection, heat shock protein
TRADD(1) 1455700 TNFRSF1A associated via death domain TRADD apoptosis array L41690 /Hs89862 0.5 kb, pA, 5's, NO 3's, no extraneous o/l
TRADD(2) 1473788 TNFRSF1A-associated via death domain TRADD Implantation array L41690
TRAF-1(1) unknown TNF receptor associated factor 1Epstein Barr virus induced mRNA TRAF-1 in-house clone U19261/Hs.2134
TRAF-1(2) 2962961 TNF receptor associated factor 1Epstein Barr virus induced mRNA TRAF-1 apoptosis array U19261/Hs.2134
TRAF-2 1014600 TNF receptor -associated factor 2 TRAF-2 apoptosis array U12597 /Hs200526  0.7 kb, pA, 3's, NO 5's, no extraneous o/l also called TRAP3, see E/G12 same gene diff clone
TRAF-3 2062637 TRAF-3 (CRAF1 ) TRAF-3 apoptosis array  U21092 0.7 kb, NO pA, 3's, NO 5's, no extraneous o/l CD40 associated factor, =TRAF3
TRAF-4 1855433 TNF receptor -associated factor 4 TRAF-4 apoptosis array AF082185/Hs8375
0.6 kb, pA, 3's no 5', no 
extraneous o/l ; some 
homology to MLN62
CART1
TRAF-5 145410 TNF receptor-associated factor 5 TRAF-5 apoptosis array U69108 /Hs29736 0.8 kb, no pA, 3's, NO 5's, no extraneous o/l TNF-receptor family members
TRAIL 139039 TNF-related apoptosis-inducing ligand TRAIL   APO2L apoptosis array U57059 0.7 kb, 5's, 3's pA, no sig O/L tumor necrosis factor ligand superfamily member 10, Apoptosis ligand TRAIL, TRAIL, TL2, TRAIL-PEN, Ly81, Apo-2 ligand, (APO2L)
TRAIL-R-2 2348250 TRAIL-R-2 (DR5 / KILLER),TNFRSF10B TNF superfamily 10B TRAIL-R-2 apoptosis array Hs.51233 0.8 kb, 3's, no extraneous o/l
Transcription activated by NFkB, associates with DR5, FADD and 
TRADD, also utilises RIP
TRAIL-R4/3 1406602 TRAIL-R-3, decoy receptor 1,TNFRSF10D with homology toTRAIL-R-4 (TRUNDD) TRAIL-R4/3 apoptosis array AF012536/AF023849
size unknown, 3' no 5', pA 
unknown, some O/L with 
others of family
no intracytoplasmic domain, 89% homologouos to TRID
TRAMP 769981 Translocating chain-associating memebrane protein (Apo3, LARD,DDR3,TNFRSF12) TRAMP apoptosis array Hs.180338
0.7 kb, pA, 5's3's, no 
extraneous o/l,
signals through TRADD, TRAF2, FADD, and FLICE, activates 
NFkB.769981 no longer in unigene list (5.1.02)
TRAP3 770804 TNF receptor-associated factor 2 TRAF2 Implantation array U12597/Hs200526 see G/E12 TRAF2 same gene diff clone
TRFBR2 469876 transforming growth receptor  beta receptor II(70-80KD) TRFBR2 Implantation array Hs.82028/M85079
TRHR Thyrotrophin-releasing hormone receptor TRHR in-house clone X72089/Hs3022 pCMVSPORT 2
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TRICK2 1133411 TNF receptor  superfamily,member 10b,TNFRSF10b
TRICK2,TRAIL-
R2,Killer apoptosis array AF018658 0.4kb, pA, no o/l, 3' seq only
pro-apoptotic trail receptor2, Tumor necrosis factor receptor superfamily, 
member 10b,Apo-2L,death receptor 5
TRIP 2307972 TRAF interacting protein TRIP apoptosis array U77845/Hs21254 no pA, NO 5's, 3's, no extraneous o/l inhibits TRAF2-mediated NF-kappaB activation
TRO 649344 trophinin TRO Implantation array U04811 MAGED3
TROAP 731099 tastin/trophinin-associated protein TROAP Implantation array U04810/Hs.171955
TRPC2 unknown transient receptor potential channel 2 TRPC2 Implantation array Hs.131910/X89067
TRPC2 unknown transient receptor potential channel 2 TRPC2 Implantation array Hs.131910/X89067
TRPD3 unknown transient receptor potential D3,tetratricopeptide repeat domain 3 TTC3,TRPD3 Implantation array Hs.118174.D83077
Tsp-1 2440915 Thrombospondin-1 THBS1 apoptosis array Hs.87409 0.6 kb, 3', pA,  no o/l no verified seq ref, from apoptosis pending list
Tsp-2 416134 Thrombospondin-2 THBS2 apoptosis array Hs.108623 0.6 kb, 3', pA, no o/l
Tsp-4 (1) 2070678 Thrombospondin-4 THBS4 apoptosis array Hs. 75774 0.6 kb, 3', pA, some homology to Tsp-3 and clk2 kinase
Tsp-4 (2) 2070678 Thrombospondin-4 THBS4 apoptosis array Hs. 75774 0.6 kb, 3', pA, some homology to Tsp-3 and clk2 kinase
Tsp3 2362163 Thrombospondin-3 THBS3 apoptosis array Hs.169875
 0.6 kb, 3', pA, some 
homology to clk2 kinase 
(CLK2)
TTR 82063 transthyretin, prealbumin, amyloidosis type 1 TTR Implantation array M10605
TUBB2 1636876 Beta-tubulin 2 TUBB2 in-house clone X02344/Hs.251653 1kb
Tweak 154742 TWEAK,tumour necrosis factor,superfamily member12
TWEAK,TNFSF
12 apoptosis array NM_003809/Hs26401
0.7 kb, pA, 5's3's, no 
extraneous o/l widely expressed TNFR ligand, secreted, weakly  pro-apoptotic
TYK2 212292 tyrosine kinase 2 TYK2 Implantation array X54637/Hs.75516 last 0.7kb
ubiqutinC 137024 ubiquitin C UBC Implantation array M26880/Hs.183704
UGB 118085 uteroglobin UGB Implantation array X13197/Hs.2240
UPA 714106 Urokinase plasminogen activator (PAI2) UPA apoptosis array Hs.77274/X02419 0.7 kb Urokinase plasminogen activator (PLAU)
USA-CYP 73425 cyclophilin H, U-snRNP-associated cyclophilin,peptidyl proplylisomerase H USA-CYP,PPIH Implantation array AF036331/Hs9880
UTS2 926809 urotensin 2 UTS2 Implantation array AF104118
vav 80384 VAV1 oncogene VAV1 apoptosis array X16316  /Hs.116237 0.7 kb, 5's, 3's, pA, no sig O/L haemopoietic-specific  exchange factor for Rac-1
vav2 2386937 vav2 oncogene VAV2 apoptosis array S76992/ AI797805Hs.104005 07 kb, 3' no 5', no pA,  homologue of the vav, note that this is not the TSC1 gene
vav3 2435565 VAV3 oncogene VAV3 apoptosis array Hs267659/AF067817 0.6kb
VCAM1 44477 vascular cell adhesion molecule 1 VCAM1 Implantation array M30257 last 0.4kb
VDAC-2 994448 Voltage-dependent anion channel 2 VDAC-2 apoptosis array Hs.78902 0.7 kb, 3' read, pA, search -> no O/L Voltage-dependent anion channel 2
VE Cad 135239 VE-Cadherin CDH5 apoptosis array X79981 1kb, 5'3, 3's, pA, no sig O/L  binds AKT, may regulate Bcl-2 expression (cadherin 5)
vegf 121 B1 vascular endothelial growth factor VEGF in-house clone Hs.73793/AB021221 mouse NB BLAST matches human
vegf 165 7B vascular endothelial growth factor VEGF in-house clone Hs.73793/AB021221 B/S11 KS +/-splice variant 165
vegf 189 13B vascular endothelial growth factor VEGF in-house clone Hs.73793/AB021221 B/S11 KS +/-splice variant 189
VEGF A vascular endothelial growth factor A VEGF A in-house clone Hs.73793/AB021221 B/S11 KS +/-,Exons 1-4
VEGF B 18 vascular endothelial growth factor B VEGF  B in-house clone Hs.78781/U52819 pCR-Script
VEGF C Vascular endothelial growth factor C VEGFC in-house clone Hs.79141/X94216 pCR-Script,
VEGF D Vascular endothelial growth factor D FIGF in-house clone Hs.11392/D89630 pCR-Script, aka FIGF C-fos induced growth factor
VEGFA 245379 Vascular endothelial growth factor A VEGF A Implantation array AF022375/Hs.73793
VEGFB 181724 Vascular endothelial growth factor B VEGF B Implantation array U48801/Hs.78781
RMRG_list .xls
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VEGFC 503189 Vascular endothelial growth factor C VEGF C Implantation array X94216 Flt4 ligand
VEGFD 160946 Vascular endothelial growth factor D (c-fos induced gf) VEGF D/FIGF Implantation array D89630
VEGFD(1) Vascular endothelial growth factor D (c-fos induced gf) VEGF D/FIGF Implantation array Hs.11392/D89630
VHL 41607 Von Hippel-Lindau syndrome VHL Implantation array NM_000551
VIM 119599 vimentin VIM Implantation array NM_003380/Hs.297753
VIP2R 2164744 Vasoactive intestinal polypeptide receptor 2 VIP2R apoptosis array Y18424 IMAGE:2164744, 3's, appears to have pA, no sig O/L
vWF 127595 von Willebrand factor VWF Implantation array K03028/Hs.110802
WAF1 309880 WAF1,p21,CDKN1A cyclin- dependent kinase inhibitor 1A,Cip1 WAF1 Implantation array U03106/Hs.179665
WIF1(1) 40908 wnt inhibitory factor 1 WIF-1 Implantation array AF122922
WISP1 2125289 WNT1 inducible signalling pathway protein 1 WISP1 Implantation array AF100779
WISP1 2125289 WNT1 inducible signalling pathway protein 1 WISP1 Implantation array AF100779
WISP2 1632487 WNT1 inducible signalling pathway protein 2 WISP2 Implantation array AF100780
WISP3 1076664 WNT1 inducible signalling pathway protein 3 WISP3 Implantation array Hs.194678/AF100781
wnt2 122762 wingless-type MMTV integration site family 2 wnt2 Implantation array X07876/Hs.89791 hom wnt13 except last 1kb.aka human irp
wnt3 1706460 wingless-type MMTV integration site family 3 wnt3 Implantation array AI159968 last 1.5kb
wnt5A 132333 wingless-type MMTV integration site family 5A wnt5a Implantation array L20861/Hs.152213
wnt5b 2094005 wingless-type MMTV integration site family 5B wnt5b Implantation array AI424438 last 0.3kb
wnt6 2115315 wingless-type MMTV integration site family 6 wnt6 Implantation array AI474287
wnt7a WHO cl.8 wingless-type MMTV integration site family 7a wnt7a Implantation array U53476 hom wnt8b except last 0.45kb/primers15/16
wnt10a 1935064 wingless-type MMTV integration site family 10a wnt10a Implantation array Hs.121540/AI366749
WNT10B 1708905 wingless-type MMTV integration site family 10B wnt10b Implantation array U81787
wnt11 501862 wingless-type MMTV integration site 11 wnt11 Implantation array Y12692
XRCC4(1) 1991768 X-ray repair complementing defective repair in CHO cells 4 XRCC4 apoptosis array  Hs.150930 0.8 kb, 3' no5', pA, no o/l
assocsiates with DNA POL 4, substrate of DNA-PKcs, (yeast homologue 
is LIF1p) seeH/E10 same clone
XRCC4(2) 1991768 X-ray repair complementing defective repair in CHO cells 4 XRCC4 apoptosis array  Hs.150930/U40622 0.8 kb, 3' no5', pA, no o/l see J/E3 same clone
ZNF313 1693595 zinc finger protein 313 ZNF313 Implantation array M10988
KEY
Implanatation array, many genes involved in angiogenesis are incorporated into this set
Genes implictaed or known to be involved in apoptosis
Exogenous control spots eg Arabidposis Thaliana with no known cross hybridisation with human sequences
Endogenous control
Genes cloned in -house
Origins of the clone unknown
The original file also contained a link to the sequence and the metagrid/subgrid layout which has been omitted from this table
Assignment to a list does not mean they are exclusive to other groups
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Expression of the VEGF and angiopoietin genes in endometrial
atypical hyperplasia and endometrial cancer
CM Holland*,1,2, K Day2, A Evans1 and SK Smith1,2
1Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB1 1QP, UK; 2Department of Obstetrics and Gynaecology,
University of Cambridge, The Rosie Hospital, Robinson Way, Cambridge CB2 2SW, UK
Angiogenesis is critical for the growth and metastasis of endometrial cancer and is therefore an important therapeutic target. Vascular
endothelial growth factor-A (VEGF-A) is a key molecule in angiogenesis, but the identification of related molecules and the
angiopoietins suggests a more complex picture. We investigated the presence of transcripts for VEGF-A, VEGF-B, VEGF-C, VEGF-D,
Angiopoietin-1 and Angiopoietin-2 in benign endometrium, atypical complex hyperplasia (ACH) and endometrioid endometrial
carcinoma using in situ hybridisation. We confirmed the presence of VEGF-A mRNA in the epithelial cells of cancers examined (13
out of 13), but not in benign endometrium or ACH. We also demonstrate, using quantitative polymerase chain reaction, that levels of
VEGF-B mRNA are significantly lower in endometrial cancer than benign endometrium. We conclude that loss of VEGF-B may
contribute to the development of endometrial carcinoma by modulating availability of receptors for VEGF-A.
British Journal of Cancer (2003) 89, 891–898. doi:10.1038/sj.bjc.6601194 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: VEGF-B; angiopoietins; endometrial cancer; endometrial hyperplasia; in situ hybridisation
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Angiogenesis is a critical event in the growth and spread of
tumours (Folkman, 1990). The vascular endothelial growth factor
family (VEGFs) and the angiopoietins are key factors in this
process (Fong et al, 1995; Shalaby et al, 1995; Ferrara et al, 1996;
Maisonpierre et al, 1997; Thurston et al, 1999). Vascular
endothelial growth factor-A is a dimeric glycoprotein existing as
four main isoforms by alternative splicing from a single gene. The
coding regions of the VEGF gene comprise eight exons. The first
four are conserved but alternative splicing of the last four gives rise
to mRNAs of 121, 145, 165, 189 and 206 amino acids, respectively
(VEGF121, VEGF145, VEGF165, VEGF189, VEGF206) (Houck et al,
1991; Tischer et al, 1991; Charnock-Jones et al, 1993). The VEGF-A
isoforms bind the tyrosine kinase receptors VEGFR-1 (flt-1) and
VEGFR-2 (KDR/flk-1) to promote endothelial cell proliferation,
migration and increased vascular permeability. Elevated levels of
VEGF-A are found in many tumours including cancers of the
endometrium (Doldi et al, 1996; Fujimoto et al, 1998) and ovarian
epithelium (Olson et al, 1994; Boocock et al, 1995; Abu-Jawdeh
et al, 1996). When VEGF-A signalling is blocked with VEGF-
neutralising antibodies (Olson et al, 1996) or dominant-negative
receptors (Millauer et al, 1994), tumour angiogenesis and growth
are impaired.
However, the family of VEGF genes has expanded with the
discovery of other VEGFs, for example, VEGF-B (Olofsson et al,
1996a), VEGF-C (Joukov et al, 1996) and VEGF-D (Achen et al,
1998), which share significant sequence homology with VEGF-A.
VEGF-B exists as two splice variants, a heparin binding isoform of
167 amino acids (VEGF-B167) and a secreted isoform of 186 amino
acids (VEGF-B186) (Olofsson et al, 1996b). Whereas VEGF-A binds
to both the VEGFR-1 and VEGFR-2 receptors, VEGF-B binds only
to the VEGFR-1 receptor (flt-1) (Olofsson et al, 1998). Vascular
endothelial growth factor-B forms homodimers and can hetero-
dimerise with VEGF-A (Olofsson et al, 1996a) to promote
endothelial cell proliferation in vitro (Olofsson et al, 1996a).
Both VEGF-C and VEGF-D are ligands for VEGFR-2 (KDR) and
the third VEGF receptor VEGFR-3 (flt-4) (Joukov et al, 1996;
Achen et al, 1998). VEGFR-3 is expressed by adult lymphatic
endothelial cells but not by adult vascular endothelium. There is a
strong association between lymphovascular density and VEGF-C
expression in human malignant mesothelioma, suggesting this
pathway as an important therapeutic target (Ohta et al, 1999).
A second family of growth factors, the angiopoietins, are ligands
for the tyrosine kinase receptor Tie-2 (Davis et al, 1996;
Maisonpierre et al, 1997). The two ligands share 60% sequence
homology and bind with equal affinity to Tie-2. Angiopoietin-1
(Ang-1) maintains pericyte/endothelial cell interactions (Hanahan,
1997; Thurston et al, 1999) while Angiopoietin-2 (Ang-2) is a
functional antagonist of Ang-1 and leads to marked vessel
regression in tumours in the absence of VEGF-A (Holash et al,
1999). Compared to Ang-1, which is widely expressed in adult
tissues, Ang-2 is selectively expressed at sites of active angiogen-
esis, for example, the corpus luteum of the ovary (Goede et al,
1998) and endometrium (Li et al, 2001).
Angiogenesis is an important feature of endometrial cancer as
microvessel density is an independent prognostic indicator of both
progression and overall survival (Kaku et al, 1997). Furthermore,
there is a progressive increase in microvessel density from benign
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endometrium through the cancer precursor, atypical complex
hyperplasia (ACH) to invasive disease (Abulafia et al, 1995).
While VEGF-A mRNA and protein are present in endometrial
cancer (Doldi et al, 1996; Guidi et al, 1996; Fujimoto et al, 1998), its
expression in ACH is unknown. Vascular endothelial growth
factor-C (Hirai et al, 2001) and VEGF-D (Yokoyama et al, 2003)
have both been correlated with a poor prognosis in endometrial
cancer, but the expression of VEGF-B has not been described. In
order to further investigate a possible role for other angiogenic
factors in endometrial cancer, we investigated the presence of
transcripts for VEGF-A, VEGF-B, VEGF-C, VEGF-D, Ang-1 and
Ang-2 in benign postmenopausal endometrium, ACH and
endometrioid endometrial carcinoma by in situ hybridisation
and used quantitative polymerase chain reaction (PCR) to
determine the levels of VEGF-B and Ang-2 mRNA in benign and
malignant endometrium.
MATERIALS AND METHODS
Patients
A total of 13 carcinoma specimens were examined using in situ
hybridisation. All were endometrioid-type carcinomas. Five benign
postmenopausal endometrial specimens and five complex atypical
hyperplasias were also examined for comparison. The age range of
the patients was 51–87 years (median 57 years). Histopathological
findings and clinical data are shown in Table 1. Presence or
absence of lymphovascular space involvement is indicated, where
reported, in the table. The survival status for each patient was
noted at the time of preparation of this manuscript. Ethical
committee approval was obtained from the committee of
Addenbrookes Hospital NHS Trust.
Tissue samples
In situ hybridisation and immunohistochemistry were performed
on formalin-fixed, paraffin-embedded endometrial tissue. Tissue
used for reverse transcription –PCR (RT –PCR) and quantitative
PCR was snap-frozen from endometrium removed during
endometrial curettage or total hysterectomy, after examination
by a histopathologist.
Production of radiolabelled riboprobes for in situ
hybridisation
Antisense and sense (control) RNA probes were generated against
VEGF-A, VEGF-B, VEGF-C, VEGF-D, angiopoietin-1 and angio-
poietin-2 (Sowter et al, 1997). For VEGF-A, probes were designed
to span the first four exons thus detecting the four commonly
occurring isoforms. The sequences were amplified in pCRscript SK
(Stratagene Ltd., Cambridge, UK) and pBluescript II KS vectors
(Stratagene Ltd., Cambridge, UK). Radioactive, single-stranded
probes incorporating 33P-UTP (Amersham International plc, Little
Chalfont, Buckinghamshire, UK) were carried out with 1 mg
plasmid template using the Ambion MAXIscript transcription kit
(Ambion Inc., Austin, TX, USA) before phenol extraction and
ethanol precipitation.
Identification of mRNA encoding VEGF-A, VEGF-B,
VEGF-C, VEGF-D, angiopoietin-1 and angiopoietin-2 by
in situ hybridisation
Tissue sections (6 mm) were cut onto slides coated with 3-
aminopropyltriethoxy-silane (Sigma Chemical, Poole, Dorset,
UK). The hybridisation procedure was performed as described
by Clark et al (1996). The riboprobe was incubated with the tissue
sections for 18 h at 551C. The sections were washed and treated
with RNAse A (Sigma Chemicals, St Louis, USA), before being
coated with autoradiographic emulsion (Amersham Pharmacia
Biotech UK Ltd, Aylesbury, UK) and exposed for 21 days at 41C.
Sections were developed with photographic developer (Kodak
D19) and counterstained with Mayer’s haemalum (BDH Chemicals,
Lutterworth, UK) before viewing.
Immunohistochemistry for cytokeratin and CD-68
Immunohistochemistry was performed on serial sections to
identify the cell types expressing the transcripts. Mouse antibodies
to human cytokeratin (clone MNF116; Dako, Ltd., High Wycombe,
Table 1 Clinical and histopathological details for patient samples used in the study
Patient Histology Age Status FIGO stage Grade LVS involved Tamoxifen use
1 Benign 51 Alive — — — N
2 Benign 57 Alive — — — N
3 Benign 80 Alive — — — N
4 Benign 63 Alive — — — N
5 Benign 68 Alive — — — N
6 ACH 56 Alive — — — N
7 ACH 58 Alive — — — N
8 ACH 52 Alive — — — N
9 ACH 69 Alive — — — N
10 ACH 52 Alive — — — N
11 Endometrioid cancer 41 Alive 1C 1 N N
12 Endometrioid cancer 56 Alive 2B 2 N/R N
13 Endometrioid cancer 48 Alive 2B 2 Y N
14 Endometrioid cancer 46 Alive 1B 2 N N
15 Endometrioid cancer 71 Alive 3A 3 N/R N
16 Endometrioid cancer 87 Alive 1B 3 N N
17 Endometrioid cancer 54 Alive 1B 3 N Y
18 Endometrioid cancer 78 Deceased 1C 3 N N
19 Endometrioid cancer 84 Deceased 4A 3 Y N
20 Endometrioid cancer 56 Alive 3B 3 N/R N
21 Endometrioid cancer 52 Alive 1B 3 N/R Y
22 Endometrioid cancer 68 Deceased 4A 3 Y Y
23 Endometrioid cancer 81 Alive 1B 3 Y N
ACH¼ atypical complex hyperplasia; LVS¼ lymphovascular space involvement N/R¼ not reported N¼ never, Y¼ yes.
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Buckinghamshire, UK) and human CD68, a macrophage marker,
(clone PG-1; Dako, Ltd.) were used as described previously (Clark
et al, 1996). Mouse IgG (Dako, Ltd.) incubated with serial sections
provided negative controls.
Reverse transcription – PCR
RNA from benign postmenopausal endometrium, ACH and
endometrioid endometrial carcinoma was analysed by RT–PCR
to determine whether mRNA for VEGF-C was present (Figure 1).
Total RNA was extracted from snap-frozen tissue using acid
phenol purification (Chomczynski and Sacchi, 1987). Samples for
PCR were unrelated to those used for in situ hybridisation. RNA
was annealed with oligo-dT primers (Pharmacia Biotech LTD., St
Albans, UK) and cDNA was synthesised using reverse transcriptase
(HT Biotechnology LTD., Cambridge, UK). Polymerase chain
reaction for VEGF-C was performed using the upstream primer 50-
TGCCGATGCATGTCTAAACT-30, and the downstream reverse
complement primer 5’-TGAACAGGTCTCTTCATCCAGC-30 for 40
cycles (15 s at 951C and 60 s at 601C).
Quantitative PCR
RNA was extracted and purified and cDNA was prepared as above.
Quantitative, real-time PCR was performed in triplicate using the
ABI PRISM 7700 Sequence Detector (Applied Biosystems, War-
rington, UK) according to the manufacturer’s instructions and the
resultant data were averaged. Non-template controls were included
in each experiment. Specific oligonucleotide primers and probes
were designed for VEGF-B using Primer Expresss 1.5 software
(Applied Biosystems, Warrington, UK). Specific primers and probe
for Ang-2 were a gift from Mrs K Day of The Reproductive
Molecular Research Group at the University of Cambridge
Department of Obstetrics and Gynaecology. Details for VEGF-B
primers and probe are shown below.
Forward primer, 50 – AGCACCAAGTCCGGATG –30
Reverse primer, 50 –GTCTGGCTTCACAGCACTG –30
Probe, 50-6FAM –AGATCCTCATGATCCGGTACCCGT– 30
A 1 ml volume of each cDNA was amplified using PCR Master
Mix (Applied Biosystems, Warrington, UK) under the following
PCR conditions: 501C for 2 min, 951C for 10 min, followed by 40
cycles of 951C for 15 s and 601C for 1 min. b-Actin and 18 s RNA
were used as endogenous control sequences for VEGF-B and
Angiopoietin-2, respectively. Preliminary experiments confirmed
that the endogenous control sequences were amplified at the same
rate as the target sequences (data not shown). The threshold cycle
(CT) was determined for each sample. CT value is the cycle number
at which the level of reporter fluorescence rises above a preset
threshold level. Normalisation was achieved by subtracting the
mean CT value for each endogenous control triplicate from the
mean CT value for each target gene triplicate. Target gene
abundance was calculated for each tissue type.
Statistical analyses
The presence or absence of specific in situ hybridisation for each
transcript was compared across the different histological cate-
gories using the two-tailed Fisher’s exact probability test. This was
computed using the R statistical computing programme (www.r-
project.org). Statistical significance was accepted as Po0.05. For
results of quantitative PCR, normalised log-transformed transcript
levels were compared between groups using the unpaired Student’s
t-test (two-tailed).
RESULTS
Expression of members of the VEGF family and
angiopoietins by in situ hybridisation
The presence of VEGF-A was detected in all cases of endometrioid
endometrial cancer (Table 2 and Figure 2) and was increased near
areas of necrosis. Hybridisation for VEGF-A was not seen in cases
of ACH or in sections of benign postmenopausal endometrium.
In contrast, hybridisation of the VEGF-B riboprobe was seen in
all the five cases of ACH (Table 2 and Figure 2). There was
continued expression for VEGF-B in low-grade tumours that
diminished as the grade of the tumour increased. Vascular
endothelial growth factor-B mRNA was also present in epithelial
and stromal compartments (Figure 2), although, unlike VEGF-A,
there was no apparent increase in hybridisation near areas of
necrosis.
Messenger RNA encoding VEGF-C was not detected in any of
the tissues examined using in situ hybridisation (Table 2 and
Figure 1). A specimen of human lymphoma was used as a positive
control and demonstrated specific hybridisation (Figure 2).
However, PCR amplification of VEGF-C cDNA was seen in all
the samples of endometrial cancer (13 out of 13) and ACH (three
out of three) examined (Figure 1), in addition to six out of 7 benign
postmenopausal endometria. These findings confirm the presence
of VEGF-C in benign, premalignant and malignant endometrium
(Hirai et al, 2001), although at levels beneath the detection
threshold for in situ hybridisation.
Messenger RNA encoding VEGF-D was present in three of the
five ACH specimens and in six of the 13 carcinomas (one
moderately differentiated tumour and five poorly differentiated
tumours). The distribution of silver grains did not correspond with
epithelial tumour cells but did co-localise with tumour-associated
macrophages (CD-68 positive cells) in serial sections (Figure 3).
Hybridisation for Ang-1 mRNA was seen in only one benign and
one ACH specimen. Similarly, mRNA encoding Ang-2 was seen in
no benign tissues and in only one of the five hyperplastic samples.
In contrast, while hybridisation was absent in well/moderately
differentiated cancers, hybridisation for Ang-2 mRNA was clearly
demonstrated in four out of nine of the poorly differentiated
tumours examined. Hybridisation was most marked in macro-
phage-rich regions of these tumours and was seen to correspond
with tumour-associated macrophages (CD-68) upon immunostain-
ing of serial sections (Figure 3). In all of the experiments described,
there was no specific hybridisation when the sense probes were
used on adjacent sections.
Transcript abundance of VEGF-B and Ang-2 in benign
endometrium and endometrial carcinoma assessed by
quantitative PCR
Real-time, quantitative PCR was carried out using cDNA generated
from benign postmenopausal endometria and endometrioid-type
endometrial adenocarcinoma. The abundance of VEGF-B tran-
script was greater in benign endometrium (n¼ 7) than in atypical
hyperplasia (n¼ 3) (P¼ 0.13) and endometrial cancer (n¼ 17)
(P¼ 0.04) (Figure 4A). Conversely, cDNA encoding Ang-2 was
246 bp
 l   r   c  A  B   C D   E  F  G  H  I   J   K  L M  N  O   P Q  R  S  T U  V  W
Figure 1 Reverse transcription PCR analysis of VEGF-C in samples of
benign endometrium (A–G), ACH (H– J) and endometrioid endometrial
carcinoma. Well differentiated carcinoma (K–M), moderately differentiated
carcinoma (N–S) and poorly differentiated carcinoma (T–W). Lane r
represents an RNA control in which the RT step was omitted and lane c
represents a negative control in which the cDNA was replaced by water.
The size of the transcripts (shown on the right of the figure) was estimated
by co-electrophoresis of a 1 kb ladder (lane l).
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Figure 2 Expression of mRNA encoding VEGF-related factors in the epithelial cells of endometrioid endometrial carcinoma and ACH. In situ hybridisation
with VEGF-A antisense probe in a moderately differentiated (FIGO grade 2) carcinoma shown under dark-field (A) and light-field (C) conditions shows
hybridisation in epithelial carcinoma cells. There is no specific hybridisation when a sense probe (negative control) is used (B). The scale bar in (B) applies to (A),
(B), (E), (F), (I) and (J). Immunostaining of a serial section with anti-human cytokeratin confirms the epithelial localisation of silver grains (D) (scale bar applies to
ACH (C) and (D). In situ hybridisation with VEGF-B antisense probe in ACH shown under dark-field (E) and light-field (G) conditions shows diffuse hybridisation
in epithelial and stromal cells. There is no specific hybridisation when a sense probe (negative control) is used (F). Immunostaining with anti-human cytokeratin
(H) identifies the epithelial and stromal cells (H) (scale bar applies to (G) and (H). In situ hybridisation with VEGF-C antisense probe in a poorly differentiated
(FIGO grade 3) carcinoma shown under dark-field conditions (I) shows no specific hybridisation when compared with a human B-cell lymphoma (J).
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Table 2 Expression of VEGF-A, VEGF-B, VEGF-C, VEGF-D, Ang-1 and Ang-2 detected by in situ
hybridisation in sections of endometrium
Endometrial histology n VEGF-A VEGF-B VEGF-C VEGF-D ANG-1 ANG-2
Benign 5 0/5 0/5 0/5 0/5 1/5 0/5
ACH 5 1/5 5/5* 0/5 3/5 1/5 1/5
FIGO G1/2 carcinoma 4 4/4* 3/4 0/4 1/4 0/4 0/4
FIGO G3 carcinoma 9 9/9* 4/9 0/9 5/9 0/9 4/9
*Po0.05.
Figure 3 Expression of mRNA encoding VEGF-D and Ang-2 in macrophages infiltrating a poorly differentiated (FIGO grade 3) endometrioid endometrial
carcinoma. In situ hybridisation with VEGF-D antisense probe shown under dark-field (A) conditions and light-field conditions (C). In situ hybridisation with
VEGF-D sense (control) probe shows no specific hybridisation (B) (scale bar applies to (A), (B), (E) and (F)). Immunostaining with anti-human CD68 in a
serial section (D), localises the silver grains to tumour associated macrophages (TAMs) (scale bar applies to (C), (D), (G) and (H)). In situ hybridisation with
Ang-2 antisense probe shown under dark-field (E) and light-field (G) conditions. In situ hybridisation with Ang-2 sense (control) probe (F) shows no specific
hybridisation. Anti-human cytokeratin staining (H) localises the hybridisation to TAMs.
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more abundant in the cancer samples (n¼ 17) than in benign
postmenopausal endometrium (n¼ 4) (Figure 4B), although this
did not reach statistical significance (P¼ 0.49).
DISCUSSION
These findings confirm the expression of VEGF-A in endometrial
cancer (Doldi et al, 1996; Guidi et al, 1996; Fujimoto et al, 1998;
Fine et al, 2000), although in contrast to other published reports
(Fujimoto et al, 1998; Fine et al, 2000), we did not demonstrate
VEGF-A mRNA in benign specimens. This may be explained by
the inclusion of both pre- and postmenopausal endometrium in
other studies (Fujimoto et al, 1998). Messenger RNA for VEGF-A is
abundant in premenopausal endometrium (Charnock-Jones et al,
1993). Our findings support those of Guidi et al (1996), who
demonstrated little or no mRNA expression in benign atrophic
endometrium. We demonstrated VEGF-A mRNA in only one out
of 5 specimens of ACH compared with 13 out of 13 endometrioid
cancers. These differences may be due to necrosis within the
malignant tissue. Hypoxia, in necrotic areas of cancer, leads to the
upregulation of transcription (Tischer et al, 1991) and increased
stability of VEGF-A mRNA (Levy et al, 1996).
Messenger RNA and protein for the related growth factor VEGF-
B have previously been identified in other tumours including
ovarian carcinoma (Sowter et al, 1997). We demonstrate, using
quantitative PCR, that mRNA encoding VEGF-B is more abundant
in benign postmenopausal endometrium than in endometrial
adenocarcinoma. The results also suggest that there may be a
relative loss of VEGF-B mRNA in ACH although this was not
statistically significant and may reflect small sample numbers. We
show, using in situ hybridisation, that where present, VEGF-B
mRNA is expressed in both epithelium and stroma of ACH and
some endometrial cancers. These findings contrast with the
overexpression of VEGF-A seen in endometrial cancers (Doldi
et al, 1996; Fujimoto et al, 1998). The distribution of VEGF-B in
both epithelial and stromal compartments of atypical hyperplasia
and some cancers is similar to that observed in ovarian cancer
(Sowter et al, 1997), but in contrast to VEGF-A, hybridisation was
not increased near areas of necrosis. Vascular endothelial growth
factor-B is not upregulated by hypoxia (Silins et al, 1997) and this
may explain the differences seen here.
The function of VEGF-B is not clear. Vascular endothelial
growth factor-1 binds VEGFR-1 (flt-1) but not VEGFR-2 (KDR)
(Olofsson et al, 1998), both of which are present in peritumoral
endothelial cells of endometrial cancers (Guidi et al, 1996). Mouse
‘knockout’ experiments suggest that the VEGFR-1 plays a role in
endothelial differentiation and/or interactions between the en-
dothelium and extracellular matrix (Fong et al, 1995), whereas
signalling through VEGFR-2 leads to endothelial cell proliferation
and migration (Waltenberger et al, 1994). Vascular endothelial
growth factor-B is therefore unlikely to promote endothelial cell
proliferation or migration directly. However, VEGF-B signalling
via VEGFR-1 may participate in the organisation of endothelial –
matrix interactions as VEGF-B increases the expression of both
uPA (urokinase-type plasminogen activator) and PAI-1 (plasmi-
nogen activator inhibitor-1) in endothelial cell cultures (Olofsson
et al, 1996a). These play a role in matrix degradation and its
inhibition, respectively.
Vascular endothelial growth factor-B could contribute to the
maintenance of host –tumour responses. Vascular endothelial
growth factor-A, produced by tumour cells, inhibits the functional
maturation of immune dendritic cells from haemopoietic progeni-
tor cells (Gabrilovich et al, 1996). This effect is mediated by
binding to VEGFR-1 (Oyama et al, 1998). Therefore, loss of VEGF-
B may contribute to the escape of tumour cells from the host
immune response by making more VEGFR-1 binding sites
available for binding by VEGF-A. Vascular endothelial growth
factor-B may thus act to suppress changes that favour the
development of endometrial cancer.
We confirmed the presence of VEGF-C mRNA in endometrial
carcinoma shown by Hirai et al (2001), but did not demonstrate
this by in situ hybridisation. Intense hybridisation for VEGF-C
mRNA is seen in endometrial natural killer cells (Li et al, 2001),
hence the VEGF-C transcript may be present in non-tumour cells
that were under-represented in our endometrial tissues.
Vascular endothelial growth factor-D binds to VEGFR-2 and
VEGFR-3 (Achen et al, 1998), both of which are present in
endometrial cancer (Guidi et al, 1996). In colon cancer, VEGFR-3
is associated with inflammatory infiltrates of TAMs (White et al,
2002) although VEGF-D has not been demonstrated in TAMs
themselves. We have shown hybridisation for VEGF-D mRNA in
ACH and both well differentiated and poorly differentiated
tumours (Table 2), although not all cases in each group were
positive. Recently, positive immunostaining for VEGF-D has been
demonstrated in both epithelium and stroma of endometrial
cancers with some cases of ACH also displaying immunopositivity
(Yokoyama et al, 2003). In the latter study, 42 and 87% of stage I/II
and stage III/IV tumours, respectively, showed significant
immunostaining. These findings may reflect differences in the
degree of inflammatory infiltration between individual tumours as
well as increased expression of VEGF-D by the tumour cells. There
is a tendency to higher TAM density in microvessel-rich tumours
(Salvesen and Akslen, 1999), and our findings indicate that TAMs
may assist in promoting angiogenesis in endometrioid endometrial
carcinoma by the secretion of VEGF-D.
Angiopoietin-1 and Ang-2 are previously unreported in
endometrial cancer. We demonstrated higher levels of Ang-2
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Figure 4 Quantitative PCR for gene transcripts in benign and malignant
endometrium. Levels of gene transcript are shown normalised to an
endogenous control sequence. Transcript levels are expressed as arbitrary
units and represent the mean for each histological group. Experiments for
each sample were performed in triplicate. (A) The level of mRNA
encoding VEGF-B is generally higher in benign postmenopausal endome-
trium than in CAH (P¼ 0.13) and endometrial cancer (P¼ 0.04). (B)
mRNA encoding Ang-2 is generally present at higher levels in endometrial
cancer than in benign postmenopausal endometrium.
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mRNA in endometrial cancers than benign endometrium, although
this did not reach statistical significance. The latter may reflect the
small numbers of samples in the benign group. Nonetheless, the
distribution of mRNA for Ang-2, assessed by in situ hybridisation,
was similar to that of VEGF-D in TAMs (Figure 3). Both Ang-2 and
VEGF-D were only seen in association with CD68-positive cells,
although CD68-positive cells, without hybridisation for either of
these factors were also present.
Angiopoietin-2 is an antagonist of Ang-1, acting through the
Tie-2 receptor and disrupting pericyte-endothelial cell interac-
tions. In the presence of VEGF-A, Ang-2 facilitates vessel sprouting
while in its absence, regression of vessel sprouts occurs
(Maisonpierre et al, 1997). However, in active tumour angiogen-
esis, a large proportion of the blood vessels lack pericytes and can
be selectively ablated by withdrawal of VEGF-A alone (Benjamin
et al, 1999). In our series, survival did not differ significantly where
hybridisation for both VEGF-A and Ang-2 was seen and this may
reflect a high proportion of immature tumour vessels lacking
pericyte coverage. Angiopoietin-2 may also alter the response of
destabilised endothelial cells to cytokines, thus modulating
angiogenesis (Laure´n et al, 1998).
We have shown that gene transcripts for the related growth
factors, VEGF-A and VEGF-B, are differentially expressed in
benign postmenopausal endometrium and endometrioid endome-
trial cancer. The reduced expression of VEGF-B in endometrial
cancers compared with benign endometrium suggests that VEGF-B
may play a role in maintaining normal cellular interactions in
endometrium and that loss of expression could contribute to
endometrial tumorigenesis.
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The effect of RU486 on the gene expression pro®le in an
endometrial explant model
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Administration of RU486 in vivo during the receptive phase rapidly renders the endometrium non-receptive to the implanting
embryo. In order to identify key pathways responsible for endometrial receptivity we have used cDNA arrays to monitor gene
expression changes in short-term endometrial explants in response to RU486. Endometrial biopsies from ®ve normal fertile
women at mid-secretory phase were cultured in the presence of estradiol and progesterone with or without RU486 for 12 h.
cDNA arrays were produced containing ~1000 sequence-veri®ed clones which included genes known to be important in angio-
genesis, apoptosis, cell signalling, extracellular matrix remodelling and cell cycle regulation. cDNA probes from the paired endo-
metrial samples were hybridized to the arrays and hybridization signals were quanti®ed. A total of 12 genes displayed
signi®cant changes in expression; six were up-regulated and six down-regulated following RU486 treatment. For ®ve of these
genes this is the ®rst report suggesting that they are regulated by steroids in the endometrium. JAK1 and JNK1 were two of the
genes shown by the arrays to be down-regulated in RU486-treated endometrial explants. This was con®rmed by real time
RT±PCR. JAK1 immunoreactivity was localized to both glandular epithelium and the stroma of normal endometrium and stain-
ing was much stronger in the luteal phase of the cycle. These results show that components of two important signalling pathways
in endometriumÐthe JAK/STAT pathway, and the JNK pathwayÐare altered by RU486. Genes whose expression is controlled
by these pathways are likely to be involved in the mechanism by which steroids render the endometrium receptive to the
implanting embryo.
Key words: cDNA array/endometrium/gene pro®ling/implantation/steroids
Introduction
In humans the uterus is receptive to blastocyst implantation between 5
and 9 days post-ovulation, a period known as the implantation window
(Wilcox et al., 1999). During this period the endometrium becomes
functionally receptive to the embryo, which is re¯ected by its
structural and biochemical transformation (Tabibzadeh and Babaknia,
1995). The action of progesterone on an estrogen-primed endome-
trium results in a particular gene expression pro®le which renders the
endometrium receptive (Giudice et al., 1999; Salamonsen et al.,
2001). If the action of progesterone is antagonized, or progesterone
levels fall, the endometrium rapidly reverts to a non-receptive state.
This is followed by other changes such as focal haemorrhage and
degradation of extracellular matrix (ECM) resulting in menstruation
(Papp et al., 2000). Based on this paradigm, several approaches have
been used to identify genes that are required for a functionally
receptive endometrium. The ®rst has been to identify structural and
molecular changes that coincide with the transition from a non-
receptive state (LH+3), to a receptive state (LH+7). As well as
morphological changes, the expression of many proteins alters during
this time. These include mucin 1 (Hey et al., 1994) placental proteins
12 and 14 (Julkunen et al., 1986; Rutanen et al., 1986), prolactin
(Maslar et al., 1979), various integrins (Lessey et al., 1992), cytokines
(Tabibzadeh et al., 1995) and heat shock proteins (Gruidl et al., 1997).
A recent microarray study reported >600 genes whose mRNA
expression levels altered between these two time-points (Carson
et al., 2002). The second approach has been to try to identify genes
that are directly regulated by the action of progesterone on
endometrium (Kumar et al., 1998; Okulicz and Ace, 1999).
An alternative approach has been to study the effects of
antiprogestins such as RU486 (mifepristone). RU486 competes with
progesterone for binding to the progesterone receptor and alters its
DNA binding characteristics (Jackson et al., 1997). It has both
antagonist and agonist activities on the action of progesterone in
regulating gene transcription and also exhibits anti-glucocorticoid,
anti-estrogenic and anti-androgenic activity (Beck et al., 1993;
McDonnell and Goldman, 1994; Hackenberg et al., 1996; Elger
et al., 2000). A single dose of RU486 (200 mg) administered to normal
cycling women 2 days after ovulation produces peak plasma levels of
~0.3±0.4310±6 mol/l within 2 h (Sarkar et al., 2002). This renders the
endometrium non-receptive (Hegele-Hartung et al., 1992; Gemzell-
Danielsson et al., 1993). RU486 has an effect on gene expression in
the uterus as early as 6 h after oral administration (Critchley et al.,
1996). This effect is likely to be due to the direct action of RU486 on
endometrium, since there is no signi®cant effect on serum progester-
one levels (Swahn et al., 1990). This is supported by the fact that
RU486 has been shown to suppress expression of leptin receptor in
endometrial explants after only 6 h in culture (Koshiba et al., 2001).
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Many studies have used antiprogestins to analyse the expression of
individual endometrial factors that might be important for implant-
ation (Danielsson et al., 1997; Schatz et al., 1997; Marions et al.,
1998; Taylor et al., 1998; Critchley et al., 1999). However, most of
these factors have been studied in isolation. To date, no attempt has
been made to study the global changes in gene expression caused by
RU486 in human endometrium as it changes from a receptive to a non-
receptive state.
In order to identify endometrial factors that are important for
implantation, we have used an endometrial explant model to identify
genes regulated by the action of RU486 on endometrium from the
receptive phase. Many previous studies using endometrial explants
have shown that they retain their steroid responsiveness in vitro for
>24 h and respond to steroids in a similar way to endometrium in vivo
(Dudley et al., 1992; Ilouz et al., 2000; Koshiba et al., 2001). These
results suggest that cultures of endometrial explants are a valid model
for studying the effects of steroid treatment in the endometrium. We
cultured mid-secretory endometrial explants with RU486 for 12 h at a
concentration similar to peak plasma levels after oral administration of
200 mg. Total RNA was isolated and used to probe cDNA arrays
containing ~1000 genes selected to include the molecular pathways
believed to be important for receptivity. These include cell adhesion,
apoptosis, signalling, cell cycle regulation, ECM remodelling and
angiogenesis. This has enabled the monitoring of early gene expres-
sion changes in secretory phase endometrium in response to RU486.
The aim was to identify genes whose expression may be involved in
the loss of endometrial receptivity.
Materials and methods
Tissue collection
This study took place with the approval of the Cambridge Local Region Ethics
Committee. Written informed consent was obtained from all patients.
Endometrial biopsies were obtained from seven normally cycling fertile
women at the mid-secretory phase (day 19±23) who underwent curettage or
hysterectomy for benign gynaecological disorders. The patients were healthy
women (aged 28±38 years, with a body mass index between 19 and 25 kg/m2).
They had regular menstrual cycles (27±30 days) and had not received hormone
therapy for the last 2 months prior to surgery. Each specimen was assessed as
normal by histological examination. Endometrial dating was performed using
published criteria (Noyes et al., 1950). Biopsies for immunohistology were
collected from similar patients throughout the menstrual cycle and con®rmed as
normal by histological examination.
Explant culture
Endometrial biopsies were washed several times in Dulbecco's minimum
essential medium (DMEM)/Ham's F-12 without Phenol Red (Life
Technologies, UK) to remove blood. The endometrial tissues were chopped
into 1±2 mm2 pieces and divided into two equal samples. These were placed in
a 4-well plate (Nunc) and incubated with 5 ml media (DMEM/F-12 without
Phenol Red), 1% L-glutamine (Life Technologies), 1% penicillin G/strepto-
mycin (Life Technologies) for 1 h to allow recovery, culture medium was then
changed (Wang et al., 1987). One part of the sample was treated with 5 ml of
DMEM/F-12 (as above) containing 10±9 mol/l estradiol + 10±7 mol/l
medroxyprogesterone acetate (all steroids purchased from Sigma, UK).
These steroid concentrations have previously been shown to elicit responses
in endometrial explant cultures (Koshiba et al., 2001) and closely resemble
plasma concentrations reported during the mid-secretory phase of the
endometrium (reviewed in Chabbert Buffet et al., 1998). The other half of
the endometrial sample was incubated with the same medium to which RU486
(10±6 mol/l) (Sigma) was added. Incubations were performed in a humidi®ed
atmosphere at 37°C in 5% CO2. The paired endometrial samples treated with
and without RU486 were ¯ash-frozen after 12 h and stored at ±70°C.
RNA extraction
Total RNA was extracted using Trizol reagent (Life Technologies) according to
the manufacturer's instructions and treated with RQ1 DNase I (Promega, UK)
for 30 min at 37°C, then re-extracted with Trizol. RNA quality was assessed by
loading 300 ng of total RNA onto an RNA Labchip (Agilent Technologies) and
analysed on an A2100 Bioanalyser (Agilent Technologies, Germany). Two
biopsies did not yield suf®cient RNA for hybridization to arrays, but were used
for the subsequent RT±PCR analysis.
Array production
cDNA arrays were produced containing ~1000 sequence-veri®ed clones
spotted in duplicate on an 8312 cm nylon Hybond N+ membrane (Amersham
Pharmacia Biotech, UK). The DNA used for spotting was produced by
ampli®cation using PCR from the corresponding IMAGE cDNA clones.
Speci®c cDNA clones were chosen that showed little or no homology to other
known genes to reduce cross-hybridization and clones were sequenced prior to
PCR to con®rm the clone identity. To check for any cross-contamination, PCR
products were electrophoresed prior to spotting on the array to ensure that each
was a single band and 50% of the PCR products used for spotting were
resequenced to verify that the correct clone was spotted. The ampli®ed PCR
fragments were puri®ed using the Millipore Multi-screen 96 system (Millipore,
UK) to a concentration of 500 mg/ml. Approximately 15 ng of each cDNA was
contact-printed onto the membrane using a BioRobotics MicroGrid robot
(BioRobotics Ltd, UK) with a 96-pin tool with 0.4 mm diameter solid pins to
create 2112 individual DNA spots, representing known genes, expressed
sequence tags (ESTs) unknown genes and calibration spikes. After spotting, the
®lters were denatured and neutralized and the DNA was cross-linked using a
UV Stratalinker, model 1800 (Stratagene, USA) at 70 000 mJ/cm2. The listing
of all the cDNA on the array can be found at http://www.path.cam.ac.uk/
~angio/.
Array hybridization
Radiolabelled cDNA probes were produced by labelling 5 mg of total RNA
from ®ve endometrial samples with [33P]dCTP using the EndoFree RT Kit
(Ambion, USA). Unincorporated [33P]dCTP was removed using NICK
columns (Amersham, Pharmacia Biotech). The ®lters were pre-hybridized at
65°C for 3 h using ExpressHyb buffer (Clontech, USA) containing 1 mg/ml
Human Cot-1 DNA (Life Technologies), 1 mg/ml Poly dA (Amersham,
Pharmacia Biotech) and 5 mg/ml Salmon sperm DNA (Sigma). cDNA probes
were denatured then added to the hybridization buffer at 13106 cpm/ml and
hybridized at 65°C for 16 h. The ®lters were washed twice in 23standard saline
citrate (SSC), 0.5% sodium dodecyl sulphate (SDS) and twice in 0.13 SSC,
0.1% SDS for 30 min each at 60°C, then dried for 30 min at 60°C. The ®lters
were exposed to low energy storage phosphor screens (Molecular Dynamics,
USA) for 48 h and scanned at 50 mm resolution using a STORM 860 Scanner
(Molecular Dynamics).
Array analysis
Hybridization signals were quanti®ed using ImaGene v5.0 (BioDiscovery Inc.,
USA). The mean signal for each spot on the array was determined. The data
from each pair of treated and untreated samples from the same patient were
then normalized to overcome minor differences in labelling and hybridization
ef®ciency. Normalization was performed by applying intensity-dependent
scaling using the `loess' function of the R-statistical software system, in a
similar fashion to that used by the SNOMAD protocol (Colantuoni et al., 2002).
The normalized transcript abundance data was then compared using a paired t-
test to identify transcripts that showed a statistically signi®cant change in
expression following exposure to RU486 across all ®ve samples. Statistical
signi®cance was de®ned as P < 0.05. The fold change values for each
endometrial biopsy were calculated by taking the background subtracted mean
signal for each cDNA spot and dividing the value obtained from the RU486-
treated portion of the biopsy by the value of the corresponding spot from the
control sample.
Real time RT±PCR
The relative expression of two genes, JAK1 and JNK1, was compared between
RU486 and control tissues by real time RT±PCR using an ABI PRISM 7700
sequence detection system (TaqMan) according to the manufacturer's
R.D.Catalano et al.
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instructions. Primers and probes were designed using the Primer Express v5.0
software (Applied Biosystems, UK) and were designed within the same region
of the cDNA clone as was spotted on the array. Areas in the cDNA that are
known to be involved in alternate splicing were avoided. Details of the primers
and probes used are detailed below. The probes were labelled with 5¢FAM and
3¢TAMRA and were puri®ed by high-performance liquid chromatography.
JAK1 primers and probes were: 5¢-CATGAGAACATTGT-
GAAGTACAAAGGA-3¢ (forward primer), 5¢-CCCGAAGGCAGAAATT-
CCAT-3¢ (reverse primer), 5¢-GCTTAATACCATTTCCTCCGTCTTCTGT-
GCAG-3¢ (probe); JNK1 primers: 5¢-TCAATGGCTCTCAGCATCCA-3¢
(forward primer), 5¢-GCCAAAGTCGGATCTGTTGAC-3¢ (reverse primer),
5¢-CATCGTCGTCTGTCAATGATGTGTCTTCAA-3¢ (probe). In addition,
the endogenous control 18S ribosomal RNA was assayed using primers and
probe from Applied Biosystems. Probe and primer optimization and real time
PCR were performed using the manufacturer's recommended conditions.
Standard curves were generated by serial dilution of a standard preparation of
total RNA isolated from luteal phase endometrium. Data are expressed in
arbitrary units relative to the level of the same gene in this standard RNA.
cDNA was produced from each endometrial sample by reverse transcription
using 5 mg of total RNA with 200 IU Superscript RT (Invitrogen, UK)
according to the manufacturer's instructions. The expression values obtained
were normalized against those from the control ribosomal 18S to account for
differing amounts of starting material.
Immunohistochemistry
Biopsies for immunohistochemistry were ®xed in neutral buffered 10%
formalin for 6 h at room temperature and paraf®n wax-embedded. Serial
sections of 5±7 mm were cut from the paraf®n blocks and mounted on APES-
coated slides, de-waxed in xylene and rehydrated in graded alcohol. Slides were
pressure-cooked at full pressure for 2 min in 10 mmol/l sodium citrate, pH 6.0.
After cooling for 5 min, slides were washed in phosphate-buffered saline
(PBS), endogenous peroxidase was quenched for 10 min in 0.3% hydrogen
peroxide in methanol and blocked in 20% goat serum, 1% bovine serum
albumin (BSA) for 30 min. Sections were incubated with rabbit anti-JAK1
(Santa Cruz, Biotechnology, USA) at 4°C for 16 h at a dilution of 1:300 for
proliferative phase sections and 1:600 for secretory phase sections in PBS, 5%
goat serum, 1% BSA. To con®rm speci®city of the JAK1 immunoreactivity, we
preincubated the anti-JAK1 antibody with a 10-fold excess of the antigenic
JAK1 peptide against which the antibody was raised. Slides were then reacted
with biotin-labelled goat anti-rabbit IgG and incubated with preformed
avidin±biotin±peroxidase complex (ABC kit; Vector Laboratories, USA).
Diaminobenzidine (Sigma) was used as a substrate. Sections were counter-
stained with haematoxylin, dehydrated and mounted.
Results
cDNA array analysis
Endometrium was collected from seven fertile women in the mid-
secretory phase of the cycle. Each sample was divided into two equal
pieces and cultured for 12 h in estradiol and progesterone with or
without the antiprogestin RU486. Total RNA was extracted from each
culture and used to probe a custom-made human cDNA array of ~1000
sequence-veri®ed clones. Representative genes were chosen to include
those important in molecular pathways involved in angiogenesis,
apoptosis, cell cycle control, ECM remodelling and cell signalling.
We also included markers for speci®c cell types in endometrium,
including cytokeratin (epithelium), vimentin (stroma) and CD45
(leukocytes). These markers provide a means to assess the relative
content of each cell type in the paired biopsies from each patient. Total
RNA from ®ve pairs of control and RU486-treated endometrial
explants was hybridized on individual arrays and then normalized.
Typical results of this analysis are shown by a representative scatter
plot comparing the signals obtained for each cDNA clone on the array
after hybridization to control and RU486-treated endometrium from
the same patient (Figure 1A). The hybridization signal values obtained
from control and treated tissue samples from ®ve women were
normalized in pairs and cDNA with signi®cant changes determined by
paired t-test. A total of 12 genes (~1.2%) displayed statistically
signi®cant changes in expression following RU486 treatment; six
cDNA decreased (Table I) and six increased (Table II). These cDNA
ful®l the following criteria: both duplicate spots on the array changed
signi®cantly, and the signal intensity was at least twice that of the
backgound. An example of the change seen for the cDNA JNK1 on the
cDNA array is shown in Figure 1B. The identity of the 12 genes
identi®ed as regulated by RU486, was con®rmed by sequencing the
actual PCR product spotted on the array corresponding to each
regulated cDNA spot.
TaqMan veri®cation of gene expression determined by
array analyses
Real time RT±PCR was used to verify the changes in RNA expression
levels indicated by the cDNA analysis. Two genes JAK1 and JNK1,
which both apparently decreased >2-fold following RU486 and which
were highly expressed, were chosen for veri®cation. cDNA was
synthesized from the same ®ve total RNA samples used for the array
Figure 1. (A) Scatter plot comparing hybridization signals obtained for each
cDNA after hybridization of arrays to control and RU486-treated secretory
endometrial explants from the same patient. The graph shows the
comparison of the relative expression of each of the ~1000 genes spotted in
duplicate in the RU486-treated RNA (y-axis) versus control RNA (x-axis)
from a representative analysis. Values have been normalized and logged
(log10). The grey band denotes a 2-fold change in signal intensity between
arrays (paired analysis). JNK1 and JAK1 are highlighted and show
signi®cant down-regulation in the treated group. (B) Part of a representative
array showing the signal from duplicate JNK1 cDNA spots following
hybridization to control or RU486-treated endometrium from the same
patient.
Endometrial gene pro®ling
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Table IA. Genes down-regulated by RU486
Gene ID Patient no. Fold change P±value
1 2 3 4 5 Mean 6 SD
vav2/1 ±2.00 ±2.23 ±1.57 ±4.14 ±4.01 ±2.79 0.17 0.008
vav2/2 ±2.06 ±2.39 ±1.47 ±4.06 ±4.30 ±2.86 0.18 0.009
JAK1/1 ±4.30 ±2.24 ±2.34 ±2.72 ±1.60 ±2.64 0.14 0.005
JAK1/2 ±2.22 ±2.42 ±2.55 ±2.97 ±1.73 ±2.38 0.09 0.001
EST31/1 ±3.02 ±1.66 ±2.81 ±1.12 ±2.87 ±2.30 0.24 0.018
EST31/2 ±3.34 ±2.01 ±2.67 ±1.70 ±3.34 ±2.61 0.13 0.002
JNK1/1 ±1.36 ±1.93 ±2.21 ±2.33 ±1.55 ±1.88 0.13 0.004
JNK1/2 ±1.29 ±1.83 ±2.11 ±2.22 ±1.58 ±1.81 0.13 0.004
TNR/1 ±1.94 ±1.78 ±1.27 ±1.98 ±1.24 ±1.64 0.15 0.010
TNR/2 ±2.00 1.67 ±1.21 ±2.48 ±1.18 ±1.71 0.20 0.026
CTSL/1 ±1.10 ±1.16 ±1.15 ±1.64 ±1.60 ±1.33 0.15 0.037
CTSL/2 ±1.30 ±1.67 ±1.15 ±1.41 ±1.89 ±1.48 0.13 0.013
The fold change shown by each duplicate (/1, /2) cDNA spotted on the array after treatment is given, together with the mean fold change derived from all ®ve
experiments.
The P-values are derived from a paired t-test.
Table IB. Identity of each Image cDNA clone spotted, the gene name and Unigene cluster
Gene ID Image clone Unigene Identity
Vav2 2386937 Hs. 352272 Oncogene, involved in formation of lameliapodia and cell spreading
JAK1 177471 Hs. 50651 Janus kinase 1, protein-tyrosine kinases, cytokine receptor signalling
EST31 Mis-assigned Not assigned Ribosomal protein similar to regions found in 45s, 28s, 60s and L4E family
JNK1 119133 Hs. 267445 Mitogen-activated protein kinase
TNR 175767 Hs. 54433 Tenascin R, extracellular matrix protein
CTSL 130796 Hs. 78056 Cathepsin L, lysosomal cysteine proteinase
Table IIA. Genes up-regulated by RU486
Gene ID Patient no. Fold change P-value
1 2 3 4 5 Mean 6 SD
cPLA2/1 2.33 1.22 1.17 1.44 1.63 1.56 0.47 0.029
cPLA2/2 1.70 1.26 1.13 1.30 1.64 1.41 0.25 0.014
GST P1/1 1.10 1.18 1.23 1.17 1.31 1.20 0.08 0.003
GST P1/2 1.87 1.30 1.20 1.25 1.24 1.37 0.28 0.021
CD94/1 1.17 1.20 1.19 1.47 1.16 1.24 0.13 0.010
CD94/2 1.23 1.18 1.18 1.80 1.41 1.36 0.26 0.022
Bak/1 1.42 1.37 1.78 1.15 1.00 1.34 0.30 0.048
Bak/2 1.58 1.27 1.25 1.22 1.18 1.30 0.16 0.008
NIK/1 1.10 1.27 1.20 1.51 1.22 1.26 0.15 0.012
NIK/2 1.36 1.39 1.20 1.34 1.19 1.29 0.09 0.001
WISP1/1 1.10 1.45 1.31 1.20 1.26 1.26 0.13 0.008
WISP1/2 1.27 1.46 1.30 0.98 1.34 1.27 0.18 0.025
The fold change shown by each duplicate (/1, /2) cDNA spotted on the array after treatment is given, together with the mean fold change derived from all ®ve
experiments.
The P-values are derived from a paired t-test.
Table IIB. Identity of each Image cDNA clone spotted, the gene name and Unigene cluster
Gene ID Image clone Unigene Function
cPLA2a 1676293 Hs. 211587 Cytosolic phospholipase A2a, signaling responses to extracellular ligands
GST P1 2224433 Hs. 226795 Glutathione S-transferase, PI, enzyme has important role in detoxi®cation
CD94 1901363 Hs. 41682 Killer cell lectin-like receptor, regulation of NK cell function
Bak 235938 Hs. 93213 BCL2 antagonist/killer 1, suppressor of apoptosis
NIK 342349 Hs. 47007 Serine/threonine protein kinase, lymphotoxin-beta receptor signaling
WISP1 2125289 Hs. 194684 WNT1 inducible signalling pathway protein 1
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analysis as well as two additional patient samples. Levels of JAK1 and
JNK1 were measured by TaqMan analysis for each cDNA sample
relative to a reference RNA and the values were corrected for
differences in loading relative to the 18S ribosomal RNA. JAK1
expression decreased by a mean of 2.7-fold and JNK1 expression
decreased by a mean of 2.1-fold in the seven RU486-treated samples
(Figures 2 and 3). The decrease in both genes was statistically
signi®cant (JAK1, P < 0.016 and JNK1, P < 0.047). Therefore the
gene list generated by the cDNA array analysis re¯ects reliable
changes in gene expression following RU486 treatment of secretory
phase endometrium.
Immunolocalization of JAK1 in endometrium
JAK1 immunostaining was predominantly in the glands in prolif-
erative endometrium with only faint staining in the stroma (Figure 4A).
The intensity of the immunostaining increased considerably in
secretory endometrium and staining was seen within the stroma as
well as in the glandular and luminal epithelium (Figure 4C).
Immunostaining was present throughout the stroma in secretory
phase endometrium but was clearly absent from lymphoid aggregates
(Figure 4E). Therefore JAK1 immunoreactivity appears to be present
within the glands throughout the menstrual cycle, but increases
dramatically within the stroma and luminal epithelium at the mid-
secretory phase. Staining of sections with JAK1 antibody preincu-
bated with the JAK1 antigenic peptide abolished JAK1 immunor-
eactivity, indicating that the staining obtained was speci®c for JAK1
(Figure 4B, D and F).
Discussion
The genes and biochemical pathways believed to be involved in
achieving a receptive uterus have been largely derived from animal
models (Giudice, 1999; Lessey et al., 2000; Sharkey and Smith, 2003).
Other than the progesterone receptor, no genes have yet been formally
shown to be essential for implantation in humans. Recently, gene
pro®ling using microarray analysis has been used to identify global
expression patterns in endometrium during the menstrual cycle (Kao
et al., 2002; Borthwick et al., 2003), the receptive phase (Carson et al.,
2002) and in-vitro decidualization (Popovici et al., 2000). Changes in
expression of hundreds of cDNA coincides with the transition from the
non-receptive to the receptive state, but it is not known which of these
molecules are critical for successful human implantation. The current
study utilized the antiprogestin RU486 on cultured human secretory
endometrium to identify steroid-regulated genes and molecular
pathways, which, when disrupted, lead to implantation failure.
Custom-made cDNA arrays which included genes known to be
important in angiogenesis, apoptosis, cell signalling, ECM remodel-
ling and cell cycle regulation, were used to identify genes which are
altered by the action of RU486 on endometrial explants.
The arrays identi®ed 12 genes whose expression was signi®cantly
altered after 12 h of treatment with RU486. The gene list represents
1.2% of the genes on the array and three show mean fold changes of
>2. Since the response to steroids alters over time, this 12 h time-point
represents the early responses of the endometrium to RU486. Previous
array studies on endometrial tissues and cell lines have revealed a
similar number (1.3±5.8%) of genes with a signi®cant change in gene
expression (Popovici et al., 2000; Carson et al., 2002; Kao et al.,
2002). A fold change of >2 is a frequently adopted cut-off for array
pro®le analysis (Claverie et al., 1999). However, subtle alterations in
transcript levels of genes below the 2-fold level should be considered
if they are repeatable over a large number of biologically independent
replicated experiments, because these smaller gene expression
changes may be due to a robust response in a few cells in a complex
tissue (Hamadeh et al., 2002). The results of the real time PCR for the
Figure 2. JAK1 expression levels in control and RU486-treated endometrial
explants determined by TaqMan PCR. Endometrial explants for biopsies 6
and 7 were not included from the array analysis as these biopsies were too
small to extract enough total RNA. Values are normalized to ribosomal 18S
for each culture and fold change in JAK1 expression for each experiment is
indicated.
Figure 3. JNK1 expression levels in control and RU486-treated endometrial
explants determined by TaqMan PCR. Endometrial explants for biopsies 6
and 7 were not included from the array analysis as these biopsies were too
small to extract enough total RNA. Values are normalized to ribosomal 18S
for each culture, and fold change in JNK1 expression for each experiment is
indicated.
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two genes JAK1 and JNK1 were in good agreement with the array
results and con®rm that the array analysis is reliable.
This study employed endometrial explants rather than isolated
primary cells. This retains normal epithelial±stromal interactions and
Figure 4. Immunolocalization of JAK1 protein in human endometrium during the proliferative and secretory phases of the menstrual cycle. JAK1
immunostaining (antibody dilution 1:300) is observed in the endometrial glands and faintly in the stroma during the proliferative phase (A). During the
secretory phase JAK1 immunostaining (antibody dilution 1:600) was increased and was also observed in the stroma and luminal epithelium as well as the
glandular epithelium (C). The lymphoid aggregates within the stroma of the secretory endometrium were devoid of staining (E). Arrows indicate lymphoid
aggregate (E, F). Negative controls B, D and F are sections stained with JAK1 antibody which had been preincubated with an excess of JAK1 blocking
peptide. Scale bar = 100 mm (A, B, C, D), 30 mm (E, F).
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such explants have been shown to exhibit normal steroid responsive-
ness for up to 72 h (Koshiba et al., 2001). Recent reconstitution studies
using endometrial tissue from mice de®cient for the estrogen or
progesterone receptor genes have shown that maintaining epithelial±
stromal cell interactions is essential if normal responses to steroids are
to occur (DeMayo et al., 2002). The use of explants retains these
interactions and also demonstrates the extent of normal patient-to-
patient variation in the expression level of individual genes. An
example of this is seen in the TaqMan data for JAK1 (Figure 2), where
the control samples vary up to 5-fold in the level of JAK1 expression.
This variability has several sources including the fact that biopsies
from different women vary in their cellular content. Secondly there is
considerable variation in gene expression between different women
even with fresh endometrial biopsies taken at LH+7 in the cycle
(R.D.Catalano and A.M.Sharkey, unpublished data). The only way to
overcome this variation is to perform multiple replicates, as we have
done in this experiment in order to obtain reliable data.
The 12 genes identi®ed represent genes involved in apoptosis,
transcription, stress response, ECM, but predominantly those involved
in cell signalling pathways. One of these, cPLA2, has been reported
previously to be up-regulated by RU486 (Kol et al., 1998). Others
have previously been reported to be expressed in the endometrium,
including BAK (Tao et al., 1998), CD94 (Semino et al., 1995),
cathepsin L (Jokimaa et al., 2001), GST Pi (Barnette et al., 1999) and
NIK (King et al., 2001). To our knowledge there are no previous
reports of steroid regulation of the expression of tenascin R, JNK1,
JAK1, VAV2 and WISP1 in endometrium.
The gene list and real time RT±PCR data indicate that the
components of two major intracellular signalling pathways, the JAK/
STAT signalling pathway, and the JNK signalling pathway, are down-
regulated by the action of RU486. Janus kinases (JAK) are
cytoplasmic protein tyrosine kinases that are activated by binding of
cytokines to their receptors. They phosphorylate cellular substrates
including the transcription factor family named signal transducers and
activators of transcription (STAT) (Schindler et al., 1995; Ihle et al.,
1996). JAK1 is recruited by three major cytokine receptor subfamilies,
class II cytokine receptors [receptors for interferon (INF)a/b, INFg
and interleukin (IL)-10], cytokine receptors that utilize the gc receptor
subunit (receptors for IL-2, IL-4, IL-7, IL-9 and IL-15) and receptors
that utilize the gp130 subunit (receptors for IL-6, IL-11, leukemia
inhibitory factor (LIF), oncostatin M (OSM), cilary neurotrophic
factor (CNTF) and cardiotrophin-1 (CT-1)). The results of this study
indicate that signal transduction through all these receptors would be
altered by the action of RU486.
Immunohistochemical analysis showed that JAK1 immunoreactiv-
ity is seen in the glands and only weakly in the stroma in proliferative
endometrium. In mid-secretory endometrium the immunostaining
increased, especially in the stroma and luminal epithelium. This
staining was abolished by preincubation of the antibody with the JAK1
peptide. The data clearly indicate that JAK1 immunoreactivity is
elevated in the stroma, endometrial glands and luminal epithelium in
the receptive endometrium. Con®rmation that JAK1 protein expres-
sion is down-regulated in explants or in vivo by RU486 will require
accurate quanti®cation by Western blot analysis. JAK2 expression has
been shown to be negligible in the proliferative phase, but is elevated
in the glands during the secretory phase with little JAK2 expression in
the stroma (Jabbour et al., 1998). Therefore JAK1 appears to have a
distinct role compared with JAK2 in the stroma and luminal
epithelium in endometrium from the receptive phase.
The JNK family comprises three protein kinases, de®ned by their
phosphorylation of the N-terminal region of c-jun (Pulverer et al.,
1991; Kallunki et al., 1996). JNK also phosphorylates the transcription
factor ATF2 (Gupta et al., 1995) and the Ets-domain transcription
factor Elk-1 (Whitmarsh et al., 1995). The JNK signalling pathways
are activated primarily by pro-in¯ammatory cytokines and stress
stimuli. Depending upon the stimulus, JNK activation may be
involved in mitogenesis, oncogenic transformation, differentiation,
or induction of apoptosis (Minden and Karin, 1997). Prolactin induces
activation of both JNK1 and JNK2 and inhibition of JNK1 activation
prevents cellular proliferation and induces apoptosis (Schwertfeger
et al., 2000). JNK1 was speci®cally down-regulated in our study and
therefore only pathways speci®cally activated by JNK1 should be
affected. Functional differences between JNK1 and JNK2 remain
unclear as they share many of the same substrates and are activated by
the same kinases. However, the recent development of JNK1 and
JNK2 knockout mice shows that they have distinct and speci®c roles in
modulating cell function. JNK1 is known to alter the expression of
>30 genes including insulin-like growth factor binding protein 3
(IGFBP-3), vimentin, cytokeratin 18 and junD (Chen et al., 2002).
Many of these genes are differentially regulated during the menstrual
cycle. JNK1-de®cient mice also show defective T-cell differentiation
and enhanced Th2 cytokine production (Dong et al., 1998). This effect
is seen even in JNK1+/±, JNK2+/± double heterozygotes, indicating
that relatively small changes in the levels of JNK gene expression can
have signi®cant phenotypic effects (Sabapathy et al., 2001). There are
four known isoforms of JNK1 which arise by differential splicing, and
whose speci®city of binding interaction differs between isoforms. The
cDNA probe and TaqMan primers used in this study hybridize to the 3¢
region common to all isoforms. We have not determined whether
expression of all these isoforms is regulated simultaneously.
The action of RU486 on secretory phase endometrium rapidly
renders this tissue non-receptive to the implanting embryo (Critchley
et al., 1999). This is accompanied by changes in expression of genes
such as integrins and leukaemia inhibitory factor, whose expression
normally coincides with the receptive state (Ghosh et al., 1998). We
have used endometrial explants treated with RU486 to identify genes
whose expression is likely to differ between receptive and non-
receptive endometrium. cDNA arrays and real time RT±PCR have
con®rmed that JNK1 and JAK1 are down-regulated in endometrium
by RU486 within 12 h. These molecules act in the signal transduction
pathways used by cytokines, growth factors and other physiological
stimuli to control cell function. These two signalling pathways,
together with the other genes we have identi®ed in this study, identify
new genes potentially involved in endometrial receptivity, and may
provide new targets for the development of novel contraceptive
agents.
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Abstract
Endometrial cancer is the most common gynecologic ma-
lignancy, frequently arising in association with obesity and
diabetes mellitus. To identify gene pathways contributing
to endometrial cancer development, we studied the trans-
criptome of 20 endometrial cancers and 11 benign endo-
metrial tissues using cDNA microarrays. Among the
transcript changes identified in endometrial cancer were
up-regulation of the nuclear hormone receptors peroxi-
some proliferator-activated receptors (PPAR) A and ;,
whereas retinoid X receptor B was down-regulated. To
clarify the contribution of PPARA to endometrial carcino-
genesis, we did experiments on cultured endometrial
carcinoma cells expressing this transcript. Treatment with
fenofibrate, an activating ligand for PPARA, significantly
reduced proliferation and increased cell death, suggesting
that altered expression of nuclear hormone receptors
involved with fatty acid metabolism leads to deregulated
cellular proliferation and apoptosis. These results support
further investigation of members of the PPAR/retinoid X
receptor pathway as novel therapeutic targets in endome-
trial cancer. [Mol Cancer Ther 2004;3(8):993–1001]
Introduction
Endometrial carcinoma is the most common gynecologic
malignancy and comprises 97% of all uterine cancers (1).
There is a peak incidence between ages 55 and 65 years, with
<5% of endometrial cancers occurring below age 40 years
(2). The majority are of an endometrioid histologic subtype
and display an association with obesity and diabetes
mellitus (2). There is a pressing need to better understand
the molecular basis for this disease, as 25% of women
present with extrauterine disease with 5-year survival rates
of f31% and 10% for Federation Internationale des
Gynaecologistes et Obstetristes stages 3 and 4 disease,
respectively (2). An improved understanding of events at
a molecular level is essential in the development of tar-
geted therapy, with a view to improving survival and cure
rates.
There are increasing efforts to gain a more global view of
the multiple, interrelated molecular changes that occur
during tumorigenesis (3–6). The gene microarray is a high-
throughput technology able to interrogate multiple genetic
changes within tissues and cells (7–9). Consequently, there
has been a marked increase in the use of microarrays to
interrogate cancers at the genomic level. In addition to
screening for candidate genes, microarrays may provide
molecular diagnoses, thus avoiding some of the weak-
nesses of conventional diagnostic techniques (4, 10).
Despite the increasing use of microarray technology in
cancer research, there have been difficulties obtaining
meaningful biological information. The cost of genome-
wide, commercially available arrays may prohibit large
experimental samples, and there are multiple sources of
variation in experimental results complicating data analysis
and interpretation (11). Large-scale gene expression anal-
yses of endometrial cancer have mostly been confined to
small sample sets and cell lines (12, 13) and have employed
genome-wide, commercially available microarray systems
(12). Previous microarray studies in endometrial cancer
have highlighted differences in the abundance of individ-
ual genes between benign and malignant tissues (12, 13),
although there has been little advance in the understanding
of pathway-specific alterations that may contribute to
endometrial tumorigenesis. Independent component anal-
ysis (ICA) is a sophisticated statistical method that aims to
identify patterns of coregulated genes rather than individ-
ual transcript changes (14). We previously have applied
high-density cDNA microarrays to determine gene tran-
script abundance in epithelial ovarian cancer (14).
Materials andMethods
Tumor Samples and RNAPreparation
Twenty frozen endometrial carcinoma tissues, three
atypical complex hyperplasias, and eight postmenopausal
benign endometrial control tissues (four atrophic and four
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benign polyps) were obtained from the Department of
Obstetrics and Gynecology, Addenbrooke’s Hospital
NHS Trust (Cambridge, United Kingdom) with ethical
approval. Samples were frozen immediately in liquid
nitrogen after surgery and stored at 70jC. Total RNA
was extracted from the frozen tissues using an acid-
guanidium thiocyanate-phenol-chloroform method (15).
Clinical information and histopathologic reports were
obtained for all frozen tissues.
Hybridization to cDNAMicroarrays
Tailored nylon microarrays comprising 1,056 cDNA
clones and including 37 expressed sequence tags were
used for transcriptome analysis. These were manufactured
in the Departments of Obstetrics and Gynecology and
Pathology, University of Cambridge (Cambridge, United
Kingdom) and designed for the study of endometrial
function and vascular biology (16) The entire gene list can
be seen at http://www.obgyn.cam.ac.uk/genearray. La-
beled cDNA was produced from total RNA preparations as
described previously (16). ULTRArray hybridization buffer
(Ambion, Austin, TX) was used, and hybridization was
carried out in 15  4 cm roller bottles as described
previously (16). Microarrays were subjected to high
stringency washes in SSC and SDS, dried at 60jC, and
exposed to low-energy storage phosphor screens (Molecu-
lar Dynamics, Sunnyvale, CA) for 64 hours. Arrays were
scanned at high resolution using a Storm 860 Phosphor-
Imager (Molecular Dynamics).
Data Analysis
Images were imported into Imagene 4.0 software (Bio-
discovery Inc., Marina del Ray, CA) for calculation of sig-
nal intensity. Total signal for each spot was squared to
correct for the square root transformation applied by the
scanning software (17). Data were processed using a
normalization algorithm method similar to that used in
the Web-based SNOMAD program (18). Normalized data
were analyzed by two complementary methods, the Web-
based Cyber-T and ICA. Cyber-T uses a Bayesian version of
the t test, which is suitable for the large-throughput
analysis required for microarray data (19). A Bayesian
P value < 0.05 was considered significant. ICA reduces the
data to a set of components that explain the data. Analysis of
those components that correlate closely with a factor(s) of
interest allows extraction of gene expression changes
contributing most strongly to that factor. The method of
ICA used is an ensemble learning method that allows
identification of components constituting the data while
at the same time providing an estimate of the inherent
‘‘noise’’ (20). The ICA model also allows refinement or
filtering of the data (20).
Quantitative, Real-time PCR (TaqMan)
Total RNA (2 Ag) was incubated with oligo(dT) primers
(1 Ag) at 68jC and reverse transcribed at 42jC using Super
Reverse Transcriptase (HT Biotechnology Ltd., Cambridge,
United Kingdom). Total RNA samples used were those
used in the microarray experiments described earlier.
cDNA (1 AL each) was amplified using PCR Master Mix
(Applied Biosystems, Warrington, United Kingdom). All
quantitative, real-time PCR experiments were done in the
ABI PRISM 7700 Sequence Detector (Applied Biosystems)
according to the manufacturer’s instructions and were
done in triplicate. The resultant data were averaged for
each sample. No-template controls were included in each
experiment. Specific oligonucleotide primers and probes
were used. These were designed for each of five genes
[cyclooxygenase-2 (COX-2), vascular endothelial growth
factor-B (VEGF-B), PPARa , PPARg , and retinoid X receptor
h (RXRh)] using Primer Express 1.5 software (Applied
Biosystems). Sequences are given below:
(a) COX-2
5V-TGATCCCCAGGGCTCAAA-3V (forward primer),
5V-ATCTGTCTTGAAAAACTGATGCGT-3V (reverse
primer),
5V-6FAM-TGATGTTTGCATTCTTTGCCCAGCACT-
TAMRA-3V (probe);
(b) VEGF-B
5V-AGCACCAAGTCCGGATG-3V (forward primer),
5V-GTCTGGCTTCACAGCACTG-3V (reverse primer),
5V-6FAM-AGATCCTCATGATCCGGTACCCGT-
TAMRA-3V (probe);
(c) PPARa
5V-GACGTGCTTCCTGCTTCATAGA-3V (forward
primer),
5V-CACCATCGCGACCAGATG-3V (reverse primer),
5V-6FAM-TGGAGCTCGGCGCACAACCA-TAMRA-
3V (probe);
(d) PPARg
5V-CAGAGCAAAGAGGTGGCCAT-3V (forward
primer),
5V-GCTTTTGGCATACTCTGTGATCTC-3V (reverse
primer),
5V-6FAM-CATCTTTCAGGGCTGCCAGTTTCGC-
TAMRA-3V (probe);
(e) RXRh
5V-CCATCCGCAAAGACCTTACATAC-3V (forward
primer),
5V-GTTCCGCTGGCGCTTG-3V (reverse primer),
5-6FAM-TGCCGGGACAACAAAGACTGCACA-
TAMRA-3V (probe).
Results for gene abundance in each sample were
normalized to abundance of an endogenous control gene.
18S rRNA was used as an endogenous control for all genes,
with the exception of VEGF-B for which h-actin was used.
Preliminary experiments to determine that each endoge-
nous control sequence was amplified at the same rate as the
target gene sequence identified that h-actin, but not 18S
rRNA, was a suitable endogenous control for VEGF-B.
Normalized log-transformed transcript levels were com-
pared across samples using one-way ANOVA and un-
paired Student’s t tests. Mean target gene abundance for
each tissue type was compared with the data obtained from
microarray experiments.
PPARa Is a Molecular Target in Endometrial Cancer994
Mol Cancer Ther 2004;3(8). August 2004
Immunohistochemistry
Immunohistochemistry for PPARa protein was done on
6 Amol/L formalin-fixed, paraffin-embedded endometrial
tissue sections identified from histopathologic archives.
Six endometrioid cancers and four samples of benign
endometrium were examined. Sections were dewaxed in
xylene and rehydrated in graduated alcohols and anti-
gens were retrieved with 0.1% trypsin for 15 minutes at
37jC. Nonspecific immunostaining was blocked with
normal goat serum and sections were incubated with
4 Ag/mL rabbit polyclonal anti-PPARa antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4jC.
Rabbit IgG (4 Ag/mL) provided a negative control. A
biotinylated goat anti-rabbit secondary antibody (1:100
dilution) was used for 30 minutes at room temperature.
Detection of the antibody reaction was carried out with
the Vectastain Elite ABC reagent (Vector Laboratories,
Burlingame, CA) combined with 3,3-diaminobenzidine
color development (Sigma Chemical Co., MI). Endoge-
nous peroxidases were blocked with 0.3% hydrogen
peroxide in methanol. Results were analyzed using the
two-tailed Fisher’s exact probability test. Statistical
significance was accepted as P < 0.05.
Cell CultureAssays
Ishikawa cells in the logarithmic growth phase were
cultured in DMEM (Sigma Chemical) supplemented with
glucose, L-glutamine, and FCS in 96-well plates. Cells were
cultured for 24 hours at 37jC and 5% CO2 with varying
doses of the PPARa agonist fenofibrate (Sigma-Aldrich Co.
Ltd., Dorset, United Kingdom) dissolved in DMSO (Sigma-
Aldrich). Control cells were treated with vehicle only. A
minimum of five replicates was done at each dose. Total
RNA was extracted from untreated Ishikawa cells, and
quantitative, real-time PCR was done for PPARa (as
above). In addition, cell proliferation in fenofibrate-treated
and DMSO-treated cells was assessed by the uptake of
5-bromo-2V-deoxyuridine (BrdUrd) using the BrdUrd La-
beling and Detection Kit III (Roche Diagnostic, East Sussex,
United Kingdom) according to the manufacturer’s instruc-
tions. Absorbance values for each well were measured on
a microtiter plate reader (Anthos Labtech Instruments,
Salzburg, Austria).
Apoptosis was measured using two different methods.
Cells were grown in 96-well plates as above. At 24 hours,
the medium was replaced with fresh complete culture
medium and fenofibrate (10–100 Amol/L). Six replicates
were done for each drug dose, and control cells were
treated with vehicle (DMSO) only. Apoptosis was quan-
tified using the APOPercentage Apoptosis Assay dye
(Biocolor Ltd., Northern Ireland, United Kingdom) ac-
cording to the manufacturer’s instructions. Dye absorb-
ance values were measured as above. In a second assay,
the medium was exchanged after 24 hours for fresh me-
dium containing 75 Amol/L fenofibrate or DMSO only.
After further incubation at 37jC for 1 hour, cells were
fixed and stained with Hoechst bisbenzamide HB 3258
(Calbiochem, La Jolla, CA) and viewed by fluorescent mi-
croscopy. Seven separate optical fields were counted for
each well, and both total numbers of cells and number of
apoptotic cells were counted. An apoptotic index was cal-
culated using the following formula: apoptotic index =
[(number of apoptotic cells) / (total cell count)]  100.
Data were analyzed using the InStat 2.1 statistical
program. For the BrdUrd and APOPercentage assays,
differences between median values across multiple treat-
ment groups were analyzed using the Kruskal-Wallis
nonparametric ANOVA method. Comparison between
median values from each treatment group and negative
control group was made using the Mann-Whitney U test.
Ratio data arising from the Hoechst nuclear staining assay
were log transformed and analyzed by Student’s t test.
Statistical significance was accepted at P < 0.05 throughout.
Reporter Studies
Ishikawa cells cultured in six-well plates were transfected
with 3 Ag luciferase reporter plasmid using 4 Ag Lipofect-
AMINE 2000 (Invitrogen, Paisley, United Kingdom). The
reporter plasmid comprised a triple repeat of the peroxi-
some proliferator response element in direct orientation
with a basal TK-luc reporter construct (21). Cells were
grown and treated, before confluence was reached, with
varying doses of fenofibrate and the specific PPARa anta-
gonist GW496471. At 24 hours, cells were harvested and
luciferase activity was measured using the Ascent Fluo-
roscan luminometer. Normalization was done against total
protein using the BCA protein assay (catalogue no. 23227,
Pierce Chemical Co. Rockford, IL). A control plasmid, pRL-
CMV (catalogue no. E2261, Promega, Southampton, United
Kingdom), was initially used as a transfection control but
was found to respond to PPAR agonists and subsequently
noted to contain a putative peroxisome proliferator re-
sponse element within the cytomegalovirus promoter re-
gion (data not shown). The reporter plasmid and
PPARa antagonist were kind donations from Dr. E.
Shoenmakers and Prof. K. Chatterjee (Cambridge Institute
for Medical Research, Cambridge, United Kingdom).
Results
Gene Microarrays Identify Differentially Expressed
Transcripts in Endometrial Carcinoma
Transcript abundance, measured by mean signal inten-
sity, was compared between benign and malignant tissues.
The expression of 204 genes was altered in the cancers
compared with the benign endometrium (P < 0.05) when
the data were analyzed using Cyber-T. Of these 204 genes,
182 were up-regulated and 22 were down-regulated in the
cancers compared with benign endometrium. The genes
that were identified by the Cyber-T analysis were assigned
to functional categories (Table 1). The ‘‘housekeeping
genes’’ included on the arrays (e.g., actin and glyceraldehyde
3-phosphate dehydrogenase) were not significantly altered
between the different tissue classes. Among the changes
seen were significant alterations in angiogenesis-related
genes. The VEGF-A splice variant (VEGF189) and angio-
poietin-2 were up-regulated by 5.7- and 4.9-fold, respec-
tively (P < 0.05). In addition, the VEGF-C and VEGF-D
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receptor tyrosine kinase, Fms-related tyrosine kinase 4
(VEGF receptor-3), was 5.4-fold more abundant in the
endometrial cancers compared with benign postmenopaus-
al endometrium. In contrast, the VEGF-related growth
factor, VEGF-B and platelet-derived growth factor recep-
tor h, were almost 2-fold down-regulated in the cancers
(P < 0.001).
Only one independent component (the ‘‘cancer’’ compo-
nent), resulting from ICA, showed statistical significance
using the Mann-Whitney U test (P < 0.001) and was
subjected to further analysis. Data for the 5% of genes
contributing most highly to this component are represented
in Fig. 1. Genes concerned with lipid metabolism were
found to be significantly overrepresented in the ICA
analysis (20). Of these, novel changes were identified in
members of the nuclear hormone receptor superfamily.
Genes encoding both PPARa (P < 0.05) and PPARg (P <
0.05) were significantly up-regulated in the cancers
compared with benign endometrium (4.3- and 6.1-fold,
respectively). Conversely, the gene encoding a heterodime-
rization partner for these two nuclear receptors, RXRh , was
down-regulated 1.4-fold (P < 0.01).
Five genes were chosen to confirm the microarray results
using quantitative, real-time PCR. Four of these genes are
Table 1. Selected examples of differentially expressed genes in endometrial carcinoma
Genbank Accession No. Gene Name P* Fold Change in Tumorsc
Transcription factors and nuclear receptors
U32849 N-myc (STAT) interactor (NMI) 0.006 8.2
L40904 PPARg 0.039 6.1
U22431 Hypoxia-inducible factor 1a (HIF1a) 0.004 5.4
X06562 Growth hormone receptor (GHR) 0.030 5.1
Y07619 PPARa 0.026 4.3
V00568 v-myc myelocytomatosis viral oncogene homologue (MYC) 0.048 2.8
X07282 Retinoic acid receptor h (RARh) 0.028 4.3
M84820 RXRh 0.001 1.4
Cell cycle and growth regulators
X76132 Deleted in colorectal carcinoma (DCC) 0.018 6.2
M74091 Cyclin C 0.009 4.5
X05908 Annexin A1 (ANXA1) 0.012 4.8
L27560 Insulin-like growth factor binding protein 5 (IGFBP5) 0.025 2.2
Angiogenic factors, receptors, and mediators
AB012911 VEGF189 0.013 5.7
AB009865 Angiopoetin-2 (ANGPT2) 0.020 4.9
U43143 Fms-related tyrosine kinase 4 (FLT4) 0.033 5.4
U48801 VEGF-B 1.48e05 1.9
Cell adhesion, recognition, and cytoskeleton
Z13009 E-cadherin 0.014 4.2
J03209 Matrix metalloproteinase-3 (MMP-3) 0.015 4.4
M14083 Plasminogen activator inhibitor type 1 (PAI-1) 0.046 2.2
M13509 Matrix metalloproteinase 1 (interstitial collagenase; MMP-1) 0.025 3.9
Growth factors, cytokines, hormones, and receptors
J02958 HGF receptor (MET) 0.009 3.0
M31172 Transforming growth factor-a (TGFa) 0.045 4.8
X06374 Platelet-derived growth factor receptor a (PDGFa) 0.045 4.5
X00588 Epidermal growth factor receptor (c-erbB; EGFR) 0.026 5.1
X04434 Insulin-like growth factor receptor 1 (IGFR1) 0.001 1.9
Intracellular signaling
X95282 Ras homologue gene family, member E (RhoE) 0.028 4.6
AB012911 Frizzled homologue 6 (Drosophila) (FZD6) 0.011 3.4
Enzymes/cellular metabolism
U04636 COX-2, prostaglandin-endoperoxide synthase 2 0.038 5.6
M14777 Glutathione S-transferase A1 (GSTA1) 0.014 4.2
M61900 Prostaglandin D2 synthase (PTGDS) 2.45e05 2.1
NOTE: Selected examples of genes found to be differentially regulated in endometrial cancer. Microarray data from 20 endometrial cancers (17 endometrioid type and 3 papillary
serous type) and 11 benign endometria were compared using Cyber-T. Fold change in the cancers compared with the benign tissues is shown with a minus sign indicating
down-regulation. The P value for each transcript change is indicated. The genes are listed in potential functional categories with Genbank accession numbers.
*Tumor versus normal as assessed by Cyber-T.
cFold changes <1.5 not included.
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components of the prostaglandin and fatty acid path-
ways (COX-2, PPARa , PPARg , and RXRh), whereas the
fifth gene, VEGF-B , is an angiogenic growth factor. In addi-
tion to their biological interest, these genes were chosen
based on their significant Bayesian P value (using Cyber-T)
and high loading value within the ICA ‘‘cancer’’ component.
The mean relative expression of these genes in cancers
compared with benign tissues was calculated from normal-
ized transcript abundance levels from real-time PCR and
compared with the mean ratio of expression levels in cancer
obtained from microarray experiments (Fig. 1B). Data from
microarray experiments analyzed using Cyber-T indicated
that transcripts for COX-2 (P < 0.01), PPARa (P < 0.01), and
PPARg (P < 0.05) were significantly up-regulated in the
endometrial cancers examined compared with the benign
endometrial samples (Table 1). Conversely, transcripts for
VEGF-B (P < 0.01) and RXRh (P < 0.01) were significantly
down-regulated in the cancers compared with the benign
tissues (Table 1). The up-regulation of COX-2, PPARa, and
PPARg and down-regulation of VEGF-B and RXRh were
confirmed using quantitative PCR (Fig. 1B). The direction
and magnitude of fold changes was similar (Fig. 1B).
PPARAProtein Is Localized to EndometrialCarcinoma
Cells but not to Stromal Cells
Paraffin-embedded tissue sections were used to con-
firm the expression of PPARa protein in endometrial can-
cers compared with benign (atrophic) endometrium. These
specimens were unrelated to those used in the micro-
array experiments, thus providing independent confirma-
tion. Specific immunostaining for PPARa protein was
seen in five of six sections of endometrial cancer (Fig. 2)
but in zero of four of the benign endometrial sections
(P < 0.05). Negative controls did not show specific
immunostaining (Fig. 2A). Immunostaining for PPAR
protein was localized to the epithelial tumor cells and
was cytoplasmic rather than nuclear (Fig. 2C). The intensity
of staining was heterogeneous with some tumor cells
demonstrating intense staining, whereas staining was
weaker in others (Fig. 2B).
PPARa Agonists Inhibit the Growth of Endometrial
Cancer Cells
Ishikawa cells were shown to have levels of PPARa
mRNA comparable with those seen in the cancer samples
(Fig. 3). These were cultured with the PPARa agonist
Figure 1. Molecular profiles of all 31 specimens. A, data
filtered using ICA show separation of benign and malignant
endometria. The transcripts are those identified by this method as
demonstrating differential expression between benign and malig-
nant endometria. Two-way hierarchical clustering is applied by
experiments and genes, with subsequent ordering of the data to
the clusters. B1-11, benign samples; M1-20, malignant samples.
Data are signal increase (red ) or decrease (green ) from the control
log mean. Signal changes >2 SDs show the brightest coloration
(see color scale). B, microarray and quantitative PCR expression
analysis of five genes differentially expressed between benign and
malignant endometria.
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fenofibrate and showed a decrease in DNA synthesis in a
dose-dependent manner after 24 hours of incubation
(Fig. 4A). The difference in BrdUrd incorporation across
the range of drug doses used was highly statistically
significant (P < 0.001) when analyzed using the Kruskal-
Wallis nonparametric ANOVA. Low doses of fenofibrate
had no significant effect on DNA synthesis (Fig. 4A).
However, a reduction in BrdUrd uptake (as measured by
dye absorbance) was seen at doses of 50 Amol/L (P = 0.01,
95% confidence interval 0.20–0.26) and 75 Amol/L (P = 0.01,
95% confidence interval 0.20–0.26).
Cells were treated with fenofibrate for 1 hour at 37jC,
and uptake of a labeling dye for fragmented DNA was
measured in a microplate reader after lysing the cells. There
was a significant and dose-dependent increase of cells
undergoing apoptosis among those treated with fenofibrate
compared with cells treated with vehicle (DMSO) alone
(P < 0.0001; Fig. 4B). This effect was maximal at 75 Amol/L
fenofibrate. In the second assay, cells were treated with
either 75 Amol/L fenofibrate or vehicle only. Nuclear
fragmentation and apoptotic bodies were frequently seen
in the treated cells but infrequently seen in the control cells
(Fig. 5A and B). However, mitotic figures were seen in
control cells consistent with increased proliferation. The
apoptotic index was f5 fold higher in treated compared
with untreated cells (P < 0.05; Fig. 5C), confirming the
results obtained from the BrdUrd proliferation assay.
Using a peroxisome proliferator response element con-
taining a luciferase reporter construct, we showed func-
tional activity of endogenous PPARa in Ishikawa cells.
Transfected cells treated with fenofibrate showed a
significant increase in luciferase activity compared with
untreated control cells (Fig. 4C). However, addition of the
highly specific PPARa antagonist GW496471 (3 Amol/L)
significantly reduced the increased luciferase activity
induced by equimolar fenofibrate.
Discussion
The use of ICA complemented Cyber-T analysis, enabling
the identification of transcript patterns differentiating
benign from malignant endometrium (20). Within these
patterns, we showed up-regulation of two ligand-activated
Figure 3. Ishikawa cells express PPARa mRNA. Quantitative PCR for
PPARa was done on RNA extracted from Ishikawa cells and compared
with mean transcript abundance in benign (n = 8) and malignant (n = 17)
endometria. Columns, mean PPARa transcript abundance relative to levels
of 18S rRNA; bars, SE. All experiments were done in triplicate.
Figure 2. PPARa protein is localized to the cytoplasm of endometrial
carcinoma cells. Paraffin-embedded sections of benign endometrium and
endometrial cancer were subjected to immunohistochemistry for PPARa.
A biotinylated secondary antibody was used for detection. A, a Federation
Internationale des Gynaecologistes et Obstetristes grade 2 endometrial
carcinoma incubated with IgG (negative control) showing no specific
immunostaining (magnification 100). B, a Federation Internationale des
Gynaecologistes et Obstetristes grade 2 endometrioid endometrial
adenocarcinoma showing positive heterogeneous immunostaining for
PPARa (magnification 100). C, a Federation Internationale des Gynae-
cologistes et Obstetristes grade 2 endometrioid endometrial adenocarci-
noma at high power showing cytoplasmic epithelial tumor cell staining but
no staining of stromal cells (magnification 400).
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transcription factors belonging to the nuclear hormone
receptor superfamily, PPARa and PPARg. These receptors
form heterodimeric complexes with RXRh that bind to
specific response elements within the promoter region of
target genes (22). We have further shown that RXRh is
significantly down-regulated in endometrial cancer.
The PPARs exist as three isoforms, PPARa, PPARh/y, and
PPARg. Genes induced by PPARa are primarily concerned
with h-oxidation in normal cells (22), whereas PPARg
regulates adipocyte differentiation and macrophage func-
tion and is linked with glucose homeostasis (23). PPARh/y
shows widespread tissue expression and is particularly
abundant during development (24), although its functions
are not fully known. Endogenous ligands for PPARh are
Figure 4. The PPARa agonist fenofibrate reduces proliferation and
increases apoptosis in Ishikawa cells. A, PPARa-expressing Ishikawa cells
in culture were treated with the PPARa agonist fenofibrate. After 24
hours, proliferation was assessed by BrdUrd uptake. Increasing doses of
fenofibrate led to reduced proliferation compared with vehicle only. B,
cultured Ishikawa cells were treated for 1 hour with fenofibrate, and
uptake of dye into apoptotic cells was measured by dye absorbance.
Apoptosis was increased in a dose-dependent manner by the addition of
fenofibrate. C, in a reporter assay, cells were treated with DMSO or
fenofibrate and 9-cis -retinoic acid (3 Amol/L) F the PPARa antagonist
GW496471 (3 Amol/L). Columns, luciferase activity (relative light units)
relative to that seen in DMSO-treated cells in duplicate assays across two
independent experiments; bars, SE.
Figure 5. The PPARa agonist fenofibrate is proapoptotic for endome-
trial cancer cells. Cultured Ishikawa cells were treated with fenofibrate
(75 Amol/L) or vehicle only for 1 hour, and apoptotic cells were counted
after nuclear staining with Hoechst bisbenzamide. A, control cells show
mitotic figures and few apoptotic cells. B, treated cells display nuclear
fragmentation and apoptotic bodies (arrows ). C, apoptosis is markedly
increased in the presence of fenofibrate. Columns, mean of three
replicates; bars, SD.
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prostaglandins and leukotrienes. In addition to these, lig-
ands for PPARa include fatty acids (25). Ligands for the
PPARs also regulate COX-2, which is critically involved in
lipid metabolism, inflammation, and tumor promotion (26).
Our findings suggest involvement of the lipid metabolic
and prostaglandin pathways in endometrial cancer devel-
opment. The prostaglandin pathway has been implicated
previously in carcinogenesis, with overexpression of COX-2
being described in several cancers including endometrium
(27, 28), malignant mesothelioma (29), cervix (30), breast
(31), and colon (32–34). In addition, there is epidemiologic
evidence of a protective effect of nonsteroidal anti-
inflammatory drugs against colon cancer (35). In the colon
cancer model, it is suggested that prostanoids may promote
tumor development via the PPAR receptors, although the
data are not conclusive (36).
PPARa is highly expressed in the cancer cells of other
malignancies [e.g., prostate (37) and bladder (38)]. Local-
ization of PPARa protein to malignant endometrial cells
suggests that up-regulation of the PPARa gene is also
significant in endometrial carcinoma. Whereas PPARh/y
is up-regulated in some endometrial cancers (27), neither
PPARa nor PPARg have been implicated previously in the
development of this disease.
Although PPARa is up-regulated in endometrial carci-
noma, proliferation was reduced by the addition of a
PPARa-activating ligand. Conversely, apoptosis was mark-
edly increased by a PPARa-activating ligand. We con-
firmed in reporter assays that addition of the same PPARa
agonist was associated with an increase in PPARa activity.
Therefore, increased apoptosis and reduction in DNA
synthesis with fenofibrate administration are associated
with an increase in PPARa activity. The downstream
effectors that mediate these changes have not been
identified. However, potential mechanisms include the
generation of reactive oxygen species as a by-product of
h-oxidation of fatty acids. PPARa regulates key enzymes
within this metabolic pathway (25). We conclude therefore
that aberrant function of the PPARa/RXR pathway occurs
in endometrial carcinogenesis. Furthermore, we suggest
that this pathway could potentially be targeted for
therapeutic benefit. The underlying mechanism for the
paradoxical effect of the PPARa agonist on cell growth is
uncertain and warrants further investigation.
Endometrioid endometrial cancer is associated with
obesity and metabolic abnormalities characterized by
insulin resistance (2). Epidemiologic data suggest an
association of dietary fat with increased endometrial cancer
risk that may be independent of the association between
increased fat intake and obesity (39). Earlier studies also
revealed higher levels of sex hormone binding globulin in
women eating a vegetarian diet (40), which could reduce
the levels of free circulating estrogens. This raises the
intriguing possibility of a link between fatty acid metabo-
lism and the action of estrogens in endometrial cancer.
There has been significant interest in the role of PPARs in
metabolic disorders, although data on PPARs and lipid
metabolism in endometrial cancer are scant. The data
presented here suggest lipid metabolism and PPAR and
RXR receptors as subjects for further study in endometrial
cancer. PPARa activators are currently used for the
treatment of hyperlipidemic disorders. The beneficial
effects of a PPARa activator on the growth of endometrial
cancer cells indicate that these drugs warrant further
investigation as novel therapeutic options for the manage-
ment of endometrial malignancy.
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Abstract
We recently published a review in this journal describing the design, hybridisation and basic data processing required to use
gene arrays to investigate vascular biology (Evans et al. Angiogenesis 2003; 6: 93–104). Here, we build on this review by
describing a set of powerful and robust methods for the analysis and interpretation of gene array data derived from primary
vascular cell cultures. First, we describe the evaluation of transcriptome heterogeneity between primary cultures derived
from different individuals, and estimation of the false discovery rate introduced by this heterogeneity and by experimental
noise. Then, we discuss the appropriate use of Bayesian t-tests, clustering and independent component analysis to mine the
data. We illustrate these principles by analysis of a previously unpublished set of gene array data in which human umbilical
vein endothelial cells (HUVEC) cultured in either rich or low-serum media were exposed to vascular endothelial growth
factor (VEGF)-A165 or placental growth factor (PlGF)-1131. We have used Aymetrix U95A gene arrays to map the eects of
these factors on the HUVEC transcriptome. These experiments followed a paired design and were biologically replicated
three times. In addition, one experiment was repeated using serial analysis of gene expression (SAGE). In contrast to some
previous studies, we found that VEGF-A and PlGF consistently regulated only small, non-overlapping and culture media-
dependant sets of HUVEC transcripts, despite causing signiﬁcant cell biological changes.
Abbreviations: ANOVA – analysis of variance; EC – endothelial cell(s); GEO – gene expression omnibus; HUVEC –
human umbilical vein EC; ICA – independent component analysis; PlGF – placental growth factor; SAGE – serial analysis
of gene expression; SAM – signiﬁcance analysis of microarrays; VEGF – vascular endothelial growth factor
Introduction
The use of gene arrays has provided valuable information
about the networks of molecular signals that regulate the
biology and pathology of blood vessel walls. However, these
studies often require the use of primary cultures of vessel
wall cells derived from multiple individuals, with the
associated problems of transcriptome heterogeneity and the
idiosyncratic transcriptome response of each individual
culture to treatment. Due to these problems, unless analysis
is performed carefully, it is easy to be mislead by seemingly
statistically ‘signiﬁcant’ results that later cannot be repeated.
While previous papers have addressed general issues in gene
array design and data analysis [1, 2] none have addressed the
speciﬁc issues that face investigators, such as vascular
biologists, who need to use primary cell cultures. These
issues include: (i) the need for biological replication using
multiple cell cultures derived from different individuals; (ii)
the need to evaluate transcriptome and phenotypic hetero-
geneity between the primary cultures used (iii) the need to
judge gene array results against an estimate of the false
discovery rate introduced by this heterogeneity and by
experimental noise; and (iv) the correct use of techniques
such as Bayesian t-tests, clustering and independent compo-
nent analysis to extract meaningful data from biologically
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replicated experiments. In this article, we attempt to illustrate
these issues by taking the reader through the analysis of a
previously unpublished set of Affymetrix gene array data.
The background to this study and its design are described
below.
Vascular endothelial growth factor (VEGF)-A is an EC
growth and survival factor. It inhibits EC apoptosis and
promotes proliferation in vitro, and it regulates vasculogen-
esis, angiogenesis, vascular remodeling and vascular per-
meability in vivo. The inactivation of a single copy of the
mouse VEGF-A gene causes embryonic lethality [3, 4].
Therapy designed to alter the activity of the VEGF-A
system is now used to treat several diseases including cancer
[5, 6], coronary artery disease [7] and peripheral vascular
disease [8]. VEGF-A activates intricate signaling networks
in EC by binding to VEGFR-2 (Flk-1/KDR) and VEGFR-1
(Flt-1). VEGF-A signaling appears to be complex, since
there is cross-talk [9] and heterodimerization [10] between
VEGFR-1 and VEGFR-2. Placenta growth factor (PlGF) is
a relative of VEGF-A that signals through VEGFR1 but not
through VEGFR2 [11]. PlGF promotes angiogenesis and
modulates VEGF-A signaling [10]. However, PlGF knock-
out mice, unlike VEGF-A knock-out mice, survive with
only a minor vascular phenotype that becomes more
apparent under pathological conditions [9]. Several previous
gene array studies have identiﬁed EC transcripts regulated
by VEGF-A [12–18], receptor-speciﬁc VEGF-A mutants
[10, 16] and PlGF [10]. These studies have each identiﬁed
lists of VEGF- or PlGF-regulated transcripts. However,
these lists only marginally overlap with one another. This
lack of concordance presents difﬁculties – for example, it is
not easy to hypothesise from these disparate results a set of
candidate VEGF-regulated transcripts that warrant further
biological and clinical investigation. The lack of concor-
dance between these previous studies may in part reﬂect the
different EC types and culture conditions used. However,
the lack of concordance may also in some cases reﬂect
inaccurate data generated by sub-optimal experimental
design and analysis, since some of these studies used an
unpaired design and contained very small numbers of
biological replicates.
To illustrate robust methods for the analysis of gene array
data from primary cell cultures, and to determine as
deﬁnitively as possible whether VEGF-A and PlGF regulate
large sets of transcripts in HUVEC, we have performed a
three-fold biologically replicated paired-design Affymetrix
gene array analysis of the effects of VEGF-A165 and PlGF-
1131 on the transcriptome of human umbilical vein EC
(HUVEC) cultured in either rich or low-serum media. We
repeated one experiment in this study using a small-scale
serial analysis of gene expression (SAGE), and conﬁrmed a
subset of our data using quantitative PCR. Our results
showed that VEGF-A and PlGF consistently regulated only
small, non-overlapping, and culture media-dependant sets of
HUVEC transcripts, despite causing signiﬁcant cell biolog-
ical changes. This set of gene array data, in which only a
few transcripts appear to be authentically regulated, is ideal
to illustrate methods for analysing gene arrays derived
from primary cells, and to illustrate the critical impor-
tance of biological replication and false discovery rate
estimation.
Materials and methods
Cell culture and RNA collection
HUVEC were isolated from umbilical cords by collagenase
digestion as described [19] and cultured to passage 5 using a
rich medium which contained a proprietary mixture of
heparin, hydrocortisone, epidermal growth factor, ﬁbroblast
growth factor and 2% foetal calf serum (large vessel EC
medium; TCS, Buckingham, UK). In some cultures HU-
VEC were partially deprived of serum and growth factors
using a low serum medium (basal EC medium {TCS}
supplemented by 2% charcoal-stripped FCS only; Gibco/
BRL, Maryland). Cells were cultured in these media in the
presence or absence of 10 ng/ml human VEGF-A165 or
10 ng/ml carrier-free human PlGF-1131 (R&D Systems,
Abingdon, UK). The collection of umbilical cords for
HUVEC isolation was approved by the local ethical
committee, and maternal consent was obtained in every
case.
Assessment of cell biology
Total and apoptotic adherent HUVEC were enumerated in
eight replicate wells in 48-well plates using an inverted
epiﬂuorescent relief-phase contrast microscope (Olympus
OM40, marker; London, UK). Apoptotic cells were deﬁned
as those which excluded trypan blue (0.2%; Sigma,
Gillingham, UK) and propidium iodine (20 lg/ml; Sigma),
but which labeled with AnnexinV (Annexin V-Fluos
staining kit used according to the manufacturer’s instruc-
tions; Roche, UK) and also showed morphological charac-
teristics of apoptosis (loss of adherence to substrate,
shrinkage, membrane blebbing and nuclear condensation).
In addition, relative viable cell numbers were estimated
using a tetrazolium compound (MTS) assay (CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay; Pro-
mega, Southampton, UK) used according to manufacturer’s
instructions.
Gene arrays
Total RNA was prepared using Trizol (Gibco/BRL)
according to the manufacturer’s instructions followed by
passage through an RNeasy column (Qiagen, Crawley,
UK). Biotin-labeled cRNA complex probes were prepared
and hybridized to Affymetrix Human U95A gene-chips
according to Affymetrix protocols (Affymetrix, London,
UK). The quality of the expression data from the chips
was assessed using Affymetrix Microarray Suite (version
5.0) and dChip software. Data from chips that failed these
quality control tests was discarded. Transcript abundance
data from all chips were globally and locally scaled [20]
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using the ‘Loess’ function of the ’R’ programming
environment (http://rweb.stat.umn.edu/R/doc/html/in-
dex.html). Expression proﬁles were then compared using
the CyberT algorithm (version 8.0; sliding win-
dow ¼ 301; Bayes conﬁdence estimate ¼ 5 [21]). To
assess false discovery rates Signiﬁcance Analysis of
Microarrays (SAM) software was used [22]. Independent
component analysis was performed as described [23] using
Matlab software. Mixed effects ANOVA analysis and
clustering (by Ward’s method to minimise the sum of
squares using the ‘Agnes’ algorithm) was performed using
the ’R’ programming environment. Further graphical
analysis was performed using GeneSpring Expression
Analysis Software (Silicon Genetics, Redwood City,
California). All data has been deposited in the NCBI
Gene Expression Omnibus (GEO accession numbers
GSM12894-GSM12926 as detailed in Table 2; http://
www.ncbi.nlm.nih.gov/geo/).
Small-scale serial analysis of gene expression (SAGE)
analysis
HUVEC were cultured as above under partial serum
deprivation conditions with and without 10 ng/ml VEGF
for 4 h. SAGE libraries were generated from 5 lg polyA
+ RNA following the SAGE protocol previously
described [24]. Brieﬂy, biotinylated Dynal bead-captured
cDNAs were ligated to linkers that contained a recog-
nition site for the tagging enzyme BsmF1 (NEB). SAGE
tags were then released with BsmF1, blunt ended, and
ligated head to head to form ditags. Ditags were released
from linkers by Nla III digestion, concatenated and
cloned into de-phosphorylated Sph I cut pGEM-3Zf+
(Promega Life Sciences), sequenced using the Applied
Biosystems Prism Dye Terminator reaction kit and run
on an ABI 373 automated sequencer (Applied Biosys-
tems, Foster City, California). A total of 6698 di-tags
were sequenced from untreated control cells and 5380
from VEGF-treated cells.
Quantitative PCR
The ABI PRISM 7700 Sequence Detection System (Taq-
Man) was used to perform real-time polymerase chain
reactions according to the manufacturer’s protocols. For all
RNAs used in the Affymetrix study, the Ct values for each
transcript were compared to those for cyclophilin A, which
according to Affymetrix results remained relatively constant
in abundance following serum deprivation and growth
factor treatment. Primers and probe sets used to conﬁrm
transcripts regulated by VEGF-A were:
Tubby:
FORWARD 5¢-CCCCCCAGGGTATCACCA-3¢
REVERSE 5¢-CCCCGGTCCATCCCTTT-3¢
PROBE FAM-5¢-AAATGCCGCATCACTCGGGA-
CAAT-3¢-TAMRA;
PTP-1B:
FORWARD 5¢-TGATCCAGACACAGCCGACCA-3¢
REVERSE 5¢-CCCATGATGAATTTGGCACC-3’
PROBE FAM-5¢-AAATGCCGCATCACTCGGGA-
CAAT-3¢-TAMRA;
RGS-3:
FORWARD 5¢-GGCTGCTTCGACCTGGC-3¢
REVERSE 5¢-AAGCGAGGGTACGAGTCCTTT-3¢
PROBE FAM-5¢-AGAAGCGCATCTTCGGGCTCA
TGGT-3¢-TAMRA;
CD34:
FORWARD 5¢-CTGGATCAAAGTAGGCAGGAC C-3¢
REVERSE 5¢-TTTTTCGGAAGAGTACAGGTGA-
GA-3¢
PROBE FAM-5¢-TGGGACCAGGTCTTGGAGCT-
GAGC-3¢-TAMRA;
Thrombomodulin:
FORWARD 5¢-CAGAGAGGCCTTTTGGAATGTG-3¢
REVERSE 5¢-TTCTAACCAGCTCCCATGGG-3¢
PROBE FAM-5¢-CCCTGAACAAGAA-
TTGGAAGC TGCCC-3¢-TAMRA
Primers and probes used to conﬁrm the PlGF-regulated
transcripts Musashi (Probe Set 31396_r_at) and Ephrin A2
(Probe Set 33090_at) were proprietary oligonucleotides
obtained from Applied Biosystems ‘Assays-on-Demand’
and used a 5¢ FAM reporter and 3¢ non-ﬂuorescent minor
groove binder (MGB).
Results
The HUVEC transcriptome
To allow interpretation of the effects of VEGF-A and PlGF on
the HUVEC transcriptome, we ﬁrst determined the consensus
transcriptome of untreated HUVEC cultures. To do this, RNA
was extracted from passage ﬁve HUVEC cultures that were
originally isolated from six different individuals and used to
prepare complex cRNA probes, which were hybridized to
12,600-element (8900 unique transcript) Affymetrix gene
arrays (U95A). The raw gene array data was normalized as
described in the methods and in our previous review [20]. The
most abundant 0.5% of HUVEC transcripts were clustered by
function and are listed in Table 1.
We then assessed the heterogeneity of transcript abun-
dance proﬁles in HUVEC cultures derived from the six
different individuals, using simple arithmetic in Microsoft
Excel. Substantial heterogeneity was found – between 25
and 30% of the 12,600 transcripts interrogated by the arrays
differed in abundance between any 2 individuals by more
than 36%, and between 2.6 and 4.7% of the 12,600
transcripts differed in abundance between any two individ-
uals by more than 75%. To statistically quantify this
heterogeneity we used analysis of variance (ANOVA) which
conﬁrmed that the overall transcriptomes of HUVEC from
the different individuals varied signiﬁcantly (F ¼ 3.4;
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Table 1. The 0.5% most abundant endothelial transcripts. Signal refers to normalized transcript abundance. Probe set denotes the Affymetrix probe set
corresponding to each transcript.
Transcript Signal Probe set
G-PROTEIN SIGNALLING
G-PROTEIN ALPHA SUBUNIT S 85.8 37449_i_at
RACK1 122.6 34608_at
CARBOHYDRATE METABOLISM
ALDOLASE A 91.8 32336_at
PHOSPHOGLYCERATE MUTASE 1 87.2 41221_at
GAPDH 138.3 M33197_3_at
CYTOSKELETON
BETA-TUBULIN 107.4 151_s_at
THYMOSIN BETA-4 119.7 31557_at
MYOSIN LIGHT CHAIN 87.8 33994_g_at
VIMENTIN 132.4 34091_s_at
GAMMA ACTIN 1 117.5 34160_at
BETA-ACTIN 164.6 X00351_M_at
RIBOSOMAL PROTEINS
RIBOSOMAL PROTEIN S3A 83.8 1653_at
RIBOSOMAL PROTEIN L10 118.8 2016_s_at
RIBOSOMAL PROTEIN S19 93.5 31330_at
RIBOSOMAL PROTEIN L28 100.9 31385_at
RIBOSOMAL PROTEIN L8 99.9 31505_at
RIBOSOMAL PROTEIN S2 125.2 31527_at
RIBOSOMAL PROTEIN S18 97.3 31545_at
RIBOSOMAL PROTEIN S10 83.6 31568_at
RIBOSOMAL PROTEIN L3 93.6 31722_at
RIBOSOMAL PHOSPHOPROTEIN P1 90.3 31956_f_at
RIBOSOMAL PHOSPHOPROTEIN P1 111.1 31957_r_at
RIBOSOMAL PROTEIN L37A 125.8 31962_at
RIBOSOMAL PROTEIN L32 81.7 32276_at
RIBOSOMAL PROTEIN S11 87.7 32330_at
RIBOSOMAL PROTEIN S14 93.4 32412_at
RIBOSOMAL PROTEIN S5 87.2 32437_at
RIBOSOMAL PROTEIN S20 121.4 32438_at
RIBOSOMAL PROTEIN L41 121.9 32466_at
RIBOSOMAL PROTEIN S21 84.6 32744_at
RIBOSOMAL PROTEIN S12 99.6 33116_f_at
RIBOSOMAL PROTEIN L38 98.3 34085_at
RIBOSOMAL PROTEIN S17 109.0 34592_at
RIBOSOMAL PROTEIN S17 104.0 34593_g_at
RIBOSOMAL PROTEIN S4 90.2 34643_at
RIBOSOMAL PROTEIN S3 108.0 34645_at
RIBOSOMAL PROTEIN S28 99.0 347_s_at
RIBOSOMAL PROTEIN L13A 84.9 35119_at
MISCELLANEOUS
LAMININ RECEPTOR (NON-INTEGRIN) 128.6 256_s_at
ANNEXIN A2 (LIPOCORT. II) 171.8 769_s_at
MIF 90.2 895_at
PLASMINOGEN ACTIVATOR INHIBITOR I 111.4 38125_at
ELONGATION FACTOR 1-ALPHA 148.6 1288_s_at
UBIQUITIN C 91.5 1367_f_at
ENOLASE 1 93.6 2035_s_at
POLYUBIQUITIN UBC 97.9 32334_f_at
BENZODIAZEPINE RECEPTOR 88.2 32806_at
CYCLOPHILIN A 97.0 33667_at
ELONGATION FACTOR 1-ALPHA 144.0 40887_g_at
ESTS
EST AI535946 114.5 33412_at
EST AI541542 113.8 35278_at
EST U34995 172.4 35905_s_at
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F > 2.8 implies P < 0.05). ANOVA tests are easily acces-
sible within most commercial statistical software packages,
and in the free ‘R’ statistical programming environment
(http://rweb.stat.umn.edu/R/doc/html/index.html), which
was used here.
Transcriptome heterogeneity data was then used to estimate
the number of biological replicates (i.e., the number of
repeated experiments using HUVEC from different individ-
uals) that would be required for a robust transcriptome
analysis of the effects of VEGF-A and PlGF on these cells.
When any 2 of the 6 individual HUVEC cultures were
compared using Microsoft Excel, we found that between 2.6
and 4.7% of the 12,600 transcripts differed by greater than
75% in abundance, as shown in Figure 1. However, when the
mean of any twoHUVEC cultures was compared to the mean
of any other two HUVEC cultures only 0.9–1.6% of
transcripts differed by greater than 75% in abundance. When
the mean of any three HUVEC cultures was compared to the
mean of any other three HUVEC cultures, only 0.1–0.4% of
transcripts differed by greater than 75% in abundance. This
analysis suggested to us that mean expression data obtained
by biologically replicating each experiment three times would
be much more useful than data from an un-replicate study. In
addition, the non-linear nature of the curve that could be ﬁtted
to these results (Figure 1) suggested that additional biological
replicates would provide diminishing returns.
Effect of VEGF-A and PlGF on EC biology
To conﬁrm that VEGF-A and PlGF were active on HUVEC
in the concentrations and culture conditions used in this
study, and to catalogue the degree of heterogeneity in the
response of biological replicates to VEGF-A and PlGF, we
examined the effects of these factors on viable cell number
and apoptosis incidence in HUVEC cultured in either rich or
low serum media. While the incidence of apoptosis in
HUVEC cultured in rich medium is low (1 to 2%), it is
signiﬁcantly elevated when these cells are cultured in low
serum medium for 24 h (9 to 15%; [25]). Neither this serum
deprivation-induced apoptosis nor total cell number was
signiﬁcantly altered by the addition to low serum media of
10 ng/ml VEGF-A165 for 4 h (ANOVA P > 0.05; data not
shown). However, the addition to low serum media of either
10 ng/ml VEGF-A165 or 10 ng/ml PlGF-1131 for 24 h
signiﬁcantly reduced the incidence of apoptosis (ANOVA
P < 0.05; Figures 2a and b) and signiﬁcantly increased cell
number (ANOVA P < 0.05; data not shown), indicating that
24 h incubation with either VEGF-A or PlGF can partially
rescue serum-deprived HUVEC cultures from apoptosis. In
HUVEC cultured in rich media, the addition to the media of
10 ng/ml VEGF-A165 for 24 h signiﬁcantly reduced the
already low incidence of apoptosis (ANOVA P<0.05;
Figure 2C) and increased cell number (ANOVA P < 0.05;
data not shown). Addition of 10 ng/ml PlGF-1131 to
HUVEC cultured in rich media slightly reduced the
apoptotic index (Figure 2d) and increased cell number, but
these results were not statistically signiﬁcant (ANOVA
P > 0.05). Each experiment was conducted three times,
each time using HUVEC isolated from a different individ-
ual. In an additional experiment, we found that the addition
of either VEGF-A165 or PlGF-1131 to culture media were
able to reduce the incidence of cell death in over-conﬂuent
HUVEC monolayers in a dose-dependant manner (Fig-
ure 2e–g). Taken together, these experiments conﬁrmed that
10 ng/ml was a biologically eective concentration of both
VEGF-A and PlGF in this culture system.
Overall effects of VEGF-A and PlGF on the HUVEC
transcriptome
Affymetrix U95A gene arrays were then used to catalogue
transcript abundance changes in HUVEC in response to the
following treatments (Table 2): (i) 10 ng/mL VEGF-A for
4 h in low serum medium; (ii) 10 ng/ml VEGF-A for 24 h
in low serum medium, (iii) 10 ng/ml VEGF-A for 24 h in
rich medium, (iv) 10 ng/ml PlGF for 24 h in low serum
medium; and (v) 10 ng/ml PlGF for 24 h in rich medium.
Each of these experiments was biologically replicated three
times, each time using HUVEC isolated from a different
individual. To minimise the confounding effects of the
transcriptome heterogeneity between cultures described
above, a paired design was used – i.e., for each biological
replicate a passage 4 HUVEC culture was split into 2 ﬂasks,
the relevant growth factor was added to one ﬂask and no
treatment applied to the other.
Since each gene array experiment simultaneously inves-
tigates many thousands of transcripts, it is likely that some
transcripts may falsely appear to have been regulated by
growth factor treatment due to chance alone. Therefore, we
assessed this ‘false discovery rate’ by applying t-tests to
Affymetrix data derived from three randomly selected pairs
of HUVEC cultures to which no experimental treatment had
been given (i.e., a negative control experiment). As would
be expected statistically, we found that approximately 1% of
the 12,600 transcripts were, by chance, associated with P-
values  0.01 (shown as ‘negative control’ in Figure 3).
Figure 1. Biological replication. (A) The % of transcripts that appear to
vary in abundance by >75% are shown when; the transcriptomes of single
HUVEC cultures were compared to one another (x-axis ¼ 1), when mean
transcriptomes from any two biologically independent HUVEC cultures
were compared to one another (x-axis ¼ 2), or when mean transcriptomes
from any three biologically independent HUVEC cultures were compared
to one another (x-axis ¼ 3).
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The t-tests were performed through the web using the freely
available the CyberT algorithm. This is a modiﬁed t-test
optimised to generate accurate t-statistics for gene array data
(in which there are usually many independent observations
but relatively few replicates) by the incorporation of a
Baysian prior based on the variance of transcripts with
related expression levels (CyberT; http://visitor.ics.uci.edu/
genex/cybert/) [21].
Next, we examined the effect of 4 hr incubation with
10 ng/ml VEGF-A165 on the transcriptome of HUVEC
cultured in low serum medium. We analysed RNAs from
this experiment using both Aymetrix arrays and SAGE. The
Aymetrix analaysis showed that the number of transcripts
associated with P-values  0.01 was approximately equal to
the number obtained in the negative control experiment
presented above and to the number expected by chance
(1%), suggesting that only very small numbers of transcripts
were authentically regulated in this experiment. SAGE
analysis has recently been correlated with gene array
analysis to detect differences between the transcriptomes
Figure 2. The cell biological effects of VEGF-A and PlGF-1. Three isolates of HUVEC were cultured in low serum media (a and b) or in rich media (c and
d) for 24 h and then cultured for a further 24 h with; no additional treatment (solid circles), 10 ng/ml VEGF-A (a and c, hollow circles) or 10 ng/ml PlGF (b
and d, hollow circles). Horizontal bars represent mean apoptotic index. (E) When HUVEC cultured in rich medium were allowed to become over-conﬂuent
for 24 h, cells with an apoptotic morphology became visible on the surface of the monolayer. Incubation with VEGF-A for 24 h reduced the number of
these dying cells in a dose-dependant manner. The number of apoptotic cells adhering to the surface of the conﬂuent monolayers following VEGF-A or
PlGF (1, 3, 10, 30 or 100 ng/ml) incubation for 24 h is shown in panels (f) and (g).
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of EC derived from different vascular sources [26]. We
performed a small-scale (approximately 5400 paired di-tags)
SAGE analysis on HUVEC cultured in low serum medium
with and without incubation with 10 ng/ml VEGF-A for
4 h. Many of the most abundant 0.5% of transcripts
identiﬁed by our SAGE analysis of untreated HUVEC were
also identiﬁed in this previous study [26], and were among
the most abundant 1% of transcripts identiﬁed by our
corresponding Affymetrix analysis (Figure 4). However,
SAGE indicated that none of these abundant transcripts was
regulated by 4 h VEGF-A incubation (Figure 4). Due to the
labour intensive nature of SAGE, additional biological
replicates could not be performed.
We then examined the effect of 24 h incubation with
10 ng/ml VEGF-A165 on the transcriptome of HUVEC
cultured in low serum medium. Again, the gene array
analaysis showed that the number of transcripts associated
with P-values  0.01 was approximately equal to the
number expected by chance alone (1%). However, when
we examined the effect of 24 h incubation with 10 ng/ml
VEGF-A165 on the transcriptome of HUVEC cultured in
rich medium, approximately 2% of the 12,600 transcripts
Table 2. Summary of experimental design. The design of the ﬁve experiments analysed in this report is described in this table. Data for each experiment
can be retrieved from the GEO database (http://www.ncbi.nlm.nih.gov/geo/) using the accession numbers shown.
Experiment HUVEC culture
media
Treatment Duration of treatment GEO accession numbers for
normalised array results
A Rich medium 10 ng/ml VEGF-A 24 h GSM12894-vs-GSM12895
GSM12896-vs-GSM12897
GSM12898-vs-GSM12899
B Low serum medium 10 ng/ml VEGF-A 4 h GSM12900-vs-GSM12901
GSM12902-vs-GSM12903
GSM12904-vs-GSM12905
C Low serum medium 10 ng/ml VEGF-A 24 h GSM12906-vs-GSM12907
GSM12908-vs-GSM12909
GSM12910-vs-GSM12911
D Rich medium 10 ng/ml PlGF-1 24 h GSM12912-vs-GSM12913
GSM12914-vs-GSM12915
GSM12916-vs-GSM12917
E Low serum medium 10 ng/ml PlGF-1 24 h GSM12918-vs-GSM12926
GSM12919-vs-GSM12920
GSM12921-vs-GSM12922
Figure 3. Percentage of total Affymetrix probe sets for which Baysian t-test
P < 0.01. ‘Negative control’ represents the comparison between two
groups, each containing data from three un-treated rich media HUVEC
cultures derived from different individuals. ‘Serum withdrawal’ (a positive
control) represents the comparison of three HUVEC cultures grown in rich
media with three HUVEC cultures isolated from the same individuals but
grown in low serum media. Treatments are; A, 24 h 10 ng/ml VEGF-A in
rich medium; (B) 4 h 10 ng/ml VEGF-A in low serum medium; (C) 24 h
10 ng/ml VEGF-A in low serum medium; (D) 24 h 10 ng/ml PlGF-1 in
rich medium; (E) 24 h 10 ng/ml PlGF-1 in low serum medium. Hatched
bars represent transcript up-regulation by treatment, solid bars down-
regulation.
Figure 4. SAGE identiﬁes the same abundant endothelial cell transcripts as
Aymetrix analysis. A scatterplot is shown of log2 transcript abundance in
HUVEC cultured in low serum media with (y-axis) or without (x-axis)
10 ng/ml VEGF-A for 4 h. Overlaid white circles show the position in the
Affymetrix dataset of the most abundant 0.5% of transcripts detected by
SAGE. The diagonal line marks the 99th percentile of the Affymetrix
experiments.
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were associated with P-values  0.01 (Figure 3) – i.e.,
approximately twice as many transcripts appeared to be
regulated than would be expected by chance. When we
investigated the effect of 24 h incubation with 10 ng/ml
PlGF-1131 on the transcriptome of HUVEC cultured in
either rich or low serum medium, no more transcripts
were associated with P-values  0.01 than would be
expected by chance alone (1%), suggesting that PlGF
regulated few if any transcripts in either culture condition.
To put these numbers into context, when the transcript-
omes of three cultures of HUVEC in rich media were
compared to the transcriptomes of three cultures of
HUVEC in low serum media derived from the same
individuals, the proportion of transcripts associated with
P-values  0.01 was over 12% (Figure 3). This implies
that the extent of transcript abundance regulation induced
by VEGF-A or PlGF in the conditions used in this study
is much less than that induced by transfer of these cells
from rich to low serum media.
We then used the freely available SAM software [22]
(http://www-stat.stanford.edu/~tibs/SAM/) as an alternative
estimate of the false discovery rate for each experiment in
our study. SAM is used as an ‘add-in’ package for Microsoft
Excel. The results of this method concurred closely with the
t-test results described above. SAM indicated that we should
expect a false discovery rate of 4.5 transcripts for every 10
that appeared to be regulated by 24 h VEGF-A treatment of
HUVEC cultured in rich medium. In contrast, SAM
indicated that we should expect incubation of HUVEC
cultured in low serum media with VEGF-A for 24 h, or
incubation of HUVEC cultured in either rich or low serum
media with PlGF for 24 h to produce a false discovery rate
of 8 to 10 transcripts for every 10 that appeared to be
regulated. To put these results in perspective, SAM
indicated that we should expect a false discovery rate of
only 0.9 transcripts for every 10 that appeared to be
regulated by the transfer of HUVEC from rich to low serum
media.
Multi-way ANOVA was performed using the ‘R’ statis-
tical environment. It also concurred with the results
described above. It showed that 24 h incubation with
10 ng/ml VEGF-A caused a small but signiﬁcant alteration
to the overall pattern of transcript abundance in HUVEC
cultured in rich media (F ¼ 5.3; F > 3.9 implies P < 0.05).
However, incubation of HUVEC cultured in low serum
media with VEGF-A for 4 or 24 h, or incubation of HUVEC
cultured in either rich or low serum media with PlGF for
24 h, did not have any signiﬁcant overall effect on the
HUVEC transcriptome (F < 3.9 in each case).
In a further attempt to detect subtle HUVEC transcrip-
tome changes associated with VEGF-A and PlGF treat-
ment, independent component analysis (ICA) was used.
ICA is a neural network (ensemble learning)-based
method useful for analysis of noisy gene array data that
can remove the effects of noise and identify sets of
linearly co-regulated transcripts (which are referred to as
‘components’) [23]. We have previously found that ICA
readily detected components in HUVEC associated with
survival factor deprivation [23], anti-apoptotic transgene
expression and treatment with cocktails of cytokines and
growth factors (our unpublished data). However, when
ICA was applied to the un-normalised data from the
experiments performed here, no components associated
with VEGF-A or PlGF treatment were detected. However
a component related to the culture of the cells in rich
media vs. low serum media was readily detected (com-
ponent 8, Figure 5a). The transcripts that contributed most
strongly to this component were those that we have
previously described as being regulated in HUVEC by the
transfer of HUVEC from rich to low serum media [25].
The detection of a component associated with the transfer
of HUVEC from rich to low serum media, but not of
components associated with exposure to VEGF-A or
PlGF is not surprising, given the large number of
transcripts regulated by the transfer of HUVEC from rich
to low serum media (12%) compared to the small number
regulated by either VEGF-A or PlGF (1 to 2%), as
described above. Additional meaningful components were
inferred by ICA. These associated with normalisation
artifacts (component 4) and experiments performed by a
particular investigator (KL) (component 27). We have
found that ICA is more powerful than other techniques
such as principal component Analysis (PCA) [23]. Since
current versions of ICA require programming skills to
use, this technique is not readily available to all
laboratories. However, we hope that an easy-to-use
version of ICA may be freely available soon, and ICA
is currently available by collaboration with our laboratory
and others.
Cluster analysis (the grouping of arrays into similar
clusters) is another useful method to search for patterns
hidden within gene array data. Cluster analysis is
available in most commercial gene array analysis pack-
ages such as GeneSpring (Silicon Genetics), in addition to
statistical programming environments such as ‘R’. Here
we have used ‘R’ to perform Ward’s method clustering
(an agglomerative clustering method that seeks to mini-
mise the sum of squares between clustered arrays). As
with ICA, Ward’s clustering failed to detect any transcript
clusters speciﬁc to VEGF-A or PlGF treatment. However,
it readily clustered the arrays from HUVEC cultured in
low serum and rich media into two distinct groups
(Figure 5b).
Effects of VEGF-A and PlGF treatment on individual
HUVEC transcripts
It is important to identify the most signiﬁcantly regulated
individual transcripts for further analysis. Here we have
done this by using Microsoft Excel to apply a set of four
criteria to all 12,600 transcripts investigated in each
experiment: (i) Bayesian t-test (cyberT) comparing abun-
dance of the transcript in the three control and treated
cultures indicated P < 0.01; (ii) the transcript showed a
greater than two-fold average regulation between the
control and treated cultures; (iii) the direction of regulation
between the control and treated cultures was the same in
150 J. Schoenfeld et al.
each of the three replicate cultures; (iv) the Affymetrix
analysis software (MAS 5.0) indicated that the transcript
was expressed above the noise in at least one cultures from
each control and treated pair. Transcripts identiﬁed by this
approach in HUVEC cultured in rich medium treated with
VEGF-A for 24 h are listed in Table 3 and are discussed
below. Our results suggested that the remaining experi-
mental treatments regulated no more transcripts that would
be expected by chance alone. This suggests that the
chances of false discovery in these experiments are very
high indeed, however, it does not of course rule out the
authentic up- or down-regulation of a very small number
of individual transcripts in each of these experiments.
Indeed, this appears to be the case. Quantitative RT-PCR
(TaqMan) was used to verify the regulation of a small
number of individual transcripts for each experiment.
These transcripts including; the transcription factor ‘tubby’,
protein tyrosine phosphatase-1B (PTP1B), regulator of G-
protein signaling-3 (RGPB3), Thrombomodulin, CD34,
Musashi and EphrinA2. For these transcripts, VEGF-A and
PlGF-induced changes in transcript abundance were con-
sistent in direction between the Affymetrix arrays and
quantitative RT-PCR, except for Musashi, which showed
concordant regulation in only one out of the three PlGF-
treated HUVEC cultured in rich media replicates (Fig-
ure 6).
Figure 5. (a) Hinton plot. Independent component analysis (ICA) identiﬁed several biologically or experimentally meaningful components (*). These were
associated with; survival factor-deprivation (component 8), normalisation effects (component 4), and experiments performed by a particular investigator
(KL) (component 27). The area of each square is proportional to the magnitude of the contribution of each genechip to each component. Positive values are
shown in yellow; negative values, in red. (b) Clustering. Ward’s method clustering grouped the arrays into those representing HUVEC cultured in rich or
low serum media. However, no consistent clustering was obtained that corresponded to the effects of VEGF-A or PlGF. The scale on the left of the
dendrogram represents the degree of similarity of the clusters.
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The transcriptome response of HUVEC to low serum
media was partially reversed when the cultures were
rescued from apoptosis by 24 h incubation with VEGF-A
It seemed possible that the transcriptome changes induced
by transferring HUVEC from rich media into low serum
media may be partly reversed when VEGF-A or PlGF was
used to rescue the low serum media cultures from apoptosis.
To test this hypothesis, we used GeneSpring software to
display (Figure 7) linked scatterplots that showed; (column
A) the effect of transferring HUVEC from rich media into
low serum media and (column B) the effect of exposing
HUVEC cultures in low serum media to VEGF-A for 24 h.
Transcripts highlighted in the plots in column A are also
highlighted automatically in the corresponding plots in
column B. This simple analysis showed that transcripts that
were not up- or down-regulated > two-fold when HUVEC
were transferred form rich to low serum media did not
appear to be regulated in any particular manner when
HUVEC cultured in low serum media were incubated with
VEGF-A for 24 h. However, transcripts that were up- or
down-regulated > two-fold when HUVEC were transferred
from rich to low serum media appeared on average to be
regulated a small amount in the opposite direction when
HUVEC cultured in low serum media were incubated with
VEGF-A for 24 h. While most of these reciprocal changes
were small, they may nevertheless together represent a
biologically important partial reversal of the transcriptome
changes induced by transferring HUVEC from rich media
into low serum media. These results are shown graphically
in histograms of fold change in Figure 7C (left panel).
Incubation with VEGF-A for only 4 h was unable to induce
the same reciprocal changes in transcript abundance (Fig-
ure 7C, right panel).
Table 3. Transcripts regulated in HUVEC cultured in rich medium by 24 h incubation with 10 ng/ml VEGF-A. FC denotes average fold change.
Transcripts regulated in HUVEC cultured in rich medium by incubation with VEGF-A for 24 h
Probe set Transcript FC CyberT P-value
Receptors
33803_at Thrombomodulin 3.6 5.88E-07
38747_at CD34 2.2 3.23E-05
34235_at G-protein coupled receptor-116 2.3 4.89E-05
1608_at HGF receptor 5.3 7.97E-05
32114_s_at Adenosine-A2 receptor 2.2 4.43E-03
836_at Patched 3.1 4.88E-03
Secreted factors
37013_at Angiotensin Converting Enzyme-1 2.1 8.08E-05
1003_s_at B cell-attracting chemokine-1 )3.1 8.09E-03
33534_at Endothelial cell-speciﬁc molecule-1 2.6 1.12E-04
209_at Neuregulin-1 )4.0 1.50E-04
41354_at Stanniocalcin-1 3.3 7.46E-04
Signaling molecules
37785_at RHO-6 2.2 5.99E-04
39318_at T-cell lymphoma-1 3.0 2.01E-03
32979_at Grb2-associated-1 2.5 4.43E-03
36008_at Phosphatase IVA-3 2.2 3.63E-04
Adhesion & Cytoskeleton
356_at Kinesin-22 )3.2 5.05E-04
753_at Osteonidogen 2.5 3.09E-04
39504_at Connexin-46 2.9 1.50E-03
Transcription factors
37710_at MADS box enhancer factor-2 2.6 5.61E-04
33484_at Ring ﬁnger protein 2 2.1 6.86E-04
40448_at Zinc ﬁnger protein-36 2.2 6.96E-04
40483_at Transcriptional activator of the c-fos promoter 4.8 3.01E-04
204_at HOX-A4 )2.7 3.85E-03
39909_g_at PCAF associated factor-65a )2.4 5.58E-03
31698_at Forkhead-14 )2.1 7.61E-03
Miscellaneous
41767_r_at Golgin-67 2.5 1.25E-03
33902_at L-glycerol-3-phosphate-NAD oxidoreductase )2.6 8.90E-03
ETSs
41494_at EST X99802 2.4 8.27E-03
Retinoic acid-inducible retroviral
1090_f_at DNA )3.3 2.49E-03
32076_at
Down syndrome critical region gene
1-like-1 2.6 9.12E-04
37178_at EST BC017169 2.7 7.27E-04
36727_at EST M64936 )2.1 1.28E-03
39501_f_at EST W28566 )2.7 2.92E-03
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Figure 6. Quantitative PCR (TaqMAN) conﬁrms the regulation of subset of transcripts. Black bars represent mean fold changes (n ¼ 3 biological
replicates) indicated by Affymetrix arrays, and open bars mean fold changes indicated by TaqMAN quantitative RT-PCR. Error bars denote standard
deviations. The experimental conditions are shown above the graph. PTP-1B denotes protein tyrosine phosphatase–1B, RGP3 denotes regulator of G-
protein signaling-3.
Figure 7. The transcriptome effects of transferring HUVEC from rich to low serum media are partially reversed by 24 h incubation with VEGF-A. The
scatterplots in column A compare HUVEC cultured in rich media (horizontal axis) with HUVEC cultured in low serum media (vertical axis). The
scatterplots in column B compare HUVEC cultured in low serum media (horizontal axis) with HUVEC cultured in low serum media with the addition of
10 ng/ml VEGF-A for 24 h (vertical axis). Transcripts highlighted in the plots in column A are automatically highlighted in the corresponding plots in
column B. The top scatter-plots show those transcripts which were not up- or down-regulated > 2-fold when HUVEC were transferred from rich to low
serum media. The middle and bottom scatter-plots show transcripts that were up- or down-regulated > 2-fold, respectively, when HUVEC were transferred
from rich to low serum media. These transcripts are on average reciprocally regulated by a small amount when HUVEC cultured in low serum media are
incubated with VEGF-A for 24 h. This is evident by the small shift up or down of groups of white highlighted transcripts in column B. Histograms of fold
change (the left hand panel of column C) show these effects clearly. However, when HUVEC cultured in low serum media are incubated with 10 ng/ml
VEGF-A for only 4hrs, no shift in the histograms is observed (the right hand panel of column C).
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HUVEC derived from different individuals mount
heterogeneous transcriptional responses to VEGF-A
As discussed above, the resting transcriptomes of HUVEC
derived from different individuals differed substantially. To
assess whether the response of HUVEC derived from
different individuals to VEGF-A was heterogeneous, we
used ANOVA. We found that the statistical ‘interaction’
between the effect of VEGF-A treatment and the effect of
the individuals from whom the HUVEC were isolated was
signiﬁcant (F ¼ 4.4 for HUVEC cultured in rich media
and F ¼ 4.9 for HUVEC cultured in low serum media;
F > 2.4 implies P < 0.05), implying that HUVEC isolated
from the different individuals respond differently to VEGF-
A. These heterogeneous responses to VEGF-A may be due
to differences dictated by the individuals from whom the
HUVEC were isolated, and/or to random experimental
factors. To assess the importance of differences dictated by
the individuals from whom the HUVEC were isolated, we
tested whether two duplicate HUVEC cultures isolated
from the same individual (and cultured at different times
from duplicate frozen vials) varied between one another in
their transcriptional responses to VEGF-A to the same
degree as any two HUVEC cultures derived from different
individuals. Between any two unrelated cultures, 25 to 39%
(average 29%) of transcripts exhibited > 1.5-fold variability
in response to VEGF-A. However, between the two
HUVEC cultures isolated from the same individual, only
15% of transcripts exhibited > 1.5-fold variability in
response to VEGF-A. This suggested that the individuals
from whom HUVEC were derived directly inﬂuenced
VEGF-induced transcriptional responses.
Discussion
Technical aspects of data analysis
In this report we have used a previously unpublished set of
experiments in HUVEC to illustrate the process of
analysing gene array data derived from primary cultured
cells. We found that, as we have previously reported [25],
the transition from rich to low serum media induced
repeatable and substantial transcriptome change in HU-
VEC. The number of transcripts regulated represented
approximately 10 times the expected false discovery rate
(determined either by comparing experimental t-test results
to the t-test results of a negative control experiment and by
SAM software). The effect of transition from rich to low
serum media on the overall pattern of transcript abundance
was also readily detected by ANOVA, Ward’s method
clustering and ICA.
In contrast, the effect of exposure to VEGF-A for 24 h
on HUVEC cultured in rich media was more subtle,
regulating only twice the number of transcripts that we
expected by regulated due to chance alone (twice the
false discovery rate). Although these transcriptome
changes were detected by ANOVA, they were too subtle
to be detected by Ward’s method clustering or ICA.
The effect of VEGF-A on HUVEC cultured in low serum
media, or of PlGF on HUVEC cultured in either rich or low
serum media, was even more subtle, since the number of
transcripts that appeared to be regulated in these experi-
ments was no greater than the number we expected to
appear to be regulated due to chance alone. These exper-
iments carried a high risk of false discovery, and therefore
must be treated with caution until validated by other means
such as the quantitative RT-PCR shown in Figure 6.
If biological replication and false discovery rate analysis
had not been performed, we would not have become aware
of the high chance of false discovery in the experiments
described above. The importance of biological replication is
further supported by the statistically signiﬁcant differences
in the transcriptome responses to VEGF-A of HUVEC
isolated from different patients. For example, ANOVA
indicated that the transcriptome responses of HUVEC to
VEGF-A differed between individuals. This result was
conﬁrmed by analyzing the effect of VEGF-A on the
transcriptomes of duplicate batches of HUVEC derived
from the same individual. This data suggests that paired
design experiments (in which each biological replicate
culture is split into two ﬂasks and a treatment applied to one
ﬂask but not the other) may be much more sensitive than un-
paired design experiments. The subtle effects of VEGF-A
on HUVEC cultured in rich media may not have been
detected if a paired design had not been used. While a set of
‘single colour’ array experiments have been use to illustrate
these principles, they apply equally to ‘two-colour’ exper-
iments, especially when one ‘colour’ is always used for a
pooled common control.
The cohorts of VEGF-regulated EC transcripts identiﬁed
by previous studies [12–18] only marginally overlap with
one another. Only a few of these previously identiﬁed
transcripts appeared to be regulated by VEGF-A in HUVEC
cultured in rich medium in our study (e.g., Thrombomodulin
[16], Ademosine A2 receptor [16], Phosphatase IVA3 [16],
and Osteonidogen [15]). This inconsistency may be largely
explained by the different culture conditions (e.g., rich or
low serum media), EC types, timing and gene array
platforms used in each study. However, it is possible that
in addition, some of these previous studies have overesti-
mated the number of VEGF-regulated transcripts due to
their sub-optimal biological replication, lack of false
discovery rate analysis and/or unpaired designs. This would
account for both the large numbers of ‘regulated’ transcripts
and their apparent inconsistency.
Previous studies using non-gene array techniques have
also identiﬁed a number of VEGF-regulated EC transcripts
including; tissue factor (thromboplastin [27]), intercellular
adhesion molecule (ICAM)-1 [28], plasminogen activators
(uPA and tPA) and plasminogen activator-inhibitor-1 [29],
interstitial collagenase [30], Bcl-2 and A1 [31]. In general,
these results are not reproduced in the published gene array
studies of VEGF-mediated transcriptome regulation [12–18]
or by our own study. The different experimental conditions
used in these various studies may in part explain this
inconsistency. However, the relative insensitivity of gene
array techniques may also play a role. For example, Bcl-2,
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ICAM-1 and tissue factor were expressed below the
threshold for reliable comparisons in our data. Interestingly,
the expression of tissue factor, which is widely recognised
as a VEGF-responsive transcript, was in fact up-regulated
5.7-fold (gene ID 36543_at) in HUVEC cultured in rich
media following 24 h incubation with 10 ng/mlVEGF-A.
However, since its expression level, even after up-regula-
tion, was is the lowest 2% of the transcripts interrogated by
the arrays and was on a par with the level of noise, it would
be unwise to over-interpret this result.
Biological insights provided by these experiments
We catalogued the most abundantly expressed transcripts in
HUVEC. These encoded cytoskeletal elements and their
regulators, ribosomal proteins, enzymes involved in carbo-
hydrate metabolism, members of the ubiquitin system, and
proteins involved in various forms of signaling (Table 1),
and overlap substantially with abundant HUVEC transcripts
identiﬁed previously [26]. Many of these abundant tran-
scripts encode proteins that perform essential functions in
diverse cell types and are not EC-speciﬁc. Presumably, the
synergistic combination of transcripts expressed at lower
levels in EC, rather than the most abundant EC transcripts,
speciﬁes unique EC structure and function.
Our study then assessed the cell biological changes
induced in HUVEC by VEGF-A and PlGF. This showed that
both factors were biologically active in the concentrations
and conditions used in this study. The cell biological effects
of VEGF-A were more pronounced in HUVEC cultured in
low serum media than in HUVEC cultured in rich media –
perhaps due to VEGF-A’s inability to further alter the already
low incidence of apoptosis and the already high incidence
proliferation of optimally-cultured cells. PlGF also had
measurable effects on HUVEC biology, although the mag-
nitude of these effects on HUVEC cultured in low serum
media was not as great as the effect of VEGF-A.
We then related these cell-biological responses to tran-
scriptome responses. We found that the most signiﬁcant
VEGF-induced transcriptome changes were in HUVEC
cultured in rich media. These are likely to contribute to
VEGF-induced proliferation and survival. They include
(listed in Table 3): (i) membrane proteins; patched (›3.1x, a
receptor for the pro-angiogenic factor sonic hedgehog);
thrombomodulin (›3.6x, an EC surface glycoprotein in-
volved in thrombin activation); CD34 (›2.2x, a sialomucin
that appears to be involved in stem cell activity); G-protein-
coupled receptor-116 (›2.3x) and the hepatocyte growth
factor receptor (›5.2x, pro-angiogenic); (ii) miscellaneous
proteins and enzymes; angiotensin converting enzyme-1
(›2.1x, involved in the regulation of blood-pressure); EC-
speciﬁc molecule-1 (›2.6x, a cytokine induced endothelial
protein of unknown function) and stanniocalcin-1 (›3.3x);
(iii) adhesion and cytoskeletal-associated molecules; Nido-
gen-2 (›2.5x, a basement membrane component), Catenin a
2 (ﬂ4.0x) and Connexin-46 (›2.9x, a gap junction protein).
(iv) cytoplasmic signaling molecules; Tyrosine Phosphatase
IVA-3 (›2.2x, regulates AT II-mediated calcium signaling
and promotes proliferation in other cell types), TCL-1
(›3.0x, an activator of AKT and therefore a potential
promoter of cell survival) and FK506 binding protein-1B
(ﬂ3.2x). DNA-binding proteins/transcription factors; Zinc
ﬁnger protein-36 (›2.2x, a component of a negative
feedback loop that interferes with TNF-a production by
destabilizing its mRNA); HOX-14 (ﬂ2.7x) and CROC-4
(›4.8x); (v) Several EST.
The relative lack of transcriptome responses to VEGF-A
and PlGF, despite signiﬁcant cell-biological responses,
suggests that post-transcriptional mechanisms, rather than
regulation of transcript abundance, may be largely respon-
sible for the effects of these factors on HUVEC cultured as
they were here. The different transcriptome responses to
VEGF-A of HUVEC cultured in rich and low serum media
is especially intriguing. Our gene array data suggests that
altered abundance in cells cultured in low serum media of
RNAs encoding transcription factors may in-part underlie
this result. For example, in HUVEC cultured in low serum
media NF-jB function appears to be reduced, in part due to
the up-regulation of transcripts encoding the NF-jB inhib-
itors IjBa, IjBa, IjBe, RelB and p100 [25]. Previous
studies have suggested that NF-jB plays an important role
in the transcriptome responses of EC to VEGF-A [32, 33].
Several other transcription factors are also up- or down-
regulated more than two-fold when HUVEC are transferred
from rich to low serum media [25], including; hnRNP-U
(ﬂ9.8x, involved in pre-mRNA processing), Gu (also ﬂ9.8x,
a helicase involved in several aspects of RNA editing and
folding), DEK (ﬂ2.9x, involved in pre-MRNA splicing),
JunD (›2.1x), HSF4 (›2.0x, suppresses heat shock protein
translation) and a further 26 transcription factors.
In conclusion, we have used a set of previously
unpublished Affymetrix gene array experiments to lead
the reader through the analysis of gene array data derived
from primary cells. We have demonstrated the critical
importance of biological replication and false discovery
rate estimation and the value of a paired experimental
design. We have demonstrated the use of ANOVA, false
discovery rate analysis software, Baysian t-tests, clustering
and independent component analysis to extract robust and
meaningful conclusions from the raw data. The experi-
ments we have analysed have shown that while the transfer
of HUVEC from rich to low serum media regulates a
substantial number of transcripts, VEGF-A and PlGF
regulated only small numbers of transcripts. The regulation
of transcripts by VEGF-A appeared to depend upon the
media in which the cells were cultured – we suggest one
explanation for this phenomenon based on the culture
media-dependent abundance of transcripts encoding tran-
scription factors. We also suggest that some previous gene
array studies that have not been optimally designed and
analysed may have overestimated the number of transcripts
regulated by VEGF-A.
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BACKGROUND: Angiogenesis and vascular remodeling play critical roles in the cyclical growth and regression of
endometrium. They also appear to play roles in the pathogenesis of endometriosis. METHODS and RESULTS:
Supernatants were collected from cultured endometrium isolated from women with and without endometriosis.
These supernatants induced endothelial cell proliferation and angiogenesis in vitro. They contained vascular endo-
thelial growth factor (VEGF)-A, and their proliferative effects on endothelial cells were partially abrogated by a
blocking anti-VEGF-A antibody. Gene array analysis showed that culture supernatants from proliferative phase
endometrium, and to a lesser extent secretory phase endometrium, induced significant changes in the transcrip-
tome of endothelial cells. We could not detect any association between endometriosis and the ability of endo-
metrial-derived soluble factors to promote angiogenesis or to regulate the endothelial transcriptome. In addition,
we could not detect any association between endometriosis and the concentration of VEGF-A in supernatants from
cultured endometrium or in menstrual effluent. CONCLUSIONS: We have shown that endometrium cultured
in vitro produced soluble factors, including VEGF-A, that promoted angiogenesis. Proliferative phase endometrium
promoted significant endothelial cell transcriptome changes that appear overall to be pro-angiogenic. These trans-
criptome changes provide insight into the dynamic control of vessel structure on which both eutopic endometrium
and endometriotic lesions depend.
Key words: endometrious/gene array/VEGF-A/transcriptome
Introduction
Angiogenesis and vascular remodeling play critical roles in
the cyclical growth and regression of the endometrium
(reviewed by Gargett et al., 2001). In the proliferative phase
of the menstrual cycle, angiogenesis occurs in the stratum
functionalis as the endometrium approximately quadruples in
thickness. In the secretory phase of the cycle, spiral arterioles
lengthen and become more coiled and the sub-epithelial capil-
lary plexus matures. In the post-menstrual phase, angiogen-
esis is involved in the repair of the superficial layer of the
remaining stratum basalis. Endometrial angiogenesis is tightly
coordinated with recruitment of vascular smooth muscle cells
to the nascent vessels (Kohnen et al., 2000). Endometrial
angiogenesis may be directly controlled by reproductive
steroids (Iruela-Arispe et al., 1999; Hague et al., 2002) and
indirectly controlled by angiogenic regulators expressed by
the diverse cell lineages present in the endometrium. Potential
regulators of endometrial angiogenesis include: nitric oxide
(Cameron et al., 1998), vascular endothelial growth factor
(VEGF)-A (Charnock-Jones et al., 1993; Donnez et al.,
1998), VEGF-B and -C (Mints et al., 2002; Moller et al.,
2002), relaxin (Unemori et al., 1999), fibroblast growth
factors (FGF) (Ferriani et al., 1993), matrix metalloprotei-
nases (MMPs) (Freitas et al., 1999), thymidine phosphorylase
(Fujiwaki et al., 1999), angiopoietin-2 (Krikun et al., 2000),
erythropoietin (Yasuda et al., 1998), adrenomedullin
(Nikitenko et al., 2000) and epidermal growth factor (EGF)
(Sandberg et al., 2001). Leukocyte-derived factors may play
a particularly important role. Angiopoietin-2, VEGF-C and
placental growth factor (PlGF) expressed by endometrial NK
leucocytes (Li et al., 2001) may drive spiral arteriole and
sub-epithelial capillary plexus changes during the secretory
phase of the cycle (Sandberg et al., 2001), while VEGF-A
expressed by intra-vascular neutrophils may promote angio-
genesis in the stratum functionalis during the proliferative
phase of the cycle (Gargett et al., 2001).
Endometriosis, the growth of ectopic endometrial frag-
ments in the peritoneum, is a debilitating disease that causes*These authors contributed equally to this work
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pain with menstruation, pain with intercourse and other
symptoms. In addition, endometriosis also causes infertility
(Haney, 1990). Despite a significant recent increase of the
disease coincident with the introduction of widespread ferti-
lity regulation, the cause of the problem remains unknown.
Tissues that grow to greater than ,1 mm3 need to establish a
blood supply to prevent necrosis (Folkman, 2002). Therefore,
for endometriotic lesions to survive they must recruit a vas-
culature from the surrounding tissues (reviewed by Smith,
1997). However, the processes that promote this angiogenesis
are as yet uncertain. They may involve both endometrial and
peritoneal factors—several examples of each have been
proposed. Potential pro-endometriotic endometrial factors
include increased proliferation capacity of endometrial endo-
thelial cells (EC) (Wingfield et al., 1995) and elevated
expression of several molecules including: the pro-angiogenic
integrin avb3 (Hii et al., 1998), hepatocyte growth factor
and its c-Met receptor (Khan et al., 2003), endoglin (Kim
et al., 2001), nitric oxide synthases (Wu et al., 2003),
urokinase receptor (Sillem et al., 1998) and tissue inhibitor
of metalloproteinases-2 (TIMP-2) (Sillem et al., 1998).
Potential peritoneal factors include: macrophage migration
inhibitory factor (MIF) in peritoneal fluid of endometriotic
women (Kats et al., 2002), steroidally-regulated VEGF-A
production by peritoneal macrophages (McLaren et al.,
1996), elevated tumour necrosis factor (TNF)-a production
from peritoneal macrophages (Noda et al., 2003; Richter
et al., 2004) and elevation of soluble TNF receptor (Steff
et al., 2004), angiogenin (Steff et al., 2004) and PlGF
(Suzumori et al., 2003).
Previously, the programmed variation of the transcriptome
of whole endometrium through the menstrual cycle has been
characterized (Borthwick et al., 2003; Kao et al., 2003).
However, the effects of soluble factors produced by cells
within the endometrium on endothelial gene expression, cell
biology and angiogenesis have not been fully investigated. In
this study, we have assessed the ability of the soluble factors
secreted by endometrium collected from non-endometriotic
and endometriotic women in the proliferative and secretory
phases of the menstrual cycle to promote EC proliferation
and angiogenesis and to modulate the EC transcriptome.
Given the important role played by VEGF-A in angiogenesis,
we have also assessed the concentration of VEGF-A in endo-
metrial culture supernatants and in menstrual effluent from
women with and without endometriosis.
Materials and methods
Collection and culture of endometrium
This study was approved by the local ethical review committee and
patient consent was obtained for the collection of all human tissues
used in this study. Since anti-inflammatory medications or medi-
cations related to reproductive steroids alter the cellular composition
of endometrium and are therefore likely to alter the pro-angiogenic
properties of endometrium, women currently on these medications
as well as women who had received courses of these drugs in the
previous 3 months were excluded. Women were also excluded who
had irregular menstrual cycles or who were using an intrauterine
device. In all women in the endometriotic group of this study the
clinical diagnosis of endometriosis was confirmed laparoscopically.
Women in the non-endometriotic group had no symptoms of endo-
metriosis and in addition, 6 out of the 10 women in this group had
the absence of endometriosis confirmed by laparoscopy. Only three
of the women in the study were smokers (two non-endometriotic
proliferative phase donors and one endometriotic secretory phase
donor). Endometrium was collected by Pipelle biopsy, and the
approximate stage of the menstrual cycle confirmed by histology.
Adhering blood clot and included myometrial tissue were removed
by washing and dissection. The endometrium was then disaggregated
by incubation with agitation in phosphate-buffered saline (PBS) con-
taining 100 mg/ml collagenase (Sigma, UK) and 100 mg/ml DNase
(Sigma, UK). The disaggregated endometrial cells were then washed
twice in PBS and plated at 70% confluence in tissue culture dishes
in a fully humidified atmosphere of 5% CO2 in a proprietary culture
medium (LVEC, large vessel endothelial cell medium; TCS,
Botolph, UK) supplemented with a mixture of heparin, hydrocorti-
sone, epidermal growth factor, fibroblast growth factor, 2% fetal calf
serum (FCS), gentamycin and amphotericin. This culture medium
maintained both EC (for which it was designed) and endometrium,
since the appearance of disaggregated endometrium after 4 days in
this culture medium was equivalent to that of endometrium cultured
in DMEM/Hams F12 (50:50 mix) supplemented with 10% FCS
(data not shown). No reproductive steroids were added to the culture
medium since reproductive steroids (Morales et al., 1995; Alvarez
et al., 1997) and their metabolites (Yue et al., 1997) have been show
to affect EC. Disaggregated monolayer cultures were chosen in
preference to explant cultures to maintain optimal oxygenation and
nutrition for all cells, and to allow visible assessment of endometrial
cell viability. After 24 h in culture the endometrial monolayers were
washed twice in medium in order to completely remove dead cells
and erythrocytes. After a further 24 h in the LVEC medium, culture
supernatants were collected, centrifuged and stored at 2708C. To
assess the cellular composition of the endometrial cultures, proli-
ferative and secretory phase endometrium were disaggregated as
described above, cultured on chamber slides for 24 h, fixed at
2208C with 50:50 acetone:ethanol, immunostained with an anti-pan
cytokeratin antibody cocktail (DAKO N1589) and a fluorescein
isothiocyanate (FITC)-conjugated secondary antibody and detected
using an epifluorescence microscope.
EC proliferation and angiogenesis assays
Human umbilical vein EC(s) (HUVEC) were isolated by collagenase
digestion as described (Jaffe et al., 1973) and cultured to passage
5 in LVEC medium. Once at passage 5, HUVEC were plated into
24-well plates at 70% confluence and supernatants from endometrial
cultures added (20% V/V) for 24 h. Viable HUVEC numbers were
then counted using a haemocytometer after trypan blue staining
(0.2% Sigma, UK). Four wells were used for each experimental con-
dition. The 20% V/V dilution of the endometrial cell culture super-
natants was chosen empirically since it on average induced maximal
HUVEC responses without inducing signs of stress in these cells
(data not shown). To prevent confounding, medium of identical
composition (LVEC medium described above) was used for culture
of all endometrial explants and all HUVEC in this study. Since
we have shown that quiescing HUEVC by transfer to low serum
medium reduces the ability of these cells to mount transcriptional
responses to growth factors (Johnson et al., 2003), the HUVEC
were not quiesced before incubation with the endometrial culture
supernatants. In additional experiments, a blocking anti-VEGF-A
monoclonal antibody (clone 26503, R&D Systems, UK) was added
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to HUVEC cultured as above, and relative cell numbers estimated
using a tetrazolium compound (MTS) assay (CellTiter 96 Aqueous
Non-Radioactive Cell Proliferation Assay; Promega) used according
to the manufacturer’s instructions.
In vitro angiogenesis assays consisted of co-cultures of HUVEC
and human dermal fibroblasts (Bishop et al., 1999). They were
purchased pre-plated in 24-well tissue culture plates from TCS
Cellworks (ZHA-1000; Botolph, UK) and cultured in the LVEC
medium for 11 days with or without the addition of endometrial
culture supernatants (20% V/V, replaced every 4 days). After
11 days cells were fixed in 2% paraformaldehyde for 20 min at 48C,
permeablized in 0.1% Triton X-100 and 0.1% Tween-20 for 30 min
at room temperature, stained with Ulex–FITC (Sigma L9006, UK)
at a concentration of 10mg/ml and Hoescht Bisbenzimide 33342
(Calbiochem 382061, UK) at a concentration of 1mg/ml. For each
experimental condition, the number of branches and total length of
capillary-like structures was measured by imaging 21 randomly
chosen 1 mm2 fields using a confocal microscope (Lieca, Germany).
Images were processed to quantify angiogenesis using the TCS
Angiogenesis assessment software (TCS, Botolph, UK).
Gene array analysis
RNA was prepared from HUVEC using Trizol reagent (Gibco/BRL,
UK) followed by clean up through an RNeasy spin column (Qiagen,
UK) and ethanol precipitation. RNA integrity was assessed using an
Agilent 2100 bioanalyser (Agilent, UK). 33P-labelled complex cDNA
probes were prepared from the RNAs and hybridized to an array of
,1000 cDNAs immobilized onto nylon filters as described (Evans
et al., 2003). Hybridization was quantified using a phosphoimager
(Molecular Dynamics Inc., CA) and IMAGENE software (Bio-
Discovery, CA). After global and local normalization (Evans et al.,
2003), transcript abundance data were compared using the
CyberT algorithm (version 7.03; sliding window ¼ 301, Bayes
estimate ¼ 10). This algorithm is an unpaired t-test, modified by the
inclusion of a Bayesian prior based on the variance of other tran-
scripts in the data set (Long et al., 2001). For further statistical analy-
sis, the ‘R’ statistical software system and GeneSpring Expression
Analysis Software (Silicon Genetics, Redwood City, CA) were used.
Quantitative polymerase chain reaction analysis
The ABI PRISM 7700 Sequence Detection System (TaqMan) was
used to perform real-time polymerase chain reactions according to
the manufacturer’s protocols. ‘Ct’ values for each transcript were
compared to those for cyclophilin A, which according to the gene
array results remained relatively constant in abundance. Primers and
probes for GSTP-1, VE-cadherin, IL1RL-1 and vimentin were pro-
prietary oligonucleotides obtained from Applied Biosystems (ABI,
UK) ‘Assays-on-Demand’ and used a 50 FAM reporter and 30 non-
fluorescent minor groove binder.
ELISA for VEGF-A
To quantify VEGF-A in endometrial culture supernatants an ELISA
assay was used (R&D systems, UK) according to the manufacturer’s
instructions, and the VEGF-A concentration determined by measur-
ing absorbance at 490 nm by comparison with a standard curve. For
each measurement six replicates were performed.
Collection of menstrual effluent
Menstrual effluent was collected by volunteers by vaginal insertion
of a menstrual cup (‘The Keeper’e, Eco Logique Inc., Canada) in
the second 24 h of bleeding. The cup was left in situ for 4 h, the
fluid sample collected and the volume measured. Menstrual cup
samples were washed with an equal volume of PBS and centrifuged
at 200 g for 10 min at 48C. The supernatant was stored at 2708C for
ELISA which was performed as described above.
Statistical analysis
All experimental data except those generated from gene arrays were
analysed using the ‘R’ statistical software package (http://rweb.stat.
umn.edu/R/doc/html/index.html). Before comparisons were made,
data were tested for normality using Chi squared tests and then for
equal variance between groups using Bartlett’s method. Based on
these results, we were able to use multi-way analysis of variance
(ANOVA). In all cases where ANOVA suggested a statistically sig-
nificant effect, post hoc Tukey’s Multiple Comparison Tests were
used to assess the source of the effect.
Results
Supernatants from cultured endometrium promote
endothelial cell proliferation and angiogenesis in vitro
To assess the effects of soluble factors derived from endome-
trium on endothelial cell biology, endometrium was collected
from five women without endometriosis in each of the mid-
proliferative (days 6–10) and mid-secretory (days 16–21)
phases of the menstrual cycle using Pipelle biopsy. Endo-
metrial cells were disaggregated, cultured (see Methods) and
culture supernatants collected over a 24 h period. These
proliferative and secretory phase endometrial culture super-
natants were applied to HUVEC (20% V/V). After 24 h
exposure to these supernatants or to medium alone (control)
or 10 ng/ml VEGF-A, cell numbers were counted. Relative to
cultures supplemented with 10 ng/ml VEGF-A (standardized
as 100%), cultures supplemented with medium alone con-
tained 40 ^ 3.5% cells, while cultures supplemented with the
proliferative and secretory phase endometrial supernatants
contained 88 ^ 19% and 84 ^ 10% cell numbers, respect-
ively (expressed as mean ^ 2 £ standard error). ANOVA
(P # 0.05) followed by Tukey’s post hoc tests indicated that
the differences in cell number between the control cultures
and the cultures supplemented with either proliferative or
secretory phase endometrial supernatants were significant.
However, the effects of the supernatants from proliferative
and secretory phase endometrial cultures were not signifi-
cantly different from one another.
To assess whether soluble factors derived from endome-
trium could promote angiogenesis in addition to promoting
endothelial proliferation, endometrial culture supernatants
were added (20% V/V) to co-cultures of HUVEC and human
dermal fibroblasts for an 11 day period. These co-cultures
spontaneously formed capillary-like structures (in vitro angio-
genesis; Bishop et al., 1999). We found that endometrial cul-
ture supernatants promoted the acquisition of capillary length
and branching (estimated by counting junction number) more
effectively than medium alone. Medium alone (n ¼ 3)
induced vessels with a mean length of 4.0 ^ 0.1 mm/mm2 and
a mean branching of 12 ^ 1.5/mm2, respectively (mean ^
SEM). However, proliferative phase supernatants (n ¼ 4)
induced vessels with a mean length of 6.5 ^ 0.1 mm/mm2 and
a mean branching of 26.3 ^ 0.9/mm2 (mean ^ SEM) and
secretory phase supernatants (n ¼ 2) induced vessels with a
C.Print et al.
2358
 at Cam
bridge U
niversity Library on M
arch 15, 2013
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
mean length of 5.8 and 6.0 mm/mm2 and a mean branching of
19 and 21/mm2 (Figure 1). Due to the small number of
secretory phase endometrial supernatants, for statistical pur-
poses the results for the two secretory phase and four prolif-
erative phase endometrial supernatant groups were combined,
and a Student’s t-test indicated that both length and branching
were significantly elevated when compared to the three con-
trol cultures (P # 0.05). The promotion of EC proliferation
and in vitro angiogenesis appears to be specific to endome-
trium, since supernatants from HUVEC themselves, primary
vascular smooth muscle cells, Jurkat T lymphocytes and pri-
mary human macrophages cultured in identical conditions to
the endometrium had no significant effect on HUVEC cell
biology or in vitro angiogenesis (data not shown). To assess
the possibility that differences in the cellular composition of
the endometrial cultures were responsible for these effects, we
analysed the cellular composition of disaggregated endome-
trium derived from three patients in the mid-proliferative and
two in the mid-secretory phases of the menstrual cycle after
culture for 24 h. These cultures contained variable
proportions (7–11%) of cytokeratinþ ve epithelial cells. The
cellular proportions were not significantly different (ANOVA;
P . 0.05) in the cultures derived from either proliferative or
secretory phase endometrium.
Supernatants from cultured endometrium regulate
the endothelial cell transcriptome
The pattern of EC transcript abundance (transcriptome) con-
tributes to the unique physical characteristics and functions
of EC, and the response of EC to extracellular signals is in
part mediated through transcriptome alteration. To assess the
transcriptome changes that were associated with (and may
have driven) endometrial supernatant-induced EC prolife-
ration and angiogenesis, we collected RNA from HUVEC
that were exposed to proliferative and secretory phase endo-
metrial culture supernatants (20% V/V) for a 24 h period.
Radio-labeled complex cDNA probes generated from these
RNAs were hybridized to nylon filter gene arrays that
Figure 1. (A) Supernatants from cultured endometrium promoted in vitro angiogenesis. Endothelial cells co-cultured with dermal fibroblasts
were detected with Ulex-FITC (Sigma, UK). Representative images of 320mm £ 1 mm fields are shown for: CO (untreated control), VE
(10 ng/ml VEGF-A165), PR and SE (supernatant from cultured proliferative- and secretory-phase endometrium, respectively). (B and C) The
length of vessels and number of inter-vessel junctions (a measure of branching) per mm2 were established for 21 randomly chosen 1 mm2
fields for each of the following conditions: three untreated cultures (control), one culture treated with 10 ng/ml VEGF-A, two cultures each
treated with secretory phase endometrial supernatants derived from different patients and four cultures each treated with proliferative phase
endometrial supernatants derived from different patients. Bars represents group means ^ SE. The mean length and number of inter-vessel
junctions of HUVEC exposed to the endometrial supernatants (n ¼ 6, composed of HUVEC exposed to two secretory phase and four prolif-
erative phase endometrial supernatants) was significantly greater than the mean length and number of inter-vessel junctions of untreated
HUVEC (Student’s t-test; P # 0.05).
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contained ,1000 genes related to endothelial cell biology
(Evans et al., 2003). Secretory phase endometrial super-
natants induced few large-scale changes in HUVEC transcript
abundance (Figure 2A). In contrast, proliferative phase endo-
metrial supernatants induced numerous large-scale changes in
HUVEC transcript abundance (Figure 2B). Transcript abun-
dance in HUVEC treated with proliferative-phase and
secretory-phase endometrial supernatants is compared in
Figure 2C. The gene array results for four transcripts differ-
entially regulated by proliferative- and secretory-phase endo-
metrial supernatants were compared with results from
TaqMan quantitative PCR and found to be concordant
(Figure 2D). For all four transcripts, t-tests on the TaqMan
data indicated a significant difference in expression between
HUVEC exposed to supernatants from proliferative and
secretory phase endometrium (P # 0.01).
To select those genes most significantly regulated in
HUVEC by cultured endometrial supernatants relative to con-
trol medium-treated HUVEC, transcripts were selected where
the ‘fold change’ was ^ 2-fold up or down and Baysian
t-test P-value was #0.05. When untreated HUVEC (n ¼ 3)
were compared to HUVEC cultured in the presence of prolif-
erative-phase endometrial supernatants (n ¼ 5) 26 transcripts
met these criteria—these are shown in Table I. However,
when untreated HUVEC (n ¼ 3) were compared to HUVEC
cultured in the presence of secretory phase endometrial
supernatants (n ¼ 5) only two transcripts met these criteria
(ADP ribosylation factor-like 2, " 2.1; and CD36, # 2.1).
However, several transcripts regulated by proliferative-phase
endometrial supernatants were in fact also regulated by
secretory-phase endometrial supernatants, but to a lesser
degree. For example, 50% of transcripts regulated ^ 2-fold
Figure 2. Gene array analysis of the response of HUVEC to endometrial culture supernatants is presented as a set of scatter-plots. White
spots denote transcripts regulated up or down, on average, by ^ 2-fold. Error bars denote SE. (A) Untreated HUVEC (n ¼ 3) compared to
HUVEC cultured in the presence of secretory phase endometrial supernatants (n ¼ 5). (B) Untreated HUVEC (n ¼ 3) compared to HUVEC
cultured in the presence of proliferative phase endometrial supernatants (n ¼ 5). (C) HUVEC cultured in the presence of proliferative phase
endometrial supernatants (n ¼ 5) compared with HUVEC cultured in the presence of secretory phase endometrial supernatants (n ¼ 5). (D)
TaqMan quantitative PCR confirmed the regulated abundance of four transcripts in five replicate experiments. Transcript abundance is pre-
sented relative to the housekeeping transcript cyclophilin-A. Black and white dots represent transcript abundance in HUVEC incubated with
proliferative and secretory phase endometrium, respectively. Horizontal lines denote means. For all four transcripts, t-tests (with Bonferroni
correction to allow for four simultaneous comparisons) indicated a significant difference between expression levels in HUVEC exposed to
supernatants from proliferative vs secretory phase endometrium (P # 0.01).
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up or down by proliferative-phase endometrial supernatants
were also regulated, in the same direction, ^ 1.6-fold up or
down by secretory phase endometrial supernatants (asterisked
in Table I).
Supernatants from cultured endometrium contain
active VEGF-A
VEGF-A is an important regulator of endothelial cell survival,
proliferation and angiogenesis, and appears to play a particu-
lar role in regulating angiogenesis in the endometrium. There-
fore, we wished to determine whether VEGF-A may mediate,
in part, the effects of cultured endometrial supernatants on
EC. Using an ELISA, we confirmed that five proliferative and
five secretory phase endometrial culture supernatants con-
tained VEGF-A at a mean concentration of 5.2 ^ 0.9 ng/ml
and 5.0 ^ 1.2 ng/ml, respectively (group mean ^ SEM).
These VEGF-A concentrations were significantly greater
(ANOVA; P # 0.01 and Tukey’s test) than those contained in
medium alone (0.36 ^ 0.2 ng/ml) or in medium conditioned
by HUVEC themselves (0.43 ^ 0.1 ng/ml). The concentration
of VEGF-A secreted by proliferative and secretory phase
endometrial cultures was not significantly different (ANOVA;
P . 0.05). We then assessed the effects of saturating quan-
tities (80 ng/ml) of an anti-VEGF-A monoclonal blocking
antibody (clone 26503) on the ability of endometrial super-
natants to promote HUVEC culture expansion. We found that
the blocking antibody significantly (but not completely) inhi-
bited the responses of the HUVEC to four out of the six endo-
metrial supernatants tested. While the blocking antibody had
no significant effect on HUVEC cultured in their optimal
medium, it did significantly reduce the expansion of serum-
starved HUVEC, presumably by reducing the VEGF-
A-derived survival signals available to these stressed cells
(Figure 3).
Endometriosis did not detectably alter the ability
of endometrium to secrete soluble factors that influence
endothelial cells
Angiogenesis is strongly implicated in the pathogenesis
of endometriosis. Therefore, we wished to assess whether sol-
uble factors produced by endometrium from women with
endometriosis have a greater effect on EC than soluble factors
produced by endometrium from women without the
disease. Endometrial biopsies were collected from endo-
metriotic patients and their secretion in culture of factors
that promoted angiogenesis and EC transcriptome change
assessed as above. Firstly, we assessed the effects on HUVEC
proliferation of proliferative (n ¼ 3) and secretory (n ¼ 3)
phase endometrial culture supernatants derived from eutopic
endometrium of endometriotic women. These effects were not
significantly different (ANOVA; P ^ 0.05; Figure 4A) from
the effects of cultured endometrial supernatants from women
without the disease. Secondly, we assessed the effects of
Table I. Transcripts differentially regulated in HUVEC cells by incubation
with supernatants from cultured proliferative phase endometrium
Name By P-value Fold change
ADP ribosylation factor-like 2 0.000168 þ2.61*
Angiopoetin 1 5.60E-06 22.39*
c-Jun N-terminal kinase 3 0.000704 22.02*
Collagen IV alpha 6 4.13E-05 þ3.28*
CXC-receptor-4 0.001395 þ2.18
Cystatin C 0.000768 þ2.10*
EST DKFZP56600424 0.000291 þ2.25
Endoglin 0.004326 þ2.40
Fibronectin-1 0.000247 þ4.49
Glutathione S transferase p1 0.000212 þ3.55*
Glyceraldehyde-3-phosphate dehydrogenase 5.00E-13 þ2.11*
Insulin-like growth factor binding protein-2 0.000591 þ3.33
Interferon gamma receptor-2 0.000271 þ2.14
Interleukin 1 receptor like-1 7.53E-07 þ3.26
Mitogen-activated protein kinase-12 0.002262 þ2.69*
Matrix metalloproteinase-2 0.000444 þ2.15*
Matrix metalloproteinase-3 0.000164 þ2.24
Myosin light chain regulator-B 0.001236 þ2.28
Plasminogen activator inhibitor-1 8.47E-06 þ3.09*
PECAM-1 (CD31) 2.13E-05 þ2.19
Rho 7 0.003470965 þ2.14*
Ryanodine receptor-1 1.89E-06 22.29*
SIVA 0.000277083 þ2.40
Tissue factor inhibitor-2 0.006458425 þ3.32*
VE-Cadherin 6.43E-05 þ3.20
Vimentin 4.93E-05 þ3.19
Transcripts that were significantly regulated in HUVEC by incubation with
proliferative phase endometrium are listed. In all cases mean transcript
abundance regulation (‘fold change’) relative to control medium-treated
HUVEC was ^ 2-fold up (þ ) or down (2), and Baysian t-test P-value (By
P-value) was #0.05. Asterisks denote those transcripts that were also up- or
down-regulated in abundance ^ 1.6-fold by exposure to supernatants from
secretory phase endometrium.
Figure 3. The effects of a blocking anti-VEGF-A antibody. Data
represent HUVEC number ^ 2 £ SD (MTS assay) after 24 h cul-
ture with endometrial supernatants (20% V/V) in presence (black
bars) or absence (white bars) of a blocking anti-VEGF-A antibody.
Control denotes medium alone, low serumþ V denotes low serum
medium (2% FCS but no other growth factors) supplemented with
10 ng/ml VEGF-A165, eoP and eoS denote culture supernatants of
endometrium collected from women with endometriosis in the pro-
liferative and secretory phases of their menstrual cycles, respect-
ively. nP and nS denote culture supernatants of endometrium
collected from women without endometriosis in the proliferative
and secretory phases of their menstrual cycles, respectively. Aster-
isks denote a significant difference in cell number attributable to the
effect of the anti-VEGF-A antibody on VEGF-A secretion by cul-
tured endometrium (ANOVA; P # 0.05). The means of four
measurements are shown, with error bars denoting 2 £ SD.
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cultured endometrial supernatants from women with endome-
triosis on the HUVEC transcriptome. The effects of prolifera-
tive phase endometrial culture supernatants derived from
women with and without endometriosis on HUVEC transcript
abundance were indistinguishable (Figure 4B). Clustering of
the array results separated HUVEC exposed to supernatants
from proliferative vs secretory phase endometrial cultures, but
could not separate HUVEC exposed to supernatants from
endometrial cultures derived from endometriotic vs non-
endometriotic women (Figure 4C). In addition, we could
detect no differences between the concentrations of VEGF-A
in endometrial supernatants derived from women with and
without the disease (ANOVA; P ^ 0.05; Figure 4D). Since
retrograde menstruation is thought to be associated with endo-
metriosis, and since VEGF-A within menstrual debris may
promote angiogenesis when endometriotic lesions first implant
in the peritoneum, we compared the concentration (Figure 4E)
and total mass (data not shown) of VEGF-A in menstrual
effluent from women with (n ¼ 16) and without (n ¼ 24)
endometriosis using ELISA. No significant differences were
detected (ANOVA; P . 0.05).
Discussion
We have shown that soluble factors derived from cultured
endometrium promote HUVEC proliferation, angiogenesis
and transcriptome change. One factor responsible for these
effects appears to be VEGF-A, since we detected VEGF-A
by ELISA in endometrial supernatants, and since a blocking
anti-VEGF-A antibody partially inhibited EC proliferation in
response to endometrial supernatants. In the small number of
patients in our study, we were unable to correlate VEGF-A
production with the stage of the menstrual cycle at which the
endometrium was collected. This is not surprising, given that
steroidal regulation of endometrial VEGF-A levels is limited
(Sharkey et al., 2000) and that regulation of VEGF-A
production in endometrium may occur on a local (e.g. in
intravascular neutrophils; Gargett et al., 2001) rather than
tissue-wide scale. Other endometrial factors may also pro-
mote EC proliferation, angiogenesis and transcriptome
change. Previously published gene array studies of
endometrium (Borthwick et al., 2003; Kao et al., 2003) pro-
vide clues to these. For example, the pro-angiogenic enzyme
MMP-3 is within the most abundant 2% of endometrial tran-
scripts (Borthwick et al., 2003). SPARC is equally abundant
in endometrium, and proteolysis of SPARC by MMP-3 pro-
duces potently pro-angiogenic peptides (Sage et al., 2003).
We could detect no difference between the pro-angiogenic
abilities of proliferative and secretory phase endometrial
supernatants, although this may have been due to the low
sample number (secretory n ¼ 2 and proliferative n ¼ 4)
examined. This concurs with the previous observation that
endometrial EC proliferation indices in vivo do not correlate
with the menstrual cycle (Rogers et al., 1998). However,
when we used gene arrays as a more sensitive indicator of
EC responses to endometrial supernatants, we found that sol-
uble factors secreted by proliferative phase endometrial cul-
tures were more effective than those secreted by secretory
phase endometrial cultures in promoting EC transcriptome
change. This suggests that, even when disaggregated and
removed from their specific endocrine environments, cultured
cells isolated from proliferative and secretory phase endomet-
rium retain their subtly different pro-angiogenic properties. A
possible explanation is suggested by a previous study (Borth-
wick et al., 2003), which found that the potent pro-angio-
genic factors Intestinal Trefoil Factor (Rodrigues et al.,
2003) and MMP-11 (Nishizuka et al., 2001) were many
times more abundant in proliferative than in secretory phase
endometrium. Although it is possible that cultures derived
from proliferative and secretory phase endometrium contain
different ratios of epithelial to stromal cells, and therefore
secrete different amounts of factors such as VEGF-A
(Gargett et al., 1999), we suggest that this is unlikely to com-
pletely explain our results. Immunohistochemistry could not
detect significant differences in the proportions of epithelial
and stromal cells between cultures derived from mid-proli-
ferative and mid-secretory phase endometrium. In addition,
the concentrations of VEGF-A did not differ significantly
when supernatants from cultures derived from mid-prolifera-
tive and mid-secretory phase endometrium were compared.
The transcriptome changes induced in EC by endomet-
rium-derived factors may partly underlie the angiogenesis
Figure 4. Endometriosis did not detectably alter the ability of endometrium to secrete soluble factors that influence endothelial cells. (A)
HUVEC were cultured with supernatants (20% V/V) taken from cultured secretory (n ¼ 3) or proliferative (n ¼ 3) phase endometrium, and
mean viable HUVEC number (^SE, relative to VEGF-A-treated cultures) was measured after 24 h. Control represents medium alone and
VEGF-A represents medium þ 10 ng/ml VEGF-A165. Black and white bars represent endometrium collected from patients with laparoscopi-
cally diagnosed endometriosis and patients without the disease, respectively. (B) Scatter-plot shows gene array analysis of the response of
HUVEC to endometrial culture supernatants. HUVEC cultured in the presence of supernatants from proliferative phase endometrium collected
from women with endometriosis (n ¼ 3) were compared to HUVEC cultured in the presence of supernatants from proliferative phase endome-
trium collected from women without the disease (n ¼ 5). (C) Ward’s method clustering grouped the arrays into those representing HUVEC
exposed to control, secretory and proliferative phase endometrial supernatants. However, the clustering could not identify whether the endo-
metrium from which the supernatants were collected were derived from women with or without endometriosis. (D) ELISA for VEGF-A in
cultured endometrial supernatants. Control 1 represents fresh medium alone; control 2, medium conditioned by confluent HUVEC for 24 h.
‘Proliferative’ and ‘secretory’ represent supernatants from endometrial cultures collected from women in the proliferative and secretory
phases of the cycle, respectively. ‘ þ end’ and ‘ 2 end’ represent supernatants from endometrium collected from women with and without
endometriosis, respectively. Error bars denote 2 £ SEM. There were no significant differences between these groups (ANOVA; P . 0.05).
(E) ELISA for VEGF-A in menstrual effluent. ‘ þ end’ denotes patients with endometriosis (n ¼ 16) and ‘ 2 end’ denotes patients without
the disease (n ¼ 24). Horizontal lines represent means. There were no significant differences between these groups (t-test; P . 0.05).
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that is also induced by these factors, since many of the
regulated EC transcripts encode promoters of angiogenesis
(Table I). These include transcripts previously found to be
up-regulated during in vitro angiogenesis (Kahn et al., 2000)
such as CXC receptor-4, collagen IVa6 and tissue factor-
inhibitor-2. Given that VEGF-A was secreted by the cultured
endometrium, it is interesting that transcripts previously
found to be up-regulated in EC by VEGF-A (Weston et al.,
2002; Yang et al., 2002) were also up-regulated by endo-
metrial supernatants, such as CXC receptor-4, MMP-2 tissue
factor-inhibitor-2 and VE-cadherin. Several other transcripts
regulated by the endometrial supernatants have clear associ-
ations with EC survival and proliferation. For example,
angiopoietin-1 was down-regulated. Angiopoietin-1 usually
functions to stabilize vessels, but is functionally inhibited by
angiopoietin-2 during angiogenesis. Endoglin (up-regulated)
is a component of the transforming growth factor beta recep-
tor complex that is essential for vessel development (Zhang
et al., 2002). PECAM-1 and VE-cadherin (both up-regulated)
are EC adhesion molecules that promote EC survival through
protein kinase B (AKT) signaling. Other regulated signaling
molecules include; ADP ribosylation factor-like-2, interleu-
kin-1 receptor-like-1, interferon g receptor-2, MAP kinase-
12, Rho-7 and SIVA. Several transcripts associated with the
extracellular matrix were regulated in EC by endometrial
supernatants. These may contribute to cyclical remodeling of
both vessels and other elements of endometrium. For
example, Plasminogen activator-inhibitor-1 and fibronectin-1
were up-regulated. MMP-2 and MMP-3 were also up-
regulated and have previously been associated with cyclical
endometrial remodelling (Ueda et al., 2002) and endometrio-
sis (Cox et al., 2001).
Previous studies (summarized in the Introduction) have
suggested that both endometrial and peritoneal factors
promote the angiogenesis that underlies endometriosis. Our
study investigated the role played by endometrial factors. We
found that endometriosis had no effect on the capacity of
endometrial culture supernatants to induce angiogenesis or
gene expression changes in EC. In addition, we found no
relationship between endometriosis and VEGF-A production
by cultured endometrium or VEGF-A concentration or mass
in menstrual effluent. This suggests that differences between
the soluble pro-angiogenic factors secreted by the endomet-
rium of endometriotic and non-endometriotic women may
not be a major determinant of this disease. It is possible that
the small size of our study (dictated by our stringent patient
selection criteria and the relative rarity of unmedicated endo-
metriotic patients) has caused us to miss a subtle role played
by soluble endometrial factors. However, it is also possible
that confounding and the lack of stringent patient selection
may have caused some previous investigators to overestimate
the role played by endometrial factors in this disease.
The importance of stringent patient selection criteria and
measures to reduce confounding has been highlighted in a
recent study published in this journal of soluble ICAM-1 in
endometriotic patients (Steff et al., 2004). Models of endo-
metriosis in which human endometrium is transplanted into
immunocompromized mice (Hull et al., 2003) will provide
powerful tools to dissect the relative roles of endometrial and
peritoneal factors.
In conclusion, we have shown that endometrium cultured
in vitro produces soluble factors, including VEGF-A, that
promote angiogenesis. Endometrium, especially from the
proliferative phase of the menstrual cycle, also promotes
significant pro-angiogenic changes to the EC transcriptome.
However, we were unable to detect any association between
endometriosis and the effects of soluble endometrial factors
on EC biology or gene expression. We believe that the
endometrial factor-induced EC transcriptome changes ident-
ified here provide insight into the dynamic control of vessel
structure on which both the eutopic endometrium and
endometriotic lesions depend. They also provide potential
therapeutic targets for the modulation of endometrial
angiogenesis.
Acknowledgements
We wish to acknowledge Kate Day and Isabelle Perault for techni-
cal assistance and Andrew Sharkey and Stephen Charnock-Jones for
advice on endometrial culture and gene array analysis, as well as
Mr Andrew Prentice and the staff of the Rosie Hospital, Cambridge,
for assistance with tissue collection. This study was funded by a
Wellbeing project grant. C.P. was funded by a Wellcome Trust
fellowship.
References
Alvarez RJ, Gips SJ, Moldovan N, Wilhide CC, Milliken EE, Hoang AT,
Hruban RH, Silverman HS, Dang CV and Goldschmidt-Clermont PJ
(1997) 17beta-estradiol inhibits apoptosis of endothelial cells. Biochem
Biophys Res Commun 237,372–381.
Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NFK and Wheatley DN
(1999) An in vitro model of angiogenesis: Basic features. Angiogenesis
3,335–344.
Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R,
Phillips SC and Smith SK (2003) Determination of the transcript profile of
human endometrium. Mol Hum Reprod 9,19–33.
Cameron IT and Campbell S (1998) Nitric oxide in the endometrium. Hum
Reprod Update 4,565–569.
Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP,
Fountain SA, Boocock CA and Smith SK (1993) Identification and locali-
zation of alternately spliced mRNAs for vascular endothelial growth factor
in human uterus and estrogen regulation in endometrial carcinoma cell
lines. Biol Reprod 48,1120–1128.
Cox KE, Piva M and Sharpe-Timms KL (2001) Differential regulation of
matrix metalloproteinase-3 gene expression in endometriotic lesions com-
pared with endometrium. Biol Reprod 65,1297–1303.
Donnez J, Smoes P, Gillerot S, Casanas-Roux F and Nisolle M (1998)
Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod
13,1686–1690.
Evans AL, Sharkey AS, Saidi S, Print CG, Catalano R, Smith SK and
Charnock-Jones DS (2003) Generation and Use of a Tailored Gene Array
to Investigate Vascular Biology. Angiogenesis 6,93–104.
Ferriani RA, Charnock-Jones DS, Prentice A, Thomas EJ and Smith SK
(1993) Immunohistochemical localization of acidic and basic fibroblast
growth factors in normal human endometrium and endometriosis and the
detection of their mRNA by polymerase chain reaction. Hum Reprod
8,11–16.
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis.
Semin Oncol 29,15–18.
Freitas S, Meduri G, Le Nestour E, Bausero P and Perrot-Applanat M (1999)
Expression of metalloproteinases and their inhibitors in blood vessels in
human endometrium. Biol Reprod 61,1070–1082.
Fujiwaki R, Hata K, Iida K, Maede Y, Watanabe Y, Koike M and
Miyazaki K (1999) Co-expression of vascular endothelial growth factor
C.Print et al.
2364
 at Cam
bridge U
niversity Library on M
arch 15, 2013
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
and thymidine phosphorylase in endometrial cancer. Acta Obstet Gynecol
Scand 78,728–734.
Gargett CE, Lederman F, Heryanto B, Gambino LS and Rogers PA (2001)
Focal vascular endothelial growth factor correlates with angiogenesis in
human endometrium; role of intravascular neutrophils. Hum Reprod 16,
1065–1075.
Gargett CE, Lederman FL, Lau TM, Taylor NH and Rogers PA (1999) Lack
of correlation between vascular endothelial growth factor production and
endothelial cell proliferation in the human endometrium. Hum Reprod 14,
2080–2088.
Gargett CE and Rogers PA (2001) Human endometrial angiogenesis. Repro-
duction 121,181–186.
Hague S, MacKenzie IZ, Bicknell R and Rees MC (2002) In-vivo angio-
genesis and progestogens. Hum Reprod 17,786–793.
Haney AF (1990) Etiology and histogenesis of endometriosis. Prog Clin Biol
Res 323,1–14.
Hii LL and Rogers PA (1998) Endometrial vascular and glandular expression
of integrin alpha(v)beta3 in women with and without endometriosis. Hum
Reprod 13,1030–1035.
Hull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG,
Tom BD, Fan TP and Smith SK (2003) Antiangiogenic agents are effec-
tive inhibitors of endometriosis. J Clin Endocrinol Metab 88,2889–2899.
Iruela-Arispe ML, Rodriguez-Manzaneque JC and Abu-Jawdeh G (1999)
Endometrial endothelial cells express estrogen and progesterone receptors
and exhibit a tissue specific response to angiogenic growth factors. Micro-
circulation 6,127–140.
Jaffe EA, Nachman RL, Becker CG and Minick CR (1973) Culture of
human endothelial cells derived from umbilical veins; identification by
morphologic and immunologic criteria. J Clin Invest 52,2745–2756.
Johnson N, Sengupta S, Lessan K, Charnock-Jones DS, Saidi S, Scott L,
Stephens R, Freeman T, Tom B, Harris M et al. (2003) Endothelial Cells
preparing to die by apoptosis initiate a program of transcriptome and gly-
come regulation. FASEB J 18,188–190.
Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J,
Grimaldi CJ, Peale F, Draksharapu A et al. (2000) Gene expression profil-
ing in an in vitro model of angiogenesis. Am J Pathol 156,1887–1900.
Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, Osteen K,
Lessey BA and Giudice LC (2003) Expression profiling of endometrium
from women with endometriosis reveals candidate genes for disease-based
implantation failure and infertility. Endocrinology 144,2870–2881.
Kats R, Collette T, Metz CN and Akoum A (2002) Marked elevation of
macrophage migration inhibitory factor in the peritoneal fluid of women
with endometriosis. Fertil Steril 78,69–76.
Khan KN, Masuzaki H, Fujishita A, Kitajima M, Sekine I and Ishimaru T
(2003) Immunoexpression of hepatocyte growth factor and c-Met receptor
in the eutopic endometrium predicts the activity of ectopic endometrium.
Fertil Steril 79,173–181.
Kim SH, Choi YM, Chae HD, Kim KR, Kim CH and Kang BM (2001)
Increased expression of endoglin in the eutopic endometrium of women
with endometriosis. Fertil Steril 76,918–922.
Kohnen G, Campbell S, Jeffers MD and Cameron IT (2000) Spatially regu-
lated differentiation of endometrial vascular smooth muscle cells. Hum
Reprod 15,284–292.
Krikun G, Schatz F, Finlay T, Kadner S, Mesia A, Gerrets R and Lockwood
CJ (2000) Expression of angiopoietin-2 by human endometrial endothelial
cells: regulation by hypoxia and inflammation. Biochem Biophys Res
Commun 275,159–163.
Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence D,
Bowen JM, Gardner L, King A et al. (2001) Angiogenic growth factor
messenger ribonucleic acids in uterine natural killer cells. J Clin Endocri-
nol Metab 86,1823–1834.
Long AD, Mangalam HJ, Chan BY, Tolleri L, Hatfield GW and Baldi P
(2001) Improved statistical inference from DNA microarray data using
analysis of variance and a Bayesian statistical framework Analysis of
global gene expression in Escherichia coli K12. J Biol Chem 276,
19937–19944.
McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Shar-
key AM and Smith SK (1996) Vascular endothelial growth factor is pro-
duced by peritoneal fluid macrophages in endometriosis and is regulated
by ovarian steroids. J Clin Invest 98,482–489.
Mints M, Blomgren B, Falconer C and Palmblad J (2002) Expression of the
vascular endothelial growth factor (VEGF) family in human endometrial
blood vessels. Scand J Clin Lab Invest 62,167–175.
Moller B, Lindblom B and Olovsson M (2002) Expression of the vascular
endothelial growth factors B and C their receptors in human endometrium
during the menstrual cycleC. Acta Obstet Gynecol Scand 81,817–824.
Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC,
Kleinman HK and Schnaper HW (1995) Estrogen promotes angiogenic
activity in human umbilical vein endothelial cells in vitro and in a murine
model. Circulation 91,755–763.
Nikitenko LL, MacKenzie IZ, Rees MC and Bicknell R (2000) Adrenome-
dullin is an autocrine regulator of endothelial growth in human endo-
metrium. Mol Hum Reprod 6,811–819.
Nishizuka I, Ichikawa Y, Ishikawa T, Kamiyama M, Hasegawa S,
Momiyama N, Miyazaki K and Shimada H (2001) Matrilysin stimulates
DNA synthesis of cultured vascular endothelial cells and induces angio-
genesis in vivo. Cancer Lett 173,175–182.
Noda T, Murakami T, Terada Y, Yaegashi N and Okamura K (2003)
Increased production of tumor necrosis factor-alpha by peritoneal fluid
mononuclear cells induced by 60 kDa heat shock protein in women with
minimal to mild endometriosis. Am J Reprod Immunol 50,427–432.
Richter ON, Dorn C, Rosing B and Ulrich U (2004) Tumour necrosis factor
alpha secretion by peritoneal macrophages in patients with endometriosis.
Arch Gynecol Obstet. In press.
Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel
E, Westley BR, May FE, Thim L, Mareel M et al. (2003) Trefoil peptides
as proangiogenic factors in vivo and in vitro: implication of cyclooxygen-
ase-2 and EGF receptor signalling. FASEB J 17,7–16.
Rogers PA, Lederman F and Taylor N (1998) Endometrial microvascular
growth in normal and dysfunctional states. Hum Reprod Update 4,
503–508.
Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P,
Maurice DH and Bassuk JA (2003) Cleavage of the matricellular protein
SPARC by matrix metalloproteinase 3 produces polypeptides that influ-
ence angiogenesis. J Biol Chem 278,7849–7857.
Sandberg T, Ehinger A and Casslen B (2001) Paracrine stimulation of capil-
lary endothelial cell migration by endometrial tissue involves epidermal
growth factor and is mediated via up-regulation of the urokinase plasmino-
gen activator receptor. J Clin Endocrinol Metab 86,1724–3170.
Sharkey AM, Day K, McPherson A, Malik S, Licence D, Smith SK and
Charnock-Jones DS (2000) Vascular endothelial growth factor expression
in human endometrium is regulated by hypoxia. J Clin Endocrinol Metab
85,402–409.
Sillem M, Prifti S, Neher M and Runnebaum B (1998) Extracellular matrix
remodelling in the endometrium and its possible relevance to the patho-
genesis of endometriosis. Hum Reprod Update 4,730–735.
Smith SK (1997) Angiogenesis. Semin Reprod Endocrinol 15,221–227.
Steff AM, Gagne D, Page M, Hugo P and Gosselin D (2004) Concentration
of soluble intercellular adhesion molecule-1 in serum samples from
patients with endometriosis collected during the luteal phase of the men-
strual cycle. Hum Reprod 19,172–178.
Steff AM, Gagne D, Page M, Rioux A, Hugo P and Gosselin D (2004)
Serum concentrations of insulin-like growth factor-1, soluble tumor necro-
sis factor receptor-1 and angiogenin in endometriosis patients. Am J
Reprod Immunol 51,166–173.
Suzumori N, Sugiura-Ogasawara M, Katano K and Suzumori K (2003)
Women with endometriosis have increased levels of placental growth fac-
tor in the peritoneal fluid compared with women with cystadenomas. Hum
Reprod 18,2595–2598.
Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda K,
Yamaguchi H, Akise D, Hung YC et al. (2002) Survivin gene expression
in endometriosis. J Clin Endocrinol Metab 87,3452–3459.
Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J
and Grove BH (1999) Relaxin stimulates expression of vascular endo-
thelial growth factor in normal human endometrial cells in vitro and is
associated with menometrorrhagia in women. Hum Reprod 14,800–806.
Weston GC, Haviv I and Rogers PA (2002) Microarray analysis of VEGF-
responsive genes in myometrial endothelial cells. Mol Hum Reprod 8,
855–863.
Wingfield M, Macpherson A, Healy DL and Rogers PA (1995) Cell prolifer-
ation is increased in the endometrium of women with endometriosis. Fertil
Steril 64,340–346.
Wu MY, Chao KH, Yang JH, Lee TH, Yang YS and Ho HN (2003) Nitric
oxide synthesis is increased in the endometrial tissue of women with endo-
metriosis. Hum Reprod 18,2668–2671.
Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A and
Gerritsen ME (2002) Vascular endothelial growth factor-induced genes in
Endometrial factors regulate endothelial biology
2365
 at Cam
bridge U
niversity Library on M
arch 15, 2013
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
human umbilical vein endothelial cells: relative roles of KDR and Flt-1
receptors. Arterioscler Thromb Vasc Biol 22,1797–1803.
Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M and Sasaki R (1998)
Estrogen-dependent production of erythropoietin in uterus and its impli-
cation in uterine angiogenesis. J Biol Chem 273,25381–25387.
Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK,
Lysko PG and Feuerstein GZ (1997) 2-Methoxyestradiol, an endogenous
estrogen metabolite, induces apoptosis in endothelial cells and inhibits
angiogenesis: possible role for stress-activated protein kinase signaling
pathway and Fas expression. Mol Pharmacol 51,951–962.
Zhang EG, Smith SK and Charnock-Jones DS (2002) Expression of CD105
(endoglin) in arteriolar endothelial cells of human endometrium throughout
the menstrual cycle. Reproduction 124,703–711.
Submitted on November 5, 2003; resubmitted on May 18, 2004; accepted on
June 16, 2004
C.Print et al.
2366
 at Cam
bridge U
niversity Library on M
arch 15, 2013
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
	                                                                                                                             Appendices 
   
The mechanisms coordinating vertebrate haematopoiesis and angiogenesis 120	  
 
PUBLICATION 7 
 
Xu, F., T. M. Hazzard, A. Evans, S. Charnock-Jones, S. Smith, and R. L. Stouffer. 
2005. Intraovarian Actions of Anti-Angiogenic Agents Disrupt Periovulatory Events 
During the Menstrual Cycle in Monkeys. Contraception 71, (4), 239-48 
Cited by 29, Impact factor 2.724 
ISSN: 0010-7824 
Journal Type 
The journal Contraception covers all aspects of contraception from cost effectiveness, 
safety and failure rates to original research such as this article on prevention of 
implantation. Manuscripts are accepted from both clinicians and researchers. 
Personal Contribution 
For this project my role was to take a secondary hybridoma producing monoclonal anti 
human VEGF-A and from it create a tertiary clone. The line (4E3) was produced from a 
cross between B cells and NSO, a mouse myeloma non - IgG producing cell. Alongside 
this, another hybridoma line (NQ10) producing mouse anti human IgG1 as an isotype 
control was produced. Antibody was then produced on a large scale in bioreactors, 
quantified by developing an in-house ELISA assay, and finally purified by FPLC 
(ÄKTAprime™, GE Healthcare) for in vivo injections. 
	    
 
ContraceptionReview article
Intraovarian actions of anti-angiogenic agents disrupt periovulatory events
during the menstrual cycle in monkeys
Fuhua Xua, Timothy M. Hazzarda, Amanda Evansb, Stephen Charnock-Jonesb,
Stephen Smithc, Richard L. Stouffera,T
aDivision of Reproductive Sciences, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006-3499, USA
bDepartment of Obstetrics and Gynecology, the Rosie Maternity Hospital, University of Cambridge, Cambridge CB2 2SW, UK
cFaculty of Medicine, Imperial College, London SW7 2AZ, UK
Received 28 October 2004; accepted 2 December 2004
Abstract
To determine if anti-angiogenic agents disrupt primate ovarian function, vehicle or a general angiostatic compound (TNP-470), specific
antagonists of vascular endothelial growth factor (soluble VEGF receptor-1, sVEGFR-1; anti-VEGF monoclonal antibody, VEGFAb) and/or
an angiopoietin antagonist (Ang-2) were administered to rhesus monkeys: (1) locally via injection into the preovulatory follicle at midcycle
or the developing corpus luteum at the midluteal phase; or (2) systemically via subcutaneous injection in the early follicular phase or at
midcycle during the natural menstrual cycle. Compared to controls, intrafollicular injection of TNP-470 or sVEGFR-1 decreased circulating
progesterone (P) levels in the subsequent luteal phase. Treatment with sVEGFR-1, but not TNP-470, also decreased the incidence of
ovulation. Intrafollicular injection of Ang-2 also prevented ovulation, as well as any functional luteal phase. In the absence of elevated P,
serum estradiol levels rose to peak levels 11–12 days post-Ang-2 treatment, at which time another large antral follicle was observed on the
contralateral (noninjected) ovary. Intraluteal and systemic injection of VEGF antagonists alone or with Ang-2 had minimal effects. Thus, anti-
angiogenic factors can act locally in the primate follicle to disrupt the gametogenic (oocyte release) and endocrine (steroid) functions of the
ovary. However, further studies are needed to optimize delivery of angiogenic agents before they can be meaningfully evaluated as possible
contraceptive agents.
D 2005 Elsevier Inc. All rights reserved.
Keywords: Vascular endothelial growth factor; VEGF; Angiopoietin-2; Ovulation; Corpus luteum function; Rhesus monkeys; Ovarian disruption1. Introduction
Aside from pathologic and trauma conditions, blood
vessel development in healthy adults is primarily limited to
the ovary and reproductive tract, that is, tissues that undergo
sequential growth and regression during the ovarian cycle.
In recent years, investigators have attempted to elucidate the
factors and processes controlling vessel development, that
is, angiogenesis, during follicle growth and subsequent
development of the corpus luteum from the post-ovulatory
follicle [1,2]. Considerable progress occurred with the
realization that two classes of factors with a high degree
of specificity of action on endothelial/peri-endothelial cells
in the vasculature, namely, the vascular endothelial growth0010-7824/$ – see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2004.12.017
T Corresponding author.
E-mail address: stouffri@ohsu.edu (R.L. Stouffer).factors (VEGF) and angiopoietins (Ang), are present in
ovarian follicles and corpora lutea (see reviews, [3–5]).
Members of the VEGF family (A-F), as well as isoforms
of individual VEGFs (e.g., the 165-amino-acid form of
VEGF-A), are found in many tissues during embryonic
development and are believed to play critical roles in
vasculogenesis [6]. However, their expression is more
limited in adults, with most interest in VEGF pertaining to
its production and actions in the vascular bed of diseased
tissues (e.g., cancers). Attention to date in the ovary has
focused on VEGF-A, and it is now evident that its lower
molecular weight, secreted forms (VEGF-121 and -165)
[7,8], its two receptors (VEGFR-1 and -2) [9,10] and
possibly two coreceptors (neuropilin-1 and -2) [11] are
expressed in ovarian tissues, including the primate ovary.
Although mounting evidence, especially from the past 5
years, suggests that VEGF-A is important for vessel71 (2005) 239–248
F. Xu et al. / Contraception 71 (2005) 239–248240development in ovarian compartments [3–5], an emerging
model (Fig. 1) proposes that the angiopoietins combine with
VEGF to control vessel maturation, function and stability
[12]. Notably, an endogenous Ang agonist, Ang-1, may act
to promote vessel maturation, whereas the endogenous Ang
antagonist, Ang-2, may cause vessel destruction [12]. There
are few reports on Ang receptor (Tie-2) expression or action
in the ovary [13–15], but there are observations that Ang-1
(not Ang-2) expression is elevated in luteinizing cells of the
ovulatory follicle [16], whereas Ang-2 expression is
associated with follicle atresia [17] and corpus luteum
regression [13].
The importance of increased vascularity for follicle
growth and subsequent corpus luteum development has
been implied for years [1–3]. If true, it could be
hypothesized that treatment with anti-angiogenic agent
would disrupt vessel development and function (and
perhaps cause vessel degeneration; Fig. 1), thereby prevent-
ing the gametogenic (oocyte) and endocrine (steroid
hormone) functions of the ovary. From an applied perspec-
tive, anti-angiogenic agents could have contraceptive
potential due to the limited sites of angiogenesis in the
adult female, and potential actions on both the ovary and
reproductive tract [18,19] as a dual approach to blocking
pregnancy initiation. Therefore, studies were designed to
examine the effects of three classes of anti-angiogenic
agents: (1) a general angiostatic compound; (2) a specific
VEGF-A antagonist; and (3) an Ang antagonist — on
ovarian function when either delivered directly into theFig. 1. A model for regulation of blood vessel development, maintenance, remod
(Ang-1) and antagonist (Ang-2), via their receptor tyrosine kinases VEGFR-1 (F
Hanahan in 1997 (reprintedwith permission fromRef. [12]. Illustration byK. Sutliff
and regression associated with follicle growth vs. atresia, and corpus luteum dev
development or function, via specific VEGF or Ang antagonist, could disrupt normadominant structure (dominant follicle or corpus luteum) of
the ovary or systemically during the menstrual cycle in a
nonhuman primate model, the rhesus monkey. The former
approach offers the advantage of examining the direct effects
of agents in the ovary, whereas the latter approach was
considered a prelude to future studies testing the contracep-
tive efficiency of antiangiogenic agents in monkeys. Due to
the limited availability of other agents, systemic delivery
was only possible using the anti-VEGF antibody.
The effects of intrafollicular delivery of general angio-
static compounds [20] and lower doses of a VEGF
antagonist [21] on ovarian function were published previ-
ously. The Results section will summarize these findings
and then describe in detail the data from studies involving
intrafollicular injection of high-dose anti-VEGF or Ang
antagonist, plus the results from studies of their local
injection into the corpus luteum or systemic delivery.2. Materials and methods
2.1. Animals
The general care and housing of rhesus monkeys was
provided by the Division of Animal Resources at the
Oregon National Primate Research Center (ONPRC) [22].
Animal protocols and experiments were approved by the
ONPRC Animal Care and Use Committee, and studies were
conducted in accordance with the Guide for the Care and
Use of Laboratory Animals [23].eling and degeneration, by VEGF and the endogenous angiopoietin agonist
lt-1) or -2 (Flk-1) and Tie-2, respectively. Although originally proposed by
,n 1997AAAS), this model can be applied to the cycle of vessel development
elopment vs. luteolysis during the ovarian cycle. Thus, blockade of vessel
l gametogenic and endocrine function of the ovary and hence impair fertility.
F. Xu et al. / Contraception 71 (2005) 239–248 241Adult, female rhesus monkeys exhibiting normal men-
strual cycles of approximately 28 days were bled daily by
saphenous venipuncture beginning 6–8 days after the onset
of menses. Serum concentrations of estradiol (E) and
progesterone (P) were measured by RIAs validated for
nonhuman primates in phase I [24,25]. In phase II, the
serum E and P levels were determined by specific electro-
chemoluminescent assay using a Roche Elecsys 2010
Analyzer (Roche, Indianapolis, IN) in the Endocrine
Services Laboratory of the ONPRC [26]. The interassay
variation was 6.1% for E and 5.4% for P, and the limit of
sensitivity was 5 pg/mL for E and 0.03 ng/mL for P.
Estradiol values were used to estimate the day of the
midcycle gonadotropin surge and time of ovulation as
previously established in our laboratory [27]. Day 1 of the
luteal phase is designated as the day when preovulatory
serum E levels (range, 250–600 pg/mL) decline to less than
100 pg/mL [27].
2.2. Intrafollicular injection
Intrafollicular injection was performed as previously
described [20,21] on anesthetized animals during surgery
to expose the ovary bearing the dominant follicle on the day
before (day 1) or the day of (day 0) the midcycle LH
surge. The needle on an insulin syringe containing 50 AL of
the test solution was inserted through the stroma of the
ovary before penetrating the follicular wall. Then 50 AL of
follicular fluid was aspirated into the syringe, diluting the
syringe contents by half, before injecting 50 AL of this
mixed solution into the follicle. Upon removal of the needle,
the follicle was observed to make sure that deflation did not
occur. Ovaries were viewed and photographed by laparos-
copy at 3 days postinjection for evidence of follicle rupture
and luteinization. Blood samples were collected on a daily
basis until the first day of menses and analyzed for serum P
levels. The day of the LH surge was confirmed, using a
mouse Leydig cell bioassay for LH [28], and verified that all
animals were injected on the day before (day 1) or the day
of (day 0) the midcycle gonadotropin surge.
A sequential experimental design was typically
employed whereby animals received an intrafollicular in-
jection of vehicle (0.1% BSA in PBS, n=14 per drug), and
then either a general angiostatic compound (TNP-470, also
known as AGM-1470; Takeda Abbot Pharmaceuticals, Lake
Forest, IL [29]), a specific VEGF antagonist (recombinant
human soluble VEGFR-1/Fc chimera, sVEGFR-1; R&D
Systems, Minneapolis, MN) or the endogenous Ang
antagonist (recombinant human angiopoietin-2, Ang-2;
R&D Systems) in subsequent treatment cycles. Although
the general protocol typically does not alter ovarian function
[28], the sequential approach beginning with vehicle
injection permits identification of the rare animal that may
be stressed and/or exhibits an aberrant ovarian cycle,
enabling such animals to be removed from the treatment
protocols. TNP-470 was selected for study based on
evidence that treatment resulted in fewer and smallercorpora lutea in mice [29]. The final delivery doses of
TNP-470 were 80 pg (n=4) and 400 ng (n=5); the former
dose achieved an initial concentration in the dominant
follicle (~200 AL antral fluid volume) that approximated the
reported IC50 for endothelial cell proliferation [30]. A
soluble VEGF receptor-1 (sVEGFR-1) compound was used
to bind and neutralize angiogenic VEGF moieties (notably
VEGF-A, but also VEGF-B), rather than sVEGFR-2 agents
which also bind lymphangiogenic moieties (VEGF-C,
VEGF-D as well as VEGF-A) [6]. The final delivery doses
of sVEGFR-1 were 1.5 Ag (n=4), 7.5 Ag (n=4) and 30 Ag
(n=3). The final delivery dose of Ang-2 was 20 Ag (n=5).
After menses in each protocol, animals were permitted to
recover for at least one menstrual cycle before blood
samples were taken to start the next protocol.
In further protocols, TNP-470- and sVEGFR1-treated
animals again acted as their own controls but were assigned
randomly to receive an intrafollicular injection of either
vehicle or the compound on day 1 or day 0. Animals were
laparotomized 3 days after the injection and the ovary
bearing the injected follicle was removed and fixed in
formaldehyde overnight before embedding in paraffin. The
paraffin-embedded tissues were serially sectioned using an
American Optical (Southbridge, MA) microtome and
mounted on Superfrost Plus slides (Fisher, Santa Clara,
CA). Slides were stained with hematoxylin and eosin and
viewed to determine if the oocyte was released from the
follicle or trapped within the luteinized tissue.
2.3. Intraluteal injection
Intraluteal injection was performed on anesthetized
animals during surgery to expose the ovary bearing the
corpus luteum on day 6 of the luteal phase [21]. The needle
on an insulin syringe containing 30 AL of solution was
inserted through the stroma of the ovary before penetrating
the corpus luteum. After injecting 10 AL of solution, 30 s
was allowed for the solution to disseminate in the corpus
luteum. Upon removal of the needle, no leakage was
observed from the injection site. Blood samples were
collected on a daily basis until the first day of menses and
analyzed for serum P levels.
Again, a sequential experimental design was typically
employed with vehicle (0.1% BSA in PBS, n=10) serving
as control in the first protocol. A dose of 1.1 Ag sVEGFR-1
(n=4), 15 Ag sVEGFR-1 (n=3) or 15 Ag sVEGFR-1
plus 20 Ag Ang-2 (n=3) was injected in subsequent treat-
ment protocols.
2.4. Systemic injection
Systemic injection was performed at subcutaneous sites.
Animals were injected with monkey IgG (10 mg, Sigma, St.
Louis, MO) on the days noted below as a control in the first
protocol. In the subsequent protocol, one group of animals
(n=4) received 10 mg anti-VEGF antibody (supplied by
Dr. Stephen Charnock-Jones, Department of Obstetrics and
Gynaecology, University of Cambridge, UK) on days 1, 3
F. Xu et al. / Contraception 71 (2005) 239–248242and 5 of the follicular phase in the menstrual cycle. Another
group of animals (n=4) received the same dose of anti-
VEGF antibody on the day before or the day of the midcycle
LH surge, and 2 days later. Blood samples were collected on
a daily basis until the first day of next menses and analyzed
for serum E and P levels.
2.5. Statistics
E and P levels in serum were analyzed by ANOVA
with repeated measures to identify differences between
controls and each treatment group (SigmaStat statistical
software version 2.0, Chicago, IL). Differences were con-
sidered significant at pb .05 and values are presented as
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Fig. 2. Serum P levels in monkeys receiving an intrafollicular injection of a
low, medium (panel A; adapted from Ref. [21]) or high (panel B;
unpublished data) dose of sVEGFR-1 compared to vehicle-injected controls
(shaded area=meanFSEM, n =13). Block rectangle depicts day of
injection (day 1 to day 0 of LH surge) of the preovulatory follicle.
Asterisks indicate significant (pb .05) differences in P concentrations on
specific days. bMQ denotes average days of onset of menstruation in
controls, whereas an bm/mV/mWQ depicts onset in low/medium/high dose of
sVEGFR-1-treated animals. Although low-dose sVEGFR-1 treatment did
not alter P levels as a group (n =4), levels were decreased in two of four
animals (see Ref. [16]) until mid late luteal phase. The medium- and high-
dose treatments significantly suppressed P levels until late luteal phase.3. Results
3.1. Phase I: intrafollicular delivery of the anti-angiogenic
agent TNP-470 [20]
We reported previously [20] that intrafollicular injection
of vehicle into the preovulatory follicle of rhesus monkeys
during spontaneous menstrual cycles resulted in circulating
patterns and levels of serum E and P that were typically
comparable to those observed in untreated animals in our
colony [31]. Only 1 of the 14 animals did not display the
typical patterns and was eliminated from further treatment
protocols. In contrast, when TNP-470 (80 pg) was injected,
serum P levels increased normally until the midluteal
(day 8) phase, but then declined prematurely by day 9
(pb .05, compared to vehicle control) and remained below
control levels until menses. Early menstruation also occurred
in three of four TNP-470-treated animals. Following a higher
dose (400 ng) of TNP-470, serum P levels were somewhat
diminished in the early luteal phase (days 3–5, pb .05), but
again reached typical levels at the midluteal phase, only to
decline prematurely by day 9 (pb .05).
Vehicle-injected ovaries displayed indices of follicle
rupture (protruding stigmata) and luteinization (yellowish
tissue with prominent vessels) by 3 days postinjection. TNP-
470-treated ovaries exhibited signs of distension (torn
surface epithelium/tunica albuginea) and luteinization, but
well-formed stigmata were not observed. However, upon
serial sectioning of the tissue, a btrappedQ oocyte was not
observed in the developing corpora lutea of TNP-470-
treated, nor in the vehicle-treated animals. Nevertheless,
the early corpus luteum in TNP-470-injected ovaries
contained pockets of abundant blood cells that were not
observed in controls.
3.2. Phase II: delivery of anti-VEGF antagonist
3.2.1. Intrafollicular injection of sVEGFR-1
We reported previously [21] the results of injecting either
vehicle or two different doses of sVEGFR-1 into the
preovulatory follicle of rhesus monkeys during naturalmenstrual cycles. As noted in phase I, vehicle injection
did not result in any changes in ovarian function in 13 of 14
animals. After vehicle injection, P levels (Fig. 2A, shaded
region) increased on day 0 and continued to rise until the
midluteal phase (days 5–10) and then declined through the
late luteal phase until menstruation. Likewise, injection of
low dose sVEGFR-1 (1.5 Ag) into the preovulatory follicle
did not significantly alter P levels as a group (n=4)
compared to controls. However, when treated animals were
examined individually [21] (data not shown), low-dose
sVEGFR-1 injection suppressed P concentrations during the
early to midluteal phase in two of four animals. However,
there was no change in the day of menstruation between the
0 3 6 9 12 15 18
0
1
2
3
4
5
Days of the Luteal Phase
sVEGFR-1, 1.1 µg, n=4
sVEGFR-1, 15 µg, n=3
M
m’
mPr
og
es
te
ro
ne
, n
g/
m
l
Fig. 3. Serum P levels in monkeys receiving an intraluteal injection of a low
or high dose of sVEGFR-1 at midluteal phase compared to vehicle-injected
controls (shaded area=meanFSEM, n =7). The arrow depicts the injection
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tration of higher dose of sVEGFR-1 (7.5 Ag) resulted in a
consistent hormonal profile (Fig. 2A). In all four animals,
serum P concentrations were significantly reduced com-
pared to controls (pb .05), with suppressed levels by the
midluteal phase, which remained low until the late luteal
phase. Again, however, there was no change in the day of
onset of menstruation after sVEGFR-1 treatment. Following
this initial report on the dose-response effects of sVEGFR-1
[21], an even greater dose (30 Ag) was tested to determine if
the luteal phase could be completely ablated. This highest
dose of sVEGFR-1 (30 Ag) significantly reduced serum P
concentrations compared to controls (pb .05) from the early
to the late luteal phase (Fig. 2B). But again, P levels rose
above baseline during the luteal phase and there was no
significant change in the day of menstruation between
treatment and control groups.
Laparoscopic evaluation established that by 3 days after
the intrafollicular injection all vehicle-injected follicles
(n=13) displayed indices of ovulation (protruding stigmata)
and luteinization (yellowish tissue with prominent capillar-
ies) [21]. Evaluation of serial sections of ovaries collected
3 days after the intrafollicular injection of vehicle revealed
an ovulatory canal [21] that ran from within the luteinizing
tissue to the surface of the ovary, as well as the absence of
an oocyte. However, 5 of 11 follicles injected with VEGFR-1
did not exhibit any signs of follicular rupture; two of three
follicles receiving the highest dose (30 Ag sVEGFR-1)
exhibited signs of distension with surface blood vessels but
not follicle rupture. Serial sections from sVEGFR-1-injected
follicles revealed that ovulation only occurred 50% of the
time (three of six animals) [21] (data not shown). In three
animals, ovulation was confirmed by the presence of an
ovulatory canal as well as by the absence of an oocyte. Inthese sections, signs of luteinization (e.g., hypertrophy of
granulosa cell layers) were apparent and similar to that
observed in control tissues. However, these sVEGFR-1-
treated tissues contained blood cells among the luteal tissue
in a quantity beyond what was observed in the control
tissues. In contrast, serial sections from 3 other animals were
devoid of any ovulatory canal, and in two out of three
animals an intact oocyte was found within the injected
follicle [21] (data not shown). These follicles displayed few
signs of luteinization, with small granulosa cells still lining
the basement membrane, and occasionally found in the antral
space. Blood cells were detectable within the antrum of two
out of three of these unruptured follicles.
3.2.2. Intraluteal injection of sVEGFR-1
In contrast to intrafollicular injection, intraluteal admin-
istration of either a low (1.1 Ag) or high (15 Ag) dose of
sVEGFR-1 at the midluteal phase (day 6) of the cycle did
not alter significantly the pattern or level of serum P
compared to vehicle-treated controls (Fig. 3). Also, there
was no difference in the day of menstruation between
controls and either low-dose or high-dose sVEGFR-1-
treated animals.
3.2.3. Systemic injection of anti-VEGF antibody
Systemic injection of anti-VEGF antibody at the begin-
ning of the menstrual cycle (days 1, 3, and 5) appeared to
delay the midcycle peak in serum E (Fig. 4) and the LH
surge (not shown) by 2–3 days, as well as the peak in serum
P in the luteal phase (Fig. 4) by 3–4 days, but these intervals
were not significantly different from controls. Also, peak
hormone levels and length of the menstrual cycle did not
vary between control and VEGF-Ab treatment groups.
Anti-VEGF antibody delivered at midcycle (day 1 to 0,
and 3 days post-LH surge) appeared to modestly but notF
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Fig. 7. Serum E levels in monkeys receiving an intrafollicular injection of
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phase when E levels in 3 treatment cycles (closed triangles) were
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treatment 3.5 ng/mL) (Fig. 5). Again, however, the length of
the luteal phase was no different between control and
treatment cycles.
3.3. Phase III: delivery of Ang-2
3.3.1. Intrafollicular injection of Ang-2
Whereas vehicle injection resulted in the expected
pattern and levels of serum P in the luteal phase, intra-
follicular injection of Ang-2 (20 Ag) resulted in P levels that
never rose above baseline for 12–13 days (Fig. 6). However,
only one of five Ang-2-treated animals exhibited menses0 3 6 9 12 15 18
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Fig. 6. Serum P levels in monkeys receiving an intrafollicular injection of
Ang-2 (20 Ag) at midcycle compared to vehicle-injected controls (shaded
area=meanFSEM, n =7). An bMQ denotes the average days of onset of
menstruation in controls, whereas Ang-2-treated animals typically did not
menstruate. An asterisk denotes the first day in the luteal phase when P
levels were significantly different between groups. Ang-2-treated animals
did not display a functional luteal phase for approximately 2 weeks.during this interval (day 7 post-LH surge). Thereafter, the
rise in serum P in Ang-treated monkey coincided with its
decline in control animals (days 15–16). After the preovu-
latory E rise at midcycle (Fig. 7), E levels declined
following the LH surge and vehicle-treated animals
exhibited the expected low levels during the luteal phase.
In contrast, following the decline at midcycle, E levels in
Ang-2-treated animals increased to reach peak levels 11–12
days after the LH surge. Three of five animals displayed
peak E levels that were comparable to the prior preovulatory
levels, whereas the other two animals exhibited lower peak0 63 9 12 15 18
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Fig. 8. Serum P levels in monkeys receiving an intraluteal injection of both
Ang-2 (20 Ag) and sVEGFR-1 (15 Ag) at midluteal phase compared to
vehicle-injected controls (shaded area=meanFSEM, n =7). P levels in
treated cycles tended to be higher than controls both before (days 2–6) and
after (days 8–11) treatment. However, P levels declined (pb .05, paired
t test) for 1 day between days 6 and 7 (asterisk) in Ang-2+sVEGFR-1-treated
animals. There was no difference between the onset of menstruation in
control (M) vs. treated (m) animals.
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the former, but not the latter, animals.
Unlike in vehicle-injected controls (n=7), laparoscopy
on day 3 did not detect any sign of ovulation in follicles
injected with Ang-2 (n=5). However, a subsequent lapa-
roscopy in one animal at 10 days post-Ang-2 injection
detected a large follicle on the opposite (noninjected) ovary.
3.3.2. Intraluteal injection of Ang-2 plus sVEGFR-1
Injection of Ang-2 (20 Ag) + sVEGFR-1 (15 Ag) into the
corpus luteum at the midluteal phase (day 6) did not
suppress serum P levels or the length of the luteal phase
compared to the control group (Fig. 8). However, serum
P levels were reduced transiently (from 8.5F0.2 to
4.0F1.3 ng/mL; day 6 vs. 7, paired t test, pb .05) for one day
following treatment.4. Discussion
The data reported herein extend our previous published
investigations demonstrating that acute local administration
of a general anti-angiogenic agent TNP-470 (phase I) [20]
or a specific VEGF-A antagonist (sVEGFR-1 chimera)
(phase II) [21] into the preovulatory follicle can inhibit the
subsequent development, function or life span of the corpus
luteum, or ovulation. In our earlier report [21], we noted that
intrafollicular injection of sVEGFR-1 resulted in a dose-
dependent (0 vs. 1.5 vs. 7.5 Ag) suppression of follicle
rupture and reduced serum P levels in the subsequent luteal
phase. Since ovulation and corpus luteum function was not
totally abolished, a higher (30 Ag) dose was tested. Al-
though follicle rupture was not evident in two of three ani-
mals, and luteal P levels were suppressed, again ovulation
and luteal function was not totally prevented. Whether
experimental conditions, such as dose or treatment interval,
could be improved to further optimize the anti-ovulatory
and anti-luteal effects of a VEGF antagonist in the pre-
ovulatory follicle is unclear. Alternatively, it is possible
that other angiogenic pathways, for example, via EG-
VEGF [32] or Ang-1 [12], complement the actions of
VEGF in the preovulatory follicle, and as such may
continue critical ovarian functions despite suboptimal
VEGF action at midcycle in primates. Nevertheless, our
histologic evidence from ovaries of animals treated with
sVEGFR-1 and vehicle, removed 3 and 6 days post-follicle
injection [21], confirmed suppression of ovulation and
luteal development/structure, as judged by trapped oocytes
in nonruptured, poorly luteinized follicles and abnormal
extracellular spaces (due either to lack of cell hypertrophy
or cell shrinkage) in the corpus luteum. These data, plus
evidence from studies by Fraser et al. [33] and Wulff et al.
[34] that VEGF antagonist treatment during the early to
midluteal phase reduces endothelial cell proliferation and
the number of small capillaries in the nonhuman primate
corpus luteum, strongly support an important role for the
angiogenic, and perhaps vascular permeability, actions ofVEGF-A in the preovulatory follicle and developing corpus
luteum during the menstrual cycle.
It is noteworthy that unlike the current results, intra-
follicular injection of a general anti-angiogenic compound,
TNP-470, did not cause a decline in circulating P levels
until the midluteal phase [20]. These compounds have
different actions; VEGF reportedly is expressed in greater
abundance in the developing vs. fully formed corpus luteum
[13,35], which may explain the immediate action of
sVEGFR-1 injection to suppress luteal function in the early
luteal phase. In any case, sVEGFR-1 is not merely delaying
normal luteal function because the duration of the luteal
phase and the time of menstruation were not affected despite
suppressed steroidogenic function.
In contrast to injection into the preovulatory follicle,
acute, local administration of sVEGFR-1 into the developed
corpus luteum at the midluteal (day 6) phase of the menstrual
cycle had no apparent effect. Neither the function, as judged
by P levels, or life span of the corpus luteum was altered. We
hypothesized that if VEGF-A is required for the maintenance
of the luteal vasculature, as well as its development, then
VEGF antagonism would be detrimental to corpus luteum
structure and function at the midluteal phase. The role of
VEGF-A in maintaining the microvasculature in some
tissues in becoming recognized [6,12], and the continued
expression of VEGF-A and its receptors in the developed
corpus luteum of several species [13,14,36–39] supports this
premise. The negative findings of our study could result from
limitations in dose, delivery or treatment interval. Unlike the
preovulatory follicle, which provides an avascular antrum as
a reservoir for injected substances, the highly vascularized
corpus luteum may rapidly lose such substances into the
circulation. Recently, Dickson et al. [40] reported that
systemic administration of a VEGF antagonist to monkeys
at the midluteal phase reduced circulating P levels by 50%,
while suppressing proliferation and increasing apoptosis of
endothelial cells in the corpus luteum. Their findings support
a role for VEGF-A in maintaining the structure and function
of the corpus luteum and its microvasulature in primates.
Further studies attempting local delivery of anti-angiogenic
agents into the corpus luteum may consider methods for
continual infusion [41,42] or establishing a local reservoir
[43] to sustain local, high levels. Alternatively, a role for
other angiogenic factors, such as EG-VEGF [32], in the
corpus luteum should be evaluated.
Also, subcutaneous administration of a neutralizing anti-
VEGF monoclonal antibody (VEGF Ab) either in the early
follicular phase or at midcycle had little effect on ovarian
function, as judged from circulating hormone patterns,
during the menstrual cycle. The VEGF Ab was utilized
rather than sVEGFR-1 because of the large quantities
required for systemic studies. Investigators using VEGF
Abs to suppress primate reproduction in vivo report
variable success from complete blockade of cyclic ovarian
function [44], to significant but partial inhibition of
circulating P levels during the luteal phase [40], to no
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(current data). Again, differences could be related to
antibody binding affinity, dose and treatment regimens.
However, recent studies suggest that antagonists that are
VEGFR-1-IgG and/or VEGFR-2-IgG chimeras, rather than
immunoneutralizing antibodies, are better at inhibiting
angiogenesis [45] and disrupting mature, preexisting
vessels [46]. The authors speculate that this is due to
higher affinity of the VEGFR moieties, compared to VEGF
Abs, for endogenous VEGF. However, the possibility that
VEGFR antagonists have a greater effect due to blockade
of other factors, for example, PlGF, VEGF-B that may act
in the ovary [47], awaits investigation.
Further testing will be required to determine if anti-
VEGF agents offer promise as contraceptive agents. Initial
reports using an anti-VEGF Ab in marmosets [48] and a
DNA vaccine against VEGFR in mice [49] reported no
antifertility effects. In the former, VEGF immunoneutrali-
zation suppressed P levels, but the pregnancy rate was not
reduced. In the latter, treatment provided protection from
cancer challenges and delayed wound healing, but did not
prevent fertility.
To our knowledge, this report also describes the first in
vivo study on the effects of exogenous Ang-2 in the ovary.
Recent studies indicate that the Ang receptor (Ang–Tie-2)
system plays an important role in blood vessel formation
and function, with the endogenous agonist Ang-1 promoting
vessel maturation and stability and the endogenous antag-
onist Ang-2 blocking Ang-1–Tie-2 interaction to cause
vessel instability. Current models propose that Ang-2 action
may be important during angiogenesis to destabilize
existing vessels and allow further growth [12]; however,
there is also evidence that Ang-2 in the relative absence of
angiogenic factors (e.g., VEGF) can cause vessel dege-
neration. To date, there are few reports on the expression
[13–16], regulation [14,16] or action of Ang agonists/
antagonists in the ovary. However, Maisonpierre et al. [17]
noted that atretic antral follicles and regressing corpora lutea
in the rat ovary contained minimal amounts of VEGF-A
mRNA, but large amounts of Ang-2 mRNA. Therefore, we
tested the hypothesis that local administration of the
antagonist Ang-2 into the preovulatory follicle in monkeys
would disrupt the balance between angiogenic (VEGF-A,
Ang-1) and angiolytic (Ang-2) factors, thereby preventing
periovulatory events and corpus luteum development.
Our data indicate that intrafollicular injection of 20 Ag
Ang-2 prevented follicle rupture and the timely rise in
circulating P expected in the subsequent 2-week luteal
phase. Since the latter P rise did not occur until after
another peak in circulating E, which in three of five
animals was reminiscent of a preovulatory E surge, we
speculated that Ang-2 treatment severely impaired or
destroyed the initial preovulatory follicle — such that it
took 12–14 days to recover or to be replaced by another
follicle at this stage. A laparoscopic evaluation of one
animal 10 days post-Ang-2 injection detected a large antralfollicle, not on the injected ovary, but on the noninjected,
contralateral ovary. This finding suggests that Ang-2
treatment caused the destruction or atresia of the preovu-
latory follicle, and the subsequent selection and growth of
another dominant follicle destined to ovulate and luteinize
approximately 2 weeks later. Our observation is consistent
with evidence from monkeys [50] and women [51] that
ablation of the dominant structure on the ovary, that is, the
follicle selected to ovulate or the corpus luteum, will reset
the ovarian cycle with maturation of the next preovulatory
follicle occurring 12—14 days later.
Further studies are ongoing to establish the dose
dependency and specificity of Ang antagonist action to
suppress the preovulatory follicle during the menstrual cycle
in monkeys [52] (unpublished results). Likewise, experi-
ments are warranted to examine the effects of Ang agonists
(Ang-1) and antagonists (Ang-2) on follicle health and
vascularity, including granulosa, theca and endothelial cell
death. Finally, despite the caveats of acute injections into the
corpus luteum (discussed earlier), it is noteworthy that
intraluteal administration of Ang-2+VEGF antagonist (but
not VEGF antagonist alone) caused a transient decline in
circulating P levels for 24 h. Therefore, additional studies
are needed to consider Ang-1/Ang-2 actions in the corpus
luteum, as well as in the follicle.
In conclusion, our investigations establish the ability of
specific VEGF-A (sVEGFR-1 chimera) and Ang (Ang-2)
antagonists, and to a lesser extent the general angiostatic
agent TNP-470, to disrupt periovulatory events and subse-
quent luteal structure and function when administered
directly into the dominant follicle during the menstrual
cycle in rhesus monkeys. Of the three mechanisms tested,
blockade of Ang action appeared most effective in dis-
rupting the gametogenic (ovulation) and steroidogenic
(P production) functions of the mature follicle. However,
since acute blockage of Ang action only temporarily blocked
ovarian function, allowing rapid recovery of ovarian
cyclicity, further studies are needed to consider whether
acute or chronic treatment with Ang antagonists offers a
potential as either an emergency (postcoital) or regular
contraceptive. Limited success following intraluteal or
systemic administration indicates the need for further studies
to optimize delivery of angiogenic agents for contraceptive
trials. It is possible that combinations of anti-angiogenic
factors will be needed to optimally suppress luteal, and
perhaps uterine, function to prevent pregnancy. Neverthe-
less, consideration of such treatment regimens as contra-
ceptives, except perhaps as acute treatments for postcoital
contraception, will be needed to evaluate potential deleteri-
ous effects in other vascular beds (e.g., the kidney) [53,54] or
in wound healing [42,49].Acknowledgments
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Abstract
Angiogenesis and vascular development are fundamental to the development of a receptive endometrium that permits implantation. The
underlying hypothesis of this project is that implantation in primates and in humans is dependent on vascular remodeling in the endometrium
and that the identification of agents that can disrupt this process prior to embryo attachment will lead to the development of new post coital
contraceptives. To identify suitable targets for postcoital contraception, we studied the expression in endometrium of the vascular endothelial
growth factor (VEGF) and angiopoietin families of angiogenic regulators. We produced a neutralizing antibody to VEGF-A, and this was
shown to inhibit implantation in rhesus monkeys, apparently through direct antagonism of the action of VEGF-A in the endometrium. This
demonstrated dproof of principleT that agents antagonizing molecules that regulate angiogenesis can be developed as contraceptive agents. A
second objective was to identify new contraceptive targets. We have developed microarrays to compare receptive endometrium with
endometrium-rendered nonreceptive by a number of experimental strategies. We have identified over 100 RNA transcripts that are acutely
regulated by administration of the antiprogestin RU486 to women, and 20 transcripts altered by antagonizing the action of VEGF-A in
endometrium. These transcripts represent new potential targets for development of novel postcoital contraceptives.
D 2005 Elsevier Inc. All rights reserved.
Keywords: Angiogenesis; Endometrium; Contraception; Microarray1. Introduction
In primates, successful implantation requires the devel-
opment of a hatched blastocyst capable of implantation and
an endometrium that is receptive to the embryo. Following
menstruation, the endometrium undergoes a complex series
of developmental changes under the influence of the ovarian
steroids, estrogen and progesterone. This results in repair of
the endometrium, proliferation and growth of epithelium and
stroma, followed by differentiation in response to increasing
levels of progesterone after ovulation. This culminates in a
tissue that becomes receptive to signals from the implanting
embryo for a limited period. In humans, embryo transfer
experiments suggest that this receptive phase extends from
approximately days 5 to 10 after the luteinizing hormone
(LH) surge [1].0010-7824/$ – see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2004.12.018
T Corresponding author. Tel.: +44 1223 333729; fax: +44 1223
333346.
E-mail address: as168@cam.ac.uk (A.M. Sharkey).Extensive angiogenesis is an integral part of the de-
velopment of the receptive endometrium. In the ovary, the
source of the steroids that drive endometrial development
changes in vascular permeability, and angiogenesis accom-
panies the maturation of the ovarian follicle and the
processes of ovulation and luteinization. In the endometri-
um, arteriogenesis produces the characteristic spiral arterio-
les, supplying an extensive capillary network that develops
just beneath the luminal epithelium and around the
endometrial glands. At the same time, there is a large-scale
influx of leucocytes consisting mainly of uterine natural
killer (NK) cells and macrophages [2]. Many of these cells
enter the endometrium from the blood stream by extrava-
sation via endometrial capillaries. These cells play vital
roles in the processes of implantation and decidualization if
pregnancy occurs, or in the induction of menstruation and
repair in a nonpregnant cycle [3]. Following attachment of
the blastocyst, implantation and placental development are
critically dependent on increased local vascular permeability
and successful remodeling of spiral arteries by the invading
trophoblast [4,5].71 (2005) 263–271
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Fig. 1. The VEGF and angiopoietin gene families and their cognate
receptors. VEGF-A, B and PlGF have alternatively spliced RNAs, which
generate isoforms of different sizes. Figures show the number of amino
acids in each isoform.
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implantation are totally dependent upon carefully controlled
angiogenesis in the endometrium and ovary. The female
reproductive tract is unusual in that it is one of the few sites
in adults where physiological angiogenesis occurs [6]. It is
therefore an attractive target for new contraceptive strategies
that target active angiogenesis. Inhibition of angiogenesis
has the potential to affect either the endometrium directly or
the ovary during ovulation and development of the corpus
luteum. Direct evidence for the importance of angiogenesis
in reproduction comes from experiments in which nonpreg-
nant cycling mice were chronically treated with the
nonspecific angiogenesis inhibitor AGM-1470 [7]. Inhibi-
tion of both endometrial maturation and corpus luteum
maturation was observed, although the endometrial effects
could have been in part due to the alteration in progesterone
production by the corpus luteum. Administration of AGM-
1470 to pregnant mice resulted in implantation failure due to
impaired decidualization and vascular development in the
placenta and embryo. Blocking the action of the specific
angiogenic growth factor vascular endothelial growth factor
(VEGF)-A in the early corpus luteum causes a failure of
progesterone production in both rats and marmosets [8,9].
1.1. Control of angiogenesis by local growth factors
Angiogenesis is believed to result from the balance
between stimulating and inhibitory factors leading to
endothelial growth or loss. Functional experiments in mice
involving gene knockouts have identified two families of
genes, the VEGF family and the angiopoietins (Ang-1 and
Ang-2), as important local regulators of angiogenesis [10].
Four different receptors are known for the VEGF family:
VEGF-R1 (flt-1), VEGF-R2 (KDR), VEGF-R3 (flt-4) and
neuropilin, and tie-2 is the receptor for Ang-1 and Ang-2
[11–15]. The VEGF family consists of five members,
VEGF-A, B, C, D and placental growth factor PlGF, and
some family members exhibit splice variants with altered
bioactivity (Fig. 1) [16].
The generation of new blood vessels from preexisting
blood vessels can occur by several different processes
including sprouting, intussusception and intercalation
[17–19]. The steps required for sprouting angiogenesis to
take place have become considerably clearer in recent years,
and many of the key factors involved in these steps have
been elucidated. Because this is the best understood form, it
is frequently assumed to be the principle mechanism in most
circumstances. In the reproductive tract, this is not the case
and there is little evidence that it occurs in the human
endometrium. Goodger and Rogers [20,21] found no
correlation with endothelial proliferation and the increase
in capillary number, and determined that endometrial
capillaries grow by elongation rather than sprouting.
In almost all situations examined to date, it seems that the
level of VEGF-A is critical in determining whether the
vessel tree grows or is pruned. For example, in tumor
models, the local decrease in VEGF-A leads to capillary lossand tumor cell death [22]. The level of VEGF mRNA and
protein is regulated at numerous levels suggesting that this
factor is at a point of convergence of many regulatory
signaling pathways. VEGF-A mRNA is up-regulated by
transcriptional activation under conditions of reduced
oxygen. These conditions also increase the stability of the
VEGF-A transcript. In addition, VEGF-A mRNA level can
be regulated by steroids, glucose and notch signaling
[23,24]. VEGF-A is encoded by several differentially
spliced transcripts, and the resulting polypeptides have
different bioavailabilities due to variable binding to heparin
sulfate proteoglycans. The relative amounts of the mRNAs
encoding these variants change throughout the menstrual
cycle [25]. These differences are important as the heparin
binding forms can be released from the extracellular matrix
reservoir by proteolytic cleavage by plasmin [26]. This is
particularly pertinent in the endometrium, since following
menstruation and activation of the clotting cascade, the
damaged vessels need to be repaired.
However, VEGF-A is by no means the sole determinant
of endothelial fate. These cells respond to antiapoptotic
signals from other angiogenic factors such as Ang-1 and
integrin-mediated stimuli from the extracellular matrix.
Antiproliferative signals are also delivered by the matrix.
In an attempt to determine the importance of individual
factors in such a complex process, reductionist models have
been employed. For example, the keratin 14 promotor
cassette has been used to overexpress cDNAs encoding
angiogenic growth factors in the skin of transgenic mice.
These studies have shown that overexpression of VEGF-A,
Ang-1 and placental growth factor all lead to an increase in
vessel number, and in the case of VEGF-A and PlGF, an
increase in vascular permeability [27–29]. Overexpression
of VEGF-C or VEGF-D leads not to an increase in vascular
structures but to an increase in lymphatic structures [30].
Studies on mice that overexpress both Ang-1 and VEGF-A
in the skin have revealed that these two factors are able to
A.M. Sharkey et al. / Contraception 71 (2005) 263–271 265interact leading to an increase in vessel number (as was seen
with VEGF-A or Ang-1 alone), but normal vascular
permeability was restored [31]. In the case of the endome-
trium, many angiogenic and antiangiogenic factors are
present, but the ways in which they interact and what the
molecular consequences for such interactions are remain
unclear. One of the major aims of this project has been to
define more clearly the spatial and temporal patterns of
expression of known angiogenic growth factors in endome-
trium through the cycle and during early pregnancy. There
are clear changes in the cellular sites of production of these
factors during the menstrual cycle, and the endothelial cells
have differing characteristics in different vessel populations
in the endometrium [32]. In light of this, it could be
proposed that regional specialization of vessels in the
endometrium has important functional consequences.
1.2. Role of vasculature in regulating endometrial function
Previously, it had been presumed that the vasculature is
merely dplumbingT to supply nutrients and remove waste
products from a tissue. However, it is now clear that the
endothelial cells actually play an active part in defining
tissue structure, architecture and function [33]. Both tissue
maintenance and its responses to physiological or patho-
logical stimuli are dependent on an appropriate vascular
supply. In the endometrium, several of the factors required
for the growth and maintenance of this vascular supply are
directly regulated by ovarian steroids. The most prominent
of these is VEGF-A, and thus, we hypothesized that
blocking the action of this factor in the postovulatory
endometrium would be sufficient to prevent the tissue’s
physiological response to the embryo and to steroids and
thereby prevent the establishment of pregnancy. We have
also investigated the effect of perturbing endothelial
function on the behavior of endometrial epithelium in
response to estradiol [34].
1.3. Identification of other therapeutic targets involved
in angiogenesis
Although the VEGF and angiopoietin families have been
most intensively studied with regard to angiogenesis in
endometrium, little is known in detail about their mecha-
nisms of action at different stages of the menstrual cycle.
The primary determinant of whether angiogenesis or
vascular homeostasis occurs is the balance between the
VEGF and Ang genes. However, angiogenesis is a complex
process involving many other gene products. It is clear that
these two gene families are not the sole targets for
therapeutic intervention targeted at angiogenesis. The
identification of other molecules that play important roles
either as controllers of angiogenesis or as downstream
mediators of angiogenesis initiated by the VEGF and Ang
systems would provide additional targets for therapies
aimed at disrupting normal endometrial development so as
to prevent implantation.Although several hundred molecules are known, which
participate in angiogenesis, there has been no systematic
attempt to study their expression in endometrium. cDNA
microarrays are a novel methodology that permits the
relative levels of thousands of RNA species to be
determined simultaneously. We, therefore, sought to use
this technique to examine patterns of expression of known
angiogenic mediators at different stages of the menstrual
cycle. The aim was to correlate gene expression patterns
with known physiological angiogenesis, and to determine
the effect on gene expression patterns of agents that
disrupt normal angiogenesis. The purpose was to identify
novel targets for antiangiogenic therapy in primate and
human endometrium.2. Rationale and objectives of the study
The prime objective of the study was to develop new
contraceptives that prevent implantation. It is clear from
rodent studies that disruption of angiogenesis in the
endometrium or the ovary can achieve this by preventing
development of a receptive endometrium. However, angio-
genesis is also essential after implantation for normal
placentation and decidualization. We aimed to target the
angiogenic events leading to a receptive endometrium rather
than postimplantation events to avoid any approach that
interfered directly with the embryo. The project encom-
passed three specific research aims:
1. To define in detail the expression pattern of the VEGF
and Ang families in human endometrium.
2. To determine whether implantation can be prevented
in the rhesus monkey by use of a neutralizing
antibody against the principle angiogenic regulator
VEGF-A. The hypothesis to be tested here is whether
a VEGF-A antagonist can modify endometrial func-
tion by a direct effect on the tissue rather than through
effects on the corpus luteum.
3. To identify novel targets for antiangiogenic therapies
by use of microarrays to examine expression of
angiogenic genes in normal endometrium. The re-
sponse of endometrium to drugs that disrupt angio-
genesis will also be determined.
An essential aspect of the project was the collaboration
with colleagues in the All India Institute of Medical Sciences
(AIIMS) in New Delhi, India, whose results in the rhesus
macaque are described in full elsewhere in this volume.3. Work completed under the study
3.1. Defining the expression of the VEGF and Ang families
in human endometrium
The VEGF and Ang families of growth factors act
together as the principle effectors controlling endothelial
fate in many tissues. Specifically, the ratio of Ang-1 and
Table 1
Localization of VEGFs and angiopoietins in endometrium and in early
pregnancy
Factor/receptor Preimplantation Early pregnancy Ref.
VEFG-A Glands and stroma Troph +Macs [40,41]
VEGF-C NK cells NK cells [42]
PlGF NK cells Trophoblast [42,43]
Ang-2 NK cells Trophoblast [42,44]
VEGF-R1 Endothelial cells Endothelial cells [45]
sVEGF-R1 Endothelial cells Trophoblast [46]
VEGF-R2 Endothelial cells and
superficial stroma
Endothelial cells [47]
VEGF-R3 ? Trophoblast unpublished
Tie-2 Endothelial cells Endothelial cells [44]
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Fig. 2. Direct effect of sflt-1 on the mitotic index of luminal epithelium in
response to E2. Ovariectomized BALB/c mice were treated with 10 Ag/kg
estradiol (E2) with or without sflt-1 in PBS (4.0 mg/kg). Twenty-four hours
later, the uterine horns were excised, fixed and paraffin embedded and the
mitotic index counted in luminal epithelial cells (percentage of mitotic
figures). Epithelial proliferation was increased by treatment with E2 and
this increase was inhibited by 4.0 mg/kg sflt-1 (pb .01, Fisher’s Exact Test).
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be responsive to changes in the level of mitogenic growth
factors such as VEGF-A [35]. We have therefore investi-
gated the sites of production and regulation of these factors.
In endometrium, VEGF-A mRNA expression has been
shown to be maximal in the secretory phase with an abrupt
increase in menstrual tissue [36–38].
Immunohistochemical studies indicate that VEGF-A is
widely distributed in the human endometrium with the
strongest staining apparent in the glandular epithelium.
However, a subset of stromal cells also produce VEGF.
Strong perivascular staining, probably in pericytes, is also
apparent. However, because several of the spliced forms of
VEGF-A are strongly heparin binding, we have used in situ
hybridization to determine the sites of production. This
analysis confirms the pattern seen by immunohistochemis-
try, with the epithelium as the major source of VEGF-A.
Although steroids regulate VEGF-A in the endometrium,
it is known that local hypoxia can also regulate VEGF
expression levels. At menstruation, blood vessels constrict
creating hypoxia in the superficial endometrium. We have
shown that both epithelial and stromal cells from endome-
trium strongly up-regulate VEGF-A expression in response
to hypoxia [36]. It is therefore clear that VEGF-A
expression and bioavailability are regulated in several ways
at different stages of the menstrual cycle, and these include
steroids as well as local factors such as hypoxia.
We have used immunohistochemistry and in situ
hybridization studies to examine the expression of the
VEGF and Ang genes and their receptors in endometrium.
These show that VEGF-A, PlGF and VEGF-C are present in
endometrium and are regulated during the menstrual cycle.
We were unable to detect VEGF-B mRNA in normal
endometrium and VEGF-D mRNA was only found in
endometrial carcinoma specimens [39]. These results,
together with published data from other studies on the
localization of the VEGF and Ang genes and their receptors,
are summarized in Table 1 [40–47].
3.2. Can neutralization of VEGF-A prevent implantation?
Gene ablation studies in mice indicate that of the many
angiogenic proteins, VEGF-A acts as a key regulator of theprocess [16]. Even small changes in the level of expression
of VEGF-A in tissue may be very significant, since
disruption of a single allele of VEGF in mice results in
abnormal blood vessel formation [48,49]. The expression
studies in endometrium suggest that VEGF-A does play an
important role during the menstrual cycle. Systemic
treatment of rats with a soluble flt-1 receptor that inhibits
VEGF-A bioactivity has previously been shown to suppress
angiogenesis in the corpus luteum and inhibit progesterone
release. This soluble flt-1 receptor competes with VEGF
receptors on endothelial cells for binding to VEGF-A and
inhibits the effects of VEGF-A. Failure of maturation of the
endometrium was also observed, which is likely to be a
result of lower progesterone secretion by the ovary [8].
There is no evidence that inhibitors of VEGF-A can affect
endometrial maturation by directly affecting angiogenesis in
the endometrium. We therefore tested whether inhibiting the
actions of VEGF-A with soluble flt-1 (sflt-1) could have a
direct effect on endometrial function in the absence of an
ovarian effect [34]. Ovariectomized mice respond to a single
injection of 17h-estradiol (E2) by edema due to increased
vascular permeability as well as DNA and RNA synthesis
and proliferation of the uterine epithelium. Mice injected
with sflt-1 (4.0 mg/kg) at the same time as E2 showed
reduced edema and a greatly decreased mitotic index of the
luminal epithelial cells (Fig. 2). Thus, anti-VEGF agents
such as sflt-1 are able to substantially modify the responses
of the endometrium to steroids through a direct effect on the
endometrium independent of the corpus luteum. There is no
evidence for VEGF receptors on the epithelial cells, so this
effect is likely to be due to alterations in endothelial cell
function. Endothelial cells are known to release factors such
as fibroblast growth factor and platelet-derived growth
factor that control epithelial cell proliferation. Normally,
E2 induces VEGF release from epithelial and stromal cells,
which may regulate release of these epithelial mitogens
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this paracrine loop.
This experiment provided proof in principle that antag-
onizing the actions on VEGF-A could directly prevent the
normal response to E2 in the endometrium. We therefore
tested whether an anti-VEGF agent could prevent implan-
tation in cycling rhesus monkeys. This study was performed
in collaboration with the AIIMS. Neutralizing antibodies
provide a potent means to inhibit the bioactivity of secreted
growth factors such as VEGF-A. They have been widely
used in studies of tumor growth, and recently, the anti-
VEGF-A neutralizing antibody Avastin has been approved
for treatment of metastatic colorectal cancer [16]. For this
study, a suitable neutralizing monoclonal antibody directed
against VEGF-A was produced in Cambridge by immuni-
zation of mice with recombinant VEGF-A165 conjugated to
keyhole limpet hemocyanin. Spleens of these mice were
collected and the B-cells fused with NSO cells. Stable cell
lines that secreted immunoglobulins that bound to immobi-
lized VEGF-A were identified. After additional rounds of
cloning and screening against other possible cross-reacting
antigens, one clone (4E3) was selected for large-scale
growth. An isotype-matched (IgG1 n) control antibody
was also prepared in a similar manner. Both cell lines were
grown in Heraeus miniperm bioreactors that produce
immunoglobulin at high concentration to facilitate purifica-
tion. The anti-VEGF-A antibody and control immunoglob-
ulin were purified by binding to protein G sepharose,
desalting (Centricon ultrafiltration) and lyophilized in 10 mg
lots. The neutralizing activity of the antibody was demon-
strated using a bioassay in which iodinated VEGF binds to
its receptors on endothelial cells. Addition of the anti-VEGF
antibody abolished 125I-VEGF binding to the cell surface.
The antibody 4E3 showed similar blocking activity in this
assay as a commercially available neutralizing polyclonal
anti-VEGF antibody raised in goats (Fig. 3).
Following production of the antibody, the effect of the
antibody on implantation in rhesus monkeys was examined.
Two specific questions were addressed:
1. Can anti-VEGF-A antibody prevent implantation in
cycling rhesus monkeys?
2. Does anti-VEGF-A antibody prevent development of
a receptive endometrium by directly inhibiting the
action of VEGF-A on endometrium?
The studies to assess the effect of the antibody in vivo
were carried out by our collaborators in AIIMS and are fully
described elsewhere in this journal. The anti-VEGF-A
antibody was administered by bolus subcutaneous injection
in several dose regimens at different times after the LH surge
and the effect on implantation rates monitored. Control
animals received the same dose of an isotype-matched
antibody. Two injections of 10 mg each on day 5 (LH+5)
and day 10 (LH+10) following the LH surge were found to
significantly reduce implantation rates. Monitoring of serum
progesterone levels showed no significant reduction in levelsF
a
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thof this hormone following antibody treatment. This finding is
extremely important since the effect on implantation cannot
be attributed to decreased production of progesterone by the
corpus luteum, which could lead to early pregnancy loss.
3.3. What effect does anti-VEGF antibody have on
the endometrium?
In order to determine whether the anti-VEGF-A anti-
body had a direct effect on monkey endometrium, animals
were first ovariectomized then allowed to recover. An
artificial hormone cycle was initiated consisting of 3 weeks
of estrogen administration followed by 1 week of proges-
terone. This regimen has previously been shown to
faithfully reproduce normal endometrial development in
this species [50]. Animals were treated during this cycle
with anti-VEGF (n=6) or control antibody (n=7) by bolus
injection on day 5 after initiation of progesterone treatment.
This is the same treatment as used to successfully prevent
implantation. RNA was isolated from endometrial biopsies
taken on day 8 of progesterone treatment. Although
endometrial histology of the biopsies from control and
anti-VEGF-treated animals appeared normal, we used
cDNA microarrays to identify possible mechanisms by
which the anti-VEGF-A antibody could alter endometrial
receptivity. This microarray was developed especially to
study angiogenesis and receptivity in the endometrium. It
consists of some 15,000 human cDNA sequences. One
thousand one hundred of these were selected for inclusion
specifically because they represent cDNAs known to be
involved in angiogenesis or receptivity. The array includes
genes involved in endothelial and smooth muscle prolifer-
ation, cell adhesion, cell signaling, apoptosis and extracel-
lular matrix remodeling [51]. This array offers the
advantage of selected angiogenesis content as well as
Fig. 4. Effect of RU486 on endometrial gene expression in vitro. The graph
shows a scatterplot comparing the hybridization signal obtained for each
spotted cDNA after hybridization of nylon custom arrays to labeled cDNA
from endometrial explants treated with or without RU486 for 12 h in vitro.
Each explant was taken in the secretory phase, divided into two and treated
with RU486 or vehicle for 12 h in vitro. The data compare the relative
A.M. Sharkey et al. / Contraception 71 (2005) 263–271268broader coverage of the transcriptome. cDNA labeled with
Cy3 dye was synthesized from a reference RNA made by
pooling endometrial samples from each of the seven control
monkeys. cDNA labeled with Cy5 dye was synthesized
from each of the control and VEGF-treated samples and
was hybridized separately to microarrays in the presence of
the Cy3 reference. Approximately 20 genes were identified
as being significantly up- or down-regulated in endometrial
samples from monkeys treated with the VEGF neutralizing
antibody. Several of the genes have previously been
described in the literature as being involved in angiogen-
esis; none has been shown before to be regulated by VEGF.
These genes are implicated in the response of endometrium
to VEGF-A withdrawal and may allow us to identify novel
pathways controlling angiogenesis and endometrial recep-
tivity. We are currently verifying these changes by real-time
reverse transcriptase polymerase chain reaction (RT-PCR),
and localization studies will be performed on selected
genes in collaboration with Dr. Sengupta (AIIMS) to
identify those that are promising mediators of local
angiogenesis in the endometrium in response to VEGF-A.
These may provide targets for future antiangiogenic
therapies in the endometrium.
expression of each of the 1000 genes spotted on the array in duplicate in the
RU486-treated RNA versus control RNA from a representative sample.
Values have been normalized and logged (log10). The gray band denotes a
twofold change in intensity. Duplicate spots corresponding to JNK1 and
JAK1 are highlighted, showing that these genes are reproducibly down-
regulated by RU486; this was verified by real-time RT-PCR.3.4. Identification of genes regulated by RU486 in
the endometrium
In order to identify further targets for antiangiogenic
strategies, we examined the response of the endometrium to
the antiprogestin RU486. Administration of RU486 in vivo
during the receptive phase rapidly renders the endometrium
nonreceptive to the implanting embryo [52]. This drug also
alters the integrity and stability of the spiral arterioles in the
endometrium, and in many women, uterine bleeding is
induced within 48 h of RU486 administration during the
midsecretory phase [53]. In an initial pilot study, we used
cDNA nylon arrays to monitor gene expression changes in
short-term endometrial explants in response to RU486 [54].
Endometrial biopsies taken at midsecretory phase from five
normal fertile women were divided and cultured in estradiol
and progesterone with or without RU486 for 12 h. cDNA
probes from the paired endometrial samples were hybridized
to the arrays and hybridization signals were quantified. A
total of 12 genes displayed significant changes in expres-
sion; six were up-regulated and six down-regulated follow-
ing RU486 treatment. For five of these genes, this is the first
report suggesting they are regulated by steroids in the
endometrium. JAK1 and JNK1 were two of the genes
shown by the arrays to be down-regulated in RU486-treated
endometrial explants (Fig. 4). This was confirmed by using
real-time RT-PCR [54]. These results show that components
of two important signaling pathways in endometrium, the
JAK/STAT pathway and the JNK pathway, are altered by
RU486. Genes whose expression is controlled by these
pathways are likely to be involved in the mechanism by
which progesterone renders the endometrium receptive tothe implanting embryo. Based on this work, we have
successfully targeted components of the JAK/STAT path-
way in endometrium. Preliminary studies suggest that this
approach can prevent implantation in mice.
We have also initiated a full-scale study using our glass
microarray system of 15,000 human cDNAs to study pipelle
biopsies from the endometrium of women treated with a
single dose of 200 mg RU486 on LH+7 of the secretory
phase of their cycles. The aim being to identify progester-
one-regulated genes that may be involved in receptivity or
the maintenance of vascular integrity in women. RNA from
three groups was compared: normal fertile women sampled
at LH+7 (n=7), endometrial biopsies taken 6 h after
administration of RU486 at LH+7 (n=5) and endometrial
biopsies taken 24 h after administration of RU486 at LH+7
(n=4). Six hours after RU486 administration, some 100
genes with altered expression were identified, and over 200
genes showed altered gene expression at 24 h. Although
RU486 can affect both glucocorticoid and androgen
receptor function, the majority of these genes are likely to
be directly regulated by progesterone. Studies are currently
underway to localize expression of genes that may be
involved in vascular integrity or in the luminal epithelium
where embryo attachment occurs. These early response
genes are likely to represent mediators of the rapid effects of
RU486 action on endometrial receptivity and vascular
integrity. A similar study of the effects of RU486 in the
A.M. Sharkey et al. / Contraception 71 (2005) 263–271 269mouse has led to the identification of several new genes that
have been shown by functional studies to be essential for
implantation [55,56]. No involvement for these genes in
implantation had previously been suspected.4. Conclusions and future work
We have sought to determine the expression pattern in
endometrium of the principal factors known to control
angiogenesis: the VEGF and Ang gene families. The site
and levels of expression throughout the cycle have been
determined for VEGF-A, B, C, D, PlGF, Ang-1 and Ang-2
with the objective of determining which of these factors had
potential as a target for antiangiogenic strategies to disrupt
implantation. These studies have shown that VEGF-B and
VEGF-D are not expressed significantly in normal endo-
metrium. Ang-1 was expressed at low levels that did not
change throughout the cycle. VEGF-C, PlGF and Ang-2 are
expressed in the mid and late secretory phase in uterine NK
cells. VEGF-C is believed to control lymphatic endothelial
cell function, whereas PlGF and Ang-2 in NK cells are
probably involved in regulating vascular changes during
decidualization and menstruation. In contrast, VEGF-A
expression is widespread in both glands and stroma during
the midsecretory phase and exhibits clear steroidal regula-
tion. In view of this and its known functions, VEGF-A
clearly represented the most promising target for antiangio-
genic therapies to disrupt implantation.
In collaboration with colleagues at AIIMS, we have
demonstrated dproof of principleT that antagonizing the
function of VEGF-A in endometrium can prevent implanta-
tion in rhesus monkeys. Preliminary experiments in mice
using sflt-1 showed that antagonizing the actions of VEGF-A
could modify the response of endometrium to steroids. A
mouse monoclonal antibody specific to VEGF-A was
produced, which was shown to neutralize the action of
VEGF-A in vitro. Administration of this antibody after
ovulation was shown to significantly reduce implantation in
rhesus monkeys. This effect appeared to be due to a direct
effect on VEGF-A action in endometrium, since there was no
significant effect on ovarian progesterone production. The
mechanism by which anti-VEGF-A antibody alters endome-
trial function was investigated by microarray analysis using
endometrium from ovariectomized monkeys. These animals
were treated with estradiol and progesterone to simulate a
normal cycle, and treated with anti-VEGF-A antibody using
the same regimen that had inhibited pregnancy. Over 20
transcripts were identified, whichwere up- or down-regulated
by anti-VEGF-A antibody. These transcripts are implicated in
the response of the endometrium to VEGF-Awithdrawal and
may allow us to identify novel pathways controlling
angiogenesis and endometrial receptivity. These changes
are currently being verified by RT-PCR and localization
studies will be performed on selected genes in collaboration
with Professor Sengupta at AIIMS to identify promising
targets for future development.In addition to using microarrays to identify novel
antiangiogenic targets, we used this approach to find other
targets for postcoital contraception. We have used micro-
arrays to monitor the response of the endometrium to a
single dose of RU486 administered as emergency contra-
ception during the receptive phase. Some 100 genes were
identified whose expression is altered within 6 h. Based on
the known actions of RU486, these are likely to represent
progesterone-regulated genes involved directly in receptiv-
ity or the maintenance of vascular integrity in women.
Localization studies and verification of these changes by
real-time RT-PCR are currently underway. We are particu-
larly concerned with identifying which of these genes are
expressed in the luminal epithelium, since such genes may
be directly involved in transition of the endometrium to a
nonreceptive state, in which the process of embryo
attachment does not occur. The RU486 and anti-VEGF
microarray studies have provided a number of potential
targets for development of novel postcoital contraceptives.
Future work will require functional studies in model
systems to determine which of these targets play an im-
portant role in implantation, and to develop suitable ther-
apeutic interventions.
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Abstract It has become increasingly clear that the
investigation of vascular development is best considered in
the context of a whole tissue environment since in vivo
endothelial cells interact closely with other cell types.
Murine embryoid bodies have been used as a model for the
early development of a vascular network and are amenable
to genetic manipulation and treatment with soluble mod-
ulators. However, quantifying morphological changes in
these complex three-dimensional structures is challenging.
In this paper we describe protocols to culture embryoid
bodies on a large scale to study vascular development to-
gether with methods to quantify changes seen when anti-
angiogenic agents or endothelial cell-specific transgenes
are introduced.
Keywords Embryoid body ! Embryonic stem cells !
Endothelial cells ! Platelet endothelial cell adhesion
molecule ! Vessel-like structures
Introduction
Embryoid body development
Embryonic stem (ES) cell lines are derived from the inner
cell mass (ICM) of early mouse embryos [1, 2]. Embryoid
bodies (EBs) form as ES cells differentiate when cultured
without feeder cells or Leukaemia Inhibitory Factor (LIF)
[3, 4]. EBs consist of three-dimensional embryo-like
structures containing cells derived from all three definitive
embryonic germ layers–endoderm, mesoderm and ecto-
derm [5]. EBs recapitulate many features of embryonic
development, although embryonic patterning is incomplete
[6, 7], as reviewed by [8]. Murine EBs are particularly
amenable to mesoderm induction and subsequent blood
and vascular development [9, 10], which is thought to
occur via a common precursor, the hemangioblast [11, 12]
(Fig. 1A). Therefore, EBs model much of the complexity
of vascular and haemopoietic development that occurs
in vivo [13–15].
Like the many in vivo methods to study vasculogenesis
[16] and angiogenesis [17] in common use (reviewed by
[18, 19]) the EB system has the advantage that blood
vessels develop in the context of whole tissues, with the
inherent paracrine and contact-mediated signalling be-
tween cells of different lineages. However, unlike in vivo
methods, the EB system does not require the use of sentient
experimental animals. Like the commonly used in vitro
methods in which extra-cellular matrices (ECM) are used
to induce vascular morphogenesis of ECs, [19, 20] the EB
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system allow well defined and easy to manipulate experi-
ments to be performed. However, the EB system also has
the disadvantage that vascular development that occurs in
the absence of blood flow, which may modulate EC sur-
vival and differentiation [21]. Therefore, the EB system fall
somewhere between the in vivo and in vitro methods of
studying vascular development, and captures many of the
advantages of both.
We chose the spinner flask approach to culture EBs
since this method of culture consistently produces large
numbers of EBs with a high degree of differentiation and
synchronism of vascular development [22, 23]. Spinner
culture allows continuous support for the delicate cystic
structures and constant motion of the nutrients that main-
tains consistent exposure to nutrients and oxygen
throughout the EB population and also prevents the
aggregation of EBs often seen in suspension cultures in
dishes. The system is also the best recapitulation of mouse
embryogenesis resembling the zygote in the fluid-like
environment of the oviduct.
One of the biggest challenges of studying vessel
differentiation in these near-in vivo conditions is to
adequately quantify the resulting complexity building upon
purely visual descriptions.
To identify vascular structures a monoclonal anti-CD31
antibody (recognizing PECAM-1, Platelet Endothelial Cell
Adhesion Molecule-1), which is widely expressed in the
vascular compartment, was used [24–26]. We have quan-
tified CD31-stained structures using what may at first ap-
pear to be complex stereology. However it is relatively
simple to perform, and permits rigorous systematic quan-
tification of vascular structures. This makes the EB system
suitable as a tool for early developmental and vascular
research.
In this article we demonstrate the utility of the EB
system to quantify the effects of both transgene expression
and soluble compounds on vascular development. For an
example of transgene expression, regulatory regions from
the mouse tie2 gene [27] were used to drive endothelial-
specific expression of wild type (wt) and mutant human
Bcl-2. For an example of a soluble compound, the anti-
angiogenic agent berberine [28, 29], a plant isoquinoline
alkaloid with a long history of use in Ayurvedic and Chi-
nese medicine, was used.
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Fig. 1 (A) Investigating vascular development in the context of a
whole tissue environment. Schematic showing EC development via
mesoderm precursors. (HSC hematopoietic stem cells, VSMC
vascular smooth muscle cell, EC endothelial cells. (B) An undiffer-
entiated ES cell colony grown on STO feeders. (image
450 lm · 350 lm).(C) ES colonies grown without STO feeders for
24 h have more defined edges and show signs of differentiation
(image 450 lm · 350 lm). (D) A single EB after 3 days in spinner
culture. (image 4500 lm · 3500 lm (E). Whole mount day 3 EB in
which endothelial precursors and nuclei were detected using an anti-
CD31 antibody (green) and Hoechst 33528 (blue), respectively
(image 4500 lm · 3500 lm). Note the increase in volume between
B, C and D, E. (F) Part of a day 10 EB, arrows highlight blood
islands. (G). Part of a cystic day 10 EB where the cavity is septate.
(H). Part of a day 13 cystic EB with distinct central blood islands. (I)
Maximum projection confocal image from a day 13 EB, stained as E.
(images F-I 4500 lm · 3500 lm) B, C, D, F, G, H were captured
using a Nikon Coolpix 995, E using a Zeiss Axiovert S100TV
microscope with appropriate filters and I using a Leica TCS Laser
Scanning Confocal Microscope
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Methods
Establishment of STO feeder lines
All cell culture was conducted in a 37"C incubator with a
humidified atmosphere of 10% CO2 in air. The mouse
embryo fibroblast line STO [30] was mitotically inactivated
by 70 Gray X-irradiation. Inactivated STO cells were see-
ded into 60 mm2 culture dishes coated with 0.1% gelatin
(Sigma-Aldrich, Poole, Dorset, UK) in 5 ml of media at a
concentration of 2–4 · 105 cells/ml. The seeding density
required for a confluent STO monolayer was determined
during pilot experiments. This may differ between different
batches of frozen STO cells and is important to optimize by
trial experiments, since sub-confluent or over-confluent
STOmonolayers provide poor substrates for ES cell culture.
The medium for STO culture consisted of DMEM (Sigma-
Aldrich) supplemented with 0.1 mM b Mercaptoethanol
(Sigma), Non-Essential Amino Acids (Gibco Invitrogen
Cell Culture, UK, 100· stock), 2 mM Glutamate (Gibco
Invitrogen Cell Culture) and 10% foetal bovine serum
(FBS) (Gibco Invitrogen Cell Culture). The FBS had pre-
viously been batch tested for optimal ES cell proliferation.
Batch testing was an essential part of the preparation before
growing EB. STO cells were seeded at least 24 h prior to
thawing the ES cells to allow the production of sufficient
LIF to prevent ES differentiation (Fig. 1B, C).
Propagation of undifferentiated ES cells
STO monolayers were washed with phosphate buffered
saline (PBS). ES cell media was prepared identically to the
STO media, with the exception that the concentration of
FBS was increased to 15%. Passage 13 R1-strain mouse ES
cells [31] were suspended at a concentration of
4 · 105 cells/ml in this medium. Medium was aspirated
from the STO cells, and 5 ml of the ES cell suspension
gently layered onto the washed STO feeder monolayer. The
media was replaced daily and not allowed to become yel-
low. To prevent differentiation, the ES cells required pas-
saging every 2–3 days. Differentiation was most easily
recognised by the appearance of flat cells around colonies
and the distinct appearance of the individual cells within
the colonies. The avoidance of ES cell differentiation is
essential since differentiation at this stage may alter the
capacity of ES cells to subsequently differentiate into EC,
and it may also reduce the usefulness of the transgenic ES
cells for the generation of transgenic mice, should this be
desired at a later time. The ES cells were fed with fresh
media 4 hours prior to passaging. For passaging 0.05%
Trypsin/EDTA was supplemented with 1% chicken serum,
providing a cyto-protective protein mixture that was not a
trypsin substrate. Care was taken to fully dissociate all of
the trypsinised ES cells to a single-cell suspension by
repeatedly passing through a 10 ml plastic pipette with a
p200 tip attached.
Differentiation of ES cells into EBs in spinner flasks
Spinner medium was prepared identically to the STO
media, but the concentration of FBS further increased to
20%. At day 0, adherent log phase ES cell colonies were
dissociated as described above and resuspended in 10 ml of
spinner media. A large proportion of the inactivated STO
feeder cells contained in the ES cell suspension were re-
moved through differential sedimentation by transferring
the ES cell suspension to a 100 mm2 gelatin coated plate at
37"C for 20 min. The gelatin coating ensures maximum
adherence of the sedimenting STO feeders compared to
undifferentiated ES cells, most of which remain in sus-
pension. Minimising the STO cell contamination reduces
potential anti-differentiation effect of STO cells, which are
likely to alter vascular EB differentiation. The Cellspin
culture system (Integra Biosciences, Letchworth, Hert-
fordshire, UK) was used, with the Cellspin control unit pre-
set at a spin rate of 25 rpm and spin angle 720" (such that it
reverses direction each two revolutions). Media (45 ml)
was pre-equilibrated in 100 ml siliconised (Sigmacote,
Sigma-Aldrich) spinner flasks (Integra Biosciences). ES
cells were recovered from the gelatin coated differential
sedimentation plates, and centrifuged at 800 g for 5 min.
Cells were fully dissociated as described to ensure the
cultures were initiated from single cells. To inoculate each
spinner flask 1.0 · 107 cells in 5 ml spinner media were
added to the 45 ml of pre-equilibrated media in each flask.
After 24 h (i.e. on day 1) a further 50 ml of spinner
media was added to each flask. Each subsequent day, flasks
were transferred to a sterile cell culture cabinet, where EB
were allowed to settle for 1 min, and 50 ml of spinner
media was aspirated and replaced with fresh pre-warmed
spinner media. For treatment with the soluble anti-angio-
genic agent berberine (berberine hemisulphate, Sigma-Al-
drich) was dissolved in sterile water to 10 mM and filtered.
EB were allowed to differentiate in spinners without
treatment for 3 days and then treated with 10 lm berberine
hemisulphate thereafter. EB were sampled on day 10 and
15 and then processed as described below.
Plasmid vectors for genetic modification of EB
For EC specific expression of transgenes in EBs, ES cells
were transfected with vectors containing promoter/en-
hancer regions of the mouse tie 2 gene generated from the
plasmid pTie2SV40 by removing the pBSKII+ backbone
and replacing it with the pBK-CMV backbone (Stratagene
Europe, Amsterdam, The Netherlands) containing an
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aminoglycoside phosphotransferase (neo) cassette. Thus
cells containing this vector, pTie2neo could be selected
with the neomycin analogue G418 sulphate (Geneticin
Gibco Invitrogen Cell Culture, for ES and EB) or Kana-
mycin (for E.coli, Sigma-Aldrich). pTie2neo was used as a
universal vector to produce further constructs in a single
cloning step by insertion of coding sequences of interest
into the unique Not I restriction site (Fig. 2A). Both human
wt Bcl-2 and the mutant Bcl-2 G145E cDNAs were cloned
in this way. Fragments were generated by PCR using a
proof reading Taq polymerase (True Fidelity DNA poly-
merase, Continental Lab Products, San Diego, CA, USA).
Clones were verified by restriction enzyme digestion and
sequencing. Plasmid DNA for ES transfection was pre-
pared using the Qiagen Endofree plasmid preparation kit
(Qiagen Ltd., West Sussex, UK) and resuspended in sterile
deionised water.
Transfection of STO feeders and ES cells
Passage 2 STO cells were made stably G418-resistant by
transfection using Lipofectamine
TM
Fig. 2). PCR conditions
were [95"C for 15 min] · 1 cycle, then [95"C for 30 s
denaturation, 58"C for 30 s annealing, 72"C for 30 s
extension] · 35 cycles for all plasmids containing inserts
of less than 1 kb in size. The extension time was increased
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Fig. 2 (A) pTie2neo endothelial specific expression vector. The gene
of interest (GOI) e.g. Bcl-2 can be inserted into a unique NotI
restriction endonuclease site between the Tie2 promoter and the polyA
cassette. Arrows labelled F and R indicate PCR primers used for
genotyping and RT-PCR in the 3¢ transcribed region of the Tie2
promoter and the 5¢ transcribed region of the Tie2 enhancer,
respectively. (B) The effects of the selection antibiotic G418 on
vessel development in EB. EB generated from a pTie2neo ES cell
clone were differentiated in spinner flasks for 13 days in the presence
or absence of G418 (500 lg/ml) and cryosectioned. The fraction of
cellular EB volume occupied by CD31-stained structures after 13
days of differentiation was quantified as described in methods from
50 images without G418 (–G418) and 30 images with G418 (+G418).
This was expressed as a percentage. Error bars represent standard
error of the mean. The fraction of cellular EB volume occupied by
ECs differed significantly between EB cultured with and without
G418 (P £ 0.01, t-test). (C) EB derived from ES cells retained and
expressed transgenes after differentiation for at least 10 days in the
absence of G418. 1.2% agarose gel showing PCR and RT-PCR
products. Oligonucleotide primers used were F and R. Lanes are; M:
1 kb plus DNA ladder (New England Biolabs), (1) positive control
(PCR using pTie2neo plasmid DNA), (2) positive control (PCR using
pTIE2neo + insert plasmid DNA), (3): PCR using 5 ng EB genomic
DNA, derived from ES cells transfected with the same construct as
lane 2, grown without G418 for 10 days of differentiation, (4) RT-
PCR using 100 ng of RNA prepared from EB containing the same
construct as lanes 2 and 3, grown without G418 for 10 days of
differentiation (no RT control not shown was negative), (5) RT-PCR
using 100 ng of RNA prepared from EB containing pTie2neo (as lane
1) grown without G418 for 13 days of differentiation, (6) RT-PCR
using 100 ng of RNA prepared from EB spontaneously differentiated
from wild type ES cells, lane (7) PCR negative control using a water
template
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to 5 min for products > 2 kb. When the parent pTie2neo
plasmid was used as a positive control for PCR, a 366 bp
product was amplified (Fig. 2C, lane 1).
RT-PCR of differentiating EB
RNA was isolated from differentiated EB using Tri-Re-
agent LS (Sigma-Aldrich), digested with 2 units of DNase
enzyme (DNA-free, Ambion Europe Ltd, Cambridgeshire,
UK) per 50 ll for 30 min at 37"C and re-purified using the
RNeasy Mini Kit (Qiagen Ltd.). RNA was then checked for
integrity and purity using an Agilent Technologies 2100
Bioanalyser (Agilent Technologies UK Limited, Cheshire,
UK). cDNA was generated using Superscript III Reverse
Transcriptase (Invitrogen, Life Technologies) from 1 lg of
RNA according to the manufacturers instructions. All
samples were checked for genomic DNA contamination by
amplification without prior reverse transcription (data not
shown).
Immunofluorescent and immunohistochemical staining
Samples (1 ml) were taken via the side arms of the spinner
flasks and collected in glass vials, EB allowed to settle,
washed two times with PBS, then either frozen in optimal
cutting temperature compound (OCT, Tissue Tek, Sakura
Inc., Torrance, CA., USA) while stirring with a glass rod to
maintain a uniform distribution, or fixed whole in acetone/
methanol (3:7) at –20"C for 20 min. Cryosections of
10 lm were cut from EB that had been frozen in OCT and
transferred to uncoated glass slides, then fixed for 10 min
at room temperature in acetone. Sections were washed in
wash buffer (PBS plus 0.01% Triton- · -100, Sigma) then
blocked for 1 h at room temperature in a humidified
chamber using PBS plus 10% goat serum (Sigma-Aldrich)
and 0.2% bovine serum albumin (fraction V, Sigma-Al-
drich). Sections were then washed and incubated overnight
at 4"C with primary antibody; a monoclonal rat anti-mouse
antibody directed against CD31 (clone MEC13.3, BD
PharMingen, Oxford, UK) at 1:100, or polyclonal rabbit
anti-human Bcl-2 (Oncogene Research, CA., USA) at
1:500 followed by three washes for 10 min at room tem-
perature in wash buffer. As secondary antibodies either
Alexa Fluor 488 goat anti-rat IgG (H + L) or Alexa Fluor
568 goat anti-rabbit IgG (H + L) (Molecular Probes Eur-
ope, Leiden, The Netherlands) were used at 1:200. Sections
were mounted using Vectashield mounting medium con-
taining DAPI (Vector Laboratories Ltd., Peterborough,
UK) and the coverslips sealed with nail varnish.
Whole fixed EB, washed in PBS, can be stored at 4"C
for up to 6 months. For whole-mount staining they were
first incubated with 1 lg/ml Hoechst 33528 (Bis-benzimide
trihydrochloride) nucleic acid-binding dye (Calbiochem
Merck Biosciences Ltd, Nottingham, UK) in PBS plus
0.01% Triton- · -100 (PBST) overnight at 4"C, then wa-
shed overnight at 4"C in PBST. Thereafter they were
stained as for immunofluorescent frozen sections but wash
times increased from 10 min to 20 minutes and Vectashield
mounting medium without DAPI was used. Whole EB
were mounted on single cavity microscope slides (Supe-
rior, West Germany).
Due to the inherent fluorescence of berberine (Ex.
420 nm, Em. 520 nm) in these experiments biotinylated
Anti-Rat IgG (H + L) (Vector Laboratories) was used at
1:200, followed by Vectastain Elite ABC kit (Vector
Laboratories) with DAB chromagen (DakoCytomation Ltd,
UK). Slides were counterstained with Carazzi’s heamat-
oxylin, then dehydrated and mounted using DPX (Fisher
Scientific Ltd, Leicestershire, UK).
Imaging and stereology
Digital images were captured with a Nikon Coolpix 995
camera attached to a Zeiss Axiovert S100TV microscope.
A Leica TCS Laser Scanning Confocal Microscope was
used for higher-resolution images and for three-dimen-
sional reconstructions of whole mount EB (LCS Leica
Microsystems, Heidelberg, GmBH). Digital 1024 · 1024
or 1300 · 1300 pixel images of fluorescently or chromo-
genically stained cryosections of EB were captured,
each covering an area of 1000 lm · 1000 lm or
2000 lm · 2000 lm respectively. Quantification of endo-
thelial differentiation was carried out after importing the
images into Computer-Aided Stereological Toolbox
(CAST) software (Olympus, Denmark). The principles of
isotropic, uniform and random (IUR) sampling were fol-
lowed as far as practically possible. Specifically, EB were
stirred during embedding in OCT to maintain a uniform
distribution of orientations, and images for quantification
were selected by systematic random sampling from each
slide. Volume fractions were determined by point counting
using a quadratic lattice and overlaying 100 intersections
over each image with a minimum of five randomly selected
images per slide and five systematically randomly selected
slides per clone. A pilot study was analysed using the
cumulative mean technique to verify that this was adequate
to ensure that sufficient images were counted. Running
means and standard deviations were plotted to ensure mean
stabilisation and standard deviation reduction to determine
the number of fields to be scored. Results of volume
fraction analysis were expressed as percentage of CD31/
DAPI or CD31/haematoxylin staining. This provided an
estimate of the proportion of the cellular regions of EB that
were occupied by endothelial marker-stained structures
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Stained sections were also scored, where relevant, for
additional features relating to EB differentiation including
the number of CD31 positive cells appearing as part of
vessel like structures (VLS). It would be useful to convert
these proportional values of VLS into absolute volumes of
VLS per EB, thus avoiding the sterological ‘reference trap’
[33]. However, we could not do this reliably, since the
irregular shape and cavitation prevented reliable assess-
ment of EB volume. For statistical analysis, log transfor-
mation of data was required to bring it to a near-Gaussian
distribution in order to allow the use of parametric statis-
tical tests such as ANOVA.
Results and discussion
Vascular development in EBs
In spinner culture ES cells aggregate to form early morula-
like structures clearly visible as solid balls of cells
(Fig. 1D) the surface of which later smoothens to resemble
a compact morula. We know that in addition to vascular
expression CD31 is also expressed in the pluripotent cells
of the mouse inner cell mass [34] and CD31 staining in
Fig. 1E suggests progenitors that give rise to vasculature
do develop from mesodermal cells located throughout the
early embryo. This is supported by evidence in Xenopus
Laevis using EC fate maps [35] and by other studies such
as those in the chick-quail system [36], and the mouse [37].
Expression of the early mesoderm marker brachyury peaks
at day 4 under these conditions (data not shown) and ECs
appeared by day 4–5 of differentiation (approximating to
day 7.5 of mouse embryonic development) and coalesced
into a rudimentary network of angioblasts [11, 38]. After
10 days EBs had increased in size by more than twenty
times (from Fig. 1D–F) and all had become cavitated,
usually with a central septate cavity (Fig. 1G), surrounded
by an endodermal coat, as shown at the top edge of the EB
in Fig. 1F. This outer layer has been shown to express the
transcription factor GATA-4, which first appears in vis-
ceral and parietal endoderm in mouse embryogenesis [39].
Cavitation of the EBs is a critical part of the differentiation
process [40], and in parallel with this process vascularisa-
tion may improve oxygen supply to the depth of the EB
[41]. By 10–13 days of differentiation blood island-like
structures (Fig. 1F, H) containing cells filled with haemo-
globin are seen near the centre of cavitated areas (Fig. 1H).
The development of vascular networks within EB is
thought to be in-part promoted by vascular endothelial
growth factor (VEGF)-A produced within the EB [42] as
well as VEGF and basic fibroblast growth factor supplied
by the serum [43]. VEGF-A further promotes survival by
the upregulation of Bcl-2 in ECs and the migration and
patterning of endothelial progenitors and cells in the em-
bryo [44].
After 13 days of differentiation angioblasts had devel-
oped into networks of CD31 positive VLS around the edges
of the central cavities (Fig. 1I) in all EBs sampled from a
synchronised culture. Confocal microscopy showed that
these CD31 staining VLS were complex, multi-cellular and
interconnected, resembling those found in the early verte-
brate yolk sac (Fig. 3). Many VLS did not appear to have
continuous lumen while others had large lumens lined by
relatively thin CD31+ve endothelial walls reminiscent of
venous sinuses (Fig. 3 B–F). Frequently networks of
varying size and shape with both sinusoid capillaries up to
150 lm diameter (Fig. 3E) and narrow capillaries seen in
the same EB. None of the vessels observed in this study
were filled with blood cells as described using quail de-
rived EBs [45].
During embryonic vessel development ECs and blood
cells are the first to develop while supporting pericytes and
smooth muscle cells appear later. Immunostaining for
smooth muscle actin together with CD31 did not reveal
pericyte investment of VLS during the time course of this
study (data not shown). Murine EBs may therefore be a
useful model for immature vessels at the plasticity window
[46] when the existence of a pericyte free endothelial
plexus makes ECs sensitive to VEGF withdrawal and anti-
angiogenic therapy [47].
Quantification of vascular-targeted transgene
expression in EBs
Having established the pattern and timing of vessel
development as described above we were then able to
genetically manipulate the system to examine and quantify
the role of apoptosis in new vessel formation. Following
vasculogenesis, de novo vessel formation from mesoderm-
derived angioblasts, angiogenic remodelling of the primary
plexus involves a subtle balance between cell growth and
apoptosis [11, 17]. Inhibition of apoptosis has been shown
to alter vascular development both in vitro [48] and in vivo
[49], although the mechanism is incompletely understood.
To test the hypothesis that apoptosis contributes to vascular
development in EBs, independent ES cell clones were
generated carrying either a wt Bcl-2 transgene (which
inhibits apoptosis, and in a small number of studies also
inhibits proliferation) or G145E mutant Bcl-2 transgene,
which contains a single base pair substitution that abro-
gates the anti-apoptotic but not the proliferation-restraining
activity of Bcl-2 [50, 51]. These ES cell clones were then
differentiated into EBs as separate populations in spinner
culture. Double immunofluoresence for CD31 and human
Bcl-2 revealed an overlaping pattern of EC and transgene
staining (Fig. 4A). The anti-Bcl-2 antibody was capable of
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detecting endogenous mouse Bcl-2, but none was detected
in this study. Endogenous mouse Bcl-2 levels are likely to
be low during early stages of EB differentiation relative to
transgene-derived Bcl-2.
Volume fraction stereology suggested that the expres-
sion of wt Bcl-2 reduced the percentage of cellular EB
volume occupied by VLS (Fig. 4B) compared to the
expression of the non-functional mutant Bcl-2 G145E.
Medians for all mutant non-functional Bcl-2 clones where
higher than those for the wt Bcl-2 clones and ANOVA of
log-transformed data further supported the suggestion that
significant differences were attributable to the effect of
wild type versus G145E mutant Bcl-2 transgene expression
(P £ 0.05). Along with the previous studies referred to
above, this experiment suggests that vascular development
may utilise apoptosis though an as-yet undefined mecha-
nism. The EB system will be useful to elucidate this
mechanism in future studies. We noted some variability
between the transfected clones (Fig. 4B). This inter-clone
variation in vascular development may be due to a com-
bination of transgene integration site and copy number
differences as well as a degree of stochastic patterning and
developmental noise. Single clone experiments may
therefore produce misleading results and several indepen-
dent transgenic ES cell clones provide a more robust
analysis of EB vascular development. Replication using
independent transgenic EB cultures has an additional
advantage in controlling for technical variation between
flasks.
In addition we noticed that EBs that are grown in the
presence of 500 lg/ml G418 contained fewer VLS than
EBs grown without antibiotic. To quantify this observation
we identified cellular regions of EBs with DAPI and stained
the VLS within these cellular regions using anti-CD31
immunohistochemistry. We found that the percentage of the
volume of cellular regions occupied by CD31 positive cells
was significantly lower (Student’s t-test P £ 0.01) in EBs
cultured in the presence of 500 lg/ml G418 than in EBs
cultured without antibiotic (Fig. 2B). As a result G418
selection was withdrawn after ES cells were transferred to
spinner flasks and we showed that, in EB cultures examined,
this approach does not result in the loss of transgene pres-
ence (Fig. 2C lanes 3 and 5) or expression (lane 4).
The progress of vascular differentiation in EBs may be
subtly altered by the addition of soluble factors
To illustrate the use of the EB system to study the effects of
soluble factors on vessel development, the isoquinoline
alkaloid berberine was used. Berberine altered the pro-
gression of EB development (Fig. 5B). However, if scored
simply on the basis of percentage of anti-CD31 compared
to nuclear staining (Fig. 5A) this was not apparent. Control
EBs became increasingly cystic between day 10 and day 15
of spinner culture, accompanied by an increase in total
(Fig. 5A) and peripheral (Fig. 5C) VLS and a corre-
sponding decrease in central CD31 staining (Fig. 5D). In
contrast, berberine treated EBs did not become cystic
Fig. 3 Confocal microscopy detected CD31-stained vascular struc-
tures within whole mount EB. (A) Pseudo-phase contrast image of a
region within an EB after 11 days of differentiation. (B) The structure
circled in panel A was revealed as a developing ‘vessel’ within the EB
by anti-CD31 staining (green, maximum projection image combining
twenty-five 1 lm confocal Z-series sections). (C–E) Developing
vessels within EB after 11 days of differentiation revealed by anti-
CD31 staining (maximum projection images). (F) A Z-series fly-
through (38 lm total depth) of branched, interconnected multi-
cellular vascular structures within an EB after 11 days of differen-
tiation. Endothelial cells and nuclei were detected using an anti-CD31
antibody (green) and Hoechst 33528 (blue), respectively. Scale bars in
A–E are 100 lm
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between day 10 and day 15 of spinner culture and did not
develop peripheral VLS (Fig. 5C). Anti-CD31 staining was
present in the centre of the berberine treated EBs (Fig. 5D)
although VLS were not formed (Fig. 5B). This suggests
angioblast precursors of the vascular network were present
much like the staining seen in early day 3–4 EBs. Ber-
berine is known to inhibit the hypoxia responsive tran-
scription factor HIF1a and subsequently the VEGF
autocrine loop [29], which results in inhibition of vessel
formation. Therefore, it is possible that berberine may have
prevented the normal hypoxic response in the centre of the
immature uncavitated EBs resulting in reduced angiogen-
esis. Since the microenvironment of solid tumours is often
hypoxic [52], murine EBs may provide a further model for
early tumour neovascularisation.
Conclusion
The EB recapitulates many of the developmental processes
that occur in an embryo, including vasculogenesis and
angiogenesis. In EBs vascular development occurs in the
context of a whole tissue including both paracrine growth
factor and contact-mediated signals between cells of sev-
eral lineages. Therefore, the EB system provides a method
to study vascular development in a near-in vivo environ-
ment while retaining the practical and ethical advantages of
in vitro experiments.
We have shown that EBs can be used to quantify the
effects of both transgene expression and pharmacological
agents on vascular development. This method can be used
on a relatively small scale as described, but could easily be
scaled up to assess anti-angiogenic agents in a medium
throughput screen.
We hope that the methods described here will contribute
to the expanded use of the EB system in vascular biology
research as an alternative or adjunct to studies involving
experimental animals.
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Abstract Endothelial cell (EC) apoptosis has been
detected in remodelling blood vessels in vivo, and
inhibition of EC apoptosis appears to alter vascular
morphogenesis in vitro, suggesting that EC apoptosis
may play a role in blood vessel remodelling. However,
apoptotic EC are difficult to quantify in vivo, and
studies of the incidence of EC apoptosis and the sites at
which it occurs in vivo have produced contradictory
results. Therefore, the specific biological roles played
by EC apoptosis remain unclear. Here, we have used a
transgenic approach to determine the biological func-
tion of EC apoptosis in vivo. Anti-apoptotic Bcl-2
transgenes were expressed in mice under control of the
EC-specific tie2 promoter. These transgenic mice died
during the second half of gestation. While the devel-
opment and remodelling of large vessels including
aortic arch arteries and great veins proceeded nor-
mally, abnormally dense and disorganised networks of
small vessels were present in the skin and internal or-
gans. In addition, vessel organisation and lumen for-
mation were disrupted in the placental labyrinth. This
study provides direct experimental evidence that
endothelial cell apoptosis plays an essential role during
embryogenesis. Our results suggest that EC apoptosis
plays an important role in determining the structure of
the microcirculation but may be dispensable for large
vessel development.
Keywords Apoptosis  Endothelial  Angiogenesis 
Vascular regression  Bcl-2  Transgenic
Abbreviations
EC Endothelial cell
HUVEC Human umbilical vein EC
BAEC Bovine aortic EC
TNF Tumour necrosis factor
FCS Foetal calf serum
PCR Polymerase chain reaction
eGFP Enhanced green fluorescent protein
IRES Internal ribosome entry site
Introduction
Blood vessels in the developing embryo, yolk sac and
placenta are continually remodelled to meet the
changing requirements of the tissues they supply [1].
There is circumstantial evidence that apoptosis of cells
within vessel walls, in particular endothelial cells (EC),
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contributes to this remodelling. For example, apoptosis
has been detected in embryonic blood vessels under-
going programmed developmental regression includ-
ing: aortic arches [2], the abdominal aorta [3], umbilical
vessels [4] and the ductus arteriosus [4]. In addition,
EC apoptosis has been detected in the developing eye
during regression of the tunica vasculosa lentis [5],
pupillary membranes [6], and hyaloid vessels [7]. EC
apoptosis has also been detected during blood vessel
development and remodelling in the placenta [8]. EC
apoptosis appears to be less frequent in adult animals
than during embryogenesis. Nevertheless, EC apopto-
sis has been hypothesised to play a role in the cyclical
remodelling of vessels within female reproductive tis-
sues [9, 10] and in several pathologies including ath-
erosclerosis [11] and cancer [12].
Further circumstantial evidence to support a role for
EC apoptosis in blood vessel remodelling and regres-
sion comes from the dramatic vascular phenotypes
produced when genes encoding regulators of EC
apoptosis are inactivated. For example, inactivation of
VEGF-A [13], AKT [14], Ang-1, Tie-2 [15] or VE-
cadherin [16] disrupted vascular development and
caused embryonic death. In addition, cell culture
studies have suggested that EC apoptosis occurs during
angiogenesis [17, 18] and may contribute to lumen
formation [19]. Inhibition of EC apoptosis by peptide
caspase inhibitors or anti-apoptotic Bcl-2 over-expres-
sion can inhibit both vessel regression [20] and vascular
morphogenesis [21, 22].
However, the role played by EC apoptosis in vessel
development and remodelling remains controversial.
Some studies have not supported the hypothesis that
EC apoptosis contributes to blood vessel remodelling.
For example, surprisingly few apoptotic EC were de-
tected in studies of vessel regression within the ovarian
corpus luteum [23] and developing rat retina [24]. The
authors of the latter study suggested that vessel
regression may in fact be mediated primarily by EC
migration, and that EC apoptosis may only occur when
the redeployment of EC is not possible [24]. Further, in
Xenopus the expression of transgenes encoding anti-
apoptotic XIAP or Bcl-xL proteins did not cause any
detectable alteration to blood vessel structure or EC
number [25]. In addition, apoptosis was not observed
when vessels were disrupted in vitro by angiogenic
inhibitors [26].
EC apoptosis appears to be controlled by a vast
network of converging signals (reviewed in [18]).
Members of the Bcl-2 family of apoptotic regulators
[27] appear to provide especially important signals for
determining EC fate. For example, over-expression of
Bcl-2 or Bcl-xL inhibited EC apoptosis induced in vitro
by serum deprivation, staurosporine, ceramide and
tumour necrosis factor (TNF)-a [28, 29]. Conversely,
inhibition of pro-survival Bcl-xL expression using anti-
sense oligonucleotides induced apoptosis in HUVEC
[30], and bcl-2 knockout mice had impaired retinal
blood vessel development [31]. A proven approach to
understand the biological role of apoptosis in specific
cell lineages has been to express lineage-specific anti-
apoptotic transgenes (including Bcl-2) in mice. This
approach has revealed the function of apoptosis in di-
verse cell types ranging from lymphocytes [32] to male
germ cells [33]. Here, we have used this approach to
investigate the role played by EC apoptosis during
mouse embryogenesis. Our results provide direct evi-
dence that the apoptosis of EC plays a role in embryo
development. Our results suggest that EC apoptosis is
required for the normal development and remodelling
of small vessels, but may be dispensable for large vessel
development.
Materials and methods
Induction of EC apoptosis under flow conditions
Human umbilical vein EC (HUVEC) was isolated from
umbilical cords of five individuals by collagenase diges-
tion as described [34] and cultured to passage 5 in basal
EC culture medium supplemented with a proprietary
mixture of heparin, hydrocortisone, epidermal growth
factor, fibroblast growth factor, 2% fetal calf serum
(FCS), gentamycin, and amphotericin (large vessel EC
medium; TCS, Botolph, UK). At passage 5, cells were
plated at 100% confluence on microscope slides coated
with matrigel (Becton Dickinson). The slides were in-
serted into a rectangular parallel flow chamber (Glyco-
tech, Gaithersburg, Maryland, USA), and cultures were
partially deprived of growth factors for 24 h by culturing
in basal medium supplemented with only 2% charcoal-
stripped FCS (Gibco/BRL), gentamycin, and ampho-
tericin. Recirculating laminar flow of media over the
cells was then established to achieve a constant wall
shear stress of 0.1 Pa as previously described [35, 36].
Annexin V-FITC and Propidium Iodine (Annexin V-
Fluos staining kit used according to the manufacturers
instructions; Roche, Basel, Switzerland) were added to
the media, and the process of apoptosis recorded using a
fluorescence phase contrast microscope placed within a
tissue culture incubator.
Transgene preparation
To generate a bicistronic transgene that would express
both Bcl-2 and GFP specifically in EC the plasmid
56 Angiogenesis (2007) 10:55–68
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pTie2Bcl-2IRESeGFP was constructed. The human
Bcl-2 coding region was excised from pVav-Bcl2 [32]
using the restriction enzyme EagI and cloned into
pIRES2-eGFP (Clontech). The resulting Bcl2-IRES-
eGFP sequences were then inserted into
pSPTgT2FpAXK [37] between the murine Tie2 pro-
moter (2 kb) and an SV40 polyA signal sequence. The
resulting plasmid was digested with XhoI and SalI to
release a Tie2-hBcl2-IRESGFP-pA fragment that was
cloned into pBSIIKS+. Finally, a murine Tie2 genomic
sequence containing a 10 kb enhancer fragment was
excised from pg50-2.11 [37] by NaeI-NotI digestion and
inserted downstream of the Tie2-hBcl2-GFP-pA se-
quences to generate the pTie2Bcl-2IRESeGFP trans-
gene plasmid. To generate the control transgene
plasmid pTie2eGFP, proofreading polymerase chain
reaction (PCR) was used to amplify all but the Bcl-
2IRESeGFP sequences from pTie2Bcl-2IRESeGFP
using the primers 5¢-AAA-AgC-ggC-CgC-TAA-TAA-
CCg-ggC-Agg-ggg-gA-3¢ and 5¢-AAA-AgC-ggC-GcG-
gAC-CTg-Cag-gAA-TTC-gAT-ATC-AAg-3¢. This
generated the transgene vector pTie2SV40 containing
(from 5¢ to 3¢); the pBSIIKS+ plasmid backbone, a Tie2
promoter (2 kb), a unique NotI site into which any
coding region could be cloned, an SV40pA-splice se-
quence and a Tie2 enhancer (10 kb). An enhanced
green fluorescent protein (eGFP) coding region was
amplified from pTie2Bcl-2IRESeGFP using 5¢-TTT-
TgC-ggC-CgC-CAC-CAT-ggT-gAg-CAA-ggg-CgA-
ggA-3¢ and 5¢-TTT-TgC-ggC-CgC-TTA-CTT-gTA-
CAg-CTC-gTC-CAT-gC-3¢ primers and sub-cloned
into the unique NotI site of pTie2SV40 to generate
pTie2eGFP. Plasmid DNA was prepared with Qiagen
Endofree Maxi kit (Qiagen, UK).
Transfection of BAEC
Passage 5 bovine aortic EC (BAEC) were cultured in
M199 media supplemented with 10% FCS. Around
4 lg of plasmid DNA (1 mg/ml) was diluted in 150 ll
with serum-free M199 medium. This was mixed with
36 ll of Superfect transfection reagent (Qiagen, UK)
by gentle pipetting and incubated at room temperature
for 10 min. Around 1.5 ml of M199 medium containing
10% FCS was then mixed with the DNA/Superfect
mixture and added to 40% confluent BAEC that had
been washed with PBS and aspirated to dryness. After
1hr incubation this media was removed and replaced
with M199 media + 10% FCS. This transfection
method delivered a control pCMVeGFP plasmid
(Clontech, Palo Alto, CA, USA) to approximately
60% of the BAEC and induced apoptosis in approxi-
mately 15% of the cells—the apoptotic cells floated off
and were removed when the cultures were washed and
media was changed 24 h after transfection. Cultures
were fixed in 2% paraformaldehyde for 20 min at 4C,
permeablised in 0.1% Triton X-100 and 0.1% Tween-
20 for 30 min at room temperature, stained with
Ulex-FITC (L9006, Sigma, Gillingham, UK) at a con-
centration of 10 lg/ml, anti-cleaved caspase 3 antibody
(G7481, Promega, Southampton, UK) at 1:100 dilution,
and Hoescht Bisbenzimide 33342 (382061, Calbio-
chem, Nottingham, UK) at a concentration of 1 lg/ml.
Generation of transgenic mice
Plasmid backbones were removed and linear DNAs for
microinjection were generated from pTie2Bcl-2IRES-
eGFP and pTie2eGFP by SalI digestion followed by
purification and electro-elution from a 0.6 % agarose
gel. Further purification was performed using Elutip-D
columns (Schleicher and Schuell, Germany) and the
eluted DNA was microdialyzed against the injection
buffer Tris HCl 10 mM pH 7.4/EDTA 0.1 mM. The
14.5 kb DNA derived from pTie2Bcl-2IRESeGFP and
the 12.4 kb DNA derived from pTie2eGFP were
microinjected into the pro-nucleus of fertilized mouse
eggs (C57BL/6 · DBA/2), and embryos transferred to
pseudo-pregnant recipients as described [38]. To
identify transgenic embryos, genomic DNA was ex-
tracted from tail biopsies or limb buds after an over-
night digestion with proteinase K (Sigma, UK) then
precipitated with isopropanol and resuspended in TE
buffer. GFP sequences within transgenes were ampli-
fied by PCR using the primers 5¢-gCA-gAA-gAA-Cgg-
CAT-CAA-ggT-3¢ and 5¢-gCg-gCg-gTC-Acg-Aac-
TCC-A-3¢ using Ready-to-Go PCR beads (Amersham,
Little Chalfont, UK) and cycle parameters of; 94C for
3 min, then 30 cycles of 30 s at 94C, 30 s at 63C and
45 s at 72C followed by 7 min extension at 72C.
Amplified products were analyzed by electrophoresis
through a 1% agarose gel. All mouse experiments were
ethically approved in accordance with the UK Home
Office regulations as prescribed in the UK Animals
(Scientific Proceedures) Act 1980.
Histology and immunohistochemistry
Embryos and their corresponding placentae were dis-
sected free of uterine decidua and separated from their
yolk sacs, weighed and photographed. Tissues were
then either snap frozen, fixed in Zinc fixative (BD
Pharmingen, Oxford, UK) or Bouin’s fixative for 6 h.
About 10 lm sections were cut from either frozen tis-
sue blocks or fixed paraffin-embedded tissue blocks,
and transferred to uncoated glass slides. EC were
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detected by overnight incubation at 4C with a rat anti-
mouse monoclonal antibody directed against CD31
(clone MEC13.3, BD Pharmingen) used at 1:100 dilu-
tion. Bcl-2-expressing cells were detected by incuba-
tion for 2 h at room temperature with a monoclonal
mouse anti-human Bcl-2 antibody (clone Bcl-2-100,
which does not cross-react with mouse Bcl-2, Sigma,
UK) used at 1:400 dilution. Vascular smooth muscle
cells and pericytes were detected using a rabbit anti-
human anti-smooth muscle actin antibody (AB15267,
AbCam, UK). Apoptotic cells were detected using a
polyclonal rabbit anti-active Caspase 3 antibody (Pro-
mega, Southampton, UK) at 1:200 dilution. Rat and
rabbit primary antibodies were detected with either
FITC-conjugated, TRITC-conjugated or peroxidase-
conjugated goat anti-rat and goat anti-rabbit IgG
(Molecular Probes Europe, The Netherlands). Mouse
primary antibodies were detected with the ‘mouse on
mouse’ peroxidase system (Vector Laboratories,
Burlington, CA) followed by incubation with strepta-
vidin-conjugated horseradish peroxidase (Vector Lab-
oratories) and 0.1% diaminobenzidine (DAB) with
0.1% hydrogen peroxidase. Sections for fluorescent/
confocal microscopy were mounted using Vectashield
mounting medium (Vector Laboratories, Burlington,
CA). Sections for bright-field microscopy were count-
erstained with Carazzi’s haematoxylin, then dehy-
drated and mounted using DPX (Fisher Scientific Ltd,
Leicester, UK). For stereology to assess the volume
fraction of cells immunostained by the anti-CD31
antibody, or the proportion of CD31-expressing cells
that were also immunostained by the anti-cleaved
caspase 3 antibody, at least thirty 750 · 750 lM fields
were chosen by systematic random sampling [39] from
at least six different sections. Volume fraction was
calculated based on point counting as described [40].
Data were log-transformed before statistical tests were
performed.
Results
A survey of embryonic EC apoptosis
Given the inconsistent observations of EC apoptosis
described in the introduction, as a first step to further
understanding this process, we wished to confirm that
EC apoptosis did in fact occur within the developing
mouse embryo. To do this we used double immuno-
histochemistry for CD31 (an EC marker) and active
caspase 3 (an apoptosis marker) to survey the inci-
dence of EC apoptosis in wild type mouse embryos at
E8.5, E10.5, E12.5 and E14.5 of gestation. At each
gestational age, between 6 and 13 separate immuno-
stained sagittal sections from three complete embryos
were examined. Few if any caspase 3+ve apoptotic EC
were detected in either large or small vessels at E8.5,
E10.5 or E12.5 (<0.5% of the vessels we studied in
cross-section in these embryos contained an apoptotic
EC). In addition, at E14.5 few if any active caspase 3+ve
apoptotic EC were detected in any large trunk vessels
(including aortic arches). In contrast, at E14.5 active
caspase 3+ve apoptotic EC were clearly detectable in
small arterioles, capillaries and post-capillary venules
found within the loose connective tissues of limb buds,
the orbit and the gut. Up to 2% of the vessels we
studied in cross-section in these tissues contained an
apoptotic EC (Fig. 1). The nuclei of most of these ac-
tive caspase 3+ve EC had a pyknotic morphology con-
sistent with apoptosis. In several cases we detected
multiple apoptotic EC in a single vessel (Fig. 1). Due
to background fluorescence it was difficult to assess EC
apoptosis in the placenta. In summary, these results
suggest that EC apoptosis does indeed occur within
developing mouse embryos, and that apoptotic EC
were most commonly detected in small vessels at the
latest gestation examined (E14.5).
It is possible that when EC undergo apoptosis, they
loose adhesion to their basement membrane and are
rapidly deported by the flowing blood. This may make
it difficult to estimate the true incidence of EC apop-
tosis. In support of this concept, we have previously
shown by time-lapse video microscopy that EC
undergoing apoptosis become separated from their
basement membrane substrate early in the apoptotic
process [41]. To explore the kinetics of EC apoptosis
under flow, we cultured HUVEC on glass slides coated
with basement membrane components (matrigel), and
pumped media over the HUVEC monolayer under
laminar flow conditions. We used a flow rate calculated
to generate a shear stress on the EC of 0.1 Pa (1 dyne/
cm2). This represents the lower end of the range of
shear stresses observed in human venules [36, 42]. We
induced apoptosis in the HUVEC by partial serum
deprivation, and observed the apoptotic process by
fluorescence microscopy. AnnexinV-FITC and Propi-
dium Iodine were added to the media to detect the
membrane changes that accompany apoptosis and
post-apoptotic necrosis, respectively. The apoptosis of
35 HUVEC was observed. We found that 24 (68%) of
the apoptotic HUVEC lost adhesion to their basement
membrane substrate and were deported in the flowing
media after initiating apoptosis (as indicated by binding
of AnnexinV-FITC and membrane blebbing) but be-
fore becoming permeable to Propidium Iodine
(Fig. 2a). Half of these 24 cells were deported in the
58 Angiogenesis (2007) 10:55–68
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flowing media within 30 min of initiating membrane
blebbing (Fig. 2b). This suggests that, due to loss of EC
adhesion and deportation of apoptotic EC into the
bloodstream, the incidence of EC apoptosis in vivo
may be underestimated by simply enumerating apop-
totic EC in situ in vessel walls.
Generation and verification of plasmids
for the production of transgenic mice
After confirming that EC apoptosis can be detected
during mouse embryogenesis, we wished to determine
the role played by EC apoptosis in vivo. To do this, we
expressed an anti-apoptotic human Bcl-2 transgene
specifically in mouse EC. We generated a transgene
plasmid pTie2Bcl-2IRESeGFP that contained mouse
Tie-2 gene regulatory sequences (including an en-
hancer region that is required for widespread expres-
sion of the tie2 gene postnatally [37]) and a human Bcl-
2 coding region. To facilitate the detection of cells in
which the transgene was expressed, the Bcl-2 coding
region was linked to an eGFP coding region by an
IRES (Fig. 3a). A control transgene plasmid
pTie2eGFP that lacked the Bcl-2 coding region was
also generated (Fig. 3b). BAEC transfected with
pTie2Bcl-2IRESeGFP were 1.8-fold more resistant to
apoptosis induced by the combination of 10 ng/ml
TNFa + 100 lg/ml cycloheximide, and 2.5-fold more
resistant to apoptosis induced by 50 nM staurosporine,
than BAEC transfected with the control plasmid
pTie2eGFP(data not shown). We could detect no dif-
ference in incidence of mitosis between BAEC trans-
fected with pTie2Bcl-2IRESeGFP and pTie2eGFP
(data not shown).
Fig. 1 Detection of EC
apoptosis in a developing
limb bud of a wild type
E14.5 mouse embryo.
Fluorescent double
immunohistochemistry was
used to detect CD31 (a, b;
red) and active caspase 3 (c, d;
green). In panels c and d
examples of apoptosis in EC
and non-endothelial cells are
indicated by closed and open
arrows, respectively. The
images were generated by
confocal microscopy, and
were overlaid onto a grey
scale pseudo-phase contrast
image to show tissue
structure. Scale bars are
125 lm. Panels e and f show
overlaid anti-CD31 and anti-
active caspase 3 images.
Panels b, c and f are higher
magnification representations
of regions within panels a, b,
and c
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Most pTie2Bcl-2IRESeGFP-transgenic mice die
during embryogenesis
The plasmids pTie2Bcl-2IRESeGFP and pTie2eGFP
were microinjected into the male pro-nuclei of ferti-
lised eggs, and the resulting embryos transferred to
pseudo-pregnant recipients. Transgene integration into
the genome of embryos was detected by PCR using
GFP-specific oligonucleotide primers (Fig. 3c).
Around 20% of embryos injected with pTie2eGFP and
collected at E12.5 carried this transgene in their gen-
ome. A similar proportion of pTie2eGFP-injected
embryos still carried the transgene at E19.5, suggesting
that carriage of the pTie2eGFP transgene had little
effect on the survival of embryos during the second
half of gestation. In contrast, while 22% of embryos
injected with pTie2Bcl-2IRESeGFP carried the trans-
gene at E12.5, only 15% of injected embryos carried
the transgene at E14.5, and only 6% of injected em-
bryos carried the transgene at E19.5 (Fig. 3d). This
indicated that the presence of pTie2Bcl-2IRESeGFP
may lead to embryo lethality during the second half of
gestation.
Vascular abnormalities become apparent between
E12.5 and E14.5
To determine the cause of pTie2Bcl-2IRESeGFP-
induced embryonic lethality, at E12.5 we examined five
pTie2Bcl-2IRESeGFP-transgenic embryos, five non-
transgenic littermate control embryos and two
pTie2eGFP-transgenic embryos. To identify transgene
expression we examined these embryos for eGFP-de-
rived fluorescence, however, while this was faintly
detectable in EC it was not sufficiently intense for reli-
able quantification. Therefore, we used immunohisto-
chemistry to identify human Bcl-2 immunoreactivity.
This was detected only within EC lining both small and
large vessels, but not in other cell types of all five
pTie2Bcl-2IRESeGFP-transgenic embryos and not in
any tissues of wild type or pTie2eGFP-transgenic animals
(Fig. 3e). The embryos expressing human Bcl-2 had no
obvious external abnormalities, and tissue sections
stained with haematoxylin and eosin or an anti-CD31
antibody revealed normal blood vessel development and
no detectable tissue abnormalities. Transgenic placentae
and yolk sacs also appeared normal at E12.5 gestation.
Fig. 2 (a) Time lapse fluorescent video microscopy was used to
determine whether EC were deported into media flowing over
their monolayer at a physiological flow rate during apoptosis.
Serum deprivation-induced apoptosis of 35 HUVECs was
observed. The timing of deportation of each cell into flowing
media relative to the timing of apoptotic membrane blebbing
was noted. Pre-blebbing indicates that apoptotic EC lost
adhesion and was deported into the flowing media before EC
displayed membrane blebbing or became Annexin V+ve. Bleb-
bing-PI indicates that apoptotic EC were deported into the
flowing media after they displayed membrane blebbing but
before they took up the PI dye.Post-PI indicates that apoptotic
EC were deported into the flowing media after they took up the
PI dye. (b) The kinetics of apoptosis for the 24 HUVEC that
were deported into the flowing media after they displayed
membrane blebbing but before they took up the PI dye was
examined in more detail. The histogram shows the time interval
in minutes between the first appearance of either membrane
blebbing or Annexin V staining and cell deportation into the
flowing media
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Fig. 3 (a) The transgene vector pTie2Bcl-2IRESeGFP. Open
bars represent regulatory sequences derived from the murine tie-
2 gene, black bars wild type human Bcl-2 and eGFP, respec-
tively, grey bars an IRES and SV40 pA sequence, and hatched
bars pBSII plasmid backbone sequences. S, K and N represent
recognition sites for restrictions endonucleases SalI, KpnI and
NotI, respectively. I denotes an IRES, and the arrows the PCR
primers used for genotyping. (b) The transgene vector
pTie2eGFP was similar topTie2Bcl-2IRESeGFP except for the
deletion of the Bcl-2 and IRES sequences. (c) PCR amplified a
340 bp transgene-specific product from genomic templates
prepared from tail biopsies of a pTie2Bcl-2IRESeGFP-trans-
genic embryo but not from a wild type littermate. (d) Embryos
carrying the pTie2Bcl-2IRESeGFP transgene die during the
second half of embryogenesis, while embryos carrying a control
pTie2eGFP transgene were unaffected. Figures represent the %
of animals derived from embryos micro-injected with each
transgene that still carry the transgenes at the given gestation.
Numbers of transgenic animals/total numbers of animals
assessed are shown in brackets. N/D denotes assay not done.
Cells in E12.5 (e) and E14.5 (f) embryonic brain that expressed
the pTie2Bcl-2IRESeGFP transgene were detected using an anti-
human Bcl-2 antibody (red-brown). Scale bars are 80 lm. (g)
E14.5 embryos expressing the pTie2Bcl-2IRESeGFP transgene
(TG) and wild type littermate controls (WT) were blotted dry
and weighed after dissection away from their yolk sacs and
placentae
Angiogenesis (2007) 10:55–68 61
123
We then examined six pTie2Bcl-2IRESeGFP-trans-
genic embryos and six non-transgenic littermate con-
trol embryos at E14.5. One transgenic embryo had no
heartbeat and poorly preserved tissues. Based on its
degree of maturity it appeared to have died at
approximately E13. Of the remaining five viable
transgenic embryos, immunohistochemistry showed
that four expressed Bcl-2 in EC (for example, Fig. 3f).
The one transgenic embryo in which Bcl-2 expression
was not detected, as well as the transgenic embryo that
had died, were excluded from subsequent analysis. The
mass of the remaining four pTie2Bcl-2IRESeGFP-
transgenic embryos was on average less than the mass
of four non-transgenic littermate controls (t-test
P £ 0.05, Fig. 3g), suggesting that pTie2Bcl-2IRES-
eGFP transgene expression retarded intra-uterine
growth. A set of further abnormalities were observed
in all four pTie2Bcl-2IRESeGFP embryos that ex-
pressed Bcl-2 in EC; (i) There were abnormally dense
networks of vessels in the embryonic skin interspersed
with patches of haemorrhage (Fig. 4A, B). Similar
abnormally dense vascular networks were faintly visi-
ble in the skin of the dead transgenic embryo described
above (data not shown). (ii) Inter-digital cleft forma-
tion appeared to be retarded relative to wild type lit-
termates (arrow, Fig. 4A, B). (iii) Anti-CD31
immunohistochemistry revealed an increased density
of capillaries, non-muscular venules and small arteri-
oles in the dermis and subcutaneous tissues (Fig. 4C),
consistent with the external appearance of these ani-
mals. (iv) Increased small vessel density was also seen
in the developing lung and heart of two of the
pTie2Bcl-2IRESeGFP-expressing embryos (Figs. 4D,
5a). Due to a technical difficulty, the thoracic regions
of sections obtained from the remaining two pTie2Bcl-
2IRESeGFP-expressing embryos were of insufficient
quality for immunohistochemistry. (v) In connective
tissues of the orbit small vessels were more extensive in
pTie2Bcl-2IRESeGFP-expressing embryos than in
non-transgenic controls (Fig. 4E). (vi) Increased den-
sity of small vessels was also consistently seen in the
developing gut (Figs. 4F, 5b) of pTie2Bcl-2IRESeGFP-
Fig. 4 Phenotype of
pTie2Bcl-2IRESeGFP-
transgenic mouse embryos.
(A) The head region of an
E14.5 wild type mouse
embryo. (B) The head region
of a pTie2Bcl-2IRESeGFP-
transgenic mouse embryo. CN
indicates capillary networks,
H haemorrhage and arrows
inter-digital clefts. Scale bar is
750 lm. (C–F) EC of E14.5
pTie2Bcl-2IRESeGFP-
transgenic (TG) and wild type
control (WT) mouse embryos
were detected using an anti-
CD31 antibody (brown).
Panels show (C) facial skin,
(D) lung, (E) eye and (F) gut.
H indicates haemorrhage, hp
the hyaloid plexus, l lumen,
mc the mesodermal
condensation, pl pigment
layer, sb segmental bronchi,
and v vessels. Scale bars are
100 lM
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expressing embryos. Interestingly, no obvious vascular
abnormalities were seen in brain, kidney or liver of
transgenic embryos. The structure of the heart, all
branches of the aorta and the large veins and arteries
of the neck, thorax and abdomen appeared to be nor-
mal. In addition, no obvious abnormalities were de-
tected in the vessels of the yolk sac. To allow for
immunohistochemistry, this analysis was conducted on
paraffin-embedded rather than plastinated sections,
which precluded a more detailed analysis of EC mor-
phology, fenestrations and contact with pericytes.
However, based on close examination of our paraffin-
embedded sections no significant differences could be
detected between the general morphology EC in both
wild type and pTie2Bcl-2IRESeGFP-expressing em-
bryos. Immunostaining for anti-active caspase 3 de-
tected very few apoptotic EC in either large or small
vessels of pTie2Bcl-2IRESeGFP-expressing embryos.
Since the expression of Bcl-2 in HUVECs transplanted
into immunodeficient mice promotes the recruitment
of pericyte-like cells [29], the perictye/vascular smooth
muscle cell investment of EC in the transgenic embryos
and their placentae was examined, however, no alter-
ation in the distribution of peri-vascular cells was de-
tected in the paraffin-embedded sections of pTie2Bcl-
2IRESeGFP-expressing embryos (data not shown).
Abnormalities in placental vasculature
The development of the placentae of all four pTie2Bcl-
2IRESeGFP-expressing conceptuses at E14.5 was dis-
rupted; (i) Transgenic placentae had an irregular
nodular external appearance and had greater average
diameter and mass than the placentae of non-trans-
genic controls (t-test P £ 0.01, Fig. 6A). (ii) The
umbilical arteries of all transgenic placentae appeared
to be dilated (data not shown). (iii) Anti-CD31
immunohistochemistry revealed that the labyrinth
layer of transgenic placentae was irregular and in some
regions expanded into the maternal decidua (Fig. 6B,
C). The usual labyrinthine structure consists of a reg-
ular array of trophoblast-lined maternal spaces and
EC-lined foetal capillaries. In contrast, the labyrinth in
the centre of pTie2Bcl-2IRESeGFP-transgenic pla-
centae contained dense networks of foetal EC, many of
which lacked an obvious lumen and contained few
foetal erythrocytes. Maternal spaces appeared to have
been partially lost and few maternal erythrocytes were
present (iv) Areas of foetal vessel haemorrhage were
also visible (Fig. 6D, E). (v) The labyrinth in the
periphery of pTie2Bcl-2IRESeGFP-transgenic placen-
tae was less severely affected, and usually both
maternal spaces and foetal capillaries remained. Pre-
sumably these relatively less affected peripheral re-
gions maintained sufficient gas and nutrient exchange
to keep the embryos alive. Nevertheless, even in these
peripheral regions there was evidence of haemorrhage
from foetal vessels (data not shown). (vi) Stereological
assessment of the overall labyrinth suggested that
foetal EC density was increased but density of
lumenised vessels was decreased in transgenic placen-
tae relative to non-transgenic littermates (Fig. 6F, G).
Since the labyrinth morphology of pTie2Bcl-2IRES-
eGFP-transgenic placentae were irregular (Fig. 6C),
we were unable to reliably estimate labyrinth volume,
and therefore were unable to infer from these vessel
density measurements of absolute blood vessel or EC
volume or number.
Fig. 5 Stereology of pTie2Bcl-2IRESeGFP-transgenic and wild
type tissues at E14.5. EC of paired E14.5 TG (black points) and
WT (hollow points) tissues were detected using an anti-CD31
antibody and the volume fraction occupied by CD31+ve cells was
calculated. Each point represents the average volume fraction
from seven 650 · 650 lM fields randomly chosen from one
section—five sections were used from each animal. *Indicates
P £ 0.05 (t-test). Numbers indicate pairs of wild type and
transgenic littermates (a) analysis of developing lung, (b)
analysis of developing small bowel
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Discussion
EC apoptosis contributes to vessel development
and regression
Several studies have detected EC apoptosis during
embryo development. However, other studies have not
detected EC apoptosis in regressing vessels where it
would be expected to occur [23, 24, 26]. Therefore, the
role played by EC apoptosis in vessel development and
remodelling remains uncertain. As a first step to better
understanding this process, we wished to confirm that
EC apoptosis occurred within the developing mouse
embryo. We detected caspase 3+ve apoptotic EC in
small vessels of E14.5 mouse embryos, however we
found EC apoptosis difficult to detect in large vessels at
this gestational age and in any vessels at the earlier
stages of gestation we examined. These results suggest
that EC apoptosis does indeed occur during mouse
development in vivo, but is relatively rare. Interest-
ingly, we observed multiple apoptotic EC in single
vessels (Fig. 1). This concords with the hypothesis that
microvascular segments regress en masse [6], possibly
after flow has been blocked by the apoptosis of a single
EC [43]. It is difficult to directly compare our results to
previously published surveys of EC apoptosis during
embryogenesis, since our study differs substantially
from others in terms of species used, gestational age
examined, tissues examined, and the techniques used
to detect apoptosis.
We then showed that apoptotic EC can be rapidly
deported into flowing media (Fig. 2). Several previous
studies are consistent with this concept. Our laboratory
previously showed that apoptotic EC lose adhesion
from their substrate and neighbouring cells early in the
apoptotic process [41]. This loss of adhesion may be
promoted by proteolytic shedding of VE-cadherin [44]
and caspase-mediated cleavage of focal adhesion ki-
nase pp125 [45]. In addition, apoptotic EC [46] and
apoptotic EC-derived microparticles [47] have been
detected in blood. Therefore, due to potentially rapid
deportation of apoptotic EC into blood, simple
Fig. 6 Phenotype of
pTie2Bcl-2IRESeGFP-
transgenic placentae. (A)
Placentae of E14.5
conceptuses expressing the
pTie2Bcl-2IRESeGFP
transgene (TG) and wild type
littermate controls (WT) were
weighed after dissection away
from the embryos and foetal
membranes. (B–E) EC of
E14.5 TG and WT placentae
were detected using an anti-
CD31 antibody (brown). (B)
and (C) show overall
placental structure, L
indicates labyrinth and d
maternal decidua. Scale bar in
C is 750 lm and in E is
100 lm. (D) and (E) show
detail of the labyrinth. FC
indicates foetal capillaries
containing nucleated foetal
erythrocytes, H haemorrhage,
MS trophoblast-lined
maternal spaces. (F and G)
EC of paired E14.5 TG (black
points) and WT (hollow
points) placentae were
detected using an anti-CD31
antibody and the mean
volume fraction of labyrinth
occupied by CD31+ve cells
was calculated from five
sections of each placenta.
*Indicates P £ 0.05 (t-test)
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enumeration of apoptotic EC in situ may underesti-
mate the incidence and importance of this process.
To determine the role played by EC apoptosis in
vivo, we then expressed EC-specific Bcl-2 transgenes in
mice. This transgene expression caused embryonic
lethality during the second half of gestation (Fig. 3d).
All embryos that expressed Bcl-2 in EC had abnor-
mally dense networks of small vessels in skin, some
internal organs and placenta (Figs. 4–6). These data
suggest that EC apoptosis performs important devel-
opmental functions in vivo. Transgene expression ap-
peared to have the greatest effect on those vessels in
which we had most readily observed EC apoptosis,
such as vessels within connective tissue, developing
limbs and gut. In contrast, transgene expression had no
observable effect on vessels in which little EC apop-
tosis was observed, such as large thoracic vessels.
Based on these results, we suggest that EC apoptosis
may play an important role in the development and
remodelling of small vessels in tissues such as limb
buds, connective tissue, and gut. However we suggest
that EC apoptosis may play a less important role in the
development and remodelling of large vessels includ-
ing the aortic arch arteries. The observation of rela-
tively little EC apoptosis in large vessels, and the lack
of any obvious effect of inhibiting EC apoptosis on
large vessels, concords with the relative stability of
large vessels and with the low rates of EC mitosis in
these vessels [48]. Since EC apoptosis may cause
thrombosis [49] and potentially damage downstream
tissues through occlusion or thrombo-embolism, it
would seem intuitive not to utilise EC apoptosis as a
developmental strategy for the regression of large
conductance vessels. In adult mice, the level of tie2-
driven transgene expression has been shown to vary
between arterioles and venules [50]. Although this may
in theory lead to a stronger phenotype in arteries than
in veins, we did not observe any systematic patterns
of human Bcl-2 expression or phenotype within
embryonic small vessels that were consistent with
artery–vein differences. Tie2 is also expressed in some
lymphatics. It is possible that aspects of the small vessel
phenotype we observed were due to Bcl-2 transgene
expression in lymphatic vessels, however we did not
observe any clear lympahtic vessel phenotype.
The phenotype of our tie2-Bcl2-transgenic mice only
became apparent after approximately E12.5. This was
initially surprising, since endogenous Tie2 is expressed
as soon as the first EC arise and persist into adulthood.
However, the phenotype of pTie2Bcl-2IRESeGFP-
transgenic mice appeared to arise at approximately the
stage when we were first able to readily detect EC
apoptosis, which is presumably a stage at which EC
apoptosis may play a major role. It is also interesting to
note that embryonic lethality occurred at a develop-
mental stage when small vessel growth and remodel-
ling was especially rapid. For example, between E12
and E14 the total foetal capillary length in the mouse
placental labyrinth increases by a factor of 3.8-fold
[51].
In Xenopus the expression of transgenes encoding
XIAP or Bcl-xL did not cause any detectable alteration
to blood vessel structure or EC number [25]. This
contrasts with our findings in mice, however these
differences may be due to the different expression
systems used as well as different mechanisms of vas-
cular development in Xenopus and mice.
Mechanisms through which EC apoptosis may
contribute to vascular development
There are several mechanisms through which EC
apoptosis may contribute to the growth, organisation
and regression of blood vessels in the embryo: (i) EC
apoptosis may play an important role in blood vessel
regression. The abnormally dense microvascular net-
works seen in a subset of pTie2Bcl-2IRESeGFP-
transgenic tissues may reflect the persistence of vessels
that were destined to regress, but were unable to do so
due to the transgene-mediated inhibition of EC apop-
tosis. (ii) The formation of new capillary loops may
involve the TGF-b/plasmin-induced apoptosis of spe-
cific EC in the walls of existing vessels [52]. (iii)
Engulfment of apoptotic EC debris by viable neigh-
bouring EC may cause the release of pro-angiogenic
factors. Golpon et al. recently found that engulfment of
apoptotic (but not necrotic) cell debris by non-profes-
sional phagocytes led to their release of pro-angiogenic
factors including VEGF-A, which were able to pro-
mote in vitro angiogenesis [53]. (iv) The negatively
charged membrane surface of apoptotic EC may pro-
mote angiogenic sprouting of adjacent vessels by
causing localized plasma membrane hyperpolarisation
[54]. (v) EC apoptosis may also promote lumen for-
mation, which in turn provides the blood flow and shear
stress that allows EC to survive and express growth
factors that promote angiogenesis [43]. Although lu-
men formation in blood vessels appears to involve
CDC42- and RhoA-mediated intracellular vacuole
formation [55], the apoptosis of centrally placed EC
may also play a role [19]. Indeed, several studies have
detected apoptotic debris within newly formed lumen
during in vitro angiogenesis [17, 18, 56]. In the current
study we have shown that the placentae of pTie2Bcl-
2IRESeGFP-transgenic mice contained reduced num-
bers of lumenised vessels and increased numbers of
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poorly perfused vessels with a closed lumen (Fig. 6).
Interestingly, a previous study detected EC apoptosis
in the lumen of developing human placental capillaries
[8]. A contribution of apoptosis to blood vessel lu-
menisation is not surprising, since apoptosis plays a role
in lumen formation in diverse tissues [57]. For example,
apoptosis is seen during the formation of lumen within
cultured kidney epithelial cell cysts, and inhibition of
this apoptosis by Bcl-2 expression inhibits formation of
the cyst lumen [58]. Apoptosis of centrally placed cells
is also seen during the development of mammary acini,
and acinar lumen formation can be delayed by Bcl-2
expression [59]. We hope that in the future, inducible
EC-specific Bcl-2 transgenic mice will allow us to
examine these mechanisms, and the role played by EC
apoptosis, in later developmental stages and in adult
diseases such as cancer and atherosclerosis.
Inhibition of EC apoptosis may secondarily disrupt
the development of non-vascular tissues
We observed that inter-digital cleft formation was re-
tarded in tie2-Bcl2-transgenic mice (Fig. 4a, b). This
appearance was analogous to that of mice in which
components of the apoptotic machinery such as
APAF-1 have been inactivated in the germline [60].
Delayed inter-digital cleft formation in tie2-Bcl2-
transgenic mice may reflect an overall slowing of
intrauterine growth (IUGR). Alternatively, it is inter-
esting to speculate whether EC apoptosis and vessel
regression may be an obligate component of inter-
digital tissue regression.
In the placentae of tie2-Bcl2-transgenic mice the
structure of the trophoblast-lined maternal spaces was
altered, even though the transgene was not expressed
in trophoblasts. We are unsure of the mechanism for
this abnormality. This may represent a purely
mechanical effect where patent and correctly orga-
nized foetal vessels are physically required to support
open maternal spaces. However, as with the inter-dig-
ital cleft formation, this phenotype may also reflect the
disrupted cross-talk between EC populations and their
neighbouring cells.
Effects of Bcl-2 expression unrelated to apoptosis
In addition to its anti-apoptotic role, Bcl-2 has been
shown in some cell types to inhibit the cell cycle [61],
promote the recruitment of peri-vascular cells [29] and
to inhibit TNFa-induced and NFjB-dependant EC
activation [62]. It is possible that subtle effects of the
pTie2Bcl-2IRESeGFP transgene on these processes
may contribute to the phenotype we observed. How-
ever, it seems unlikely that these processes are the
dominant cause of the phenotype. We demonstrated
that pTie2Bcl-2IRESeGFP expression in BAEC con-
ferred resistance to apoptosis but had no detectable
effect on EC proliferation in vitro, in agreement with
previous publications [20, 28]. Further, we could detect
no alteration in pericyte or vascular smooth muscle cell
behaviour in pTie2Bcl-2IRESeGFP-transgenic mice. It
is unlikely that the eGFP transgene significantly al-
tered vascular development since the survival of em-
bryos carrying the pTie2eGFP transgene was not
altered and since GFP appeared to be expressed at
very low levels, possibly due to our deliberate use of an
inefficient IRES to drive its translation.
Conclusion
We have investigated the function of EC apoptosis
during vascular development by expressing an anti-
apoptotic Bcl-2 transgene in mice under control of the
EC-specific tie2 promoter. This study provides direct
experimental evidence that EC apoptosis plays an
essential role during embryogenesis. Specifically, it
appears to play a key role in determining the structure
of the microcirculation in the placenta and in a subset
of embryonic tissues, but may be dispensable for large
vessel development.
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Maternal endometrial vascular endothelial growth factor (VEGF) is considered important in blastocyst implantation. However,
there is no direct evidence to support this conjecture in the primate. In the present study, we have examined this hypothesis by
testing whether immunoneutralization of VEGF during the peri-implantation stage of gestation affects embryo implantation in the
rhesus monkey. Adult female animals (nZ36) during mated ovulatory cycles were randomly assigned to one of the experimental
groups treated subcutaneously with either isotype-matched mouse immunoglobulin (group 1: control, nZ8) or monoclonal
mouse antibody against VEGF-A (anti-VEGF Mab; group 2: 10 mg on day 5 after ovulation, nZ8; group 3: 20 mg on day 5 after
ovulation, nZ8; group 4: 10 mg on day 10 after ovulation, nZ4; group 5: 10 mg on days 5 and 10 after ovulation, nZ8). Anti-
VEGF Mab-treated animals in groups 2–4 did not show any marked inhibition in pregnancy establishment. On pooled analysis,
however, anti-VEGF Mab administration in groups 2–5 (nZ28) resulted in a significant (P!0.04) decline in the number of viable
term pregnancy when compared with control animals. The observed difference was explained by the fact that 10 mg anti-VEGF
Mab given to each animal on days 5 and 10 after ovulation in group 5 (nZ8) inhibited pregnancy establishment significantly
(P!0.02) when compared with control group 1. There was no significant change in serum concentrations of estradiol-17b,
progesterone, and free VEGF among groups. Furthermore, animals treated with anti-VEGF Mab (nZ8) as in group 5 revealed
marked decrease in immunoreactive VEGF, fms-like tyrosine kinase-1, and kinase-insert domain region in trophoblast cells
associated with shallow uterine invasion on day 13 of gestation when compared with samples from control group animals (nZ8).
Thus, VEGF action is required for successful blastocyst implantation in the rhesus monkey.
Reproduction (2007) 133 1199–1211Introduction
Blastocyst implantation in the rhesus monkey is initiated
around days 7–9 after ovulation and fertilization. Local
signaling between the pre-implantation stage embryo
and the endometrium is likely to play a critical role
ensuring synchronous growth and differentiation of
embryonic and endometrial cells in a time- and stage-
specific manner (Lopata 1996, Ghosh & Sengupta 1998).
Of various factors, vascular endothelial growth factor-A
(VEGF-A), a potent regulator of the integrity, per-
meability, and proliferation of blood vessels (Ferrara &
Smith 1997), appears to be important in embryo–
endometrium interaction at blastocyst implantation inq 2007 Society for Reproduction and Fertility
ISSN 1470–1626 (paper) 1741–7899 (online)rodents (Rabbani & Rogers 2001, Rockwell et al. 2002).
In the human and the monkey, menstrual cycle-
dependent changes in endometrial VEGF-A have been
reported (Shifren et al. 1996, Nayak & Brenner 2002).
Expression of VEGF189 mRNA, an extracellular matrix-
bound isoform, was found to be dependent on
progesterone action in cynomolgus monkey (Greb
et al. 1997) and in human uterus (Ancelin et al. 2002).
The endometrial expression of both VEGF mRNA and
protein reportedly occurs during the mid-secretory stage
in the human (Charnock- Jones et al. 1993, Li et al.
1994). The fms-like tyrosine kinase-1 (FLT-1 and
VEGFR1) and the kinase-insert domain region (KDRDOI: 10.1530/rep.1.01228
Online version via www.reproduction-online.org
1200 J Sengupta and othersand VEGFR2) are high-affinity tyrosine kinase receptors
for VEGF. They are co-expressed in capillaries during the
mid-secretory period and this observation correlates well
with the increased microvascular density and vascular
permeability observed at this time (Krussel et al. 1999,
Meduri et al. 2000). However, VEGF is secreted
preferentially into lumina of endometrial glands in
polarized human endometrial cell cultures, suggesting
that apically secreted VEGF may also function as an
endometrial signal for blastocyst development and/or
implantation (Hornung et al. 1998). The expression of
VEGF mRNA and its protein has been detected in
trophoblast cells and in maternal glandular and vascular
compartments of lacuna and early villous stages of
implantation–placentation in the rhesus monkey (Ghosh
et al. 2000). Failure of pregnancy in the rhesus monkey
following early luteal phase, mifepristone treatment was
reportedly associated with endometrial dysynchroniza-
tion along with downregulation in expression and
secretion of VEGF (Ghosh et al. 1998).
Taken together, this evidence suggests two potential
roles for endometrial VEGF during implantation: a role in
endometrial blood vessels and the establishment of
receptivity and also a role in blastocyst implantation and
trophoblast invasion. However, to date, there has been
no direct evidence to show that VEGF is essential for
successful implantation in the primate. In the present
study, we have examined this hypothesis by testing
whether immunoneutralization of VEGF-A during the
receptive preparation of endometrium (day 5 after
ovulation) and/or the implantation window (day 10
after ovulation) of gestational cycle affects embryo
implantation in the rhesus monkey.Materials and Methods
Animals and experimental procedures
Proven-fertile, adult female rhesus monkeys (nZ40)
showing two consecutive menstrual cycles of normal
length (26–30 days) were placed for mating with male
monkeys of proven fertility during cycle days 8–16.
Peripheral blood samples were collected for hormone
assays and vaginal smears were checked daily for the
presence of spermatozoa. Ovulation was detected by
rapid assay from the daily serum profiles of estradiol (E2)
and progesterone (P), as described in the following
section. The assumed day of ovulation was taken 24 h
after the day of peak rise of serum E2 and had showed
clearly detectable serum P level. The details have been
given elsewhere (Ghosh & Sengupta 1993). Vaginal
smears were immediately scored on a scale of 4: poor,
good, very good, and excellent based on number,
viability, and forward movement of spermatozoa. Four
female monkeys were removed from this study when
they had either failed to ovulate and/or sperm profiles
were found to be consistently poor. Thus, femaleReproduction (2007) 133 1199–1211monkeys (nZ36) showing positive ovulation and very
good to excellent vaginal sperm profiles were randomly
assigned to one of the experimental groups (groups 1–5),
and received s.c. injection of either isotype-matched
mouse immunoglobulin (IgG) or monoclonal mouse
antibody against VEGF (anti-VEGF Mab). The doses and
timings of the different treatment regimes are shown in
Table 1. All injections were administered between 1000
and 1030 h on the assigned day. Sera were obtained from
daily blood samples collected by venipuncture from
experimental animals from cycle days 8 to 40, or the
onset of next menstrual cycle and stored at K70 8C till
their use in immunoassays to determine the peripheral
concentrations of E2, P, and monkey chorionic gonado-
tropin (mCG) as described below to monitor the
pregnancy outcome for animals in groups 1–5. The
pregnancy establishment was checked by per-rectum
uterine palpation as described previously (Ghosh et al.
1997) and the pregnant animals were routinely mon-
itored until they delivered. The normal length of
gestation in monkeys of our colony is 170G15
(meanGS.D.) days.
An additional 16 ovulated and successfully mated
females were classified into two groups, eight in each
group, and they were treated with either control mouse
isotype-matched IgG (like group 1 in Table 2), or anti-
VEGF Mab (like group 5 in Table 1). They were
laparotomized under ketamine anesthesia (12 mg/kg
body weight; Parke Davis, Mumbai, India) on day 13
post-ovulation for performing hysterectomy under
aseptic conditions to collect implantation sites and
maternal endometrium (Sengupta et al. 2003). Tissues
were fixed and processed for histology and immunohis-
tochemistry to localize the site of expressions of VEGF
and its receptors, KDR and FLT-1 in fetal and maternal
compartments. Endothelial cells were stained for von
Willebrand factor (vWF)-associated antigen and plate-
let–endothelial cell adhesion molecule (PECAM, CD31),
and cytokeratin, neural cell adhesion molecule (NCAM,
CD56), and PECAM were used for the immunolocaliza-
tion of trophoblast cells as described previously
(Sengupta & Ghosh 2002, Sengupta et al. 2003, Ghosh
et al. 2004).
The Primate Research Facility of the All India Institute
of Medical Sciences provided routine animal care and
management. The present study was conducted with the
approval of the Ethics Committee for the Use of Non-
Human Primates in Biomedical Research of the All India
Institute of Medical Sciences.Anti-VEGF Mab and isotype-matched IgG
A neutralizing Mab directed against VEGF-A was
produced by immunization of mice with recombinant
human VEGF-A165 conjugated to keyhole limpet
hemocyanin as described previously (Sharkey et al.
2005). Both anti-VEGF-A antibody and control IgGwww.reproduction-online.org
Table 1 Effects subcutaneous administration of isotype matched mouse immunoglobulin (control IgG) or mouse monoclonal antibody against
vascular endothelial growth factor (anti-VEGF Mab) during peri-implantation stage of mated ovulated cycles of rhesus monkeys on the
pregnancy outcome.
Number of animals showing
Group
(n) Treatment s.c. (mg)
Day of treatment
p.ov
Biochemical
pregnancya
Term
pregnancy
Aborted
pregnancy
Number of animals failed to be
pregnant (length of menstrual
cycle, days)
1 (8) Control IgG (10, 10) 5 and 10 6 6 0 2 (27,31)
2 (8) Anti-VEGF Mab (10) 5 3 3 0 5 (26,28,28,31,32)
3 (8) Anti-VEGF Mab (20) 5 5 3 2b 3 (27,31,31)
4 (4) Anti-VEGF Mab (10) 10 4 3 1c 0
5 (8) Anti-VEGF Mab (10,10) 5 and 10 1 0** 1d 7* (27,29,29,29,30,32)
p.ov., after ovulation. **P!0.01, *P!0.02 as compared to group 1.
aBased on detectable mCG. bDays 18 and 133 of gestation, respectively. cDay 139 of gestation. dDay 135 of gestation.
VEGF antibody for post-coital contraception 1201(isotype-matched, IgG1k) were purified by binding to
protein G sepharose, desalting (Centricon ultrafiltration)
and lyophilized in 10 mg lots. The neutralizing activity
of the antibody was demonstrated using a bioassay in
which iodinated VEGF binds to its receptors on
endothelial cells as described previously (Sharkey
et al. 2005).Table 2 Characteristics of primary antibodies used for immunohisto-
chemistry.
Antigen
Specification of
antisera Dilution (mg/ml) Source
VEGF Goat IgG 1.0 R&D Systems
FLT-1 Goat IgG 2.5 R&D Systems
KDR Goat IgG 1.5 R&D Systems
Cytokeratin Mouse IgG 1.8 DAKO
Vimentin Mouse IgG 4.5 DAKO
vWF Rabbit IgG 25.0 DAKO
NCAM (CD56) Mouse IgG 1.0 NeoMarkers
PECAM (CD31) Mouse IgG 2.5 NeoMarkers
R&D Systems, Minneapolis, MN, USA. DAKO, Glostrup, Denmark.
NeoMarkers, Fremont, CA, USA.Estimation of serum concentrations of E2, P, mCG,
VEGF, and mouse IgG
Serum concentrations of E2 and P were measured by
competitive ELISA using reagents and protocols provided
by DRG International Inc. (NJ, USA). The results were
analyzed using log–logit transformation of the data and
the hormone values were log transformed for further
analysis. The assay sensitivity was 4.6 pg/ml and
0.5 ng/ml for E2 and P respectively; intra- and inter-
assay coefficients of variations for E2 assays were 6.3 and
7.8% respectively, and those for P assays were 4.8 and
6.5% respectively.
Serum concentration of mCG was measured by the
sandwich enzyme-linked immunoabsorbent technique
reported earlier (Ghosh et al. 1997). The Mab (Mab 518
B7) was generated against bovine luteinizing hormone
(LH) and it was horse radish peroxidase (HRP)
conjugated, and the polyclonal antiserum was raised in
rabbits against human chorionic gonadotropin (hCG
cr-121). Positive and negative controls were added to
each plate and all the samples were assayed in one run.
The assay sensitivity for mCG was 0.03 ng/ml.
Serum concentrations of free VEGF antigen in animals
of the different groups were measured to discern if anti-
VEGF Mab administration affected systemic VEGF levels.
Serum levels of free VEGF were estimated using ELISA kit
from R&D Systems (Minneapolis, MN, USA) according
to manufacturer’s instruction. A seven-point standard
curve was plotted using twofold serial dilution to
calculate the concentration of free VEGF in the sample.
The assay sensitivity for VEGF was found to be 65 pg/ml;
intra- and inter-assay coefficients of variations for VEGF
antigen were 3.6 and 5.1% respectively.www.reproduction-online.orgSerum concentrations of immunoreactive mouse IgGs,
the anti-VEGF mouse Mab (anti-VEGF Mab), and
isotype-matched control mouse IgG, were estimated
using a mouse IgG ELISA kit from Roche diagnostics
GmbH (Manheim, Germany) according to manufac-
turer’s instructions. Standards, antibodies, solutions, and
reagents for this assay were supplied by the manufac-
turer. Serum samples collected from each animal before
treatment with isotype-matched IgG or anti-VEGF Mab
were used as internal negative baseline controls. The
assay sensitivity for anti-mouse IgG was 10 ng IgG/ml;
intra- and inter-assay coefficients of variations for mouse
IgG were 2.7 and 5.9% respectively.Serumprofiles andclearancekineticsof serummouse IgG
Data for mouse IgG concentration in serum versus time
for rhesus monkeys injected subcutaneously with either
control IgG or anti-VEGF Mab were analyzed using
standard formulations for one compartment model
(Shargel & Yu 1999). The clearance rate constant (k),
time to reach maximal level of concentration (Tmax), and
the concentration of antibody at this level (Cmax), area
under curve (AUC) of antibody, and mean resident time
(MRT) were subsequently estimated using standard
methods (Shargel & Yu 1999).Reproduction (2007) 133 1199–1211
1202 J Sengupta and othersEndometrial tissue/implantation stage morphology and
immunohistochemistry
Sixteen females were successfully mated during days
8–16 of their ovulatory cycles and eight were treated
with control mouse isotype-matched IgG (like group
1 in Table 1), and the other eight females were
treated with anti-VEGF Mab (like group 5 in Table 1).
On day 13 post-ovulation, endometrial tissue from
the uterine corpus was removed by hysterectomy,
washed in fresh ice-cold PBS (pH 7.2) to remove
adhering blood, and immediately fixed in neutral
phosphate-buffered paraformaldehyde (4%, w/v). The
samples were embedded in paraffin wax and
examined for normal histology as described
previously (Sengupta et al. 2003, Ghosh et al.
2004). Paraffin sections (5 mm) were employed for
hematoxylin staining and for immunohistochemical
localization of VEGF, FLT-1, and KDR. Trophoblast
cells and plaque–epithelial cells were identified by
immunostaining with antibody against cytokeratin,
invasive extravillous (interstitial) trophoblast cells
were identified from immunolocalization of NCAM
(CD56) and PECAM (CD31), and endothelial cells by
immunostaining with antibody against PECAM and
vWF as described elsewhere (Sengupta & Ghosh
2002, Sengupta et al. 2003, Ghosh et al. 2004). The
sources of antibodies and dilutions of stock
antibodies were optimized based on four to five
points titration as shown in Table 2. Final
visualization was achieved using the ABC peroxidase
kits (Vector Laboratories, Burlingame, CA, USA) and
freshly prepared diaminobenzidine hydrochloride
with hydrogen peroxide (Sigma Chemical). Specificity
of the antibodies was assessed by omitting primary
antibodies, immunosorption of primary antibodies
with target peptides, replacing primary antibodies
with unrelated IgG from same species and other
species, omitting secondary antibodies, and replacing
secondary antibody with unrelated labeled IgGs from
same species and other species. Labeled and
unlabeled IgGs, non-immune sera, and other supplies
were purchased from Vector Laboratories and Sigma
Chemical.
The sections (5 mm) of primary implantation sites
and endometrial tissue samples after hematoxylin
staining and immunostaining were independently
examined by three investigators and microphotographs
were taken using a Leica DMRBE microscope
attached with a Leitz DMRD microphotograph
processor and a digital camera.Statistical analysis
The pregnancy outcome in different groups was analyzed
using the Fisher’s exact probability test (Zar 1999). The
AUCs for serum E2, P, VEGF, and mouse IgG, and k,Cmax,Reproduction (2007) 133 1199–1211and Tmax for mouse IgG in monkey serum samples, and
body weights and crown–rump lengths of neonates in
different groups were subjected to ANOVA followed by
multiple comparison tests (Zar 1999). Statistical corre-
lation between the circulatory concentrations of VEGF
antigen and the Mab in animals of groups 2–5 was
examined using standard SPSS v. 10.0.1 statistical
analysis software.Results
Pregnancy outcome
Table 1 provides a summary of the data obtained in the
pregnancy outcome of monkeys in groups 1–5 following
s.c. injection of isotype-matched mouse IgG and anti-
VEGF Mab. Although there was an apparent decline in
the number of mCG-positive pregnancy cycles in groups
treated with anti-VEGF Mab in groups 2–4 (12
pregnancies from 20 animals) compared with control
animals (six pregnancies from eight animals), this
difference was statistically not significant (P!0.4).
Similarly, there was statistically no significant (P!0.2)
change in the number of successful term pregnancy in
animals of groups 2–4 (9 out of 20 animals) compared
with the control group. However, administration of anti-
VEGF Mab to animals on days 5 and 10 after ovulation at
10 mg doses on each day as in group 5 resulted in
significant inhibition of establishment of pregnancy as
marked by mCG positivity (P!0.02) and term pregnan-
cies (P!0.01) when compared with that found in the
control group of animals injected with isotype-matched
IgG at same dosage and schedule. Collectively, anti-
VEGF Mab administration in groups 2–5 resulted in a
significant (P!0.04) decline in the number of term
pregnancies (9 out of 28 animals), however, with no
significant (P!0.2) change in total number of mCG-
positive pregnancy cycle when compared with control-
treated animals (group 1).
As shown in Table 1, 4 out of 13 pregnant animals
from anti-VEGF Mab-treated groups had pregnancy loss
at different time points of pregnancy. However, the 30%
abortion rate in anti-VEGF Mab-treated animals was
statistically not significant (P!0.4) when compared with
the cumulative abortion profile (22%) in our monkey
colony. Three cases of abortion were observed between
days 133 and 139 of gestation (Table 1) and these
females exhibited failure to establish implantation stage
rise in serum P levels as shown in Fig. 1J. As expected,
the body weights (236.7G28.9 g) and crown–rump
(C–R) lengths (16.3G1.5 cm) of aborted fetuses were
significantly (P!0.001) lower than the body weights
(435.6G63.2 g) and C–R lengths (21.5G1.7 cm) of
neonates from all the groups, however, no gross physical
abnormality was observed in the aborted fetuses.
The gestation lengths for live births in all the groups
ranged between 157 and 182 days, and there was nowww.reproduction-online.org
Figure 1 Serum profiles of estradiol-17b, E2 (blank square)
and progesterone, P (solid circle) in non-pregnant (A, C, E,
G, and I) and pregnant (B, D, F, H, and J) animals from
groups 1 (A and B), 2 (C and D), 3 (E and F), 4 (G and H),
and 5 (I and J). The first day of mCG detection in the
circulation (hatched bar) is shown. The details of different
treatment groups are given in Table 1.
VEGF antibody for post-coital contraception 1203marked change in the gestation length between control-
and anti-VEGF Mab-treated groups. Although neonates
from anti-VEGF antibody-treated mothers showed a
tendency of lower body weights (380–450 g) when
compared with neonates from control-treated mothers
(500–520 g), the difference was not significant.
Anti-VEGF Mab or control IgG exposure during the
pre- and peri-implantation stages did not affect the
length of the luteal phase (26–32 days) in monkeys
that remained non-pregnant in the treatment cycles
(Table 1).www.reproduction-online.orgSerum E2, P, mCG, and VEGF
Figure 1 shows the representative serum profiles of E2
and P, and the day of first mCG detection in the animals
following antibody injection under the different treat-
ment schedules detailed in Table 1. Despite differences
in serum profiles for these hormones in individual
animals, analyses of AUCs for E2 and P during the luteal
phase showed no difference among groups (P!0.3).
Interestingly, three cases of abortion between days 135
and 139 showed failure in serum progesterone riseReproduction (2007) 133 1199–1211
1204 J Sengupta and othersduring implantation (Table 1 and Fig. 1J). Evidently, the
sample size (nZ3) is too small to make any comment.
Serum mCG was detected in all pregnant monkeys
between days 12 and 18 after ovulation. An analysis of
the data of AUCs for free VEGF antigen in serum samples
of animals of groups 1–5 (nZ36) revealed no significant
change in AUCs for VEGF antigen between the pregnant
animals from the control treatment (2177.2G229.7 pg/
ml per day) group (group 1) and the non-pregnant
animals from anti-VEGF Mab treatment (2039.6G
247.3 pg/ml per day) groups (groups 2–5). The concen-
trations of free VEGF were marginally higher (P!0.05) in
serum samples of pregnant animals exposed to anti-
VEGF Mab (3783.2G278.6 pg/ml per day) compared
with the antigen concentration (2177.2G229.7 pg/ml
per day) in pregnant animals exposed to isotype-
matched IgG (group 1).Serum profiles and clearance kinetics of mouse IgG
Table 3 shows serum profiles and clearance kinetics of
mouse IgG respectively, in monkeys belonging to groups
2–5. As expected, there was a clear increase in serum
mouse IgG after each injection. A single s.c. injection of
anti-VEGF Mab irrespective of its dose resulted in
maximum level of antibody being reached between 1.3
and 2.3 days in animals of groups 2–4. In animals of
group 5 injected s.c. twice (10C10 mg) with anti-VEGF
Mab on days 5 and 10 after ovulation, maximal levels in
sera occurred a week after the first injection. The Cmax
varied from 2.3 to 4.6 mg/ml in monkeys exposed to
10 mg anti-VEGF Mab. The mean resident time (MRT)
was 3.2–5.5 days. No significant difference was obtained
between the clearance rates (k) among the different
treatment groups. Analyses of AUCs for Mab concen-
tration in sera of animals receiving 20 mg anti-VEGF
Mab in group 3 showed significantly higher values when
compared with the Mab concentration in animals in
groups 2 and 4 (P!0.01) that had received 10 mg Mab,
and with animals of group 5 (P!0.02) administered with
10C10 mg Mab against VEGF. Statistically no corre-
lation was found between the circulatory concentrations
of VEGF antigen and the Mab in animals of groups 2–5.Table 3 Serum profiles and clearance kinetics of monoclonal antibody follo
Parameter
10 mg Mab on day
5 p.ov. (Group 2)
Clearance rate constant, k 0.2G0.1
Time to reach maximal concentration, Tmax (days) 1.3G0.7
Concentration at maximal level, Cmax (mg/ml) 4.3G1.8
Area under curve, AUC (mg/ml per day) 28.6G10.3†
p.ov., after ovulation. Results are shown as meansGS.D. *P!0.01, †P!0.0
Reproduction (2007) 133 1199–1211Histological characteristics of primary implantation
sites and endometrial samples following exposure to
mouse antibody
In order to examine the implantation sites and endo-
metrial histology of animals treated with either isotype-
matched mouse IgG or anti-VEGF Mab, additional
number of animals were treated identically to groups 1
and 5 as shown in Table 1 and primary implantation sites
and/or endometrial samples were collected on day 13
after ovulation. Of samples collected from eight mated
animals exposed to control mouse IgG on days 5 and 10
after ovulation (like group 1, Table 1), seven samples
showed typical primary implantation sites (Fig. 2A), and
one sample revealed late secretory stage histology.
Typical lacuna stage implantation sites exhibited
embryonic disk with secondary yolk sac development
typical of a stage in which cytokeratin-positive tropho-
blast cells blocked arterioles, extensive plaque acini (pl)
flanked area enclosing embryonic disk, glands showed
hypertrophied features, and dilated blood vessels were
abundant at sites of implantation (Fig. 3A and E).
In endometrial samples collected on day 13 after
ovulation from eight mated animals exposed to anti-
VEGF Mab (10 mg each day) on days 5 and 10 after
ovulation (like group 5 in Table 1), only one sample
exhibited clear-cut blastocyst implantation (Fig. 2B),
while one sample revealed typical late secretory stage
histology (Fig. 2D). The primary implantation site of the
implantation stage sample from the anti-VEGF Mab
treatment group showed highly superficial embryo
implantation, with small chorionic diameter (Fig. 2B).
Based on serial sectioning of the primary implantation
site, a small area of embryonic cells were located within
the embryonic cavity without any distinctive organiz-
ation in the formation of embryonic disk; lacunae
showed extensive vascular congestion with disruption
of lacunar septae (Fig. 2B); extensive cytokeratin-positive
pl (Fig. 3B) and dilated blood vessels (Fig. 3F) were,
however, seen at the site of implantation. Other six
endometrial samples retrieved after VEGF Mab treatment
showed epithelial plaque response (Fig. 2C) and
scattered cytokeratin-positive trophoblast cells adjoining
blood vessels (Fig. 3C and G).wing s.c. administration.
Treatment (Group number)
20 mg Mab on day
5 p.ov. (Group 3)
10 mg Mab on day
10 p.ov. (Group 4)
10 mg Mab on days
5 and 10 p.ov (Group 5)
0.3G0.2 0.3G0.2 0.4G0.3
1.3G0.4 2.3G0.6 7.0G1.1
11.9G7.2 2.3G0.9 4.6G1.4
58.4G10.3 21.6G5.1† 34.7G10.9*
2 compared with Group 3.
www.reproduction-online.org
Figure 2 Histology of primary implantation sites
collected on day 13 post-ovulation from rhesus
monkeys treated with control IgG (A) or anti-VEGF
Mab (B–D) on days 5 and 10 post-ovulation. In control
IgG-treated sample (A), well-developed plaque acini
(pl) flank the primary lacuna stage implantation site,
cytotrophoblast cells enclose lacunae (l), extensive
trophoblast plate region (bracket) below the embryonic
disk (arrow). In anti-VEGF Mab-exposed sample (B), a
superficially located primary implantation site shows
plaque acini (pl) flanking dilated blood vessels (BV),
highly scattered cytotrophoblast cells within a shallow
trophoblast plate (bracket); chorion membrane
enclosing cytotrophoblast cells with disrupted lacunar
septae and extensive vascular congestion (asterisk) are
seen; embryonic cells show clear lack of organization
in forming putative embryonic disk (arrow). In anti-
VEGF Mab-exposed samples (C and D), small glands
(gl), typical plaque acini (pl), and scattered cytotro-
phoblast adjoining superficial dilated venules (BV) are
found (C); late secretory stage histological features
evident with effete glands (gl) within moderately
edematous mucosal ground substance (D).
BarsZ100 mm.
VEGF antibody for post-coital contraception 1205Immunolocalization of VEGF, FLT-1, KDR, PECAM,
and NCAM
We examined the distribution of immunoreactive VEGF,
FLT-1, and KDR in endometrial samples collected from
animals that were treated with control IgG (nZ7) and
anti-VEGF Mab (nZ7); as described above, these
samples did not exhibit typical late secretory changes.
VEGF immunoreactivity in cytotrophoblast cells lining
lacunae and in cytotrophoblast cell columns was
markedly lower in implantation stage tissue from anti-
VEGF Mab-exposed animal (Fig. 4E and F) when
compared with animals exposed to IgG (Fig. 4A and
B). In control IgG-exposed animals, cells of embryonic
disk, cytotrophoblast cells, cell columns, and syncytio-
trophoblast cells were immunopositive for KDR
(Fig. 4C), while FLT-1 expression was found primarily
in syncytiotrophoblast cells (Fig. 4D). Following anti-
VEGF Mab exposure, trophoblast cells showed very low
immunostaining for KDR (Fig. 4G) and FLT-1 (Fig. 4H),
however, these cells were immunopositive for both
cytokeratin (Fig. 3B and C) and PECAM (Fig. 5E, F1, F2
and I). In the maternal compartment of anti-VEGF Mab-www.reproduction-online.orgexposed animals, VEGF expression (Fig. 4E, F and I),
expression for KDR (Fig. 4G and J), and FLT-1 (Fig. 4H
and K) in pl, gland, and stromal cells were comparable
with that found in primary implantation sites in IgG-
exposed animals (Fig. 4A–D). Immunoreactivity for
NCAM was predominantly present in syncytiotropho-
blast cells, invasive extravillous (interstitial) trophoblast
cells, endothelial, and endovascular trophoblast cells
(Fig. 5C and D), and these cells were also immuno-
positive for PECAM (Fig. 5A and B). In lacuna stage
samples obtained after control IgG treatment, cytotro-
phoblast cells, endometrial glands, and stromal cells
were negative for NCAM, however, large endometrial
granulocytes surrounding glands and spiral arterioles
were immunopositive for NCAM (Fig. 5K). There was no
distinctive staining for NCAM in trophoblast cells of the
primary implantation site recovered from anti-VEGF
Mab-exposed animal (Fig. 5G-H2), except for a few
trophoblast cells lining chorion (Fig. 5H1). Large
endometrial granulocytes adjoining pl of the same
section and in samples in which only pl were obtained
showed distinctive immunoreactivity for NCAM (Fig. 5J).Reproduction (2007) 133 1199–1211
Figure 3 Immunohistochemical localization of cytokeratin (A–C), von Willebrand factor (vWF), (E–G) in primary implantation sites obtained on day
13 post-ovulation from animals treated with control IgG (A and E) or anti-VEGF Mab (B and F), and in endometrial samples collected on day 13 post-
ovulation from anti-VEGF Mab-treated animals (C and G). Cytokeratin immunostaining detected in syncytiotrophoblast cells (arrows) lining lacunae
(l), cytotrophoblast cells of cell columns (*), invasive cytotrophoblast cells (brackets) adjoining immunostained plaque acinar cells (pl) (A).
Cytotrophoblast cells within chorion membrane (*), chorionic plate, and plaque cells showed immunopositive staining for cytokeratin (B). Strong
immunostaining for vWF found in endothelial cells lining dilated venules (bv) (E and F). Cytokeratin-positive plaque cells (pl), (C) and vWF
immunostaining of blood vessels (bv), (G) found in endometrial samples collected on day 13 post-ovulation from anti-VEGF Mab-treated animals.
Control immunohistochemistry of primary implantation site samples showing trophoblast cell columns (*), syncytiotrophoblast (arrow) lining
lacunae (l) following incubation in medium lacking primary antibody for cytokeratin (D), and following incubation in medium lacking primary
antibody for vWF (H) showing plaque acinar cells (pl) adjoining dilated blood vessels. BarsZ15 mm.
1206 J Sengupta and othersPECAM expression in the maternal endometrium was not
discernibly affected by anti-VEGF Mab treatment
(Fig. 5E, F2 and I).Discussion
In the present study, we have examined the hypothesis
whether immunoneutralization of VEGF-A during the
receptive preparation of endometrium (day 5 after
ovulation) and/or the implantation window (day 10
after ovulation) of gestational cycle affects embryo
implantation in the rhesus monkey. In addition, we
have avoided applying multiple injections around the
time of implantation based on the rationale that such
treatment might markedly suppress ovarian function.
Systemic injection of anti-VEGF mouse Mab during the
receptive and implantation stages of gestation inhibited
blastocyst implantation in the rhesus monkey. In
addition, in animals treated with anti-VEGF Mab, the
expression of both VEGF and its receptors, KDR and FLT-
1, exhibited changes in expression in early conceptus
tissue suggesting a complex involvement of VEGF in
both blastocyst implantation and placental development
(Ghosh et al. 2000, Demir et al. 2004). Thus, the results
from the present study indicate that VEGF plays a critical
physiological role in the process of implantation andReproduction (2007) 133 1199–1211placentation in primates. The observation of the present
study corroborates well with our earlier pilot study
(Ghosh & Sengupta 2005).
Contrary to our observations, Rowe et al. (2002)
observed that anti-VEGF Mab administration via i.v.
route on days 0–10 of luteal phase to marmosets did not
affect the pregnancy rate, although plasma progesterone
secretion was markedly suppressed compared with
animals exposed to mouse g-globulin during the same
period. We believe that the observed differences in the
results of pregnancy outcome after anti-VEGF Mab
administration between marmosets and rhesus monkeys
arise from the difference in the process of blastocyst
implantation in these species. In the marmoset, there is a
prolonged period of time when the implantation site
expands in the plane of uterine epithelium (trophoblast
plate stage) with fusion of syncytiotrophoblast with
uterine epithelial cells, but even at day 31 after ovulation
syncytiotrophoblast cells do not breach maternal blood
vessels; uterine blood vessels are invaded only around
days 45–60 of gestation by trophoblast cells expressing
FLT-1 (Enders & Lopata 1999, Wulff et al. 2002, Rowe
et al. 2003). In contrast, in the macaque and the baboon,
soon after embryo attachment, there is invasion of
maternal blood vessels around days 12 of gestation by
trophoblast cells similar to the human (Enders & Schlafkewww.reproduction-online.org
Figure 4 Immunohistochemical localization of VEGF (A, B, E, F, and I), KDR (C, G, and J), and FLT-1 (D, H, and K) in primary implantation sites
obtained on day 13 post-ovulation from animals following treatment with control IgG (A–D) or anti-VEGF Mab (E–H) and in day 13 post-ovulation
endometrial samples of anti-VEGF Mab treatment (I–K). Strong immunoprecipitation of VEGF protein found in trophoblast cells within the chorionic
plate, in cell columns (*), in cells lining embryonic cavity (arrows), and lacunae (l) (A); inset in A is shown in B. On the other hand, there is absence of
VEGF immunostaining in cytotrophoblast cells of cell columns (*), in syncytiotrophoblast lining lacunae (arrow-heads), in invasive trophoblast cells
(brackets) (E and F). VEGF immunostaining is, however, detected in plaque acini (pl), endothelial cells lining dilated blood vessels (bv) (E); inset is
shown in F. Immunopositivity for KDR (C) is seen in cytotrophoblast cells of cell columns (*) and in extravillous cytotrophoblast cells at base of
column (arrows), while FLT-1 protein immunoprecipitation (D) is found in syncytiotrophoblast cells (*) lining lacunae in implantation sites from IgG-
exposed animals. Generally low expression of KDR (G) and FLT-1 (H) in trophoblast cells (arrows) and in plaque acinar cells (pl) within trophoblast
plate region of the primary implantation site from anti-VEGF Mab-treated animal. In endometrial samples from anti-VEGF Mab-treated animals,
VEGF (I), KDR (J), and FLT-1 (K) immunostaining found in plaque acinar cells (pl) adjoining blood vessel (bv), stromal cells, and in few trophoblast
cells (arrows) found in luminal border. Control immunochemistry of primary implantation site samples, trophoblast cell column (*) adjoining blood
vessel (bv) incubated with immunoadsorbed primary antibody against VEGF-A protein with recombinant human antigen, VEGF165 (L); trophoblast
cells (arrows) of sample incubated in medium lacking primary antibody for KDR (M); syncytiotrophoblast (arrow) showing no immunoprecipitation
for FLT-1 following incubation of sample in medium lacking primary antibody for FLT-1 (N). BarsZ15 mm (B–D and F–N), 50 mm (A), and 100 mm (E).
VEGF antibody for post-coital contraception 12071986). Thus, it is possible that the timing of VEGF
immunoneutralization in the marmoset in the luteal
phase of mated cycle was inadequate to block VEGF-
induced paracrine actions on trophoblast cell invasive
functions necessary for pregnancy establishment. In fact,
the results of the present study also indicate that thewww.reproduction-online.orgtiming of anti-VEGF Mab administration is important in
efficacious inhibition of pregnancy in rhesus monkeys.
For example, in pregnancy outcome experiment, admin-
istration of 10 mg anti-VEGF Mab on days 5 and 10 after
ovulation in eight animals yielded no viable pregnancy,
although one animal exhibited mCG on day 18 afterReproduction (2007) 133 1199–1211
Figure 5 Immunohistochemical localization of PECAM (A, B, E, F1, F2, and I) and NCAM (C, D, G, H1, H2, J, and K) in primary implantation sites
obtained on day 13 post-ovulation from animals following treatment with control IgG (A–D and K) or anti-VEGF MAb (E–H2) and in day 13 post-
ovulation endometrial samples after anti-VEGF Mab treatment (I and J). Strong immunoprecipitation of PECAM protein is seen in trophoblast cells of
cell columns (cc), in invasive trophoblast cells (*) within the chorionic plate, and in endothelial cells (arrows) lining dilated blood vessel (bv); inset in
A is shown in B. In implantation site from anti-VEGF Mab-treated animal, shallow trophoblast plate (bracket) shows immunopositive staining for
PECAM in endothelial cells lining dilated blood vessels (bv) and in trophoblast cells (arrows) (E); insets in E are shown in F1 and F2. NCAM protein
immunoprecipitation found in invasive trophoblast cells (arrows) at the feto-maternal border, in endovascular trophoblast cells lining dilated blood
vessel (bv) of implantation site sample from an IgG-treated animal (C); inset in C is shown in D; NCAM immunostaining also found in large
granulated lymphocytes (arrows) adjoining glands (gl), (K). In anti-VEGF Mab-exposed animal, NCAM immunostaining is not evident in trophoblast
cells (G) except for few trophoblast cells lining chorion (H1) or in maternal cells (H2) of implantation stage sample. In endometrial samples from anti-
VEGF Mab-treated animals, PECAM immunostaining clearly detected in trophoblast cells adjoining luminal border (*), in endothelial cells of dilated
blood vessels (bv) (I); NCAM immunostaining seen in large endometrial granulated lymphocyte adjoining blood vessel (bv) (J). Control
immunochemistry of primary implantation site samples of IgG-exposed animal showing absence of immunoprecipitation in endothelial cells of
blood vessel (bv), in endovascular cytotrophoblast cells (*), in gland (gl) following incubation in medium lacking primary antibody for PECAM (L) and
NCAM (M). BarsZ15 mm (B, D, F1, F2, H1–J, and L), 50 mm (E and K), 100 mm (A, C, and G), and 250 mm (M).
1208 J Sengupta and othersovulation; similar results were obtained in another set of
eight animals that were treated with same regimen of
anti-VEGF Mab followed by collection of uteri on day 13
after ovulation for histology and immunohistochemistry.
Previously, studies with rodent models have shown
that VEGF action is critical for blastocyst implantation,
since timed administration of antibody against VEGFReproduction (2007) 133 1199–1211resulted in reduced numbers of implantation sites and
inhibition of uterine vascular permeability (Rabbani &
Rogers 2001, Rockwell et al. 2002). However, there was
a possibility that inhibition of VEGF action might have
affected ovarian steroid synthesis in these studies
(Kashida et al. 2001, Rockwell et al. 2002). In a pre-
clinical safety study using cynomolgus monkeys, it haswww.reproduction-online.org
VEGF antibody for post-coital contraception 1209been observed that administration of recombinant
humanized Mab against VEGF for 4 or 13 weeks at
twice weekly doses of 10 and 50 mg/kg resulted in
defective corpora lutea formation (Ryan et al. 1999). In
the present study, however, the systemic administration
of anti-VEGF Mab in the rhesus monkey did not result in
any apparent inadequacy in ovarian function. This is in
contrast to the observed pregnancy inhibition following
administration of antibody to VEGF-receptor 2 in mice
that was associated with compromised ovarian function
as marked by a significant fall in circulatory progesterone
concentration and administration of progesterone pro-
tected the antibody-treated animals from pregnancy loss
(Pauli et al. 2005). In the present study, there was no
apparent difference in serum E2 or P levels between
pregnant animals following anti-VEGF Mab and those
following control IgG injection. This is critical, since it
indicates that the effects on pregnancy rates in this study
might have resulted from local inhibition of VEGF action
in the endometrium and/or developing conceptus. Other
groups have observed in the rhesus monkey that systemic
injection of anti-VEGF antibody on day 3 after ovulation
did not result in significant change in serum pro-
gesterone levels (Xu et al. 2005) and such an antibody
(AA98) preferentially binds to the newly formed blood
vessels at the feto-maternal interface of the implantation
site (Liu et al. 2005). It is possible that the sensitivity of
blood vessels to VEGF withdrawal depends on their
degree of vascular maturation (Otani et al. 1999). We
speculate that if anti-VEGF Mab is given at the time of
and immediately after ovulation, while vascularization
of the corpus luteum is occurring as in the case of the
cynomolgus experiment (Ryan et al. 1999), the vessels
would be susceptible to disruption and ovarian steroid
production would be affected (Zimmerman et al. 2001).
On the other hand, if VEGF action is neutralized after the
corpus luteum has vascularized as in the present study,
no significant effect on ovarian steroid production may
be seen due to the existence of a sufficient local cytokine
network (Otani et al. 1999), while newly forming blood
vessels at feto-maternal interface become more vulner-
able (Liu et al. 2005). This possibility is also further
substantiated by our observation that the serum concen-
trations of free VEGF were generally higher in pregnant
animals exposed to anti-VEGF Mab compared with that
in non-pregnant and control pregnant animals. Although
the physiological basis and significance of higher serum
VEGF in the antibody-treated pregnant monkeys is not
known, it may be speculated that the animals that could
mount rebound increase in antigen after antibody
treatment are less vulnerable to pregnancy loss after
antibody administration.
VEGF mRNA and protein expression are elevated in
mid-secretory stage of endometrium with increased
protein secretion in the primate (Charnock-Jones et al.
1993, Li et al. 1994). Pregnancy failure due to
endometrial insufficiency, a block in pre-implantationwww.reproduction-online.orgembryo development and viability in the rhesus monkey
after early luteal phase mifepristone exposure is
associated with low VEGF expression and secretion
(Ghosh et al. 1998). Furthermore, a dialogue between
embryo and endometrium is considered essential for
blastocyst implantation and may involve the synthesis
and secretion of hCG and VEGF from embryonic and
maternal sources respectively (Licht et al. 2001). Several
reported studies earlier indicated a possible role of VEGF
in the regulation of invasive and migratory capacities of
early placental trophoblasts (Lash et al. 2003, Anteby
et al. 2004). Thus, it appears that the observed high
incidence of pregnancy failure following anti-VEGF Mab
treatment might have been precipitated by inadequate
trophoblast invasion and placental formation associated
with their lower expression of VEGF, KDR, and FLT-1.
However, it is not evident why conceptus tissues were
primarily affected, while maternal endometrium did not
show any clear-cut change in histology and in immuno-
positive profiles for proteins VEGF, KDR, and FLT-1
following anti-VEGF Mab treatment. It becomes yet
more complex with the recognition of the fact that
administered antibody to a pregnant animal tends to
remain in the maternal compartment and generally does
not reach to the embryonic tissue (Pauli et al. 2005). It
would be interesting to investigate a comparative
differential display in the protein–protein interactions
using proteomics approach in the maternal endome-
trium between control and anti-VEGF Mab treatment,
rather than the functional cluster of VEGF action
associated proteins only (Graham et al. 2005).
Our data also support a role for NCAM or CD56 in
trophoblast invasion (Blankenship & King 1996, Slukvin
et al. 2000). NCAM is a multifunctional protein and
considered as a receptor that responds to both
homophilic and heterophilic cues as a mediator of cell
adhesion and neural cell migration via two distinct
domains for NCAM and heparan sulfate (Hinsby et al.
2004). Trophoblast cell invasion of spiral arterioles is
likely to involve migratory and invasive behavior of
NCAM-mediated cell-type segregation, involving
changes in cadherin-mediated adhesion and cell polarity
(Burrows et al. 1994, Blankenship & King 1996, Proll
et al. 1999). In the present study, we observed a clear
decline in expression of cell adhesion molecule NCAM
and it was associated with shallow uterine invasion and
failure to invade spiral arterioles in anti-VEGF Mab-
exposed animals. In the present study, we also observed
that extravillous trophoblast cells and vascular endo-
thelium expressed immunopositive PECAM-1, and that
its expression was not markedly modified in anti-VEGF
Mab-treated samples. Although there is evidence in the
literature to suggest that PECAM-1 expression in
conceptus may play important role in embryo develop-
ment, as well as in trophoblast cell invasion of the spiral
arteries (Blankenship & Enders 1997, Robson et al.Reproduction (2007) 133 1199–1211
1210 J Sengupta and others2001), its actual physiological role has been debated
(Lyall et al. 2001).
An important physiological consideration in the present
study had been the timing of anti-VEGF Mab treatment for
effective pregnancy inhibition. The best opportunity for
therapeutic intervention was considered to be the point
when pro-inflammatory responses are induced for support-
ing an evolutive pregnancy with heightened vascular
permeability along with an influx at the site of blastocyst
implantation of pro-inflammatory blood cells, vasotropic
growth factors, such as VEGF and placenta growth factor
(PlGF), and pro-inflammatory cytokines, such as leukemia
inhibitory factor (LIF), IL-1a, IL-1b, and IL-6 (Ghosh et al.
2000, 2004, Sengupta et al. 2003).
Finally, we conclude that inadequate invasion by
trophoblast cells following timed systemic mid-luteal
phase administration of sufficient amount of murine
VEGF Mab results in pregnancy failure. This provides the
proof of concept that VEGF action is required for
successful blastocyst implantation in the rhesus monkey.Acknowledgements
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Abstract
Background: The T-box transcription factor Brachyury (T) is essential for formation of the posterior mesoderm and the
notochord in vertebrate embryos. Work in the frog and the zebrafish has identified some direct genomic targets of
Brachyury, but little is known about Brachyury targets in the mouse.
Methodology/Principal Findings: Here we use chromatin immunoprecipitation and mouse promoter microarrays to
identify targets of Brachyury in embryoid bodies formed from differentiating mouse ES cells. The targets we identify are
enriched for sequence-specific DNA binding proteins and include components of signal transduction pathways that
direct cell fate in the primitive streak and tailbud of the early embryo. Expression of some of these targets, such as Axin2,
Fgf8 and Wnt3a, is down regulated in Brachyury mutant embryos and we demonstrate that they are also Brachyury
targets in the human. Surprisingly, we do not observe enrichment of the canonical T-domain DNA binding sequence 59-
TCACACCT-39 in the vicinity of most Brachyury target genes. Rather, we have identified an (AC)n repeat sequence, which
is conserved in the rat but not in human, zebrafish or Xenopus. We do not understand the significance of this sequence,
but speculate that it enhances transcription factor binding in the regulatory regions of Brachyury target genes in
rodents.
Conclusions/Significance: Our work identifies the genomic targets of a key regulator of mesoderm formation in the early
mouse embryo, thereby providing insights into the Brachyury-driven genetic regulatory network and allowing us to
compare the function of Brachyury in different species.
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Introduction
Brachyury (T) is expressed in the primitive streak, tailbud and
notochord of the early mouse embryo [1,2]. It plays a key role in
early development: mouse embryos lacking functional Brachyury
protein do not gastrulate properly, fail to form a differentiated
notochord, lack structures posterior to somite seven, and have
defects in left-right patterning [3,4,5]. The expression patterns of
the Xenopus [6] and zebrafish [7,8] Brachyury orthologues resemble
those of the mouse, and these genes play similar roles in early
development [8,9,10,11], indicating that Brachyury function has
been conserved throughout evolution.
In an effort to understand how Brachyury exerts its effects, we
have searched for genomic targets of this transcription factor. In
previous work using Xenopus embryos we have used differential
screening approaches to isolate target genes such as eFGF [12],
members of the Bix family [13,14] and Wnt11 [15], while a
chromatin immunoprecipitation-microarray (ChIP-chip) ap-
proach in the zebrafish embryo has allowed us to identify more
than 200 potential targets of No-tail a (Ntla), the orthologue of
Brachyury [16]. In this paper, we apply a ChIP-chip approach to
identify targets of Brachyury during mouse embryonic stem (ES)
cell differentiation. ES cells provide an abundant source of
material as they differentiate towards embryoid bodies (EBs), and
we predict that the identification of Brachyury targets in these
cells will shed light on ES cell differentiation as well as help
identify such targets in the early embryo. This work might also
indicate the extent to which the biological function of Brachyury
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33346
has been conserved in vertebrates and provide information on
how Brachyury binding motifs are disposed within target cis-
regulatory regions.
Our results show that Brachyury targets in differentiating ES
cells are enriched for sequence-specific DNA binding proteins
and components of signal transduction pathways that direct cell
fate in the primitive streak and tailbud of the early embryo.
Interestingly, most binding peaks were not enriched for the
canonical T-box binding site 59-TCACACCT-39 [17,18] but
did contain a repeating AC motif. Amongst the signal
transduction pathway components were regulators of the
WNT and FGF pathways. These include Axin2 (Axil/Conductin),
which encodes a negative regulator of Wnt signalling, as well as
Wnt3a and Fgf8. Significantly, expression of all three genes is
down regulated in homozygous Brachyury mutant embryos and
we show by ChIP-qPCR that these are also genomic targets of
BRACHYURY in differentiating human ES cells. These results
are consistent with work in the zebrafish emphasising the
importance of Wnt and Fgf signal transduction pathway
components as Brachyury targets [16]. In demonstrating that
expression of Axin2 in the early mouse embryo is regulated by
Brachyury as well as by TCF/Lef proteins [19,20,21,22], our
results emphasise the complex interplay between signalling
pathways in the regulation of gene expression in the early
embryo.
Results
ES cell culture
Preliminary experiments demonstrated that our ES cell culture
regime yielded embryoid bodies of uniform size, similar to that of
EBs grown on hydrophobic surfaces [23], and that expression of
Brachyury usually peaked at day 4 of differentiation (Fig. 1).
Immunohistochemical analysis indicated that approximately 15%
of cells in our embryoid bodies express Brachyury (data not
shown).
ChIP-chip and bioinformatic analysis
Binding sites of Brachyury were identified by ChIP-chip
experiments and the closest gene was identified using version
NBI35.1 of the annotated mouse genome (see Material and
Methods). Following filtration, our analysis gave a list of 520
enriched probes representing 396 genes (Table S1). Genomic
quantitative PCR on a selection of genes called as bound or
unbound confirmed that our ChIP-chip approach identified
genuine binding events (Fig. S1).
Brachyury is expressed at its highest levels in the primitive streak
and haematopoietic progenitors at E7.5 to E8.5. Later expression
is restricted to the tailbud and notochord (E12.5), and then to
parts of the brain and tail [2]. Of the Brachyury targets identified
in our embryoid body experiments whose expression patterns are
known, most (63%) are activated during this period of 7.5 to
17.5 dpc of mouse development (Fig. 2A). And of these 250
genes, many are restricted to the primitive streak or its
mesodermal derivatives, with 30% (75 transcripts) expressed
exclusively in the mesoderm (Fig. 2A). In addition to Axin2, Wnt3a
and Fgf8, which are discussed below, genes that have been
reported to be co-expressed with Brachyury include Msgn1, whose
expression is down regulated in Brachyury mutants [24], Meis1 [25]
Trim 28 [26] and Zic2 [27], which are expressed in the primitive
streak during gastrulation, Foxa2, present in the node and
notochord [28], and Adam19 (meltrin beta), present in tailbud
mesenchyme [29]. These and other transcripts (see below) are
also co-expressed with Brachyury (or are activated shortly after
Brachyury) in embryoid bodies, and typical profiles of Msgn1, Meis1
and Foxa2 expression are shown in Fig. 2B.
The targets we identify include components of the WNT,
MAPK, JNK, TGF-b, Hedgehog, FGF and G-protein coupled
signal transduction pathways (Table S2). Analysis of the targets
yielded a set of gene ontology (GO) terms consistent with the
function of Brachyury during gastrulation [30].
In particular, cellular component analysis highlights gene
products involved in morphogenesis, cell adhesion and cell
Figure 1. Temporal expression pattern of Brachyury during early ES cell differentiation. The graph shows a quantitative RT-PCR profile
from an embryoid body spinner culture. Brachyury expression is calculated relative to beta actin. Images show undifferentiated R1 cells on mouse
embryo fibroblast feeders at day 0, early blast colonies at day 2, and embryoid bodies at days 3, 4 (when they are cross-linked) and 5.
doi:10.1371/journal.pone.0033346.g001
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polarity. Targets such as Gdf5, Lmx1b and Dlx5 are involved in
morphogenesis (Fig. S2A: GO:0048598; P,1026), Gabra1, Gfra3
and Cbln3 are involved in anchoring the plasma membrane to
cytoskeletal proteins (Fig. S2B: GO:0030054; P = 161023) and
others encode proteins involved in cell adhesion, such as the
glycosyltransferases B4galnt2 and Cml4/Nat8. This last observation
is consistent with data showing that glycosyltransferases, and
especially galactotransferases, are mis-expressed in T/T mutant
mice [31], that the extracellular matrix is reduced in such embryos
[32], and that cells have fewer cytoplasmic processes, especially in
the somites and mesenchyme [32]. Significantly, over-expression
of Cml4, or its Xenopus orthologue Camello (Xcml), inhibits
gastrulation in Xenopus [33].
Interestingly, another group of targets is associated with germ
cells (Table S3), including Asap1 (Ddef1), which encodes an ADP-
ribosylation factor GTPase-activating protein implicated in
metastatic prostate cancer [34], and also the Wilms’ tumour gene
WT1 [35].
Transcription factor targets
Of the 396 genes identified as potential targets of Brachyury,
53 (13.4%) are transcription factors (Table S4), and indeed gene
ontology analysis demonstrates significant enrichment for
sequence-specific DNA binding proteins (Fig. S2C
GO:0043565, p,1025). Several families of transcription factors
are represented, including the Ets, paired box, homeobox,
winged helix/forkhead, bZip and zinc finger families. Under our
ES cell culture conditions, expression of many of these
transcription factors peaks either at the same time as Brachyury
(Foxa2, Foxe1) or just afterwards (BapX1, Ebf2, Erg, Hoxa13, Meis1,
Msgn1, Nkx2.6 and Slug) (Fig. 2B). As we discuss below, our data
provide a basis for deciphering the transcription factor genetic
regulatory network underlying mesoderm formation in ES cells
and in the embryo.
T-box protein binding motifs
Previous work indicates that Brachyury interacts with the
sequence 59-TCACACCT-39 [16,36,37,38]. To our surprise,
neither nested MICA nor RSAT identified this motif as
significantly enriched in the DNA sequences selected in our
experiments. Rather, both packages identified enrichment of the
simple sequence repeat (AC)n (Fig. S3A). However, although it was
not enriched, we did observe that several regulatory regions
contain a sequence resembling a T-box site (in which 1 to 3
nucleotides differ from the consensus) close to an AC repeat. These
genes include Axin2, Ctnnb1/b-catenin, Erg, Etv1, Fgf8, Fev, Foxa2,
Foxe1, Fyb, Id4, Meis1, and Hoxa3 where the T-box like sites may be
positioned either 59 or 39 to the repeat sequence.
To assess the significance of these observations we first
performed electrophoretic mobility shift assays (Fig. S3B). As
expected, the T-domain of mouse Brachyury binds the canonical
TCACACCT sequence, binding can be competed by unlabelled
oligonucleotide, and the complex can be ‘super-shifted’ by a
Brachyury antibody. The (AC)n repeat motif also forms a
complex with Brachyury, but although the complex can also be
‘supershifted’, unlabelled oligonucleotide competes very poorly.
Finally, when both motifs are present in the radiolabelled
oligonucleotide, competition using an excess of cold oligonucle-
otide in which just the T-box site is mutated is poor, and so is
competition in which just the (AC)n region is mutated. Together,
these observations indicate that the (AC)n sequence interacts only
weakly with Brachyury, if at all, and that its role may be
restricted to stabilizing binding to an adjacent or even a distant
T box site.
If true, such a role is likely to be restricted to rodent species.
Our dataset contains 111 peaks with associated AC repeats
longer than eight nucleotides (Table S5). Comparison with rat,
human, zebrafish and Xenopus genomes shows that 38 of these
AC-rich regions are unique to the mouse while 68 are also
present in the rat. Sixteen of the AC repeats are present in the
human genome, of which 11 are also present in rat. However,
none of the repeats are conserved in zebrafish or Xenopus
(Table S5).
Axin2 and Wnt3a as targets of Brachyury
Amongst the identified Brachyury targets are many genes
encoding positive and negative regulators of the Wnt signalling
pathway (Fig. 3A). Enrichment peaks in the promoter regions of
Dkk1, Ctnnb1/b-catenin, Dvl3, and c-catenin/Jup show Brachyury
binding (Fig. 3B, C, D and E) and also reveal the presence of AC
repeats (green bars) and imperfect T-binding sites (blue bars). Of
these Wnt-related genes, Wnt3a and Axin2 both show strong
Brachyury binding peaks around their transcription start sites in
our ChIP-chip analyses (Figs. 4A, 5A), and their temporal
expression patterns both resemble that of Brachyury in our
embryoid body system (Figs. 4B, 5B). For Wnt3a, a variant
Brachyury site is positioned close to an AC repeat sequence in the
first intron, and a canonical TCACACCT Brachyury site is
upstream of the transcription start site (Fig. 4A). In the case of
Axin2, a canonical Brachyury site is positioned close to a variant
site and to an AC repeat (Fig. 5A).
To ask whether Brachyury is required for expression of
Wnt3a and Axin2, we crossed mice that are heterozygous for a
Brachyury mutation [39] and assessed expression of the two
genes. In wild-type embryos at E7.5 the expression patterns of
Brachyury, Wnt3a and Axin2 overlap significantly (Fig. S4).
Expression of Wnt3a in Brachyury homozygous mutant embryos
at this stage resembles that in heterozygous and wild type
individuals, as has been reported previously [40], but by E8.5,
when Wnt3a expression is restricted to the primitive streak, its
expression is significantly down regulated in Brachyury mutant
embryos (Fig. 4C,D).
Like Wnt3a, Axin2 is expressed in Brachyury mutant embryos at
7.5 dpc, but this expression is more variable than that of Wnt3a,
and is sometimes reduced or even absent (data not shown). By
E8.5, when Axin2 is expressed in the headfold, tailbud and
primitive streak of wild type embryos, its expression in the
posterior region of Brachyury mutant embryos is very weak or
absent (Fig. 5C,D). Together, these data indicate that Brachyury is
Figure 2. Analysis of Brachyury targets. (A) Pie chart showing the times in development at which Brachyury target gene expression begins in
the mouse embryo (as a percentage of total; n = 396). Most genes (63%) start to be expressed between E7.5, when Brachyury is expressed in the
primitive streak, notochord and tailbud, and E17.5, when expression is restricted to trunk mesenchyme. Of targets showing this temporal expression
pattern, 30% are restricted to mesodermal derivatives, as indicated in the bar chart to the right. Others are expressed in various combinations of
ectoderm, mesoderm and endoderm. (B) Temporal expression of transcription factor targets of Brachyury during ES cell differentiation in spinner
culture, obtained by RT-PCR. The three panels in the top row were taken from a batch of cells in which Brachyury expression peaked at day 4 of
culture; the rest were taken from a batch in which Brachyury expression peaked at day 3. All show means of triplicate measurements and are
normalised to levels of beta actin. Foxa2 and Foxe1 in the top row peak with Brachyury at day 4; genes in the lower panel peak later than Brachyury.
doi:10.1371/journal.pone.0033346.g002
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Figure 3. Components of the Wnt pathway as Brachyury targets. (A) The Wnt signalling pathway. Arrows indicate positive interactions and
bars represent negative interactions. Targets identified in this study are outlined in bold. (B–E) Brachyury binding in genomic regions around Dkk1
(B); Ctnnb1/b-catenin (C); Dvl3 (D); and c-Catenin/jup/plakoglobin (E). Each target shows fold enrichment against chromosomal position. Blue bars
represent the T box-like site TSACANNT (N= any base, S =G/C) and green bars represent (AC)n. Stars above bars represent sequence on the reverse
strand. Plots are average of triplicate chip results, aligned to the mm8 Feb. 2006 assembly.
doi:10.1371/journal.pone.0033346.g003
Figure 4. Analysis of Wnt3a, a positive regulator of the Wnt pathway. (A) Location analysis of Wnt3a. The figure (and Figs. 5, 6) shows fold
enrichment against chromosomal position. Plot is the mean of triplicate chip results, aligned to the mm8 Feb. 2006 assembly. Blue bars represent the
T box-like site TSACANNT (N= any base, S =G/C); green bars represent (AC)n; red bars the consensus TCACACCT. Stars above bars represent sequence
on reverse strand. (B) Quantitative RT-PCR expression profile for Wnt3a during ES cell differentiation, expressed relative to beta actin. (C, D) Expression
of Wnt3a studied by in situ hybridisation; in each, the top image shows a dorsal view, and the bottom image a lateral view. (C) Phenotypically wild
type (+/+ or +/T) embryo at E8.5–8.75, and (D) a mutant (T/T) embryo from crosses of Brachyury heterozygous mutant mice. Wnt3a expression is
detected with NBT/BCIP (purple) and the insets show a lateral view after double staining for Brachyury detected with INT/BCIP (orange brown). Note
that in the wild type embryo Wnt3a is expressed in tailbud and paraxial mesoderm. In the mutant embryo expression of Wnt3a staining is absent or
greatly reduced (n = 3). Scale bars indicate 250 mm.
doi:10.1371/journal.pone.0033346.g004
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required for the proper expression of Wnt3a and Axin2, which
encode key components of the WNT signalling pathway (see
Discussion).
Fgf8 as a target of Brachyury
A strong Brachyury binding peak was also detected 59 of the
transcription start site of Fgf8 (Fig. 6A), with a variant Brachyury
site (59-TCACAGAT-39; underlined bases differ from consensus)
positioned 63 nucleotides from an (AC)19 repeat. The temporal
expression profile of Fgf8 resembles that of Brachyury during
embryoid body differentiation (Fig. 6B), and the gene is co-
expressed with Brachyury in the primitive streak of embryos at E7.5
and E8.0–E8.25 (Fig. S5; Fig. 6C). Expression of Fgf8 in mutant
Brachyury embryos at E8.0 is greatly reduced (Fig. 6C), indicating
that Brachyury is required for expression of this gene as it is for
Wnt3a and Axin2.
Figure 5. Analysis of Axin2, a negative regulator of the Wnt pathway. (A) Location analysis of Axin2. For details see legend to Fig. 4. (B)
Quantitative RT-PCR expression profile for Axin2 during ES cell differentiation, expressed relative to beta actin. (C, D) Expression of Axin2 studied by in
situ hybridisation; in each, the top image shows a dorsal view, and the bottom image a lateral view. (C) Phenotypically wild type (+/+ or +/T) embryo
at E8.5–8.75 and (D) a mutant (T/T) embryo, both derived from crosses of Brachyury heterozygous mutant mice. Axin2 expression is detected with
NBT/BCIP (purple) and the insets show a lateral view after double staining for Brachyury detected with INT/BCIP (orange brown). Note that in the wild
type embryo Axin2 is expressed in tailbud, paraxial mesoderm and lateral margin of the neural folds. In the mutant embryo expression of Axin2 is
greatly reduced (n = 9). Scale bars are 250 mm.
doi:10.1371/journal.pone.0033346.g005
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Figure 6. Fgf8 as a target of Brachyury. (A) Location analysis of Fgf8. For details of methods see legend to Fig. 4. (B) Quantitative RT-PCR
expression profile for Fgf8 during ES cell differentiation, expressed relative to beta actin. (C) Expression of Fgf8 studied by in situ hybridisation. The
images show a phenotypically wild type (+/+ or +/T) embryo (top pair) and a mutant T/T (bottom pair) embryo derived from crosses of Brachyury
heterozygous mutant mice. The wild type embryo is orientated with anterior to the left and posterior to the right; the mutant is viewed from the
posterior. Fgf8 expression is detected with NBT/BCIP (purple) and Brachyury with INT/BCIP (orange brown). In the wild type embryo Fgf8 is expressed
in the primitive streak and paraxial mesoderm; such expression is absent or greatly reduced in the mutant. Scale bars indicate 200 mm.
doi:10.1371/journal.pone.0033346.g006
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AXIN2, JUP, FGF8 and WNT3A are conserved targets of
BRACHYURY in the human
Because some of the Brachyury targets we discovered in the
mouse were not previously identified in the frog or the zebrafish
[16], we decided to investigate whether these are conserved in
other species, in an attempt to further validate our results. For this
purpose we decided to look for BRACHYURY binding in the
human genome.
We have recently optimised culture conditions that cause
human embryonic stem cells to differentiate into mesoderm-like
cells [41]. These cell populations express BRACHYURY at high
levels and, importantly, they also up regulate other mesoderm
markers, including many of the Brachyury targets we have
identified in the mouse, namely, DKK1, HOXA13, ID4, JUP,
KRT8, MEIS1, MSGN1, SNAI2, and WNT3A.
We therefore made use of this newly developed in vitro
differentiation system to ask if BRACHYURY binds the homologous
human regulatory regions of some key mouse targets: AXIN2, FGF8,
JUP and WNT3A. As in the mouse, these regions contain imperfect
T-binding motifs (data not shown). Our experiments involving ChIP-
qPCR with hESC-derived mesoderm cells indeed detected a strong
enrichment for these sequences, thus indicating that BRACHYURY
binds to the same genomic regions in the human (Fig. 7A).
Interestingly, these promoter sequences seem to be conserved
between the mouse and human genomes, but not in the zebrafish
or in other vertebrates (Fig. 7B) suggesting that these targets might
be unique to mammals.
Discussion
We have identified genomic targets of Brachyury in differen-
tiating mouse ES cells, demonstrating that embryoid bodies
provide sufficient material for chromatin immunoprecipitation
experiments and that they represent an effective model of early
mouse development. Although they do not undergo proper
morphogenesis, they do generate pattern, as illustrated by the
formation of beating cardiomyocytes [42]. The embryoid bodies
produced in our experiments form cardiomyocytes after eight to
ten days in culture, close to the time at which the heart tube forms
during normal development. As discussed below, at least three
Brachyury targets (Wnt3a, Axin2 and Fgf8) are expressed in the
early mouse embryo during formation of the primitive streak, and
their proper expression during development requires Brachyury
function. We also note that several targets are expressed in
primordial germ cells, perhaps the first differentiated population to
emerge during early gastrulation [43,44,45]. These cells express
Brachyury until E12.5, when the gene is down regulated in a non-
migrating population [46,47]. Although Brachyury may not be
involved directly in the specification of the germ cells [48,49] it
may regulate their migration and their potency.
Classification of Brachyury targets and comparison with
zebrafish and frog
Our work has identified 396 potential targets of Brachyury, and
gene ontology analysis indicates that many of these encode
sequence-specific DNA binding proteins and proteins involved in
cell adhesion and embryonic morphogenesis. Analysis of the
former category will help in the elucidation of the genetic
regulatory network that underlies mesoderm formation (see
below). The latter category includes cell junction proteins and
glycosyltransferases [31], consistent with the finding that the
extracellular matrix of homozygous mutant Brachyury mouse
embryos is poorly developed [32] and that cells have fewer
Figure 7. Conservation of BRACHYURY binding in the human genome. (A) ChIP-qPCR performed on samples from differentiated hECSs
using a specific anti-BRACHYURY IgG and a non-specific control IgG. Graph shows enrichment for regulatory regions of Brachyury targets (AXIN2,
FGF8, JUP, WNT3A) and a negative control region (NCAPD2). Results are expressed relative to input chromatin divided by the enrichment for the non-
specific control antibody. (B) BRACHYURY binding in the human genome. The short red lines below the chromosomal coordinates (hg19) depict the
position of the PCR amplicons relative to the beginning of the human genes (blue). The three bottom tracks show the genome sequence
conservation between human and mouse, zebrafish and vertebrate genomes (Genome Browser, http://genome.ucsc.edu/).
doi:10.1371/journal.pone.0033346.g007
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cytoplasmic processes, both of which may contribute to the failure
of mutant cells to move out of the primitive streak and to the
failure of elongation of the antero-posterior axis [30]. Amongst the
other genes regulated by Brachyury are those encoding cytokines
and components of signal transduction pathways, and in most of
these respects our results are reminiscent of those obtained in
similar experiments using the zebrafish embryo [16].
It is significant that embryoid bodies resemble developing
embryos in this way, and it is also important to note the overlap
between the Brachyury targets identified in this study and the Ntl
targets identified in the zebrafish [16]. Both studies identified
transcriptional regulators as being enriched, including members of
the homeobox, winged helix, paired box, zinc finger and odd-
paired families. There are also similarities in the functions of genes
regulated by the two orthologues. These functions include
gastrulation (where the zebrafish study identified wnt11, snail1a
and blf and this analysis Wnt3a, Snail2 and genes such as Gdf5, Etv1,
Krt5, Krt8, Lmx1b, Syk, and Gnaq); muscle specification (where both
studies identified Msgn1 and Pax3); posterior identity (where the
zebrafish study identified fgfr4, fgfr28, vent, vox, and notch3 and this
analysis Fgf8 [50]) and left-right patterning (zebrafish genes include
cx43.4 [51] and our mouse targets Rttn [52], Fgf8 [53], and
cytoplasmic dyneins Dync1li1, Dync2li1 [54] and Dpcd [55]).
The fact that there are some differences between the mouse and
zebrafish targets may derive from the presence of an additional
Brachyury gene in the zebrafish genome [8] or from the ‘sharing’ of
gene function between different T box family members. For
example, the Bix genes were identified as targets of Brachyury and
VegT in Xenopus [13,14], but their mouse ortholog Mixl1 seems to
be regulated mainly by Eomesodermin [56,57]. Furthermore, as
illustrated in Fig. 7B, some regulatory sequences of mammalian
genes (Axin2, Fgf8, Jup and Wnt3a) share little homology with those
of their zebrafish orthologues. It is possible that Brachyury binds
different locations in different genomes, which has been noted for
other transcription factors [58], despite target conservation. It is
also likely that Brachyury binds not only to promoters near the
gene transcription start site but also to distant enhancers [59],
which is indeed the case in the human genome (T. Faial et al., in
preparation). We note that both the mouse and zebrafish arrays
were based on promoter regions, so that enhancer binding is not
available in these datasets, perhaps explaining why some targets
seem to be unique to each species.
Canonical and non-canonical T-box binding sites
Our previous work searching for targets of zebrafish Ntl showed
that the canonical T-box site TCACACCT was enriched in the
vicinity of Ntl target genes [16]. A significant enrichment of this
motif was not observed in the present experiments for the majority
of targets. Rather, we identified a novel (AC) n repeat sequence
that recognised, albeit weakly, the Brachyury T domain in
electrophoretic mobility shift experiments. We do not yet fully
understand the significance of this observation. Mouse Brachyury
binds to an imperfect T-box site palindrome in the Nanog promoter
[60], but no other Brachyury target has been characterised in any
detail in this species. It is possible that mouse Brachyury resembles
Drosophila Brachyenteron, where modular variations on the T-box
consensus binding sequence determine the degree of transcrip-
tional activation [61]. A similar system controls notochord
formation in Ciona, with regulatory motifs comprising Ci-
Brachyury and Ci-foxA binding sites [62].
Moreover, many transcription factors bind directly to DNA in
distal enhancer elements [59], and are then linked to the promoter
region by chromatin looping, allowing interaction with other
proteins involved in transcription regulation [59]. It is likely that in
some mouse targets, canonical Brachyury binding motifs are not
present in the promoter region but rather in upstream or
downstream regulatory regions. Our results show that this does
occur in the human genome (T. Faial et al., in preparation).
It is also possible that the AC repeats cause the transient
formation of left handed DNA helices and bends, changing the
chromatin architecture and encouraging transcription factor
binding [63]. Brachyury may be an example of a protein with a
secondary recognition motif [64] and that the presence of both an
AC repeat and a TCACACCT sequence allows stable binding
that cannot be competed by an excess of just the TCACACCT
sequence (Fig. S3B). Repetitive sequences may also function as
pre-sites; that is, as regions of DNA that are predisposed to evolve
into new regulatory sequences [65].
Brachyury modulation of Wnt and Fgf signalling
Several components of the Wnt signal transduction pathway
were identified as Ntl targets in the zebrafish, and we find that the
same is true for Brachyury in the mouse. In an effort to determine
whether Brachyury regulates expression of these potential targets
during normal mouse development we asked whether Wnt3a and
Axin2 are expressed normally in Brachyury homozygous mutant
embryos, and found that although both genes are expressed at
E7.5 (albeit rather variably in the case of Axin2), neither is
expressed at E8.5 in mesodermal derivatives (Figs. 4, 5). This
suggests that Brachyury is not required for the initial activation of
Wnt3a or Axin2, but is needed for maintenance of their expression.
Together with the observation that Wnt3a maintains Brachyury
expression in the early mouse embryo via TCF/Lef signalling
[20,21], and that Axin2 is down regulated in Wnt3a mutants [66],
our data indicate that Brachyury and Wnt signalling cooperate to
create a regulatory network that specifies the formation of
posterior mesoderm in the mouse embryo.
Part of this network may involve Fgf signalling. Brachyury and
Fgf signalling form part of an autoregulatory loop in Xenopus and
zebrafish embryos [67,68,69,70], and we note that Fgf8 is a target
of Brachyury in embryoid bodies, and that its expression is down
regulated in Brachyury mutant embryos (Fig. 6).
Finally, our work reveals that the promoter regions of AXIN2,
FGF8 and WNT3A are also bound by BRACHYURY (Fig. 7A) in
human ES cells as they differentiate into mesoderm-like cells [41].
These results further substantiate the identity of these genes as bona
fide Brachyury targets and suggest that the regulation of these key
signalling components is conserved during human development.
Making a genetic regulatory network for mesoderm
Attempts to understand the Brachyury genetic regulatory
network are important not only because Brachyury is required
for proper formation of mesoderm in the vertebrate embryo, but
because it is sufficient for the formation of some mesodermal cell
types, at least in Xenopus [71]. The identification of new Brachyury
targets will enable the integration of Brachyury with other
components of genetic regulatory networks that include it, such
as the Ets family member Elk-1 and the caudal homologue, Cdx2
[72] and to ask to what extent such networks have been conserved
during evolution.
Materials and Methods
Ethics statement
Animal procedures were performed under a UK Home Office
project license within the conditions of the Animals (Scientific
Procedures) Act 1986.
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Mouse ESC culture
Embryonic stem (ES) cell culture was as described [73] except
that mitotically inactivated primary mouse embryonic fibroblasts
(MEFs) were used as feeders. Culture dishes were coated with
0.1% gelatin (Sigma-Aldrich). MEFs and ES cells were maintained
in DMEM (Sigma-Aldrich) supplemented with 0.1 mM b-
mercaptoethanol, non-essential amino acids (Gibco Invitrogen),
2 mM glutamate (Gibco Invitrogen), and batch-tested 10%
(MEFs) or 15% (ES cells) foetal bovine serum (FBS) (Gibco
Invitrogen). ES cell medium was also supplemented with
Leukaemia Inhibitory Factor (LIF) (ESGROH, Millipore) at 103
units/ml [74]. Early passage R1 mouse ES cells [75] were
passaged every 2 days and medium was changed daily to prevent
differentiation.
ES cells were differentiated in spinner flasks to produce large
numbers of embryoid bodies (EBs) undergoing synchronized
differentiation [76,77]. The Cellspin culture system (Integra
Biosciences) was set at 25 rpm and spin angle 720u so as to avoid
aggregation of EBs. Spinner medium was prepared as above, but
with LIF omitted and FBS increased to 20%. On day 0, adherent
log phase ES cell colonies were dissociated and resuspended in
10 ml spinner medium. Feeder cells were depleted by differential
sedimentation at 37uC for 20 min.
Medium (45 ml) was pre-equilibrated in 100 ml silicon-coated
(Sigmacote, Sigma-Aldrich) spinner flasks (Integra Biosciences). ES
cells were recovered from the gelatin-coated differential sedimen-
tation plates and centrifuged at 800 g for 5 min. Cells were fully
dissociated to ensure that cultures were initiated from single cells,
and each spinner flask was inoculated with 107 cells in 5 ml
medium. After 24 h (day 1 of differentiation) a further 50 ml
spinner medium was added to each flask. Each day thereafter EBs
were allowed to sink and 50 ml medium was aspirated and
replaced with 50 ml fresh pre-warmed spinner medium.
Human ESC culture
Human ESCs (H9 [WiCell, Madison, WI]) were maintained
and differentiated as previously described [41]. Briefly, hESCs
were induced to express BRACHYURY by culturing them in a
chemically defined medium (CDM) supplemented with FGF2
(20 ng/ml), LY294002 (10 mM) and BMP4 (10 ng/ml) (termed
FLyB medium). Cells were collected for ChIP after 36 h of culture
in FLyB medium, when BRACHYURY expression peaked.
Quantitative RT-PCR
Gene expression was analysed by real-time RT-PCR. RNA was
isolated from differentiated EBs using Tri-Reagent LS (Sigma-
Aldrich), digested with DNA-free DNAse I (Ambion), and checked
for integrity using an Agilent Technologies 2100 Bioanalyser.
cDNA was generated from l mg RNA using Superscript III Reverse
Transcriptase (Invitrogen, Life Technologies), and this was followed
by real-time PCR using the LightCycler 480 SYBR Green I master
kit (Roche). Mouse beta actin primers were used as an endogenous
control to express relative expression levels (Table S6).
Antibodies
Several anti-Brachyury antibodies were tested for use in this
work. Of these, the goat polyclonal C19 antibody (SC-17745,
Santa Cruz Biotechnology), raised against a C-terminal sequence
of human Brachyury, performed best in chromatin immunopre-
cipitation. This antibody, raised against a divergent region of
Brachyury that does not include the T box, has been well
characterised in previous studies [78,79,80]. It gave the expected
pattern of staining in early mouse embryos (Fig. S6A,B) and
recognised Brachyury protein (of the correct size) in immunopre-
cipitation experiments followed by western blots (Fig. S6C). Such
experiments failed to detect Brachyury in ES cells in which
Brachyury expression was inhibited by use of ShRNA constructs
(Fig. S6D,E).
Whole-mount in situ hybridization
Wild type mouse embryos were collected from MF1 or 129
strains, and Brachyury mutant embryos from BTBR T+tT/
J6BTBR T+tT/J heterozygote crosses [39]. Embryos were fixed
overnight in 4% paraformaldehyde in phosphate-buffered saline
(PBS), after which they were dehydrated and stored in 100%
methanol at 220uC. The mouse Brachyury coding sequence was
subcloned into pCS2+ and used to generate a probe. An Axin2
probe was generated from IMAGE clone 1361800 (Geneservice), a
Wnt3a probe from IMAGE clone pENTR223.1 100015989 after
subcloning into pCS2+ (Table S7), and an Fgf8 probe from
IMAGE clone 6513131 (Geneservice) in pCMV-SPORT 6.1.
Digoxigenin labelled or fluorescein labelled antisense RNA probes
were generated using T7 RNA polymerase from linearised
templates and whole mount in situ hybridisation was performed
as described [81]. Alkaline phosphatase was detected using (i) BM
purple; (ii) 2-[4-iodophenyl]-3-[4-nitrophenyl]-5- phenyltetrazo-
lium chloride (250 mg/ml) plus magenta phosphate (250 mg/ml)
(INT/Mag); or (iii) nitro blue tetrazolium (175 mg/ml) plus 5-
bromo-4-chloro-3-indolyl phosphate (337.5 mg/ml) (NBT/BCIP)
(Roche). These gave dark blue, orange brown or purple staining
respectively. A final concentration of 5% polyvinyl alcohol (Sigma-
Aldrich) was used in the staining reaction.
Whole-mount immunohistochemistry
Embryos were fixed as described above and rehydrated to PBS
for staining. Free aldehyde groups were blocked using 1 M
glycine, embryos were washed in PBS/0.1% Tween 20 (PBST),
and endogenous peroxidases were blocked using 3% hydrogen
peroxide in PBS. Embryos were incubated overnight at 4uC in
1:400 C19 antibody in PBST supplemented with 0.2% bovine
serum albumin (BSA) and 10% heat inactivated FBS. They were
then washed, incubated with 1:400 rabbit anti-goat biotinylated
IgG (E0466, Dako), and stained using Vectastain Elite ABC
substrate (Vector laboratories) with Sigma Fast Nickel Enhanced
DAB chromagen (Sigma).
In vitro translation and western blotting
Brachyury mRNA was synthesized using the pCS2+ construct
described above and the Ambion mMessage mMachine (Applied
Biosystems/Ambion). mRNA was translated in a rabbit reticulo-
cyte lysate (Promega). In vitro translation products and embryoid
body extracts were subjected to polyacrylamide gel electrophoresis
(PAGE) and western blots were performed using CAPS transfer
buffer (10 mM CAPS pH 11, 10% Methanol). Membranes were
blocked with 5% milk powder in PBST overnight, and antibodies
were diluted in the same solution. Washes were in PBST. Primary
antibodies were R&D Systems anti-T and SantaCruz anti-T (see
above). Both were used at a dilution of 1:250. Secondary
antibodies were HRP-linked SantaCruz D anti-goat IgG
(1:20,000) and HRP-linked Amersham NA934V anti-rabbit IgG
(1:100,000). All antibody incubations were 1 hour at room
temperature. Both endogenous and in vitro translated T proteins
were immunoprecipitated for western blotting using the Santacruz
Exactacruz D anti-goat system (SC-45041, Santa Cruz) to avoid
detection of heavy and light chains of the IP antibody. Detection
used the Pierce Supersignal West Dura Extended Duration
Substrate (Thermo Scientific).
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Chromatin immunoprecipitation (mouse ESCs)
Chromatin immunoprecipitation/location analysis was based
on the Agilent Mammalian ChIP-chip Protocol, incorporating the
Whole Genome Amplification GenomePlex Kit (Sigma) [82].
Intact EBs (1.56109 cells) were fixed in 1 M formaldehyde for
20 min when Brachyury expression was at its highest level (usually
after 4 days of differentiation). This was followed by quenching
and isolation of nuclei. Our protocol differs from a previously-
published procedure [83] in that EBs are not disrupted before
fixation. Nuclei were sonicated using a Misonix 3000 ultrasoni-
cator to create fragments of 500 bp, and these were immunopre-
cipitated using polyclonal goat anti-Brachyury C-19 (Santa Cruz
Biotechnology) or normal goat IgG (Santa Cruz Biotechnology) as
an isotype control. Following washing and elution steps, cross-links
were reversed overnight at 65uC. Samples were analysed by
promoter-specific primers or amplified by GenomePlex whole
genome amplification for microarray studies.
Chromatin immunoprecipitation (human ESCs)
ChIP was performed as previously described [83] with some
modifications. Briefly, H9 hESCs (one confluent 10 cm dish) were
collected after 36 hr of culture in FLyB medium [41], when
BRACHYURY expression peaked. Cells were fixed as described
[83], the nuclei were isolated and sonicated using a Misonix 4000
to obtain DNA fragments of around 1000 bp. Samples were
incubated at 4uC overnight using 10 mg of an anti-BRACHYURY
goat IgG (R&D systems) and with10 mg of a non-specific goat IgG
as a control. The chromatin was immunoprecipitated by adding
100 ml of Protein G Dynabeads (Invitrogen), then incubating at
4uC 1 h, and collecting the beads using a magnetic rack. After
washing the beads, the chromatin was eluted and the crosslinking
was reversed at 65uC overnight. Samples were then treated with
RNAse and Proteinase K and the DNA was extracted by phenol/
chloroform, ethanol-precipitated and finally eluted in nuclease-free
water. This experiment was repeated three times with similar
results.
Verification of target enrichment was performed on a selection
of targets using genomic quantitative PCR. DNA fragments were
amplified using Fast SYBRH Green Master Mix (Applied
Biosystems) according to manufacturers instructions on a 7500
Fast Real-Time PCR System (Applied Biosystems). Promoter
specific primers (Table S8) were designed to amplify the
homologous regions of mouse T-binding sites (AXIN2, FGF8,
JUP and WNT3A). NCAPD2 was used as a negative control gene.
Microarray hybridization, analysis and verification of
binding targets
Agilent Technologies mouse promoter 244K (G4490A) 60-mer
oligonucleotide arrays (‘‘chips’’) covering 17,000 mouse genes and
extending 5.5 kb upstream and 2.5 kb downstream of transcrip-
tional start sites were hybridized with 5 mg amplified chromatin
per sample. Arrays were annotated to NBI35.1 of the mouse
genome. Immunoprecipitated (or isotype control) and total input
samples were labelled with Cy5 or Cy3 respectively. Hybridiza-
tions were performed and analysed in triplicate using indepen-
dently differentiated cultures. The isotype control experiment was
performed once to confirm no significant enrichment over input
chromatin (data not shown).
Microarrays were scanned using an Agilent scanner to a
resolution of 5 mm. Data were extracted using Agilent G2567AA
Feature Extraction Software (v.9.1). The significance of binding
events was determined using Agilent Chip Analytics 1.3 software.
Initial analysis was done using Chip Analytics defaults settings and
then further filtered using the parameters P(x) ,0.01 and P(x)
,0.005. The confidence of binding calls is represented as a P-
value: P(x) defines the value for each probe, and P(x) uses the
intensities of neighbouring probes to assess peak shape, in an effort
to eliminate false positives. Original raw data files can be accessed
from GEO Gene Expression Omnibus http://www.ncbi.nlm.nih.
gov/geo (accession GSM417692/GSM417704 for design 1 and 2
Brachyury data; GSM417714/GSM417756 for design 1 and 2
isotype control data).
Verification of enrichment was performed on a selection of
targets using promoter specific genomic quantitative PCR.
Promoter specific primers (Table S8) were designed so as to span
bound peaks using mouse build mm8 promoter sequence retrieved
from the UCSC genome browser (http://genome.ucsc.edu/).
Negative control genes from the list not called as bound were
included. Results were expressed relative to input chromatin
divided by relative enrichment for the isotype control antibody.
Bioinformatic analyses and Motif Finding
The GOToolBox (http://burgundy.cmmt.ubc.ca/GOToolBox/)
[84] was used to access Gene Ontology (GO) resources and to search
for any functional bias in our dataset. The Benjamini and Hochberg
multiple testing correction was applied to assess the significance of
enrichment ratios. Target probes and surrounding promoter
sequences were scanned for the published consensus in vitro T-box
binding motif TCACACCT [17,18] using NestedMICA http://
www.sanger.ac.uk/Software/analysis/nmica/index.shtml [85]. We
also used Regulatory Sequence Analysis Tools (RSAT) http://rsat.
ulb.ac.be/rsat/ [86], to scan each target gene over a region25 kb to
+1 kb relative to its ATG for over-represented cis-regulatory
modules, applying background models and taking promoter
sequences from 400 random mouse promoters as the control set.
Sequences representing enriched motifs were then stacked into
positional weight matrices and converted to sequence logos using
WebLogo (http://weblogo.berkeley.edu/logo.cgi) [87].
Electrophoretic mobility shift assays
The T domain of mouse Brachyury was amplified by PCR
(primer sequences in Table S7) and inserted in-frame into the
glutathione-S-transferase (GST) fusion vector pGEX-6P-1. The
fusion protein was expressed in E. coli by isopropyl-b-D-
thiogalactoside induction and purified at 4uC using GSTrap FF
columns and Pre-Scission Protease (GE Healthcare), leaving only a
glycine and a proline residue attached to the protein. This was
concentrated using Amicon Ultra 4 columns (Millipore), and the
identity of the resulting protein was confirmed by SDS PAGE and
mass spectrometry.
Double stranded oligomers containing (i) the core Brachyury
consensus binding sequence TCACACCT, (ii) a simple AC repeat,
or (iii) the core Brachyury sequence together with the AC repeat,
and mutated versions of each, had identical BglII/BamH1 59
overhangs (Table S7). These were PAGE purified, annealed, and
end-labelled with [a-32P] dCTP using Klenow fragment. Unin-
corporated nucleotides were removed using Sephadex G-50
columns (GE Healthcare). Binding reactions were incubated on
ice for 40 minutes in 16 EMSA binding buffer (25 mM HEPES
pH8.0, 100 mM KCl, 1 mM DTT, 0.1% NP-40, 5% glycerol,
10 mM EDTA), 0.5% milk powder and 50 ng/ml dI/dC using
30,000 cpm/ml and 8–10 fmol labelled oligomer. Competition
reactions using 4 pmol cold oligomers were pre-incubated for
10 min on ice. In supershift experiments goat polyclonal anti-
Brachyury N19 antibody (SC-17743, Santa Cruz) was added after
binding and then incubated a further 20 min on ice.
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Supporting Information
Figure S1 Validation of targets. Box plot showing genomic
quantitative PCR of bound promoter regions for targets Axin2,
Foxe1, Mapre2, Nkx2.6, Pax3, Rttn, Van Gogh and the published
target Nanog, and unbound or negative promoter regions Nanog 39,
1700010C24Rik and beta actin. Boxes represent the interquartile
range, the upper edge being the 75th percentile and lower edge the
25th percentile. The whiskers show the minimum and maximum
values. Values above the line are enriched in chromatin
immunoprecipitations. Data were obtained from five independent
chromatin immunoprecipitations. Probes recognising Nanog were
not present on Agilent 244K promoter arrays.
(TIF)
Figure S2 Functional analysis of target genes. Bar charts
show Gene Ontology (GO) annotations for (A) biological process;
(B) cellular component; and (C) molecular function using the
GOToolBox. Horizontal bars represent enrichment ratio (ob-
served frequency/expected frequency) and vertical axis gives the
GO term followed by the GO identification number in brackets
and hierarchy level. Colour bars indicate statistical significance.
GO terms related to the function of Brachyury are highlighted in
red boxes.
(TIF)
Figure S3 Interaction of the mouse Brachyury T domain
with DNA. (A) Sequences surrounding bound probes are
enriched for an (AC)n repeat relative to their genomic neighbours.
The motif was generated using the NestedMICA position weight
matrix. This may represent a secondary Brachyury recognition
motif. (B) Electrophoretic mobility shift assays. Panel a: Binding
reactions using 32P-labelled TCACACCT. Lane 1, no protein;
lane 2, control protein derived from empty vector; lanes 3–6,
mouse T domain protein: lane 4 includes excess unlabelled probe;
lane 5 includes excess unlabelled mutated probe; lane 6 is a
‘supershift’ using anti-T N-19 (SC-17743, Santa Cruz). Notice that
the Brachyury T domain binds the T site oligonucleotide and that
binding is competed by cold wild-type oligonucleotide but not by a
mutated oligonucleotide. Panel b: Lanes 7–9 include 32P-labelled
TCACACCT; lane 10 uses the indicated mutated version of this
oligonucleotide. Note that the Brachyury T domain does not bind
the mutated oligonucleotide. Panel c: Binding reaction using a 32P-
labelled AC repeat oligonucleotide. Lanes 11–13 as panel a; lane
14 includes excess unlabelled probe; lane 15 includes excess of an
unlabelled mutated probe; lane 16 is a ‘supershift’. Notice that the
Brachyury T domain binds the AC repeat oligonucleotide weakly
but that binding does not seem to be competed by cold wild-type
oligonucleotide. The complex however is ‘supershifted’ using the
Brachyury antibody. Panel d: Binding reactions using a 32P
labelled motif that includes both the T site TCACACCT and an
AC repeat. Lanes 17–20 show that Brachyury binds this
oligonucleotide, and that binding is competed by cold wild-type
oligonucleotide. Lanes 21 and 22 show that binding is not
competed significantly by unlabelled oligonucleotides in which
either motif is mutated. Lane 23 shows a ‘supershift’. Experiments
in (a–d) were performed under identical conditions and exposed
for the same times.
(TIF)
Figure S4 The expression domains of Brachyury,Wnt3a
and Axin2 overlap in E7.75 mouse embryos. (A) Expression
of Axin2 analysed using a fluorescein labelled antisense probe
detected with NBT/BCIP (purple). (B) The embryo in (A) analysed
using a digoxigenin labelled antisense Brachyury probe detected
with INT/Mg phosphate (brown). (C) Expression of Wnt3a
analysed using a fluorescein labelled antisense probe detected
with NBT/BCIP (purple). (D) The embryo in (C) analysed using a
digoxigenin labelled antisense Brachyury probe detected with INT/
Mg phosphate (brown). All embryos orientated as in (A). Scale bars
are 200 mm.
(TIF)
Figure S5 The expression domains of Brachyury and
Fgf8 overlap in the primitive streak of E7.75 mouse
embryos. (A). Expression of Fgf8 analysed using a fluorescein
labelled antisense probe detected with NBT/BCIP (purple). (B).
The embryo in (A) analysed using a digoxigenin labelled antisense
Brachyury probe detected with INT/Mg phosphate (brown). Black
bars are 200 mm.
(TIF)
Figure S6 Verification of anti Brachyury antibody. (A)
Immunohistochemistry of E9.5 embryo using Santa Cruz anti-
human T C19 with nickel enhanced DAB substrate. Staining is
present in the notochord (arrowhead), pre-somitic mesoderm
(arrow) and tailbud. Staining was absent in controls in which
primary or secondary antibodies were omitted. (B) Expression of
Brachyury RNA in an E9.5 embryo studied by in situ hybridisation.
Note similarity to (A). Bars in (A) and (B) represent 250 mm. (C)
Western blot testing antibody specificity. Size markers are shown
to the left. Lane 1: Mouse Brachyury reticulocyte lysate translation
product; lane 2: unprogrammed reticulocyte lysate translation
product; lane 3: Immunoprecipitated material derived from
Brachyury reticulocyte lysate translation product; lane 4: Super-
natant of immunoprecipitated material in lane 3; lane 5:
Immunoprecipitated material derived from day 4 embryoid
bodies; lane 6: Supernatant of immunoprecipitated material in
lane 5; lane 7: Immunoprecipitated material derived from day 4
embryoid bodies, having omitted first antibody; lane 8: Superna-
tant of immunoprecipitated material in lane 7. All immunopre-
cipitations used Santa Cruz anti-T C19. Western blots used R&D
Systems anti-T as a primary antibody and SantaCruz D anti-goat
IgG HRP linked secondary antibody. (D) Strategy to create ES cell
clones lacking Brachyury. Clones were created using 65 bp
ShRNA duplexes targeting the first exon of Brachyury (T).
Sequences were inserted into the XhoI/HindIII site of the pSingle
ShRNA vector (Clontech) which includes a tetracyclin-controlled
transcriptional repressor that in turn regulates the expression of
the ShRNA sequence. Selection of stable lines is achieved by
culture in G418 and induction of ShRNA expression occurs
through addition of 1 mg/ml doxycycline. (E) Western blot analysis
of day 5 embryoid body extracts from clones containing ShRNA
constructs targeted to Brachyury exon 1 (T1) or a scrambled version
of this sequence (Ts), either treated with doxycycline (+) or left
untreated (2). Samples were immunoprecipitated as in (C). Note
loss of Brachyury band in lane 3.
(TIF)
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Supplementary Table S1 
Full Gene List 
Gene Common Name Chromosome Peak Position 
0610040J01Rik unknown chr5 promoter 
1110004B13Rik Tmem107 chr11 promoter 
1110014K08Rik D030012E24Rik chr11 promoter 
1110032A13Rik RNA binding protein chr18 divergent 
1110059G10Rik unknown chr9 inside 
1190002N15Rik C3orf58 chr9 inside 
1200009I06Rik 1600013K19Rik/sec6 chr12 inside 
1300014I06Rik unknown chr13 promoter 
1700012A16Rik unknown chr1 promoter 
1700029I08Rik unknown chr17 promoter 
2310079F23Rik unknown chr5 promoter 
2410146L05Rik Ooep, oocyte expressed protein homolog (dog)  chr9 promoter 
2610207I05Rik 5430435M13Rik, C130002K18Rik, mKIAA0421, smg1 chr7 inside 
4732495E13Rik transmembrane protein 184b chr15 inside 
4930404H21Rik unknown/C16orf65 homolog chr7 inside 
4930408O21Rik hypothetical PDZ domain containing protein Uqcrc2 chr7 promoter 
4930412F15Rik unknown chr4 promoter 
4930441O14Rik unknown chr13 inside 
4930504O13Rik unknown chr11 promoter 
4930546H06Rik B230206P06Rik chr17 inside 
4930556P03Rik Bcdin3d BCDIN3 domain containing chr15 promoter 
4930578I06Rik unknown chr14 inside 
5330431N19Rik Dpcd, deleted in primary ciliary dyskinesia chr19 inside 
6330514A18Rik polo-like kinase 5  chr10 inside 
6430573F11Rik unknown chr8 inside 
9030425E11Rik ACAM; ASP5; CLMP; AW557819 chr9 promoter 
9530068E07Rik Keratinocytes-associated transmembrane protein 2 chr11 inside 
A230056P14Rik unknown chr7 inside 
A630055G03Rik LOC381034 chr16 promoter 
A730017C20Rik unknown function chr18 promoter 
AA407270 unknown chr9 promoter 
Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 C, Mrp2, multidrug resistance protein 2 chr19 promoter 
Abhd1 Abhydrolase domain containing 1,LABH-1, LABH1 chr5 promoter 
Acly ATP citrate lyase A730098H14Rik chr11 inside 
Adam19 A Disintegrin and metallopeptidase domain 19 (meltrin beta) chr11 inside 
Adam24 A Disintegrin and metallopeptidase domain 24 (testase 1) Dtgn5 chr8 promoter 
Adam5 A Disintegrin and metallopeptidase domain 5 tMDCII chr8 promoter 
Adamts10 ADAM metallopeptidase with thrombospondin type 1 motif 10, kuz, kuzbanian chr17 inside 
Adar adenosine deaminase, RNA-specific, ADAR1, mZaADAR chr3 inside 
Aipl1 aryl hydrocarbon receptor-interacting protein-like 1 chr11 divergent 
Akap10 A kinase (PRKA) anchor protein 10 chr11 promoter 
Aldoc aldolase 3, C isoform Aldo3, Aldolase C, Scrg2, zebrin II chr11 inside 
Ankrd13d ankyrin repeat domain 13 family, member D chr19 inside 
Anxa7 annexin A7 Anx7, synexin chr14 inside 
Apoa2 apolipoprotein A-II,Alp-2, Apoa-2, ApoA-II, Hdl-1 chr1 inside 
Appbp1 amyloid beta precursor protein binding protein1, Nae1, NEDD8 activating enzyme E1  chr8 divergent 
Aqp11 aquaporin 11 chr7 promoter 
Aqp4 aquaporin 4 chr18 promoter 
Arhgef4 rho/rac guanine nucleotide exchange factor (GEF) 4 chr1 promoter 
Arid1a AT rich interactive domain 1A (Swi1 like) BAF250a chr4 promoter 
Atcay ataxia, cerebellar, Cayman type homolog (human), BNIP-H, ji chr10 inside 
Athl1 ATH1, acid trehalase-like 1 (yeast) chr7 downstream 
Atoh7 atonal homolog 7 (Drosophila), Math5 chr10 promoter 
Atp1a3 ATPase, Na+/K+ transporting, alpha 3 polypeptide, Atpa-2 chr7 promoter 
Atp6v1d ATPase H+ transporting lysosomal V1 subunit D, lysosomal 34kDa, VATD, Vma8 chr12 inside 
AU041783 Afap1l2, actin filament associated protein 1-like 2 chr19 inside 
AW544981 Mouse E7.5 Extraembryonic  cDNA Library chr15 promoter 
Axin2 Axin2/axil/conductin chr11 promoter 
B230218O03 maybe related Homo sapiens neuroplastoma apoptosis-related RNA-binding protein (CUGBP2) chr2 promoter 
B4galnt2 beta-1,4-N-acetyl-galactosaminyl transferase 2  Dlb-1, Dlb1, Galgt2 chr11 inside 
Bapx1 NK3 homeobox 2  Bapx1, Nkx-3.2, Nkx3-2 chr5 promoter 
BC002017 phospholipid scramblase 1Plscr1 MmTRA1a, MmTRA1b, MuPLSCR2, NOR1, Tras1/2 chr9 Unknown 
BC017647 unknown chr11 inside 
BC019143 1300010F03Rik chr14 Unknown 
BC035295 Csnrp2 cysteine-serine-rich nuclear protein 2 chr15 promoter 
BC048651 LOC330277, NYD-SP18 chr6 promoter 
BC052496 Grap2,GRB2-related adaptor protein 2, Gads, GRAP-2, Grb2-related adaptor downstream of Sch, GRB2L, GrbX, Grf40, GRID, GrpL, Mona, P38  chr15 Unknown 
BC054059 SMAF1likely orthologue of H. sapiens small adipocyte factor 1 (SMAF1) chr2 inside 
BC072639 2010300C02Rik  chr1 unknown 
BC100404 Cpm, carboxypeptidase M chr10 unknown 
Bcl6 B-cell leukemia/lymphoma 6 Bcl5 chr16 promoter 
Blr1 burkitt lymphoma receptor 1 Blr1, CXCR-5, Gpcr6 chr9 promoter 
Bmp1 bone morphogenetic protein 1 chr14 inside 
Boc biregional cell adhesion molecule-related/down-regulated by oncogenes (Cdon) binding protein chr16 inside 
C030030A07Rik transmembrane protein 72 chr6 inside 
C1qtnf6 C1q and tumor necrosis factor related protein 6, CTRP6 chr15 inside 
C230095G01Rik unknown chr6 promoter 
C78339 unknown chr13 promoter 
C79407 DNA binding protein chr12 promoter 
Cables2 Cdk5 and Abl enzyme substrate 2 ik3-2  chr2 promoter 
Camk2a calcium/calmodulin-dependent protein kinase II alpha alpha-CaMKI chr18 inside 
Cant1 C  calcium activated nucleotidase 1, SCAN-1, Shapy, Apy1h chr11 promoter 
Capns1 calpain, small subunit 1, Capa4, Capn4 chr7 promoter 
Car10 CA-RP X chr11 inside 
Carhsp1 calcium regulated heat stable protein 1  chr16 promoter 
Cbln3 cerebellin 3 precursor protein  chr14 inside	  
Ccdc52 coiled-coil domain containing 52   chr16 inside	  
Ccdc85a coiled-coil domain containing 85A chr11 promoter 
Ccl1 chemokine (C-C motif) ligand 1, Scya1, Tca-3 chr11 inside 
Cd300e CD300e antigen Cd300le, Clm2, Trem5 chr11 promoter 
Cdc42ep5 CDC42 effector protein (Rho GTPase binding) 5, Borg3, CEP5 chr7 promoter 
Cdk9 cyclin-dependent kinase 9 (CDC2-related kinase) PITALRE chr2 inside 
Cebpa CCAAT/enhancer binding protein (C/EBP), alpha chr7 promoter 
Ces6 carboxylesterase 6 9130231C15Rik chr8 promoter 
Chn2 chimerin (chimaerin) 2, Rho GTPase-activating protein 3  chr6 promoter 
Chrm2 cholinergic receptor, muscarinic 2, cardiac AChR M2, M2 chr6 promoter 
Chrnb1 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) Achr-2, Acrb chr11 inside 
Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 GalNAc4ST-1 chr7 promoter 
Cit Citron, Cit-k, citron kinase, citron-N, CRIK, CRIK-SK chr5 inside 
Clnk cytokine-dependent hematopoietic cell l linker MIST D5Dmo5 chr5 inside 
Cml4 camello-like 4, Nat8 N-acetyltransferase 8 (GCN5-related, putative) chr6 promoter 
Cmtm2b CKLF-like MARVEL transmembrane domain containing 2B  chr8 inside 
Cnga3 cyclic nucleotide gated channel alpha 3 CNG3 chr1 promoter 
Cnn1 calponin 1 calponin h1, CN, CnnI chr9 promoter 
Coq10b coenzyme Q10 homolog B (S. cerevisiae) chr1 promoter 
Coq2 coenzyme Q2 homolog, prenyltransferase (yeast) chr5 promoter 
Cryba2 crystallin beta A2 chr1 inside	  
Crygn crystalline gamma N chr5 inside	  
Ctla4 cytotoxic T-lymphocyte-associated protein 4, Cd152, Ctla-4, Ly-56 chr1 promoter 
Ctnnb1 catenin (cadherin associated protein), beta 1 Catnb, Mesc chr9 promoter 
Ctrc chymotrypsin C (caldecrin) ELA4, Elastase iv chr4 inside 
Cugbp2 CUG triplet repeat, RNA binding protein 2, ETR-3, Napor-2 chr2 promoter 
Cygb cytoglobin, Staap chr11 promoter 
D030011O10Rik Dennd5b, DENN/MADD domain containing 5B  chr6 promoter 
D130058I21Rik Smtnl2 smoothelin-like 2 chr11 promoter 
D630039A03Rik unknown chr4 inside	  
Ddef1 development and differentiation enhancing Asap1 chr15 inside	  
Defb27 beta defensin 27,similar to beta defensin 123  predicted gene chr2 inside	  
Dhrs3 dehydrogenase/reductase (SDR family) member 3 chr4 inside	  
Diras2 DIRAS family, GTP-binding RAS-like 2 chr13 promoter 
Dkk1 dickkopf homolog 1 (Xenopus laevis) chr19 inside	  
Dlx5 distal-less homeobox 5 chr6 inside	  
Dnase1l3 deoxyribonuclease 1-like 3 chr14 divergent 
Dpp4 dipeptidylpeptidase 4, CD26, THAM chr2 promoter 
Dscr1l1 regulator of calcineurin 2,Csp2, Dscr1l1, MCIP2, ZAKI-4, new symbol Rcan2  chr17 promoter 
Dvl3 dishevelled 3, dsh homolog (Drosophila) chr16 inside	  
Dync1li1 dynein cytoplasmic 1 light intermediate chain 1, Dnclic1, LIC-1 chr9 inside	  
Dync2li1 dynein cytoplasmic 2 light intermediate chain 1, D2lic, LIC3, mD2LIC chr17 promoter 
E130309D14Rik unknown chr11 downstream 
E430004N04Rik Themis, thymocyte selection associated, Gasp, Tsepa chr10 promoter 
Ebf1 early B-cell factor 1 O/E-1, Olf-1, Olf1 chr11 inside 
Ebf2 early B-cell factor 2 D14Ggc1e, Mmot1, O/E-3 chr14 promoter 
EG574403 predicted gene, conserved chr11 promoter 
Elavl4 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D) chr4 promoter 
Elmod1 ELMO domain containing 1 chr9 promoter 
Epb4.1l4a erythrocyte protein band 4.1-like 4a /NBL4 chr18 inside 
Epb4.9 dematin, erythrocyte protein band 4.9 chr14 promoter 
Ephx1 epoxide hydrolase 1, microsomal Eph-1, Eph1 chr1 promoter 
Erg avian erythroblastosis virus E-26 (v-ets) oncogene related chr16 promoter 
Etv1 ets variant gene 1, ER81, Etsrp81 chr12 promoter 
Eva1 Mpzl2 myelin protein zero-like 2  chr9 inside 
Fabp1 fatty acid binding protein 1, liver Fabpl, L-FABP, MGC:13855 chr6 promoter 
Farp1 FERM, RhoGEF (Arhgef) and pleckstrin domain protein 1 (chondrocyte-derived) Cdep chr14 inside	  
Fbxl10 F-box and leucine-rich repeat protein 10 Cxxc2, Jhdm1b, KDM2B, JEMMA (Jumonji domain, EMSY-interactor, methyltransferase motif) chr5 inside	  
Fev FEV (ETS oncogene family) mPet-1, Pet1 Fifth Ewing Variant chr1 promoter 
Fgf8 Fibroblast growth factor 8, Aigf chr19 promoter 
Foxa2 Forkhead box A2 Hnf-3b, HNF3-beta, Hnf3b, HNF3beta, Tcf-3b, Tcf3b chr2 promoter 
Foxe1 Forkhead box E1 (thyroid transcription factor 2), Titf2 chr4 promoter 
Foxi2 Forkhead box I2  chr7 promoter 
Foxn1 Forkhead box N1, Hfh11, whn chr11 promoter 
Fut8 fucosyltransferase 8, alpha (1,6) fucosyltransferase chr12 promoter 
Fxyd6 FXYD domain-containing ion transport regulator 6, Php chr9 promoter 
Fyb FYN binding protein, ADAP, FYB-120/130 chr15 promoter 
Gabra1 gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 1 chr11 promoter 
Gabra2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 chr5 inside 
Gabrb2 gamma-aminobutyric acid ( GABA) A receptor, beta 2 chr11 promoter 
Gcnt2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme, IGnTA, IGnTB, IGnTC chr13 promoter 
Gdf5 growth differentiation factor 5 (cartilage-derived morphogenetic protein-1), CDMP-1 chr2 inside 
Gdpd4 glycerophosphodiester phosphodiesterase domain containing 4 chr7 promoter 
Gfra3 glial cell line derived neurotrophic factor family receptor alpha 3 chr18 promoter 
Glt8d1 glycosyltransferase 8 domain containing 1 chr14 inside 
Glt8d3 glycosyltransferase 8 domain containing 3  chr15 promoter 
Gm879 gene model 879 chr11 promoter 
Gnaq guanine nucleotide binding protein, alpha q polypeptide  Dsk1, Dsk10, G alpha q, Gq chr19 promoter 
Gnaz guanine nucleotide binding protein, alpha z subunit  Gz chr10 inside 
Gnb2l1 RACK1 receptor for activated kinase C1 chr11 promoter 
Gsg1 germ cell-specific gene 1 chr6 promoter 
Gstm7 glutathione S-transferase, mu 7, Cd203c, GSTm2 muscle chr3 inside 
H2afy2 H2A histone family, member Y2 macroH2A2 chr10 promoter 
Hcrtr1 hypocretin (orexin) receptor 1OX1R chr4 promoter 
Hdgfrp2 hepatoma-derived growth factor, related protein 2 HRP-2 chr17 INSIDE 
Hnrpl Hnrnpl heterogeneous nuclear ribonucleoprotein L, Hnrpl chr7 promoter 
Hnrpul1 heterogeneous nuclear ribonucleoprotein U-like 1, E1B-AP5 chr7 inside 
Hoxa13 homeo box A13 Hox-1.10 chr6 promoter 
Hoxa3 homeo box A3 chr6 divergent 
Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 17(beta)HSD type 3 chr13 inside	  
I830134H01Rik unknown chr19 inside	  
Ica1 islet cell autoantigen 169kDa, ICA69 chr6 inside	  
Id4 inhibitor of DNA binding 4  Idb4 chr13 promoter 
Igsf11 immunoglobulin superfamily, member 11 chr16 promoter 
Il1r1 interleukin 1 receptor, type i chr1 inside 
Il21 Interleukin-21 chr3 promoter	  
Il6 interleukin 6 chr5 promoter	  
Irx6 Iroquois related homeobox 6 (Drosophila) chr8 inside 
Junb Jun-B oncogene/AP-1 activator protein 1 chr8 divergent 
Jup junction plakoglobin, gamma-catenin, PG, plakoglobin chr11 promoter 
Kcnd3 potassium voltage-gated channel, member 3 potassium channel Kv4.3L chr3 inside 
Kcnn4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 IK1, mIKCa1, SK4 chr7 promoter	  
Kctd13 potassium channel tetramerisation domain containing 13, Poldip1 chr7 promoter	  
Kif23 kinesin family member 23, C87313, CHO1, Knsl5, MKLP-1, MKLP1 chr9 inside 
Krt16 keratin 16, K16, Krt1-16 chr11 promoter	  
Krt5 keratin 5, K5, Krt2-5, Tfip8 chr15 promoter	  
Krt8 Card2, cytokeratin 8, EndoA, K8, Krt-2.8, Krt2-8 chr15 promoter	  
Lama4 laminin, alpha 4 chr10 promoter	  
Lancl1 LanC (bacterial lantibiotic synthetase component C)-like 1, LanC-like protein 1, p40 chr1 promoter	  
Laptm5/E3 lysosomal-associated protein transmembrane 5 Retinoic acid-inducible E3 protein  chr4 promoter	  
Large like-glycosyltransferase BPFD#36, enr, fg, froggy chr8 promoter	  
Lctl lactase-like, KLPH, klotho gamma,Klotho/lactase-phlorizin hydrolase- related protein chr9 promoter	  
Leprotl1 leptin receptor overlapping transcript-like 1 chr8 divergent 
Lhfpl2 lipoma HMGIC fusion partner-like 2 chr13 promoter 
Lhx5/Lim2 LIM homeobox protein 5 chr5 inside 
Lif leukemia inhibitory factor chr11 promoter	  
Lifr leukemia inhibitory factor receptor, soluble differentiation-stimulating factor receptor chr15 promoter	  
Lmx1b LIM homeobox transcription factor 1 beta LMX1.2 chr2 inside 
Lphn3 latrophilin 3, LEC3, lectomedin 3 chr5 promoter	  
Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 Img, LIG-1 chr6 promoter	  
Lrrc4c leucine rich repeat containing 4C, netrin g1 ligand chr2 promoter	  
Map2k5 mitogen activated protein kinase kinase 5 MAPK/ERK kinase 5, Mapkk5, MEK5 chr9 promoter	  
Map3k11 mitogen activated protein kinase kinase kinase 11 2610017K16Rik, Mlk3, PTK1 chr19 inside 
Map3k2 mitogen activated protein kinase kinase kinase 2, MEK kinase 2, Mekk2 chr18 promoter 
Map3k3 mitogen activated protein kinase kinase kinase 3 MAPKKK3, Mekk3 chr11 promoter	  
Mapre2/EB1/EB2 microtubule-associated protein, RP/EB family, member 2 C820009F03Rik, EB2, RP1 chr18 promoter	  
Marcks myristoylated alanine rich protein kinase C substrate Macs chr10 inside 
Marcksl1 MARCKS-like 1, F52, MacMARCKS, Macs-2, Macs-3, Macs2, Macs3, Mlp, Mrp chr4 promoter 
Mbp myelin basic protein golli-mbp, Hmbpr chr18 inside	  
Med4 mediator of RNA polymerase II transcription, subunit 4 homolog (yeast), DRIP36, HSPC126, p36 TRAP/SMCC/PC2 subunit, TRAP36, Vdrip chr14 inside	  
Meis1 Meis homeobox 1 chr11 promoter 
MGC117608 possible psuedogene similar to mitochondrial protein L32 chr6 inside 
Mical1 microtubule associated monoxygenase, calponin and LIM domain containing, Nical chr10 promoter	  
Morn2 MORN repeat containing 2 Mopt chr17 promoter	  
Mov10 Moloney leukemia virus 10 chr3 promoter	  
Mrpl14 mitochondrial ribosomal protein L14, MRP-L32, Rpml32 chr17 inside 
Mrps23 mitochondrial ribosomal protein S23, Rpms23 chr11 promoter 
Msgn1 mesogenin 1 chr12 downstream 
Msi2 Musashi homolog 2 (Drosophila) msi2h, Musashi 2 chr11 promoter 
Mttp microsomal triglyceride transfer protein chr3 inside 
Nat3 N-acetyltransferase 3 chr8 promoter	  
Ndn necdin Peg6 chr7 promoter	  
Nedd4l neural precursor cell expressed, developmentally down-regulated gene 4-like 1, Nedd4b chr18 inside	  
Neu3 neuraminidase 3 ganglioside sialidase, membrane sialidase chr7 inside	  
Ngb neuroglobin chr12 inside	  
Nhlrc1 NHL repeat containing 1, EPM2B, Malin chr13 promoter 
Nhp2l1 NHP2 non-histone chromosome protein 2-like 1(S. cerevisiae), FA-1, Fertilization antigen-1, Fta1, Ssfa1 chr15 promoter 
Nkx2-6 NK2 transcription factor related, locus 6 tinman, Tix chr14 inside 
Nlrp4b NLR family, pyrin domain containing 4B  chr7 promoter 
Npffr2 neuropeptide FF receptor 2 Gpr74, NPFF2 chr5 promoter 
Nsl1 NSL1, MIND kinetochore complex component, homolog (S. cerevisiae)  chr1 promoter	  
Nudt16 nudix (nucleoside diphosphate linked moiety X)-type motif 16 chr9 promoter	  
Oas1f 2'-5' oligoadenylate synthetase 1F chr5 inside 
Olfr1026 olfactory receptor 1026 GA_x6K02T2Q125-47402610-47403533, MOR196-4 chr2 promoter	  
Olfr1388 olfactory receptor 1388 GA_x6K02T2QP88-5991012-5990077, MOR256-28 chr11 promoter	  
Olfr209 olfactory receptor 209 GA_x54KRFPKG5P-55590495-55589578, MOR182-6  chr16 promoter	  
Olfr473 olfactory receptor 473 GA_x6K02T2PBJ9-10262759-10263691, MOR204-4 chr7 promoter	  
Olfr702 olfactory receptor 702 GA_x6K02T2PBJ9-9202245-9201289, MOR260-4 chr7 promoter	  
Olfr71 olfactory receptor 71 GA_x6K02T2N78B-16230286-16231224, mOR17, MOR262-4 chr4 promoter	  
Olfr907 olfactory receptor 907 GA_x6K02T2PVTD-32204729-32205661, MOR165-5 chr9 promoter	  
Olfr934 olfactory receptor 934 GA_x6K02T2PVTD-32678895-32677963, MOR224-6 chr9 promoter	  
Olfr95 olfactory receptor 95 GA_x6K02T2PSCP-1651760-1650822, MOR263-6 chr17 downstream 
Otop2 otopetrin 2 chr11 inside 
Ovgp1 oviductal glycoprotein 1, 120kDa, Chit5, MOGP, muc 9,  OGP, Ovgp1, oviductin chr3 promoter	  
Oxr1 oxidation resistance, C7, C7B chr15 promoter	  
Pabpn1 poly(A) binding protein, nuclear 1PAB2, Pabp3, poly(A) binding protein II chr14 promoter	  
Palmd palmdelphin, PALML chr3 inside 
Park7 Parkinson disease (autosomal recessive, early onset) 7, DJ-1, Dj1 chr4 divergent 
Parvg parvin, gamma chr15 promoter 
Pax2 paired box gene 2 chr19 promoter 
Pax3 paired box gene 3 chr1 inside	  
Pax5 paired box gene 5, B cell-specific activator protein EBB-1 BSAP chr4 inside	  
Pcdha7 protocadherin alpha 7 Crnr4 chr18 promoter 
Pck2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) chr14 promoter 
Pcolce2 procollagen C-endopeptidase enhancer 2, Pcpe2 chr9 promoter 
Pde2a phosphodiesterase 2A, cGMP-stimulated chr7 promoter 
Pde7b phosphodiesterase 7B chr10 inside	  
Pdpk1 3-phosphoinositide dependent protein kinase-1 Pdk1, Pkb kinase chr17 inside	  
Pdss1 prenyl (solanesyl) diphosphate synthase, subunit 1, mSPS1, Tprt chr2 promoter 
Pdx1 pancreatic and duodenal homeobox 1,IDX-1, IPF-1, Ipf1, Mody4, pdx-1, STF-1 chr5 promoter 
Pelp1 proline, glutamic acid and leucine rich protein 1 chr11 promoter 
Pfn4 profilin family, member 4 chr12 inside 
Pigc phosphatidylinositol glycan anchor biosynthesis, class C chr1 promoter 
Pigk phosphatidylinositol glycan anchor biosynthesis, class K  chr3 promoter 
Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1, RDGB-BETA, RDGBB1 chr11 divergent 
Pogk pogo transposable element with KRAB domain, BASS2 chr1 promoter 
Pold3 polymerase (DNA-directed), delta 3, accessory subunit, C85233, GC12, P66, P68 chr7 promoter 
Ppargc1a peroxisome proliferative activated receptor, gamma, coactivator 1 alpha, Pgc-1alpha, Pgc-1alphaa, Pgc1, Pgco1, PPAR Gamma Coactivator-1 chr5 promoter 
Ppargc1b peroxisome proliferative activated receptor, gamma coactivator 1 beta, Perc, PGC-1beta/ERRL1 chr18 inside 
Ppm1m protein phosphatase 1M chr9 divergent 
Ppp2r2b protein phosphatase 2 (formerly 2A) regulatory subunit B (PR 52), beta isoform PP2A-PR55B, PR55-BETA, SCA12 chr18 promoter 
Pqlc3  PQ loop repeat containing chr12 promoter 
Prcp prolylcarboxypeptidase (angiotensinase C) chr7 promoter 
Prkag3 protein kinase, AMP-activated, gamma 3 non-catatlytic subunit, AMPKg3L, AMPKg3S chr1 promoter 
Prlpa prolactin family 4, subfamily a, member 1 PLP-A, Prlpa chr13 promoter 
Prune prune homolog (Drosophila) Prune-M1 chr3 inside 
Psap prosaposin SGP-1 chr10 inside 
Psmd2 proteasome (prosome, macropain) 26S subunit, non-ATPase, TEG-190, Tex190 chr16 promoter 
Ptgir prostaglandin i receptor (ip) IP, prostacyclin receptor chr7 promoter 
Ptk2b 
 PTK2 protein tyrosine kinase 2 beta, CAKbeta, calcium-dependent tyrosine kinase, cellular 
adhesion kinase beta, proline-rich tyrosine kinase 2, PYK2, Raftk, related adhesion focal tyrosine 
kinase 
chr14 inside 
Ptn Pleiotrophin, Osf1, heparin-binding growth factor 8, HBGF-8, HB-GAM, heparin-binding growth-associated molecule chr6 inside 
Pyy peptide YY chr11 promoter 
Qpct glutaminyl-peptide cyclotransferase (glutaminyl cyclase) chr17 promoter 
R74862 expressed sequence R74862 chr7 promoter 
Rab11fip4 RAB11 family interacting protein 4 (class II), RAB11-FIP4 chr11 inside	  
Rab15 RAB15, member RAS oncogene family chr12 inside	  
Rab17 RAB17, member RAS oncogene family chr1 promoter 
Rab5b RAB5B, member RAS oncogene family chr10 promoter 
Rab6b RAB6B, member RAS oncogene family chr9 promoter 
Ralgps2 Ral GEF with PH domain and SH3 binding motif  chr1 inside	  
Rbed1 RNA binding motif and ELMO domain 1, ELMOD3, RBM29 chr6 inside	  
Rbp1 retinol binding protein 1, cellular,  Crbp, CRBPI chr9 promoter 
Rgs2 regulator of G-protein signaling 2 GOS8 chr1 inside 
Rhou Ras homolog gene family, member U, Arhu, CDC42L1, mG28K, WRCH1 chr8 promoter 
Ripk5 receptor interacting protein kinase 5 dusty protein kinase chr1 inside 
Rnf207 ring finger protein 207  chr4 divergent 
Rnf26 ring finger protein 26 chr9 promoter 
Robo4 roundabout homolog 4 (Drosophila), Magic roundabout chr9 first intron 
Rpl36 ribosomal protein L36 chr17 inside 
Rsl1 regulator of sex limited protein 1 rslcan-9 chr13 promoter 
Rttn rotatin (no turning) chr18 promoter 
Rufy3 RUN and FYVE domain containing 3, mKIAA0871, Rpipx chr5 inside 
Sart2 dermatan sulfate epimerase new symbol Dse chr10 promoter 
Schip1 schwannomin interacting protein 1 merlin chr3 promoter 
Scml4 sex comb on midleg-like 4 (Drosophila) chr10 promoter 
Scrg1 scrapie responsive gene 1 chr8 inside 
Sec22a SEC22 vesicle trafficking protein-like A (S. cerevisiae), Sec22l2 chr16 promoter 
Sema4a sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A, Semab, SemB chr3 promoter 
Serpinb1c serine (or cysteine) peptidase inhibitor, clade B, member 1c EIC, ovalbumin chr13 promoter 
Serpinb6c serine (or cysteine) peptidase inhibitor, clade B, member 6c ovalbumin, Spi3C, SPIC chr13 promoter 
Sertad2 SERTA domain containing 2, SEI-2, Sei2, Trip-Br2 chr11 promoter 
Sh3px3 SH3 and PX domain containing 3  sorting nexin chr9 divergent 
Slc16a6 solute carrier family 16 (monocarboxylic acid transporters), member 6 chr11 promoter 
Slc17a5 solute carrier family 17 (anion/sugar transporter), member 5  chr9 promoter 
Slc25a29 solute carrier family 25 (mitochondrial carrier, palmitoylcarnitine transporter) 29   chr12 promoter 
Slc25a37 solute carrier family 25, member 37,  Frascati, Mfrn, mitoferrin, Mscp chr14 promoter 
Slc30a7 solute carrier family 30 (zinc transporter), member 7, ZnT-7, ZnT7 chr3 inside	  
Slc37a2 solute carrier family 37 (glycerol-3-phosphate transporter), member cI-2, G3PP, Slc37a1  chr9 inside	  
Slc41a3 solute carrier family 41, member 3, SLC41A1-L2 chr6 promoter 
Slc5a3 solute carrier family 5 (inositol transporters), member 3 Smit1 chr16 promoter 
Slc5a6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6 chr5 inside 
Slc5a8 solute carrier family 5 (iodide transporter), member 8 MGC:19357, SMCT chr10 promoter 
Slu7 SLU7 splicing factor homolog (S. cerevisiae) chr11 inside 
Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 brm, Snf2l2 chr19 promoter 
Snai2 snail homolog 2 (Drosophila), Slug, Slugh, Snail2 chr16 inside 
Snx26 sorting nexin 26 Tcgap chr7 promoter 
Sppl3 signal peptide peptidase 3, Usmg3 chr5 promoter 
Srrp serine-arginine repressor protein chr4 promoter 
Sstr3 somatostatin receptor 3, Smstr3, sst3 chr15 inside 
St6galnac1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1, Siat7a, ST6GalNAc I chr11 promoter 
St8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 3 Siat8c, ST8SiaIII chr18 inside 
Stk38 serine/threonine kinase 38, Ndr1 chr17 promoter 
Stmn1 stathmin 1, Lag, Lap18, leukemia associated phosphoprotein p18, metablastin, oncoprotein 18, op18, p18, p19, pig, PP17, PP18, PR22, prosolin, SMN chr4 inside 
Stra13 stimulated by retinoic acid 13 chr11 downstream 
Stra6 stimulated by retinoic acid gene 6 chr9 promoter 
Stxbp1 syntaxin binding protein 1, Munc-18a, N-sec1, Rb-sec1, Sxtbp1, Unc18h chr2 inside	  
Sumo2 SMT3 suppressor of mif two 3 homolog 2 (yeast), Smt3b, Smt3h2, SUMO-2 chr11 inside	  
Syk spleen tyrosine kinase chr13 promoter 
Synpr synaptoporin  chr14 inside	  
Syt1 synaptotagmin I chr10 inside	  
Tbc1d21 TBC1 domain family, member 21 chr9 promoter 
Tbc1d9b TBC1 domain family, member 9B  chr11 inside 
Tbl1xr1 transducin (beta)-like 1X-linked receptor 1, C21, DC42, Ira1, TBLR1 chr3 promoter 
Tcf19 transcription factor 19  chr17 inside	  
Tcl1b2 T-cell leukemia/lymphoma 1B, 2 chr12 inside	  
Tfg Trk-fused gene chr16 promoter 
Tgfa Transforming growth factor alpha chr6 promoter 
Tiprl TIP41, TOR signalling pathway regulator-like (S. cerevisiae)  chr1 promoter 
Tmbim4 transmembrane BAX inhibitor motif containing 4 chr10 inside	  
Tmcc2 transmembrane and coiled-coil domains 2 chr1 inside	  
Tmem10 transmembrane protein10, Opalin, oligodendrocytic myelin paranodal inner loop protein chr19 promoter 
Tmprss11e transmembrane protease, serine 11e DESC1 chr5 inside 
Tnfrsf19 RELT tumor necrosis factor receptor chr7 inside 
Tnni2 troponin I, skeletal, fast 2 chr7 promoter 
Toe1 target of EGR1, member 1 (nuclear) chr4 divergent 
Tox thymus high mobility group box protein  chr4 inside 
Trim28 tripartite motif protein 28, KAP-1, KRIP-1, Tif1b chr7 promoter 
Trpd52l3 tumor protein D52-like 3  chr19 promoter 
Trpm6 transient receptor potential cation channel, subfamily M, member 6 CHAK2 chr19 promoter 
Tspan11 tetraspanin 11  chr6 promoter 
Tspan31 tetraspanin 31, Sas, Tspan31 chr10 divergent 
Ttll12 tubulin tyrosine ligase-like family, member 12 chr15 promoter 
Ttll6 tubulin tyrosine ligase-like family, member 6 chr11 promoter 
Ubxd3 UBX domain containing 3  chr4 promoter 
Uqcrh ubiquinol-cytochrome c reductase hinge protein chr4 inside 
Usp18 ubiquitin specific peptidase 18   UBP43 chr6 promoter 
Usp25 ubiquitin specific peptidase 25 chr16 promoter 
Utp18 UTP18, small subunit (SSU) processome component, homolog (yeast), Wdr50 chr11 inside 
V1rd6 vomeronasal 1 receptor, D6 V3R6 chr7 promoter 
Vangl1 vang-like 1(van gogh, Drosophila), KITENIN, Lpp2, mStbm, stbm 2 chr3 inside 
Vax1 ventral anterior homeobox 1 chr19 promoter 
Veph1 ventricular zone expressed PH domain homolog 1 (zebrafish), Veph chr3 promoter 
Vil2 villin 2  cytovillin, ezrin, p81  NB ezrin is new symbol chr17 promoter 
Vps25 vacuolar protein sorting 25 (yeast) chr11 promoter 
Wasf1 WASP family 1,Scar, WAVE, WAVE-1 chr10 promoter 
Wdr33 WD repeat domain 33  chr18 promoter 
Wnt3a wingless-related MMTV integration site 3A chr11 inside 
Wt1 wilms tumor  (Nephroblastoma) homolog chr2 promoter 
Xlkd1 lymphatic vessel endothelial hyaluronan receptor 1, lymphatic vessel endothelial HA receptor-1, Lyve-1 chr7 inside 
Xpo6 exportin 6, Ranbp20 chr7 inside 
Zap70 zeta-chain (TCR) associated protein kinase Srk, TZK, ZAP-70 chr1 promoter 
Zbtb41 zinc finger and BTB domain containing 41 homolog  chr1 promoter 
Zdhhc17 zinc finger, DHHC domain containing 17, Hip14 chr10 inside 
Zfp206 zinc finger and SCAN domain containing 10 Zfp206, Zscan10 chr17 inside 
Zfp27 zinc finger protein 27 mkr-4 mszf76 chr7 promoter 
Zfp276 zinc finger protein (C2H2 type) 276  chr8 promoter 
Zic2 Zic finger protein of the cerebellum 2, GENA 29, Ku, odd-paired homolog chr14 inside 
Zic5 zinc finger protein of the cerebellum 5, odd-paired related, Opr chr14 divergent 
Zw10 ZW10 homolog (Drosophila), centromere/kinetochore protein MmZw10 chr9 promoter 
Hoxc8 Homeo box C8 chr15 promoter 
Lef1 Lymphoid Enhancer Binding Factor 1 chr3 inside 
Sall1 Spalt-like transcription factor 1 Msal-3 chr8 promoter 
Sox1 SRY-box containing gene 1 chr8 promoter 
 
Supplementary Table S2 
 
Members of Key Signaling Pathways 
 
Target Gene 
 Key pathway Role 
Non-canonical & 
additional 
pathways  
Axin2/conductin Wnt signaling pathway 
Inhibitor of wnt signaling, 
associates 
APC/βcatenin/GSKβ3/DVL 
Crosstalk TGFβ 
pathway (Smad 3) 
Crosstalk MEKK1 
SAPK stress 
pathway 
Ctnnb1/β catenin Wnt signaling pathway LEF/TCF dependent transcriptional activation 
A Component of 
adherens junctions 
Dkk1/dickkopf 
homolog 1 Wnt signaling pathway 
Antagonist wnt signaling, anterior 
side embryo  
Dvl3/dishevelled 3 Wnt signaling pathway 
Dvl1/3 <<< Dvl2 pool  
Signaling canonical pathway 
sensitive to Dvl3 levels 
JNK signaling    
PCP pathway 
Nodal pathway 
Jup/Ctnng 
plakoglobin/γ-catenin 
Wnt signaling pathway 
Associates APC and axin 
Possible TCF/LEF transcriptional 
activity 
A Component of 
adherens junctions 
and desmosomal 
plaques 
Ppp2r2b Wnt signaling pathway Modulation of PP2A activity Tight junctions  
Wnt3a  Wnt signaling pathway AP elongation, somite, tailbud formation 
JNK signaling PCP 
pathway 
Map2k5/MEK5 MapK signaling pathway In vivo activator of ERK5  
Map3k11/PTK1/MLK3  MapK signaling pathway Positive regulator JNK signaling 
NF-κβ signaling 
JNK pathway TNF 
signaling 
Map3k2/MEKK2  MapK signaling pathway 
Activates MEK5 
Required for T cell signaling 
GnRH signaling 
pathway 
Map3k3/MEKK3 MapK signaling pathway 
Activates MEK5 cardiovascular 
development 
GnRH signaling 
pathway 
Cdc42ep5/CEP5 c-Jun N-Terminal Kinase (JNK) pathway Regulation of cell shape Rho GTPase 
Junb JNK pathway Regulates erythroid cell survival, proliferation, and differentiation 
Smad interacting 
protein 
Syk JNK pathway Cell-cell adhesion via E cadherin & α catenin 
NF-κβ signaling 
B cell Receptor 
Signaling 
T cell Receptor 
Signaling 
Ras/MAPK 
signaling 
BMP1 TGFβ signaling pathway Tolloid related  
Fut 8 TGFβ signaling pathway Required for VEGFR2 expression 
N-glycan 
biosynthesis 
Keratin sulphate 
biosynthesis 
Integrin mediated 
signaling 
GDF5 TGFβ signaling Embryonic limb morphogenesis Cytokine-cytokine 
pathway receptor interaction 
BOC Hedgehog Signaling pathway 
Robo related, sonic hedgehog 
receptor 
Required myogenesis 
 
ERG Fgf signaling Regulation angiogenesis   
 Receptor signaling 
B cell receptor 
signaling 
FGF8 Fgf signaling L-R determinant, competence to respond to nodal signals 
actin cytoskeleton 
signaling 
Adam 19  Integrin signaling Heart development & dendritic cell marker  
Adam 24 Testase 1 Integrin signaling 
Protease implicated in sperm 
function during epididymal 
maturation or fertilization 
 
Rhou / WRCH1 Integrin signaling 
Wnt-1 responsive Cdc42 hom 
stimulates cells to reenter the cell 
cycle 
 
Akap10 (D-AKAP2) G-protein Coupled Receptor signaling 
Localisation camp dep PKA , 
implicated heart rhythm regulation 
AMP mediated 
signaling 
Arhgef4 G-protein Coupled Receptor signaling cell migration & cell-cell adhesion 
Rho guanine 
nucleotide exchange 
factor 
Camk2a G-protein Coupled Receptor signaling  
B cell receptor 
signaling 
Gnaq  G-protein Coupled Receptor signaling 
Vascular smooth muscle 
contraction 
cell morphogenesis 
GnRH signaling 
pathway 
Wnt pathway  
Gnaz G-protein Coupled Receptor signaling   
Gnb2l1/Rack1 G-protein Coupled Receptor signaling 
Localized to proliferating 
endothelial cells  
Ptk2b, Pyk2, Raftk G-protein Coupled Receptor signaling 
Cell adhesion 
Activation EGFR 
GnRH signaling 
pathway 
Calcium signaling 
pathway 
Lphn3/LEC3 
 
G-protein Coupled 
Receptor signaling Ca
2+independent receptor neuropeptide signaling pathway 
Rgs2 G-protein Coupled Receptor signaling 
Negative regulator of G coupled 
receptor signalling  
Sstr3 G-protein Coupled Receptor signaling 
May activate G-proteins at tight 
junctions 
Neuroactive ligand-
receptor interaction 
Bcl6 B cell Receptor signaling 
Repressor of transcription, 
memory B cell development  
Chn2 T cell Receptor signaling Proliferation & migration SMC 
Rac-specific GTPase 
activating proteins 
Dpp4/CD26 T cell Receptor signaling   
Zap70  T cell Receptor signaling 
Like syk non receptor PK. 
Associates TCR zeta chain NK-κβ signaling 
IL6 Cytokine/Jak/STAT pathway 
First cytokine developing 
circulation osteoblasts to 
osteoclasts 
 
Lif Cytokine/Jak/STAT pathway 
Down regulated on differentiation 
cell morphogenesis 
Gastrulation is 
inhibited in mouse 
embryos 
overexpressing LIF 
Lifr Cytokine/Jak/STAT pathway Down regulated on differentiation  
Acly Insulin Receptor signaling 
Synthesis Acetyl CoA 
May have additional tissue specific 
function development 
TCA cycle CO2 
fixation 
TGFα ErbB/HER signaling Angiogenesis, cell proliferation  
Pck2/PEPCK PPAR signaling pathway  
Adipocytokine 
signaling pathway 
Gcnt2 
Sphingolipid 
Metabolism & N-
Glycan Metabolism 
Branching enzyme responsible 
conversion fetal to adult blood 
antigens 
 
Neu3 
Sphingolipid 
Metabolism & N-
Glycan Metabolism 
skeletal muscle differentiation 
Suppression of apoptosis 
Mobilises membrane ruffles 
 
St8sia3 
Sphingolipid 
Metabolism & N-
Glycan Metabolism 
Fetal blood formation & neuronal 
development  
Hsd17b3 Androgen & Estrogen Metabolism Lipid biosynthesis   
St6galnac1 O-glycan Biosysnthesis Decreases cell adhesion & increases cell migration  
Pde2aPdpk1  Purine Metabolism Phosphodiesterase activity Cell communication  
Pde7b Purine Metabolism Phosphodiesterase activity  
Pold3 Purine  & Pyrimidine Metabolism 
DNA replication & repair subunit 
DNA polδ  
Prune Purine Metabolism Pyrophosphatase activity  
Nedd4l  Protein Ubiquitination pathway ubiquitin protein-ligase activity  
Sumo2 Protein Ubiquitination pathway Protein modification NK-κβ signaling 
Usp18 Protein Ubiquitination pathway Deubiquitinating enzyme  
Usp25 Protein Ubiquitination pathway Deubiquitinating enzyme  
Appbp1 NEDD8 conjugation pathway Neddylation 
Apoptosis and cell 
cycle progression 
Ephx1 
NFR2 Mediated 
Oxidative Stress 
Response 
Protective enzyme  
Gstm7  
NFR2 Mediated 
Oxidative Stress 
Response 
 Glutathione metabolism 
Rab5b Clathrin & Calveolar Mediated Endocytosis Establishment of localization 
small GTPase 
mediated signal 
transduction 
Abcc2Mrp2 RXR Activation Membrane transport multidrug resistance ABC Transport 
Robo4 
Src Family Kinase 
Activation 
 
Vascular -specific inhibits 
endothelial migration Slit-Robo signaling 
Cit Protein serine/threonine kinase activity 
Tissue specific neural tube 
regulator of cytokinesis 
Rho interacting 
kinase 
Dscr1l1 Rcan2 Calcium mediated signaling Regulation of calcineurin 
calcineurin-NFAT 
pathway. 
 
Supplementary Table S3 
Germ Cell Associated Targets 
Gene Alt. Symbol  Name 
1700012A16Rik MGI1919086  
1700029I08Rik AV259599, Actl9 Actin-like 9 
Ooep 2410146L05Rik, Floped, Moep19 Ooep, oocyte expressed protein homolog (dog) 
4930412F15Rik MGI2441678  
4930441O14Rik   
4930504O13Rik   
4930578I06Rik AI429111  
Adam5 tMDCII A Disintegrin and metallopeptidase domain 5 
Adam19 Mltnb A Disintegrin and metallopeptidase domain 19 (meltrin beta) 
Adam24 Dtgn5 A Disintegrin and metallopeptidase domain 24 (testase 1) 
Asap1 Ddef1 Development and differentiation enhancing Asap1 ArfGAP with SH domain, ankyrin repeat and PH domain 1 
Cmtm2b Cklfsf2b  1700013O04Rik 
CKLF-like MARVEL transmembrane domain containing 2B 
homolog of human CKLFSF2 
Fam196b Gm6041 EG574403 
Predicted gene, conserved 
Family with sequence similarity 196, member B 
Gsg1  Germ cell-specific gene 1, germ cell associated 1 
Hsd17b3 17(beta) HSD type 3 Hydroxysteroid (17-beta) dehydrogenase 3 
Id4 Idb4 Inhibitor of DNA binding 4, bHLHb27 
Morn2 Mopt MORN repeat containing 2 Mopt 
Pfn4 2900024P18Rik Profilin family, member 4 testis specific 
Ttll6 633044416Rik tubulin tyrosine ligase-like family, member 6 
Wdr33 WDC146 WD repeat domain 33, 1110001N06Rik, 2310011G05Rik, 2810021O11Rik, 8430413N20Rik 
Wt1 D630046I16Rik Wilms tumor  (Nephroblastoma) homolog 
Zfp206 Zscan10 zinc finger and SCAN domain containing 10 	  	  
Supplementary Table S4 
Transcription Factors Bound 
Gene Alt. Symbol  Name 
Anxa7 Anx7 Annexin A7, synexin 
Arid1a BAF250a AT rich interactive domain 1A (Swi1 like) 
Atoh7 Math5 Atonal homolog 7 (Drosophila) 
Bapx1 Nkx-3.2 NK3 homeobox 2 
Bcl6 Bcl5 B-cell leukemia/lymphoma 6 
C79407  DNA binding protein 
Cdk9 PITALRE Cyclin-dependent kinase 9 (CDC2-related kinase) 
Cebpa  CCAAT/enhancer binding protein (C/EBP), alpha 
Ctnnb1 Catnb; Mesc Catenin (cadherin associated protein), beta 1 
Ddef1 Asap1 Development and differentiation enhancing 
Dlx5  Distal-less homeobox 5 
Ebf1 O/E-1, Olf1 Early B-cell factor 1 
Ebf2 D14Ggc1e, Mmot1, O/E-
3 
Early B-cell factor 2 
Erg  Avian erythroblastosis virus E-26 (v-ets) oncogene related 
Etv1 ER81, Etsrp81 Ets variant gene 1 
Fbxl10 Jhdm1b, JEMMA F-box and leucine-rich repeat protein 10, Jumonji domain, EMSY-
interactor, methyltransferase motif 
Fev mPet-1, Pet1  FEV (ETS oncogene family), Fifth Ewing Variant 
Foxa2 HNF3beta, Tcf3b Forkhead box A2 
Foxe1 Titf2 Forkhead box E1 (thyroid transcription factor 2) 
Foxi2 B130055A05Rik Forkhead box I2 
Foxn1 Hfh11, whn Forkhead box N1 
Hoxa13 Hox-1.10 Homeo box A13 
Hoxa3**  Homeo box A3 
Irx6  Iroquois related homeobox 6 (Drosophila) 
Jun B AP-1  Jun-B oncogene/AP-1 activator protein 1 
Lhx5 Lim2 LIM homeobox protein 5 
Lmx1b LMX1.2 LIM homeobox transcription factor 1 beta 
Meis1 C530044H18Rik Meis homeobox 1 
Msgn1  Mesogenin 1 
Nkx2-6 Tix NK2 transcription factor related, locus 6 Tinman 
Pax 2  Paired box gene 2 
Pax 3  Paired box gene 3 
Pax 5 EBB-1 Paired box gene 5, B cell-specific activator protein 
Pdx1 IDX-1, Ipf1, Mody4, 
STF-1 
Pancreatic and duodenal homeobox 1 
Ppargc1a Pgc-1alpha, Pgc1, 
Pgco1 
Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha 
Ppargc1b ERRL1, PGC1 beta Peroxisome proliferative activated receptor, gamma, coactivator 1 beta 
Snai2 Slug, Snail2 Snail homolog 2 (Drosophila) 
Snx26 Tcgap Sorting nexin 26 
Stra13  Stimulated by retinoic acid 13 
Stra6  Stimulated by retinoic acid gene 6 
Tcf19 5730403J10Rik Transcription factor 19 
Tfg Trk-fused gene Trk-fused gene 
Tox 1700007F02Rik Thymus high mobility group box protein 
Trim28 KAP-1, KRIP-1 Tripartite motif protein 28 
Usp18 UBP43 Ubiquitin specific peptidase 18 
Usp25  Ubiquitin specific peptidase 25 
Vax1  Ventral anterior homeobox 1 
Wt1 D630046I19Rik Wilms tumor (Nephroblastoma) homolog 
Zbt41 8430415N23Rik 
9830132G07Rik 
Zinc finger and BTB domain containing 41 homolog 
Zfp206 Zscan10 Zinc finger and SCAN domain containing 10 Zfp206 
Zfp27 mkr-4 mszf76 Zinc finger protein 27 
Zfp276 D8Ertd370e, 
D8Ertd377e 
Zinc finger protein (C2H2 type) 276 
zic2 GENA 29, Ku Zinc finger protein of the cerebellum 2 odd-paired homolog 
zic5 Opr Zinc finger protein of the cerebellum 5 odd-paired related 
** Agilent software miss-called HoxA2 as target, binding peak in 5’UTR HoxA3 
 
Supplementary Table S5 
List of genes with AC repeats (with at least 8 nucleotides), their peak coordinates and 
sequence conservation analysis (presence of at least 8 nucleotides) in other species 
Gene Peak Coordinates Conservation 
1700029I08Rik chr17:33034104-33034403 R 
1700029I08Rik chr17:33034240-33034539 R 
4732495E13Rik chr15:79229514-79229813 R 
4930404H21Rik chr7:133438288-133438587 R 
4930556P03Rik chr15:99303073-99303372 - 
AA407270 chr9:71391930-71392229 H 
AA407270 chr9:71391930-71392229 H 
Abcc2 chr19:43832060-43833309 R 
Adar chr3:89817795-89818142 R 
Ankrd13d chr19:4271423-4271722 - 
Aqp11 chr7:97614984-97615283 - 
Atp6v1d chr12:79779006-79779305 R 
BC035295 chr15:100324504-100324803 R 
BC048651 chr6:29268348-29268647 R 
BC052496 chr15:80395457-80395824 - 
Bcl6 chr16:23906124-23906653 R 
Boc chr16:44476590-44477179 R, H 
Car10 chr11:92916538-92916837 R, H 
Carhsp1 chr16:8591255-8591554 - 
Ccdc85a chr11:28484974-28485273 - 
Cebpa chr7:34824106-34824552 R 
Chn2 chr6:54197731-54198030 R 
Chrnb1 chr11:69610020-69610319 - 
Cit chr5:116227765-116228064 - 
Cit chr5:116227898-116228197 - 
Cml4 chr6:85798316-85798615 - 
Cnga3 chr1:37158481-37158780 R 
Cnn1 chr9:21847791-21848090 R 
Coq2 chr5:100918565-100918864 - 
Crygn chr5:24265622-24265921 - 
D130058I21Rik chr11:72232485-72232784 R 
Dkk1 chr19:30614182-30615042 - 
Dpp4 chr2:62213205-62213504 R 
Dvl3 chr16:20431495-20431777 R 
Ebf2 chr14:66183281-66183930 R 
Etv1 chr12:39287680-39288047 R 
Fabp1 chr6:71128736-71129035 - 
Fev chr1:74824484-74824783 R, H 
Fgf8 chr19:45798051-45798373 R 
Foxa2 chr2:147741739-147742038 - 
Foxe1 chr4:46361799-46362327 R 
Fyb chr15:6524500-6524799 R 
Gdf5 chr2:155634454-155634753 H 
Hcrtr1 chr4:129642547-129643326 R, H 
Hnrpul1 chr7:25461007-25461306 - 
Hoxa13 chr6:52190959-52191258 R 
Hoxa2 chr6:52102665-52103432 R, H 
Id4 chr13:48270971-48271270 - 
Junb chr8:87873059-87873358 R, H 
Kcnn4 chr7:24077403-24077702 R 
Lama4 chr10:38656104-38656934 R 
Lhfpl2 chr13:95155518-95155817 - 
Lhx5/Lim2 chr5:120694575-120694874 R 
Map2k5 chr9:63180895-63181194 R 
Mapre2 chr18:23942472-23942710 - 
Mbp chr18:82610668-82610967 R 
Meis1 chr11:18922898-18923197 H 
MGC117608 chr6:12058209-12058508 - 
Morn2 chr17:80196589-80196888 - 
Mov10 chr3:104946714-104947013 - 
Mrpl14 chr17:45150894-45151193 R 
Mttp chr3:138067297-138067596 R 
Nat3 chr8:70450322-70450621 R 
Nlrp4b chr7:9561454-9561753 R 
Npffr2 chr5:90600955-90601254 R 
Oas1f chr5:121109912-121110211 R 
Olfr473 chr7:107719324-107719623 R 
Olfr71 chr4:43729710-43730009 - 
Olfr934 chr9:38735851-38736150 R 
Otop2 chr11:115124749-115125048 R 
Pax3 chr1:78077797-78077993 R 
Pdzd9 chr7:120469324-120469623 R 
Pelp1 chr11:70227398-70228397 R 
Pigk chr3:152650934-152651233 R 
Pitpnc1 chr11:107287768-107288067 R 
Pogk chr1:168247826-168248125 H 
Pold3 chr7:99997329-99997628 - 
Ppm1m chr9:106060544-106060843 - 
Pqlc3 chr12:17027118-17027417 R 
Prune chr3:95366332-95366631 R 
Psmd2 chr16:20560174-20560473 - 
Ptn chr6:36738757-36739401 R, H 
Rab17 chr1:92802585-92802884 - 
Rab6b chr9:102969066-102969365 - 
Rsl1 chr13:67669189-67669488 R 
Rttn chr18:89104706-89105203 R 
Rufy3 chr5:89658618-89658917 R, H 
Sart2 chr10:33899902-33900432 R 
Sart2 chr10:33897285-33897822 R, H 
Schip1 chr3:68658542-68658841 R 
Serpinb1c chr13:32905891-32906190 - 
Sertad2 chr11:20439814-20440113 - 
Slc41a3 chr6:90566229-90566838 - 
Smarca2 chr19:26669021-26669320 - 
St6galnac1 chr11:116594420-116594719 R 
Syk chr13:52604075-52604374 R, H 
Tcl1b2 chr12:105548348-105548647 R 
Tiprl chr1:167074926-167075225 - 
Tnfrsf19 chr7:100736389-100736688 R 
Tnni2 chr7:142250655-142250954 - 
Tox chr4:6916154-6916453 R 
Trim28 chr7:11923729-11924028 - 
Tspan31 chr10:126478722-126478891 - 
Ttll6 chr11:95947178-95947477 R, H 
Ubxd3 chr4:138009399-138009698 - 
V1rd6 chr7:5615400-5615699 R 
V1rg3 chr7:11100370-11100974 - 
Vil2 / ezrin chr17:6635815-6636274 R 
Wasf1 chr10:40567697-40567996 R 
Zfp27 chr7:29617531-29617830 R 
Zic2 chr14:121611987-121612286 R 	  
Key Species 
- Mouse 
R Rat 
H Human 	  
Supplementary Table S6 
PCR primers used for quantitative RT-PCR analysis 
Primer  Type Sequence 5’ →  3’ Amplicon bp 
βactinF Endogenous control AGGTCATCACTATTGGCAACGA 117 
βactinR Endogenous control CACTTCATGATGGAATTGAATGTAG
TT 
 
BrachyuryF Primitive streak GCTTCAAGGAGCTAACTAACGAG 117 
BrachyuryR Primitive streak CCAGCAAGAAAGAGTACATGGC  
Axin2F Wnt Target gene TGACTCTCCTTCCAGATCCCA 
 
105 
Axin2R Wnt Target gene TGCCCACACTAGGCTGACA 
 
 
Ctnnb1F Wnt Target gene ATGGAGCCGGACAGAAAAGC 108 
Ctnnb1R Wnt Target gene CTTGCCACTCAGGGAAGGA  
Dkk1F  Wnt Target gene CTCATCAATTCCAACGCGATCA 105 
Dkk1R  Wnt Target gene GCCCTCATAGAGAACTCCCG  
Dvl3F Wnt Target gene GTCACCTTGGCGGACTTTAAG 128 
Dvl3R Wnt Target gene AAGCAGGGTAGCTTGGCATTG  
JupF Wnt Target gene TGGCAACAGACATACACCTACG 135 
JupR Wnt Target gene GGTGGTAGTCTTCTTGAGTGTG  
Wnt3a F Wnt Target gene CTCCTCTCGGATACCTCTTAGTG 
 
186 
Wnt3a R Wnt Target gene GCATGATCTCCACGTAGTTCCTG 
 
 
Bapx1F Target gene TCCAGGCGATCCTCAACAAGA 248 
Bapx1R Target gene GGCTGAGTCTGAGTCCCAAC  
ERGF Target gene ACCTCACCCCTCAGTCCAAA 105 
ERGR Target gene TGGTCGGTCCCAGGATCTG  
FevF 
 
Target gene ACGCCTACCGCTTTGACTTC 
 
186 
FevR 
 
Target gene AAGCTGCCATCAAGTTGAGTT 
 
 
Foxa2F Target gene TAG CGG AGG CAA GAA GAC C 150 
Foxa2R Target gene CTT AGG CCA CCT CGC TTG T  
Foxe1F Target gene ATCGCGCTCATCGCTATGG 108 
Foxe1R Target gene GGGGTTGTCGCGGTAGAAC  
Hoxa2F Target gene TACGAATTTGAGCGAGAGATTGG 116 
Hoxa2R Target gene GTCGAGGTCTTGATTGATGAACT  
Hoxa3F Target gene TCAGCGATCTACGGTGGCTA 250 
Hoxa3R Target gene GAGGCAAAGGTGGTTCACCC  
Meis1F 
 
Target gene GCAAAGTATGCCAGGGGAGTA 
 
235 
Meis1R 
 
Target gene TCCTGTGTTAAGAACCGAGGG 
 
 
Msgn1F Target gene CTTCTGACACCGCTGGTCTG 188 
Msgn1R Target gene GTGACTGCCGTAGCCATCG  
Pax3F Target gene GGGCAGAATTACCCACGCA 177 
Pax3R Target gene CTGGCGAGAAATGACGCAA  
Nkx2.6F  Target gene GCATTCCTGGTCCCTACAAA 78 
Nkx2.6R Target gene AGCTAGCGTCGTAGGGAGTG  
snai2F/Slug Target gene TGGTCAAGAAACATTTCAACGCC 131 
snai2R/Slug Target gene GGTGAGGATCTCTGGTTTTGGTA  
 
Supplementary Table S7 
Mouse in situ, T-box and EMSA primers 
Primer Sequence 5’ →  3’ 
Wnt3a Bam F AGGGATCCATGGCTCCTCTCGGATAC 
 Wnt3a Xba R CGTCTAGACTACTTGCAGGTGTGCA  
 T BamH1 F AGGGATCCATGAGCTCGCCGGGCACAGAGA 
T Box Xho1 R  ACCGCTCGAGGGTGCCAGCACCAGGA   
Sequencing Primer pGEX 5’ F GGGCTGGCAAGCCACGTTTGGTG 
Sequencing Primer pGEX 3’ R CCGGGAGCTGCATGTGTCAGAGG 
Motif 1 F BamH1 end AGATCTCGGTTTTCACACCTATAGACCGGATCC 
Motif 1 R Bgl II end GGATCCGGTCTATAGGTGTGAAAACCGAGATCT 
Mutated Motif 1F  AGATCTCGGTTTGCACGCTTATAGACCGGATCC 
Mutated Motif 1R GGATCCGGTCTATAAGCGTGCAAACCGAGATCT 
Motif 2 F BamH1 end AGATCTCAAACACACACACCTAGAGATCC 
Motif 2 R Bgl II end GGATCTCTAGGTGTGTGTGTTTGAGATCT 
Mutated Motif 2F AGATCTCAAACTCGCACTCCTAGAGATCC 
Mutated Motif 2R GGATCTCTAGGAGTGCGAGTTTGAGATCT 
Motif 3 F Bgl II AGATCTCGGTTTCACACCTATAGACCTACACACACACCTAGAGATCC 
Motif 3 R BamH1  GGATCTCTAGGTGTGTGTGTAGGTCTATAGGTGTGAAACCGAGATCT 
Mutated 3 F T site intact (AC)n altered AGATCTCGGTTTCACACCTATAGACCTACTCGCACTCCTAGAGATCC 
Mutated 3 R T site intact (AC)n altered GGATCTCTAGGAGTGCGAGTAGGTCTATAGGTGTGAAACCGAGATCT 
Mutated 3 F T site altered (AC)n intact AGATCTCGGTTGCACGCTTATAGACCTACACACACACCTAGAGATCC 
Mutated 3 R T site altered (AC)n intact GGATCTCTAGGTGTGTGTGTAGGTCTATAAGCGTGCAACCGAGATCT 
 The motifs investigated in EMSA experiments are highlighted in bold. Nucleotides in blue bold indicate mutated versions of these motifs. Nucleotides in red bold were 
included in oligonucleotides designed for unlabelled competition experiments and were absent from oligonucleotides intended for end labelling. 
 
Supplementary Table S8 
PCR primers used for genomic quantitative PCR 
 
MOUSE 
Primer Sequence 5’ →  3’ Amplicon 
bp Bound genes   
Axin2 F TGGAAAGGAATTCGAAGGTG 176 
Axin2 R CTTCCTTGCACACTCATGGA  
Foxe1 F CACCCAGTGCTCACTGAAGA 144 
Foxe1 R CACGGTGAAGCCAGTACCTT  
Mapre2 F GCCACTGTGCACTCTGCTTA 176 
Mapre2 R CAGTTTCTTGCCCATCAGGT  
Nkx2.6 F AGAAGGGGCAAACAAGGAAT 184 
Nkx2.6 R GGCTGGTTGTGCCAAACTAT  
Pax3 F AATCTCCCTCCCTTGCAAAT 199 
Pax3 R CACTCCCTAGCCAGCAGAAC  
Rttn F GCTGGAGGTTGGGAAAAGAT 158 
Rttn R CTTCAAAAACAGGGCTGCAT  
Vangogh F TATGGTTGGGGCTTTGATGT 148 
Vangogh R GCAACTGCATCCCTGAAAAT  
Published Target   
Nanog 5’F GCTTGAACCAGCCAGTTCTC 200 
Nanog 5’R TTCCTCTCCCTCAGCTACCA  
Negative Regions/Genes   
Nanog 3’ F CACCCACCCATGCTAGTCTT 150 
Nanog 3’ R ACCCTCAAACTCCTGGTCCT  
1700010C24Rik F GCTTTGCCACAGCAGACATA 128 
1700010C24Rik R AGCCAACAAGGTGGACATTC  
β Actin F GGGAATACTCTGGGCTCTCC 132 
β Actin R CCCTGGCCTTGTATTTCTCA  
 
HUMAN 
Primer Sequence 5’ →  3’ Amplicon 
bp Bound genes   
AXIN2 F AGCCCTAACCCCTGACCCCC 105 
AXIN2 R TGTGCAGCCGGGGAGGATCT  
FGF8 F AGCGATCAGTGGCATCGCGG 128 
FGF8 R TGGCAGGAGGAGCGGGAGAC  
JUP F CCCCTAAGCCGACCAGCGGA 108 
JUP R GGGAAGCAGAGAGGGCCGGA  
WNT3A F TTGGCCACACAGGGAAGCGG 82 
WNT3A R GTGGGGATGGGGGAGGGGTC  
Negative Region/Gene   
NCAPD2 F GAGCCTTTCCACACCATCAT 109 
NCAPD2 R GCCGAGGTGGAATTCAAATA  
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